nct_id,title,official_title,overall_status,phase,sponsor,start_date,primary_completion_date,completion_date,first_posted_date,last_update_date,planned_primary_outcomes,planned_secondary_outcomes,results_outcome_measures,results_participant_flow,results_baseline,results_adverse_events,site_count,site_countries,sites_compact,start_year,Pathologic_Complete_Response,Event_Free_Survival,Disease_Free_Survival,Overall_Survival,Best_Overall_Response,Duration_of_Response,Progression_Free_Survival,Overall_Response,Target_Response,Non_target_Response,Symptomatic_Deterioration,Disease_Recurrence,Pathologic_Complete_Response_pCR,Objective_Response_Rate,Time_to_Progression,detected_endpoint_names,planned_endpoint_count,reporting_gap_flag,consort_participant_flow,consort_recruitment,consort_baseline,consort_numbers_analyzed,consort_outcomes_estimation,consort_ancillary_analyses,consort_harms,consort_results_score,HER2_flag,BRCAm_flag,NM_new_medicine,EI_extension_of_indication,nm_ei_explanation,sponsor_class,has_results,completion_year,years_since_completion,multi_country_flag,phase_bucket
NCT01009437,Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer,A Phase I/II Trial of Short Course Pre-Operative Ritonavir To Determine Akt Inhibition in Breast Cancer,COMPLETED,PHASE1,"Masonic Cancer Center, University of Minnesota",2010-05-26,2014-07,2014-07,2009-11-06,2017-12-05,['Inhibition of breast cancer by targeting Hsp90-Akt pathway'],"['Activation of apoptosis markers', 'Modulation of autophagy markers', 'Alteration of plasma levels of eicosanoids', 'Induction of Hsp70 in peripheral blood mononuclear cells', 'Reduction of ERα in ERα+ tumors', 'Changes in TNF-α and IL-6 levels as well as reduction in intratumoral nuclear NF-kB and phospho-Stat3', 'Alteration of urine eicosanoid levels', 'Alteration of plasma and urine eicosanoid levels resulting from tumor resection.', 'Induction of the unfolded protein response (UPR) assayed by grp78 or related markers (phospho-PERK, ATF-4, and CHOP)', 'inhibition of tumor growth markers (Ki67 LI, Hsp90, phosphorylated AKT)']",,,,,2,United States,"Masonic Cancer Center, University of Minnesota [Minneapolis, United States] | The Kimmel Cancer Center at Jefferson University [Philadelphia, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2014.0,11.0,0,Phase 1
NCT01035268,Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella,Adipose Tissue Transfer for Moderate Breast Cancer Conservative Treatment Sequella. Adipocyte Transplant for Esthetical Relapse Treatment of Breast Conservative Treatment,TERMINATED,PHASE3,Institut Claudius Regaud,2010-02-08,2015-10,2017-02-21,2009-12-18,2018-08-22,['Verify that the disturbances of the radiological follow-up in 1 year will not be more frequent for the patient benefiting from fatty transfer with regard to a simple surveillance.'],"['Estimate the technique on the cosmetic plan : On the quality and on the stability of the result. On the satisfaction of the patient.', 'Estimate the technique on the carcinological plan : Estimate the rate of local relapse and\\or in distance. Estimate the rate of survival of the patients.']",,,,,23,France,"CHU de Besançon [Besançon, France] | Clinique Saint Antoine [Bois-Guillaume, France] | CHU Pellegrin [Bordeaux, France] | Institut Bergonie [Bordeaux, France] | Pole de Sante de Leonard de Vinci [Chambray-lès-Tours, France] | Hopital Henri Mondor [Créteil, France] | Centre Hospitalier La Croix Rousse [Lyon, France] | Hopital Edouard Herriot [Lyon, France] | CHR Marseille Conception [Marseille, France] | Institut Paoli Calmettes [Marseille, France] | Centre Val d'Aurelle [Montpellier, France] | Clinique Brétéché [Nantes, France] | INSTITUT CURIE - Site Paris [Paris, France] | Hopital Saint Louis [Paris, France] | Centre Eugene Marquis [Rennes, France] | Centre Henri Becquerel [Rouen, France] | INSTITUT CURIE - René Huguenin [Saint-Cloud, France] | INSTITUT DE CANCEROLOGIE DE L'OUEST - Centre René Gauducheau [Saint-Herblain, France] | Hôpitaux Universitaires de Strasbourg [Strasbourg, France] | CHU Rangueil [Toulouse, France] | Institut Claudius Regaud [Toulouse, France] | Centre Alexis Vautrin [Vandœuvre-lès-Nancy, France] | Institut Gustave Roussy [Villejuif, France]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of adipose tissue transfer in the context of breast cancer treatment, which suggests an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2017.0,8.0,0,Phase 3
NCT01084057,Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer,Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer,COMPLETED,PHASE1,City of Hope Medical Center,2010-05-17,2012-11-12,2019-09-27,2010-03-10,2019-11-05,"['Dose limiting toxicity defined as any treatment-related grade 3 or greater non-hematologic toxicity, grade 4 febrile neutropenia, thrombocytopenia or grade 4 neutropenia as a result of unresolved toxicity']","['Objective response rate and/or clinical benefit rate', 'Toxicity profile']",,,,,2,United States,"City of Hope [Duarte, United States] | South Pasadena Cancer Center [South Pasadena, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT01084642,Female Cancer Patients' Preference For Sexual Health Interventions,A Pilot Study Surveying Female Cancer Patients' Preference For Sexual Health Interventions,COMPLETED,,Memorial Sloan Kettering Cancer Center,2010-03-04,2017-07-03,2017-07-03,2010-03-10,2017-07-06,"[""Participant' awareness of sexual health issues & preference for sexual health intervention""]","[""To assess & describe female cancer patients' attitudes towards & preference of methods to receive sexual health information (verbal or written) & psychosexual education patient information cards or intervention modality (telephone, in-person or online).""]",,,,,1,United States,"Memorial Sloan Kettering Cancer Center [New York, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a survey on female cancer patients' preferences for sexual health interventions, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT01091545,Malmö Breast Tomosynthesis Screening Trial,Malmö Breast Tomosynthesis Screening Trial,COMPLETED,,Region Skane,2010-02-01,2017-12-31,2019-09-30,2010-03-24,2019-11-13,['Sensitivity and specificity for breast cancer detection for DBT and DM respectively'],"['What kind of cancers are detected and not detected with DBT?', 'Cost-effectiveness of DBT in screening']",,,,,1,Sweden,"Malmö Breast Screening Unit, Skåne University Hospital [Malmo, Sweden]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a screening trial for breast cancer detection using digital breast tomosynthesis (DBT) but does not indicate the introduction of a new medicine or an extension of indication for an existing treatment.,OTHER,False,2019.0,6.0,0,NA/Other
NCT01116869,China CellSearch Study,"A Multi-Center, Prospective Study to Evaluate the Ability of CTC Enumeration Using the CellSearch® Circulating Tumor Cell Kit to Predict Prognosis and to Assess the Agreement Between CTC and Imaging Determined Response in MBC Patients 一项评价CellSearch® 循环肿瘤细胞检测试剂盒对复发转移性乳腺癌患者进行循环肿瘤细胞检测 以预测病人预后的能力及循环肿瘤细胞检测和影像学疗效判断之间一致性的多中心、前瞻性的研究",COMPLETED,,"Johnson & Johnson Medical, China",2010-03-25,2011-06-22,2014-01-06,2010-05-05,2019-11-15,['Ability of CTC levels to predict progression-free survival (PFS) in MBC patients.'],"['Ability of CTC levels to predict overall survival (OS) in MBC patients.', ""Agreement between CTC counts (3-4 weeks and 6-8 weeks) after the initiation of a new line of systemic therapy and the patient's response as determined by imaging evaluation (6-8 weeks after the initiation of therapy) in MBC patients.""]",,,,,1,China,"307 Hosptial of PLA [Beijing, China]",2010.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the ability of an existing diagnostic tool (CellSearch® Circulating Tumor Cell Kit) to predict prognosis and assess treatment response in metastatic breast cancer (MBC) patients, indicating an extension of its indication rather than a new medicine.",INDUSTRY,False,2014.0,11.0,0,NA/Other
NCT01127295,Pharmacology of Adjuvant Hormonotherapy in Breast Cancer,"Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer",COMPLETED,PHASE4,Institut Claudius Regaud,2010-06-17,2017-12-01,2017-12-01,2010-05-20,2018-03-02,['Correlation between pharmacokinetic and pharmacogenetic parameters'],"['To estimate the relation between plasmatic concentrations, pharmacogenetic characteristic and adverse effects.', 'To estimate the relation between the genetic polymorphisms and premature relapses in the first 3 years of treatment', 'To estimate the link between plasmatic concentrations and the premature relapse (in the first 3 years)', 'To estimate the declared therapeutic observance to the real exposure at the treatment measured by plasmatic concentrations.', 'appearance auto-antibody and correlate to the clinical data']",,,,,24,France,"Clinique Calabet [Agen, France] | Clinique Claude Bernard [Albi, France] | Centre Hospitalier d'Auch [Auch, France] | CHU de Bordeaux [Bordeaux, France] | Clinique Tivoli [Bordeaux, France] | Institut Bergonié [Bordeaux, France] | Polyclinique Bordeaux Nord [Bordeaux, France] | Centre Hospitalier de Brive [Brive-la-Gaillarde, France] | Centre Hospitalier de Cahors [Cahors, France] | Centre Hospitalier Intercommunal de Castres-Mazamet [Castres, France] | Hôpital Dupuytren CHU Limoges [Limoges, France] | Centre Hospitalier de Mont de Marsan [Mont-de-Marsan, France] | Centre Hospitalier de Montauban [Montauban, France] | Centre Val d'Aurelle [Montpellier, France] | Hôpital Caremeau CHU Nîmes [Nîmes, France] | Centre Hospitalier de Pau [Pau, France] | Centre Catalan d'Oncologie [Perpignan, France] | Centre Hospitalier de Rodez [Rodez, France] | Polyclinique de l'Ormeau [Tarbes, France] | Claudius Regaud [Toulouse, France] | CHU de Rangueil [Toulouse, France] | Clinique Pasteur - Département d'Oncologie Médicale [Toulouse, France] | Clinique Pasteur - Département de Radiothérapie [Toulouse, France] | Clinique Saint-Jean du Languedoc [Toulouse, France]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2017.0,8.0,0,Other
NCT01131195,Metronomic Therapy in Metastatic Breast Cancer.,"Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial.",COMPLETED,PHASE3,Swiss Cancer Institute,2010-07-19,2012-12-14,2018-02-28,2010-05-26,2019-05-15,['Incidence of grade 3-5 adverse events'],"['Objective response (OR)', 'Disease control (DC)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Time to specific grade 3-5 adverse events']",,,,,23,Switzerland,"Hirslanden Klinik Aarau [Aarau, Switzerland] | Kantonspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Spitalzentrum Biel [Biel, Switzerland] | RSV-GNW Spitalzentrum Oberwallis [Brig, Switzerland] | Kantonsspital Graubuenden [Chur, Switzerland] | Kantonsspital Frauenfeld [Frauenfeld, Switzerland] | Kantonsspital Freiburg [Fribourg, Switzerland] | Hopital Cantonal Universitaire de Geneve [Geneva, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Kantonsspital Luzern [Luzerne, Switzerland] | Oncology Institute of Southern Switzerland - IOSI Ticino [Mendrisio, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Kantonsspital - St. Gallen [Sankt Gallen, Switzerland] | Hopital Regional de Sion-Herens-Conthey [Sion, Switzerland] | Regionalspital Thun [Thun, Switzerland] | Spital Uster [Uster, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland] | Onkozentrum - Klinik im Park [Zurich, Switzerland] | Onkozentrum Hirslanden [Zurich, Switzerland] | City Hospital Triemli [Zurich, Switzerland] | UniversitaetsSpital Zuerich [Zurich, Switzerland]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2018.0,7.0,0,Phase 3
NCT01138085,"Safety, Pharmacokinetics (PK) of AKT and MEK Combination","A Phase I Dose Escalation Open-Label Safety, Pharmacokinetic and Pharmacodynamic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795",COMPLETED,PHASE1,GlaxoSmithKline,2010-05-04,2014-11-19,2014-11-19,2010-06-07,2017-11-13,"['Part 1A: To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination orally, once daily continuously', 'Part 1B:To determine the safety, tolerability and recommended Phase II dose of GSK1120212 and GSK2141795 administered in combination with an alternate schedule (i.e., at least one agent is dosed intermittently)', 'Parts 2A/2B: To evaluate the clinical activity of GSK1120212 and GSK2141795 administered in combination in subjects with solid tumors that are predicted to be sensitive to the inhibition of MEK and/or AKT, including TNBC and BRAF-wild type melanoma']","['To characterize the PK of GSK1120212 and GSK2141795 for a once daily continuous dosing schedule (Part 1A) and/or an intermittent dosing schedule (Part 1B).', 'Part 1A, Part 1B: To evaluate the clinical activity of GSK1120212 and GSK2141795 in subjects with solid tumors.', 'Parts 1 and 2: To characterize the durability of response with GSK1120212 and GSK2141795 dosed orally in combination', 'To evaluate the pharmacodynamic (PD) response in tumors after treatment with the combination of GSK1120212 and GSK2141795.', 'To explore relationships between study drug PK, PD and clinical activity']",,,,,10,United States,"GSK Investigational Site [Aurora, United States] | GSK Investigational Site [New Haven, United States] | GSK Investigational Site [Boston, United States] | GSK Investigational Site [Boston, United States] | GSK Investigational Site [New Brunswick, United States] | GSK Investigational Site [Nashville, United States] | GSK Investigational Site [Dallas, United States] | GSK Investigational Site [Houston, United States] | GSK Investigational Site [San Antonio, United States] | GSK Investigational Site [Salt Lake City, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2014.0,11.0,0,Phase 1
NCT01138384,Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer,A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer,COMPLETED,PHASE1; PHASE2,NCIC Clinical Trials Group,2010-10-27,2014-05-14,2015-02-13,2010-06-07,2023-08-04,"['Toxicity, maximum administered dose and the recommended phase II dose']","['Pharmacokinetic evaluation of lapatinib', 'Preliminary evidence of efficacy']",,,,,5,Canada,"BCCA - Cancer Centre for the Southern Interior [Kelowna, Canada] | BCCA - Vancouver Cancer Centre [Vancouver, Canada] | Cancer Centre of Southeastern Ontario at Kingston [Kingston, Canada] | London Regional Cancer Program [London, Canada] | McGill University - Dept. Oncology [Montreal, Canada]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,NETWORK,False,2015.0,10.0,0,Phase 2
NCT01139957,Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer,Prospective Study of Risk-Reducing Salpingo-Oophorectomy (RRSO) and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer: Extended Follow-Up of Select GOG-0199 Study Participants,COMPLETED,,Gynecologic Oncology Group,2010-06-07,2020-04-10,2020-04-10,2010-06-09,2020-09-02,"['Prospective incidence of ovarian cancer (including fallopian tube cancer), primary peritoneal cancer, breast cancer, and all cancer', 'Ovarian cancer mortality rates', 'Breast cancer mortality rates', 'Quality of life']",[],,,,,141,United States,"University of Alabama at Birmingham Cancer Center [Birmingham, United States] | Gynecologic Oncology Group of Arizona [Phoenix, United States] | Mayo Clinic in Arizona [Scottsdale, United States] | UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States] | University of Colorado Hospital [Aurora, United States] | Hartford Hospital [Hartford, United States] | Smilow Cancer Hospital Care Center at Saint Francis [Hartford, United States] | The Hospital of Central Connecticut [New Britain, United States] | Yale University [New Haven, United States] | Beebe Medical Center [Lewes, United States] | Christiana Care Health System-Christiana Hospital [Newark, United States] | Florida Gynecologic Oncology [Fort Myers, United States] | Mayo Clinic in Florida [Jacksonville, United States] | Sarasota Memorial Hospital [Sarasota, United States] | Women's Cancer Associates [St. Petersburg, United States] | Tripler Army Medical Center [Honolulu, United States] | Saint Alphonsus Cancer Care Center-Boise [Boise, United States] | Rush University Medical Center [Chicago, United States] | University of Chicago Comprehensive Cancer Center [Chicago, United States] | NorthShore University HealthSystem-Evanston Hospital [Evanston, United States] | Carle Cancer Center [Urbana, United States] | Indiana University/Melvin and Bren Simon Cancer Center [Indianapolis, United States] | Saint Vincent Hospital and Health Care Center [Indianapolis, United States] | University of Kansas Cancer Center [Kansas City, United States] | Menorah Medical Center [Overland Park, United States] | Saint Luke's South Hospital [Overland Park, United States] | Kansas City NCI Community Oncology Research Program [Prairie Village, United States] | Saint Elizabeth Medical Center South [Edgewood, United States] | Norton Hospital Pavilion and Medical Campus [Louisville, United States] | Maine Medical Center-Bramhall Campus [Portland, United States] | Greater Baltimore Medical Center [Baltimore, United States] | MedStar Franklin Square Medical Center/Weinberg Cancer Institute [Baltimore, United States] | Walter Reed National Military Medical Center [Bethesda, United States] | National Institutes of Health Clinical Center [Bethesda, United States] | Union Hospital of Cecil County [Elkton, United States] | Tufts Medical Center [Boston, United States] | UMass Memorial Medical Center - Memorial Division [Worcester, United States] | Michigan Cancer Research Consortium NCORP [Ann Arbor, United States] | Saint Joseph Mercy Hospital [Ann Arbor, United States] | Bronson Battle Creek [Battle Creek, United States] | Spectrum Health Big Rapids Hospital [Big Rapids, United States] | Beaumont Hospital - Dearborn [Dearborn, United States] | Wayne State University/Karmanos Cancer Institute [Detroit, United States] | Ascension Saint John Hospital [Detroit, United States] | Hurley Medical Center [Flint, United States] | Genesys Regional Medical Center-West Flint Campus [Flint, United States] | Cancer Research Consortium of West Michigan NCORP [Grand Rapids, United States] | Mercy Health Saint Mary's [Grand Rapids, United States] | Spectrum Health at Butterworth Campus [Grand Rapids, United States] | Allegiance Health [Jackson, United States] | Sparrow Hospital [Lansing, United States] | Saint Mary Mercy Hospital [Livonia, United States] | Mercy Health Mercy Campus [Muskegon, United States] | Saint Joseph Mercy Oakland [Pontiac, United States] | Lake Huron Medical Center [Port Huron, United States] | William Beaumont Hospital-Royal Oak [Royal Oak, United States] | Ascension Saint Mary's Hospital [Saginaw, United States] | Munson Medical Center [Traverse City, United States] | Saint John Macomb-Oakland Hospital [Warren, United States] | Metro Health Hospital [Wyoming, United States] | Fairview Ridges Hospital [Burnsville, United States] | Mercy Hospital [Coon Rapids, United States] | Fairview Southdale Hospital [Edina, United States] | Unity Hospital [Fridley, United States] | Hutchinson Area Health Care [Hutchinson, United States] | Minnesota Oncology Hematology PA-Maplewood [Maplewood, United States] | Saint John's Hospital - Healtheast [Maplewood, United States] | Abbott-Northwestern Hospital [Minneapolis, United States] | Hennepin County Medical Center [Minneapolis, United States] | University of Minnesota/Masonic Cancer Center [Minneapolis, United States] | New Ulm Medical Center [New Ulm, United States] | North Memorial Medical Health Center [Robbinsdale, United States] | Mayo Clinic in Rochester [Rochester, United States] | Metro Minnesota Community Oncology Research Consortium [Saint Louis Park, United States] | Park Nicollet Clinic - Saint Louis Park [Saint Louis Park, United States] | Regions Hospital [Saint Paul, United States] | United Hospital [Saint Paul, United States] | Saint Francis Regional Medical Center [Shakopee, United States] | Lakeview Hospital [Stillwater, United States] | Ridgeview Medical Center [Waconia, United States] | Rice Memorial Hospital [Willmar, United States] | Minnesota Oncology Hematology PA-Woodbury [Woodbury, United States] | University of Missouri - Ellis Fischel [Columbia, United States] | Saint Luke's Hospital of Kansas City [Kansas City, United States] | North Kansas City Hospital [Kansas City, United States] | Heartland Hematology and Oncology Associates Incorporated [Kansas City, United States] | Research Medical Center [Kansas City, United States] | Saint Luke's East - Lee's Summit [Lee's Summit, United States] | Liberty Radiation Oncology Center [Liberty, United States] | Heartland Regional Medical Center [Saint Joseph, United States] | Saint Joseph Oncology Inc [Saint Joseph, United States] | Washington University School of Medicine [St Louis, United States] | Nebraska Cancer Research Center [Lincoln, United States] | Missouri Valley Cancer Consortium [Omaha, United States] | Nebraska Methodist Hospital [Omaha, United States] | Alegent Health Immanuel Medical Center [Omaha, United States] | Alegent Health Bergan Mercy Medical Center [Omaha, United States] | Creighton University Medical Center [Omaha, United States] | Dartmouth Hitchcock Medical Center [Lebanon, United States] | University of New Mexico Cancer Center [Albuquerque, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Laura and Isaac Perlmutter Cancer Center at NYU Langone [New York, United States] | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | UNC Lineberger Comprehensive Cancer Center [Chapel Hill, United States] | Carolinas Medical Center/Levine Cancer Institute [Charlotte, United States] | FirstHealth of the Carolinas-Moore Regional Hospital [Pinehurst, United States] | Aultman Health Foundation [Canton, United States] | University of Cincinnati/Barrett Cancer Center [Cincinnati, United States] | Good Samaritan Hospital - Cincinnati [Cincinnati, United States] | Case Western Reserve University [Cleveland, United States] | Cleveland Clinic Cancer Center/Fairview Hospital [Cleveland, United States] | Cleveland Clinic Foundation [Cleveland, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | Riverside Methodist Hospital [Columbus, United States] | Hillcrest Hospital Cancer Center [Mayfield Heights, United States] | UH Seidman Cancer Center at Lake Health Mentor Campus [Mentor, United States] | University of Oklahoma Health Sciences Center [Oklahoma City, United States] | Oklahoma Cancer Specialists and Research Institute-Tulsa [Tulsa, United States] | Bryn Mawr Hospital [Bryn Mawr, United States] | Paoli Memorial Hospital [Paoli, United States] | Lankenau Medical Center [Wynnewood, United States] | Main Line Health NCORP [Wynnewood, United States] | Women and Infants Hospital [Providence, United States] | Sanford Cancer Center Oncology Clinic [Sioux Falls, United States] | Sanford USD Medical Center - Sioux Falls [Sioux Falls, United States] | Brooke Army Medical Center [Fort Sam Houston, United States] | Wilford Hall Medical Center [Lackland Air Force Base, United States] | University of Vermont Medical Center [Burlington, United States] | University of Virginia Cancer Center [Charlottesville, United States] | Virginia Commonwealth University/Massey Cancer Center [Richmond, United States] | Carilion Clinic Gynecological Oncology [Roanoke, United States] | Marshfield Clinic-Chippewa Center [Chippewa Falls, United States] | Marshfield Clinic Cancer Center at Sacred Heart [Eau Claire, United States] | University of Wisconsin Hospital and Clinics [Madison, United States] | Marshfield Medical Center-Marshfield [Marshfield, United States] | Marshfield Clinic-Minocqua Center [Minocqua, United States] | Ascension Saint Mary's Hospital [Rhinelander, United States] | Marshfield Medical Center-Rice Lake [Rice Lake, United States] | Marshfield Clinic - Weston Center [Weston, United States] | Marshfield Clinic - Wisconsin Rapids Center [Wisconsin Rapids, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on cancer incidence and mortality rates among women at increased genetic risk of ovarian cancer, focusing on risk-reducing surgery and screening. It does not indicate the development of a new medicine or an extension of indication for an existing medicine.",NETWORK,False,2020.0,5.0,0,NA/Other
NCT01140282,Exercise Program for Early Breast Cancer Survivors,Combined Exercise Program for Early Breast Cancer Survivors,COMPLETED,,University of Southern California,2012-05-21,2017-09-28,2018-10-01,2010-06-09,2019-06-18,"['Changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and HbA1c', 'Improvement of physical fitness, cardiorespiratory fitness, and muscle strength', 'Feasibility of a supervised exercise program for cancer survivors', 'Maintain positive benefits of an exercise intervention']",[],,,,,1,United States,"USC Norris Comprehensive Cancer Center [Los Angeles, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an exercise program for breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT01156168,Biomarkers in Tissue Samples From Patients With Breast Cancer Treated With Bevacizumab,VEGF Gene Amplification/Deletion and Haplotype as Biomarkers for Bevacizumab in Breast Cancer,COMPLETED,,ECOG-ACRIN Cancer Research Group,2011-04-05,2011-09-08,2011-09-08,2010-07-02,2017-05-17,['Comparison between VEGF haplotype and median overall survival (OS) and grade 3/4 hypertension (HTN)'],['Comparison between VEGF amplification/deletion and VEGF expression'],,,,,0,,,2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses biomarkers related to the use of Bevacizumab in breast cancer, indicating an extension of indication for an existing medicine rather than a new medicine.",NETWORK,False,2011.0,14.0,0,NA/Other
NCT01157767,Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation,A Feasibility Study of the Effects of a Directed Exercise Program of Breast Cancer Patients Undergoing Chemotherapy With or Without Radiation,COMPLETED,,Memorial Sloan Kettering Cancer Center,2010-05-11,2021-08-23,2021-08-23,2010-07-07,2021-09-01,"['To evaluate compliance with and demonstrate the feasibility of an at-home, directed exercise program during adjuvant chemotherapy and radiation (if applicable).']","['To describe how this exercise program affects weight maintenance and percent body fat during adjuvant chemotherapy and radiation.', 'To describe how this exercise program affects early post-operative lymphedema rates, monitoring the strength training specifics -including the number of repetitions and sets of each exercise, frequency, and order of exercises.']",,,,,1,United States,"Memorial Sloan Kettering Cancer Center [New York, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT01162200,Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,A Phase I Study of Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer,COMPLETED,PHASE1,University of Texas Southwestern Medical Center,2010-10-04,2015-07-25,2015-12-28,2010-07-14,2020-08-20,['The maximum tolerated dose to the lumpectomy cavity in patients with early stage breast cancer'],"['Dose-limiting toxicity', 'The cosmesis of breast']",,,,,2,United States,"University of Texas Southwestern Medical Center [Dallas, United States] | UT Southwestern Medical Center [Dallas, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2015.0,10.0,0,Phase 1
NCT01219075,Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer,Soy Treatment for High-risk Women,COMPLETED,,University of Southern California,2010-07-01,2022-11-24,2022-11-24,2010-10-13,2023-11-18,['Number of participants with reduced MRI volume (MRIV)'],"['Percentage of cells that stain positive for Ki67, caspase 3, ratio of Ki67/caspase, ER alpha and ER beta']",,,,,1,United States,"University of Southern California [Los Angeles, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of soy isoflavones supplementation in women at high risk for or with breast cancer, indicating an extension of indication for an existing treatment rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT01219699,"A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene","A Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",COMPLETED,PHASE1,Novartis Pharmaceuticals,2010-10-05,2015-02-05,2020-04-16,2010-10-13,2020-09-22,['Incidence rate of dose limiting toxicities (DLT).'],"['Overall safety and tolerability of BYL719 as single agent and in combination with fulvestrant', 'PK parameters of BYL719 as single agent and in combination with fulvestrant - AUC-tlast and AUC0-inf.', 'PK parameters of BYL719 as single agent and in combination with fulvestrant - Cmax.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - Tmax.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - CL/F.', 'Pharmaconkinetics of BYL719 as single agent and in combination with fulvestrant - Vz/F.', 'Pharmacokinetics of BYL719 as single agent and in combination with fulvestrant - Terminal half-life (t1/2)', 'Preliminary efficacy of BYL719 as single agent and in combination with fulvestrant by measuring ORR.', 'Progression-free survival at maximum tolerated dose']",,,,,11,Germany; Netherlands; Spain; United Kingdom; United States,"UCSF Medical Center [San Francisco, United States] | Massachusetts General Hospital [Boston, United States] | Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4) [Nashville, United States] | Vanderbilt Univeristy SC [Nashville, United States] | MD Anderson Cancer Center/University of Texas MD Anderson [Houston, United States] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain] | Novartis Investigative Site [Oxford, United Kingdom]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on BYL719, which is being tested as a new treatment for advanced solid malignancies, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01234857,A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3),"A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients",COMPLETED,PHASE2,Merck Sharp & Dohme LLC,2010-09-17,2013-10-15,2013-10-15,2010-11-04,2017-05-31,['Progression free survival (PFS)'],"['Objective response rate (ORR)', 'Overall survival (OS)']",,,,,0,,,2010.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Ridaforolimus and Dalotuzumab, which are being tested in combination for a specific cancer type, indicating a new medicine approach rather than an extension of indication for existing treatments.",INDUSTRY,False,2013.0,12.0,0,Phase 2
NCT01248897,Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib,A Study of Biomarker Profiles in Asia Pacific erbB2+/HER2 Breast Cancer Patients Treated With Lapatinib and Other Anti-erbB2/HER2 Therapy,COMPLETED,,GlaxoSmithKline,2010-08-17,2013-12-01,2014-09-05,2010-11-25,2018-06-19,['Progression free survival'],"['Response rate', 'Overall survival', 'Progression free survival']",,,,,17,Hong Kong; Philippines; Singapore; South Korea,"GSK Investigational Site [Hong Kong, Hong Kong] | GSK Investigational Site [Pokfulam, Hong Kong] | GSK Investigational Site [Tuenmen, Hong Kong] | GSK Investigational Site [Wan Chai, Hong Kong] | GSK Investigational Site [Pasay, Philippines] | GSK Investigational Site [Singapore, Singapore] | GSK Investigational Site [Busan, South Korea] | GSK Investigational Site [Busan, South Korea] | GSK Investigational Site [Busan, South Korea] | GSK Investigational Site [Gangwon-do, South Korea] | GSK Investigational Site [Incheon, South Korea] | GSK Investigational Site [Kyunggi-do, South Korea] | GSK Investigational Site [Seoul, South Korea] | GSK Investigational Site [Seoul, South Korea] | GSK Investigational Site [Seoul, South Korea] | GSK Investigational Site [Seoul, South Korea] | GSK Investigational Site [Songpa-gu, Seoul, South Korea]",2010.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study involves the use of Lapatinib, which is an existing medication, in a specific patient population (erbB2+/HER2 breast cancer patients) and assesses its effectiveness alongside other therapies, indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2014.0,11.0,1,NA/Other
NCT01263145,MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer,Phase Ib Dose Escalation and Biomarker Study of MK-2206 in Combination With Standard Doses of Weekly Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Advanced Breast Cancer,COMPLETED,PHASE1,National Cancer Institute (NCI),2011-01-05,2012-10-19,2012-10-19,2010-12-20,2017-08-25,"['Antitumor activity of the combination in metastatic breast cancer (Expansion phase)', 'MTD of the combination of MK-2206 and paclitaxel defined as the dose level in which less than or equal to 1 out of 6 patients develop dose limiting toxicity assessed using Common Terminology Criteria for Adverse Events version 4 (Phase I)']","['Change in average number of circulating tumor cells (CTCs)', 'Change in multiplex proteomics', 'Change in percentage of biomarkers assessed using immunohistochemistry', 'Change in percentage of marker of proliferation Ki-67 (Ki-67) positive cells', 'Change in reverse phase proteomic arrays (RPPA)', 'Pharmacokinetic parameters of Akt inhibitor MK2206', 'Pharmacokinetic parameters of paclitaxel']",,,,,3,United States,"Dana-Farber Cancer Institute [Boston, United States] | Vanderbilt University/Ingram Cancer Center [Nashville, United States] | M D Anderson Cancer Center [Houston, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,1,"The trial involves MK2206, which is a new medicine being tested in combination with paclitaxel for treating advanced solid tumors and metastatic breast cancer, indicating both a new medicine and an extension of indication for the existing treatment.",NIH,False,2012.0,13.0,0,Phase 1
NCT01320111,Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment,Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH,2010-07-01,2014-08-31,2014-08-31,2011-03-22,2017-02-20,['Progression free survival (PFS)'],['Secondary Efficacy Variables'],,,,,1,Germany,"Germany Multiple Sites All Over Germany Recruiting Multiple Sites, Germany Contact: iOMEDICO AG [Freiburg im Breisgau, Germany]",2010.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares an existing treatment (Paclitaxel) with a combination that includes an existing drug (Sorafenib) for a specific patient population (metastatic breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2014.0,11.0,0,Phase 2
NCT01324479,Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,COMPLETED,PHASE1,Novartis Pharmaceuticals,2012-02-29,2017-07-04,2017-07-04,2011-03-29,2020-12-19,['Incidence rate of dose-limiting toxicities and adverse events'],['Objective response by local investigator assessment'],,,,,47,Australia; Canada; France; Germany; Hong Kong; Israel; Italy; Netherlands; Norway; Singapore; South Korea; Spain; Taiwan; Thailand; United States,"Highlands Oncology Group [Fayetteville, United States] | University of Chicago SC [Chicago, United States] | Karmanos Cancer Institute Wayne St Karmanos [Detroit, United States] | Sarah Cannon Research Institute Dept of Onc [Nashville, United States] | University of Texas/MD Anderson Cancer Center Dept of Onc [Houston, United States] | Novartis Investigative Site [Westmead, Australia] | Novartis Investigative Site [Woolloongabba, Australia] | Novartis Investigative Site [Ottawa, Canada] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [La Tronche, France] | Novartis Investigative Site [Lille Cédex, France] | Novartis Investigative Site [Strasbourg, France] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Frankfurt, Germany] | Novartis Investigative Site [Freiburg im Breisgau, Germany] | Novartis Investigative Site [Göttingen, Germany] | Novartis Investigative Site [Hanover, Germany] | Novartis Investigative Site [Oldenburg, Germany] | Novartis Investigative Site [Shatin, New Territories, Hong Kong] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Haifa, Israel] | Novartis Investigative Site [Kfar Saba, Israel] | Novartis Investigative Site [Ramat Gan, Israel] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Ancona, Italy] | Novartis Investigative Site [Meldola, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Reggio Emilia, Italy] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Rotterdam, Netherlands] | Novartis Investigative Site [Oslo, Norway] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Gyeonggi-do, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Granada, Spain] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Oviedo, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Zaragoza, Spain] | Novartis Investigative Site [Tainan City, Taiwan] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Songkhla, Thailand]",2012.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on assessing the safety and tolerability of INC280, which indicates it is a study of a new medicine.",INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01337765,"Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients","A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors",COMPLETED,PHASE1,Pfizer,2011-07-08,2013-03-22,2013-03-22,2011-04-19,2020-10-09,['Incidence of Dose Limiting Toxicities'],"['Number of participants with adverse events and serious adverse events', 'Overall response rate, duration of response, time to response and progression free survival', 'Time versus plasma concentration profiles of BEZ235 and MEK162', 'Treatment-induced PI3K and MEK/ERK pathway signaling inhibition and evidence of biological activity in tumor']",,,,,6,Australia; Canada; France; Spain; United States,"Massachusetts General Hospital Mass General 2 [Boston, United States] | University of Texas/MD Anderson Cancer Center MD Anderson PSC [Houston, United States] | Pfizer Investigative Site [Parkville, Australia] | Pfizer Investigative Site [Toronto, Canada] | Pfizer Investigative Site [Villejuif, France] | Pfizer Investigative Site [Barcelona, Spain]",2011.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2013.0,12.0,1,Phase 1
NCT01339442,BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer,"A Phase 1 Trial of BKM 120, a Novel Oral Selective Phosphatidylinositol-3-kinase (PI3K) Inhibitor, in Combination With Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer",COMPLETED,PHASE1,Washington University School of Medicine,2011-11-14,2016-12-21,2016-12-28,2011-04-20,2017-01-25,"['MTD of BKM120 in combination with fulvestrant', 'Number of participants with adverse events after treatment with BKM120 in combination with fulvestrant']","['Anti-tumor effect (PR, CR, SD and PD) of BKM120 in combination with fulvestrant', 'Steady state blood concentration of BKM120', 'Tumor PI3K pathway abnormalities in tissue from previous biopsy or collected at baseline', 'Effects of study therapy on blood levels of fasting C-peptide', 'Effects of study therapy on blood levels of glucose', 'Samples will be analyzed for markers of PI3K signaling (including pAKT, pS6, Cyclin D1, subcellular localization of FOXO3a, phosphoproteomics), tumor cell proliferation (Ki67) and apoptosis (cleaved caspase 3 or TUNEL staining).', 'Examine the PIK3CA mutation status in circulating DNA at baseline thru last treatment']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01339650,"Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",COMPLETED,PHASE1,"AbbVie (prior sponsor, Abbott)",2011-05-06,2017-11-30,2017-11-30,2011-04-21,2018-01-02,['Pharmacokinetic profile'],['Safety (number of subjects with adverse events and/or dose limiting toxicities)'],,,,,3,Netherlands,"Univ Med Center Groningen [Groningen, Netherlands] | Univ Med Ctr, St. Radboud [Nijmegen, Netherlands] | Erasmus Medisch Centrum [Rotterdam, Netherlands]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,1,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT01349842,Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer,CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer,COMPLETED,PHASE3,Institut Curie,2010-03-02,2016-01,2018-11-06,2011-05-09,2019-03-21,['Overall Survival'],"['Measure of safety and tolerability', 'Improvement of quality of life', 'Time to progression, to discontinuation of therapy after 3rd line.', 'Comparison of CTC with usual serum tumour markers', 'Medico-economical analysis', 'Estimate the clinical interest, in particular forecast, of the circulating tumoral DNA']",,,,,7,France,"Centre Georges Francois Leclerc [Dijon, France] | Clinique Victor Hugo [Le Mans, France] | Chu Limoges [Limoges, France] | Institut Curie [Paris, France] | Hopital Saint Louis [Paris, France] | Institut Rene Huguenin Curie [Saint-Cloud, France] | Institut de Canacerologie de L'Ouest [Saint-Herblain, France]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[""Overall Survival"",""Time to Progression""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the use of circulating tumor cells to guide chemotherapy in metastatic breast cancer, which suggests an extension of indication for existing chemotherapy treatments rather than testing a new medicine.",OTHER,False,2018.0,7.0,0,Phase 3
NCT01357863,Role of Early Versus Late Switch to Lapatinib-Capecitabine,Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil,TERMINATED,,GlaxoSmithKline,2010-07-15,2010-12-13,2010-12-13,2011-05-23,2018-09-14,['Time to disease progression (TTP)'],"['Overall response rate (ORR) determined by treating physician', 'One year overall survival (OS)', 'Serious adverse events (SAEs)', 'Clinical Global Impression (CGI)']",,,,,13,Brazil,"GSK Investigational Site [Vitória, Brazil] | GSK Investigational Site [Salvador, Brazil] | GSK Investigational Site [Salvador, Brazil] | GSK Investigational Site [Salvador, Brazil] | GSK Investigational Site [Goiânia, Brazil] | GSK Investigational Site [Goiânia, Brazil] | GSK Investigational Site [Natal, Brazil] | GSK Investigational Site [Porto Alegre, Brazil] | GSK Investigational Site [Florianópolis, Brazil] | GSK Investigational Site [São José dos Campos, Brazil] | GSK Investigational Site [Belo Horizonte, Brazil] | GSK Investigational Site [Rio de Janeiro, Brazil] | GSK Investigational Site [São Paulo, Brazil]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[""Time to Progression"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the use of Lapatinib-Capecitabine in patients who have already been treated with Trastuzumab, indicating an extension of indication for this combination therapy in a specific patient population.",INDUSTRY,False,2010.0,15.0,0,NA/Other
NCT01373710,Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis,Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis,COMPLETED,PHASE1; PHASE2,Institut Curie,2011-05-19,2018-04,2018-04-09,2011-06-15,2019-07-10,['Phase I : To determine the Trastuzumab maximum tolerated dose (MTD) when weekly administrated by intrathecal or intraventricular route.'],"['Phase I : Recommended dose (RD will be used in Phase II)', 'Phase I&II : Toxicity during treatment', 'Time to neurologic progression', 'Biological response: CSF cellularity and protein concentration', 'Radiological response: cerebrospinal meningitis and neuraxis MRI', 'Impact on quality of life', 'Impact on survival (overall survival, survival without neurological progression, progression-free survival)', 'Pharmacokinetics: dose of trastuzumab in CSF and plasma', 'FCGR3A Genetic status influence on efficacy trastuzumab in metastatic breast cancer', 'Phase II : Determination of antitumor activity trastuzumab when administrated by IT or intra-ventricular in terms of neurological progression free survival at 2 months']",,,,,10,France,"François Baclesse Center [Caen, France] | Rene Huguenin Hospital [Saint-Cloud, France] | Oscar Lambret Center [Lille, France] | Léon Bérard Center [Lyon, France] | Institut Bergonié [Bordeaux, France] | CHU Grenoble [Grenoble, France] | Institut du Cancer de Montpellier [Montpellier, France] | Institut Univesitaire du Cancer de Toulouse [Toulouse, France] | Institut Curie - Claudius Regaud Hospital [Paris, France] | Pitie Salpetriere Hospital [Paris, France]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 2
NCT01386411,Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer,Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer,COMPLETED,,Memorial Sloan Kettering Cancer Center,2011-06-28,2017-11-03,2017-11-03,2011-07-01,2017-11-08,['To determine the relative proportions of women offered genetic testing after a breast cancer diagnosis who decide to have BRCA testing'],"['To determine the relative proportions of women who decide to undergo prophylactic mastectomy (PM)', 'To assess the factors associated with the decision to choose pre- or post surgical testing.']",,,,,1,United States,"Memorial Sloan Kettering Cancer Center [New York, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses decision-making processes related to genetic testing and surgical options for women with breast cancer, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT01407562,"Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors,TERMINATED,PHASE1,"Rutgers, The State University of New Jersey",2010-09-17,2016-03-29,2016-03-29,2011-08-02,2022-09-28,['Establish the maximum tolerated dose (MTD) of pazopanib with weekly paclitaxel and carboplatin on a 28- day cycle'],"['Determine the drug-drug interactions with paclitaxel, carboplatin, and pazopanib']",,,,,1,United States,"Rutgers Cancer Institute of New Jersey [New Brunswick, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01425294,Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment,"A Multicenter, Non-interventional, Prospective Study to Collect Efficacy and Safety Data in Chinese Patients Who Have Received Faslodex 250mg Treatment Under the Condition of Actual Usage in Clinical Practice",TERMINATED,,AstraZeneca,2011-08-01,2016-01-30,2016-01-30,2011-08-30,2017-12-05,"[""To evaluate the effectiveness of Faslodex 250mg monthly to treat post-menopausal women with ER+ locally advanced or MBC in terms of progression-free survival (PFS), by collecting real world data according to Chinese physicians' clinical practice.""]","['Objective response rate (ORR)', 'Frequency of Adverse Events', 'Severity of Adverse Events']",,,,,23,China,"Research Site [Beijing, China] | Research Site [Fuzhou, China] | Research Site [Guangzhou, China] | Research Site [Guiyang, China] | Research Site [Tangshan, China] | Research Site [Harbin, China] | Research Site [Wuhan, China] | Research Site [Changsha, China] | Research Site [Hohhot, China] | Research Site [Kunshan, China] | Research Site [Nanjing, China] | Research Site [Nantong, China] | Research Site [Xuzhou, China] | Research Site [Changchun, China] | Research Site [Qingdao, China] | Research Site [Weifang, China] | Research Site [Shanghai, China] | Research Site [Chengdu, China] | Research Site [Tianjin, China] | Research Site [Kunming, China] | Research Site [Hanghzou, China] | Research Site [Hangzhou, China] | Research Site [Zhoushan, China]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the effectiveness of Faslodex 250mg in a specific patient population (post-menopausal women with ER+ locally advanced or MBC), which suggests it is an extension of indication for an existing medication rather than testing a new medicine.",INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT01434303,"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only","Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed",COMPLETED,PHASE1,National Cancer Institute (NCI),2012-01-10,2016-02-16,2016-02-16,2011-09-14,2019-05-20,['RP2D for entinostat in combination with lapatinib ditosylate defined as the highest dose level in which 6 patients have been treated with at most 1 patient experiencing dose limiting toxicity'],"['Incidence of grade III or IV toxicities, graded according to Common Terminology Criteria for Adverse Events version 4']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,NIH,False,2016.0,9.0,0,Phase 1
NCT01440010,TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry,TARGeted Intraoperative radioTherapy With the INTRABEAM-System as an Advanced Boost in Patients With Breast Cancer - A Quality Control Registry in Germany (TARGIT BQR),COMPLETED,,Universitätsmedizin Mannheim,2011-09-01,2020-12-31,2020-12-31,2011-09-23,2022-06-02,['Local recurrence rate'],"['Toxicity, Overall survival']",,,,,1,Germany,"University Medical Center Mannheim [Mannheim, Germany]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of an existing treatment (INTRABEAM) in a new context (as a boost for breast cancer), indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,NA/Other
NCT01463891,Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S),Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer,COMPLETED,,"Eisai Co., Ltd.",2011-07-19,2012-12-26,2013-11-27,2011-11-02,2023-07-24,['Effectiveness Diagnosed by Imaging'],[],,,,,223,Japan," [Anjo, Japan] |  [Inazawa, Japan] |  [Kariya, Japan] |  [Komaki, Japan] |  [Nagakute, Japan] |  [Nagoya, Japan] |  [Okazaki, Japan] |  [Seto, Japan] |  [Tahara, Japan] |  [Toyohashi, Japan] |  [Daisen, Japan] |  [Yokote, Japan] |  [Goshogawara, Japan] |  [Hirosaki, Japan] |  [Kuroishi, Japan] |  [Misawa, Japan] |  [Mutsu, Japan] |  [Asahi, Japan] |  [Funabashi, Japan] |  [Ichihara, Japan] |  [Ichikawa, Japan] |  [Kashiwa, Japan] |  [Kimitsu, Japan] |  [Matsudo, Japan] |  [Sakura, Japan] |  [Matsuyama, Japan] |  [Niihama, Japan] |  [Iizuka, Japan] |  [Kasuga, Japan] |  [Kitakyushu, Japan] |  [Kurume, Japan] |  [Omuta, Japan] |  [Yame, Japan] |  [Yanagawa, Japan] |  [Minamisoma, Japan] |  [Nihommatsu, Japan] |  [Ena, Japan] |  [Hashima, Japan] |  [Minokamo, Japan] |  [Ōgaki, Japan] |  [Sekimachi, Japan] |  [Tajimi, Japan] |  [Takayama, Japan] |  [Maebashi, Japan] |  [Ōta, Japan] |  [Shibukawa, Japan] |  [Takasaki, Japan] |  [Aki, Japan] |  [Fukuyama, Japan] |  [Hatsukaichi, Japan] |  [Higashihiroshima, Japan] |  [Kure, Japan] |  [Mihara, Japan] |  [Onomichi, Japan] |  [Abashiri, Japan] |  [Asahikawa, Japan] |  [Date, Japan] |  [Eniwa, Japan] |  [Hakodate, Japan] |  [Kitahiroshima, Japan] |  [Kitami, Japan] |  [Kushiro, Japan] |  [Muroran, Japan] |  [Obihiro, Japan] |  [Sapporo, Japan] |  [Shibetsu, Japan] |  [Akashi, Japan] |  [Amagasaki, Japan] |  [Himeji, Japan] |  [Kobe, Japan] |  [Nishinomiya, Japan] |  [Toyooka, Japan] |  [Higashiibaraki, Japan] |  [Inashiki, Japan] |  [Kamisu, Japan] |  [Kasama, Japan] |  [Koga, Japan] |  [Moriya, Japan] |  [Tsukuba, Japan] |  [Ushiku, Japan] |  [Kahoku, Japan] |  [Kanazawa, Japan] |  [Komatsu, Japan] |  [Nomi, Japan] |  [Takamatsu, Japan] |  [Akune, Japan] |  [Chigasaki, Japan] |  [Ebina, Japan] |  [Isehara, Japan] |  [Kamakura, Japan] |  [Kawasaki, Japan] |  [Odawara, Japan] |  [Sagamihara, Japan] |  [Yokohama, Japan] |  [Yokosuka, Japan] |  [Arao, Japan] |  [Tamana, Japan] |  [Kōtari, Japan] |  [Ise, Japan] |  [Matsusaka, Japan] |  [Suzuka, Japan] |  [Tsu, Japan] |  [Yokkaichi, Japan] |  [Murata, Japan] |  [Ōsaki, Japan] |  [Sendai, Japan] |  [Iida, Japan] |  [Komagane, Japan] |  [Matsumoto, Japan] |  [Saku, Japan] |  [Suwa, Japan] |  [Shimabara, Japan] |  [Ikoma, Japan] |  [Kashihara, Japan] |  [Yamatotakada, Japan] |  [Minamiuonuma, Japan] |  [Kurashiki, Japan] |  [Maniwa, Japan] |  [Tamano, Japan] |  [Wake, Japan] |  [Naha, Japan] |  [Nakagami, Japan] |  [Shimajiri, Japan] |  [Tomigusuku, Japan] |  [Urasoe, Japan] |  [Higashiosaka, Japan] |  [Hirakata, Japan] |  [Ibaraki, Japan] |  [Izumiōtsu, Japan] |  [Katano, Japan] |  [Neyagawa, Japan] |  [Sayama, Japan] |  [Takatsuki, Japan] |  [Yao, Japan] |  [Karatsu, Japan] |  [Fujimino, Japan] |  [Fukaya, Japan] |  [Hidaka, Japan] |  [Hiki, Japan] |  [Kawaguchi, Japan] |  [Kumagaya, Japan] |  [Toda, Japan] |  [Tokorozawa, Japan] |  [Kusatsu, Japan] |  [Ōtsu, Japan] |  [Rittō, Japan] |  [Izumo, Japan] |  [Matsue, Japan] |  [Fujieda, Japan] |  [Fujinomiya, Japan] |  [Gotemba, Japan] |  [Hamamatsu, Japan] |  [Izunokuni, Japan] |  [Numazu, Japan] |  [Shimada, Japan] |  [Sunto, Japan] |  [Ashikaga, Japan] |  [Oyama, Japan] |  [Adachi City, Japan] |  [Akishima, Japan] |  [Bunkyo, Japan] |  [Chiyoda City, Japan] |  [Chūō, Japan] |  [Fuchū, Japan] |  [Fussa, Japan] |  [Hachiōji, Japan] |  [Hino, Japan] |  [Katsushika-ku, Japan] |  [Kita-ku, Japan] |  [Koto, Japan] |  [Machida, Japan] |  [Meguro City, Japan] |  [Minato, Japan] |  [Mitaka, Japan] |  [Nerima City, Japan] |  [Ōta-ku, Japan] |  [Setagaya City, Japan] |  [Shibuya City, Japan] |  [Shinagawa, Japan] |  [Shinjuku, Japan] |  [tabashi City, Japan] |  [Tachikawa, Japan] |  [Taitō City, Japan] |  [Tama, Japan] |  [Kurayoshi, Japan] |  [Yonago, Japan] |  [Nakaniikawa, Japan] |  [Namerikawa, Japan] |  [Oyabe, Japan] |  [Takaoka, Japan] |  [Tsuruoka, Japan] |  [Hagi, Japan] |  [Iwakuni, Japan] |  [Nagato, Japan] |  [Shimonoseki, Japan] |  [Chūō, Japan] |  [Kofu, Japan] |  [Minamikoma, Japan] |  [Aomori, Japan] |  [Chiba, Japan] |  [Fukui, Japan] |  [Fukuoka, Japan] |  [Fukushima, Japan] |  [Gifu, Japan] |  [Hiroshima, Japan] |  [Kagoshima, Japan] |  [Kochi, Japan] |  [Kumamoto, Japan] |  [Kyoto, Japan] |  [Miyazaki, Japan] |  [Nagano, Japan] |  [Nagasaki, Japan] |  [Niigata, Japan] |  [Okayama, Japan] |  [Okinawa, Japan] |  [Osaka, Japan] |  [Ōita, Japan] |  [Saga, Japan] |  [Saitama, Japan] |  [Shizuoka, Japan] |  [Tokushima, Japan] |  [Tottori, Japan] |  [Toyama, Japan]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text indicates a study on the effectiveness and safety of Eribulin Mesylate in a specific patient population (inoperable or recurrent breast cancer), suggesting an extension of indication for an already approved drug.",INDUSTRY,False,2013.0,12.0,0,NA/Other
NCT01478477,"Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole",Prevention of Aromatase Inhibitor-Induced Joint Symptoms With Omega 3 Fatty Acid Supplementation: a Randomized Placebo Controlled Pilot Study,COMPLETED,,Ohio State University Comprehensive Cancer Center,2011-10-04,2014-01-09,2014-01-09,2011-11-23,2023-02-27,['Pain score change after 6 months (6 months -baseline) based on the FACT-B/ES instrument'],"['Pain score change after 6 months (6 months -baseline) based on the HAS and BPI instruments', 'Compliance rates with oral supplements (omega-3 fatty acid and placebo)', 'Feasibility of using the instruments HAS, BPI-short, FACT-B/ES for the assessment of joint symptoms', 'Effectiveness of blinding', 'Correlation of guess with pain scores', 'Relationship between serum and RBC omega-3 fatty acid levels, inflammatory blood markers and MRI changes and the joint symptoms']",,,,,1,United States,"Ohio State University Medical Center [Columbus, United States]",2011.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2014.0,11.0,0,NA/Other
NCT01484483,An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya,Breast Cancer Care (BRECC) Registry - Development of a Breast Cancer Registry to Determine the Magnitude of Breast Cancer and Current Clinical Care Patterns in Kenya,COMPLETED,,Hoffmann-La Roche,2011-08-08,2019-12-06,2019-12-06,2011-12-02,2019-12-23,"['Incidence of breast cancer in Kenya', 'Breast cancer treatment patterns (drugs/dosage/schedule) in clinical practice in Kenya']","['Progression-free survival', 'Overall survival', 'Patient demographics of breast cancer patients in Kenya', 'Pathology: Prevalence of tumour types', 'Correlation between risk factors and clinical outcome', 'Therapy duration/compliance', 'Safety: Incidence of adverse events']",,,,,1,Kenya,"University of Nairobi School of Medicine; Internal Medicine and Therapeutics [Nairobi, Kenya]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an observational study focused on the incidence of breast cancer and clinical care patterns in Kenya, without introducing a new medicine or extending the indication of an existing treatment.",INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT01495247,"Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer","A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,Novartis Pharmaceuticals,2012-01-30,2014-05-19,2014-05-19,2011-12-19,2020-12-08,['Phase lb: Dose Limiting Toxicities (DLTs) the first cycle of treatment'],"['Phase lb: Frequency and severity of adverse events', 'Phase lb: Progression free survival (PFS)', 'Phase lb: Overall Response Rate (ORR)', 'Phase lb: Clinical Benefit Rate (CBR)']",,,,,3,France; Spain,"Novartis Investigative Site [Dijon, France] | Novartis Investigative Site [Saint-Herblain Cédex, France] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain]",2012.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating BEZ235, which is a new drug being tested in combination with Paclitaxel for a specific patient population with HER2 negative breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2014.0,11.0,1,Phase 2
NCT01503034,Pregnant Women With a Breast Cancer Diagnosed Between 2000 and 2014,"Study of Tumor Characteristics, Patient Care and Prognosis of Women With Breast Cancer During a Pregnancy Diagnosed Between 2000 and 2014",COMPLETED,,Centre Oscar Lambret,2010-12-14,2015-09-28,2015-09-28,2012-01-02,2018-04-03,['Overall survival'],"['the support of breast cancer cases occured during pregnancy', 'Tumor characteristics', 'Disease-free survival', 'Case-control comparison']",,,,,37,France,"Clinique Sainte Catherine [Avignon, France] | Cabinet Dr Le Guen Naas [Baud, France] | Centre Hospitalier Universitaire [Besançon, France] | Institut Bergonié [Bordeaux, France] | CHR [Brest, France] | Centre François Baclesse [Caen, France] | Centre Hospitalier René Dubos [Cergy-Pontoise, France] | Centre Jean Perrin [Clermont-Ferrand, France] | Centre Léonard de Vinci [Dechy, France] | Centre Georges François Leclerc [Dijon, France] | Centre Hospitalier Départemental de Vendée [La Roche-sur-Yon, France] | Centre Oscar Lambret [Lille, France] | Centre de Pharmacovigilance [Lille, France] | Centre Hospitalier de Bretagne Sud [Lorient, France] | Centre Léon Bérard [Lyon, France] | Institut Paoli Calmettes [Marseille, France] | CHRU La Peyronie et Centre Val d'Aurelle [Montpellier, France] | Centre Catherine de Sienne [Nantes, France] | Centre Antoine Lacassagne [Nice, France] | Institut Curie [Paris, France] | Hôpital Saint-Louis [Paris, France] | Hôpital Cochin [Paris, France] | Hôpital Tenon [Paris, France] | Centre Hospitalier Lyon-Sud [Pierre-Bénite, France] | Institut Jean Godinot [Reims, France] | Polyclinique de Courlancy [Reims, France] | Centre Eugene Marquis [Rennes, France] | Centre Henri Becquerel [Rouen, France] | Clinique Radiologique [Saint-Brieuc, France] | Centre René Huguenin [Saint-Cloud, France] | Centre René Gauducheau [Saint-Herblain, France] | Centre Paul Strauss [Strasbourg, France] | Institut Claudius Régaud [Toulouse, France] | Cabinet Dr Leroy [Tourcoing, France] | Hôpital Bretonneau - Centre régional de cancérologie Henry Kaplan [Tours, France] | Centre Alexis Vautrin [Vandœuvre-lès-Nancy, France] | Institut Gustave Roussy [Villejuif, France]",2010.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study focused on breast cancer in pregnant women, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2015.0,10.0,0,NA/Other
NCT01580800,National Breast Cancer and Lymphedema Registry,National Breast Cancer and Lymphedema Registry,TERMINATED,,Stanley Rockson,2011-09-12,2018-03-02,2018-03-02,2012-04-19,2018-06-29,['Preemptive diagnostic and treatment strategies'],[],,,,,1,United States,"Stanford University School of Medicine [Stanford, United States]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text does not mention a new medicine or an extension of indication for an existing medicine. It refers to a registry and strategies related to breast cancer and lymphedema without specifying any medicinal products.,OTHER,False,2018.0,7.0,0,NA/Other
NCT01602406,Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,"A Multicenter, Open-label, Dose Escalation, Phase I Study of LJM716 Administered Intravenously in Combination With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2012-09-21,2017-08-02,2017-08-02,2012-05-21,2020-12-19,['Incidence rate of Dose Limiting Toxicities'],"['Number of adverse events', 'Number of serious adverse events', 'Pharmacodynamic response to LJM716 in tumor tissue', 'Progression-free survival', 'Duration of response', 'Serum concentration of anti-LJM716 antibodies', 'Serum concentration of LJM716 when administered in combination with trastuzumab', 'Frequency of partial responses according to Response Evaluation Criteria In Solid Tumors (RECIST)', 'Frequency of complete responses according to RECIST', 'Frequency of stable disease according to RECIST']",,,,,11,Belgium; France; Italy; Netherlands; South Korea; Spain; Taiwan; United Kingdom; United States,"Novartis Investigative Site [Boston, United States] | Novartis Investigative Site [Chapel Hill, United States] | Novartis Investigative Site [Philadelphia, United States] | Novartis Investigative Site [Wilrijk, Belgium] | Novartis Investigative Site [Saint-Herblain, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Valencia, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Oxford, United Kingdom]",2012.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01612650,Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis,Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis,COMPLETED,,Centre Oscar Lambret,2012-02-24,2017-03-16,2017-03-16,2012-06-06,2018-03-23,['determine the benefit of tomosynthesis for diagnosis'],"['determine best incidence of realization', 'measurement of breast irradiation', 'evaluate non focused ultrasound residual place for 2 - 3 - 4 density breast', 'number of additional cancer detected by tomosynthesis']",,,,,4,France,"Oscar Lambret Center [Lille, France] | Centre Hospitalier - Pavillon Paul Gelé [Roubaix, France] | Centre Hospitalier [Valenciennes, France] | Clinique des Dentellières [Valenciennes, France]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the assessment of diagnostic techniques (tomosynthesis and ultrasound) rather than introducing a new medicine or extending the indication of an existing medicine.,OTHER,False,2017.0,8.0,0,NA/Other
NCT01612871,Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer,Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer? Pilot Study.,COMPLETED,PHASE4,Institut Claudius Regaud,2012-06-27,2016-01-28,2016-01-28,2012-06-06,2018-03-05,['Rates of patients for which specific tissular miRNAs are detected in blood before treatment (D0)'],"['Analysis of the larger-scale circulating miRNAs in plasma of these patients before (D0) and after one month (D28) of treatment with tamoxifen or anti aromatase', 'Correlation between the specific miRNAs initial expression and the appearance of an objective response or clinical benefit of hormone therapy and the time to progression', 'Rate of objective responses, defined as the number of patients with a complete or partial response.', 'The time to progression, defined as the time from patient inclusion to the date of the first documented tumor progression']",,,,,2,France,"Centre Val d'Aurelle - Paul Lamarque [Montpellier, France] | Institut Claudius REGAUD Toulouse [Toulouse, France]",2012.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on the use of circulating miRNAs as biomarkers to assess hormone sensitivity in breast cancer patients undergoing treatment with existing therapies (tamoxifen or anti-aromatase), indicating an extension of indication rather than a new medicine.",OTHER,False,2016.0,9.0,0,Other
NCT01615068,An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry),An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).,COMPLETED,,"Genentech, Inc.",2012-06-05,2017-11-16,2017-11-16,2012-06-08,2018-07-16,['Distribution of patients receiving unique treatment regimen/sequence of treatment regimens'],"['Progression-free survival (PFS)', 'Overall survival (OS)', 'Post-progression survival (PPS)', 'Time-to-treatment failure (TTF)', 'Response rate (RR)', 'Safety: Incidence of adverse events', 'Patient-reported outcome assessment (PRO)']",,,,,142,United States,"St. Vincent'S Hospital; Birmingham Hematology Oncology Associates, Llc [Birmingham, United States] | University of South Alabama; Mitchell Cancer Institute [Mobile, United States] | Arizona Oncology Associates, PC - NAHOA [Sedona, United States] | Arizona Oncology [Tucson, United States] | Genesis Cancer Center [Hot Springs, United States] | NEA Baptist Clinic [Jonesboro, United States] | Hematology Oncology Services of Arkansas [Little Rock, United States] | Highlands Oncology Group [Rogers, United States] | East Valley Hem/Onc Med Group; Metropolitan Hem Onc. [Burbank, United States] | South Bay Oncology Hematology Partners [Campbell, United States] | California Cancer Associates for Research & Excellence, Inc. [Encinitas, United States] | ROBERT A. MOSS, M.D., F.A.C.P., Inc [Fountain Valley, United States] | California Oncology of the Central Valley [Fresno, United States] | Cancer Care Associates [Fresno, United States] | St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr [Fullerton, United States] | University of Southern California [Los Angeles, United States] | UCLA School of Medicine [Los Angeles, United States] | Comprehensive Cancer Care [Palm Springs, United States] | Univ of Calif, San Francisco; Breast Cancer Center [San Francisco, United States] | Coastal Integrative Cancer Care [San Luis Obispo, United States] | Central Coast Medical Oncology [Santa Maria, United States] | Sutter Pacific Medical Foundation [Santa Rosa, United States] | Kaiser Permanente Of Colorado [Denver, United States] | Rocky Mountain Cancer Center - Denver [Denver, United States] | Mile High Oncology [Littleton, United States] | Connecticut Oncology Group [Middletown, United States] | Yale Cancer Center [New Haven, United States] | Hematology Oncology P.C. [Stamford, United States] | MedStar Washington Hosp Center [Washington D.C., United States] | Lynn Cancer Institute - West [Boca Raton, United States] | University of Miami; Dept Sylvester Cancer Center [Deerfield Beach, United States] | Florida Cancer Specialists - Fort Myers (New Hampshire Ct) [Fort Myers, United States] | Memorial Cancer Institute [Hollywood, United States] | Baptist - MD Anderson Cancer Center [Jacksonville, United States] | Florida Oncology Associates [Jacksonville, United States] | Lakeland Regional Cancer Center [Lakeland, United States] | Md Anderson Cancer Center Orlando [Orlando, United States] | Florida Cancer Research Institute [Plantation, United States] | Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) [St. Petersburg, United States] | Space Coast Medical Associates [Titusville, United States] | Peachtree Hematology & Oncology Consultants, Pc [Atlanta, United States] | Northwest Georgia Oncology Centers PC - Marietta [Marietta, United States] | Summit Cancer Care PC [Savannah, United States] | Kootenai Cancer Center [Post Falls, United States] | Alton Memorial Hospital; Outpatient Clinic and Infusion Center [Alton, United States] | Rush University Medical Center [Chicago, United States] | Mid-Illinois Hematology [Normal, United States] | Oncology Specialists, S.C. [Park Ridge, United States] | Orchard Healthcare Research Inc. [Skokie, United States] | Carle Cancer Center [Urbana, United States] | Oncology Hematology Assoc [Evansville, United States] | McFarland Clinic [Ames, United States] | University of Iowa [Iowa City, United States] | Mercy Medical Ctr-North Iowa ; Mercy Cancer Center [Mason City, United States] | Cancer Center of Kansas [Wichita, United States] | James Graham Brown Cancer Center, University of Louisville [Louisville, United States] | Baptist Hospital East [Louisville, United States] | Mary Bird Perkins Cancer Ctr [Baton Rouge, United States] | Medical Oncology LLC [Baton Rouge, United States] | Lafayette General Medical Center [Lafayette, United States] | Mercy Oncology / Hematology Center; Oncology [Portland, United States] | Western Maryland Health Sys [Cumberland, United States] | Associates in Oncology/Hematology P.C. [Rockville, United States] | Capitol Hematology & Oncology [Silver Spring, United States] | St. Joseph Medical Center [Towson, United States] | Carroll County Cancer Center [Westminster, United States] | Berkshire Hematology, Oncology Pc [Pittsfield, United States] | Cancer & Hematology Centers of Western Michigan [Grand Rapids, United States] | West Michigan Cancer Center [Kalamazoo, United States] | Southdale Cancer Clinic U of M Medical Center, Fairview- Edina [Edina, United States] | Minnesota Oncology Hematology, Pa [Minneapolis, United States] | Park Nicollet Clinic Cancer Center [Saint Louis Park, United States] | Jackson Oncology Associates, PLLC [Jackson, United States] | Jefferson City Medical Group [Jefferson City, United States] | Research Medical Center; Pharmacy [Kansas City, United States] | Christian Hospital; Outpatient Cancer and Infusion Center [St Louis, United States] | St. John'S Mercy Medical Center; David C. Pratt Cancer Center [St Louis, United States] | Billings Clinic Research Center [Billings, United States] | Montana Cancer Specialists [Missoula, United States] | Southeast Nebraska Cancer Center;; Southeast Nebraska Hematology and Oncology [Lincoln, United States] | Cancer Alliance of Nebraska [Omaha, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | Dartmouth Hitchcock Medical Center; Gastroenterology Section [Lebanon, United States] | Portsmouth Regional Hospital; Hem/Onc Clinic [Portsmouth, United States] | Summit Medical Group [Berkeley Heights, United States] | Onc & Hematology Specialists [Denville, United States] | Hackensack University Medical Center [Hackensack, United States] | Hematology Oncology Associates; Carol G. Simon Ctr [Morristown, United States] | Luckow Pavillion, Valley Hosp; Office of Clinical Trials [Paramus, United States] | The Mary Imogene Bassett Hospi [Cooperstown, United States] | North Shore Hem Onc Associates [East Setauket, United States] | Queens Hospital Center [Jamaica, United States] | Beth Israel Comprehensive Cancer Center Pharmacy [New York, United States] | Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion [New York, United States] | Hope A Women's Cancer Center [Asheville, United States] | Gaston Hematology/Oncology [Gastonia, United States] | Cone Health Cancer Center [Greensboro, United States] | Southeastern Regional Medical Center [Lumberton, United States] | First Health of the Carolinas [Pinehurst, United States] | Metro Health Medical Center [Cleveland, United States] | Mid Ohio Onc Hematology Inc [Columbus, United States] | Signal Point Clinical; Research Center, LLC [Middletown, United States] | Flower Memorial Hospital [Sylvania, United States] | Mercy Clinic Oklahoma Communties, Inc [Oklahoma City, United States] | Cancer Care Assoc-15th St [Tulsa, United States] | Providence Cancer Center [Portland, United States] | Hematology & Oncology Assoc; North Eastern Pennsylvania [Dunmore, United States] | Lancaster Cancer Center, Ltd. [Lancaster, United States] | Temple University Hospital [Philadelphia, United States] | Allegheny General Hospital; Transplantation Services [Pittsburgh, United States] | Univ of Pittsburgh Sch of Med; Magee-Womens Hospital [Pittsburgh, United States] | Guthrie Clinic [Sayre, United States] | Charleston Hematology Oncology [Charleston, United States] | Medical Univ of South Carolina [Charleston, United States] | South Carolina Oncology Associates - SCRI [Columbia, United States] | Chattanooga Oncology and Hematology Associates, PC [Chattanooga, United States] | Kingsport Hematology Oncology Associates [Kingsport, United States] | Center for Biomedical Research LLC [Knoxville, United States] | Boston Baskin Cancer Foundation [Nashville, United States] | Sarah Cannon Research Inst. [Nashville, United States] | Hendrick Cancer Center [Abilene, United States] | Texas Oncology [Bedford, United States] | St. Joseph Regional Cancer Ct [Bryan, United States] | Texas Oncology-Baylor Sammons Cancer Center [Dallas, United States] | Texas Oncology- El Paso Cancer Treatment Center Gateway [El Paso, United States] | Texas Oncology, P.A. - Fort Worth [Fort Worth, United States] | Texas Oncology - Houston (Gessner) [Houston, United States] | Texas Oncology, P.A. - McAllen; South Texas Cancer Center-McAllen [McAllen, United States] | Texas Oncology - Paris [Paris, United States] | Tyler Hematololgy Oncology, PA [Tyler, United States] | Texas Oncology, PA [Waco, United States] | Texas Oncology, P.A.; Duke Slayton Cancer Center [Webster, United States] | Northern Utah Associates [Ogden, United States] | Huntsman Cancer Institute; Oncology [Salt Lake City, United States] | Lynchburg Hem Onc Clinic Inc [Lynchburg, United States] | Peninsula Cancer Institute [Newport News, United States] | Virginia Cancer Institute [Richmond, United States] | Shenandoah Oncology Associates [Winchester, United States] | Virginia Mason Medical Center [Seattle, United States] | West Virginia University Hospitals Inc [Morgantown, United States] | University of Wisconsin [Madison, United States] | Columbia Saint Mary's; Medical Oncology [Milwaukee, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on treatment patterns and outcomes in patients with HER2 positive metastatic breast cancer, indicating an extension of indication for existing treatments rather than introducing a new medicine.",INDUSTRY,False,2017.0,8.0,0,NA/Other
NCT01624441,Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer,A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,National Cancer Institute (NCI),2012-08-21,2013-09-10,2013-09-10,2012-06-20,2018-03-30,"['MTD of dinaciclib given in combination with epirubicin hydrochloride, determined according to incidence of dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4']","['Predictive value of MCL-1, LMW-E, and tumor grade as predictors of biologic response (i.e. induction of apoptosis) in tumors treated with therapy', 'Clinical benefit rate (complete response [CR] + partial response [PR] + stable disease [SD]), assessed using Response Evaluation Criteria in Solid Tumors (RECIST)', 'Changes in proliferation as measured by Ki67 and apoptosis as measured by TUNEL']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Dinaciclib, which is being tested in combination with Epirubicin for a specific patient population (metastatic triple-negative breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",NIH,False,2013.0,12.0,0,Phase 1
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction",COMPLETED,PHASE1,National Cancer Institute (NCI),2012-08-03,2018-11-29,2020-09-01,2012-07-11,2025-02-07,"['Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method']","['Child-Pugh classification of hepatic dysfunction', 'Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria']",,,,,12,Canada; United States,"City of Hope Comprehensive Cancer Center [Duarte, United States] | University of California Davis Comprehensive Cancer Center [Sacramento, United States] | Emory University Hospital/Winship Cancer Institute [Atlanta, United States] | University of Chicago Comprehensive Cancer Center [Chicago, United States] | Johns Hopkins University/Sidney Kimmel Cancer Center [Baltimore, United States] | National Cancer Institute Developmental Therapeutics Clinic [Bethesda, United States] | Wayne State University/Karmanos Cancer Institute [Detroit, United States] | Mayo Clinic in Rochester [Rochester, United States] | Case Western Reserve University [Cleveland, United States] | Penn State Milton S Hershey Medical Center [Hershey, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | University Health Network-Princess Margaret Hospital [Toronto, Canada]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,NIH,False,2020.0,5.0,1,Phase 1
NCT01639911,Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors,STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors,COMPLETED,PHASE1,University of Illinois at Chicago,2013-08-14,2016-07-28,2016-07-28,2012-07-13,2019-07-22,['Optimally Tolerated Dose'],['Toxicity Profile'],,,,,1,United States,"University of Illinois Cancer Center [Chicago, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2016.0,9.0,0,Phase 1
NCT01641562,Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction,Diagnosis and Prediction of Subclinical Cardiac Dysfunction Induced by Therapy With Taxanes in Patients With Breast Cancer,COMPLETED,,Carol Davila University of Medicine and Pharmacy,2012-01-01,2016-10-30,2017-01-31,2012-07-17,2020-07-17,['CARDIOTOXICITY PREDICTION SCORE'],"['GENETIC DISORDERS AND CARDIOTOXICITY', 'DIAGNOSTIC ACCURACY FOR CARDIOTOXICITY', 'EVALUATION PROTOCOL FOR CARDIOTOXICITY']",,,,,1,Romania,"University and Emergency Hospital [Bucharest, Romania]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses diagnostic methods and prediction of cardiac dysfunction related to taxane therapy in breast cancer patients, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT01645839,Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer,Role of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Patients Wih Leptomeningeal Metastasis of Breast Cancer. A Randomized Phase III Study.,COMPLETED,PHASE3,Centre Oscar Lambret,2011-08-30,2018-08,2019-03-01,2012-07-20,2019-06-12,['Leptomeningeal disease-related neurological progression-free survival (LM-PFS)'],"['Response of leptomeningeal metastases', 'Progression free survival (PFS)', 'Overall survival', 'Tolerance to DepoCyte® according to NCI CTCAE V4.0', 'Q-TWiST']",,,,,10,France,"Centre Hospitalier Universitaire Groupe Sud [Amiens, France] | Centre Hospitalier Universitaire Lyon [Bron, France] | Centre G.F. Leclerc [Dijon, France] | CHU de Grenoble [Grenoble, France] | Centre Oscar Lambret [Lille, France] | Centre Hospitalier Bretagne Sud [Lorient, France] | Centre Val d'Aurelle [Montpellier, France] | Centre Hospitalier Universitaire de Nice [Nice, France] | Centre Antoine Lacassagne [Nice, France] | Hôpital Salpétrière [Paris, France]",2011.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of an existing medication (Liposomal Cytarabine, DepoCyte®) for a new indication (meningeal metastasis of breast cancer), indicating an extension of indication.",OTHER,False,2019.0,6.0,0,Phase 3
NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer,A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer,COMPLETED,PHASE1,Eli Lilly and Company,2012-07-31,2019-04-04,2022-02-02,2012-08-01,2022-04-08,['Recommended Phase 2 dose'],"['Pharmacokinetics: Maximum concentration (Cmax)', 'Pharmacokinetics: Time of maximal concentration', 'Number of participants with tumor response', 'Potential of LY3023414 to inhibit CYP3A4-mediated metabolism']",,,,,8,Italy; Puerto Rico; United States,"UCLA Medical Center [Los Angeles, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Peggy and Charles Stephenson Oklahoma Cancer Center [Oklahoma City, United States] | Penn Presbyterian Medical Center [Philadelphia, United States] | Sarah Cannon Cancer Center [Nashville, United States] | Tennessee Oncology PLLC [Nashville, United States] | Azienda Ospedaliero - Universitaria S. Luigi Gonzaga [Orbassano, Italy] | Fundacion de Investigacion de Diego [San Juan, Puerto Rico]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT01656538,A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer,COMPLETED,PHASE2,Canadian Cancer Trials Group,2013-02-20,2016-11-18,2018-02-14,2012-08-03,2023-08-04,['Progression free survival'],"['Response rate', 'Tumour and tissue response of potential molecular factors', 'Number of patients with adverse events']",,,,,7,Canada,"BCCA - Cancer Centre for the Southern Interior [Kelowna, Canada] | BCCA - Vancouver Cancer Centre [Vancouver, Canada] | BCCA - Vancouver Island Cancer Centre [Victoria, Canada] | Juravinski Cancer Centre at Hamilton Health Sciences [Hamilton, Canada] | Cancer Centre of Southeastern Ontario at Kingston [Kingston, Canada] | Ottawa Hospital Research Institute [Ottawa, Canada] | Allan Blair Cancer Centre [Regina, Canada]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the use of Reolysin in combination with standard therapy (Paclitaxel) for advanced/metastatic breast cancer, indicating an extension of indication for an existing treatment.",NETWORK,False,2018.0,7.0,0,Phase 2
NCT01660776,BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology,BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology,COMPLETED,,Rennes University Hospital,2012-06-07,2017-10-02,2019-10-02,2012-08-09,2019-11-06,"[""Description of one or several blood cell types producing soluble PD-L1 in DLBCL, metastatic breast cancer, Hodgkin's lymphoma and non-small cell lung cancer""]","['Analysis of PD-L1 membrane protein expression on circulating tumor cells by multiparameter flow cytometry and Veridex® in DLBCL and metastatic breast cancer, and bone marrow tumor cells by flow cytometry in DLBCL', ""Analysis of PD-L1 membrane protein expression on circulating endothelial cells with the Veridex® technology in DLBCL, Hodgkin's lymphoma and metastatic breast cancer (subpart ended in late 2012)"", 'Analysis of PD-L1 membrane protein expression on monocytes, B and T lymphocytes in all cohorts', 'Development of an ELISPOT technique to detect soluble PD-L1 in the supernatants of sorted primary cells (subpart ended mid 2013)', 'Evaluation of the techniques (by immunomagnetic or cell-sorting) used to separate circulating tumor cells expressing PD-L1', 'Correlation between the PD-L1 expression *) in the plasma, **) in the tumor and ***) in the bronchoalveolar liquid in non-small cell lung cancer', 'Evaluation of the response to treatment according to soluble PD-L1 expression in non-small cell lung cancer', 'Evaluation of the susceptibility to develop a disease according to PD-L1 gene SNP in DLBCL and non-small cell lung cancer']",,,,,4,France,"Rennes EFS [Rennes, France] | Rennes University Hospital [Rennes, France] | Institut Paoli Calmette [Marseille, France] | Montpellier University Hospital [Montpellier, France]",2012.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the assessment of PD-L1 as a biomarker in various cancers, indicating an extension of indication for existing treatments that target PD-L1, rather than introducing a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT01661153,An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer,A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer,COMPLETED,,Hoffmann-La Roche,2011-03-02,2016-09-14,2016-09-14,2012-08-09,2017-08-25,['Progression-free survival'],"['Dosage/schedule/number of cycles of Avastin treatment in clinical practice', 'Safety: Incidence of adverse events']",,,,,2,Croatia,"Uni Hospital Split; Oncology & Radiotherapy [Split, Croatia] | General Hospital Varazdin [Varaždin, Croatia]",2011.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study evaluates the use of Avastin (Bevacizumab) in combination with Paclitaxel for a specific patient population (HER2-Negative Metastatic Breast Cancer), indicating an extension of indication for an existing treatment.",INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT01676753,Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression,COMPLETED,PHASE1,Jo Chien,2016-12-28,2020-06-30,2022-02-28,2012-08-31,2022-09-21,"['Maximum tolerated dose (MTD)', 'Proportion of participants with reported dose-limiting toxicities (DLTs)']",['Overall Response Rate'],,,,,1,United States,"University of California, San Francisco [San Francisco, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Dinaciclib, which is a cyclin-dependent kinase inhibitor being tested in combination with Pembrolizumab for a specific indication (advanced breast cancer), indicating it is a new medicine.",OTHER,False,2022.0,3.0,0,Phase 1
NCT01701050,Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index,COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index,COMPLETED,,"Janssen Diagnostics, LLC",2013-04-01,2016-11-10,2016-11-10,2012-10-04,2017-03-08,['Rapid Disease Progression'],['Progression Free Survival (PFS)'],,,,,20,Canada; United States,"Arizona Oncology Associates [Phoenix, United States] | Florida Cancer Specialists [Fort Myers, United States] | Florida Cancer Specialists [St. Petersburg, United States] | Dana-Faber Cancer Institute [Boston, United States] | University of Michigan Comprehensive Cancer Center [Ann Arbor, United States] | Minnesota Oncology Hematology [Minneapolis, United States] | Mayo Clinic [Rochester, United States] | Nebraska Cancer Specialists [Omaha, United States] | Comprehensive Cancer Centers of Nevada [Henderson, United States] | New York Oncology Hematology [New York, United States] | Waverly Hematology Oncology [Cary, United States] | Duke University [Durham, United States] | Northwest Cancer Specialists [Portland, United States] | Abramson Cancer Center, University of Pennsylvania [Philadelphia, United States] | Thomas Jefferson University [Philadelphia, United States] | Tennessee Oncology, PLLC [Nashville, United States] | Texas Oncology - Baylor [Dallas, United States] | Texas Oncology [Houston, United States] | Mt. Sinai Hosp., Marvette Koffler Breast Center [Toronto, Canada] | Princess Margaret Hospital [Toronto, Canada]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on the characterization of circulating tumor cells in patients with metastatic breast cancer, which suggests an extension of indication for existing therapies rather than the development of a new medicine.",INDUSTRY,False,2016.0,9.0,1,NA/Other
NCT01703520,Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).,"Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden",COMPLETED,,Organon and Co,2011-05-01,2017-11-30,2017-11-30,2012-10-10,2024-05-10,"['Stage 1 - Person-Years of Exposure to Finasteride by Participant Age and Year', 'Stage 1 - Initial Incidence Rates of Male Breast Cancer Stratified by Exposure to Finasteride', 'Stage 1 - All-Cause Mortality Rates in Males with Breast Cancer by Exposure to Finasteride', 'Stage 2 - Odds (or Likelihood) of Exposure to Finasteride in Male Breast Cancer Cases Relative to Controls']",[],,,,,0,,,2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study investigates the relationship between Finasteride and male breast cancer, indicating an extension of the indication for an existing medication (Finasteride) rather than introducing a new medicine.",INDUSTRY,False,2017.0,8.0,0,NA/Other
NCT01703585,Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples,A Feasibility Study of Genomic Profiling Methods and Timing of Sample Collection to Evaluate Clonal Evolution and Tumor Heterogeneity,COMPLETED,,"University Health Network, Toronto",2012-10-04,2018-05-01,2018-05-01,2012-10-10,2018-05-09,['Patient recruitment for paired core and fine needle biopsy greater than or equal to 50% of those screened or approached.'],"['The rate of acceptable tumor samples from fresh core needle biopsy samples/total number of fresh core needle biopsy samples greater than or equal to 90%', 'The rate of acceptable tumor samples from fresh fine needle biopsy samples/total number of fresh fine needle biopsy samples greater than or equal to 50%', 'Successful analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 50%', 'Analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples from time from patient recruitment to final results, less than a defined period of time, in greater than or equal to 90%', 'Actionable genomic result analysis of fresh core needle biopsy samples and fresh fine needle biopsy samples greater than or equal to 30%']",,,,,1,Canada,"Princess Margaret Cancer Centre [Toronto, Canada]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study focused on genomic profiling methods and sample collection timing, without indicating the development of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2018.0,7.0,0,NA/Other
NCT01712815,PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer,Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer,TERMINATED,,University of Southern California,2013-11-22,2022-11-01,2022-11-01,2012-10-24,2023-08-14,"['Change of FMAU-PET score vs. change of Ki-67 from the baseline to post-chemotherapy', 'Incidence of adverse events']",[],,,,,1,United States,"USC Norris Comprehensive Cancer Center [Los Angeles, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the evaluation of a PET/CT imaging technique in the context of chemotherapy response in breast cancer, which suggests an extension of indication for existing imaging methods rather than introducing a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2012-11-05,2022-03-01,2022-03-01,2012-11-12,2022-03-07,"['Maximum Tolerated Dose', 'assessing toxicity by the number of adverse events']",['CNS progression-free survival'],,,,,6,United States,"Memoral Sloan Kettering Cancer Center [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Cancer Center @ Suffolk [Commack, United States] | Memorial Sloan Kettering Westchester [Harrison, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering Nassau [Uniondale, United States]",2012.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT01740336,A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer,"A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer",COMPLETED,PHASE2,"Genentech, Inc.",2013-02-06,2015-10-20,2015-12-10,2012-12-04,2017-04-24,['Progression-Free Survival (PFS) Assessed as per Modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)'],"['Percentage of Participants With Adverse Events', 'Percentage of Participants With Objective Tumor Response Assessed as per Modified RECIST v1.1', 'Percentage of Participants Acheiving Clinical Benefit (Partial Response, Complete Response or Stable Disease Lasting for at Least 6 Months) Assessed as per Modified RECIST v1.1', 'Duration of Confirmed Objective Response Assessed as per Modified RECIST v1.1', 'Population Pharmacokinetics (PK) for GDC-0941', 'Population PK for Paclitaxel']",,,,,97,Australia; Austria; Belgium; Czechia; South Korea; Spain; United Kingdom; United States,"Arizona Oncology Associates, PC - NAHOA [Sedona, United States] | Pacific Cancer Medical Center [Anaheim, United States] | California Cancer Associates for Research & Excellence, Inc. [Encinitas, United States] | Kaiser Permanente - Hayward [Hayward, United States] | Kaiser Permanente - Oakland [Oakland, United States] | Bay Area Cancer Research Group, LLC [Pleasant Hill, United States] | Kaiser Permanente Medical Center - Roseville [Roseville, United States] | Kaiser Permanente Sacramento Medical Center [Sacramento, United States] | Kaiser Permanente - San Francisco (2238 Geary) [San Francisco, United States] | University of California at San Francisco [San Francisco, United States] | Kaiser Permanente - San Jose [San Jose, United States] | Kaiser Permanente - Santa Clara [Santa Clara, United States] | Kaiser Permanente - South San Francisco [South San Francisco, United States] | Kaiser Permanente - Vallejo [Vallejo, United States] | Kaiser Permanente - Walnut Creek [Walnut Creek, United States] | Helen & Harry Gray Cancer Center-Hartford Hospital-CCD PRIME; Research [Hartford, United States] | Clinical Research of South Florida [Coral Gables, United States] | Cancer Specialists of North Florida [Orange Park, United States] | Hematology - Oncology Associates of Treasure Coast [Port Saint Lucie, United States] | Phoebe Putney Memorial Hospital [Albany, United States] | Joliet Oncology-Hematology; Associates, Ltd. [Joliet, United States] | Oncology Specialists, S.C. [Park Ridge, United States] | Illinois Cancer Care [Peoria, United States] | Cotton-O'Neil Clinical Research Center, Hematology and Oncology; Cotton O'Neil Cancer Center [Topeka, United States] | Hematology Oncology Clinic [Baton Rouge, United States] | Metairie Oncologist, LLC [Metairie, United States] | Maine Research Associates [Auburn, United States] | Dana Farber Cancer Institute [Boston, United States] | Beth Israel Deaconess Med Ctr [Brookline, United States] | Henry Ford Health System [Detroit, United States] | Billings Clinic Cancer Center-CCD PRIME [Billings, United States] | Nebraska Cancer Specialists; Oncology Hematology West, PC [Omaha, United States] | ProHEALTH Care Associates LLP [Lake Success, United States] | Summa Health System [Akron, United States] | Aultman Hospital; Aultman Hospital Cancer Center [Canton, United States] | TriHealth Oncology Institute [Cincinnati, United States] | Abington Memorial Hospital [Abington, United States] | Hematology and Oncology Associates of Sc [Greenville, United States] | Shivers Cancer Center at University Medical Center Brackenridge [Austin, United States] | Texas Oncology [Bedford, United States] | Texas Oncology, P.A. - El Paso; West [El Paso, United States] | Texas Oncology - Memorial City [Houston, United States] | Texas Oncology, P.A. ;Sherman Cancer Center [Sherman, United States] | Northern Utah Associates [Ogden, United States] | Shenandoah Oncology Associates [Winchester, United States] | Puget Sound Cancer Centers [Edmonds, United States] | Swedish Health Services [Seattle, United States] | Royal Prince Alfred Hospital [Camperdown, Australia] | Concord Repatriation General Hospital [Concord, Australia] | Port Macquarie Base Hospital;North Coast Cancer Institute [Port Macquarie, Australia] | Sydney Haematology & Oncology Clinic [Wahroonga, Australia] | Calvary Mater Newcastle; Medical Oncology [Waratah, Australia] | Border Medical Oncology [Wodonga, Australia] | Royal Brisbane and Women's Hospital [Herston, Australia] | Mater Adult Hospital [Mackay, Australia] | Ashford Cancer Center Research [Kurralta Park, Australia] | Royal Hobart Hospital [Hobart, Australia] | Bendigo Hospital; Oncology [Bendigo, Australia] | Peninsula and South Eastern Haematology and Oncology Grou [Frankston, Australia] | Royal Perth Hospital; Medical Oncology [Perth, Australia] | Lkh-Univ. Klinikum Graz [Graz, Austria] | LKH - Universitätsklinikum der PMU Salzburg [Salzburg, Austria] | Krankenhaus Hietzing m.Neurolog. Zentrum Rosenhuegel [Vienna, Austria] | Klinikum Wels-Grieskirchen [Wels, Austria] | Institut Jules Bordet [Brussels, Belgium] | UZ Antwerpen [Edegem, Belgium] | UZ Leuven Gasthuisberg [Leuven, Belgium] | CHU Ambroise Paré [Mons, Belgium] | Clinique Ste-Elisabeth [Namur, Belgium] | Sint Augustinus Wilrijk [Wilrijk, Belgium] | Fakultni nemocnice Brno [Brno, Czechia] | Masarykuv onkologicky ustav [Brno, Czechia] | Krajska nemocnice Liberec a.s. [Liberec, Czechia] | Multiscan s.r.o. [Pardubice, Czechia] | Vseobecna fakultni nemocnice v Praze [Prague, Czechia] | Nemocnice Na Bulovce [Prague, Czechia] | Thomayerova nemocnice [Praha 4 - Krc, Czechia] | Chungbuk National University Hospital [Cheongju-si, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Institut Catala d´Oncologia Hospital Germans Trias i Pujol [Badalona, Spain] | Institut Catala d Oncologia Hospital Duran i Reynals [Barcelona, Spain] | Complejo Hospitalario de Jaen [Jaén, Spain] | Hospital General Univ. Gregorio Maranon [Madrid, Spain] | START Madrid. Centro Integral Oncologico Clara Campal; CIOCC [Madrid, Spain] | Royal Sussex County Hospital [Brighton, United Kingdom] | Royal Surrey County Hospital [Guildford, United Kingdom] | Leicester Royal Infirmary [Leicester, United Kingdom] | Barts Hospital [London, United Kingdom] | The Christie [Manchester, United Kingdom] | Freeman Hospital [Newcastle upon Tyne, United Kingdom] | Nottingham University Hospitals City Campus [Nottingham, United Kingdom] | Royal Stoke University Hospital [Stoke-on-Trent, United Kingdom] | Royal Cornwall Hospital [Truro, United Kingdom] | New Cross Hospital [Wolverhampton, United Kingdom]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves GDC-0941, which is being tested in combination with Paclitaxel for a specific cancer indication, indicating it is a new medicine being evaluated.",INDUSTRY,False,2015.0,10.0,1,Phase 2
NCT01753908,Broccoli Sprout Extract in Treating Patients With Breast Cancer,A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer,COMPLETED,EARLY_PHASE1,Roswell Park Cancer Institute,2013-05-21,2018-07-23,2018-08-23,2012-12-20,2019-10-31,"['Changes in apoptosis (cleaved caspase 3)', 'Changes in cell proliferation (Ki-67)', 'Changes in estrogen receptor expression (ER alpha and ER beta)', 'Changes in NQO1 expression']",[],,,,,1,United States,"Roswell Park Cancer Institute [Buffalo, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study is investigating the effects of Broccoli Sprout Extract on patients with breast cancer, which suggests an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,Phase 1
NCT01755130,Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer,Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care,TERMINATED,,M.D. Anderson Cancer Center,2014-05-13,2021-06-02,2021-06-02,2012-12-24,2021-06-29,"['Number of images successfully obtained from laser optoacoustic and ultrasonic imaging system assembly (LOUISA) 3-dimensional (3D)', 'False positive rate of LOUISA 3D and standard of care ultrasound']",[],,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a diagnostic imaging system and its application in breast cancer care, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT01777958,HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy,"Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)",COMPLETED,,Hoffmann-La Roche,2013-06-14,2020-11-25,2020-11-25,2013-01-29,2020-12-14,['Median progression-free survival in routine clinical practice'],"['Dosage/schedule: Initiation/duration/modification/discontinuation of Perjeta administration', 'Clinical/demographic patients characteristics at initiation of treatment', 'Safety: Incidence of adverse events', 'Patient reported outcome: Quality of life (FACT B questionnaire)']",,,,,1,Germany,"AGAPLESION Markus-Krankenhaus [Frankfurt, Germany]",2013.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT01783756,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis","Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab",COMPLETED,PHASE1; PHASE2,Jonsson Comprehensive Cancer Center,2013-06-26,2019-05-10,2019-05-10,2013-02-05,2019-11-12,"['CNS objective response rate defined as either a complete response or partial response provided there is no progression of extra-CNS disease, increasing steroid requirements, or worsening of NSS measured using RECIST v1.1']","['Body system, severity and relation with study treatment of adverse events graded according to the National Institute of Health (NIH)/ National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v4.0', 'Progression-free survival (PFS) by the RECIST v1.1', 'Overall survival (OS)', 'Extra CNS response according to RECIST1.1']",,,,,1,United States,"Jonsson Comprehensive Cancer Center [Los Angeles, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT01793948,Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer,COMPLETED,EARLY_PHASE1,Anna Maria Storniolo,2013-04-16,2018-01-09,2018-01-09,2013-02-18,2018-03-30,['Changes in the phosphorylation of proteins after metformin exposure'],"['Changes in ordinal level of breast density', 'Proportion of patients experiencing adverse events assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0']",,,,,1,United States,"Indiana University Melvin and Bren Simon Cancer Center [Indianapolis, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the effects of Metformin, which is an existing medication, in a new patient population (overweight or obese post-menopausal women at elevated risk for breast cancer), indicating an extension of its indication.",OTHER,False,2018.0,7.0,0,Phase 1
NCT01795586,A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients,A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer,COMPLETED,PHASE1,H. Lee Moffitt Cancer Center and Research Institute,2013-02-06,2015-02-24,2022-05-11,2013-02-20,2022-10-31,['Maximum Tolerated Dose (MTD)'],['Response Rate (RR)'],,,,,1,United States,"H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT01815476,The Prone Breast Radiation Therapy Trial,A Multicentre Randomized Controlled Clinical Trial for the Reduction of Acute Skin Reaction in Adjuvant Breast Radiation in Large Breasted Women Using a Prone Technique - The Prone Breast Trial,COMPLETED,,Toronto Sunnybrook Regional Cancer Centre,2013-05-04,2018-04,2019-06,2013-03-21,2019-09-11,['Moist Desquamation'],"['Breast Pain', 'Radiation exposure of adjacent normal organs at risk']",,,,,2,Canada,"British Columbia Cancer Agency - Vancouver Island centre [Victoria, Canada] | Sunnybrook Odette Cancer Centre [Toronto, Canada]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT01835236,Trastuzumab & Pertuzumab Followed by T-DM1 in MBC,"A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer",COMPLETED,PHASE2,Swiss Cancer Institute,2013-03-03,2018-01-11,2020-05-26,2013-04-18,2021-03-30,['Overall survival (OS) - Analysis Population: ITT Population 1'],"['OS - Analysis Population: ITT Population 2', 'Progression Free Survival (PFS) of first-line treatment ignoring first Central Nervous System (CNS) lesion', 'PFS of second-line treatment', 'PFS of second-line treatment ignoring first CNS lesion', 'Time to failure of strategy (TFS) of first- plus second-line treatment', 'Overall survival OS', 'Objective response (OR) of first-line treatment (based on investigator assessment)', 'Disease control (DC) of first-line treatment (based on investigator assessment)', 'OR of second-line treatment (based on investigator assessment)', 'DC of second-line treatment (based on investigator assessment)', 'Adverse events (AEs) according to the NCI CTCAE v4.0 of first-line treatment', 'AEs according to the NCI CTCAE v4.0 of second-line treatment', 'AEs grade ≥2 until first progression (ignoring first CNS lesion)', 'Quality of Life (QoL)', 'PFS of third-line treatment']",,,,,71,France; Germany; Netherlands; Switzerland,"Hopital Sud - Amiens [Amiens, France] | ICO - Paul Papin [Angers, France] | Institut Sainte Catherine [Avignon, France] | Centre Hospitalier de Blois [Blois, France] | Institut Bergonie [Bordeaux, France] | Hôpital Morvan (Brest) [Brest, France] | Centre Francois Baclesse [Caen, France] | Centre Hospitalier Alpes Leman [Contamine-sur-Arve, France] | Centre Georges François Leclerc [Dijon, France] | Centre Hospitalier de Dracenie [Draguignan, France] | Hopital Michallon - Centre Hospitalier Universitaire de Grenoble [Grenoble, France] | Clinique Hartmann [Levallois-Perret, France] | Centre Oscar Lambret [Lille, France] | Chu de Limoges - Hopital Dupuytren [Limoges, France] | Centre Hospitalier - Site Hopital du Scorff [Lorient, France] | Clinique de la Sauvegarde [Lyon, France] | Fondation Hopital Ambroise Pare - Hopital Europeen [Marseille, France] | Istitut Paoli Calmettes [Marseille, France] | Institut Regional du Cancer Montpellier Val d'Aurelle [Montpellier, France] | Centre Azureen de Cancerologie [Mougins, France] | Polyclinique de Gentilly [Nancy, France] | Centre Catherine de Sienne [Nantes, France] | Centre Antoine Lacassagne [Nice, France] | Hopital Saint Louis [Paris, France] | Centre Hospitalier de Pau [Pau, France] | Centre Hospitalier de Perpignan - Hopital Saint Jean [Perpignan, France] | Institut Jean Godinot [Reims, France] | Clinique Mathilde [Rouen, France] | Centre Henri Becquerel [Rouen, France] | Curie Site Saint-Cloud [Saint-Cloud, France] | ICO - Rene Gauducheau [Saint-Herblain, France] | Institut de Cancerologie de la Loire [Saint-Priest-en-Jarez, France] | Hopitaux Universitaire de Strasbourg - Hopital Civil [Strasbourg, France] | Hopitaux du Leman - Site Georges Pianta [Thonon-les-Bains, France] | Institut Claudius Regaud [Toulouse, France] | Centre Hospitalier de Valence [Valence, France] | Universitäts-Frauenklinik Ulm [Ulm, Germany] | Almelo_Ziekenhuisgroep Twente [Almelo, Netherlands] | VUmc University Medical Center [Amsterdam, Netherlands] | Antoni van Leeuwenhoek / Slotervaart hospital [Amsterdam, Netherlands] | Reinier de Graaf Gasthuis [Delft, Netherlands] | Deventer Ziekenhuis [Deventer, Netherlands] | Catharina Ziekenhuis [Eindhoven, Netherlands] | Medisch Centrum Leeuwarden [Leeuwarden, Netherlands] | Leiden_Leids Universitair Medisch Centrum (LUMC) [Leiden, Netherlands] | St. Antonius Ziekenhuis, Ioc Nieuwegein [Nieuwegein, Netherlands] | St. Franciscus Gasthuis Rotterdam [Rotterdam, Netherlands] | Vlietland Ziekenhuis [Schiedam, Netherlands] | Orbis Medisch Centrum [Sittard, Netherlands] | Haga Ziekenhuis [The Hague, Netherlands] | Hirslanden Klinik Aarau [Aarau, Switzerland] | Kantonspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli [Bellinzona, Switzerland] | Inselspital, Bern [Bern, Switzerland] | RSV-GNW Spitalzentrum Oberwallis [Brig, Switzerland] | Spitalzentrum Oberwallis [Brig, Switzerland] | Kantonsspital Graubuenden [Chur, Switzerland] | Kantonsspital Frauenfeld / Brustzentrum Thurgau [Frauenfeld, Switzerland] | Hopitaux Universitaires de Geneve [Geneva, Switzerland] | Centre Hospitalier Universitaire Vaudois CHUV [Lausanne, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Kantonsspital Liestal [Liestal, Switzerland] | Kantonsspital Luzern [Luzerne, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Kantonsspital St. Gallen [Sankt Gallen, Switzerland] | Zentrum fuer Tumordiagnostik und Praevention [Sankt Gallen, Switzerland] | SpitalSTS AG Simmental-Thun-Saanenland [Thun, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland] | Universitäts Spital Zürich [Zurich, Switzerland]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial involves the use of Pertuzumab and Trastuzumab in combination for HER2-positive metastatic breast cancer, which suggests an extension of indication for these existing drugs rather than the introduction of a new medicine.",OTHER,False,2020.0,5.0,1,Phase 2
NCT01846091,Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer,Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2013-04-09,2019-09-18,2019-11-26,2013-05-03,2023-02-14,"['MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) as assessed by the National Cancer (NCI) CTCAE v. 4.0', 'Number of toxicity incidents defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment']","['Number of responses using Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1', 'Time to tumor progression']",,,,,1,United States,"Mayo Clinic [Rochester, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[""Overall Survival"",""Time to Progression""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT01853306,"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors","A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors",COMPLETED,PHASE1,AbbVie,2013-03-18,2017-05-03,2017-06-29,2013-05-15,2017-11-21,"['Part 2 - Dose Escalation Cohort: Pharmacokinetic testing', 'Part 1 - Pharmacokinetic profile', 'Part 3 - Safety Expanded Cohort: Number of subjects with adverse events', 'Part 3 - Safety Expanded Cohort: Vital signs', 'Part 3 - Safety Expanded Cohort: Laboratory tests']",['The number of participants with adverse events who receive the extended release formulations of veliparib.'],,,,,0,,,2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT01857193,Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer,"A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2013-09-06,2018-03-14,2020-04-16,2013-05-20,2021-04-13,"['Dose Escalation: Incidence of Dose Limiting Toxicity (DLT)', 'Dose Expansion: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)']","['Dose Escalation: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'Dose Escalation and Expansion: Overall Response Rate (ORR)', 'Dose Escalation and Expansion: Disease Control Rate (DCR)', 'Dose Escalation and Expansion: Clinical Benefit Rate (CBR)', 'Dose Expansion: Duration of Response (DOR)', 'Dose Expansion: Progression Free Survival (PFS)', 'Dose Escalation: Pharmacokinetics (PK) parameter: AUC0-24h at Day 1 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: AUC0-24h at at Day 15 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: Cmax at Day 1 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: Cmax at Day 15 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: Tmax at Day 1 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: Tmax at Day 15 of Cycle 1', 'Dose Escalation: Pharmacokinetics (PK) parameter: Racc at Day 15 of Cycle 1']",,,,,13,Belgium; France; Hong Kong; Spain; United States,"Highlands Oncology Group [Fayetteville, United States] | Sylvester Comprehensive Cancer Center Main Center [Miami, United States] | Massachusetts General Hospital Onc Dept [Boston, United States] | Karmanos Cancer Institute Dept of Onc [Detroit, United States] | Memorial Sloan Kettering Oncology Dept. [New York, United States] | Oregon Health and Science University SC-5 [Portland, United States] | University of Texas MD Anderson Cancer Center Onc Dept [Houston, United States] | Northwest Medical Specialties [Tacoma, United States] | Novartis Investigative Site [Wilrijk, Belgium] | Novartis Investigative Site [Saint-Herblain, France] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01861509,BP-C1 in Metastatic Breast Cancer Patients,"Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer. A Phase ID Study",COMPLETED,PHASE1,Meabco A/S,2014-01-19,2016-01-20,2016-01-20,2013-05-23,2019-10-07,"['Single-dose PK: Maximum Observed Serum Concentration (Cmax) for Platinum', 'Single-dose PK: Time to Reach Maximum Observed Serum Concentration (Tmax) for Platinum', 'Single-dose PK: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC(0-t)) for Platinum', 'Single-dose PK: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC(0-∞))', 'Single-dose PK: Serum Decay Half-Life (T1/2) for Platinum', 'Multiple-dose PK: Maximum Observed Serum Concentration at Steady State (Css,max) for Platinum', 'Multiple-dose PK: Time to Reach Maximum Observed Serum Concentration at steady state (Tss,max) for Platinum', 'Multiple-dose PK: Minimum Observed Serum Concentration at Steady State (Css,min) for Platinum', 'Multiple-dose PK: Average Serum concentration at steady state (Css,av) for Platinum', 'Multiple-dose PK: Area Under the Curve within a dosing interval of tau (=24 hr) at steady state (AUCss,tau) for Platinum', 'Multiple-dose PK: Serum Decay Half-Life (T1/2) for Platinum']","['Interleukin Serum levels (Interferon γ and β, Tumour Necrosis Factor (TNF-α), IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-21 and IL-25)', 'Change (%) in the sum of diameters of target lesions', 'Number of target lesions', 'Treatment response']",,,,,2,Israel; Thailand,"Oncology Unit. Sheba Medical Centre [Ramat Gan, Israel] | Lampang Cancer Center [Lampang, Thailand]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text describes a study of BP-C1 in metastatic breast cancer patients, indicating that BP-C1 is being tested as a new treatment for this condition, which classifies it as a New Medicine.",INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT01862081,"A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer",,COMPLETED,PHASE1,"Genentech, Inc.",2013-07-16,2017-06-09,2017-06-09,2013-05-24,2017-11-28,"['Safety: Incidence of adverse events', 'Safety: Incidence of dose limiting toxicities']","['Area under the curve from time 0 to the last measurable concentration (AUC0-last)', 'Time to maximum observed plasma concentration (Tmax)', 'Maximum observed plasma concentration (Cmax)', 'Minimum observed plasma concentration (Cmin)', 'Objective response according to RECIST v1.1', 'Duration of response according to RECIST v1.1', 'Progression-free survival (PFS) according to RECIST v1.1']",,,,,14,Belgium; Canada; Spain; United States,"Florida Cancer Specialists - Tampa (Dr. MLK Blvd) [Tampa, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Barbara Ann Karmanos Cancer Institute [Detroit, United States] | Sarah Cannon Research Institute [Nashville, United States] | Vanderbilt University Medical Center [Nashville, United States] | Texas Oncology, P.A; Baylor Sammons Cancer Center [Dallas, United States] | Texas Oncology, P.A. - Fort Worth [Fort Worth, United States] | Virginia Oncology Associates [Norfolk, United States] | Yakima Valley Memorial Hospital/North Star Lodge [Yakima, United States] | UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy [Leuven, Belgium] | Princess Margaret Hospital [Toronto, Canada] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain]",2013.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves GDC-0032, which is being assessed for safety and pharmacokinetics in combination with other treatments for specific types of cancer, indicating it is a new medicine.",INDUSTRY,False,2017.0,8.0,1,Phase 1
NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.,COMPLETED,PHASE1,Providence Health & Services,2012-04-27,2016-05-17,2018-08-15,2013-05-27,2019-03-21,['Determine the maximum tolerated dose and safety profile of radiation administered in combination with anti-OX40 in patients with metastatic breast cancer.'],['Estimate the response rate of combined modality treatment in both irradiated and non-irradiated tumors.'],,,,,1,United States,"Portland Providence Medical Center [Portland, United States]",2012.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT01875666,"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",COMPLETED,EARLY_PHASE1,UNC Lineberger Comprehensive Cancer Center,2013-08-05,2016-12-19,2016-12-19,2013-06-12,2020-09-04,['difference in kinome activation pre and post treatment'],['predictability in kinome activation'],,,,,5,United States,"University of Alabama at Birmingham [Birmingham, United States] | IU Simon Cancer Center [Indianapolis, United States] | Dana Farber Cancer Institute [Boston, United States] | Lineberger Comprehensive Cancer Center, UNC [Chapel Hill, United States] | MD Anderson [Houston, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text discusses the response of HER2 positive breast cancer to existing treatments (Trastuzumab, Pertuzumab, and Lapatinib), indicating an investigation into the effectiveness of these established drugs rather than testing a new medicine.",OTHER,False,2016.0,9.0,0,Phase 1
NCT01878695,Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer,Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer,COMPLETED,PHASE1,Sidney Kimmel Cancer Center at Thomas Jefferson University,2012-07-26,2015-05-14,2015-05-14,2013-06-17,2025-05-02,['Efficacy'],"['Safety', '2. To access the changes in HIF-1 alpha and p65 subunit of NFB in tumor stroma in pre and post therapy breast tissue treated with NAC', 'To evaluate potential effects of NAC on quality of life and fatigue']",,,,,1,United States,"Jefferson Myrna Brind Center for Integrative Medicine [Philadelphia, United States]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the effects of N-Acetyl Cysteine (NAC), which is already an established treatment, in a new context (stage 0/I breast cancer), indicating an extension of its indication.",OTHER,False,2015.0,10.0,0,Phase 1
NCT01881880,Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging,Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging,TERMINATED,,"University Hospital, Montpellier",2012-11-19,2015-08,2015-12,2013-06-20,2024-05-29,"['diagnostic performance of preoperative bilateral Combo mode (MG+Tomosynthesis) versus mammography among women with breast cancer for the detection of additional multifocal, multicentric, and contralateral cancers.']","['performance of MG vs Combo (MG+Tomosynthesis) for the diagnosis of multicentricity', 'performance of MG vs Combo (MG+Tomosynthesis) for the diagnosis of multifocality']",,,,,6,France,"Private Hospital oh Antony [Antony, France] | UH Grenoble [Grenoble, France] | Oscar Lambret Center [Lille, France] | Jean Mermoz Hospital [Lyon, France] | UH Montpellier [Montpellier, France] | Hospital Valenciennes [Valenciennes, France]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the diagnostic performance of a combination of existing imaging modalities (mammography and tomosynthesis) for breast cancer detection, indicating an extension of indication rather than a new medicine.",OTHER,False,2015.0,10.0,0,NA/Other
NCT01884285,AZD8186 First Time In Patient Ascending Dose Study,"A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014",COMPLETED,PHASE1,AstraZeneca,2013-07-09,2019-03-31,2020-02-07,2013-06-24,2020-05-29,['Safety and tolerability'],"['Part A: The number of evaluable patients with dose limiting toxicities (DLTs).', 'Part A, B, C + D: Antitumor activity of AZD8186 monotherapy or in combination', 'Part A, B, C and D: Anti-tumour activity of AZD8186 monotherapy or in combination', 'Part A + B: Plasma concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean resistance time)', 'Part A + B: 4 beta-hydroxy cholesterol concentration in blood samples.', 'Part B: Obtaining a preliminary assessment of the antitumour activity of AZD8186 as monotherapy', 'Part B: Obtaining a preliminary assessment of AZD8186 drug effect in the tumour', 'Part A: Urine concentrations of AZD8186 and pharmacokinetic parameters (Cmax, tmax, AUC, terminal rate constant, clearance, half life, volume of distribution and mean residence time)', 'Part C: safety and tolerability assessed by dose limiting toxicity of AZD8186 with abiraterone acetate (and prednisone)', 'Part C: pharmacokinetics of and exposure to AZD8186, its major metabolite M1, and abiraterone', 'Part C: steady state exposure to abiraterone', 'Part C: steady state exposure of AZD8186 in combination with abiraterone acetate', 'Part D: Measure the dose limiting toxicity of AZD8186 in combination with AZD2014.', 'Part D: Single dose and multiple dose pharmacokinetics of and assess exposure to AZD8186, its major metabolite M1, and AZD2014 when co-administered', 'Part D: Measure the exposure to AZD2014 following the last weekly dose of AZD2014 in the absence and presence of multiple dose AZD8186.', 'Part D: Measure the exposure on the 4th administred dose of AZD8186 in the absence and presence of multiple dose AZD2014']",,,,,13,Canada; Spain; United Kingdom; United States,"Research Site [Boston, United States] | Research Site [Detroit, United States] | Research Site [New York, United States] | Research Site [Seattle, United States] | Research Site [Madison, United States] | Research Site [Toronto, Canada] | Research Site [Barcelona, Spain] | Research Site [Barcelona, Spain] | Research Site [Pozuelo de Alarcón, Spain] | Research Site [Cambridge, United Kingdom] | Research Site [London, United Kingdom] | Research Site [Manchester, United Kingdom] | Research Site [Sutton, United Kingdom]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01891227,Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer,"Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial",COMPLETED,PHASE2,Arbeitsgemeinschaft medikamentoese Tumortherapie,2013-08-09,2018-03-15,2018-03-15,2013-07-03,2018-11-07,['Efficacy of capecitabine + bendamustine combination regimen'],"['Safety profile of a combination with capecitabine and bendamustine', 'Clinical benefit', 'Progression free survival', 'Overall survival', 'Quality of life', 'Predefined subgroup analysis in terms of response']",,,,,8,Austria,"Hämatologie und Onkologie/Interne E, LKH Feldkirch [Feldkirch, Austria] | Universitätsklinik f. Frauenheilkunde und Geburtshilfe, Klin. Abt. f. Gynäkologie [Graz, Austria] | Universitätsklinik f. Innere Medizin, Klin.Abt. f. Onkologie [Graz, Austria] | Univ.-Klinik f. Frauenheilkunde; Klinische Abt. f. Gynäkologie u. Geburtshilfe [Innsbruck, Austria] | KH Barmh. Schwestern Linz, Innere Medizin I Hämatologie/Onkologie [Linz, Austria] | Kepler Universitätsklinikum, Med Campus III, Klinik f. Interne 3 - Schwerpunkt Hämatologie u. Onkologie [Linz, Austria] | Universitätsklinik für Innere Medizin III [Salzburg, Austria] | Landeskrankenhaus Steyr, Interne Medizin II [Steyr, Austria]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the combination of capecitabine and bendamustine in a specific patient population (women with pretreated locally advanced or metastatic Her2-negative breast cancer), indicating an extension of indication for existing drugs rather than testing a new medicine.",OTHER,False,2018.0,7.0,0,Phase 2
NCT01918254,A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein,"Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein",COMPLETED,PHASE1,Hoffmann-La Roche,2013-08-06,2016-10-07,2016-10-07,2013-08-07,2017-09-12,"['Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'Percentage of Participants With Adverse Events', 'Percentage of Participants With Anti-Human Antibodies (HAHAs) to lumretuzumab [RO5479599]', 'Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Maximum Serum Concentration (Cmax) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Trough Serum Concentration (Ct) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Time to Reach Maximum Serum Concentration (tmax) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Clearance (CL) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Volume of distribution (V) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Accumulation Ratio of lumretuzumab [RO5479599]', 'Pharmacokinetics: Elimination Half-Life (t1/2) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Serum Concentration at the Time of Tumor Progression (Cprog) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Serum Concentration at the Time of Tumor Response (Complete response [CR]/Partial Response [PR]) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Serum Concentration at the Time of DLT of lumretuzumab [RO5479599]', 'Pharmacokinetics: Serum Concentration at the Time of Tumor and Skin Biopsy (Cb) of lumretuzumab [RO5479599]', 'Pharmacokinetics: Serum Concentration at the Time of Infusion-Related Reactions (IRR) of lumretuzumab [RO5479599]', 'Recommended Phase II Dose of lumretuzumab [RO5479599]']","['Percentage of Participants With Best Overall Response of CR or PR (Objective Response) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1) Criteria', 'Percentage of Participants With Best Overall Response of CR or PR or SD (Disease Control), Assessed Using RECIST V1.1 Criteria', 'Duration of Response, Assessed Using RECIST V1.1 Criteria', 'Progression-Free Survival Assessed Using RECIST V1.1 Criteria', 'Overall Survival']",,,,,13,Denmark; France; Germany; Spain,"Rigshospitalet, Onkologisk Klinik [København Ø, Denmark] | Centre Francois Baclesse; Comite Sein [Caen, France] | Institut régional du Cancer Montpellier [Montpellier, France] | Institut Curie; Oncologie Medicale [Paris, France] | Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O) [Toulouse, France] | Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung) [Essen, Germany] | University of Hannover; Medical School [Hanover, Germany] | Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg [Heidelberg, Germany] | Hospital del Mar; Servicio de Oncologia [Barcelona, Spain] | Hospital Univ Vall d'Hebron; Servicio de Oncologia [Barcelona, Spain] | Hospital Universitario 12 de Octubre; Servicio de Oncologia [Madrid, Spain] | Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica [Madrid, Spain] | Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia [Valencia, Spain]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT01939847,IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,IMAGE Study: Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins,COMPLETED,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2013-09-19,2015-05-14,2017-02-01,2013-09-11,2019-02-28,"['Time to report molecular profiling in tissue', 'Time to report molecular profiling in blood']","['Ability to make treatment suggestions', 'Decisions about Molecular Profiling Tumor Board (MPTB) suggestion', 'Progression-free survival', 'Changes in plasma tumor DNA (ptDNA)', 'Similarities and differences of the profiling results with the different assays in tissue']",,,,,1,United States,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins [Baltimore, United States]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2017.0,8.0,0,NA/Other
NCT01941784,Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy,Taking Health Realization Into Valued Eating and Exercise (THRIVE): A Feasibility Study of an Intervention to Prevent Weight Gain for Breast Cancer Survivors During Chemotherapy,COMPLETED,,Wake Forest University Health Sciences,2013-11-25,2017-03-01,2017-04-12,2013-09-13,2019-01-25,"['Feasibility of conducting the weight gain prevention intervention, measured as the percent of screened participants that are eligible and agree to participate']","['Effect of the intervention on body composition', 'Effect of the intervention on self-efficacy', 'Effect of the intervention on perceived stress', 'Effect of the intervention on fatigue', 'Effect of the intervention on 6 minute walk distance', 'Effect of the intervention on fruit, vegetable, and fat intake', 'Effect of the intervention on physical activity participation', 'Effect of the intervention on health-related quality of life', 'Sample size for future larger trials']",,,,,1,United States,"Comprehensive Cancer Center of Wake Forest University [Winston-Salem, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a feasibility study of a health education intervention aimed at preventing weight gain in breast cancer patients undergoing chemotherapy. It does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2017.0,8.0,0,NA/Other
NCT01950182,Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer,"A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype",COMPLETED,PHASE3,Sun Yat-sen University,2013-09-16,2020-05-31,2020-05-31,2013-09-25,2020-07-15,['progression-free survival (PFS)'],[],,,,,1,China,"Sun Yat-sen University Cancer Center [Guangzhou, China]",2013.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of Trastuzumab, which is an existing medication, in combination with chemotherapy or endocrine therapy for a specific subtype of breast cancer, indicating an extension of its indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,Phase 3
NCT01957514,"Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy",Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer,TERMINATED,,University of Washington,2013-10-28,2018-06-30,2018-06-30,2013-10-08,2021-09-30,"['Incidence of adverse events resulting from performing multiple biopsies measured by the presence of biopsy-related complications, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03', 'Infrastructure for acquiring, storing, retrieving and analyzing panomic data from clinical tumor specimens in a clinically relevant timeframe from participating sites']","['Change in subject perceptions regarding panomic data and its application to cancer treatment assessed by Intensive Trial of OMics in Cancer baseline and follow up questionnaires', 'Develop process improvements', 'Development and improvement of infrastructure for storing and working with data from subject biopsies', 'Methods required to analyze and integrate data across subjects and with data from the public domain', 'Molecular changes associated with treatment response or resistance', 'Number or frequencies of biopsies or leukapheresis runs', 'Removal of any unnecessary biopsies or generation of redundant data']",,,,,2,United States,"Fred Hutch/University of Washington Cancer Consortium [Seattle, United States] | Northwest Medical Specialties PLLC [Tacoma, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text focuses on collecting and analyzing samples from patients with metastatic, triple-negative breast cancer receiving existing anti-cancer therapy. It does not indicate the testing of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT01959386,A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer,Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin),COMPLETED,,Hoffmann-La Roche,2013-11-07,2019-01-31,2019-01-31,2013-10-10,2020-03-03,"['Percentage of Participants With Pathologic Complete Response (pCR) (For Participants Treated in Neo-Adjuvant Setting), According to Response Evaluation Criteria in Solid Tumor (RECIST), or Modified RECIST, or Cheson Criteria (As per Center Practice)', 'Percentage of Participants Who Were Alive and Disease Free at Year 2 (For Participants Treated in the Adjuvant Setting), According to RECIST, or Modified RECIST, or Cheson Criteria (As per Center Practice)']","['Percentage of Participants with Adverse Events', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Scores', 'European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Questionnaire Score', 'Mean Trastuzumab Dose', 'Duration of Trastuzumab Treatment', 'Percentage of Participants By Reason for Trastuzumab Discontinuation or Interruption', 'Percentage of Participants Who Received Concomitant Treatment (Chemotherapy or Any Other Treatment)']",,,,,1,Germany,"Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde [Mainz, Germany]",2013.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Pathologic Complete Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT01971515,First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,"A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies",COMPLETED,PHASE1,EMD Serono,2013-12-13,2018-08-09,2018-08-09,2013-10-29,2018-09-19,"['Number of dose limiting toxicities (DLTs) in Dose Escalation and Trastuzumab or Tamoxifen combination arms', 'Number of subjects with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and deaths in cohort for subjects with PAM pathway alterations']","['Observed Maximum Plasma Concentration (Cmax)', 'Time To Reach Maximum Plasma Concentration (Tmax)', 'Area Under Plasma Concentration Versus Time Curve From Time Zero to Last Sampling Time (AUC0-t)', 'Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf)', 'Area Under Plasma Concentration Versus Time Curve Within One Dosing Interval (AUCtau)', 'Apparent Terminal Half-life ( t1/2)', 'Apparent Oral Clearance (CL/F)', 'Apparent Oral Clearance Steady State (CLss/F)', 'Apparent Volume of Distribution (Vz/F)', 'Apparent Volume of Distribution at Steady State (Vss/F)', 'Factor to Assess the Increase of Drug Concentration in Plasma Until Steady State is Reached [Racc(AUC)]', 'Factor to Assess the Maximal Increase of Drug Concentration in Plasma [Racc (Cmax)]', 'Number of subjects with best overall response according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) or Cheson 2007', 'Percentage of subjects with clinical benefit', 'Disease control rate (DCR) for Cohort 2 only', 'Progression-free survival (PFS) rate for Cohorts 2 and 3 only']",,,,,15,United States,"University of Alabama at Birmingham [Birmingham, United States] | Cedars Sinai Medical Center [Los Angeles, United States] | University of California at San Diego, Moores Cancer Center [San Diego, United States] | Sylvester Comprehensive Cancer Center [Miami, United States] | Metairie Oncology [Metairie, United States] | Massachusetts General Hospital [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Henry Ford Hospital [Detroit, United States] | Washington University School of Medicine [St Louis, United States] | Mount Sinai [New York, United States] | Medical University of South Carolina [Charleston, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States] | University of Texas Health Science Center at San Antonio [San Antonio, United States] | Fletcher Allen Health Care, Inc. [Burlington, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT01975142,Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.,Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.,COMPLETED,PHASE2,Institut Curie,2013-11-07,2018-02-13,2019-01-21,2013-11-04,2019-03-21,['Tumor response rate to T-DM1 in patients with HER2 amplified circulating tumor cells'],"['Detection rate of HER2 amplified circulating tumor cells, heterogeneity rate between circulating tumor cells and correlations with patient characteristics', 'Technical failure rate and reproducibility of HER2 FISH on circulating tumor cells', 'Correlation between HER2 FISH and immunofluorescence on circulating tumor cells', 'Progression-free survival', 'Disease control rate (responses and stable diseases)', 'Correlation between treatment efficacy and HER2 FISH results (level of amplification, absolute number and percentage of amplified cells)', 'Changes in CTC numbers during treatment', 'Circulating tumor DNA before and during treatment', 'Treatment toxicity']",,,,,10,France,"Clinique Victor Hugo [Le Mans, France] | Institut de Cancérologie HARTMANN [Levallois-Perret, France] | Centre Oscar Lambret [Lille, France] | Chu de Limoges [Limoges, France] | Centre Val d'Aurelle - P. Lamarque [Montpellier, France] | Institut Curie [Paris, France] | Chu Saint-Louis [Paris, France] | Institut Curie - Hôpital René HUGENIN [Saint-Cloud, France] | Centre Catherine de Sienne [Vandœuvre-lès-Nancy, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2013.0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,"[""Overall Response"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT01975558,The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study,The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study,COMPLETED,,"Insel Gruppe AG, University Hospital Bern",2014-06-26,2019-11-12,2019-11-12,2013-11-04,2020-03-02,['Change from baseline in radiation metabolites'],['New potential biomarkers for radiation biodosimetry'],,,,,1,Switzerland,"Department of Radio-Oncology, Bern University Hospital [Bern, Switzerland]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a pilot study on radiation metabolites and potential biomarkers for radiation biodosimetry, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT01976169,Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer,COMPLETED,PHASE1,University of Texas Southwestern Medical Center,2014-01-24,2021-05-19,2021-05-19,2013-11-05,2022-02-08,"['Maximum Tolerated Dose (MTD)', 'Dose Limiting Toxicities (DLT)']",[],,,,,1,United States,"UT Southwestern Medical Center [Dallas, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text describes a study involving PD-0332991 in combination with T-DM1 for treating advanced HER2-positive breast cancer, indicating an extension of indication for an existing treatment rather than a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT01983501,A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,"A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine; T-DM1)",COMPLETED,PHASE1,Seagen Inc.,2014-02-28,2017-10-10,2020-09-03,2013-11-14,2020-09-21,['Incidence of adverse events'],"['Incidence of clinical lab abnormalities', 'Frequency of dose reductions in tucatinib', 'Frequency of dose reductions in T-DM1', 'Objective response rate (ORR)', 'Duration of response', 'Disease control rate (DCR)', 'Clinical benefit rate (CBR)', 'Progression-free survival (PFS)']",,,,,11,Canada; United States,"University of Alabama [Birmingham, United States] | University of Colorado Cancer Center [Aurora, United States] | University of Kansas [Kansas City, United States] | Dana Farber Cancer Institute [Boston, United States] | Providence Cancer Center [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | Northwest Medical Specialties [Tacoma, United States] | London Health Sciences Centre [London, Canada] | Princess Margaret Cancer Centre [Toronto, Canada] | Hospital de la Cite-de-la-Sante [Laval, Canada] | Jewish General Hospital [Montreal, Canada]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT01989546,"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",COMPLETED,PHASE1; PHASE2,National Cancer Institute (NCI),2014-02-04,2020-03-26,2020-03-26,2013-11-21,2021-02-23,"['Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy']",['Response Rate (Complete Response (CR) + Partial Response (PR) of Treatment With Talazoparib (BMN 673) in Participants With Deleterious Breast Cancer (BRCA) Mutations'],"[{""type"":""PRIMARY"",""title"":""Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy"",""timeFrame"":""Cycle 1, day 8"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""44.4"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Response Rate (Complete Response (CR) + Partial Response (PR) of Treatment With Talazoparib (BMN 673) in Participants With Deleterious Breast Cancer (BRCA) Mutations"",""timeFrame"":""Restaging scans will be carried out every 2 cycles (8 weeks) until the end of treatment (average, 7 months)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""OTHER_PRE_SPECIFIED"",""title"":""Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)"",""timeFrame"":""Date treatment consent signed to date off study, approximately 28 months and 24 days."",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null,""lower"":null,""upper"":null}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""9""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Talazoparib (BMN 673)"",""n"":""9""}]}],""dropWithdraws"":[{""type"":""Clinical Progression"",""reasons"":[{""group"":""Talazoparib (BMN 673)"",""n"":""1""}]},{""type"":""Disease progression on study"",""reasons"":[{""group"":""Talazoparib (BMN 673)"",""n"":""8""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""4"",""spread"":null}]},{""title"":""Age, Continuous"",""unit"":""years"",""paramType"":""MEAN"",""dispersionType"":""STANDARD_DEVIATION"",""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""61.23"",""spread"":""12.33""}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""5"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""4"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""1"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""8"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null},{""group"":""Talazoparib (BMN 673)"",""value"":""0"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Talazoparib (BMN 673)"",""value"":""9"",""spread"":null}]}]","[{""group"":""Talazoparib (BMN 673)"",""serious_affected"":3,""serious_at_risk"":9,""other_affected"":9,""other_at_risk"":9}]",1,United States,"National Institutes of Health Clinical Center, 9000 Rockville Pike [Bethesda, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,1,1,1,0,0,0,1,4,0,0,1,0,"The trial is testing BMN 673, which is identified as a new oral PARP inhibitor for patients with advanced solid tumors and BRCA mutations, indicating it is a new medicine.",NIH,True,2020.0,5.0,0,Phase 2
NCT02011815,Exploring Biological Linkage Between Circadian Disruption and Cancer Progression,A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression,COMPLETED,,Seoul National University Hospital,2013-11-10,2019-02-15,2019-06-15,2013-12-13,2019-09-24,['Progression-free survival'],"['Circadian disruption', 'Objective sleep cycle measures', 'Physiological measures', 'Sleep quality measures', 'Quality of Life measure', 'Cancer related Fatigue', 'Distress related measure', 'Posttraumatic Stress-related symptom measure', 'Menopausal symptom measure', 'Personality measure', 'Genetic polymorphism', 'Epigenetic Change', 'Cortisol level', 'Melatonin', 'Inflammatory markers', 'Overall survival']",,,,,1,South Korea,"Seoul National University Hospital [Seoul, South Korea]",2013.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study exploring the biological linkage between circadian disruption and cancer progression, but does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02013492,Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery,A Pilot Study of Beta-Blockers in Patients With Advanced Cancer,COMPLETED,EARLY_PHASE1,William Carson,2014-01-21,2015-06-12,2015-06-12,2013-12-17,2022-12-06,"['Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events (CTCAE) V. 4.0', 'Change in vascular endothelial growth factor (VEGF)', 'Effect of beta-adrenergic blockade on the tumor microenvironment', 'Effect of beta-adrenergic blockade on the host immune system']","['Progression-free survival', 'Overall survival']",,,,,1,United States,"Ohio State University Comprehensive Cancer Center [Columbus, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of Propranolol Hydrochloride, a drug already approved for other indications, in a new context (treating patients with advanced cancer), which qualifies as an extension of indication.",OTHER,False,2015.0,10.0,0,Phase 1
NCT02019524,Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,COMPLETED,PHASE1,"COL George Peoples, MD, FACS",2013-09-30,2016-12-06,2016-12-06,2013-12-24,2020-03-18,['Primary vaccination strategy'],"['Short-term immunity', 'Optimal booster inoculation strategy', 'Delayed Type Hypersensitivity evaluation']",,,,,1,United States,"University of Texas M.D. Anderson Cancer Center [Houston, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves two new peptide vaccines (E39 and J65) targeting folate binding protein in breast and ovarian cancer patients, indicating the development of new medicines.",FED,False,2016.0,9.0,0,Phase 1
NCT02025192,A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,"A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer",COMPLETED,PHASE1,Seagen Inc.,2013-12-31,2017-10-03,2020-03-16,2013-12-31,2020-06-04,"['Incidence of adverse events', 'Severity of adverse events']","['Incidence of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis)', 'Severity of clinical lab abnormalities (hematology, chemistry, liver function tests, coagulation, urinalysis)', 'Frequency of dose reductions in tucatinib (ONT-380', 'Frequency of dose reductions in capecitabine', 'Plasma concentrations of tucatinib (ONT-380) and metabolite', 'Plasma concentrations of capecitabine and metabolites', 'Objective response rate (ORR)', 'Duration of response', 'Disease control rate', 'Clinical benefit rate (CBR)', 'Progression-free survival (PFS)']",,,,,5,United States,"University of Colorado [Aurora, United States] | Providence Cancer Center [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | Northwest Medical Specialties [Tacoma, United States]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating Tucatinib (ONT-380), which is a new medicine being tested in combination with other treatments for HER2+ metastatic breast cancer.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT02028364,Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women,Pet Imaging as a Biomarker of Everolimus Added Value in Hormone Refractory postmenopausaL Women,COMPLETED,PHASE2,Jules Bordet Institute,2014-01-12,2021-07-06,2021-08-09,2014-01-07,2023-08-24,['PFS based on RECIST criteria 1.1.'],"['Overall survival (OS)', '* Proportion of FDG-PET/CT metabolic non-responders/FDG-PET/CT metabolic responders * Estimate the most suitable second FDG-PET/CT time point (2 weeks versus 4 weeks after initiation of treatment).', 'Biomarker Assessment']",,,,,5,Belgium,"institut Jules Bordet [Brussels, Belgium] | Cliniques Universtaires Saint-Luc [Brussels, Belgium] | UZ Leuven [Leuven, Belgium] | CHU Ambroise Paré [Mons, Belgium] | Clinique et Maternité Sainte Elisabeth [Namur, Belgium]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Everolimus in a specific patient population (hormone refractory postmenopausal women) and evaluates its added value, indicating an extension of indication rather than a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02032277,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,"A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)",COMPLETED,PHASE3,AbbVie,2014-04-02,2016-03-18,2020-11-12,2014-01-10,2021-01-20,['Pathological Complete Response (pCR).'],"['Event Free Survival (EFS)', 'Overall Survival (OS)', 'Rate of eligibility for breast conservation after therapy (BCR).']",,,,,158,Australia; Belgium; Canada; Czechia; France; Germany; Hungary; Italy; Netherlands; Russia; South Korea; Spain; Taiwan; United Kingdom; United States,"Scottsdale Healthcare /ID# 120473 [Scottsdale, United States] | Mayo Clinic - Scottsdale /ID# 139932 [Scottsdale, United States] | Arizona Oncology Associates, PC-HOPE /ID# 126137 [Tucson, United States] | Usc /Id# 123310 [Los Angeles, United States] | Pacific Cancer Care /ID# 120476 [Salinas, United States] | Sharp Memorial Hospital /ID# 119861 [San Diego, United States] | Stanford University School of Med /ID# 130316 [Stanford, United States] | Cedars-Sinai Medical Center - West Hollywood /ID# 137275 [West Hollywood, United States] | Christiana Care Health Service /ID# 137823 [Newark, United States] | Florida Cancer Specialists - Fort Myers /ID# 121835 [Fort Myers, United States] | Florida Cancer Specialists - Fort Myers /ID# 126379 [Fort Myers, United States] | Mayo Clinic /ID# 132349 [Jacksonville, United States] | Mount Sinai Comp Cancer Ctr /ID# 133008 [Miami, United States] | Miami Cancer Institute - Baptist Health South Florida /ID# 126145 [Miami, United States] | UF Health Cancer Center /ID# 141589 [Orlando, United States] | Moffitt Cancer Center /ID# 124063 [Tampa, United States] | University of Illinois - Chicago /ID# 134329 [Chicago, United States] | Northwestern University Feinberg School of Medicine /ID# 133848 [Chicago, United States] | University of Chicago DCAM /ID# 120467 [Chicago, United States] | Loyola University Medical Ctr /ID# 120455 [Maywood, United States] | OSF St. Anthony Medical Center /ID# 139424 [Rockford, United States] | Indiana Univ School Medicine /ID# 118215 [Indianapolis, United States] | Community Rgnal Cancer Care N /ID# 120456 [Indianapolis, United States] | Horizon Oncology Research Center /ID# 116815 [Lafayette, United States] | Cancer Center of Kansas /ID# 134720 [Wichita, United States] | Univ Maryland School Medicine /ID# 119235 [Baltimore, United States] | St. Joseph Mercy Hospital /ID# 135875 [Ypsilanti, United States] | Minnesota Oncology Hematology, PA /ID# 126144 [Minneapolis, United States] | St. Lukes Cancer Institute /ID# 118775 [Kansas City, United States] | Comprehensive Cancer Ctrs Neva /ID# 126136 [Las Vegas, United States] | Solinksy Center for Cancer Care /ID# 131970 [Manchester, United States] | Rutgers Cancer Institute of NJ /ID# 120477 [New Brunswick, United States] | Columbia Univ Medical Center /ID# 141588 [New York, United States] | Hope Womens Cancer Centers /ID# 119179 [Asheville, United States] | Univ NC Chapel Hill /ID# 132893 [Chapel Hill, United States] | Univ NC Chapel Hill /ID# 147695 [Chapel Hill, United States] | Novant Health Oncology Special /ID# 139890 [Winston-Salem, United States] | Sanford Roger Maris Cancer Cen /ID# 132394 [Fargo, United States] | Oncology Hematology Care, Inc - Blue Ash /ID# 120478 [Cincinnati, United States] | University Hospitals Case Medical Center /ID# 141691 [Cleveland, United States] | Fairview Hospital /ID# 141626 [Cleveland, United States] | Cleveland Clinic Main Campus /ID# 126378 [Cleveland, United States] | The Ohio State University /ID# 141587 [Columbus, United States] | Lehigh Valley Health Network /ID# 133372 [Allentown, United States] | Guthrie Medical Group, PC /ID# 124397 [Sayre, United States] | Women and Infants Hospital /ID# 123476 [Providence, United States] | Avera Cancer Institute /ID# 120466 [Sioux Falls, United States] | Tennessee Oncology, PLLC /ID# 124566 [Nashville, United States] | Texas Oncology - Bedford /ID# 126135 [Bedford, United States] | Texas Oncology - Medical City Dallas /ID# 126140 [Dallas, United States] | Texas Oncology - Medical City Dallas /ID# 126141 [Dallas, United States] | UT Southwestern Medical Center /ID# 133849 [Dallas, United States] | The Ctr for Cancer and Blood D /ID# 120479 [Fort Worth, United States] | Texas Oncology - Memorial City /ID# 126139 [Houston, United States] | Texas Oncology - Plano East /ID# 126143 [Plano, United States] | Texas Oncology - Tyler /ID# 126142 [Tyler, United States] | University of Utah /ID# 118677 [Salt Lake City, United States] | University of Virginia /ID# 122975 [Charlottesville, United States] | Virginia Commonwealth Univ /ID# 141586 [Richmond, United States] | Virginia Oncology Associates /ID# 127260 [Virginia Beach, United States] | Univ of Wisconsin Hosp/Clinics /ID# 120457 [Madison, United States] | The Tweed Hospital /ID# 120235 [Tweed Heads, Australia] | Cabrini Health /ID# 120236 [Malvern, Australia] | Royal Melbourne Hospital /ID# 127717 [Parkville, Australia] | Western Health Sunshine Hosp. /ID# 120715 [St Albans, Australia] | Fiona Stanley Hospital /ID# 120716 [Murdoch, Australia] | St. John of God Hosp - Murdoch /ID# 131788 [Murdoch, Australia] | St. John of God Subiaco Hosp /ID# 120717 [Subiaco, Australia] | Cliniques Universitaires Saint Luc /ID# 120719 [Woluwe-Saint-Lambert, Belgium] | Grand Hôpital de Charleroi /ID# 116678 [Charleroi, Belgium] | CHU Brugmann /ID# 120376 [Brussels, Belgium] | UZ Antwerp /ID# 120720 [Edegem, Belgium] | AZ Groeninge /ID# 120718 [Kortrijk, Belgium] | CHU UCL Namur /ID# 116677 [Namur, Belgium] | Sunnybrook Health Sciences Ctr /ID# 123312 [Toronto, Canada] | CHUM - Notre-Dame Hospital /ID# 141694 [Montreal, Canada] | Jewish General Hospital /ID# 141629 [Montreal, Canada] | CHUQ-Hospital St. Sacrement /ID# 141619 [Québec, Canada] | Fakultni Nemocnice Olomouc /ID# 120725 [Olomouc, Czechia] | Masarykuv onkologikcy ustav /ID# 120726 [Brno, Czechia] | FN Hradec Kralove /ID# 120596 [Hradec Králové, Czechia] | Hopital Universitaire Purpan /ID# 120731 [Toulouse, France] | Centre Oscar Lambret /ID# 119958 [Lille, France] | Centre Leon Berard /ID# 120740 [Lyon, France] | Jean Perrin Centre /ID# 125277 [Clermont-Ferrand, France] | Hosp European, Georges Pompid /ID# 120736 [Paris, France] | Hopital Rene Huguenin /ID# 120729 [Saint-Cloud, France] | Institut Curie /ID# 116679 [Paris, France] | Universitaetsklinikum Schleswig-Holstein /ID# 133454 [Kiel, Germany] | Universitaetsklinikum Ulm /ID# 133453 [Ulm, Germany] | Gemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 133472 [Augsburg, Germany] | Helios Klinikum Berlin Buch /ID# 133465 [Berlin, Germany] | Studiengesellschaft Onk Bielef /ID# 133471 [Bielefeld, Germany] | Klinikum Bremen Mitte gGmbH /ID# 132875 [Bremen, Germany] | St. Johannes Hospital /ID# 133478 [Dortmund, Germany] | Kliniken Esslingen /ID# 133475 [Esslingen am Neckar, Germany] | Klinikum Frankfurt Hoechst /ID# 145301 [Frankfurt, Germany] | Wilke/Wagner/Petzoldt, Fuerth /ID# 133481 [Fürth, Germany] | Evangelisches Krankenhaus /ID# 133457 [Gelsenkirchen, Germany] | Elisabeth Krankenhaus /ID# 133461 [Kassel, Germany] | St. Vincenz Krankenhaus /ID# 133466 [Limburg, Germany] | Onk Zentrum am Rotkreuz /ID# 133482 [Munich, Germany] | Klinikum recht der Isar der TU /ID# 133449 [Munich, Germany] | Sana Klinikum Offenbach /ID# 133455 [Offenbach, Germany] | Leopoldina-Krankenhaus /ID# 133484 [Schweinfurt, Germany] | Johanniter-Krankenhaus Genthin /ID# 133463 [Stendal, Germany] | St. Josefs-Hospital /ID# 133464 [Wiesbaden, Germany] | Marienhospital Witten /ID# 133470 [Witten, Germany] | National Institute of Oncology /ID# 120828 [Budapest, Hungary] | Magyar Honvedseg Egeszsegugyi Kozpont /ID# 120834 [Budapest, Hungary] | Uzsoki Utcai Korhaz /ID# 120825 [Budapest, Hungary] | Debreceni Egyetem Klinikai Kozpont /ID# 116681 [Debrecen, Hungary] | Petz Aladar Megyei Oktato Korh /ID# 120835 [Győr, Hungary] | Bacs-Kiskun Megyei Korhaz /ID# 120833 [Kecskemét, Hungary] | BAZ Megyei E.O. Korhaz /ID# 122215 [Miskolc, Hungary] | University of Szeged /ID# 120823 [Szeged, Hungary] | Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz /ID# 120818 [Szolnok, Hungary] | A.O.U. Policlinico S.Orsola-Malpighi /ID# 122855 [Bologna, Italy] | Misericordia General Hospital /ID# 119536 [Grosseto, Italy] | IRCCS-I.R.S.T. srl Meldola /ID# 120255 [Meldola, Italy] | Istituto Europeo di Oncologia /ID# 120845 [Milan, Italy] | IRCCS Fondazione Salva Maugeri /ID# 120848 [Pavia, Italy] | Vrije Universiteit Medisch Centrum /ID# 126302 [Amsterdam, Netherlands] | Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 120944 [Moscow, Russia] | Kursk Regional Oncology Dispen /ID# 116688 [Kursk, Russia] | archangel Clinical Oncology /ID# 120935 [Arkhangelsk, Russia] | Medical Radiological Res Ctr /ID# 124017 [Obninsk, Russia] | Pyatigorsk Oncology Dispensary /ID# 120945 [Pyatigorsk, Russia] | Leningrad Reg Onc Dispensery /ID# 120938 [Saint Petersburg, Russia] | Birch A Healthcare /ID# 116695 [Saint Petersburg, Russia] | National Cancer Center /ID# 119525 [Goyang, South Korea] | Ajou University Hospital /ID# 118856 [Suwon, South Korea] | Kyungpook National University Chilgok Hospital /ID# 118855 [Daegu, South Korea] | Severance Hospital /ID# 116699 [Seoul, South Korea] | Samsung Medical Center /ID# 119276 [Seoul, South Korea] | Korea University Anam Hospital /ID# 118857 [Seoul, South Korea] | Seoul National University Hospital /ID# 116698 [Seoul, South Korea] | Asan Medical Center /ID# 116696 [Seoul, South Korea] | Hospital Universitario A Coruña - CHUAC /ID# 135108 [A Coruña, Spain] | Hospital Universitario Germans Trias i Pujol /ID# 135112 [Badalona, Spain] | Hospital General Universitario Alicante /ID# 135115 [Alicante, Spain] | Hospital Parc de Salut del Mar /ID# 135110 [Barcelona, Spain] | Hospital Santa Creu i Sant Pau /ID# 145400 [Barcelona, Spain] | Hospital Universitario Arnau de Vilanova de Lleida /ID# 120979 [Lleida, Spain] | Hospital Universitario Ramon y Cajal /ID# 135113 [Madrid, Spain] | Hospital Clinico Universitario San Carlos /ID# 119959 [Madrid, Spain] | Hospital Universitario Virgen del Rocio /ID# 135114 [Seville, Spain] | Fundacion Instituto Valenciano Oncologia IVO /ID# 135116 [Valencia, Spain] | Hospital Clinico Universitario de Valencia /ID# 123076 [Valencia, Spain] | Hospital General Universitario de Valencia /ID# 135111 [Valencia, Spain] | Hospital Universitario Miguel Servet /ID# 119195 [Zaragoza, Spain] | National Taiwan Univ Hosp /ID# 122895 [Taipei City, Taiwan] | Changhua Christian Hospital /ID# 119085 [Changhua County, Taiwan] | Chi Mei Hospital - Liouying /ID# 120982 [Tainan City, Taiwan] | Univ Hosp Bristol NHS Foundati /ID# 120989 [Bristol, United Kingdom] | Charing Cross Hospital /ID# 120990 [London, United Kingdom] | Nottingham Univ Hospitals NHS /ID# 122218 [Nottingham, United Kingdom] | Royal Stoke Univ Hospital /ID# 120984 [Stoke-on-Trent, United Kingdom]",2014.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2020.0,5.0,1,Phase 3
NCT02040935,A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants,"HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer",COMPLETED,PHASE3,Hoffmann-La Roche,2014-02-21,2018-09-14,2018-09-14,2014-01-20,2019-08-22,['Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)'],"['Pharmacokinetics: Trough Concentrations (Ctrough) of Trastuzumab', 'Health Survey Short Form-36 (SF-36) Score', 'Mood and Anxiety Questionnaire (MASQ) Score', 'Percentage of Participants Choosing to Return to Hospital Administration']",,,,,17,Netherlands,"Medisch Centrum Alkmaar [Alkmaar, Netherlands] | Meander Medisch Centrum; Locatie Lichtenberg [Amersfoort, Netherlands] | Amphia ziekenhuis, locatie langendijk [Breda, Netherlands] | IJsselland Ziekenhuis [Capelle aan den IJssel, Netherlands] | Reinier de Graaf Gasthuis; Oncology [Delft, Netherlands] | Ziekenhuis Gelderse Vallei; Inwendige Geneeskunde [Ede, Netherlands] | Martini Ziekenhuis [Groningen, Netherlands] | Kennemer Gasthuis [Haarlem, Netherlands] | Ziekenhuisgroep Twente, Hengelo [Hengelo, Netherlands] | Tergooiziekenhuizen, loc. Hilversum [Hilversum, Netherlands] | Spaarne Ziekenhuis Haarlem; Oncologie [Hoofddorp, Netherlands] | St. Antonius Ziekenhuis Nieuwegein [Nieuwegein, Netherlands] | Franciscus Ziekenhuis [Roosendaal, Netherlands] | Zuyderland ziekenhuis locatie Geleen [Sittard-Geleen, Netherlands] | Haga Ziekenhuis [The Hague, Netherlands] | VieCuri - Medisch Centrum voor Noord-Limburg [Venlo, Netherlands] | Isala Klinieken [Zwolle, Netherlands]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study investigates the administration of an existing medicine (Trastuzumab) in a new method (subcutaneous administration at home) for patients with HER2-positive early breast cancer, indicating an extension of its indication.",INDUSTRY,False,2018.0,7.0,0,Phase 3
NCT02045368,Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R,STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R),COMPLETED,PHASE1,"IGF Oncology, LLC",2014-01-28,2016-09-30,2016-09-30,2014-01-24,2019-08-22,['Maximum Tolerated Dose (MTD)'],"['Adverse Effects', 'Disease Response based on RECIST Criteria']",,,,,1,United States,"University of Illinois at Chicago [Chicago, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2016.0,9.0,0,Phase 1
NCT02051751,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy,COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-03-05,2016-08-19,2016-08-19,2014-01-31,2020-12-08,"['Dose escalation : Dose Limiting Toxicity (DLT)', 'Dose expansion : Number of patients with adverse events as a measure of safety and tolerability']","['Dose escalation:Number of patients with adverse events as a measure of safety and tolerability', 'Dose escalation : BYL719 and Paclitaxel Plasma concentrations', 'Dose expansion: Clinical benefit Rate in the breast cancer cohort', 'Dose expansion: Progression free survival', 'Dose expansion: Overall response rate', 'Dose expansion : Duration of Response', 'Dose expansion: Plasma pharmacokinetics of BYL719 given in combination with paclitaxel in breast cancer and HNSCC patients']",,,,,5,France; Italy; Spain; United States,"Highlands Oncology Group [Fayetteville, United States] | Horizon Oncology Center BioAdvance [Lafayette, United States] | Novartis Investigative Site [Toulouse, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Barcelona, Spain]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT02056886,Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer,"Multicentric, National, Prospective, Comparative, Non Randomized Study, Assessing Medico-economic Impact of Three Strategies of Sentinel Lymph Node Analysis in Immediately Operable Breast Cancer",COMPLETED,,Institut Cancerologie de l'Ouest,2013-10-21,2018-01-02,2022-02-15,2014-02-06,2022-04-29,['Medico-economic study : medical cost between 3 different sentinel lymph node analysis (histological analysis or molecular biology) in the management of patients treated for invasive breast carcinoma.'],[],,,,,17,France,"ICO Paul Papin [Angers, France] | Institut Bergonie [Bordeaux, France] | Jean Perrin [Clermont-Ferrand, France] | Institut du Sein -Clinique Saint-Amé [Lambres-lez-Douai, France] | Oscar Lambret [Lille, France] | Institut Paoli Calmettes [Marseille, France] | HEGP [Paris, France] | Institut Curie [Paris, France] | CHU [Pierre-Bénite, France] | Eugène Marquis [Rennes, France] | Henri BECQUEREL [Rouen, France] | Institut Curie [Saint-Cloud, France] | Clinique Mutualiste [Saint-Etienne, France] | Jean-Marc cancérologie CLASSE [Saint-Herblain, France] | CHU [Saint-Priest-en-Jarez, France] | IUCT-O [Toulouse, France] | Institut de Cancérlogie de Lorraine [Vandœuvre-lès-Nancy, France]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study comparing different strategies for sentinel lymph node analysis in breast cancer but does not introduce a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT02058381,A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer,A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer,COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-05-06,2018-06-19,2018-06-19,2014-02-10,2020-03-09,['Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)'],"['Incidence, type, intensity, severity and seriousness of Adverse Events (AEs) during the first 2 cycles dose interruptions, reductions and dose intensity during the study', 'Alpelisib/buparlisib: plasma concentrations and PK parameters, including but not limited to AUC0-t, AUC0-inf, AUC0-24, Cmax, tmax, CL/F, half-life t1/2 and other PK parameters if deemed appropriate. Tamoxifen: trough plasma concentrations', 'Preliminary anti-tumor activity acccording to RECIST 1.1 : It will include overall response rate, clinical benefit, progression free survival and proportion of patients who are alive without progression at 9 months from the date of treatment start', 'Index score from the EQ-5D-5L; and WPAI-GH scores for work time missed, impairment while working, overall work impairment, and activity impairment']",,,,,15,Hong Kong; South Korea; Taiwan; Thailand,"Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Seongnam-si, South Korea] | Novartis Investigative Site [Gyeonggi-do, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Kuei-Shan Chiang, Taiwan] | Novartis Investigative Site [New Taipei City, Taiwan] | Novartis Investigative Site [Kaohsiung City, Taiwan] | Novartis Investigative Site [Taichung, Taiwan] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Bangkok, Thailand] | Novartis Investigative Site [Chiang Mai, Thailand]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02076620,L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours,Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours,COMPLETED,PHASE1,Philogen S.p.A.,2013-01-16,2018-01-25,2018-01-25,2014-03-03,2022-04-04,['Dose limiting toxicity (DLT)'],"['Pharmacokinetics assessment of L19TNFα', 'Human anti-fusion protein antibodies (HAFA) levels', 'Objective response rate (ORR)', 'Median progression free survival (mPFS)', 'Median overall survival (OS)']",,,,,2,Germany; Italy,"Universitätsklinikum Münster [Münster, Germany] | Fondazione IRCCS Istituto Nazionale dei Tumori [Milan, Italy]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02077933,"Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors","A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.",COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-05-14,2019-04-12,2019-04-12,2014-03-04,2020-12-08,"['Dose escalation : Incidence of dose Limiting Toxicity (DLTs)', 'Dose expansion: Number of patients with adverse events as a measure of safety and tolerability']","['Dose escalation: Number of patients with adverse events as a measure of safety and tolerability', 'Dose escalation : alpelisib, everolimus and exemestane (when applicable) Plasma concentrations', 'Dose escalation : alpelisib, everolimus drug-drug interaction', 'Dose expansion: Progression free survival (Doublet cohorts)', 'Dose expansion : Duration of Response (Doublet and breast cancer cohorts)', 'Dose expansion: Clinical benefit Rate (Doublet and breast cancer cohorts)', 'Dose expansion: Overall response rate (Doublet and breast cancer cohorts)']",,,,,22,France; Germany; Hong Kong; Hungary; Italy; Netherlands; Spain; United Kingdom; United States,"Highlands Oncology Group [Fayetteville, United States] | Memorial Sloan Kettering Cancer Center SC - BYL719Z2102 [New York, United States] | Novartis Investigative Site [Bordeaux, France] | Novartis Investigative Site [Bordeaux, France] | Novartis Investigative Site [Paris, France] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Berlin, Germany] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Essen, Germany] | Novartis Investigative Site [Hanover, Germany] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Budapest, Hungary] | Novartis Investigative Site [Ancona, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Modena, Italy] | Novartis Investigative Site [Verona, Italy] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Manchester, United Kingdom]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,"A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-05-19,2018-04-17,2018-04-17,2014-03-17,2020-12-17,"['Incidence of Dose limiting toxicities (DLTs) - Phase lb only', 'Progression free survival (PFS) - Phase ll only']","['Safety and Tolerability of the combinations of LEE011 with fulvestrant, LEE011 + BKM120 with fulvestrant and LEE011 + BYL719 with fulvestrant', 'Plasma concentration-time profiles of LEE011, BKM120, BYL719 and fulvestrant.', 'Overall Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS) (phase l only)', 'Overall Survival (OS) - Phase II only']",,,,,11,France; Italy; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,"University of Alabama at Birmingham/ Kirklin Clinic Dept Onc [Birmingham, United States] | Dana Farber Cancer Institute Onc. Dept. [Boston, United States] | Sarah Cannon Research Institute Onc Dept [Nashville, United States] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Modena, Italy] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Leicester, United Kingdom]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"LEE011 is being studied in combination with other agents for a specific patient population, indicating it is a new medicine being evaluated for its efficacy in treating advanced breast cancer.",INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02101320,Hand-held Gamma Camera in the SNOLL Procedure,Contribution of a Hand-held Gamma Camera (TreCam) to the SNOLL(Occult Breast Lesion Localization Plus Sentinel Node Biopsy) Procedure in Breast Cancer,COMPLETED,,Assistance Publique - Hôpitaux de Paris,2015-05-20,2018-06-19,2018-06-19,2014-04-02,2019-07-31,"[""Rate of further surgery for non in sano or inadequate (less than 3 mm security margins) lumpectomy piece's margins.""]","['Size, volume and weight of the lumpectomy.', 'Status of resection margins', 'Cosmetics results: 4 point Score', 'Morbidity', 'Volume of resection / tumor volume', 'Duration of utilization of TreCam at The day before surgery and before induction of anesthesia for the location of the breast injection site and SLN.', 'Duration of utilization of TreCam at at the end of the SLN procedure for verifying the absence of radioactivity.', 'Duration of utilization of TreCam at each step of the procedure during the breast exploration before lumpectomy.', ""Duration of utilization of TreCam at at the end of lumpectomy for acquisition of images of the tumor's bed after removal of the radioactive target and for acquisition of image of the lumpectomy's specimen."", 'Difficulties in data acquisition Using a scale of 4 items : VERY EASY, EASY, DIFFICULT, IMPOSSIBLE', ""Comparison between imaging data provided in preoperative time by TreCam and by standard LS: image's quality, location of the injection's site, location and number of SLN.""]",,,,,1,France,"Service de gynécologie-Obstétrie [Bondy, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of a hand-held gamma camera (TreCam) in a specific procedure (SNOLL) for breast cancer, indicating an extension of indication for the device rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02103634,NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer,NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer,COMPLETED,,Case Comprehensive Cancer Center,2014-03-01,2018-12-21,2018-12-21,2014-04-04,2020-07-29,['Sensitivity of NaF PET/MRI'],"['Image Quality', 'Positive predictive value of MRI sequences', 'Negative predictive value of MRI sequences', 'Specificity of MRI sequences', 'attenuation correction', 'localization', 'Evaluation of Bone Metastases']",,,,,1,United States,"University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center [Cleveland, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the evaluation of an imaging technique (NaF PET/MRI) for assessing bone metastases in breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02122588,OVArian Cancer Non-Interventional Study - OVATAR,OVArian Cancer Non-Interventional Study. Treatment hAbits and Epidemiology of BRCA in Russian Federation - OVATAR,COMPLETED,,AstraZeneca,2014-06-30,2018-05-31,2018-05-31,2014-04-24,2019-05-21,"['Evaluation of 1st line chemotherapy treatment of serous and endometrioid ovarian, peritoneal and fallopian tube cancer (drugs by INN (International Nonproprietary Name), doses, regimen)']","['Data collection of patients characteristics (gender, age, race, co-morbidities, family history of ovarian and breast cancer)', 'Data collection of disease information (including genetic testing results)', 'Proportion of BRCAm+ among serous and endometrioid ovarian, peritoneal and fallopian tube cancer in Russia.', 'Evaluation of response to 1st line chemotherapy treatment of serous and endometrioid BRCAm+ ovarian, peritoneal and fallopian tube cancer', 'Assessment of relapses after 1st line of Pt (Platinum)-containing regimen for BRCAm+ patients', 'Evaluation of 2nd line chemotherapy treatment of serous and endometrioid ovarian, peritoneal and fallopian tube cancer (drugs by INN, doses, regimen) for BRCAm+ patients who have progressed after 1st line chemotherapy']",,,,,22,Russia,"Research Site [Arkhangelsk, Russia] | Research Site [Chelyabinsk, Russia] | Research Site [Irkutsk, Russia] | Research Site [Izhevsk, Russia] | Research Site [Kaluga, Russia] | Research Site [Khabarovsk, Russia] | Research Site [Moscow, Russia] | Research Site [Novorossiysk, Russia] | Research Site [Novosibirsk, Russia] | Research Site [Obninsk, Russia] | Research Site [Omsk, Russia] | Research Site [Orenburg, Russia] | Research Site [Pyatigorsk, Russia] | Research Site [Rostov-on-Don, Russia] | Research Site [Saint Petersburg, Russia] | Research Site [Samara, Russia] | Research Site [Sochi, Russia] | Research Site [Tomsk, Russia] | Research Site [Tula, Russia] | Research Site [Tver', Russia] | Research Site [Ufa, Russia] | Research Site [Vladimir, Russia]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,1,0,1,"The trial focuses on evaluating the treatment and response of existing chemotherapy regimens in a specific patient population (BRCAm+ ovarian cancer), indicating an extension of indication rather than testing a new medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02124148,A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer,A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors,COMPLETED,PHASE1,Eli Lilly and Company,2014-06-18,2020-02-13,2020-02-13,2014-04-28,2020-04-01,"['Part A: Maximum Tolerated Dose and Schedule of Prexasertib in Combination with Cisplatin', 'Part B: Maximum Tolerated Dose of Prexasertib in Combination with Cetuximab', 'Part C: Maximum Tolerated Dose of Prexasertib in Combination with Pemetrexed', 'Part D: Maximum Tolerated Dose of Prexasertib in Combination with Fluorouracil (5-FU)', 'Part E: Maximum Tolerated Dose of Prexasertib in Combination with LY3023414']","['Pharmacokinetics: Maximum Plasma Concentration of Prexasertib', 'Pharmacokinetics: Area Under the Plasma Concentration Curve of Prexasertib', 'Pharmacokinetics: Maximum Plasma Concentration of Cisplatin (Total Platinum)', 'Pharmacokinetics: Area Under the Plasma Concentration Curve of Cisplatin (Total Platinum)', 'Pharmacokinetics: Maximum Plasma Concentration of Cetuximab', 'Pharmacokinetics: Maximum Plasma Concentration of Pemetrexed', 'Pharmacokinetics: Area Under the Plasma Concentration Curve of Pemetrexed', 'Pharmacokinetics: Maximum Plasma Concentration of 5-FU', 'Pharmacokinetics: Maximum Plasma Concentration of LY3023414', 'Pharmacokinetics: Area Under the Plasma Concentration Curve of LY3023414', 'B2, E2, E3 Dose Expansion: Overall Response Rate', 'B2, E2, E3 Dose Expansion: Disease Control Rate', 'B2, E2, E3 Dose Expansion: Progression-Free Survival', 'B2, E2, E3 Dose Expansion: Duration of Response']",,,,,5,United States,"Florida Cancer Specialists [Sarasota, United States] | University of Oklahoma Health Sciences Center [Oklahoma City, United States] | Sarah Cannon Research Institute SCRI [Nashville, United States] | Tennessee Oncology PLLC [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT02138812,Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,"An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",TERMINATED,PHASE1,Bayer,2014-05-09,2017-04-28,2017-10-02,2014-05-15,2018-10-12,"['Maximum tolerated dose (MTD)', 'Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.', 'Plasma concentration of Paclitaxel characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax', 'Plasma concentration of BAY1161909 characterized by Cmax']",[],,,,,6,United States," [Santa Monica, United States] |  [New Haven, United States] |  [Boston, United States] |  [Detroit, United States] |  [Nashville, United States] |  [San Antonio, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02152943,"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-Positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance",COMPLETED,PHASE1,M.D. Anderson Cancer Center,2014-07-17,2020-12-14,2020-12-14,2014-06-02,2020-12-19,"['Maximum tolerated dose and/or recommended phase II dose', 'Clinical benefit rate']",[],,,,,5,United States,"M D Anderson Cancer Center [Houston, United States] | MD Anderson in Katy [Houston, United States] | MD Anderson League City [Nassau Bay, United States] | MD Anderson in Sugar Land [Sugar Land, United States] | MD Anderson in The Woodlands [The Woodlands, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.","A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.",COMPLETED,PHASE1,Novartis Pharmaceuticals,2014-06-27,2016-10-26,2016-10-26,2014-06-03,2020-12-19,"['Incidence of dose-limiting toxicities (DLTs)', 'Safety and tolerability of the combination of LEE011, buparlisib, and letrozole']","['Safety and tolerabiity of the combination of LEE011, buparlisib, and letrozole', 'Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles', 'Pharmacokinetic paramters such as AUClast and Cmax of LEE011, buparlisib, and letrozole in order to characterize the PK profiles', 'Disease control rate', 'PFS (progression free survival)']",,,,,6,Spain; United States,"University of California at Los Angeles UCLA SC [Los Angeles, United States] | Horizon Oncology Center SC [Lafayette, United States] | Medical University of South Carolina SC [Charleston, United States] | South Texas Accelerated Research Therapeutics SC [San Antonio, United States] | University of Utah / Huntsman Cancer Institute SC-3 [Salt Lake City, United States] | Novartis Investigative Site [Madrid, Spain]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2016.0,9.0,1,Phase 1
NCT02158507,"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer",COMPLETED,,University of Alabama at Birmingham,2014-09-04,2021-07-22,2021-07-22,2014-06-09,2025-02-03,['Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib'],"['Number of subjects with objective response rate (ORR) at 4 years post baseline (Complete responses [CRs] plus partial responses [PRs]', 'Number of subjects with progression free survival (PFS) at 4 years after start of study.', 'DNA methylation and RNA transcriptome will be evaluated before and after therapy; baseline pattern will be compared with the post treatment pattern to identify markers of response or resistance.', 'Measure numbers of circulating tumor cells before and after therapy', 'Peak Plasma concentration of Veliparib and Palatinib when given in combination.', 'Measure level of the M30 before and after therapy']",,,,,1,United States,"University of Alabama at Birmingham [Birmingham, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2021.0,4.0,0,NA/Other
NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer","A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2014-06-16,2021-07-07,2021-07-07,2014-06-19,2021-07-09,"['maximum tolerated dose (MTD) of BYL719', 'recommended dose for expansion (RDE)']","['Toxicity will be assessed using the NCI Common Toxicity Criteria, version 4.0, unless otherwise specified. The type, severity, timing and relationship of each adverse event will be documented.']",,,,,6,United States,"Memorial Sloan Kettering at Basking Ridge [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Commack [Commack, United States] | Memoral Sloan Kettering Westchester [Harrison, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering Rockville Centre [Rockville Centre, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves LJM716 and BYL719, which are new investigational drugs being evaluated for safety and tolerability in a specific patient population, indicating a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT02183805,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer,Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer,TERMINATED,PHASE2,Sun Yat-sen University,2014-06-17,2020-12-15,2020-12-15,2014-07-08,2021-07-23,['Progression free Survival'],['Overall Survival'],,,,,1,China,"Sun Yat-sen University Cancer Center [Guangzhou, China]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text describes a study on an existing treatment (chemotherapy followed by stem cell transplantation) being used for a specific indication (metastatic triple-negative breast cancer), which suggests an extension of indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02187822,Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases,A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer,TERMINATED,PHASE1,H. Lee Moffitt Cancer Center and Research Institute,2014-10-09,2018-02-20,2018-03-31,2014-07-11,2021-02-04,['Maximum Tolerated Dose (MTD) of TPI 287'],"['Disease Control Rate (DCR)', 'Progression Free Survival (PFS) Rate']",,,,,1,United States,"H. Lee Moffitt Cancer Center and Research Institute [Tampa, United States]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02189174,Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,"A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies",TERMINATED,PHASE1,Novartis Pharmaceuticals,2014-08-07,2015-11-12,2015-11-12,2014-07-14,2021-12-03,"['Incidence of DLT', 'Objective response rate (ORR) as per RECIST v1.1']","['Incidence of Adverse Events (AEs) and Serious Advers Events (SAEs)', 'Severity of AEs and SAEs and dose reductions and interruptions', 'Duration of response (DOR)', 'Progression free survival (PFS)', 'Best overall response (BOR)', 'Plasma concentration and Pharmacokinetics (PK) parameters of CLR457', 'Changes from baseline in glucose metabolism markers (fasting glucose and insulin)', 'Pre- and post- treatment immunohistochemistry of PI3K pathway molecules in newly obtained paired tumor samples']",,,,,7,Canada; Japan; Singapore; Spain; United States,"Massachusetts General Hospital SC-9 [Boston, United States] | Memorial Sloan Kettering SC-4 [New York, United States] | Tennessee Oncology SC [Nashville, United States] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Barcelona, Spain]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2015.0,10.0,1,Phase 1
NCT02192333,Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors,Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14),COMPLETED,,Fred Hutchinson Cancer Center,2015-08-03,2017-10-07,2019-12-31,2014-07-16,2020-10-09,"['Mean of the two z scores of the two highest scores for the symptoms that determined the participant\'s eligibility as ""high need"" assessed using patient-reported outcomes (PRO) survey']","['Barriers to health care assessed using the patient-reported outcomes (PRO) survey', 'Change in depression assessed using the patient-reported outcomes (PRO) survey', 'Change in distress assessed using the patient-reported outcomes (PRO) survey', 'Change in fatigue assessed using the patient-reported outcomes (PRO) survey', 'Change in pain assessed using the patient-reported outcomes (PRO) survey', 'Change in sleep assessed using the patient-reported outcomes (PRO) survey', 'Confidence in survivorship information assessed using the patient-reported outcomes (PRO) survey', 'General health assessed using the patient-reported outcomes (PRO) survey', 'Health behaviors assessed using the patient-reported outcomes (PRO) survey', 'Health care utilization assessed using the patient-reported outcomes (PRO) survey', 'Medications assessed using the patient-reported outcomes (PRO) survey', 'Mood and worries assessed using the patient-reported outcomes (PRO) survey', 'Musculoskeletal symptoms assessed using the patient-reported outcomes (PRO) survey', 'Neuropathy assessed using the patient-reported outcomes (PRO) survey', 'Post-traumatic stress assessed using the patient-reported outcomes (PRO) survey', 'Quality of life assessed using the patient-reported outcomes (PRO) survey', 'Reclassification of subject from high need to low need', 'Reproductive health assessed using the patient-reported outcomes (PRO) survey', 'Sexual function assessed using the patient-reported outcomes (PRO) survey', 'Social support assessed using the patient-reported outcomes (PRO) survey']",,,,,6,United States,"UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States] | University of Colorado Cancer Center - Anschutz Cancer Pavilion [Aurora, United States] | Dana-Farber Cancer Institute [Boston, United States] | UNC Lineberger Comprehensive Cancer Center [Chapel Hill, United States] | University of Pennsylvania/Abramson Cancer Center [Philadelphia, United States] | Fred Hutch/University of Washington Cancer Consortium [Seattle, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study focused on survivorship care and symptom management in young adult cancer survivors, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02216162,PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program,"PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program Including a Regular Physical Training, a Medical and Nutritional Follow-up, on Adjuvant Hormonal Treatment Compliance in Breast Cancer Patients Over 70 Years.",COMPLETED,,Hospices Civils de Lyon,2014-04-11,2019-02,2019-02-04,2014-08-13,2025-10-02,['Compliance of an adjuvant hormonal therapy'],"['Intensity and duration of musculoskeletal adverse events', 'Activities of daily living, functional walking capacity and changes in balance', 'Quality of life', 'Nutritional status', 'Analgesics consumption']",,,,,1,France,"Claire Falandry [Lyon, France]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT02216786,A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer,A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer,COMPLETED,PHASE2,Queen Mary University of London,2014-01-16,2021-12-31,2021-12-31,2014-08-15,2024-12-02,['Progression-free survival'],"['Progression-free survival', 'Objective response', 'Average change (%) in tumour size', 'Clinical Benefit (CB)']",,,,,79,France; Georgia; Germany; Hungary; Portugal; Romania; South Korea; Spain; United Kingdom,"ICO Paul Papin [Angers, France] | Institut Sainte Catherine [Avignon, France] | Antoine Lacassagne Centre De Lutte Contre Le Cancer De Nice [Nice, France] | Hospital Center Private Saint-Grégoire [Saint-Grégoire, France] | Centre Paul Strauss [Strasbourg, France] | Clinic Health House [Tbilisi, Georgia] | Institute of Clinical Oncology [Tbilisi, Georgia] | S. Khechinashvili University Clinic [Tbilisi, Georgia] | Tbilisi Cancer Center [Tbilisi, Georgia] | Frauenärztliche Gemeinschaftspraxis - Onkologie [Braunschweig, Germany] | Kliniken Essen-Mitte Senologie [Essen, Germany] | Klinik für Gynäkologie & Geburtshilfe/Brustzentrum [Frankfurt, Germany] | Praxis für interdisziplinäre Onkologie & Hämatologie [Freiburg im Breisgau, Germany] | MediProjekt GbR Hannover [Hannover, Germany] | SLK-Kliniken Heilbronn GmbH [Heilbronn, Germany] | Dokusan GmbH [Herne, Germany] | St. Vincentius Kliniken [Karlsruhe, Germany] | Schwerpunktpraxis Hämatologie / Onkologie MVZ Lahr [Lahr, Germany] | Klinikum Neumarkt [Neumarkt, Germany] | Onkologische Praxis [Oldenburg, Germany] | Praxis für Innere Medizin [Singen, Germany] | MVZ Klinik Dr. Hancken GmbH [Stade, Germany] | Mutterhaus der Borromäerinnen [Trier, Germany] | Schwarzwald Baar Klinikum, Villingen-Schwenningen [Villingen-Schwenningen, Germany] | Uzsoki Street Hospital [Budapest, Hungary] | Bacs-Kiskun County Hospital [Kalocsa, Hungary] | University of Pecs, Institute of Oncology [Pécs, Hungary] | Zala County Szent Rafael Hospital [Zalaegerszeg, Hungary] | Hospital da Luz [Lisbon, Portugal] | Ipo Porto [Porto, Portugal] | Center of Oncology Euroclinic [Bucharest, Romania] | Oncology Center Sf Nectarie [Caracal, Romania] | Cluj County Clinical Emergency Hospital, Clinical Department of Medical Oncology [Cluj-Napoca, Romania] | Oncology Institute ""Prof. Dr. Ion Chiricuta"" [Cluj-Napoca, Romania] | Oncology Center Oncolab Craiova [Craiova, Romania] | National Cancer Center South Korea [Goyang, South Korea] | Korea University Medical Center Guro Hospital [Seoul, South Korea] | Yonsei University Health System [Seoul, South Korea] | Hospital Universitari Vall D'Hebron [Barcelona, Spain] | Instituto Oncologico Dr. Rosell [Barcelona, Spain] | Consorcio Hospitalario Provincial de Castellon [Castelló, Spain] | Cafeteria Hospital San Pedro de Alcantara [Cáceres, Spain] | Hospital Ico Josep Trueta [Girona, Spain] | University Hospital Arnau de Vilanova [Lleida, Spain] | Hospital Clinico Universitario San Carlos [Madrid, Spain] | Hospital Son Llàtzer [Palma, Spain] | Hospital Son Espases [Palma de Mallorca, Spain] | Hospital Universitario de Canarias [San Cristóbal de La Laguna, Spain] | Hospital Universitari Sant Joan de Reus [Tarragona, Spain] | Wansbeck General Hospital [Ashington, United Kingdom] | Princess of Wales Hospital [Bridgend, United Kingdom] | Royal Sussex County Hospital [Brighton, United Kingdom] | Kent and Canterbury Hospital [Canterbury, United Kingdom] | Cumberland Infirmary [Carlisle, United Kingdom] | Broomfield Hospital [Chelmsford, United Kingdom] | University Hospital of North Durham [Durham, United Kingdom] | Calderdale Royal Hospital [Halifax, United Kingdom] | Huddersfield Royal Infirmary [Huddersfield, United Kingdom] | Kidderminster Hospital [Kidderminster, United Kingdom] | Royal Glamorgan Hospital [Llantrisant, United Kingdom] | Queen Mary University of London [London, United Kingdom] | Charring Cross Hospital [London, United Kingdom] | King's College Hospital [London, United Kingdom] | Mount Vernon Hospital [London, United Kingdom] | Queen Elizabeth Hospital, Woolwich [London, United Kingdom] | Saint Bartholomew's Hospital [London, United Kingdom] | The Royal Free Hospital [London, United Kingdom] | The Kent Oncology Centre [Maidstone, United Kingdom] | North Tyneside General Hospital [North Shields, United Kingdom] | Nottingham City Hospital [Nottingham, United Kingdom] | Derriford Hospital [Plymouth, United Kingdom] | Weston Park Hospital [Sheffield, United Kingdom] | Solihull Hospital [Solihull, United Kingdom] | Southend University Hospital [Southend-on-Sea, United Kingdom] | Royal Stoke University Hospital [Stoke-on-Trent, United Kingdom] | King's Mill Hospital [Sutton in Ashfield, United Kingdom] | Great Western Hospital [Swindon, United Kingdom] | Wrexham Maelor [Wrexham, United Kingdom] | Yeovil District Hospital [Yeovil, United Kingdom]",2014.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves AZD2014, which is a dual mTOR inhibitor being tested in combination with Fulvestrant for the treatment of metastatic or advanced breast cancer, indicating it is a new medicine.",OTHER,False,2021.0,4.0,1,Phase 2
NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer,COMPLETED,PHASE1,Mayo Clinic,2014-12-05,2016-03-28,2018-10-01,2014-08-19,2018-10-03,['Maximum tolerated dose (MTD) of alisertib in combination with fulvestrant graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0'],['Tumor response (complete or partial response) using Response Evaluation Criteria in Solid Tumors version 1.1'],,,,,1,United States,"Mayo Clinic [Rochester, United States]",2014.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02224261,Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery,Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery: a Randomized Controlled Trial,COMPLETED,,University of Alcala,2016-01-10,2019-12-10,2019-12-10,2014-08-25,2023-09-28,['Change from baseline in Subjective pain at one month (post-intervention); and 3 and 6 months post-intervention'],['Change from baseline in Range of shoulder motion at one month (post-intervention); and 3 and 6 months post-intervention'],,,,,1,Spain,"Physiotherapy in women´s health research group. University of Alcalà [Alcalà de Henares, Spain]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses the effectiveness of physical therapy for a specific condition (Axillary Web Syndrome) after breast cancer surgery, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02225470,Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes,"An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane",COMPLETED,PHASE3,"Eisai Co., Ltd.",2013-09-26,2017-09-29,2018-06-22,2014-08-26,2018-08-28,"['Progression-Free Survival (PFS) of Eribulin Arm by tumor assessment : Time to disease progression', 'Progression-Free Survival (PFS) of Vinorelbine Arm by tumor assessment: Time to disease progression', 'Maximum observed plasma concentration (Cmax) of Eribulin Arm in a minimum of 15 subjects', 'Time at which the highest drug concentration occurs (tmax) of Eribulin Arm in a minimum of 15 subjects', 'Area under the plasma concentration-time curve (AUC) of Eribulin Arm in a minimum of 15 subjects', 'Terminal phase rate constant (lambda Z) of Eribulin Arm in a minimum of 15 subjects', 'Terminal elimination phase half-life (t1/2) of Eribulin Arm in a minimum of 15 subjects', 'Distribution volume at steady-state (Vss) of Eribulin Arm in a minimum of 15 subjects', 'Total clearance (CL) of Eribulin Arm in a minimum of 15 subjects']","['Overall Survival (OS)', 'Duration of Response', 'Objective Response Rate (ORR)', 'Evaluate safety parameters such as electrocardiograms', 'Evaluate safety assessments parameters such as vital signs( VS)', 'Evaluate safety parameters such as adverse events (AEs)', 'Evaluate safety parameters such as laboratory measurements']",,,,,35,China,"04 Eisai Trial Site [Bengbu, China] | 37 Eisai Trial Site [Hefei, China] | 01 Eisai Trial Site [Beijing, China] | 03 Eisai Trial Site [Beijing, China] | 33 Eisai Trial Site [Beijing, China] | 35 Eisai Trial Site [Beijing, China] | 07 Eisai Trial Site [Fuzhou, China] | 08 Eisai Trial Site [Fuzhou, China] | 20 Eisai Trial Site [Guangzhou, China] | 36 Eisai Trial Site [Guangzhou, China] | 10 Eisai Trial Site [Nanning, China] | 12 Eisai Trial Site [Shijiazhuang, China] | 11 Eisai Trial Site [Harbin, China] | 38 Eisai Trial Site [Zhengzhou, China] | 14 Eisai Trial Site [Wuhan, China] | 15 Eisai Trial Site [Wuhan, China] | 05 Eisai Trial Site [Changsha, China] | 13 Eisai Trial Site [Changsha, China] | 34 Eisai Trial Site [Changsha, China] | 18 Eisai Trial Site [Nanjing, China] | 31 Eisai Trial Site [Nanjing, China] | 16 Eisai Trial Site [Changchun, China] | 17 Eisai Trial Site [Changchun, China] | 06 Eisai Trial Site [Dalian, China] | 19 Eisai Trial Site [Shenyang, China] | 21 Eisai Trial Site [Yinchuang, China] | 24 Eisai Trial Site [Xi'an, China] | 28 Eisai Trial Site [Xi'an, China] | 22 Eisai Trial Site [Qingdao, China] | 09 Eisai Trial Site [Shanghai, China] | 23 Eisai Trial Site [Taiyuan, China] | 26 Eisai Trial Site [Chengtu, China] | 27 Eisai Trial Site [Tianjin, China] | 30 Eisai Trial Site [Yunnan, China] | 40 Eisai Trial Site [Hangzhou, China]",2013.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares Eribulin and Vinorelbine in a specific patient population with previously treated breast cancer, indicating an extension of indication for Eribulin rather than testing a new medicine.",INDUSTRY,False,2018.0,7.0,0,Phase 3
NCT02227082,Olaparib and Radiotherapy in Inoperable Breast Cancer,Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer,COMPLETED,PHASE1,The Netherlands Cancer Institute,2013-10-21,2019-09,2020-08,2014-08-27,2021-08-04,['The incidence of dose limiting toxicities.'],"['Acute toxicity', 'Late toxicity']",,,,,1,Netherlands,"The Netherlands Cancer Institute [Amsterdam, Netherlands]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves the use of Olaparib, which is an existing medication, in combination with radiotherapy for a specific indication (inoperable breast cancer), indicating an extension of its use rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,Phase 1
NCT02229136,Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus,Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis,COMPLETED,PHASE2,US Oncology Research,2014-09-04,2022-11,2022-11,2014-08-29,2022-12-01,['Incidence of Grade ≥ 2 stomatitis'],"['Incidence of all side effects', 'Percentage of patients requiring dose interruptions and/or dose reductions of everolimus', 'Reduction in pain score on questionnaires']",,,,,1,United States,"12 sites incl Yakima, WA, Boulder, CO, and Austin, TX [US, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares existing treatments (Miracle Mouthwash Plus Hydrocortisone and Prednisolone Mouth Rinse) for a specific condition (mouth sores caused by Everolimus), indicating an extension of indication rather than testing a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT02248090,AZD9496 First Time in Patients Ascending Dose Study,"Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,AstraZeneca,2014-10-22,2017-01-31,2019-04-03,2014-09-25,2019-06-24,['Safety and tolerability'],"['Single and multiple dose pharmacokinetics of AZD9496', '4β-hydroxycholesterol concentration in blood', 'Antitumour activity']",,,,,6,South Korea; United Kingdom; United States,"Florida Cancer Specialists [Sarasota, United States] | Research Site [New York, United States] | Sarah Cannon [Nashville, United States] | Seoul National Univ. Hospital [Seoul, South Korea] | Research Site [Cambridge, United Kingdom] | Christie [Manchester, United Kingdom]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02250118,Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer,Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer,TERMINATED,PHASE1,Institut Curie,2014-12-09,2017-04-12,2017-10-17,2014-09-26,2017-11-06,['To determine the maximum tolerated dose (MTD)'],"['Study of the pleural and serum pharmacokinetics', 'Study of pleural and serum Vascular Endothelial Growth Factor (VEGF) levels', 'Determination of time until new punction or death', 'Total number of pleural drainage procedures', 'Drainage-free survival and overall survival', 'Evaluation of dyspnoea', 'Evaluation of quality of life']",,,,,1,France,"Institut Curie - Hôpital René Huguenin [Saint-Cloud, France]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT02263495,Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer,"A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy",COMPLETED,PHASE2,Asan Medical Center,2014-12-19,2017-05-11,2019-06-17,2014-10-13,2020-07-14,['Progression free survival'],"['overall survival', 'neuropathic scale', 'toxicity of study drugs', 'duration of response', 'objective response rate', 'clinical benefit rate']",,,,,2,South Korea,"Samsung Medical Center [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT02266173,Observational Study of Pertuzumab Safety in Participants With Breast Cancer,Post-Marketing Surveillance of Perjeta in Breast Cancer,COMPLETED,,Hoffmann-La Roche,2015-02-05,2021-03-08,2021-03-08,2014-10-16,2021-05-03,['Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)'],['Percentage of Participants With Overall Response as Determined Using Response Evaluation Criteria in Solid Tumors (RECIST)'],,,,,37,South Korea,"Inje university Haeundae Paik Hospital [Busan, South Korea] | Pusan National University Hospital [Busan, South Korea] | Kosin University Gospel Hospital [Busan, South Korea] | Kyungpook National University Chilgok Hospital [Daegu, South Korea] | Keimyung University Dongsan Medical Center [Daegu, South Korea] | Chungnam National University Hospital [Daejeon, South Korea] | National Health Insurance Service Ilsan Hospital [Gyeonggi-do, South Korea] | Hallym University Sacred Heart Hospital [Gyeonggi-do, South Korea] | Soonchunhyang University Bucheon Hospital [Gyeonggi-do, South Korea] | St. Vincent's Hospital [Gyeonggi-do, South Korea] | Ajou University Medical Center [Gyeonggi-do, South Korea] | The Catholic University of Korea Bucheon St. Mary's Hospital [Gyeonggi-do, South Korea] | Pusan National University Yangsan Hospital [Gyeongsangnam-do, South Korea] | Catholic Univ. of Incheon St.Mary's Hospital [Incheon, South Korea] | Inha University Hospital [Incheon, South Korea] | Gil Hospital. Gachon University [Incheon, South Korea] | Catholic Kwandong University International St. Mary'S Hospital. [Incheon, South Korea] | Chonnam National University Hwasun Hospital [Jeollanam-do, South Korea] | Wonkwang University School of Medicine & Hospital [Jeonlabuk-do, South Korea] | Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Samsung Medical Center [Seoul, South Korea] | Inje University, Sanggye-Paik Hospital [Seoul, South Korea] | Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences [Seoul, South Korea] | Korea University Anam Hospital [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Konkuk University Medical Center [Seoul, South Korea] | Gangdong Kyung Hee University Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | Seoul St Mary's Hospital [Seoul, South Korea] | ChungAng University Hospital [Seoul, South Korea] | Yeouido St. Mary's Hospital [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Korea University Guro Hospital [Seoul, South Korea] | SMG-SNU Boramae Medical Center [Seoul, South Korea] | Ulsan University Hosiptal [Ulsan, South Korea]",2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses a post-marketing surveillance study of Pertuzumab (Perjeta) in breast cancer, indicating an extension of its indication for use in this specific patient population.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT02269813,PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe),PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe),COMPLETED,,West German Study Group,2015-04-01,2016-03-31,2016-09-30,2014-10-21,2019-08-13,"['Measure the impact of MammaPrint on adjuvant treatment decisions in discordant groups (ET/POOR and CT/GOOD) in stage-1/2, HR+, HER2- breast cancer and test whether these impacts each exceed a pre-determined compliance threshold.', 'Assess the incremental cost-effectiveness of MammaPrint in terms of cost and quality-adjusted life years within a health economic context using the impacts measured in this trial as well as the predictive impact demonstrated in previous trials.']","['Measure the impacts of MammaPrint on adjuvant treatment decisions (physician chemotherapy intention) and compare with previous trials involving MammaPrint or other tests.', 'Measure rate (by incidence) and severity (by Common Toxicity Criteria) of treatment-related serious adverse events stratified by whether or not patient received adjuvant chemotherapy.', ""Assess change in patients' decisional conflict status and anxiety levels before and after MammaPrint results via questionnaire, stratified by the four groups (2 concordant and 2 discordant)."", ""Assess investigators' confidence in treatment recommendations before and after MammaPrint results were known via questionnaire."", 'Assess concordance of final treatment intention and treatment actually received by number of patients.', 'Assess concordance of TargetPrint ER, PR and HER2 results with locally assessed IHC/FISH ER, PR and HER2 by number of patients.', 'Compare clinical subtype based on IHC/FISH ER, PR, HER2 and Ki-67 (St Gallen 2013) with BluePrint molecular subtype by diagnostic definition of subtype.', 'Assess concordance of MammaPrint, BluePrint and TargetPrint in multi-centric breast cancer by number of patients.', 'Assess the combined switch rate in the two concordant groups (ET/GOOD) and (CT/POOR) and verify that it is lower than the switch rate in both discordant groups by number of patients.', 'Perform descriptive sub-analysis in pre- and post-menopausal women by switch percentages.', 'Perform cross-validation with other adjuvant breast cancer studies by switch rate, if available.']",,,,,3,Austria; Germany; Switzerland,"Medizinische Universität Innsbruck Universitätsklinik für Frauenheilkunde [Innsbruck, Austria] | Breast Center of the University of Munich (LMU) [Munich, Germany] | Kantonsspital St.Gallen [Sankt Gallen, Switzerland]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2016.0,9.0,1,NA/Other
NCT02275403,Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma,Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN),COMPLETED,PHASE2,The Christie NHS Foundation Trust,2015-04-13,2018-12-17,2018-12-17,2014-10-27,2019-01-31,['Change in Measure Yourself Medical Outcome Profile (MYMOP2) score of the most troubling symptom of CIPN'],"['Change in grade of CIPN', 'Change in use of concomitant CIPN related medication', 'Change in chemotherapy dosage', 'Pain related scores', 'Quality of life', 'Acupuncture treatment compliance', 'Preliminary health economic evaluation of cost effectiveness', 'Uptake of the offer of acupuncture at 10 weeks']",,,,,2,United Kingdom,"The Christie NHS Foundation Trust [Manchester, United Kingdom] | The Royal Oldham Hospital [Oldham, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial evaluates the effectiveness of acupuncture as an adjunct to standard care for chemotherapy-induced peripheral neuropathy (CIPN) rather than testing a new medicine or an extension of indication for an existing medicine.,OTHER,False,2018.0,7.0,0,Phase 2
NCT02278965,Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,COMPLETED,PHASE1,Katherine D. Crew,2015-01-22,2017-04-19,2017-04-19,2014-10-30,2022-08-17,['Number of participants successfully completing the 1-year intervention'],"['Percent in reduction of mammographic density', 'Change in fasting serum insulin microunits per milliliter', 'Change in C-peptide nanograms per milliliter', 'Change in insulin-like growth factor 1 (IGF-1) nanograms per milliliter', 'Change in insulin-like growth factor binding protein 1 (IGFBP-1) nanograms per milliliter', 'Change in insulin-like growth factor binding protein 3 (IGFBP-3) milligrams per liter', 'Change in fasting serum glucose milligrams per deciliter', 'Change in total cholesterol milligrams per deciliter', 'Change in high-density lipoprotein (HDL) milligrams per deciliter', 'Change in low-density lipoprotein (LDL) milligrams per deciliter', 'Change in Leptin microunits per liter', 'Change in adiponectin micrograms per milliliter', 'Change in serum C-reactive protein milligrams per deciliter', 'Change in Interleukin-6 picograms per milliliter', 'Change in body mass index (BMI)', 'Change in systolic blood pressure', 'Change in diastolic blood pressure', 'Change in homeostatus model assessment (HOMA) score']",,,,,1,United States,"Columbia University [New York, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study involves the use of Metformin and Omega-3 Fatty Acids in women with a history of early-stage breast cancer, indicating an extension of indication for these existing medications rather than introducing a new medicine.",OTHER,False,2017.0,8.0,0,Phase 1
NCT02286362,An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer,,COMPLETED,,Hoffmann-La Roche,2015-01-14,2016-11-10,2016-11-10,2014-11-07,2017-09-27,"['Safety (composite outcome measure): Incidence, nature, and severity according to NCI-CTCAE v. 4.0 of: adverse events (AEs), serious AEs, grade >/= 3 AEs, non-serious adverse drug reaction or causality unknown, AESI (congestive heart failure)']","['Demographic data', 'Number of modalities regarding dose and injection site of Herceptin SC administration', 'Patient-reported outcome: Quality of Life using the EORTC QLQ-C30 questionnaire']",,,,,97,France,"Clinique Du Docteur Calabet; Cromg [Agen, France] | C H Du Pays D'Aix En Provence; Hopital De Jour [Aix-en-Provence, France] | Ch Du Pays D Aix; Maternite Gynecologie [Aix-en-Provence, France] | Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire [Aix-en-Provence, France] | Centre Hospitalier Albi; Oncologie [Albi, France] | Clinique Claude Bernard; Onco Hematologie [Albi, France] | Hopital Prive D Antony; Oncologie [Antony, France] | Cmc De Tronquieres;Chimiotherapie Et Radiotherapie [Aurillac, France] | Ch D Auxerre; Oncologie [Auxerre, France] | Clinique Du Docteur Maymard; Hopital De Jour Chimiotherapie [Bastia, France] | Hopital De Falconaja Furiani; Hopital De Jour [Bastia, France] | Centre Oncologie Du Pays Basque [Bayonne, France] | HOPITAL JEAN MINJOZ; Oncologie [Besançon, France] | Centre Pierre Curie [Beuvry, France] | Ch De Beziers; Hematologie [Béziers, France] | Hopital Avicenne; Cancerologie [Bobigny, France] | Clinique Tivoli; Chimiotherapie Radiotherapie [Bordeaux, France] | Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie [Bordeaux, France] | Centre Hospitalier Fleyriat; Oncologie/Hematologie [Bourg-en-Bresse, France] | Hopital Augustin Morvan; Federation De Cancerologie [Brest, France] | Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie [Brest, France] | CMC de Bligny; Oncologie Court Sejour [Briis-sous-Forges, France] | Hopital Pierre Nouveau; Medecine A [Cannes, France] | CH Carcassonne; Service Onco Hematologie [Carcassonne, France] | Clinique Montreal; Chimiotherapie [Carcassonne, France] | Medipole De Savoie; Departement Oncologie [Challes-les-Eaux, France] | Hopital Prive Paul d Egine; Chimiotherapie Ambulatoire [Champigny-sur-Marne, France] | CH de Cholet; oncologie [Cholet, France] | Hopital Antoine Beclere; Hopital De Jour [Clamart, France] | Centre De Radiotherapie Et D'Oncologie; Oncologie [Compiègne, France] | Groupe Hospitalier Public Du Sud De L'Oise GHPSO; Oncologie [Creil, France] | Chi De Creteil; Radiotherapie Oncologie [Créteil, France] | Hopital Henri Mondor; Oncologie Medicale [Créteil, France] | Centre Leonard De Vinci;Chimiotherapie [Dechy, France] | Centre De Radiotherapie Du Parc [Dijon, France] | Ch De La Dracenie; Hopital De Jour [Draguignan, France] | Clinique Claude Bernard; Chimiotherapie [Ermont, France] | Chi Emile Durkheim Site Epinal; Oncologie [Épinal, France] | Chi De Frejus Saint Raphael; Oncologie [Fréjus, France] | Chi Alpes Du Sud Site De Gap; Med Interne Et Polyvalente [Gap, France] | Centre Mistral; Chirurgie Cancerologie Gynecologiques [Guilherand-Granges, France] | CH de Marne la vallee; Oncologie Medicale [Jossigny, France] | Hopital Albert Michallon; Oncologie [La Tronche, France] | Hopital Louis Pasteur; Oncologie Hematologie [Le Coudray, France] | Ch Du Mans; Medecine Hematologie Oncologie [Le Mans, France] | Polyclinique Du Bois; Oncologie [Lille, France] | Clinique Chenieux; Oncology [Limoges, France] | Ch De Longjumeau; Hopital De Jour Et Semaine [Longjumeau, France] | Ch De Lons Le Saunier; Medecine 5 [Lons-le-Saunier, France] | Ch Bretagne Sud Site Scorff; Oncologie Medicale [Lorient, France] | Clinique De La Sauvegarde; Chimiotherapie [Lyon, France] | Clinique Saint Faron; Sce Oncologie Radiotherapie [Mareuil-lès-Meaux, France] | Ctre Hosp Prive Beauregard; Hop De Jour Chimiotherapie [Marseille, France] | Hopital Clinique Claude Bernard; Oncologie Medicale [Metz, France] | Hopital Layne; Medecine Ambulatoire [Mont-de-Marsan, France] | Ghi Le Raincy Montfermeil; Oncologie Medicale [Montfermeil, France] | Ch De Montlucon; Hematologie Cancerologie [Montluçon, France] | Clinique Clementville; Hopital De Jour [Montpellier, France] | Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE [Nancy, France] | Centre Catherine de Sienne; Chimiotherapie [Nantes, France] | Polyclinique Du Languedoc; Chimiotherapie [Narbonne, France] | Ch Georges Renon; Oncologie Radiotherapie [Niort, France] | Hopital Caremeau; Hematologie Oncologie [Nîmes, France] | Hopital Caremeau; Maternite Gynecologie [Nîmes, France] | Clinique Valdegour [Nîmes, France] | CROM [Osny, France] | Ch Pitie Salpetriere; Oncologie Medicale [Paris, France] | GH Paris Saint Joseph; Hopital De Jour Oncologie [Paris, France] | Ch Francois Mitterrand; Medecine Oncologie [Pau, France] | Centre Catalan D' Oncologie [Perpignan, France] | Hopital Saint Jean; Centre Henri Pujol [Perpignan, France] | Polyclinique Francheville; Med Chimiotherapie Radiotherapie [Périgueux, France] | CH Rene Dubos; Oncologie [Pontoise, France] | CH Annecy Genevois site Annecy; Oncologie [Pringy, France] | Chi De Cornouaille; Oncologie Hospitalisation [Quimper, France] | Institut Jean Godinot; Pavillon Rubis [Reims, France] | Clinique de la Theuillerie; Oncologie [Ris-Orangis, France] | Clinique Armoricaine Radiologie; Cons Externes [Saint-Brieuc, France] | Clinique Francois 1er; Service De Chimiotherapie [Saint-Dizier, France] | Chp Saint Gregoire; Cancerologie Radiotherapie [Saint-Grégoire, France] | Clinique de L'Union; Oncologie [Saint-Jean, France] | CH de Saint Jean De Maurienne; Had St Jean De Maurienne [Saint-Jean-de-Maurienne, France] | Clinique Mutualiste L Estuaire [Saint-Nazaire, France] | Centre Hospitalier De Sens; Medecine Generale Oncologie [Sens, France] | Ch Gaston Ramon; Hopital De Jour [Sens, France] | Centre Clinical; Oncologie Medicale [Soyaux, France] | Clinique De L Estree; Oncologie Medicale [Stains, France] | Clinique Medico Chir Charcot; Chir Cancerologie [Ste Foy Les Lyon, France] | Institut D Oncologie Medical [Strasbourg, France] | Strasbourg Oncologie Libérale [Strasbourg, France] | Hopital Civil; Hematologie Oncologie [Strasbourg, France] | Hopitaux Du Leman Site Thonon; Maternite Gynecologie [Thonon-les-Bains, France] | Clinique Pasteur; Oncologie Medicale [Toulouse, France] | Clinique Saint Jean Languedoc; Oncologie Medicale [Toulouse, France] | Hopital Bretonneau; Clinique D'Oncologie & de Radiotherapie [Tours, France] | Centre Alexis Vautrin; Oncologie Medicale [Vandœuvre-lès-Nancy, France] | Hopital Prive Villeneuve d Ascq;Chimiotherapie Radiotherapie [Villeneuve-d'Ascq, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study evaluates the safety of Herceptin, which is an existing medication, administered subcutaneously for a specific patient population (early HER2-positive breast cancer), indicating an extension of its indication.",INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT02305628,An Observational Study of Herceptin SC Safety in Breast Cancer,Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer,COMPLETED,,Hoffmann-La Roche,2015-06-26,2020-01-31,2020-01-31,2014-12-02,2020-11-16,"['Safety (composite outcome measure): Incidence of adverse events (AEs), serious adverse events (SAEs), adverse events of special interest, pregnancies, adverse drug reactions (ADRs); unexpected ADRs; expected ADRs']","['Efficacy: Pathological Complete Response (pCR) in neoadjuvant early breast cancer (EBC)', 'Efficacy: Overall response per Response Evaluation Criteria in Solid Tumors (RECIST)']",,,,,23,South Korea,"Pusan National University Hospital [Busan, South Korea] | Kosin University Gospel Hospital [Busan, South Korea] | Keimyung University Dongsan Medical Center [Daegu, South Korea] | Myongji Hospital [Gyeonggi-do, South Korea] | Hallym University Sacred Heart Hospital [Gyeonggi-do, South Korea] | Ajou University Medical Center [Gyeonggi-do, South Korea] | Pusan National University Yangsan Hospital [Gyeongsangnam-do, South Korea] | Gyeongsang National University Hospital [Gyeongsangnam-do, South Korea] | Gachon University Gil Medical Center [Incheon, South Korea] | Inha University Hospital [Incheon, South Korea] | Chonnam National University Hwasun Hospital [Jeollanam-do, South Korea] | Wonkwang University School of Medicine & Hospital [Jeonlabuk-do, South Korea] | Samsung Medical Center [Seoul, South Korea] | Inje University, Sanggye-Paik Hospital [Seoul, South Korea] | Korea Cancer Hospital of Korea Institute of Radiological and Medical Sciences [Seoul, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Cheil General Hospital & Women's Healthcare Center [Seoul, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | ChungAng University Hospital [Seoul, South Korea] | Borame Medical Center [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Miz Medi Hospital [Seoul, South Korea] | Ulsan University Hosiptal [Ulsan, South Korea]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT02305641,An Observational Study of Kadcyla Safety in Breast Cancer,Post-Marketing Surveillance of Kadcyla in Breast Cancer,COMPLETED,,Hoffmann-La Roche,2015-05-21,2021-08-10,2021-08-10,2014-12-02,2023-01-11,"['Safety (composite outcome measure): Incidence of serious adverse events (SAEs), adverse drug reactions (ADRs); unexpected adverse events and ADRs; expected ADRs; non-serious ADRs']","['Efficacy (composite outcome measure): Tumor response to Kadcyla treatment including complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD)']",,,,,38,South Korea,"Inje University Busan Paik Hospital [Busan, South Korea] | Dong-A University Hospital [Busan, South Korea] | Kosin University Gospel Hospital [Busan, South Korea] | Pusan National University Hospital [Busan, South Korea] | Kyungpook National University Chilgok Hospital [Daegu, South Korea] | Keimyung University Dongsan Medical Center [Daegu, South Korea] | Yeungnam University Medical Center; Surgical Department of Breast and Internal Secretion [Daegu, South Korea] | Chungnam National University Hospital [Daejeon, South Korea] | Uijeongbu St. Mary's Hospital [Gyeonggi-do, South Korea] | Hallym University Sacred Heart Hospital [Gyeonggi-do, South Korea] | Soonchunhyang University Bucheon Hospital [Gyeonggi-do, South Korea] | Bucheon St Mary's hospital [Gyeonggi-do, South Korea] | St. Vincent's Hospital [Gyeonggi-do, South Korea] | Pusan National University Yangsan Hospital [Gyeongsangnam-do, South Korea] | Gachon University Gil Medical Center [Incheon, South Korea] | Inha University Hospital [Incheon, South Korea] | Catholic Kwandong University International St. Mary'S Hospital. [Incheon, South Korea] | Chonbuk National Uni Hospital [Jeollabuk-do, South Korea] | Chonnam National University Hwasun Hospital [Jeollanam-do, South Korea] | Presbyterian Medical Center [Jeonju, South Korea] | Wonkwang University School of Medicine & Hospital [Jeonlabuk-do, South Korea] | NHIC Ilsan Hospital [Kyonggi-do, South Korea] | Severance Hospital, Yonsei University Health System [Seoul, South Korea] | Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences [Seoul, South Korea] | Korea University Anam Hospital [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Kangbuk Samsung Hospital [Seoul, South Korea] | Konkuk University Medical Center [Seoul, South Korea] | Gangdong Kyung Hee University Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | ChungAng University Hospital [Seoul, South Korea] | Yeouido St. Mary's Hospital [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | SMG-SNU Boramae Medical Center [Seoul, South Korea] | Ajou University Hospital [Suwon, South Korea] | Ulsan University Hosiptal [Ulsan, South Korea]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the safety and efficacy of Kadcyla in the context of breast cancer, indicating that it is being evaluated for an existing indication rather than introducing a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT02309177,"Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer","A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-pacitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-paclitaxel/Carboplatin in Stage Iiib/iv Non-small Cell Lung Cancer or Nab-paclitaxel in Metastastic Breast Cancer",COMPLETED,PHASE1,Celgene,2015-01-12,2018-09-12,2018-09-12,2014-12-05,2019-05-31,"['Evaluate Dose Limiting Toxicity (DLT) of each combination regimen', 'Evaluate the safety of the nab-paclitaxel/nivolumab combination regimens', 'Grade 3 or 4 TEAE']","['Treatment Emergent Adverse Events', 'Progression-free survival', 'Overall Survival', 'Disease Control Rate', 'Overall Response Rate', 'Duration of Response']",,,,,15,United States,"UC Davis Cancer Center [Sacramento, United States] | University of California Los Angeles [Santa Monica, United States] | Yale Cancer Center [New Haven, United States] | H. Lee Moffitt Cancer Center and Research Institute University of South Florida [Tampa, United States] | Northwestern University-NMDTI [Chicago, United States] | Dana-Farber / Harvard Cancer Institute [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | John Theurer Cancer Center at Hackensack University Medical Center [Hackensack, United States] | Regional Care Cancer Centers NJ [Morristown, United States] | Levine Cancer Institute [Charlotte, United States] | Oncology Hematology Care, Inc. [Cincinnati, United States] | Ohio State Medical Center [Columbus, United States] | University of Pennslyvania [Philadelphia, United States] | Seattle Cancer Center Alliance [Seattle, United States] | Medical College of Wisconsin [Milwaukee, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT02311543,Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer,Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Lymph Node Dissection for Breast Cancer. A Multicenter Randomized Phase III Trial.,COMPLETED,PHASE3,Swiss Cancer Institute,2015-03-18,2017-05-23,2017-06-27,2014-12-08,2019-05-15,['Total volume of axillary drainage'],"['Volume of axillary drainage per 24 hours', 'Total duration of axillary drainage in days', 'Duration of postoperative hospital stay in days', 'Patients with clinically relevant seroma', 'Number of clinically relevant seroma aspirations', 'Total volume of all clinically relevant seroma aspirations in ml']",,,,,16,Switzerland,"Kantonsspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitätsspital Basel [Basel, Switzerland] | CSSI Bellinzona/Lugano, Ospedale San Giovanni [Bellinzona, Switzerland] | Brustzentrum, Klinik Engeried [Bern, Switzerland] | Kantonsspital Graubünden [Chur, Switzerland] | Spital Thurgau AG, Brustzentrum [Frauenfeld, Switzerland] | Hôpitaux universitaires de Genève [Geneva, Switzerland] | Centre Hospitalier Universitaire Vaudois CHUV [Lausanne, Switzerland] | Tumor- und Brustzentrum ZeTuP St. Gallen [Sankt Gallen, Switzerland] | Kantonsspital St. Gallen [Sankt Gallen, Switzerland] | CHVC Hôpital de Sion [Sion, Switzerland] | Kantonsspital Winterthur, Brustzentrum [Winterthur, Switzerland] | Brust-Zentrum Seefeld [Zurich, Switzerland] | Stadtspital Triemli [Zurich, Switzerland] | UniversitätsSpital Zürich, Klinik für Gynäkologie [Zurich, Switzerland]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial evaluating a surgical sealing patch's impact on lymphatic drainage after a specific surgical procedure for breast cancer, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,Phase 3
NCT02316509,A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,"An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer",COMPLETED,PHASE1,"Genentech, Inc.",2015-03-17,2020-01-10,2020-01-10,2014-12-15,2020-10-05,"['Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of GDC-0927', 'Percentage of Participants With Adverse Events (AEs)']","['Percentage of Participants With Objective Response Assessed by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)', 'Percentage of Participants With Clinical Benefit Assessed by RECIST v1.1', 'Part I: Maximum Observed Plasma Concentration (Cmax) of GDC-0927', 'Part II: Cmax of GDC-0927', 'Part I: Time to Reach Cmax (Tmax) of GDC-0927', 'Part II: Tmax of GDC-0927', 'Part I: Area Under the Plasma Concentration Versus Time Curve (AUC) of GDC-0927', 'Part II: AUC of GDC-0927', 'Plasma Half-Life (t1/2) of GDC-0927', 'Part II: t1/2 of GDC-0927', ""Part I: Change From Baseline in Corrected QT (QTc) Interval Using Fridericia's Formula, as Assessed by Electrocardiogram (ECG)"", ""Part II: Change From Baseline in QTc Interval Using Fridericia's Formula, as Assessed by ECG"", 'Part I: Change From Baseline in RR Interval, as Assessed by ECG', 'Part II: Change From Baseline in RR Interval, as Assessed by ECG']",,,,,13,Spain; United States,"Massachusetts General Hospital. [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Sarah Cannon Cancer Center [Germantown, United States] | Vanderbilt Ingram Cancer Ctr [Nashville, United States] | ICO I Hospitalet Hospital Duran i Reynals Instituto Catalan de Oncologia de Hospitalet ICO [L'Hospitalet de Llobregat, Spain] | Onkologikoa - Kutxaren Institutu Onkologikoa [Donostia / San Sebastian, Spain] | Hospital Univ Vall d'Hebron; Servicio de Oncologia [Barcelona, Spain] | MD Anderson Cancer Center Madrid - España; Servicio de Farmacia [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital General Universitario Gregorio Maranon [Madrid, Spain] | HM Sanchinarro - CIOCC [Madrid, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT02324062,Cancer Genetics Hereditary Cancer Panel Testing,University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing,COMPLETED,,University of Southern California,2014-06-12,2017-01-05,2017-01-05,2014-12-24,2017-04-11,['Develop Hereditary Cancer panel repository'],"['Analyze frequency of genes found on HCP panel in high-risk population', 'Follow medical management of subjects after multi-gene panel testing', 'Descriptive analysis of patient information gained through process']",,,,,2,United States,"University of Southern California/ Kenneth Norris, Jr. Comprehensive Cancer Center and Hospital [Los Angeles, United States] | Stanford University [Stanford, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a study related to hereditary cancer panel testing and does not indicate the development of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2017.0,8.0,0,NA/Other
NCT02326857,Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment,Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment,COMPLETED,,National Cancer Institute (NCI),2014-12-23,2014-12-23,2020-09-23,2014-12-30,2020-09-25,['Characterize distribution of invasive breast cancer stage II and III molecular profiles'],"['Association of molecular profile with tumor histological type, size,lymph node status and surrogate markers', 'Proportion of participants in each molecular profile who achieve pCR to neoadjuvant chemotherpay', 'RCB following neoadjuvant chemotherapy', 'Predictive and prognostic gene expression signatures', 'Survival-OS, DFS, and TFF', 'Demographic and epidemiological characteristics of the population by molecular profile']",,,,,9,Argentina; Brazil; Chile; Mexico; Uruguay,"Instituto Leloir [Buenos Aires, Argentina] | Instituto Nacional de Cancer (INCA) [Rio de Janeiro, Brazil] | Instituto do C(SqrRoot) ncer do Estado de S(SqrRoot) o Paulo [São Paulo, Brazil] | Instituto de Salud Publica [Santiago, Chile] | Instituto Jalisciense de Cancerologia [Guadalajara, Mexico] | Universidad de Guadalajara [Guadalajara, Mexico] | Universidad de Sonora [Sonora, Mexico] | Institito Nacional de C(SqrRoot)(Degree)ncer [Montevideo, Uruguay] | Instituto Pasteur de Montevideo [Montevideo, Uruguay]",2014.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,NIH,False,2020.0,5.0,1,NA/Other
NCT02333370,"A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer","A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer",COMPLETED,PHASE1,Novartis Pharmaceuticals,2015-02-04,2022-09-29,2022-09-29,2015-01-07,2023-06-08,"['Phase Ib Dose escalation - Frequency of dose limiting toxicities (DLTs)', 'Phase Ib Dose Expansion: Number of participants with adverse events (AEs)', 'Phase Ib Dose Expansion: Number of participants with serious adverse events (SAEs)']","['Number of participants with adverse events (AEs) - Phase Ib dose escalation', 'Number of participants with serious adverse events (SAEs) - Phase Ib dose escalation', 'Overall Response Rate (ORR) - Phase Ib dose expansion', 'Clinical Benefit Rate (CBR) - Phase Ib dose expansion', 'Composite Plasma pharmacokinetics (PK) parameters of LEE011 (and relevant metabolites) and letrozole - Phase Ib', 'Progression Free Survival (PFS) as per RECIST v1.1- phase Ib dose expansion', 'Overall Survival (OS) - Phase Ib dose expansion', 'Disease Control Rate (DCR) - Phase Ib dose expansion', 'Duration of Response (DOR) - Phase Ib dose expansion']",,,,,15,Hong Kong; Japan; Singapore,"Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Nagoya, Japan] | Novartis Investigative Site [Sapporo, Japan] | Novartis Investigative Site [Yokohama, Japan] | Novartis Investigative Site [Osaka, Japan] | Novartis Investigative Site [Suita, Japan] | Novartis Investigative Site [Hidaka, Japan] | Novartis Investigative Site [Kitaadachi-gun, Japan] | Novartis Investigative Site [Sunto Gun, Japan] | Novartis Investigative Site [Bunkyo Ku, Japan] | Novartis Investigative Site [Bunkyo Ku, Japan] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Shinagawa-ku, Japan] | Novartis Investigative Site [Shinjuku-ku, Japan] | Novartis Investigative Site [Singapore, Singapore]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT02338245,Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab,Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy,COMPLETED,PHASE2,ASLAN Pharmaceuticals,2014-12-29,2016-05-19,2016-08-25,2015-01-14,2017-10-17,"['To compare the efficacy of ASLAN001 in combination with capecitabine, to lapatinib in combination with capecitabine in the percentage change from baseline tumor size at Week 12']","['Safety for all metastatic breast cancer (MBC) subjects (Physical examination, body weight, vital signs, ECG parameter, hematology, clinical laboratory tests and Adverse Events)', 'To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by PFS and tumor volume', 'To further compare the efficacy of ASLAN001 in combination with capecitabine to lapatinib in combination with capecitabine, as measured by the Objective Response Rate (ORR), Duration of Response (DoR), and Overall Survival (OS)']",,,,,19,Australia; Hong Kong; New Zealand; Philippines; Singapore; South Korea; Taiwan,"Australia [Western Australia, Australia] | Hong Kong [Hong Kong, Hong Kong] | New Zealand [Christchurch, New Zealand] | New Zealand [Tauranga, New Zealand] | Philippines [Bacolod City, Philippines] | Philippines [Dasmariñas, Philippines] | Singapore [Singapore, Singapore] | Singapore [Singapore, Singapore] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | South Korea [Seoul, South Korea] | Taiwan [Linkou District, Taiwan] | Taiwan [Kaohsiung City, Taiwan] | Taiwan [Taichung, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan] | Taiwan [Taipei, Taiwan]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"ASLAN001 is being studied as a new treatment option in combination with capecitabine for metastatic breast cancer (MBC), indicating it is a new medicine.",OTHER,False,2016.0,9.0,1,Phase 2
NCT02347163,Pre-operative Zoledronate in Triple Negative Breast Cancer,"A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level",TERMINATED,PHASE2,Mario Negri Institute for Pharmacological Research,2015-02-03,2018-06-08,2018-06-08,2015-01-27,2018-11-06,"['Assessment of zoledronate effect on Ki67 proliferative surrogate biomarker expression, according to p53 expression']","['Effect of zoledronate on critical genes/proteins related to p53 and mevalonate pathways, p53/PIN1 and YAP/TAZ (FFPE core biopsy will be tested for critical genes/proteins expression (by RT-PCR and IHC), including p53/PIN1 and YAP/TAZ)', 'Assessment of zoledronate safety (valuated by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale, version 4.0 and by the occurrence of serious adverse reactions)']",,,,,4,Italy,"Azienda Ospedaliera Spedali Civili di Brescia [Brescia, Italy] | Azienda Ospedaliera Papa Giovanni XXIII [Bergamo, Italy] | Oncologia 2 Istituto Oncologico Veneto IRCCS [Padua, Italy] | Fondazione Salvatore Maugeri - IRCCS [Pavia, Italy]",2015.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the effect of Zoledronate, which is an existing medication, in a new context (pre-operative treatment for triple negative breast cancer), indicating an extension of its indication.",OTHER,False,2018.0,7.0,0,Phase 2
NCT02358200,Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,"Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer",TERMINATED,PHASE1,Pamela Munster,2015-02-23,2019-01-08,2019-01-08,2015-02-06,2020-01-10,['Overall Response Rate (ORR)'],['Intolerable Toxicity'],,,,,1,United States,"University of California San Francisco [San Francisco, United States]",2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT02362958,A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer,Sun Yat-sen University Cancer Center,COMPLETED,PHASE2,Sun Yat-sen University,2015-01-09,2020-05-31,2020-05-31,2015-02-13,2020-07-15,['progression-free survival'],[],,,,,1,China,"Sun Yat-sen University Cancer Center [Guangzhou, China]",2015.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study involves Lapatinib, which is an existing medication, being tested in a specific patient population (trastuzumab-refractory metastatic breast cancer), indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02365662,A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,TERMINATED,PHASE1,AbbVie,2015-01-09,2018-03-15,2018-03-15,2015-02-19,2018-03-30,"['Number of participants with adverse events', 'Maximum Plasma Concentration (Cmax) of ABBV-221', 'Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221', 'Maximum tolerated dose of ABBV-221', 'Area Under the Plasma Concentration-time Curve of ABBV-221', 'Recommended Phase 2 dose of ABBV-221']","['Assess the effect of systemic ABBV-221 administration on QT prolongation', 'Objective Response Rate (ORR)']",,,,,5,Spain; United States,"Massachusetts General Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Fundacion Jimenez Diaz [Madrid, Spain] | Hosp Univ Madrid Sanchinarro [Madrid, Spain]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02366949,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,"An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies",COMPLETED,PHASE1,Bayer,2015-02-27,2018-03-30,2019-04-18,2015-02-19,2020-04-07,"['Maximum tolerated dose (MTD)', 'Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability.', 'Maximum observed drug concentration (Cmax) of BAY1217389 in plasma', 'Area under the concentration versus time curve from zero to 12 hours (AUC [0-12]) of BAY1217389 in plasma', 'Area under the concentration versus time curve from zero to 96 hours (AUC [0-96]) of BAY1217389 in plasma', 'Maximum observed drug concentration (Cmax) of paclitaxel in plasma', 'Area under the concentration versus time curve from zero to infinity (AUC) of paclitaxel in plasma']",[],,,,,7,Netherlands; United States," [Santa Monica, United States] |  [Denver, United States] |  [New Haven, United States] |  [Hackensack, United States] |  [Houston, United States] |  [San Antonio, United States] |  [Rotterdam, Netherlands]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02368275,"Genetic, Neurophysiological and Psychological Risk Factors for Neuropathic Pain","Role of Genetic, Neurophysiological and Psychological Factors in the Development of Postsurgical Neuropathic Pain After Breast Surgery for Cancer",COMPLETED,,Hospital Ambroise Paré Paris,2017-03-01,2020-07-30,2020-09-30,2015-02-23,2021-04-30,['neuropathic pain'],['chronic postsurgical pain'],,,,,2,France,"Hôpital Foch [Suresnes, France] | Hôpital Ambroise Paré [Boulogne-Billancourt, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses risk factors and the development of postsurgical neuropathic pain, indicating an extension of indication for existing treatments related to chronic postsurgical pain.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02370277,Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer,Changes in Intestinal Microbiota in Association With Chemotherapy Treatment,COMPLETED,,University of Southern California,2014-12-16,2016-06-15,2018-08-22,2015-02-24,2019-06-18,"['Change in intestinal microbiota (composition, abundance, and diversity)']","['Change in body composition based on dual-energy x-ray absorptiometry (DEXA)', 'Baseline estradiol and estrone levels', 'Change in estrogen levels']",,,,,1,United States,"USC Norris Comprehensive Cancer Center [Los Angeles, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of chemotherapy on intestinal bacteria in breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02371174,Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.,An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.,COMPLETED,,"Eisai Co., Ltd.",2014-09-03,2018-01-21,2018-01-21,2015-02-25,2018-07-13,"['Number of participants with adverse events and serious adverse events', 'Number of participants with peripheral neuropathy', 'Number of participants with adverse drug reactions', 'Time to onset of peripheral neuropathy', 'Time to resolution of peripheral neuropathy']",['Overall survival'],,,,,2,Japan," [Osaka, Japan] |  [Tokyo, Japan]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02375048,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI,Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI),TERMINATED,PHASE2,Istituto Clinico Humanitas,2015-01-19,2018-02-01,2018-02-01,2015-03-02,2018-10-24,"['Toxicity will be measured with CTCAE v.4.0', 'Cosmesis will be measured with Harvard scale']","['Rate of Local Control', 'Disease Free Survival', 'Overall Survival', 'Quality of Life Questionnaire']",,,,,1,Italy,"Istituto Clinico Humanitas [Rozzano, Italy]",2015.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2018.0,7.0,0,Phase 2
NCT02375958,PCA062 in pCAD-positive Tumors.,"A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors",COMPLETED,PHASE1,Novartis Pharmaceuticals,2015-04-15,2018-07-17,2018-07-17,2015-03-03,2020-12-19,['Incidence rate of dose limiting toxicities'],"['Incidence and severity of serious/adverse events', 'Pharmacokinetic parameter Cmax', 'Presence of PCA062 anti-bodies', 'Overall response rate', 'Duration of response', 'Progression free survival', 'Disease control rate', 'Best overall response', 'Pharmacokinetic paramater Tmax']",,,,,7,France; Italy; Japan; Singapore; Spain; United States,"Novartis Investigative Site [Houston, United States] | Novartis Investigative Site [San Antonio, United States] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Madrid, Spain]",2015.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on PCA062, which is being tested in a new patient population (p-CAD positive tumors), indicating it is a new medicine.",INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT02376985,Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT,Evaluation of Oral Care to Prevent Oral Mucositis in Estrogen Receptor Positive Metastatic Breast Cancer Patients Treated With Everolimus: Phase III Randomized Control Trial,COMPLETED,PHASE3,Comprehensive Support Project for Oncology Research,2015-03-26,2018-03-31,2018-10-16,2015-03-03,2019-10-21,['Incidence of oral mucositis (Over Grade 1) after everolimus treatment'],"['Incidence of oral mucositis (Over Grade 2)', 'Incidence of oral mucositis (Over Grade 3)', 'Incidence of oral mucositis (Over Grade 1)', 'Incidence of oral mucositis (Over Grade 2)', 'Incidence of oral mucositis (Over Grade 3)', 'Time to the onset of oral mucositis', 'Duration of each Grade of oral mucositis', 'Each ratio of patients in suspension, or dose-reduction of everolimus treatment due to oral mucositis', 'Oral Assessment Guide (Revised)', 'Health-related quality of life (HRQOL)']",,,,,1,Japan,"Tokai University, School of Medicine [Isehara, Japan]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the use of Everolimus, which is an existing medication, in a specific patient population (ER Positive Metastatic Breast Cancer) for the prevention of oral mucositis, indicating an extension of its indication.",OTHER,False,2018.0,7.0,0,Phase 3
NCT02389842,PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib,"PIPA: a Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination with PAlbociclib, with the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers",COMPLETED,PHASE1,Royal Marsden NHS Foundation Trust,2015-03-25,2018-10-31,2021-05-26,2015-03-17,2024-09-26,"['Recommended dose for Phase II', 'Safety and Toxicity Profile (National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)', 'Preliminary anti-tumour assessment of triplet combination (RECIST criteria version 1.1) in patients with PIK3CA mutant advanced ER+ve HER2-ve breast cancer.']",['Pharmaockinetics Profile (AUC0-24 and Cmax)'],,,,,2,United Kingdom,"The Royal Marsden NHS Foundation Trust [London, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial involves a combination of existing drugs (PI3K inhibitors and PAlbociclib) being tested for a specific mutation in breast cancer, indicating an extension of indication rather than a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer,COMPLETED,PHASE1,AbbVie,2015-04-14,2019-07-05,2019-07-05,2015-03-18,2019-11-29,"['Maximum Tolerated Dose of ABBV-075', 'Time to Cmax (peak time, Tmax) for ABBV-075', 'Number of participants with adverse events', 'Maximum observed plasma concentration (Cmax) of ABBV-075', 'Area under the curve (AUC)']","['Duration of overall response (DOR)', 'Objective Response Rate (ORR)', 'Progression Free Survival (PFS)']",,,,,10,United States,"Scottsdale Healthcare /ID# 132963 [Scottsdale, United States] | City of Hope /ID# 154053 [Duarte, United States] | UC Davis Comp Cancer Ctr /ID# 154644 [Sacramento, United States] | Yale University /ID# 136982 [New Haven, United States] | University of Chicago /ID# 155453 [Chicago, United States] | Indiana Univ School Medicine /ID# 132946 [Indianapolis, United States] | Duke Univ Med Ctr /ID# 154647 [Durham, United States] | Mary Crowley Cancer Research /ID# 154059 [Dallas, United States] | Univ TX, MD Anderson /ID# 132276 [Houston, United States] | UT MD Anderson Cancer Center /ID# 164122 [Houston, United States]",2015.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02400060,Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer,Increasing Adherence to Adjuvant Hormonal Therapy Among Breast Cancer Patients: Phase 2 - Pilot Test of Intervention for Feasibility,COMPLETED,,Ohio State University Comprehensive Cancer Center,2015-03-26,2020-06-30,2020-06-30,2015-03-26,2025-06-29,"['Optimal usage of AHT (includes initiation, continuation and adherence)', 'Acceptance assessed via medical records of receiving a prescription for AHT and filling it', 'Continuation assessed via self-report of taking at least one dose per week', 'Adherence assessed via self-report of taking the prescribed dose at least 6 of 7 days per week']","['Change in biomarkers', 'Patient and physician responses to the intervention and study participation']",,,,,4,United States,"Southeastern Medical Oncology Center-Goldsboro [Goldsboro, United States] | Comprehensive Cancer Center of Wake Forest University [Winston-Salem, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | Fletcher Allen Health Care-Medical Center [Burlington, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT02402712,Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,,COMPLETED,PHASE3,Hoffmann-La Roche,2015-05-06,2019-02-22,2019-02-22,2015-03-30,2019-09-06,"['Incidence of adverse events (AEs)', 'Incidence and severity of adverse events Grade >/= 3, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0', 'Incidence of cardiac events (composite outcome measure): congestive heart failure (CHF) and cardiac death']","['Progression-free survival, tumor assessments according to RECIST v1.1', 'Overall survival', 'Objective response rate, defined as a complete response (CR) or a partial response (PR)', 'Incidence of anti-Herceptin, anti-rHuPH20 antibodies']",,,,,112,Belgium; Bulgaria; Canada; France; Germany; Hungary; Italy; Mexico; Poland; Portugal; Spain; United Kingdom,"AZ Sint Jan [Bruges, Belgium] | UZ Brussel [Brussels, Belgium] | Cliniques Universitaires St-Luc [Brussels, Belgium] | CHU Sart-Tilman [Liège, Belgium] | Clinique Saint-Joseph [Liège, Belgium] | Sint Augustinus Wilrijk [Wilrijk, Belgium] | Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC [Gabrovo, Bulgaria] | Multiprofile Hospital for Active Treatment Central Onco Hospital OOD [Plovdiv, Bulgaria] | University Multiprofile Hospital for Active Treatment Sveti Georgi EAD [Plovdiv, Bulgaria] | Comprehensive Cancer Center-Plovdiv [Plovdiv, Bulgaria] | Specialized Hospital for Active Treatment of Oncological Diseases - Sofia District EOOD [Sofia, Bulgaria] | Specialized Hospital for Active Cancer Treatment, Dr. Mark Antonov Markov - Varna Ltd [Varna, Bulgaria] | MDOZS Vrasta Ltd. [Vratsa, Bulgaria] | Moncton Hospital [Moncton, Canada] | Royal Victoria Regional Health Centre [Barrie, Canada] | Centre Hospitalier Regional Metz-Thionville - Hopital de Mercy [Ars-Laquenexy, France] | Medipole De Savoie; Departement Oncologie [Challes-les-Eaux, France] | Hopital Prive Sainte Marie [Chalon-sur-Saône, France] | Centre Hospitalier Louis Pasteur [Chartes Le Coudray, France] | Pole Sante Republique; Pharmacie Oncologique [Clermont-Ferrand, France] | Centre Georges Francois Leclerc [Dijon, France] | Groupe Hospitalier Mutualiste de Grenoble [Grenoble, France] | CHU de Grenoble [Grenoble, France] | Hopital Europeen [Marseille, France] | Centre Hospitalier de Mont de Marsan - Hopital Layne [Mont-de-Marsan, France] | Hopital Saint Joseph; Service de Rhumatologie [Paris, France] | Centre Hospitalier Lyon Sud [Pierre-Bénite, France] | Strasbourg Oncologie Libérale [Strasbourg, France] | Gustave Roussy [Villejuif, France] | Studienzentrum Aschaffenburg [Aschaffenburg, Germany] | Onkologische Schwerpunktpraxis Dr. Joerg Schilling [Berlin, Germany] | Universitaetsklinikum Erlangen [Erlangen, Germany] | Kliniken Essen-Mitte [Essen, Germany] | Universitätsklinikum Essen [Essen, Germany] | Praxis für Interdisziplinäre Onkologie und Hämatologie GbR [Freiburg im Breisgau, Germany] | Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I [Lübeck, Germany] | Onkologische Schwerpunktpraxis Lübeck [Lübeck, Germany] | Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz [Mainz, Germany] | Suedharz Klinikum Nordhausen gGmbH [Nordhausen, Germany] | Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe [Offenbach, Germany] | Johanniter-Krankenhaus Genthin - Stendal GmbH; Gynäkologie und gynäkologische Onkologie [Stendal, Germany] | Klinikum Mutterhaus der Borromaeerinnen [Trier, Germany] | Universitätsklinikum Würzburg [Würzburg, Germany] | Szent Margit Hospital; Dept. of Oncology [Budapest, Hungary] | Ogyi, Orszagos Gyogyszereszeti Intezet [Budapest, Hungary] | Semmelweis Egyetem [Budapest, Hungary] | Szent Imre Egyetemi Oktatokorhaz [Budapest, Hungary] | Orszagos Onkologiai Intezet [Budapest, Hungary] | Magyar Honvedseg Egeszsegugyi Kozpont; Fázis I-es Klinikai Farmakológiai Vizsgálóhely [Budapest, Hungary] | Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház [Miskolc, Hungary] | Azienda Ospedaliera Regionale San Carlo [Potenza, Italy] | Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori [Meldola, Italy] | Azienda Ospedaliero - Universitaria di Modena Policlinico [Modena, Italy] | Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova [Reggio Emilia, Italy] | Ospedale Infermi di Rimini [Rimini, Italy] | Istituti Fisioterapici Ospitalieri [Rome, Italy] | Ospedale Policlinico San Martino [Genoa, Italy] | Asst Papa Giovanni XXIII [Bergamo, Italy] | Istituto Europeo Di Oncologia [Milan, Italy] | Istituto Clinico Humanitas [Rozzano (MI), Italy] | Asst Della Valtellina E Dell'Alto Lario [Sondrio, Italy] | Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele [Catania, Italy] | Ospedale Santa Maria Annunziata [Bagno a Ripoli, Italy] | Azienda Ospedaliera Universitaria Careggi [Florence, Italy] | Azienda USL 5 di Pisa [Pisa, Italy] | Ospedale Santo Stefano, Azienda USL Centro Prato [Prato, Italy] | Azienda Ospedaliera Santa Maria di Terni [Terni, Italy] | Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant'Anna [Cona (Ferrara), Italy] | Ospedale Sacro Cuore Don Calabria [Negrar, Italy] | IOV - Istituto Oncologico Veneto IRCCS [Padua, Italy] | ""Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Trento"" [Verona, Italy] | Consultorio de Medicina Especializada [México, Mexico] | Grupo Medico Camino [DF, Mexico] | Superare Centro de Infusion S.A. de C.V. [México, Mexico] | Fundacion de Cancer de Mama.A.C. [México, Mexico] | Centro Medico San Jose [Monterrey, Nuevo Leon, Mexico] | Cancerología [Querétaro, Mexico] | Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie [Bialystok, Poland] | Uniwersyteckie Centrum Kliniczne [Gdansk, Poland] | Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii [Gdansk, Poland] | Szpitale Pomorskie Sp. z o. o. [Gdynia, Poland] | Przychodnia Lekarska KOMED [Konin, Poland] | Szpital Uniwersytecki w Krakowie [Krakow, Poland] | Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli [Lublin, Poland] | Samodzielny Publiczny Zakład Opieki Zdrowotnej MSW z W-MCO w Olsztynie [Olsztyn, Poland] | Samodzielny Publiczny Zakład Opieki Zdrowotnej Opolskie Centrum Onkologii [Opole, Poland] | Szpital Kliniczny; Przemienienia Panskiego;Uniwersytetu Medyczny im.; Karola Marcinkowskiego w Pozna [Poznan, Poland] | Wielkopolskie Centrum Onkologii [Poznan, Poland] | Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie; Klinika Onkologiczna [Warsaw, Poland] | MAGODENT Sp. z o.o. [Warsaw, Poland] | Hospital de Braga [Braga, Portugal] | Instituto Portugues Oncologia de Coimbra Francisco Gentil, EPE [Coimbra, Portugal] | Hospital da Luz [Lisbon, Portugal] | Centro Hospitalar de Lisboa Norte, EPE - Hospital Santa Maria [Lisbon, Portugal] | IPO do Porto; Servico de Oncologia Medica [Porto, Portugal] | Complexo Hospitalario Universitario de Santiago (CHUS) - Hospital Clinico Universitario [Santiago de Compostela, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Universitario Reina Sofia [Córdoba, Spain] | Hospital Universitario Ramon y Cajal [Madrid, Spain] | Hospital General Universitario Gregorio Maranon [Madrid, Spain] | Hospital Universitario Puerta de Hierro - Majadahonda [Madrid, Spain] | Fundacion Instituto Valenciano de Oncologia (IVO) [Valencia, Spain] | Betsi Cadwaladr University Health Board [Bangor Gwynedd, United Kingdom] | Velindre Cancer Centre [Cardiff, United Kingdom] | Dorset County Hospital [Dorchester, United Kingdom] | University Hospitals of Leicester NHS Trust - Leicester Royal Infirmary [Leicester, United Kingdom] | Guys and St Thomas NHS Foundation Trust, Guys Hospital [London, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom] | Mount Vernon Cancer Centre [Northwood, United Kingdom] | Peterborough City Hospital [Peterborough, United Kingdom] | Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital [Portsmouth, United Kingdom] | Royal Cornwall Hospitals NHS Trust [Truro, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the safety and tolerability of Herceptin SC in combination with Perjeta and Docetaxel for patients with HER2-positive advanced breast cancer, indicating an extension of indication for an existing treatment.",INDUSTRY,False,2019.0,6.0,1,Phase 3
NCT02403869,Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy,Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy,COMPLETED,,Celgene,2014-03-12,2019-01-31,2019-01-31,2015-03-31,2022-06-30,['Definitive deterioration at 6 months'],"['Definitive deterioration at 3 months', 'Definitive deterioration at 9 months', 'Definitive deterioration at 12 months', 'Time to Definitive deterioration (TTDD)', 'Overall survival', 'TTDD as a prognostic factor', 'Quality of life', 'Quality of life every 3 months', 'Chemotherapy-induced peripheral neuropathy', 'Chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20', 'Definitive deterioration']",,,,,29,Spain,"Hospital Juan Ramón Jiménez [Huelva, Spain] | Hospital Virgen de Valme [Seville, Spain] | Hospital Virgen del Rocío [Seville, Spain] | Hospital Miguel Servet [Zaragoza, Spain] | Hospital Universitario Lozano Blesa [Zaragoza, Spain] | Hospital Son Llatzer [Palma de Mallorca, Spain] | Hospital Universitario Son Espases [Palma Mallorca, Spain] | Hospital Universitario Canarias [La Laguna, Santa Cruz de Tenerife, Spain] | Hospital Universitario Burgos [Burgos, Spain] | Complejo Hospitalario de León [León, Spain] | Hospital Bierzo [León, Spain] | Hospital Universitario Salamanca [Salamanca, Spain] | Hospital Virgen de la Salud. Toledo [Toledo, Spain] | Centro Médico Teknon [Barcelona, Spain] | Hospital Clinic Barcelona [Barcelona, Spain] | Hospital Universitario San Joan de Reus [Reus, Tarragona, Spain] | Corporación Sanitaria Parc Taulí- Sabadell [Sabadell, Spain] | H. Infanta Cristina de Badajoz [Badajoz, Spain] | H. San Pedro de Alcántara [Cáceres, Spain] | Complejo Hospitalario de Ourense [Ourense, Spain] | Complejo Hospitalario de Pontevedra-Montecelo [Pontevedra, Spain] | Complejo Hospitalario Universitario de Santiago Compostela [Santiago de Compostela, Spain] | Complejo Hospitalario de Vigo [Vigo, Spain] | Hospital Universitario de Navarra [Pamplona, Spain] | Hospital Universitario Elche [Elche, Spain] | Hospital Universitario y Politécnico La Fe [Valencia, Spain] | Hospital Universitario Gregorio Marañón [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital Infanta Sofía [Madrid, Spain]",2014.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,"[""Symptomatic Deterioration"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on quality of life in patients with metastatic breast cancer undergoing second-line monochemotherapy, but it does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT02404506,Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer,Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial,TERMINATED,PHASE2,Swiss Cancer Institute,2015-08-17,2020-12-30,2021-07-22,2015-03-31,2021-09-29,['Disease Control (DC)'],"['Time to treatment failure (TTF)', 'Objective response (OR)', 'Time to progression (TTP)', 'Overall survival (OS)', 'Adverse events (AEs)', 'Patient reported neuropathy (PRO Form) and characterization of patients based on cancer-specific geriatric assessment (C-SGA)']",,,,,26,Switzerland,"Kantonsspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Praxis für ambulante Tumortherapie [Basel, Switzerland] | Istituto Oncologico della Svizzera Italiana [Bellinzona, Switzerland] | Klinik Engeried / Oncocare [Bern, Switzerland] | Inselspital, Bern [Bern, Switzerland] | Spitalzentrum Biel [Biel, Switzerland] | Kantonsspital Graubünden [Chur, Switzerland] | Kantonsspital Frauenfeld / Brustzentrum Thurgau [Frauenfeld, Switzerland] | HFR Fribourg - Hôpital cantonal [Fribourg, Switzerland] | Clinique de Genolier [Genolier, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Clinica Sant'Anna - Oncologia Varini & Calderoni & Christinat [Lugano, Switzerland] | Kantonsspital Luzern [Luzerne, Switzerland] | Onkologie Zentrum Spital Männedorf [Männedorf, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Onkologiepraxis Dr. med. Isabella Schönenberger [Sankt Gallen, Switzerland] | Tumorzentrum ZeTUP [Sankt Gallen, Switzerland] | Kantonsspital - St. Gallen [Sankt Gallen, Switzerland] | Rundum Onkologie am Bahnhofpark [Sargans, Switzerland] | Onkologiezentrum Bürgerspital Solothurn [Solothurn, Switzerland] | Regionalspital [Thun, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland] | Onkozentrum - Klinik im Park [Zurich, Switzerland] | Brust-Zentrum AG Zürich [Zurich, Switzerland]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of Eribulin, which is an existing medication, as a first-line treatment specifically in elderly patients with advanced breast cancer, indicating an extension of its indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02408393,MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery,MIRs03: A Double-blind Randomized Trial of Paravertebral Block With Ropivacaine Before Breast Cancer Surgery: Effects on Chronic Postoperative Pain,COMPLETED,PHASE3,Institut Curie,2015-03-27,2018-07,2019-03-09,2015-04-03,2019-07-10,['To compare chronic pain 3 months after breast surgery in each arm'],"['To measure the extend of dermatomes blocked', 'To measure acute postoperative pain (Visual Analog Scale (VAS)', 'To determine analgesic consumption', 'To examine incidence of nausea and vomiting', 'To characterize chronic pain (Neuropathic Pain Diagnostic DN4 Questionnaire)', 'To evaluate the frequency of chronic pain (BPI questionnaire and Neuropathic Pain Diagnostic (DN4)', 'To compare presence of lymphedema', 'To evaluate anxiety and depression evaluation (Hospital Anxiety and Depression questionnaire (HAD)', 'To evaluate complications of paravertebral block (CTCAE V4.03)', 'To determine the number of patients reporting pain at 6 months']",,,,,6,France,"Centre Jean PERRIN [Clermont-Ferrand, France] | Centre Léon Bérard [Lyon, France] | Centre Antoine LACASSAGNE [Nice, France] | INSTITUT CURIE - Site Paris [Paris, France] | Institut Curie site Saint-Cloud [Saint-Cloud, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effects of an existing medication (Ropivacaine) in a new context (paravertebral block before breast cancer surgery), indicating an extension of indication rather than a new medicine.",OTHER,False,2019.0,6.0,0,Phase 3
NCT02410044,Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer,"Open-labeled, Multicenter, Non-interventional Prospective PRO/QoL Registry for Patients With Osteoprotective Treatment for Bone Metastases of Breast or Prostate Cancer",COMPLETED,,iOMEDICO AG,2014-12-23,2019-08-16,2020-08-16,2015-04-07,2020-09-10,['Patient Reported Outcomes (PRO) regarding bone pain and the impact of bone pain on quality of life and daily activities in patients with bone metastases treated with osteoprotective agents.'],['Patient Reported Outcomes regarding the impact of treatment on daily life'],,,,,1,Germany,"Multiple sites all over Germany [Multiple Locations, Germany]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a registry focused on patient-reported outcomes related to existing treatments for bone metastases, rather than introducing a new medicine or extending the indication of an existing one.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT02423356,Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin,The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin,COMPLETED,,Daniel Rushing,2015-04-23,2018-02-01,2018-02-01,2015-04-22,2018-08-21,['Composite cardiotoxicity'],['Serum cardiac biomarkers as predictors of composite cardiotoxicity'],,,,,2,United States,"Indiana University Health Hospital [Indianapolis, United States] | Indiana University Melvin and Bren Simon Cancer Center [Indianapolis, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of strain echocardiography to predict cardiotoxicity in patients receiving a standard chemotherapy regimen (doxorubicin), indicating an extension of indication for an existing treatment.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02426489,Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System,Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System,TERMINATED,,Weinberg Medical Physics LLC,2015-07-01,2016-05-08,2016-05-08,2015-04-27,2021-10-07,"['Diagnostic accuracy of combination MRI/positron emission mammography (diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments)']",[],,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a diagnostic method (MRI-PEM) for breast cancer rather than a new medicine or an extension of indication for an existing medicine.,INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT02432950,Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer,PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors,COMPLETED,,City of Hope Medical Center,2016-01-07,2018-01-15,2022-12-19,2015-05-04,2023-03-21,['Change in body weight'],"['Change in body chemistry (lipid panel; comprehensive metabolic panel; complete blood count; fasting blood glucose; insulin resistance)', 'Change in body composition (BMI)', 'Change in physical fitness (measured using a handgrip dynamometer)', 'Change in quality of life score (FACT-B+4)', 'Change in serum inflammatory markers (C-reactive protein; cytokines)', 'Compliance metrics (days glucometer sensor not utilized; days body weight not recorded; days journal entries not made; days meal cards not created; weekly counseling sessions missed)', ""DNA repair capacity (comet assay's mean olive tail moment; number of gamma-H2A histone family, member X foci)"", 'Incidence of adverse events reported as possibly or definitely related to wearing the glucometer sensor following the PNP diet']",,,,,1,United States,"City of Hope Medical Center [Duarte, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT02462200,Shave Margins in Breast Conservation Therapy,Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial,TERMINATED,PHASE2,Washington University School of Medicine,2016-06-13,2019-11-27,2019-11-27,2015-06-03,2020-06-25,"['Proportion of patients with positive margins on pathological specimen analysis', 'Patient perceptions of the surgery as measured by BREAST-Q questionnaire and novel 3-dimensional breast imaging', 'Compare intraoperative NIR fluorescence from goggle system with pathologic tissue exam results']","['Relationship between CSM and volume of tissue excised in association iwth post-operative aesthetic outcomes', 'Cost-effectiveness of routine CSM in BCS as measured by operative time, specimen processing, and resource usage', 'Disease status associated with cancer biomarkers', 'Tumor characteristics associated with cancer biomarkers']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT02474173,Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,"Phase 1b Study of HSP90 Inhibitor, AT13387 (Onalespib) in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer",TERMINATED,PHASE1,National Cancer Institute (NCI),2016-01-15,2022-10-26,2022-10-26,2015-06-17,2022-11-04,"['Recommended phase 2 dose (R2PD)', 'Toxicity profile of onalespib in combination with paclitaxel']","['Pharmacokinetic (PK) parameters of onalespib', 'Pharmacokinetic (PK) parameters of paclitaxel', 'Overall response rate (partial response [PR]+ complete response [CR])', 'Response duration', 'Progression-free survival']",,,,,4,United States,"University of Kentucky/Markey Cancer Center [Lexington, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | University of Pittsburgh Cancer Institute (UPCI) [Pittsburgh, United States]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Onalespib, which is identified as a new HSP90 inhibitor being tested in combination with Paclitaxel for a specific cancer type, indicating it is a new medicine.",NIH,False,2022.0,3.0,0,Phase 1
NCT02479607,Effects of an ICT-platform for Assessment and Management of Patient-reported Symptoms During Treatment for Breast Cancer,PhONEME - ParticipatOn Ehealth MobilE. Effects of an Interactive ICT-platform for Assessment and Management of Symptoms in Patients Treated for Breast Cancer.,COMPLETED,,Karolinska Institutet,2015-06-30,2017-10,2017-10,2015-06-24,2018-08-08,"['Questionnaire Scale for Functional Health Literacy (S-FHL-Swedish version)', 'Questionnaire Scale for Communicative and Critical Health Literacy (S-C & C HL - Swedish version)', 'Questionnaire Individualized Care Scale (ICS)', 'Questionnaire Sense of Coherence Scale (KASAM)', 'European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)', 'Questionnaire Memorial Symptom Assessment Scale (MSAS)']",['Health care costs'],,,,,1,Sweden,"Karolinska University Hospital [Stockholm, Sweden]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on an ICT platform for managing patient-reported symptoms during breast cancer treatment, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT02482311,"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours",COMPLETED,PHASE1,AstraZeneca,2015-07-01,2018-01-25,2019-08-22,2015-06-26,2023-07-03,"['Number of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) as a measure of safety and tolerability.']","['Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Response (DoR)', 'Progression Free Survival (PFS)', 'PK profile: Plasma concentrations of AZD1775 and PK parameters (Cmax, C8hr, tmax, AUC, tlast, t½λz)', 'QTc prolongation']",,,,,16,Canada; United States,"Research Site [Fayetteville, United States] | Research Site [San Francisco, United States] | Research Site [West Hollywood, United States] | Research Site [Fort Myers, United States] | Research Site [Indianapolis, United States] | Research Site [Detroit, United States] | Research Site [Charlotte, United States] | Research Site [Oklahoma City, United States] | Research Site [Philadelphia, United States] | Research Site [Greenville, United States] | Research Site [Nashville, United States] | Research Site [Houston, United States] | Research Site [Milwaukee, United States] | Research Site [Edmonton, Canada] | Research Site [Vancouver, Canada] | Research Site [Toronto, Canada]",2015.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing AZD1775 monotherapy in patients with advanced solid tumours, indicating it is a new medicine being evaluated for its safety and efficacy.",INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT02483377,Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer,"Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women",TERMINATED,,University of Southern California,2015-03-05,2017-02-07,2017-02-07,2015-06-26,2017-04-20,"['Number of missed appointments from the time of initial diagnosis to the completion of primary treatment (chemotherapy, surgery and radiation as applicable) as measured by CCCQ', 'Number of patients enrolled on clinical trials (interventional and non-interventional)', 'Number of special referrals made', 'Overall experience with breast cancer (broadly) and at LAC+USC as measured by experience-based questionnaire', 'Usefulness, accessibility, and quality of the patient navigation model as measured by Continuity/Coordination of Care Questionnaire (CCCQ)']",[],,,,,1,United States,"USC / Norris Comprehensive Cancer Center [Los Angeles, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses patient navigation and treatment planning for Latina patients with breast cancer, focusing on process evaluation and patient experience rather than introducing a new medicine or extending the indication of an existing treatment.",OTHER,False,2017.0,8.0,0,NA/Other
NCT02483923,Analgesic Effect to Postoperative Pain After Mastectomy: Ultrasound-guided Serratus Anterior Plane Block,,COMPLETED,,Yonsei University,2015-06-16,2016-02-28,2016-02-28,2015-06-29,2018-07-17,['Total opioid consumption'],"['Postoperative pain scale (Numeric rating scale 0-10) at PACU', 'Total intraoperative remifentanil consumption(mcg)', 'Additional analgesics requirements (dose/number)', 'incidence and intensity of postoperative nausea and vomiting(NRS:0-10)', 'Total hospital staying time']",,,,,1,South Korea,"Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine [Seoul, South Korea]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the analgesic effect of an existing technique (ultrasound-guided serratus anterior plane block) for a specific postoperative pain scenario (after mastectomy), indicating an extension of indication rather than testing a new medicine.",OTHER,False,2016.0,9.0,0,NA/Other
NCT02485119,Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies,"An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies",COMPLETED,PHASE1,Bayer,2015-08-14,2017-04-28,2017-07-04,2015-06-30,2018-06-04,"['Number of Treatment-emergent Adverse Events (TEAEs) as a measure of safety and tolerability', 'Intensity of TEAEs acc. to NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.03', 'Cmax (maximum drug concentration in plasma after single dose administration ) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'Cmax,norm (Cmax divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'Cmax/D (Cmax divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast) (area under the plasma concentration vs time curve from time 0 to the last data point) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast)norm (AUC(0-tlast) divided by dose (mg) per kg body weight) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'AUC(0-tlast)/D (AUC(0-tlast) divided by dose (mg)) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me', 'tmax (time to reach maximum drug concentration in plasma) for BAY94-9343, total antibody compound, DM4, metabolite DM4-Me']","['Tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors)', 'Level of mesothelin expression using IHC (Immunohistochemistry) staining for the tumor tissue obtained from fresh or archival tumor tissue', 'Plasma levels of soluble mesothelin', 'Immunogenicity evaluation based on anti-BAY94-9343 antibody count']",,,,,2,Japan,"National Cancer Center Hospital East [Kashiwa, Japan] | National Cancer Center Hospital [Tyuo, Japan]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02487524,Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer,Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer,COMPLETED,,Helsinki University Central Hospital,2014-10-28,2016-04-22,2016-04-22,2015-07-01,2024-07-03,['Composite factors related to the persistence of pain after nerve injury'],[],,,,,1,Finland,"Helsinki University Central Hospital [Helsinki, Finland]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses biomarkers related to neuropathic pain in women treated for breast cancer, but does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2016.0,9.0,0,NA/Other
NCT02491957,Impact of LOFT Therapy™ on Breast Cancer Survivors,Impact of LOFT Therapy™ on Breast Cancer Survivors: A Pilot Study,COMPLETED,,Kathy Miller,2015-07-28,2018-03-29,2018-03-29,2015-07-08,2018-08-13,['Feasibility of LOFT therapy in breast cancer survivors (< 3 years from diagnosis) treated with either chemotherapy and/or anti-estrogen therapy'],"['Safety of LOFT intervention in this population patient reported adverse events', 'Heart rate', 'Power per body weight (muscle power)', 'Endurance', 'Daily activity', 'Fatigue', 'Quality of life', 'Biochemical parameters of chronic inflammation', 'Biochemical parameters of metabolism and insulin homeostasis', 'Anabolic hormone secretion', 'Biochemical parameters of bone turnover']",,,,,2,United States,"Indiana University Health Hospital [Indianapolis, United States] | Indiana University Melvin and Bren Simon Cancer Center [Indianapolis, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the impact of LOFT Therapy™ on breast cancer survivors, indicating it is being evaluated for a specific patient population rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02506556,Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer,"A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.",COMPLETED,PHASE2,"Peter MacCallum Cancer Centre, Australia",2015-09-07,2021-10-26,2021-10-26,2015-07-23,2022-08-16,['Objective response rate'],"['Clinical Benefit Rate', 'Progression free survival', 'Safety and tolerability of BYL719']",,,,,1,Australia,"Peter MacCallum Cancer Centre [East Melbourne, Australia]",2015.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing BYL719, a selective PI3K Alpha inhibitor, in a new patient population (advanced breast cancer) and does not indicate it is an extension of an existing indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02511639,Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients,MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy,COMPLETED,PHASE3,Istituto Oncologico Veneto IRCCS,2014-07-30,2020-02-28,2020-07-31,2015-07-30,2020-12-03,['Progression free survival'],"['Overall survival', 'Response rate', 'Safety profile']",,,,,16,Italy,"Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona [Ancona, Italy] | Ospedale Papa Giovanni XXIII [Bergamo, Italy] | Policlinico Sant'Orsola Malpighi [Bologna, Italy] | ASL Brindisi ""Antonio Perrini"" [Brindisi, Italy] | Azienda Spedali Civili di Brescia [Brescia, Italy] | A.S.O. S.Croce e Carle di Cuneo [Cuneo, Italy] | Azienda Ospedaliero - Universitaria ""Policlinico - Vittorio Emanuele"" [Catania, Italy] | Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna [Cona, Italy] | Ospedale Misericordia di Grosseto [Grosseto, Italy] | Istituto Nazionale dei Tumori IRCCS [Milan, Italy] | Azienda Ospedaliera Universitaria di Parma [Parma, Italy] | IRCCS - Azienda Ospedaliera S.M. Nuova [Reggio Emilia, Italy] | Ospedale Civile Santa Chiara [Trento, Italy] | Azienda Ospedaliero-Universitaria ""Santa Maria della Misericordia"" [Udine, Italy] | Ospedale Sacro Cuore - Don Calabria [Negrar, Italy] | Ospedale dell'Angelo [Mestre, Italy]",2014.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,Phase 3
NCT02514681,A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer,"A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer",COMPLETED,PHASE3,Japan Breast Cancer Research Group,2015-08-01,2018-12-31,2022-08-10,2015-08-04,2025-09-10,['Progression-free survival (assessed by investigators)'],"['Progression-free survival (assessed by independent review)', 'PFS in patients treated with trastuzumab emtansine (T-DM1) as the latest regimen', 'Response rate', 'Duration of response, Overall survival', 'Patient-reported-outcome', 'Safety assessed by Incidence/Grade of Serious Adverse Events (SAEs), Pertuzumab-specific adverse events, laboratory abnormalities Percentage and number of subjects who discontinued for adverse event.', 'Biomarkers']",,,,,3,Japan,"Aichi Cancer Center [Chikusa-ku, Japan] | Kumamoto University Hospital [Kumamoto, Japan] | Japan Breast Cancer Research Group [Chuo-ku, Nihonbashi, Koami-cho, Japan]",2015.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the efficacy and safety of Pertuzumab retreatment in patients who have previously been treated with Pertuzumab, indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,Phase 3
NCT02541188,Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea,,TERMINATED,,"University Hospital, Montpellier",2014-10-02,2016-10-02,2017-01-02,2015-09-04,2021-12-10,"['Genetic analysis of Breast Cancer susceptibility gene 1 (BRCA 1)', 'Genetic analysis of Breast Cancer susceptibility gene 2 (BRCA 2)']","['Analysis TNM grade', 'Analysis histoprognostic grade Scarf Bloom and Richardson (SBR)', 'analysis of hormone receptor ER', 'growth factors analysis (Ki 67)', 'analysis of HER2', 'analysis of hormone receptor PR']",,,,,1,France,"CHU de Montpellier [Montpellier, France]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,The text discusses genetic analysis and various prognostic factors related to breast cancer but does not indicate the development of a new medicine or an extension of indication for an existing treatment.,OTHER,False,2017.0,8.0,0,NA/Other
NCT02551263,Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer,Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer,COMPLETED,,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",2015-07-22,2020-07,2020-07,2015-09-16,2021-06-11,['Overall survival (OS) of the first line chemotherapy'],"['Overall survival (OS) of the second and third line chemotherapy', 'Progression-free survival (PFS) of the first, second and third line chemotherapy', 'Post progression survival (PPS) of the first, second and third line chemotherapy', 'Time to treatment failure (TTF) of the first, second and third line chemotherapy', 'New metastasis-free survival (nMFS) of the first, second and third line chemotherapy', 'Assessment and comparison of Quality Adjusted Life Years (QALYs) in the first, second and third line chemotherapy, using Japanese version of the EQ-5D-5L value set', 'Serious adverse events']",,,,,2,Japan,"Kobe City Medical Center General Hospital [Kobe, Japan] | Kyoto University Hospital [Kyoto, Japan]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial is exploring the efficacy of Eribulin in different lines of chemotherapy for a specific type of breast cancer, indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02553967,Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO),Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO),COMPLETED,,Centre Oscar Lambret,2016-01-07,2019-11-25,2021-04-15,2015-09-18,2021-10-14,['BOLD signal change (difference in intensity and anatomic location) in the regions activated during breast palpation between the reconstructed breast and the non-operated breast.'],"['BOLD signal change (difference in intensity and anatomic location) in the regions activated during breast palpation between the breast reconstructed using an autologous flap and a prosthesis.', 'BOLD signal change (difference in intensity and anatomic location) in the regions activated during breast palpation between the reconstructed breast and the mastectomy scar before reconstruction.', 'Topography variation in brain sensory projection area after total mastectomy and breast reconstruction.', 'Satisfaction score and pre and postoperative quality-of-life score (Breast Q) according to a Likert scale.']",,,,,1,France,"Centre Oscar Lambret [Lille, France]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study related to breast reconstruction and functional MRI assessments, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT02555696,Abraxane in Treatment of Metastatic Breast Cancer,Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting,COMPLETED,,Celgene,2012-05-31,2016-02-28,2016-12-31,2015-09-21,2017-02-23,['Adverse Events'],['Overall Response'],,,,,13,Austria,"LKH Feldkirch [Feldkirch, Austria] | Medical University Graz [Graz, Austria] | Medical University Innsbruck [Innsbruck, Austria] | LKH Leoben [Leoben, Austria] | KH Barmherzige Schwestern Linz [Linz, Austria] | LKH Salzburg [Salzburg, Austria] | LKH St. Pölten [Sankt Pölten, Austria] | LKH Steyr [Steyr, Austria] | Medical University Vienna [Vienna, Austria] | KH SMZ Ost [Vienna, Austria] | LKH Vöcklabruck [Vöcklabruck, Austria] | Klinikum Wels [Wels, Austria] | LKH Wr. Neustadt [Wiener Neustadt, Austria]",2012.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the assessment of Abraxane, which is already an established treatment, in a specific context (metastatic breast cancer) indicating an extension of its indication rather than introducing a new medicine.",INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT02560662,PhysSurg-B : Physical Activity in Relation to Surgical Operations - Breast Cancer,"PhysSurg-B : Physical Activity in Relation to Surgical Operations, a Prospective Open-label Randomized Controlled Multicenter Study of the Effect of Physical Activity on Recovery After Breast Cancer Surgery",COMPLETED,,Vastra Gotaland Region,2016-01-27,2019-03-10,2020-02-11,2015-09-25,2024-01-26,"['Change in self-reported physical and psychological recovery', 'Sick leave']","['Length of hospital stay', 'Adverse events', 'Re-operations and re-admittances', 'Mortality', 'Health economy']",,,,,1,Sweden,"Sahlgrenska University Hospital [Gothenburg, Sweden]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on the effects of physical activity on recovery after breast cancer surgery, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2020.0,5.0,0,NA/Other
NCT02566408,"Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity","Attitudes, Beliefs and Preferences of Older Breast Cancer Survivors Towards Physical Activity",COMPLETED,,Case Comprehensive Cancer Center,2015-10-14,2016-10-01,2016-10-01,2015-10-02,2020-01-03,"['Qualitative analysis of in-depth interviews to identify features which foster initial enrollment of African Americans and Socioeconomic Status disadvantaged breast cancer survivors in breast cancer studies', 'Qualitative analysis of in-depth interviews to identify attitudes towards physical activity.', 'Qualitative analysis of in-depth interviews to identify attitudes towards the physical activity program.']",[],,,,,1,United States,"University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center [Cleveland, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses qualitative research on attitudes and beliefs of breast cancer survivors towards physical activity, but does not mention any new medicine or an extension of indication for an existing treatment.",OTHER,False,2016.0,9.0,0,NA/Other
NCT02576548,A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.,"A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors",COMPLETED,PHASE1,MedImmune LLC,2015-09-23,2018-05-23,2018-05-23,2015-10-15,2019-06-18,"['Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs) and dose-limiting (DLTs).']","['Objective Response Rate (ORR)', 'Peak Plasma Concentration (Cmax)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'Area under the plasma concentration versus time curve (AUC)']",,,,,5,United States,"Research Site [Stanford, United States] | Research Site [Sarasota, United States] | Research Site [Indianapolis, United States] | Research Site [Charlotte, United States] | Research Site [Nashville, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating MEDI4276, which appears to be a new drug being tested in a specific patient population (adults with HER2-expressing advanced solid tumors), indicating it is a New Medicine.",INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT02585388,Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.,"A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer",TERMINATED,PHASE2,ARCAGY/ GINECO GROUP,2015-10-23,2017-05-15,2017-05-15,2015-10-23,2023-09-06,['Progression free survival (PFS)'],"['Evaluation of partial and complete response rate by RECIST 1.1', 'duration of response', 'clinical benefit after 24 weeks of treatment', 'overall survival', 'Toxicity according to criteria NCI CTAEv4.03', 'health-related quality of life']",,,,,47,France,"Centre Hospitalier de l'Agglomération Montargoise [Amilly, France] | ICO Paul Papin [Angers, France] | Institut Sainte-Catherine [Avignon, France] | Centre Hospitalier de la Côte Basque [Bayonne, France] | Centre Hospitalier Fleyriat [Bourg-en-Bresse, France] | CHU de Brest [Brest, France] | Clinique Pasteur [Brest, France] | Centre Hospitalier Alpes Léman [Contamine-sur-Arve, France] | CH de la Dracénie [Draguignan, France] | Centre Hospitalier Intercommunal des Alpes du Sud [Gap, France] | Groupe Hospitalier Mutualiste de Grenoble [Grenoble, France] | CHU de Grenoble [Grenoble, France] | Hôpital Privé Drôme Ardèche - Clinique Pasteur [Guilherand-Granges, France] | Hôpital Privé Drôme Ardèche [Guilhérand-Granges, France] | CHD Vendée [La Roche-sur-Yon, France] | Centre Hospitalier de Laon [Laon, France] | CH Chartres Hôpital Louis Pasteur [Le Coudray, France] | Centre Hospitalier Le Mans [Le Mans, France] | Centre Léon Berard [Lyon, France] | Hôpital Privé Jean Mermoz [Lyon, France] | Hôpital Privé Jean Mermoz [Lyon, France] | CH Layne [Mont-de-Marsan, France] | CH Montélimar [Montélimar, France] | Centre Azuréen de Cancérologie [Mougins, France] | Oracle [Nancy, France] | Centre Catherine de Sienne [Nantes, France] | CHR Orléans [Orléans, France] | Centre Hospitalier de Pau [Pau, France] | Polyclinique Francheville [Périgueux, France] | Centre Hospitalier Lyon Sud [Pierre-Bénite, France] | Hopital privé des côtes d'armor [Plérin, France] | Centre Hospitalier Annecy-Genevois [Pringy, France] | Centre Hospitalier de la Région d'Annecy [Pringy, France] | Centre Hospitalier de Quimper [Quimper, France] | Institut du Cancer Courlancy Reims [Reims, France] | Institut Jean Godinot [Reims, France] | Centre Hospitalier de Romans sur Isère [Romans-sur-Isère, France] | Hôpitaux Drôme Nord - Site de Romans [Romans-sur-Isère, France] | CHP Saint Grégoire [Saint-Grégoire, France] | ICO Gauducheau [Saint-Herblain, France] | Polyclinique Côte Basque Sud [Saint-Jean-de-Luz, France] | Institut de Cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France] | Centre Hospitalier de Soissons [Soissons, France] | Hôpitaux Universitaires de Strasbourg [Strasbourg, France] | Hôpitaux du Léman [Thonon-les-Bains, France] | Centre Hospitalier Jean Bernard [Valenciennes, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2015.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the addition of a non-steroidal aromatase inhibitor to an existing treatment (oral vinorelbine) in patients with pretreated metastatic breast cancer, indicating an extension of indication for the aromatase inhibitor.",OTHER,False,2017.0,8.0,0,Phase 2
NCT02586987,"A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours","A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",COMPLETED,PHASE1,AstraZeneca,2015-12-28,2018-07-25,2019-09-20,2015-10-27,2019-11-18,"['Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Adverse Events', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of safety laboratory tests', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of blood pressure (BP)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Electrocardiogram (ECG)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of physical examinations', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Echocardiogram (ECHO)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of pulse', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of body temperature', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of respiratory rate', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Multigated Acquisition (MUGA)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (best corrected visual acuity)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (Intraocular pressure)', 'Safety and tolerability of Selumetinib in combination with MEDI4736, and in combination with MEDI4736+ tremelimumab by assessment of Ophthalmic examination (slit lamp fundoscopy)']","['Long-term tolerated dose and exposure predicted to result in biological activity (including but not limited to Response Evaluation Criteria in Solid Tumours (RECIST)', 'Objective response rate (ORR)', 'Change in tumour size', 'Best Objective Response (BoR)', 'Duration of Response (DoR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'MEDI4736 and/or tremelimumab anti-drug antibody (ADA) level in Plasma']",,,,,6,United States,"Research Site [Chicago, United States] | Research Site [Boston, United States] | Research Site [Las Vegas, United States] | Research Site [New Brunswick, United States] | Research Site [Charlotte, United States] | Research Site [Pittsburgh, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02594371,"Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer","An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer",COMPLETED,PHASE3,"Athenex, Inc.",2015-12-02,2019-07-25,2022-06-30,2015-11-03,2022-08-03,"['Tumor response as determined by response criteria', 'Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information']","['Progression-free survival (PFS)', 'Overall survival (OS)']",,,,,45,Argentina; Chile; Colombia; Dominican Republic; Ecuador; El Salvador; Guatemala; Honduras; Panama; Peru,"Centro de Investigacion Pergamino SA [Pergamino, Argentina] | Clinica Universitaria Privada Reina Fabiola [Córdoba, Argentina] | IONC [Córdoba, Argentina] | Centro Oncologico Infinito [Santa Rosa, Argentina] | Fundación Koriza [Santa Rosa, Argentina] | Clinica Viedma [Viedma, Argentina] | CEMEDIC [Buenos Aires, Argentina] | COIBA [Buenos Aires, Argentina] | Fundación Investigar [Buenos Aires, Argentina] | Fundación Centro Oncológico Riojano Integral (CORI) [La Rioja, Argentina] | CAIPO [San Miguel de Tucumán, Argentina] | Centro Medico San Roque [San Miguel de Tucumán, Argentina] | Hospital Provincial del Centenario [Santa Fe, Argentina] | Instituto de Oncologia de Rosario [Santa Fe, Argentina] | Sanatorio Britanico [Santa Fe, Argentina] | Fundación Arturo López Pérez [Santiago, Chile] | Hospital de Referencia de Salud Cordillera Unidad de Patología Mamaria [Santiago, Chile] | Hospital San Borja Arriarán [Santiago, Chile] | IRAM [Santiago, Chile] | Clínica Alemana Temuco [Temuco, Chile] | Instituto Nacional de Cancerología E.S.E. [Bogotá, Colombia] | Fundación Colombiana de Cancerología Clinica Vida [Medellín, Colombia] | Fundación Hospitalaria San Vicente de Paúl [Medellín, Colombia] | Hemato Oncologos S.A. [Valle, Colombia] | Hospital Metropolitano de Santiago (HOMS) [Santiago de los Caballeros, Dominican Republic] | Clinical Research [Santo Domingo, Dominican Republic] | Hospital General de la Plaza de la Salud [Santo Domingo, Dominican Republic] | Hospital SOLCA [Guayaquil, Ecuador] | Hospital Carlos Andrade Martín [Quito, Ecuador] | Hospital SOLCA [Quito, Ecuador] | Espemedic [San Salvador, El Salvador] | Hospital Diagnotico Clinica Oncologica & Cancer Research [San Salvador, El Salvador] | American Cancer Center [Guatemala City, Guatemala] | CELAN Clínica Médica [Guatemala City, Guatemala] | Clinica Privada [Guatemala City, Guatemala] | Clínica Privada [Guatemala City, Guatemala] | Grupo Angeles, S.A. [Guatemala City, Guatemala] | Oncomedica en Guatemala [Guatemala City, Guatemala] | CRESEM [Quetzaltenango, Guatemala] | Excel Medica [Cortés, Honduras] | Tecnología en Investigación [Cortés, Honduras] | Centro Hemato Oncológico Panamá [Panama City, Panama] | Clínica Oncológica Miraflores [Lima, Peru] | Hospital Cayetano Heredia [Lima, Peru] | Hospital Nacional del Arzobispo Loayza [Lima, Peru]",2015.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating Oraxol, which is a new formulation of a drug (Paclitaxel) for the treatment of metastatic breast cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT02598427,Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis,TERMINATED,PHASE1,Kimberly Blackwell,2017-05-01,2018-02-22,2018-02-22,2015-11-05,2018-02-28,"['Safety as measured by adverse events', 'Maximum tolerated dose as measure by dose limiting toxicity']","['Response rate as measured by brain MRI', 'Changes in cell-free circulating tumor DNA (ctDNA) in response to treatment']",,,,,1,United States,"Duke University Medical Center [Durham, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2018.0,7.0,0,Phase 1
NCT02599506,Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment,Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment and Follow-up Into Survivorship of 100 Breast Cancer patients-a Pilot Study,COMPLETED,,University of St Andrews,2015-12-01,2016-06-01,2016-10-31,2015-11-06,2018-10-01,['Fear of Recurrence Level-ACCRE FCR'],"['The Positive and Negative Affect Schedule (PANAS)', '5 EQ-5D-3L']",,,,,1,United Kingdom,"NHS Lothian Edinburgh Cancer Centre [Edinburgh, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a pilot study on the fear of cancer recurrence during radiation treatment and does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2016.0,9.0,0,NA/Other
NCT02605083,A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Effector Therapeutics,2015-12-03,2019-01-11,2019-03-22,2015-11-16,2020-11-02,"['Maximum tolerated dose (MTD)/Recommended dose (RD)', 'Overall response rate (ORR)']","['Safety (Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03))', 'Plasma concentration of eFT508 as characterized by maximum serum concentration (Cmax)', 'Plasma concentration of eFT508 as characterized by Area Under the Curve (AUC)', 'Changes in eIF4E phosphorylation in peripheral blood cells (PBMCs)', 'Tumor control evaluated by modified RECIST criteria v 1.1']",,,,,4,United States,"SCRI at HealthONE [Denver, United States] | Florida Cancer Specialists [Sarasota, United States] | Tennessee Oncology, PLLC [Nashville, United States] | MD Anderson Cancer Center [Houston, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on a new drug (eFT508) being tested in subjects with advanced solid tumors, indicating it is a New Medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 2
NCT02605915,Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer,"A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer",COMPLETED,PHASE1,Hoffmann-La Roche,2015-12-31,2019-11-13,2019-11-13,2015-11-16,2020-02-05,"['Percentage of Participants With Dose Limiting Toxicities (DLT) - Cohort 1A, 1B, 1C, 1D, 1F', 'Percentage of Participants With DLT - Cohort 1E', 'Percentage of Participants With Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.0 (NCI CTCAE V4.0)']","['Maximum Serum Concentration (Cmax) of Atezolizumab', 'Minimum Serum Concentration (Cmin) of Atezolizumab', 'Cmin of Trastuzumab', 'Cmin of Trastuzumab Emtansine', 'Cmin of Pertuzumab', 'Cmin of Doxorubicin', 'Cmin of Cyclophosphamide', 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Atezolimumab', 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab', 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Trastuzumab Emtansine', 'Percentage of Participants With Anti-Therapeutic Antibody (ATA) Response to Pertuzumab', 'Number of Treatment Cycles Received', 'Percentage of Participants With Various Dose Intensity', 'Plasma Concentration of Doxorubicin', 'Plasma Concentration of Cyclophosphamide', 'Plasma Concentration of 4-Hydroxycyclophosphamide', 'Plasma Concentration of Docetaxel']",,,,,20,United States,"University of Alabama at Birmingham [Birmingham, United States] | University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute [Little Rock, United States] | Joliet oncology hematology associates [Joliet, United States] | Horizon Oncology Research, Inc. [Lafayette, United States] | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins [Baltimore, United States] | Karmanos Cancer Center; Department of Oncology [Detroit, United States] | HCA Midwest Division [Kansas City, United States] | Montefiore Medical Center, Advanced Women's Health Center, Clinical Trials and Research Unit; Depart [The Bronx, United States] | Levine Cancer Institute [Charlotte, United States] | Duke Cancer Center [Durham, United States] | Oncology Hematology Care Inc [Cincinnati, United States] | St. Luke's University Health Network [Bethlehem, United States] | Kimmel Cancer Center Thomas Jefferson University [Philadelphia, United States] | Magee Womens Hospital [Pittsburgh, United States] | Tennessee Oncology - Chattanooga; Tennessee Oncology - East Third Street [Chattanooga, United States] | West Clinic [Germantown, United States] | Tennessee Oncology [Nashville, United States] | MD Anderson Cancer Center [Houston, United States] | Cancer Therapy and Research Center CTRC at UTHSCSA [San Antonio, United States] | Medical College of Wisconsin [Milwaukee, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the safety and pharmacokinetics of Atezolizumab in combination with other treatments for specific types of breast cancer, indicating an extension of indication for an existing medicine rather than a new medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02608593,Breast Reconstruction Outcomes With and Without StratticE,Breast Reconstruction Outcomes With and Without StratticE (BROWSE),COMPLETED,,Manchester University NHS Foundation Trust,2016-08-19,2019-10-31,2019-10-31,2015-11-18,2020-05-22,['Percentage of patients planned loss of implant within 12 months of immediate reconstruction'],"['Quality of Life questionnaire', 'In-patient treatment costs', 'Ipsilateral Revision rates', 'Cosmesis', 'Breast Reconstruction softness', 'Regional pain', 'loco-regional cancer recurrence', 'Morbidity']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses breast reconstruction outcomes with a specific product (StratticE), indicating an evaluation of its effectiveness in a specific context, which suggests an extension of indication rather than a new medicine.",OTHER_GOV,False,2019.0,6.0,0,NA/Other
NCT02611310,A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC),Saudi Arabia - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer,TERMINATED,,Hoffmann-La Roche,2017-01-19,2018-11-12,2018-11-12,2015-11-20,2020-01-07,['Progression-Free Survival (PFS)'],"['Number of Participants With Adverse Events', 'Overall Survival (OS)', 'Objective Response Rate (ORR) Per Anti-Cancer Treatment Regimen', 'Duration of Response (DoR) Per Anti-Cancer Treatment Regimen', 'Quality of Life, as Assessed by the EuroQol 5-Dimensions Questionnaire (EQ-5D)', 'Overall Health Status, as Assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B)']",,,,,3,Saudi Arabia,"King Abdullah Medical City-Holy Makkah [Holy Makkah, Saudi Arabia] | National Guard King Abdulaziz Medical City; Oncology [Riyadh, Saudi Arabia] | King Fahad Medical City; Gastroentrology [Riyadh, Saudi Arabia]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on treatment patterns and outcomes for a specific patient population with HER2-positive unresectable locally advanced or metastatic breast cancer, indicating an extension of indication for existing treatments rather than testing a new medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02613923,A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer,A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer,COMPLETED,,Case Comprehensive Cancer Center,2015-08-04,2017-03-23,2017-07-23,2015-11-25,2019-05-09,"['Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups', 'Difference in change in Insomnia Severity Index (ISI) score between groups', 'Difference in change in sleep duration between groups']","['Difference in change of SF-12 score from baseline to post-intervention between groups', 'Correlation of joint changes in biomarker levels with PSQI and ISI', 'Difference in Change in Pittsburgh Sleep Quality Index (PSQI) score between groups', 'Difference in change in Insomnia Severity Index (ISI) score between groups', 'Difference in change in sleep duration between groups']",,,,,1,United States,"University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center [Cleveland, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot intervention aimed at improving sleep outcomes among women at high risk of breast cancer, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT02625506,Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block,Efficacy of Adding Tramadol as Adjunctive Analgesic With Levobupivacaine in Modified Pectoral Nerve Block for Modified Radical Mastectomy Surgery,COMPLETED,,Mansoura University,2012-06-01,2015-12-01,2016-01-01,2015-12-09,2020-09-11,['Postoperative pain'],"['Changes in heart rate', 'Changes in blood pressure', 'Changes in peripheral oxygen saturation', 'Changes in end-tidal carbon dioxide tension', 'Time for first analgesic request from extubation', 'Total analgesics received for 24 hrs after surgery']",,,,,1,Egypt,"Mansoura University, Mansoura Oncology Center [Al Mansurah, Egypt]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the efficacy of adding Tramadol as an adjunctive analgesic to Levobupivacaine in a specific surgical context, indicating an extension of indication for Tramadol rather than introducing a new medicine.",OTHER,False,2016.0,9.0,0,NA/Other
NCT02627274,"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)",COMPLETED,PHASE1,Hoffmann-La Roche,2015-12-07,2022-11-10,2022-11-10,2015-12-10,2022-11-22,"['Percentage of Participants With Dose-Limiting Toxicities (DLTs)', 'Maximum Tolerated Dose (MTD) of RO6874281', 'Optimal Biological Dose (OBD) of RO6874281', 'Recommended Dose for Further Development of RO6874281', 'Systemic Clearance (CL) of RO6874281', 'Volume of Distribution at Steady State (Vss) of RO6874281', 'Area Under the Concentration-Time Curve (AUC) of RO6874281', 'Maximum Observed Serum Concentration (Cmax) of RO6874281']","['Number of T Cells in the Peripheral Blood', 'Number of Natural Killer (NK) Cells in the Peripheral Blood', 'Density of Cluster of Differentiation (CD)8+ Cells in Tumor Samples', 'Density of CD3-/Perforin+ Cells in Tumor Samples', 'Density of CD20 Cells in Tumor Samples', 'Percentage of Participants With Overall Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)', 'Percentage of Participants With Disease Control According to RECIST v1.1', 'Progression-Free Survival (PFS) According to RECIST v1.1', 'Percentage of Participants With Overall Response According to Modified RECIST', 'Percentage of Participants With Disease Control According to Modified RECIST', 'PFS According to Modified RECIST', 'Percentage of Participants With Overall Response According to iRECIST', 'Percentage of Participants With Disease Control According to iRECIST', 'PFS According to iRECIST']",,,,,26,Belgium; Canada; Denmark; France; Italy; Netherlands; Spain; United Kingdom; United States,"University of Arizona Cancer Center [Tucson, United States] | UCSD - Moores Cancer Center [La Jolla, United States] | Banner MD Anderson Cancer Center [Greeley, United States] | Washington University; Division of Oncology [St Louis, United States] | The Ohio State University [Columbus, United States] | UZ Antwerpen [Edegem, Belgium] | Juravinski Cancer Clinic; Department of Oncology [Hamilton, Canada] | Princess Margaret Cancer Center [Toronto, Canada] | Rigshospitalet; Onkologisk Klinik [København Ø, Denmark] | Institut Bergonie; Oncologie [Bordeaux, France] | Centre Georges Francois Leclerc [Dijon, France] | Centre Leon Berard [Lyon, France] | Institut Claudius Regaud; Departement Oncologie Medicale [Toulouse, France] | Institut Gustave Roussy; Sitep [Villejuif, France] | IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica [Meldola, Italy] | Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo [Milan, Italy] | Istituto Europeo di Oncologia; Svil. Nuovi Farmaci per Terapie Innovative [Milan, Italy] | Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck [Milan, Italy] | Ospedale Policlinico S. Matteo; Phase I Clinical Trial Unit and Experimental Therapy [Pavia, Italy] | Antoni Van Leeuwenhoek Ziekenhuis; Gastro-Enterologie [Amsterdam, Netherlands] | Erasmus MC [Rotterdam, Netherlands] | Clinica Universitaria de Navarra [Pamplona, Spain] | Hospital Univ Vall d'Hebron; Servicio de Oncologia [Barcelona, Spain] | Leicester Royal Infirmary [Leicester, United Kingdom] | Guys and St Thomas NHS Foundation Trust, Guys Hospital [London, United Kingdom] | Christie Hospital [Manchester, United Kingdom]",2015.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates RO6874281, which is described as an immunocytokine targeting Fibroblast Activation Protein-α (FAP), indicating it is a new medicine being tested for safety and efficacy.",INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT02632071,ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer,Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer,COMPLETED,PHASE1,Columbia University,2016-03-01,2020-09-30,2020-09-30,2015-12-16,2021-01-07,['Maximum tolerated dose (MTD) of ACY-1215 (Ricolinostat)'],['Number of adverse events related to ACY-1215 (Ricolinostat)'],,,,,1,United States,"Columbia Irving University Medical Center [New York, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves ACY-1215 (Ricolinostat), which is being tested in combination with Nab-paclitaxel for a specific cancer indication, indicating it is a new medicine being evaluated for efficacy and safety in a new context.",OTHER,False,2020.0,5.0,0,Phase 1
NCT02646748,Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors",COMPLETED,PHASE1,Incyte Corporation,2016-01-25,2019-11-07,2020-11-20,2016-01-06,2022-03-31,"['Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse events']","['Part 1 and 2: Objective Response Rate (ORR) as determined by radiographic disease assessments per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) v1.1 criteria', 'Part 1 and 2: Change in the number of Tumor Infiltrating Lymphocytes(TILs) and the ratio of CD8+ lymphocytes to FOXP3+ cells infiltrating tumor post-treatment versus pretreatment by IHC']",,,,,17,United States,"University of California San Francisco Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | John Wayne Cancer Institute at Providence Saint John's Health Center [Santa Monica, United States] | Georgetown University Medical Center Lombardi CCC [Washington D.C., United States] | Hematology-Oncology Associates of Treasure Coast [Port Saint Lucie, United States] | Emory University, Winship Cancer Institute [Atlanta, United States] | University of Kentucky, Markey Cancer Center [Lexington, United States] | The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision) [Bethesda, United States] | Beth Israel Medical Deaconess Medical Center [Boston, United States] | Dana Farber Cancer institute [Boston, United States] | Karmanos Cancer Center [Detroit, United States] | Henry Ford Hospital System [Detroit, United States] | St. Luke's Hospital of Kansas City [Kansas City, United States] | NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone [New York, United States] | Duke Cancer Institute [Durham, United States] | UPMC CancerCenters, Hilman Cancer Center [Pittsburgh, United States] | HOPE Cancer Center of East Texas [Tyler, United States] | Utah Cancer Specialists [Salt Lake City, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a combination of Pembrolizumab with new agents (Itacitinib and INCB050465) in advanced solid tumors, indicating the exploration of a new treatment regimen rather than an extension of indication for an existing medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT02649686,Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab,COMPLETED,PHASE1,Canadian Cancer Trials Group,2016-05-17,2017-09-25,2019-11-12,2016-01-07,2023-08-04,['Confirm the recommended phase II dose of durvalumab given to patients with advanced/recurrent HER-2 positive metastatic breast cancer (MBC) who are receiving treatment with trastuzumab'],"['Number of participants with treatment related adverse events as assessed by CTCAE V 4.0', 'Measure response rate of durvalumab measured by RECIST 1.1/Immune Response Criteria) in patients receiving trastuzumab', 'Measure clinical benefit rate of durvalumab measured by RECIST 1.1/Immune Response Criteria) in patients receiving trastuzumab', 'Assess PD-L1 expression in paired biopsies pre and post treatment with durvalumab as a marker of response/benefit']",,,,,3,Canada,"BCCA - Vancouver Cancer Centre [Vancouver, Canada] | Ottawa Hospital Research Institute [Ottawa, Canada] | University Health Network [Toronto, Canada]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of durvalumab in a specific patient population (HER-2 positive metastatic breast cancer) who are already receiving trastuzumab, indicating an extension of indication for durvalumab rather than a new medicine.",NETWORK,False,2019.0,6.0,0,Phase 1
NCT02650635,"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors","Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors",TERMINATED,PHASE1,Mayo Clinic,2016-02-05,2016-09-26,2017-06-01,2016-01-08,2018-09-05,['Change in pharmacodynamics after TLR8 agonist VTX-2337 alone vs TLR8 agonist VTX-2337+cyclophosphamide'],"[""Duration of response, assessed by irDOR, defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented"", 'Incidence of adverse events of cyclophosphamide and TLR8 agonist VTX-2337, using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0', 'Overall response rate assessed by irBORR', 'Overall survival (OS)', 'PFS as measured by serial imaging studies and assessed by irRECIST']",,,,,1,United States,"Mayo Clinic in Arizona [Scottsdale, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT02650661,Efficacy of a Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively,A Randomized Controlled Trial of Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively in Cancer Survivors,COMPLETED,,Seoul National University Hospital,2015-11-23,2016-06,2018-01,2016-01-08,2018-10-19,"['Change in percentage of patients meeting the exercise goal', 'Change in percentage of patients meeting the body mass index (BMI) goal', 'Change in percentage of patients meeting the posttraumatic growth inventory (PTGI) goal']","['Change in percentage of patients meeting diet goal', 'Change in execution level of health habits', 'Change in level of anxiety and depression', 'Change in level of fatigue', 'Change in level of self-management strategy', 'Change in level of social support and spiritual well-being', 'Cost effectiveness analysis']",,,,,4,South Korea,"Eun Sook Lee [Ilsan, South Korea] | Sung Kim [Seoul, South Korea] | Eun Mi Nam [Seoul, South Korea] | Kyung Hae Jung [Seoul, South Korea]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial evaluating a management program for cancer survivors, focusing on health strategies rather than testing a new medicine or extending the indication of an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02650752,Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2016-01-06,2021-01-22,2021-01-22,2016-01-08,2021-01-26,['maximum tolerated dose (MTD)'],[],,,,,9,United States,"University of Michigan Health System [Ann Arbor, United States] | Memoral Sloan Kettering Cancer Center [Basking Ridge, United States] | Memorial Sloan Kettering Monmouth [Middletown, United States] | Memorial Sloan Kettering Cancer Center @ Suffolk [Commack, United States] | Memorial Sloan Kettering Westchester [Harrison, United States] | Queens Cancer Center of Queens Hospital [Jamaica, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Memorial Sloan Kettering at Mercy Medical Center [Rockville Centre, United States] | Memorial Sloan Kettering Nassau [Uniondale, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT02652923,Contrast Ultrasound Detection of Sentinel Lymph Nodes,Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients,COMPLETED,PHASE1; PHASE2,Sidney Kimmel Cancer Center at Thomas Jefferson University,2016-01-01,2022-01-12,2022-01-12,2016-01-12,2023-01-23,"['Dose optimization (1.0 vs 2.0 ml) based on the degree and duration of Sonazoid contrast-enhancement of the visualized LCs and SLNs', 'Number of subdermal Sonazoid volunteers with AEs, clinical assessments, and safety laboratory tests outside normal ranges (established by historical controls)', 'Number SLNs in patients with breast cancer identified by lymphosonography and by isotope mapping with Tc-99m sulfur colloids.']",[],,,,,1,United States,"Thomas Jefferson University [Philadelphia, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the use of contrast ultrasound for detecting sentinel lymph nodes in breast cancer patients, focusing on dose optimization and safety assessments, but does not introduce a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT02662621,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors,Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for Early Diagnosis of Malgnant Solid Tumors,COMPLETED,,Centre Georges Francois Leclerc,2015-12-15,2015-12-15,2019-04-08,2016-01-25,2025-06-05,['concentration of HSP70 exosomes in the blood and urine'],[],,,,,1,France,"CGFL [Dijon, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focused on quantifying a stress protein for monitoring and early diagnosis of malignant solid tumors, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02664103,Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer,A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer,COMPLETED,PHASE2,Sanofi,2016-01-23,2017-11-06,2017-11-06,2016-01-26,2018-02-01,"['Proportion of patients with adverse events', 'Assessment of PK parameter: maximum concentration (Cmax)', 'Assessment of PK parameter: time to reach Cmax (Tmax)']","['Disease Control Rate (DCR)', 'Objective Response Rate (ORR)', 'Time to Progression (TTP)', 'Proportion of patients compliant with treatment']",,,,,5,India,"Investigational Site Number 356009 [Kollkata, India] | Investigational Site Number 356002 [Mumbai, India] | Investigational Site Number 356007 [New Delhi, India] | Investigational Site Number 356008 [Trivandrum, India] | Investigational Site Number 356001 [Vellore, India]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study involves a fixed-dose combination of existing drugs (Capecitabine and Cyclophosphamide) for a specific patient population (advanced breast cancer), indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2017.0,8.0,0,Phase 2
NCT02666261,A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany,A Non-interventional Study on the Epidemiology and Testing of HER2 in Breast Cancer in Germany,COMPLETED,,Hoffmann-La Roche,2016-03-04,2018-02-28,2018-02-28,2016-01-28,2019-03-21,['Number of HER2 Positive Samples'],"['Number of HER2 Positive Samples by Carcinoma Subtype (No Special Type\\Ductal, Lobular, Other Special Type)', 'Number of HER2 Positive Samples by Sample Extraction (Biopsy versus Resectate)', 'Number of HER2 Positive Samples by Tumor-Node-Metastasis (TNM) Classification', 'Number of HER2 Positive Samples by Sample Source (Primary Tumor, Local Lymph Nodes, Metastasis)', 'Number of HER2 Positive Samples by Applied Method of Tissue Fixation', 'Number of HER2 Positive Samples by Testing Platform', 'Number of HER2 Positive Samples by Automation of Testing', 'Number of HER2 Positive Samples by Antibody Clone Antibody or Test Certification', 'Number of HER2 Positive Samples by Scoring Algorithm', 'Number of HER2 Positive Samples by Round Robin Tests', ""Number of HER2 Positive Samples by Institute's Accreditation"", ""Number of HER2 Positive Samples by Institute's Certification"", 'Number of HER2 Positive Samples by Tumor Grading', 'Number of HER2 Positive Samples by Participant Age', 'Number of HER2 Positive Samples by Hormone Receptor Status']",,,,,64,Germany,"Klinikum Augsburg; Institut für Pathologie [Augsburg, Germany] | Sozialstiftung Bamberg; Institut für Pathologie [Bamberg, Germany] | Klinikum Bayreuth [Bayreuth, Germany] | Institut für Pathologie, Zytologie & Molekularpathologie in Bergisch Gladbach [Bergisch Gladbach, Germany] | Gemeinschaftspraxis für Pathologie Stefan Berger, Jörg Linke und Ellen Fietze [Berlin, Germany] | Vivantes Klinikum Neukölln; Fachbereich Pathologie [Berlin, Germany] | HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie [Berlin, Germany] | Gemeinschaftspraxis; Institut für Pathologie am Evangelischen Waldkrankenhaus [Berlin - Spandau, Germany] | Praxis am St. Agnes-Hospital Bocholt [Bocholt, Germany] | Institut für Pathologie und Zytologie an der Augusta-Kranken-Anstalt [Bochum, Germany] | Universitätsklinikum Bonn; Zentrum für Pathologie Pathologisches Institut [Bonn, Germany] | Klinikum Coburg GmbH - Institut für Pathologie [Coburg, Germany] | Institut f. Pathologie, der Univers. Köln [Cologne, Germany] | Kliniken der Stadt Köln gGmbH Krankenhaus Merheim [Cologne, Germany] | Städtisches Klinikum Dessau; Institut für Pathologie [Dessau, Germany] | Gemeinschaftspraxis für Pathologie Dr. Dykgers, Dr. Langwieder, Dr. Rees [Dortmund, Germany] | Städtisches Klinikum Dresden; Institut für Pathologie ""Georg Schmorl"" (Friedrichstadt) [Dresden, Germany] | Evangelisches Krankenhaus BETHESDA zu Duisburg GmbH; Institut für Pathologie [Duisburg, Germany] | Krankenhaus Düren gem. GmbH; Institut und Praxisgemeinschaft für Pathologie [Düren, Germany] | Universitätsklinikum Erlangen; Pathologisches Institut [Erlangen, Germany] | OptiPath Gemeinschaftspraxis für Pathologie [Frankfurt, Germany] | Universitätsklinikum Freiburg Institut f.Pathologie [Freiburg im Breisgau, Germany] | Pathologische Institut Friedrichshafen/Bodensee (Gemeinschaftspraxis für Pathologie und Zytologie) [Friedrichshafen, Germany] | Klinik am Eichert; Institut für Pathologie [Göppingen, Germany] | Universitätsklinikum Göttingen, Institut für Pathologie [Göttingen, Germany] | Institut für Pathologie, MVZ am Lukaskrankenhaus [Grevenbroich, Germany] | Klinikum Oberberg; Pathologisches Institut Kreiskrankenhaus Gummersbach [Gummersbach, Germany] | Pathologisches Institut am Allg. KH Stadt Hagen; Stambolis, Wolf von Rhüden, Ruwe [Hagen, Germany] | Universitätsklinikum Halle (Saale), Institut für Pathologie [Halle, Germany] | Kath. Marienkrankenhaus gGmbH [Hamburg, Germany] | Fachärzte Dres Tiemann & Schulte Partnerschaft; Institut für Hämatopathologie Hamburg [Hamburg, Germany] | Gemeinschaftspraxis für Pathologie Hamm, Dres. Diebold/Niemann [Hamm, Germany] | Gemeinschaftspraxis Dr. Hartmut Fitz, Dr. Sebastian Blasius und PD Dr. Christian August [Hanau, Germany] | Dres. Wolfgang Beschow Eckehardt Kupsch Herbert Radner u.w. [Hanover, Germany] | Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe [Hanover, Germany] | Pathologisches Institut [Heidelberg, Germany] | Institut für Pathologie Hildesheim [Hildesheim, Germany] | Gemeinschaftspraxis für Pathologie Ingolstadt Dr. König, Dr. Popp, Prof. Dr. Adam [Ingolstadt, Germany] | Universitätsklinikum Jena; Institut für Pathologie [Jena, Germany] | Städtisches Klinikum Karlsruhe gGmbH; Pathologisches Institut [Karlsruhe, Germany] | Institut Für Pathologie Nordhessen [Kassel, Germany] | Institut für Pathologie Kassel [Kassel, Germany] | Institut für Pathologie, Universitäsklinikum Schleswig-Holstein [Kiel, Germany] | Klinikum Konstanz gGmbH, Institut und Praxis für Pathologie [Konstanz, Germany] | Gemeinschaftspraxis für Pathologie Lübeck; Turzynski, Lebeau, Gocht, Leuenroth [Lübeck, Germany] | Universitätsklinikum Magdeburg; Institut für Pathologie und Neuropathologie [Magdeburg, Germany] | Klinikum Magdeburg GmbH [Magdeburg, Germany] | Klinikum Mannheim; Pathologisches Institut [Mannheim, Germany] | Institut für Pathologie [Mühlhausen, Germany] | Pathologie München-Nord [München, Germany] | Institut für Pathologie der Universität Münster, Albert Schweitzer Campus, Gebäude D17 [Münster, Germany] | Institut für Pathologie am Clemenshospital Münster [Münster, Germany] | Dietrich Bonhoeffer Kliniken Neubrandenburg, Institut für Pathologie [Neubrandenburg, Germany] | Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss [Neuss, Germany] | Evangelisches Krankenhaus Oberhausen GmbH, Institut f.Pathologie [Oberhausen, Germany] | Pathocom - Gemeinschaftspraxis Bischofsstraße Osnabrück [Osnabrück, Germany] | Pathologisches Institut Recklinghausen [Recklinghausen, Germany] | Klinikum am Steinenberg / Ermstalklinik [Reutlingen, Germany] | Diakoniekrankenhaus Institut f.Pathologie [Rotenburg (Wümme), Germany] | Leopoldina Krankenhaus der Stadt Schweinfurt GmbH; Pathologie [Schweinfurt, Germany] | HELIOS Klinikum Schwerin; Frauenklinik [Schwerin, Germany] | Gemeinschaftspraxis PD Dr.med. Meinald Schultz und Dr.med. Petra Lüders [Stendal, Germany] | Robert-Bosch-Krankenhaus; Pathologisches Institut [Stuttgart, Germany] | Gemeinschaftspraxis für Pathologie Weiden; am Klinikum Weiden; Giedl, Stelter und Meier [Weiden, Germany]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,"The text describes a non-interventional study focused on the epidemiology and testing of HER2 in breast cancer, without indicating the introduction of a new medicine or an extension of indication for an existing treatment.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02676986,"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer",Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer,COMPLETED,PHASE2,Queen Mary University of London,2015-08-10,2016-12-31,2016-12-31,2016-02-09,2024-07-05,"['Determine the difference in geometric mean change in Ki67 expression between the two treatment groups of patients in the ER+ Cohort', 'Determine the individual anti-proliferative response (RRΔKi67) for patients in the AR+ TNBC cohort']","['Determine the geometric mean change in Ki67 expression at the end of study treatment (Mean ΔKi67) for patients in the AR+ TNBC cohort', 'Determine the geometric mean Ki67 expression at the end of study treatment (Mean Ki67post) for patients in the ER+ cohort', 'Determine the individual end-of treatment anti-proliferative response (RRKi67-Post) for all patients.', 'Determine the individual anti-proliferative response (RRΔKi67) for patients in the ER+ cohort.', 'Determine the geometric mean change in Caspase-3 between end of study treatment and pre-treatment tumour samples (Mean ΔCaspase-3).', 'Determine the individual apoptotic response (RRΔCaspase-3).', 'Establish the safety and tolerability of enzalutamide alone and in combination with exemestane in this population through review of all AEs and SAEs assessed by CTCAE v4.03', 'Measure the plasma levels of circulating hormones in blood samples collected prior to and at the end of study treatment.']",,,,,41,Germany; Ireland; Spain; United Kingdom; United States,"MD Anderson Cancer Centre [Houston, United States] | Evangelisches Krankenhaus Bergisch Gladbachg GmbH Frauenklinik [Bergisch Gladbach, Germany] | Charité Campus Mitte [Berlin, Germany] | Brustzentrum City St. Gertraudenkrankenhaus [Berlin, Germany] | Evangelisches Waldkrankenhaus Spandau [Berlin, Germany] | Johanniter Krankenhaus Bonn [Bonn, Germany] | Onkologische Schwerpunktpraxis Bremen [Bremen, Germany] | Klinikum Chemnitz GmbH [Chemnitz, Germany] | Brustzentrum Uniklinik Köln [Cologne, Germany] | St. Elisabeth Krankenhaus Köln [Cologne, Germany] | Brustzentrum Holweide [Cologne, Germany] | Kliniken-Essen-Mitte, Senology [Essen, Germany] | Agaplesion Markus Krankenhaus [Frankfurt, Germany] | Evangelische Kliniken Gelsenkirchen [Gelsenkirchen, Germany] | Hannover Diakovere Henriettenstift [Hannover, Germany] | Klinikum Kassel [Kassel, Germany] | Klinikum Kempten [Kempten, Germany] | UKSH -Campus Kiel [Kiel, Germany] | DRK Kliniken Berlin Köpenick [Köpenick, Germany] | UKSH Lübeck [Lübeck, Germany] | UKSH Lüneburg, Städtisches Krankenhaus [Lüneburg, Germany] | Johannes wesling Klinikum (Minden Hospital) [Minden, Germany] | Brustzentrum Niederrhein / ÜBAG Prof. Nitz Mönchengladbach [Mönchengladbach, Germany] | Onkologisches Zentrum am Rotkreuzklinikum München [München, Germany] | Helios-Kliniken Schwerin [Schwerin, Germany] | Johanniter Frauenklinik Stendal [Stendal, Germany] | Praxisnetzwerk Trosidorf [Troisdorf, Germany] | GRN Klinik Weinheim [Weinheim, Germany] | Marienhospital Witten [Witten, Germany] | Belfast Health and Social Care Trust [Belfast, Ireland] | Vall Hebron Hospital [Barcelona, Spain] | Royal Cornwall Hospitals NHS Trust [Truro, United Kingdom] | Ninewells Hospital and Medical School NHS Tayside [Dundee, United Kingdom] | Royal Devon and Exeter NHS Foundation Trust [Exeter, United Kingdom] | Barts Health NHS Trust [London, United Kingdom] | Guy's and St Thomas' NHS Foundation Trust [London, United Kingdom] | University Hospital of South Manchester [Manchester, United Kingdom] | North Manchester Hospital, Pennine Acute Hospitals NHS Trust [Manchester, United Kingdom] | Churchill Hospital Oxford University Hospitals NHS Trust [Oxford, United Kingdom] | University Hospital of North Tees [Stockton-on-Tees, United Kingdom] | Royal Surrey County Hospital NHS Foundation Trust [Surrey, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves the use of enzalutamide, which is an existing medication, in combination with exemestane for a new indication (preoperative treatment in primary breast cancer).",OTHER,False,2016.0,9.0,1,Phase 2
NCT02681120,Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer,Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer,COMPLETED,,"Tarah J Ballinger, MD",2016-10-07,2020-01-30,2020-01-30,2016-02-12,2021-10-14,"['Change in breast density via MRI from baseline', 'Change in breast density via mammography from baseline']","['Comparison of number of crown-like structures in obese breast tissue and normal breast tissue', 'Comparison of number of crown-like structures in obese breast tissue and normal breast tissue', 'Change in aromatase expression markers in obese tissue from baseline', 'Comparison of aromatase expression markers in normal weight breast tissue with obese breast tissue', 'Change in aromatase expression markers in obese tissue from baseline', 'Comparison of aromatase expression markers in normal weight breast tissue with obese breast tissue', 'Change in other correlative blood markers (inflammatory, insulin, hormonal) from baseline', 'Change in other correlative blood markers (inflammatory, insulin, hormonal) from baseline']",,,,,3,United States,"Indiana University Health North Hospital [Carmel, United States] | Indiana University Health Hospital [Indianapolis, United States] | Indiana University Melvin and Bren Simon Cancer Center [Indianapolis, United States]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focusing on the effects of weight loss on breast tissue and blood biomarkers, which does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02682693,Denosumab as an add-on Neoadjuvant Treatment (GeparX),Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX),COMPLETED,PHASE2,GBG Forschungs GmbH,2017-02-13,2019-12-31,2020-12-31,2016-02-15,2021-02-02,"['pcR rates of neoadjuvant treatment with or without denosumab in addition to nab-paclitaxel and EC.', 'pcR (ypT0 ypN0) rates of nab-Paclitaxel weekly for 12 weeks or 2 of 3 weeks for 12 weeks']","['To test for interaction of denosumab treatment with RANK expression.', 'To assess the pCR rates per arm for both randomizations separately for TNBC and HR-/HER2+ tumors.']",,,,,1,Germany,"Charité Campus Mitte [Berlin, Germany]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2020.0,5.0,0,Phase 2
NCT02684032,A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,"PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)",COMPLETED,PHASE1,Celcuity Inc,2016-06-14,2022-01-19,2022-01-19,2016-02-17,2022-07-27,"['Number of participants with dose limiting toxicities', 'Objective response rate observed in patients in the dose expansion portion', 'Objective response rate observed in patients in the dose expansion portion']","['Tumor response observed in patients in the dose escalation portion', 'Duration of response', 'QTc interval (corrected QT interval)', 'Maximum observed plasma concentration', 'Progression free survival']",,,,,41,United States,"University of Alabama at Birmingham [Birmingham, United States] | University of Alabama at Birmingham [Birmingham, United States] | Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. [Corona, United States] | Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. [Fountain Valley, United States] | Keck Hospital of USC - Norris Healthcare Center (HC3) [Los Angeles, United States] | Keck Hospital of USC [Los Angeles, United States] | LAC+USC Medical Center [Los Angeles, United States] | USC/Norris Comprehensive Cancer Center / Investigational Drug Services [Los Angeles, United States] | USC/Norris Comprehensive Cancer Center [Los Angeles, United States] | Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc. [Riverside, United States] | UCSF - Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | UCSF - Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP) [Aurora, United States] | University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) [Aurora, United States] | University of Colorado Hospital - Clinical Trials Office (CTO) [Aurora, United States] | University of Colorado Hospital- Anschutz Cancer Pavilion (ACP) [Aurora, United States] | Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus [Tampa, United States] | Moffitt Cancer Center [Tampa, United States] | Emory University Hospital Midtown [Atlanta, United States] | Emory University Hospital [Atlanta, United States] | The Emory Clinic [Atlanta, United States] | Winship Cancer Institute [Atlanta, United States] | Massachusetts General Hospital [Boston, United States] | University of Michigan [Ann Arbor, United States] | Karmanos Cancer Institute [Detroit, United States] | Karmanos Cancer Institute [Farmington Hills, United States] | UNC Cancer Hospital Infusion Pharmacy [Chapel Hill, United States] | UNC Hospitals, The University of North Carolina at Chapel Hill [Chapel Hill, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | The Ohio State University Wexner Medical Center James Cancer Hospital [Columbus, United States] | Stefanie Spielman Comprehensive Breast Cancer [Columbus, United States] | Thomas Jefferson University - Clinical and Regulatory [Philadelphia, United States] | Thomas Jefferson University [Philadelphia, United States] | Vanderbilt Breast Center at One Hundred Oaks [Nashville, United States] | Henry-Joyce Cancer Clinic [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | U.T. MD Anderson Cancer Center [Houston, United States] | Virginia Cancer Specialists, PC [Fairfax, United States] | Seattle Cancer Care Alliance (SCCA) Investigational Drug Services [Seattle, United States] | Seattle Cancer Care Alliance [Seattle, United States] | University of Washington Medical Center [Seattle, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT02687490,Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer,"A Prospective, Single-center, Open-Label, Phase II Study of Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer",COMPLETED,PHASE2,Fudan University,2017-02-24,2020-12-01,2020-12-15,2016-02-22,2021-03-01,['Progression Free Survival (PFS)'],"['Objective Response Rate (ORR)', 'Number of Participants with Adverse Events as a Measure of Safety and Tolerability', 'Overall Survival (OS)']",,,,,1,China,"Fudan University Cancer Hospital [Shanghai, China]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the use of Abraxane, which is an existing medication, in a specific patient population (those with visceral metastases dominant metastatic breast cancer), indicating an extension of its indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02688166,Cardiac MRI Biomarker Testing (GCC 1618),Cardiac Magnetic Resonance Imaging and Biomarker Testing for Evaluating Cardiac Injury Resulting From Radiation Therapy in Cancer: A Pilot Study,TERMINATED,,"University of Maryland, Baltimore",2018-02-01,2022-09-09,2022-09-09,2016-02-23,2022-10-13,"['Evaluate for evidence of changes in cardiac function measured by cardiac MRI prior to and following external beam radiotherapy who are receiving moderate doses of radiation to the heart.', 'Evidence of changes in cardiac function as measured by serum biomarkers following external beam radiotherapy who are receiving moderate doses of radiation to the heart.']","['Correlate changes in cardiac function measured by cardiac MRI with radiotherapy dose volume histograms evaluating multiple components of the heart.', 'Correlate changes in cardiac function measured by serum biomarkers with radiotherapy dose volume histograms evaluating multiple components of the heart.']",,,,,1,United States,"Ummc Msgccc [Baltimore, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on evaluating cardiac function and biomarkers in patients undergoing radiation therapy, indicating an extension of indication for existing cardiac MRI and biomarker testing in a new patient population.",OTHER,False,2022.0,3.0,0,NA/Other
NCT02704312,Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer,A Feasibility Study of Patient Comfort and Dosimetry Evaluation in Prone Breast Radiotherapy.,TERMINATED,,University Hospital Center of Martinique,2015-11-30,2021-08,2022-02-11,2016-03-10,2022-03-08,['Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk'],['Quality of Life Questionnaire'],,,,,1,Martinique,"CHU de Martinique [Fort-de-France, Martinique]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a feasibility study related to dosimetry and patient comfort in radiotherapy for breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT02718144,Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer,COMPLETED,PHASE1; PHASE2,Pantarhei Oncology B.V.,2017-06-01,2019-12-31,2019-12-31,2016-03-24,2021-06-18,['The number of patients with a dose limiting toxicity (DLT)'],"['Questionnaire on estrogen deficiency symptoms', 'Pharmacokinetics: estetrol trough levels', 'Preliminary anti-tumour response according to RECIST 1.1']",,,,,2,Germany,"Katholisches Klinikum Mainz [Mainz, Germany] | Universitatsmedizin Mainz [Mainz, Germany]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 2
NCT02723877,PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO),"An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR309 and Eribulin Combination in Patients With Locally Advanced or Metastatic HER2 Negative and Triple-Negative Breast Cancer",COMPLETED,PHASE1; PHASE2,PIQUR Therapeutics AG,2016-03-28,2018-10-03,2018-10-03,2016-03-31,2019-03-22,"['Number of patients with treatment related Adverse Events and Serious Adverse Events as assessed by NCI CTCAEV4.03', 'RECIST the Response criteria for solid tumors will be used to identify clinical benefit rate (CBR) including complete Response (CR), partial Response (PR) and stable disease (SD)']","['Number of patients with Adverse Events and Serious Adverse Events and number of anormal laboratory values that constitute an Adverse Events on their own', 'Number and percent of patients having each ECOG (Eastern Oncology Cooperative Group) performance status level will be presented for baseline and each post-baseline measurement.', 'Assessment of PQR309 and Eribulin blood concentration', 'Physical examination, Body weight in kg', 'Physical examination, ECG', 'Vital signs like heart rate', 'Vital signs like blood pressure', 'Vital signs like body temperature', 'Objective Response Rate (ORR), is defined as the best overall response (confirmed CR or PR) recorded for each patient since baseline.', 'Time to Response (TTR) is defined, for patients with tumor response, as the time from the date of study entry to the first documentation of response (complete or partial)', 'Duration of response (DOR) is defined, for the patients with tumor response, as the time from the date of the first confirmed response to disease progression.', 'Progression- free survival (PFS) is defined as the time from study entry to progression or death due to any cause', 'Time to treatment failure (TTF) is defined as the time from study entry to any treatment failure including disease progression or discontinuation of treatment', '1-year survival, defined as the time from study entry to death as a result of any cause at 1-year cut-off date', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC(Racemate)', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'PK parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: cmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-24', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: AUC0-∞', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: t1/2', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: tmax', 'Pharmacokinetic (PK) parameters of PQR309 and eribulin will include: RAC (Racemate)', 'Changes in glucose levels', 'Changes in Insulin levels', 'Changes of Routine laboratory -Haematology', 'Changes of Routine laboratory -blood chemistry', 'Changes of Routine laboratory -urinanalysis']",,,,,5,Spain; United Kingdom,"Hospital Universitarsi Vall d'Hebron [Barcelona, Spain] | Insitut Català d´Oncologia [Barcelona, Spain] | Fundación Instituto Valenciano de Oncología [Valencia, Spain] | Barts Cancer Institute [London, United Kingdom] | Churchill hospital [Oxford, United Kingdom]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 2
NCT02725489,Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers,Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers,COMPLETED,PHASE2,Mary Crowley Medical Research Center,2016-06-03,2019-12-30,2020-12-02,2016-04-01,2021-01-27,['Number of treatment-emergent AEs of Vigil + Durvalumab'],"['Overall response rate (ORR)', 'Disease status', 'IFNγ-ELISPOT conversion rate (negative to positive) during on-study treatment']",,,,,1,United States,"Mary Crowley Cancer Research Center [Dallas, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves Durvalumab, which is an existing medication, in combination with Vigil for a new application in advanced women's cancers, indicating an extension of indication.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02730091,"A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease","A Randomized Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease",TERMINATED,PHASE3,Centre Hospitalier Universitaire de Besancon,2016-02-24,2020-03-23,2020-03-23,2016-04-06,2021-02-01,['progression-free survival (PFS)'],"['health-related quality of life using HRQoL QLQ-C30 and BR23', 'overall response rate (ORR)', 'clinical benefit rate (CBR)', 'Safety assessed by NCI CTCAE version 4.0"",']",,,,,1,France,"CHU Besançon [Besançon, France]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2020.0,5.0,0,Phase 3
NCT02733601,Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria,BreCaReAl: Breast Cancers Registry in Algeria,COMPLETED,,AstraZeneca,2016-05-29,2022-03-31,2022-03-31,2016-04-11,2023-04-03,['Survival status at 05 years (percentage of patients still alive at 05 years)'],"['incidence all cases', 'Incidence by age', 'Incidence by stage']",,,,,3,Algeria,"Research Site [East of Algeria, Algeria] | Research Site [Middle of Algeria, Algeria] | Research Site [Ouest of Algeria/ Oran Region, Algeria]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses epidemiology and survival statistics related to breast cancer but does not mention a new medicine or an extension of indication for an existing treatment.,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,"A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy",TERMINATED,PHASE1,Novartis Pharmaceuticals,2016-06-14,2021-09-13,2021-09-13,2016-04-12,2022-08-01,"['Incidence of dose limiting toxicities (DLTs)', 'Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719']","['Overall response rate (ORR)', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)', 'Disease control rate (DCR)', 'Plasma concentration of study medications', 'Plasma concentration under fasted condition and fed condition', 'Levels of Pharmacodynamic marker Estrogen receptor (ER)', 'Levels of Pharmacodynamic marker Progesterone receptor (PgR)', 'Levels of Pharmacodynamic marker pS6', 'Pharmacokinetics (PK) parameter AUC', 'PK parameter Cmax', 'PK parameter Tmax', 'PK parameter Cmin']",,,,,10,Belgium; France; Germany; Italy; Japan; Singapore; United States,"Massachusetts General Hospital Massachusetts General Hospital [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | MD Anderson Cancer Center SC - LSZ102X2101 [Houston, United States] | Novartis Investigative Site [Brussels, Belgium] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Koto Ku, Japan] | Novartis Investigative Site [Singapore, Singapore]",2016.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02739425,The Efficacy of Sentimag in Detection of Sentinel Node Biopsy,SMART Study: Sentimag Along With Routine Technique in Detection of Sentinel Node Biopsy,COMPLETED,,The Royal Wolverhampton Hospitals NHS Trust,2016-09-22,2018-05-01,2018-05-01,2016-04-15,2019-06-06,"['Proportion of successful sentinel node biopsies (SLNB, detection rate per patient) with either the magnetic or the standard technique']","['Detection rate per node', 'Malignancy rate: proportion of nodes and patients with a malignant result in the definite pathological analysis.', 'Concordance rate: proportion of successful labelling with the standard and new technique per patient and per node', 'Malignancy concordance: proportion of successful labelling with the standard and new technique per malignancy positive patients and nodes']",,,,,1,United Kingdom,"The Royal Wolverhampton NHS Trust [Wolverhampton, United Kingdom]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,The text discusses the efficacy of Sentimag in a specific application (detection of sentinel node biopsy) rather than introducing a new medicine. It indicates an extension of indication for an existing technique.,OTHER_GOV,False,2018.0,7.0,0,NA/Other
NCT02744079,Comparison of Healthy Diets on Breast Cancer Markers,A Pilot Presurgical Trial of Insulin Inhibition by a Ketogenic Diet in Operable Breast Cancer,COMPLETED,,Albert Einstein College of Medicine,2018-06-22,2020-08-25,2020-08-25,2016-04-20,2020-08-31,"['TUNEL comparison of each dietary intervention at surgical removal to measure change in apoptosis in tumor cells', 'Ki-67 comparison of each dietary intervention at surgical removal to measure change in proliferation of tumor cells']",[],,,,,1,United States,"The Albert Einstein College of Medicine of Yeshiva University [The Bronx, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on dietary interventions and their effects on breast cancer markers, rather than testing a new medicine or extending the indication of an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02753686,Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy,Treatment of Canadian Men and Pre/Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy,COMPLETED,,Novartis Pharmaceuticals,2016-03-15,2022-12-01,2022-12-01,2016-04-28,2023-02-15,['Duration on Treatment'],"['Treatment Sequencing', 'Monitoring Patterns', 'Overall Survival (OS)', 'Health Care Resource Utilization (HCRU)', 'Health Related Quality of Life (HRQoL - EORTC QLQ-C30)', 'HRQoL BR23', 'Work-Related Productivity']",,,,,25,Canada,"Novartis Investigative Site [Calgary, Canada] | Novartis Investigative Site [Burnaby, Canada] | Novartis Investigative Site [North Vancouver, Canada] | Novartis Investigative Site [Richmond, Canada] | Novartis Investigative Site [Vancouver, Canada] | Novartis Investigative Site [Moncton, Canada] | Novartis Investigative Site [Moncton, Canada] | Novartis Investigative Site [Cambridge, Canada] | Novartis Investigative Site [Kingston, Canada] | Novartis Investigative Site [Kitchener, Canada] | Novartis Investigative Site [London, Canada] | Novartis Investigative Site [Newmarket, Canada] | Novartis Investigative Site [Ottawa, Canada] | Novartis Investigative Site [Sault Ste. Marie, Canada] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Windsor, Canada] | Novartis Investigative Site [Greenfield Park, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Québec, Canada] | Novartis Investigative Site [Regina, Canada] | Novartis Investigative Site [Saskatoon, Canada]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the treatment of a specific patient population (men and pre/peri/post-menopausal women) with ER+ advanced breast cancer using existing therapies (hormone therapy ± targeted therapy), indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT02754011,Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative,"Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes",COMPLETED,PHASE1,UNICANCER,2017-02-02,2022-02-28,2022-12-23,2016-04-28,2023-12-07,['Determination of the maximum tolerated dose (MTD) and the recommended dose for phase 2 (RP2D) of ribociclib and capecitabine combination'],"['Evaluate safety of ribociclib and capecitabine combination', 'Characterize the pharmacokinetic (PK) profile of ribociclib and capecitabine combination', 'Evaluate the anti-tumor activity of ribociclib and capecitabine combination', 'Evaluate anti-tumor activity and safety of the ribociclib and capecitabine combination RP2D according to RH status', 'Evaluate the anti-tumor activity of ribociclib and capecitabine depending on Rb status']",,,,,2,France,"Centre Leon Berard [Lyon, France] | Institut de Cancérologie de l'Ouest [Saint-Herblain, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT02757651,KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,Phase I 'Run in' Study Followed by Randomised Phase II Trial Testing Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Women With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response,COMPLETED,PHASE1; PHASE2,"Institute of Cancer Research, United Kingdom",2017-01-19,2020-11-12,2020-11-12,2016-05-02,2020-11-27,"['Phase I: Patient reported maximum intra-tumoural pain intensity over duration of treatment', 'Phase II: Tumour response 3 months post-radiotherapy according to RECIST 1.1 criteria']","['Phase I: Proportion of patients with severe pain at any time before and up to 24 hours after any of the KORTUC injections. Server Sever pain is defined as scoring a max grade ≥5 above baseline', 'Phase II: Proportion of patients with severe pain at any time before and up to 24 hours after any of the KORTUC injections. Server pain is defined as scoring a max grade ≥5 above baseline Frequency and duration of pain score ≥1 at each time point', 'Phase I: Tumour response 3 months post- radiotherapy according to RECIST 1.1 criteria', 'Phase II: Local progression-free survival at 24 months']",,,,,1,United Kingdom,"The Royal Marsden NHS Foundation Trust [London, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 2
NCT02768337,Cambridge Brain Mets Trial 1,"Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy",TERMINATED,PHASE1; PHASE2,Cambridge University Hospitals NHS Foundation Trust,2015-03-10,2020-08-12,2021-08-12,2016-05-11,2024-01-31,['Ratio of afatinib concentration in: [resected brain metastases] / [plasma] - each measured in (ng/mL) on day 12'],['Safety of afatinib alone and combined with targeted low-dose radiotherapy - assessed by number of participants with treatment- related adverse events as assessed by CTCAE v4.0'],,,,,6,United Kingdom,"Cambridge University Hospitals NHS Foundation Trust [Cambridge, United Kingdom] | University Hospitals Birmingham NHS Foundation Trust [Birmingham, United Kingdom] | The Beatson West of Scotland Cancer Centre [Glasgow, United Kingdom] | Clatterbridge Cancer Centre [Liverpool, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom] | Oxford University Hospitals NHS Foundation Trust [Oxford, United Kingdom]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of afatinib, which is an existing medication, in a new context (cerebral metastases) and in combination with low-dose targeted radiotherapy, indicating an extension of its indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02771353,The HeartSpare Plus 1B Trial,"The HeartSpare Plus 1B Trial: A Randomised Phase II Trial Comparing the Resource Impact, Acute Toxicity and Feasibility of Different Pan-lymph Node Radiotherapy Techniques for Breast Cancer Patients",COMPLETED,PHASE2,Royal Marsden NHS Foundation Trust,2016-12-12,2019-01-15,2019-01-15,2016-05-13,2022-04-19,['Linear Accelerator time'],"['Acute toxicity - Skin', 'Acute toxicity - lung (pneumonitis)', 'Acute toxicity - oesophagitis', 'Acute toxicity - fatigue', 'Acute toxicity - quality of life', 'Intermediate toxicity - lung (pneumonitis)', 'Intermediate toxicity - fatigue', 'Intermediate toxicity - quality of life', 'Intermediate toxicity - lymphoedema/ shoulder dysfunction', 'Organ at risk dose - ipsilateral lung', 'Organ at risk dose - contralateral lung', 'Organ at risk dose - heart', 'Organ at risk dose - contralateral breast', 'Organ at risk dose - thyroid', 'Organ at risk dose - humeral head', 'Organ at risk dose - brachial plexus', 'Organ at risk dose - Left anterior descending coronary artery', 'Organ at risk dose - oesophagus', 'Time taken to plan and check radiotherapy', 'Inter-fraction reproducibility']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on comparing different radiotherapy techniques for breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT02774785,Does Intra-operative MarginProbe Use Reduce Re-excision Rates?,Reducing Re-excisions After Breast Conserving Surgery: A Randomized Controlled Trial Comparing the MarginProbe Device in Addition to Standard Operating Procedure Versus Standard Operating Procedure Alone in Preventing Re-excision,COMPLETED,,Manchester University NHS Foundation Trust,2016-03-22,2019-12-17,2021-02-16,2016-05-17,2021-11-02,"['To determine if intraoperative margin assessment after excision of a cancer reduces second operations (reexcision or mastectomy), compared to standard surgical practice by 9 months after primary surgery.']","['Quality of Life', 'EQ5D', 'To compare the number of patients in both groups presenting with disease free margins greater than 1mm (circumferentially) after breast cancer surgery, using a laboratory histopathological assessment.', 'Total number of re-excisions', 'Cosmetic Outcome']",,,,,1,United Kingdom,"Manchester University NHS Foundation Trust [Manchester, United Kingdom]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses the use of a device (MarginProbe) in a surgical context to reduce re-excision rates after breast cancer surgery, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2021.0,4.0,0,NA/Other
NCT02783222,EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer,EFFECT: A Randomized Phase II Study to Evaluate the EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly Patients With advanCed breasT Cancer,COMPLETED,PHASE2,Fondazione Sandro Pitigliani,2013-01-30,2017-09-22,2017-12,2016-05-26,2018-01-10,['Event-free survival (EFS)'],"['Objective response rate (ORR)', 'Clinical benefit rate (CBR)', 'Progression free survival (PFS)', 'Overall survival (OS)', 'Incidence of adverse events']",,,,,14,Italy,"A.O.U. Ospedali Riuniti [Ancona, Italy] | Centro Di Riferimento Oncologico [Aviano, Italy] | Azienda Ospedaliera Papa Giovanni Xxiii [Bergamo, Italy] | Spedali Civili Brescia [Brescia, Italy] | Ospedale Antonio Perrino [Brindisi, Italy] | Ospedale Ss. Trinita' [Frosinone, Italy] | Ospedale Vito Fazzi [Lecce, Italy] | Ausl 12 Viareggio [Lucca, Italy] | Istituto Europeo Oncologia [Milan, Italy] | A.O.U. Federico Ii Di Napoli [Napoli, Italy] | Istituto Oncologico Veneto [Padua, Italy] | Fondazione Maugeri [Pavia, Italy] | A.O.U. S. Maria Della Misericordia Di Udine [Udine, Italy] | Ospedale Civile Maggiore [Verona, Italy]",2013.0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Event-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates different doses of an existing drug (Nab-paclitaxel) in a specific patient population (elderly with advanced breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2017.0,8.0,0,Phase 2
NCT02785887,Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients,Impact of Geriatrician-implemented Interventions on Chemotherapy Delivery in Vulnerable Elderly Patients With Early or Metastatic Solid Malignancies: the GIVE Trial,COMPLETED,,Azienda USL 4 Prato,2014-08-01,2018-09-25,2018-09-25,2016-05-30,2019-02-15,['Relative dose intensity'],"['Occurrence of treatment-related toxicity', 'Occurrence of hospitalization', 'Early mortality']",,,,,3,Italy,"Ospedale Vito Fazi [Lecce, Italy] | Ospedale San Paolo [Milan, Italy] | Istituto Oncologico Veneto [Padua, Italy]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a trial focused on the impact of geriatrician interventions on chemotherapy delivery in elderly oncology patients, which does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02786797,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors,COMPLETED,,University of South Florida,2016-03-07,2020-07,2020-07,2016-06-01,2020-07-28,['Change in Executive Functioning from baseline to 6 months.'],"['Change in Executive Function from baseline to 6 months.', 'Change in Visuospatial Memory from baseline to 6 months.', 'Change in Verbal Memory from baseline to 6 months.', 'Change in Logical Memory from baseline to 6 months.', 'Change in Attention and Concentration from baseline to 6 months.', 'Change in Verbal fluency from baseline to 6 months.', 'Change in Cognitive Functioning from baseline to 6 months.']",,,,,5,United States,"Sarasota Memorial Hospital [Sarasota, United States] | Moffitt Cancer Center [Tampa, United States] | University of South Florida [Tampa, United States] | USF Health Carol and Frank Morsani Center [Tampa, United States] | Florida Hospital Tampa [Tampa, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the efficacy of a treatment (MBSR) for cognitive impairment in breast cancer survivors, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02794493,Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer,"A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of Traditional Chinese Medicine Formula LC09 for Treatment of Capecitabine-Induced Hand and Foot Syndrome",COMPLETED,PHASE3,China-Japan Friendship Hospital,2015-04-01,2017-12-31,2018-04-25,2016-06-09,2019-07-25,"['Grade of hand foot syndrome over time as measured by NCI CTCAE version 4.03 PPE syndrome criteria', 'Assessment of patient reported pain using a 1-10 score.']","['Instrumental Activities of Daily Living Scale', 'Dermatology Life Quality Index (DLQI) Total Score', 'Chemotherapy completion rate', 'Incidence of reduced dosage of capecitabine thereby', 'Incidence of cessation of capecitabine thereby']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing a Traditional Chinese Medicine formula (LC09) for the treatment of a specific condition (Hand and Foot Syndrome) induced by a chemotherapy drug (Capecitabine), indicating it is a new medicine.",OTHER,False,2018.0,7.0,0,Phase 3
NCT02800317,RISAS Procedure in Node Positive Breast Cancer Following NAC,Primary Radioactive Iodine Seed Localisation in the Axilla in Axillary Node Positive Breast Cancer Combined With Sentinel Node Procedure (RISAS) Following Neoadjuvant Chemotherapy,COMPLETED,,Erasmus Medical Center,2017-03-30,2020-07-01,2021-12-03,2016-06-15,2022-02-10,"['Identification rate and accuracy (sensitivity, negative predictive value (NPV) and false negative rate (FNR)) of RISAS-procedure for identifying axillary pCR, with 95% confidence intervals will be calculated.']","['The identification rate and accuracy (sensitivity, NPV and FNR) of both techniques used in RISAS-procedure (i.e. SLNB and MARI) for identifying axillary pCR, will be calculated separately as well.']",,,,,14,Netherlands,"Wilhelmina Hospital [Assen, Netherlands] | Amphia Hospital [Breda, Netherlands] | Albert Schweitzer Hospital [Dordrecht, Netherlands] | Martini Hospital [Groningen, Netherlands] | Zuyderland Medical Center [Heerlen, Netherlands] | Hospital Group Twente [Hengelo, Netherlands] | Treant [Hoogeveen, Netherlands] | Maastricht University Medical Center [Maastricht, Netherlands] | Bravis Hospital [Roosendaal, Netherlands] | Erasmus Medical Center [Rotterdam, Netherlands] | Ikazia Hospital [Rotterdam, Netherlands] | Maasstad Hospital [Rotterdam, Netherlands] | Franciscus Gasthuis & Vlietland [Schiedam, Netherlands] | University Medical Center Utrecht [Utrecht, Netherlands]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT02806050,Palbociclib and FES PET,Early Identification of Patients Who Benefit From Palbociclib in Addition to Letrozole,COMPLETED,PHASE2,University Medical Center Groningen,2016-09-16,2022-09-28,2022-09-28,2016-06-20,2022-10-12,['The relation between low uptake on FES-PET to response per lesion'],"['quantitative FES-uptake and correlation with progression free survival', 'analysis of circulating tumor DNA and correlation with FES-PET results and progression free survival']",,,,,1,Netherlands,"University Medical Center Groningen [Groningen, Netherlands]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Palbociclib in combination with Letrozole, indicating an extension of its indication for early identification of patients who may benefit from this combination therapy.",OTHER,False,2022.0,3.0,0,Phase 2
NCT02820961,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,"A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer",COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-06-29,2018-09-10,2021-07-12,2016-07-01,2021-12-15,"['Cmax, maximum plasma concentration', 'Tmax, time at which maximum plasma concentration was observed', 'AUC0-t, area under the plasma concentration-time curve from time zero to the last measurable concentration', 'AUC0-inf, area under the plasma concentration-time curve from time zero extrapolated to infinity', 'T1/2, elimination half-life', 'lambda z , apparent terminal phase elimination constant (λz)', 'AUC0-τ where τ=168 hours for entinostat and τ=24 hours for exemestane', 'Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs resulting in the permanent discontinuation of study drug, and deaths occurring within 30-days of the last dose of study drug', 'Changes from baseline in laboratory, vital signs, and electrocardiogram (ECG) values']","['Best overall tumor response', 'Overall survival']",,,,,3,United States,"Sarah Cannon Research Institute HealthONE [Denver, United States] | Florida Cancer Specialists [Sarasota, United States] | Sarah Cannon Research Institute [Nashville, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT02824484,A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE,Promoting Post-traumatic Growth in Cancer Patients: a Study Protocol for a Randomized Controlled Trial of Guided Written Disclosure,COMPLETED,,Azienda USL Reggio Emilia - IRCCS,2015-11-01,2019-11-18,2021-12-31,2016-07-06,2025-06-25,['Change in post-traumatic growth from baseline to post-intervention assessment and at 6 months follow-up. Post-Traumatic Growth Inventory (PTGI) will be used to assess this outcome'],"['Change in constructed meaning from baseline to post-intervention assessment and at 6 monts follow-up. Constructed Meaning Scale (CMS) will be used to assess this outcome', 'Change in intrusive thoughts and avoidance from baseline to post-intervention assessment and at 6 months follow-up. Impact of Event Scale (IES) will be used to assess this outcome', 'Change in anxiety and depression from baseline to post-intervention assessment and at 6 months follow-up. Hospital Anxiety and Depression Scale (HADS) will be used to assess this outcome']",,,,,1,Italy,"Arcispedale S. Maria Nuova-IRCCS [Reggio Emilia, Italy]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study protocol for a psychological intervention aimed at promoting post-traumatic growth in cancer patients, rather than testing a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2021.0,4.0,0,NA/Other
NCT02826512,"A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients","A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study",TERMINATED,PHASE2,The Netherlands Cancer Institute,2018-05-15,2022-07-01,2022-07-01,2016-07-11,2022-07-18,['Progression free survival'],"['Objective response rate', 'Duration of response', 'Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03']",,,,,3,Netherlands,"Antoni van Leeuwenhoek [Amsterdam, Netherlands] | Deventer ziekenhuis [Deventer, Netherlands] | Erasmus Medical Center Cancer Institute [Rotterdam, Netherlands]",2018.0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,1,0,1,"The trial is evaluating Niraparib, which is already an approved drug, for a specific patient population (advanced, BRCA1-like, HER2-negative breast cancer), indicating an extension of its indication.",OTHER,False,2022.0,3.0,0,Phase 2
NCT02827370,CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer,CAREFOR Study: Precision Nutrition Caloric Restriction for Oncology Research: Precision Medicine Driving Precision Nutrition During Neoadjuvant Chemotherapy for Breast Cancer,COMPLETED,,Sidney Kimmel Cancer Center at Thomas Jefferson University,2016-06-16,2019-07-01,2019-12-15,2016-07-11,2025-04-29,"['Pathologic complete response assessed in tissue', 'Incidence of adverse events evaluated by CTCAE version 4.0']","['Number of study participants who receive the dietary intervention to the historical controls', 'Weight changes', 'Change in insulin', 'Change in serum', 'Distant metastases', 'Progression-free survival', 'Overall survival']",,,,,1,United States,"Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy [Philadelphia, United States]",2016.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Pathologic Complete Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT02833766,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer,Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial,TERMINATED,PHASE2,Swiss Cancer Institute,2016-10-28,2020-10-31,2021-08-03,2016-07-14,2021-09-29,['Progression-free survival (PFS)'],"['Objective response rate (ORR)', 'Duration of response (DOR)', 'Time to Progression (TTP)', 'PFS', 'Overall survival (OS)', 'Adverse events (AEs)']",,,,,15,Switzerland,"Kantonsspital Aarau [Aarau, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Inselspital, Bern [Bern, Switzerland] | Kantonsspital Graubuenden [Chur, Switzerland] | Hopitaux Universitaires de Geneve [Geneva, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Kantonsspital Luzern [Lucerne, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Kantonsspital St. Gallen [Sankt Gallen, Switzerland] | Hôpital de Sion [Sion, Switzerland] | Spital STS AG [Thun, Switzerland] | Kantonsspital Winterthur [Winterthur, Switzerland] | Onkozentrum - Klinik im Park [Zurich, Switzerland] | Universitätsspital Zürich [Zurich, Switzerland]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing a new formulation (anti-EGFR-immunoliposomes loaded with doxorubicin) in a specific patient population (advanced triple negative EGFR positive breast cancer), indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT02834494,"Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave),","3D Elastography (Shear Wave) : Assessment of Response to Neo-adjuvant Chemotherapy (NACT) : in Vivo Quantification, for Patients With a Locally Advanced Breast Cancer.",COMPLETED,,Institut Curie,2016-02-22,2020-09-09,2020-09-09,2016-07-15,2024-01-31,['Assess the accuracy of the sequential measurements by 3D Shear Wave Elastography (SWE) for predicting histological response to neoadjuvant chemotherapy'],"['Elastic properties before treatment (especially ratio between tumor and glandular breast or fat tissues close to the tumors)', 'peritumoral environmental elasticity properties', 'Reliable early biomarker of histological response.', 'tumor volume changes under treatment by 3D ultrasound', 'Compare changes in tumor elasticity under chemotherapy to variables obtained by other imaging modalities (Breast MRI) performed in clinical routine', 'Compare changes in tumor elasticity under neoadjuvant chemotherapy to changes in diffusion apparent coefficient by using technic Supersonic Shear Imaging (Explorer, Supersonic Imagine).', 'Compare changes in tumor volume to histological response (Gold Standard : surgery after neoadjuvant chemotherapy according to "" Residual Cancer Burden "" score', 'Compare predictive value (semi-quantitative et quantitative measurements) of tumor elasticity', 'Assess vascular shape and its evolution under treatment by Ultrasensitive Doppler technic ""Ultra-Fast Doppler""', 'Compare tumor elasticity to conventional histological parameters']",,,,,1,France,"Institut Curie Paris [Paris, France]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT02843126,Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer,,COMPLETED,PHASE1; PHASE2,"Fuda Cancer Hospital, Guangzhou",2016-07-01,2017-07-01,2019-07-01,2016-07-25,2019-09-12,['Relief degree evaluated by the RECIST'],"['Progress free survival (PFS)', 'Overall survival (OS)']",,,,,1,China,"Fuda cancer institute in Fuda cancer hospital [Guangzhou, China]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves the combination of an existing drug (Trastuzumab) with a new treatment approach (NK Immunotherapy) for a specific condition (Recurrent Breast Cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT02844335,Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer,,COMPLETED,PHASE1; PHASE2,"Fuda Cancer Hospital, Guangzhou",2016-07-01,2017-07-01,2019-07-01,2016-07-26,2019-09-12,['Relief degree'],"['Progress free survival（PFS）', 'Overall survival（OS）']",,,,,1,China,"Cancer Institute in Fuda cancer hospital [Guangzhou, China]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text suggests a combination treatment approach for an existing condition (advanced breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT02858934,Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer,Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer,COMPLETED,,Andre Nazac,2017-03-08,2022-03-03,2022-03-03,2016-08-08,2022-07-20,"['Duration of the surgical procedure', 'Quantity of blood lost', 'Dindo score', 'Wound disruption (yes/no)', 'Wound infection (yes/no)', 'Number of adverse events']","['QLQ-C30 questionnaire', 'QLQ-C30 questionnaire', 'EORTC QLQ-BR23 questionnaire', 'EORTC QLQ-BR23 questionnaire', 'Number of adverse events', 'Local recurrence (yes/no)']",,,,,3,Belgium,"CHU Brugmann [Brussels, Belgium] | UZ Brussel [Brussels, Belgium] | AZ Sint Blasius [Dendermonde, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study for a radiotherapy approach in early breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT02860585,Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation,,COMPLETED,,Institut Paoli-Calmettes,2013-09-27,2016-02-29,2016-02-29,2016-08-09,2017-09-26,['Overall Survival according to Immunohistochemical subtypes .'],['Progression free Survival according to Immunohistochemical subtypes .'],,,,,1,France,"Institut Paoli-Calmettes [Marseille, France]",2013.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effectiveness of a treatment (high-dose chemotherapy with autologous stem cell transplantation) in a specific patient population (metastatic breast cancer), indicating an extension of indication for existing therapies.",OTHER,False,2016.0,9.0,0,NA/Other
NCT02865239,Feasibility Study of Breast MRI in Decubitus Position,,COMPLETED,,Institut de Cancérologie de Lorraine,2015-06-25,2015-08-20,2015-08-20,2016-08-12,2018-08-08,['Percentage of lesions where the topography is discordant between the positions (prone and supine).'],"['Comfort patient in supine position compared to the prone position using a self-administered questionnaire', 'distance from the anterior border of the lesion to the nipple in supine position compared to the prone position', 'distance from cutaneous projection of the lesion to the nipple in supine position compared to the prone position', 'distance from lesion to pectoralis major muscle in supine position compared to the prone position', 'Quandrant of the lesions and positions on a clock in supine position compared to the prone position']",,,,,1,France,"Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a feasibility study comparing breast MRI positions and does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2015.0,10.0,0,NA/Other
NCT02866955,Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.,,COMPLETED,PHASE2,Institut de Cancérologie de Lorraine,2011-06-15,2014-08-08,2015-08-28,2016-08-15,2020-03-09,['Progression-free survival after a 6- month monotherapy with Estramustine in patients with HER2-/RH+ breast cancer progressing'],"['Risks of thrombosis', 'Clinical benefit of estramustine', 'Correlation between the answer rate and biomarkers', 'Tolerance of estramustine treatment', 'Tolerance of tamoxifen treatments', 'Proportion of patients developing thromboembolic events']",,,,,21,France,"Institut Sainte Catherine [Avignon, France] | CHU Besançon-Jean Minjoz [Besançon, France] | Polyclinique de Blois [Blois, France] | CHU Avicenne [Bobigny, France] | Polyclinique Bordeaux Nord Aquitaine [Bordeaux, France] | CHRU Brest [Brest, France] | Centre O. Lambret [Lille, France] | CLCC Léon Bérard [Lyon, France] | Hôpital Privé Clairval [Marseille, France] | CHBM Site du Mittan [Montbéliard, France] | CLCC Val d'Aurel [Montpellier, France] | Centre Catherine de Sienne [Nantes, France] | Centre Antoine Lacassagne [Nice, France] | CHU Tenon [Paris, France] | Hôpital Européen Georges Pompidou [Paris, France] | Institut Jean Godinot [Reims, France] | Polyclinique Courlancy Reims [Reims, France] | Clinique armoricaine [Saint-Brieuc, France] | Centre Paul Strauss [Strasbourg, France] | Clinique Sainte Anne [Strasbourg, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2011.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the efficacy of Estramustine in a specific patient population (breast cancer patients who have progressed after treatment with aromatase inhibitors), indicating an extension of indication for an existing medication.",OTHER,False,2015.0,10.0,0,Phase 2
NCT02867644,Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer,Randomized Trial Comparing the Contribution of Conversational Hypnosis Versus Standard Care on Patient Anxiety During a Preoperative Breast Tracking,TERMINATED,,Institut de Cancérologie de Lorraine,2016-11-17,2020-10-16,2020-10-16,2016-08-16,2022-12-20,['Compare anxiety of patients undergoing for a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)'],"['Compare the pain felt by patients during a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)', ""Compare the manipulator's satisfaction during a preoperative breast marking under ultrasound according two different procedures (standard care versus standard care with conversational hypnosis)"", 'Evaluate the receptivity of women to conversational hypnosis', 'Assess the impact of conversational hypnosis on completion of the examination']",,,,,7,France,"CH Bastia [Bastia, France] | Chu Bordeaux-Pellegrin [Bordeaux, France] | CHRU de Brest [Brest, France] | Centre Léon Bérard [Lyon, France] | APHM La Timone [Marseille, France] | Centre Paul Strauss [Strasbourg, France] | Institut de Cancerologie de Lorraine [Vandœuvre-lès-Nancy, France]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial text discusses a comparison of standard care with conversational hypnosis for managing anxiety and pain in patients undergoing imaging for breast cancer. It does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2020.0,5.0,0,NA/Other
NCT02881203,Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart,BRAVEHeart - Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart,COMPLETED,,University of Sydney,2018-09-15,2021-09-30,2022-09-30,2016-08-26,2023-07-27,['Accuracy of Breathe Well'],"['Difference in set up times for Breathe Well vs RPM', 'Patient comfort', 'Staff perception of Breathe Well', 'To develop the use of EPID for real time MLC tracking during breast radiotherapy', 'To compare actual and planned doses']",,,,,1,Australia,"Royal North Shore Hospital [St Leonards, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study related to breast radiotherapy techniques and patient comfort, but it does not indicate the introduction of a new medicine or an extension of an existing indication for a drug.",OTHER,False,2022.0,3.0,0,NA/Other
NCT02888366,A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer,A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer,COMPLETED,,"Menssana Research, Inc.",2017-03-01,2018-08-30,2018-08-30,2016-09-05,2018-10-29,['A PROSPECTIVE VALIDATION STUDY OF A RAPID POINT-OF-CARE BREATH TEST FOR BREAST CANCER'],[],,,,,4,United States,"University of Southern California [Los Angeles, United States] | Hackensack Medical Center, Mountainside Hospital [Montclair, United States] | St. Michael's Medical Center [Newark, United States] | MD Anderson Cancer Center [Houston, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a validation study for a diagnostic test (breath test for breast cancer) rather than a new medicine or an extension of indication for an existing medicine.,INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02890069,"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)",COMPLETED,PHASE1,Novartis Pharmaceuticals,2016-10-14,2022-02-22,2022-02-22,2016-09-07,2023-01-11,"['Phase 1: Incidence of dose limiting toxicities (DLTs)', 'Frequency of dose interruptions and reductions', 'Frequency and severity of treatment-emergent adverse events (AEs) and serious adverse events (SAEs)', 'Changes between baseline and post-baseline laboratory parameters and vital signs', 'Dose intensities']","['Changes from baseline in ECG parameters in patients recieving PDR001 in combination with Panobinostat', 'Best overall response (BOR)', 'Time to reach max concentration (Tmax) for PDR001', 'Presence of anti-PDR001 antibodies', 'Progression free survival (PFS)', 'Treatment Free Survival (TFS)', 'Maximum and minimum plasma concentrations of LCL161 (Cmax and Cmin)', 'Maximum and minimum Plasma concentrations of everolimus (Cmax and Cmin)', 'Maximum and minimum plasma concentrations of panobinostat (Cmax and Cmin)', 'Concentration of anti-PDR001 antibodies', 'Maximum and minimum serum concentration of PDR001 (Cmax and Cmin)', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for PDR001, as applicable', 'Progression free survival (PFS) per irRC', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for LCL161, as applicable', 'Time to reach max concentration (Tmax) for LCL161', 'Time to reach max concentration (Tmax) for Everolimus', 'Time to reach max concentration (Tmax) for Panobinostat', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for Everolimus, as applicable', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for Panobinostat, as applicable', 'Maximum and minimum Plasma concentrations of QBM076 (Cmax and Cmin)', 'Maximum and minimum Plasma concentrations of HDM201 (Cmax and Cmin)', 'Time to reach max concentration (Tmax) for QBM076', 'Time to reach max concentration (Tmax) for HDM201', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for QBM076, as applicable', 'Area under the concentration-time curve calculated to the last concentration point (AUClast) for HDM201, as applicable']",,,,,25,Germany; Netherlands; South Korea; Spain; Taiwan; United Kingdom; United States,"UCLA Santa Monica Hematology / Oncology SC [Santa Monica, United States] | Sidney Kimmel Comprehensive Cancer Center [Baltimore, United States] | Massachusetts General Hospital [Boston, United States] | The Regents of the University of Michigan [Ann Arbor, United States] | Washington University Medical School SC [St Louis, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | UT Health San Antonio Mays Cancer Center [San Antonio, United States] | Huntsman Cancer Institute [Salt Lake City, United States] | Seattle Cancer Care Alliance [Seattle, United States] | Novartis Investigative Site [Jena, Germany] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Amsterdam, Netherlands] | Novartis Investigative Site [Leiden, Netherlands] | Novartis Investigative Site [Rotterdam, Netherlands] | Novartis Investigative Site [Utrecht, Netherlands] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Seoul, South Korea] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [Pamplona, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Taipei, Taiwan] | Novartis Investigative Site [Sutton, United Kingdom] | Novartis Investigative Site [Manchester, United Kingdom] | Novartis Investigative Site [Oxford, United Kingdom]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT02891759,Compare Outcomes Between Two Acellular Dermal Matrices,"A Single-Blinded Randomized Prospective Trial to Compare Outcomes Between Two Acellular Dermal Matrices Used for Immediate, Post-Mastectomy Breast Reconstruction",COMPLETED,PHASE2,Washington University School of Medicine,2017-01-31,2022-10-27,2022-10-27,2016-09-07,2023-05-06,['Incidence of premature tissue expander (TE) removal'],"['Patient satisfaction as measured by Breast Q', 'Health related quality of life as measured by Breast Q', 'Duration of drain use', 'Incidence of analgesic use for pain', 'Incidence of infection as measured by presence or absence of cellulitis', 'Incidence of non-infectious complications', 'Nature of second surgery as measured by type of surgery enrolled patients undergo to address their tissue expander after its initial insertion', 'Degree of acellular dermal matrices (ADM) incorporation', 'Comparison of direct hospital costs', 'Comparison of physician reimbursements', 'Amount of tissue expander fill', 'Immediate implant type as measured by volume (cc)', 'Immediate implant type as measured by manufacturer', 'Immediate implant type as measured by shape', 'Immediate implant type as measured by fill', 'Immediate implant type as measured by surface characteristics']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares outcomes between two existing acellular dermal matrices used in a specific surgical context (post-mastectomy breast reconstruction), indicating an extension of indication rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies,COMPLETED,PHASE1,Emory University,2016-10-24,2021-10-15,2021-10-15,2016-09-13,2023-10-10,"['Incidence of adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0', 'Incidence of dose limiting toxicities defined as grade 3 or higher toxicity', 'Recommended phase 2 dose (RP2D) as the highest doses of palbociclib and cisplatin or palbociclib and carboplatin']","['Overall response rate (complete response + partial response) assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria', 'Pharmacokinetic (PK) characteristics of carboplatin including maximum concentration (Cmax)', 'Pharmacokinetic (PK) characteristics of cisplatin including maximum concentration (Cmax)']",,,,,1,United States,"Emory University/Winship Cancer Institute [Atlanta, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT02897778,Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-08-24,2017-03-13,2017-03-13,2016-09-13,2022-04-28,"['Change from Baseline in Heart Rate (HR)', 'Change from Baseline in Electrocardiogram Procedures', 'Change from Baseline in T-Cell Morphology']","['Number of Participants with Treatment-emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)', 'Number of Participants with Clinically Significant Abnormalities in Laboratory Values Reported as a TEAE', 'Change from Baseline in Vital Signs', 'Change from Baseline in ECG Values', 'Change from Baseline in QTc', 'Cmax (Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'Tmax (Time of Maximum Plasma Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-24 (Area under the Plasma Concentration-time Curve from Time Zero to 24 hours) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-t (Area under the Plasma Concentration-time Curve from Time Zero to the Last Measurable Concentration) of Entinostat when given as a Single Supratherapeutic Dose', 'AUC0-inf (Area under the Plasma Concentration-time Curve from 0-time Extrapolated to Infinity) of Entinostat when given as a Single Supratherapeutic Dose', 't1/2 (Elimination Half-life and Apparent Plasma Terminal Phase Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose', 'λz (Terminal Elimination Rate Constant) of Entinostat when given as a Single Supratherapeutic Dose']",,,,,1,United States,"The START Center for Cancer Care [San Antonio, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2017.0,8.0,0,Phase 1
NCT02898727,A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer,A Phase II Study of Local Therapy Only (Stereotactic Radiosurgery and/or Surgery) for Treatment of up to 5 Brain Metastases From HER2 Positive Breast Cancer,COMPLETED,,Trans Tasman Radiation Oncology Group,2017-11-20,2021-07-22,2021-12-31,2016-09-13,2022-11-22,['to assess the percentage of patients treated with whole brain radiotherapy within 12 months after completion of local therapy'],"['To describe distant brain failure incidence (overall and by number of treated metastases)', 'To describe local brain failure incidence, at any site of SRS or surgery', 'To describe extra-cranial failure incidence', 'To describe the pattern of first failure', 'To describe overall survival and cause of death (neurologic vs. non-neurologic)', 'To describe adverse events and need for corticosteroids', 'To describe neurocognitive function using the mini-mental state examination (MMSE)']",,,,,1,Australia,"Peter MacCallum Cancer Centre [Melbourne, Australia]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on local therapy for treating brain metastases specifically from HER2 positive breast cancer, indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT02900248,"CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice","Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)",TERMINATED,,CureOne,2017-10-02,2019-03-29,2019-03-29,2016-09-14,2019-04-02,"['Best Overall Response', 'Time to Treatment Progression']","['Overall Survival', 'Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population.', 'To determine rate of enrollment into existing and future therapeutic clinical trials.']",,,,,1,United States,"Teton Cancer Institute [Idaho Falls, United States]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an observational registry study focusing on patients with advanced malignancy or myelodysplasia, but does not indicate the testing of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",COMPLETED,PHASE1,Novartis Pharmaceuticals,2016-08-23,2021-03-17,2021-03-17,2016-09-14,2022-03-29,"['Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Changes between baseline and post-baseline laboratory parameters and vital signs.', 'Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)', 'Frequency of dose interruptions', 'Dose intensities', 'Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety', 'Frequency of dose reductions']","['Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs)', 'Changes from baseline in electrocardiogram (ECG) parameters', 'Best overall response (BOR)', 'Progression free survival (PFS) per irRC and RECIST v1.1', 'Treatment Free Survival (TFS)', 'Presence and/or concentration of anti-PDR001 antibodies.', 'Serum concentration of PDR001, canakinumab, CJM112', 'Plasma concentrations of trametinib and EGF816', 'Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate).', 'PK parameters (Eg. TMax) of EGF816', 'PK parameters (Eg. TMax) of trametinib', 'PK parameter (Eg. TMax) of PDR001', 'PK parameters (Eg. TMax) of canakinumab', 'PK parameters (Eg. TMax) of CJM112', 'Presence and/or concentration of anti-canakinumab antibodies.', 'Presence and/or concentration of anti-CJM112 antibodies.']",,,,,23,Belgium; Canada; France; Israel; Italy; Singapore; Spain; Taiwan; United States,"Sidney Kimmel Comprehensive Cancer Center SC-3 [Baltimore, United States] | Dana Farber Cancer Center [Boston, United States] | Sarah Cannon Research Institute [Nashville, United States] | University of Texas MD Anderson Cancer Center [Houston, United States] | Novartis Investigative Site [Brussels, Belgium] | Novartis Investigative Site [Wilrijk, Belgium] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Lyon, France] | Novartis Investigative Site [Paris, France] | Novartis Investigative Site [Toulouse, France] | Novartis Investigative Site [Villejuif, France] | Novartis Investigative Site [Tel Aviv, Israel] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Rozzano, Italy] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Barcelona, Spain] | Novartis Investigative Site [L'Hospitalet de Llobregat, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Tainan City, Taiwan] | Novartis Investigative Site [Taoyuan District, Taiwan]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves PDR001, which is being studied in combination with other drugs, indicating it is a new medicine being evaluated for safety and efficacy.",INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02909452,Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,"A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)",COMPLETED,PHASE1,Syndax Pharmaceuticals,2016-09-20,2019-07-17,2021-02-09,2016-09-21,2022-01-25,"['Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events (AEs) resulting in the permanent discontinuation of study drug, and deaths occurring within the reporting period required for the study', 'Changes from baseline in laboratory results', 'Changes from baseline in vital signs', 'Changes from baseline in ECG results']","['AUC0-t (area under the curve to last observed concentration time) of entinostat when given in combination with pembrolizumab', 'AUC0-inf (area under the curve extrapolated to infinity) of entinostat when given in combination with pembrolizumab', 'Cmax (maximum plasma concentration) of entinostat when given in combination with pembrolizumab', 'Tmax (time to maximum plasma concentration) of entinostat when given in combination with pembrolizumab', 'T1/2 (elimination half life) of entinostat when given in combination with pembrolizumab', 'Vd (clearance and volume of distribution) of entinostat when given in combination with pembrolizumab']",,,,,1,United States,"The START Center for Cancer Care [San Antonio, United States]",2016.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT02911155,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,COMPLETED,,National Cancer Institute (NCI),2016-09-21,2020-05-01,2020-05-01,2016-09-22,2020-05-05,['U.S. nuclear medicine tecnologist'],"['Administer questionnaire', 'Obtain badge doses']",,,,,1,United States,"University of Minnesota, School of Public Health Environmental Health Sciences [Minneapolis, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses risks associated with nuclear medicine technologists and does not indicate the development of a new medicine or an extension of indication for an existing medicine.,NIH,False,2020.0,5.0,0,NA/Other
NCT02913729,Pre- Versus Postoperative Accelerated Partial Breast Irradiation,Pre- Versus Postoperative Accelerated Partial Breast Irradiation in Early Stage Breast Cancer Patients,TERMINATED,,The Netherlands Cancer Institute,2016-11-10,2022-02-28,2022-02-28,2016-09-26,2022-09-29,['Cosmetic outcome'],"['tumor response', 'postoperative complications']",,,,,6,France; Netherlands; Portugal; Spain,"Institut Curie [Saint-Cloud, France] | Institut Gustave-Roussy [Villejuif, France] | Antoni van Leeuwenhoek [Amsterdam, Netherlands] | University Medical Center Utrecht (UMCU) [Utrecht, Netherlands] | Champilamaud Cancer Center [Lisbon, Portugal] | University General Hospital Valencia-Erasa [Valencia, Spain]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses a treatment (Accelerated Partial Breast Irradiation) in the context of early-stage breast cancer patients, which suggests an extension of indication for an existing treatment rather than the introduction of a new medicine.",OTHER,False,2022.0,3.0,1,NA/Other
NCT02923037,Hatha Yoga in Breast Cancer Survivors,Feasibility and Preliminary Efficacy of Hatha Yoga in Breast Cancer Survivors: Pilot Study,TERMINATED,,Vanderbilt-Ingram Cancer Center,2016-09-01,2018-11,2019-03,2016-10-04,2019-03-26,"['Pose Modifications', 'Assess safety']",[],,,,,1,United States,"Vanderbilt University School of Nursing [Nashville, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses a pilot study on the feasibility and efficacy of Hatha Yoga for breast cancer survivors, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT02924584,"Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan",THE TREATMENT FOR RECURRENT FEMALE BREAST CANCER AFTER INITIAL ENDOCRINE THERAPY AMONG TAIWANESE POPULATION,COMPLETED,,Pfizer,2017-02-01,2017-02-28,2018-04-30,2016-10-05,2025-06-26,['clinical use of aromatase inhibitors in breast cancer'],"['prevalence', 'dose exposure', 'overall survival', 'treatment cost']",,,,,1,Taiwan,"National Cheng Kung University [Tainan City, Taiwan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the clinical use of aromatase inhibitors in the context of recurrent breast cancer, indicating an extension of indication for an existing treatment rather than introducing a new medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT02931864,Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer Survivors,Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on Quality of Life in Breast Cancer Survivors,COMPLETED,,National University of Singapore,2016-12-06,2020-03-14,2020-03-14,2016-10-13,2020-09-23,"['Change from baseline quality of life score at 8 weeks', 'Change from baseline quality of life score at 12 weeks', 'Change from baseline quality of life score at 24 weeks']","['Change from baseline social support score at 8 weeks', 'Change from baseline social support score at 12 weeks', 'Change from baseline social support score at 24 weeks', 'Change from baseline self-efficacy score at 8 weeks', 'Change from baseline self-efficacy score at 12 weeks', 'Change from baseline self-efficacy score at 24 weeks', 'Change from baseline symptom score at 8 weeks', 'Change from baseline symptom score at 12 weeks', 'Change from baseline symptom score at 24 weeks', 'Change from baseline psychosocial adjustment to illness score at 8 weeks', 'Change from baseline psychosocial adjustment to illness score at 12 weeks', 'Change from baseline psychosocial adjustment to illness score at 24 weeks', 'Change from baseline fear of recurrence score at 8 weeks', 'Change from baseline fear of recurrence score at 12 weeks', 'Change from baseline fear of recurrence score at 24 weeks', 'Change from baseline anxiety and depression score at 8 weeks', 'Change from baseline anxiety and depression score at 12 weeks', 'Change from baseline anxiety and depression score at 24 weeks', 'Change from baseline mindfulness score at 8 weeks', 'Change from baseline mindfulness score at 12 weeks', 'Change from baseline mindfulness score at 24 weeks']",,,,,2,Singapore,"National Cancer Centre Singapore [Singapore, Singapore] | National University Hospital [Singapore, Singapore]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a program focused on symptom management and mindfulness training for breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02935920,A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy,A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy,COMPLETED,,Vejle Hospital,2016-04-11,2019-06-30,2019-12,2016-10-18,2020-02-05,"['The difference in PREM (patient reported experience measure) as reported by patients in the individualized and standard follow-up groups, respectively']","['Comparison of resources spent on individualized follow-up based on PRO-data and standard follow-up.', 'The difference in CollaboRATE-score between the individualized and standard follow-up.', 'Comparison of Health related quality of life in the individualized follow-up versus standard follow-up.', 'Elucidation of issues of importance and concern to postmenopausal woman with breast cancer in adjuvant endocrine therapy during follow-up after primary treatment. What symptoms and side effects trouble them most during follow-up?', 'Evaluation of current information level during primary treatment']",,,,,1,Denmark,"Vejle hospital, Department of Oncology [Vejle, Denmark]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT02941536,Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer,Prospective Evaluation of Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Stereotactic Radiotherapy for Encephalic Metastases of Breast Cancer,COMPLETED,,AC Camargo Cancer Center,2016-11-01,2018-10-15,2018-10-30,2016-10-21,2018-12-27,['Brain progression-free survival'],['Overall survival'],,,,,1,Brazil,"AC Camargo Cancer Center [São Paulo, Brazil]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study evaluating the correlation between circulating tumor cells and disease control after radiotherapy for breast cancer metastases, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT02941835,Preoperative Breast Irradiation,"Preoperative Breast Irradiation, the PROBI Trial. A Phase I/II Feasibility Trial",TERMINATED,,The Netherlands Cancer Institute,2018-03-12,2018-08-09,2018-08-09,2016-10-21,2019-10-22,['Postoperative surgical complications'],"['Radiological response', 'Pathological response', 'cosmetic outcome']",,,,,1,Netherlands,"Netherlands Cancer Institute [Amsterdam, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2018.0,7.0,0,NA/Other
NCT02947165,Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,"A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies",COMPLETED,PHASE1,Novartis Pharmaceuticals,2017-04-25,2021-06-18,2021-06-18,2016-10-27,2022-01-31,"['Incidence of DLTs, AEs, SAEs and dose reductions / interruptions for NIS793', 'Incidence of DLTs, AEs, SAEs and dose reductions/interruptions for NIS793 in combination with PDR001']","['Best overall response (BOR)', 'Disease control rate (DCR)', 'Overall response rate (ORR)', 'Progression free survival (PFS)', 'Duration of response (DOR)', 'Serum concentration-time profiles of NIS793 single agent and NIS793 in combination with PDR001', 'Presence of anti-NIS793 and anti-PDR001 antibodies', 'Concentration of anti-NIS793 and anti-PDR001 antibodies', 'Area under the curve (AUC) for NIS793 single agent and NIS793 in combination with PDR001.', 'Cmax for NIS793 single agent and NIS793 in combination with PDR001.', 'Tmax for NIS793 single agent and NIS793 in combination with PDR001.', 'Half life of NIS793 as single agent and in combination with PDR001.', 'Characterization of tumor infiltrating lymphocytes (TILs) by H&E', 'Characterization of tumor infiltrating lymphocytes by immunohistochemistry using markers such as CD8 and PD-L1']",,,,,12,Austria; Canada; Germany; Hong Kong; Italy; Japan; Switzerland; Taiwan; United States,"Sarah Cannon Research Institute SC [Nashville, United States] | Huntsman Cancer Institute SC [Salt Lake City, United States] | Novartis Investigative Site [Salzburg, Austria] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Ulm, Germany] | Novartis Investigative Site [Würzburg, Germany] | Novartis Investigative Site [Hong Kong, Hong Kong] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Rozzano, Italy] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Sankt Gallen, Switzerland] | Novartis Investigative Site [Taipei, Taiwan]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT02948764,Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,RESPONDER Trial - Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer,COMPLETED,,Heidelberg University,2017-03-08,2019-05-24,2019-09-15,2016-10-28,2020-03-25,"['false negative VAB results, reported as the false negative rate (= FNR)']","['negative predictive value (NPV)', 'positive predictive value (PPV)', 'false positive rate (FPR)']",,,,,1,Germany,"University Breast Unit, Department of Gynecology, University of Heidelberg [Heidelberg, Germany]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT02952729,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,"A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2",COMPLETED,PHASE1,Mersana Therapeutics,2016-11-21,2019-01-28,2019-01-28,2016-11-02,2021-02-24,['Maximum tolerated dose or recommended Phase 2 dose'],"['Time of maximum observed concentration of XMT-1522', 'Maximum concentration of XMT-1522', 'Area under the concentration curve of the last measurable concentration of XMT-1522', 'Antineoplastic effects of XMT-1522', 'Anti-drug antibody']",,,,,5,United States,"Moffitt Cancer Center [Tampa, United States] | Massachusetts General Hospital [Boston, United States] | Sarah Cannon Research Institute [Nashville, United States] | Mary Crowley Cancer Research Center [Dallas, United States] | South Texas Accelerated Research Therapeutics (START) [San Antonio, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes a Phase 1b study of XMT-1522, which is a new drug being tested in humans for the treatment of advanced breast cancer and other tumors, indicating it is a new medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02952989,A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,"A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors",TERMINATED,PHASE1,Seagen Inc.,2017-02-23,2019-06-24,2019-06-24,2016-11-02,2019-07-19,"['The number of participants with adverse events that are related to treatment', 'The number of participants with laboratory abnormalities that are related to treatment', 'Incidence of dose-limiting toxicities (DLTs)']","['Pharmacokinetic assessments', 'Markers of fucosylation status', 'Objective response rate', 'Disease control rate', 'Duration of response', 'Clinical benefit rate', 'Progression-free survival', 'Overall survival']",,,,,11,United States,"University of Alabama at Birmingham [Birmingham, United States] | City of Hope National Medical Center [Duarte, United States] | University of Colorado Hospital / University of Colorado [Aurora, United States] | Winship Cancer Institute / Emory University School of Medicine [Atlanta, United States] | Dana Farber Cancer Institute [Boston, United States] | Karmanos Cancer Institute / Wayne State University [Detroit, United States] | Duke University Medical Center [Durham, United States] | Providence Portland Medical Center [Portland, United States] | Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | Seattle Cancer Care Alliance / University of Washington [Seattle, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT02954471,Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia,"A Retrospective, Observational Molecular Epidemiology Study of HER2 Expression in Patients With Early / Metastatic Breast Cancer in Saudi Arabia",COMPLETED,,Hoffmann-La Roche,2016-10-21,2019-09-17,2019-09-17,2016-11-03,2019-09-20,['Percentage of Participants With Positive HER2 Test Result'],"['Percentage of Participants With Estrogen Receptor/Progesterone Receptor Positive Breast Cancer', 'Percentage of Participants by Type of First-line and Subsequent Treatment Regimens Used', 'Kaplan-Meier Estimate of Overall Survival (OS)', 'Kaplan-Meier Estimates of Progression-free Survival (PFS) as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)', 'Percentage of Participants With Complete Response as Assessed Using RECIST', 'Percentage of Participants With Partial Response as Assessed Using RECIST', 'Percentage of Participants With Progressive Disease as Assessed Using RECIST', 'Percentage of Participants with Stable Disease as Assessed Using RECIST', 'Percentage of Participants With Adverse Events']",,,,,3,Saudi Arabia,"King Fahad Specialist Hospital; Oncology [Dammam, Saudi Arabia] | King Faisal Specialist Hospital & Research Centre [Jeddah, Saudi Arabia] | National Guard King Abdulaziz Medical City; Oncology [Riyadh, Saudi Arabia]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on HER2 expression in breast cancer patients, which suggests an investigation into the use of existing treatments for a specific patient population, indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT02970344,I HEAL for Breast Cancer Survivors With Diabetes,Improving Health Engagement and Lifestyle Management for Breast Cancer Survivors With Diabetes,COMPLETED,,Duke University,2017-04-20,2021-12-01,2021-12-01,2016-11-22,2022-03-15,"['Change in physical symptoms', 'Change in psychological distress', 'Change in psychological distress']","['Accessing change in Diabetes self-management behaviors via self reported medication adherence', 'Accessing change in Diabetes self-management behavior via Barriers to taking medication', 'Accessing change in Diabetes self-management behavior via Adherence to diabetes self-management behaviors', 'Accessing change in Diabetes self-management behavior via Use of home blood glucose monitoring', 'Improved glycemic control', 'Change in self-efficacy', 'Change in Physical Activity', 'Assessing change in Physical Activity']",,,,,1,United States,"Duke University Medical Center [Durham, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on improving health engagement and lifestyle management for breast cancer survivors with diabetes, indicating an extension of indication for existing treatments to a new patient population.",OTHER,False,2021.0,4.0,0,NA/Other
NCT02971761,Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC),COMPLETED,PHASE2,City of Hope Medical Center,2017-06-01,2020-10-28,2022-08-16,2016-11-23,2024-02-20,['Response Rate (Complete Response or Partial Response)'],"['Progression-free Survival', 'Clinical Benefit Rate', 'Overall Survival', 'Progression-free Survival']","[{""type"":""PRIMARY"",""title"":""Response Rate (Complete Response or Partial Response)"",""timeFrame"":""Up to 36 months"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""12"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Progression-free Survival"",""timeFrame"":""Time to disease progression/relapse or death as a result of any cause, assessed up to 36 months"",""unit"":""months"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2.6"",""spread"":null,""lower"":""1.9"",""upper"":""3.1""}]},{""type"":""SECONDARY"",""title"":""Clinical Benefit Rate"",""timeFrame"":""At 16 weeks"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""4"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Overall Survival"",""timeFrame"":""Time to death as a result of any cause, assessed up to 36 months"",""unit"":""months"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""25.5"",""spread"":null,""lower"":""10.4"",""upper"":""30.9""}]},{""type"":""SECONDARY"",""title"":""Progression-free Survival"",""timeFrame"":""Up to 1 year"",""unit"":""months"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2.6"",""spread"":null,""lower"":""1.9"",""upper"":""3.1""}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""n"":""18""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""n"":""16""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""n"":""2""}]}],""dropWithdraws"":[{""type"":""GTx-024 drug supply was withdrawn"",""reasons"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""n"":""2""}]}]}]}","[{""title"":""Age, Continuous"",""unit"":""years"",""paramType"":""MEDIAN"",""dispersionType"":""FULL_RANGE"",""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""64"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""16"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""0"",""spread"":null}]},{""title"":""Race/Ethnicity, Customized"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""8"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""5"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""1"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""16"",""spread"":null}]},{""title"":""Number of previous lines of therapy"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""9"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""7"",""spread"":null}]},{""title"":""Performance Status (ECOG)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""7"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""9"",""spread"":null}]},{""title"":""Nottingham Histological grade"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""5"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""9"",""spread"":null}]},{""title"":""Initial tumor stage"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""6"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""8"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""2"",""spread"":null}]},{""title"":""Prior surgery"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""7"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""9"",""spread"":null}]},{""title"":""Prior radiation"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""15"",""spread"":null},{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""value"":""1"",""spread"":null}]}]","[{""group"":""Treatment (Pembrolizumab, Enobosarm)"",""serious_affected"":4,""serious_at_risk"":18,""other_affected"":18,""other_at_risk"":18}]",7,United States,"City of Hope Corona [Corona, United States] | City of Hope Medical Center [Duarte, United States] | City of Hope Antelope Valley [Lancaster, United States] | City of Hope Mission Hills [Mission Hills, United States] | City of Hope Rancho Cucamonga [Rancho Cucamonga, United States] | City of Hope South Pasadena [South Pasadena, United States] | City of Hope West Covina [West Covina, United States]",2017.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response"",""Overall Survival""]",2,1,1,1,1,0,1,0,1,5,0,0,0,0,,OTHER,True,2022.0,3.0,0,Phase 2
NCT02975128,Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance,Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance,TERMINATED,,Radboud University Medical Center,2018-02-19,2019-07-31,2019-07-31,2016-11-29,2020-05-29,['Frequency of successful complete tumor excision by the BLES system.'],"['Quality of the margin evaluation of the biopsy specimen and the eventual surgical specimen.', 'In biopsy specimen in which the margin is not completely tumor free, but the Dutch criterion for successful surgery is met (no more than focal (4 mm) margin involvement), we will specifically analyse the residual tumor burden in the surgical excision.', 'Assess in retrospect whether we can predict successful tumor extraction based upon other factors than tumor size alone.']",,,,,2,Netherlands,"Radboudumc [Nijmegen, Netherlands] | Canisius Wilhelmina Hospital [Nijmegen, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a surgical procedure and evaluation methods for breast cancer excision rather than introducing a new medicine or extending the indication of an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT02978495,Neoadjuvant Carboplatin in Triple Negative Breast Cancer,Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial).,COMPLETED,PHASE2,Barretos Cancer Hospital,2017-05-17,2019-12-02,2021-10-22,2016-12-01,2022-12-28,"['Pathological complete response (pCR), defined as absence of invasive cancer in the breast and axillary lymph nodes.']","['Disease free survival (DFS)', 'Overall survival (OS)']",,,,,1,Brazil,"Barretos Cancer Hospital [Barretos, Brazil]",2017.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,Phase 2
NCT02983279,"Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer",Caloric Restriction for Oncology Research: Pre-operative Caloric Restriction Prior to Definitive Oncologic Surgery,COMPLETED,,Sidney Kimmel Cancer Center at Thomas Jefferson University,2016-09-20,2021-10-27,2022-12-29,2016-12-06,2025-04-29,['Change in miR-21 expression assessed in serum'],"['Overall adherence with diet intervention defined as 90% of all logged events meeting the diet restriction target', 'Change in body composition, assessed via BodyMetrix', 'Change in prostate tumor gene expression', 'Change in weight, defined as a percent change', 'Change in temperature', 'Change in genomic expression of microRNA 21 (miR-21)', 'Change in insulin', 'Change in biome analysis assessed by rectal swab', 'Change in psycho-social outcomes, assessed by the FACT-B', 'Changes in nutritional status assessed by a Mini Nutritional Assessment (MNA)', 'Local recurrence, assessed through patient records', 'Distant metastases, assessed through patient records', 'Progression free survival, assessed through patient records', 'Overall survival, assessed through patient records', 'Change in weight, defined by body mass index as weight in kg divided by height in meters squared', 'Change in blood pressure', 'Change in heart rate', 'Change in respiratory rate', 'Change in psycho-social outcomes, assessed by the FACT-P', 'Change in psycho-social outcomes, assessed by the FACT-En', 'Change in psycho-social outcomes, assessed by the POMIS cancer fatigue short form']",,,,,1,United States,"Thomas Jefferson University [Philadelphia, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses caloric restriction as a pre-operative intervention for patients with various types of cancer, but it does not introduce a new medicine or extend the indication of an existing medicine. It focuses on dietary intervention rather than pharmacological treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT02990845,Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer,A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer,TERMINATED,PHASE1; PHASE2,National Taiwan University Hospital,2017-09-15,2022-08-16,2022-08-16,2016-12-13,2023-02-22,['The PFS rate at 8 months'],"['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'The PFS based on RECIST 1.1', 'The overall response rate (ORR) based on RECIST 1.1', 'The clinical benefit rate (CBR) based on RECIST 1.1', 'The duration of overall response (DOR) based on RECIST 1.1']",,,,,1,Taiwan,"National Taiwan University Hospital [Taipei, Taiwan]",2017.0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2022.0,3.0,0,Phase 2
NCT02993094,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,TERMINATED,PHASE1; PHASE2,Arbeitsgemeinschaft medikamentoese Tumortherapie,2016-11-21,2020-08-15,2020-08-15,2016-12-15,2020-11-30,['Maximum tolerated dose (MTD)'],"['Safety profile based on adverse events evaluation', 'Overall response rate', 'Clinical benefit rate', 'Progression-free survival (PFS)', 'Quality of Life of MBC patients']",,,,,12,Austria,"Universitätsklinik für Innere Medizin Graz [Graz, Austria] | Universitätsklinik für Frauenheilkunde Innsbruck [Innsbruck, Austria] | Klinikum Kreuzschwestern Wels GmbH [Wels, Austria] | Landeskrankenhaus Feldkirch, Innere Med. II, Interne E [Feldkirch, Austria] | UK Graz: Universitätsklinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie [Graz, Austria] | LKH Hochsteiermark: Department für Hämato-Onkologie [Leoben, Austria] | BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie [Linz, Austria] | KUK Linz: Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie [Linz, Austria] | PMU Salzburg: Universitätsklinik für Innere Medizin III [Salzburg, Austria] | Landeskrankenhaus Steyr, Innere Medizin II Onkologie [Steyr, Austria] | AKH Wien Universitätsklinik für Frauenheilkunde: Klin. Abt. f. Allg. Gynäkologie und gynäkologische Onkologie [Vienna, Austria] | LK Wiener Neustadt: Innere Medizin, Hämatologie und internistische Onkologie [Wiener Neustadt, Austria]",2016.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Ixazomib (MLN9708), which is being tested in combination with Carboplatin for a specific patient population (pretreated women with advanced triple negative breast cancer), indicating it is a new medicine being evaluated for a new use.",OTHER,False,2020.0,5.0,0,Phase 2
NCT02994914,GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance,GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance : GERABEL Study,TERMINATED,,Centre Hospitalier Universitaire de Saint Etienne,2016-12-05,2020-06-26,2020-06-26,2016-12-16,2022-02-22,['Measure of the tolerance'],"['Tolerance', 'Quality of Life Questionnaire', 'Radiotherapy compliance', 'Correlation between tolerance and distance from the therapeutic center', 'Correlation between tolerance and way of transport', 'Correlation between tolerance and the number of concomitant treatments', 'Correlation between tolerance and the nature of concomitant treatments', 'Correlation between tolerance and the supportive cares']",,,,,3,France,"Centre Hospitalier Emile Roux [Le Puy-en-Velay, France] | Groupement Hospitalier Portes de Provence [Montélimar, France] | Institut de Cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on treatment compliance and tolerance in elderly breast cancer patients undergoing radiotherapy, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT02996240,"Breast, Omega 3 Free Fatty Acid, Ph 0","A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Breast Cancer (CTMS# 16-0119)",COMPLETED,,The University of Texas Health Science Center at San Antonio,2017-06-12,2019-09-27,2021-02-22,2016-12-19,2021-03-17,"['Change in serum colony stimulating factor at surgery', 'Change in circulating levels of pro-inflammatory cytokines.', 'Change in circulating levels of eicosanoids.', 'Change in circulating levels of metabolics.']",[],,,,,1,United States,"CTRC at University of Texas Health Science Center San Antonio [San Antonio, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the impact of Omega 3 Free Fatty Acid supplementation on breast cancer, indicating an extension of indication for an existing treatment rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03000257,A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors,"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181 as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,AbbVie,2016-12-14,2022-03-29,2022-03-29,2016-12-22,2022-04-14,"['Part 1: Recommended Phase 2 Dose (RPTD) for Budigalimab', 'Part 1: Maximum tolerated dose (MTD) of Budigalimab', 'Part 1 and Part 3: Terminal Half-life (t1/2) of Budigalimab', 'Part 1 and Part 3: Maximum Observed Serum Concentration (Cmax) of Budigalimab', 'Part 1 and Part 3: Time to Cmax (Tmax) of Budigalimab', 'Part 1 and Part 3: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Budigalimab', 'Part 2: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Rovalpituzumab Tesirine Combination', 'Part 3: Recommended Phase 2 Dose (RPTD) and Schedule for Budigalimab and Venetoclax Combination.', 'Part 3: Maximum Observed Serum Concentration (Cmax) for Venetoclax', 'Part 3: Area Under the Serum Concentration Time Curve from Time 0 to 24 Hours Post-dose (AUC(0-24)) of Venetoclax', 'Part 3: Time to Cmax (Tmax) of Venetoclax', 'Part 1, Part 2, Part 3: Number of Participants with Adverse Events']","['Part 2: Terminal Half-life (t1/2) of Budigalimab', 'Part 2: Terminal Half-life (t1/2) of Rovalpituzumab Tesirine', 'Part 2: Maximum Observed Serum Concentration (Cmax) of Rovalpituzumab Tesirine', 'Part 2: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Rovalpituzumab Tesirine', 'Part 2: Area Under the Serum Concentration Time Curve from Time 0 to Last Measurable Concentration (AUCt) of Budigalimab', 'Part 2: Time to Cmax (Tmax) of Budigalimab', 'Part 2: Time to Cmax (Tmax) of Rovalpituzumab Tesirine', 'Part 1 and Part 3: Objective response rate (ORR)', 'Part 1 and Part 3: Clinical benefit rate (CBR, defined as CR, PR or SD)', 'Part 1 and Part 3: Progression-free survival (PFS)', 'Part 1, Part 2 and Part 3: Duration of objective response (DOR)']",,,,,26,Australia; Austria; Belgium; Canada; Finland; France; Japan; Spain; Taiwan; United States,"Moores Cancer Center at UC San Diego /ID# 157374 [La Jolla, United States] | The University of Chicago Medical Center /ID# 157375 [Chicago, United States] | Carolina BioOncology Institute /ID# 157376 [Huntersville, United States] | South Texas Accelerated Research Therapeutics /ID# 157378 [San Antonio, United States] | Virginia Cancer Specialists - Fairfax /ID# 157377 [Fairfax, United States] | Blacktown Hospital /ID# 167386 [Blacktown, Australia] | St Vincent's Hospital Melbourne /ID# 167552 [Fitzroy Melbourne, Australia] | Linear Clinical Research /ID# 170797 [Nedlands, Australia] | Medizinische Universitaet Graz /ID# 168752 [Graz, Austria] | Universitair Ziekenhuis Antwerpen /ID# 170702 [Edegem, Belgium] | UZ Gent /ID# 170881 [Ghent, Belgium] | Cross Cancer Institute /ID# 167603 [Edmonton, Canada] | Tampere University Hospital /ID# 166839 [Tampere, Finland] | Docrates Cancer Center /ID# 166838 [Helsinki, Finland] | Institut Bergonie /ID# 162662 [Bordeaux, France] | Institut du Cancer de Montpellier - Val d'Aurelle /ID# 163999 [Montpellier, France] | Centre Leon Berard /ID# 162660 [Lyon, France] | Institut Gustave Roussy /ID# 162753 [Villejuif, France] | National Cancer Center Hospital East /ID# 166433 [Kashiwa-shi, Japan] | National Hospital Organization Kyushu Cancer Center /ID# 206229 [Fukuoka, Japan] | National Cancer Center Hospital /ID# 166279 [Chuo-ku, Japan] | Hospital Universitario Fundacion Jimenez Diaz /ID# 163862 [Madrid, Spain] | Hospital Universitario HM Sanchinarro /ID# 163861 [Madrid, Spain] | Hospital Clinico Universitario de Valencia /ID# 163925 [Valencia, Spain] | National Taiwan University Hospital /ID# 163997 [Taipei, Taiwan] | Taipei Medical University Hospital /ID# 163998 [Taipei, Taiwan]",2016.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03000764,RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer,Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer.,COMPLETED,,Institut de Cancérologie de Lorraine,2017-05-10,2018-04-18,2018-04-25,2016-12-22,2018-08-08,['Global mRNA alternative splicing and expression of non-coding RNAs profiles in healthy dermal fibroblasts'],"['Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on cultured fibroblasts', 'Transcriptomic signature of pathological induced fibrosis when comparing the primary outcome between the two populations on serum', 'Individual radiosensitivity on healthy dermal fibroblasts', 'Comparison of the overall mRNA splicing and non-coding RNA expression profiles between non irradiated and irradiated dermal fibroblasts in the same individual', 'Changes in cellular distribution of the main non-coding RNAs whose expression varies significantly within the pre-identified signature between the 2 groups of patients', 'seric HSP proteins potentially predictive of pathological induced fibrosis', 'Cellular distribution of specific HSP on fibroblast culture in each group of patients', 'Potential interactions between DNA damage response proteins and candidate HSP']",,,,,1,France,"Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on biomarkers related to radiation-induced fibrosis in breast cancer patients, indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03000920,Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI),Multicenter Randomized Controlled Trial Evaluating the Effectiveness and Cost-effectiveness of the Use of Short Message Service (SMS) in the Screening Invitation Strategy for Breast Cancer.,COMPLETED,,"University Hospital, Tours",2017-05-02,2018-12-01,2019-06-30,2016-12-22,2019-07-18,"['Phase 1: Compare the participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of sending an SMS before the invitation letter (vs sending the invitation letter alone = usual strategy).', 'Phase 2: Compare participation rates in organized breast cancer screening (and the cost by screened woman) in response to a strategy of replacing the reminder 1 by mail with a reminder 1 by SMS ( reminder 1 mail = usual strategy).']",[],,,,,4,France,"ADOC41 [Blois, France] | ADOC28 [Chartres, France] | CREDEP [Châteauroux, France] | CCDC [Tours, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03003169,Mastectomy in Ambulatory Breast Surgery,Mastectomy in Ambulatory Breast Surgery,COMPLETED,,Institut de Cancérologie de Lorraine,2016-04-08,2017-12-31,2017-12-31,2016-12-26,2022-04-07,['Impact of the type of hospitalization (ambulatory / conventional) according to the type of surgery (total / partial mastectomy) on quality of life 15 days after Intervention.'],"['Impact of type of hospitalization (ambulatory / conventional) depending on the type of surgery (total / partial mastectomy) on anxiety / depression of the patient 15 days after surgery.', 'Patient satisfaction by type of hospitalization (ambulatory / conventional) for each type of surgery (total / partial mastectomy)', 'Complication rate within 15 days the intervention according to the type of hospitalization (ambulatory / conventional) for each type of surgery (total / partial mastectomy)', 'Estimate the conversion rate from ambulatory surgical to conventional surgery']",,,,,1,France,"Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the impact of hospitalization types on quality of life and patient outcomes related to mastectomy surgeries, but does not introduce a new medicine or an extension of indication for an existing treatment.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03013504,"A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients","A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients with HER2+ Early Breast Cancer",COMPLETED,PHASE3,Prestige Biopharma Limited,2018-02-19,2019-04-19,2022-01-13,2017-01-06,2024-11-06,['total pathological complete response rate (tpCR)'],"['total breast pathological complete response rate (bpCR)', 'Overall response rate (ORR)', 'Overall Survival (OS)', 'Event-free Survival (EFS)', 'Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)', 'Cardiac dysfunction', 'Immunogenecity', 'Clearance (Pharmacokinetic)', 'Area under the curve (AUC, Pharmacokinetic)', 'Plasma half life (Pharmacokinetic)']",,,,,15,Belarus; Bulgaria; Estonia; France; Georgia; Hungary; Italy; Malaysia; Poland; Russia; Spain; Thailand; Ukraine,"Minsk Clinical Oncological Dispensary [Minsk, Belarus] | Complex Oncology Center [Plovdiv, Bulgaria] | East Tallinn Central Hospital [Tallinn, Estonia] | Centre René Huguenin (Institut Curie) [Saint-Cloud, France] | S. Khechinashvili University Hospital [Tbilisi, Georgia] | National Institute of Oncology [Budapest, Hungary] | University of Debrecen [Debrecen, Hungary] | Modena Hospital [Modena, Italy] | Beacon International Specialist Centre [Kuala Lumpur, Malaysia] | Hospital Kuala Lumpur [Kuala Lumpur, Malaysia] | Szpital Specjalistyczny Brzeziny [Brzeziny, Poland] | LLC ""Vitamed"" [Moscow, Russia] | Hospital Universitario Virgen Macarena [Seville, Spain] | Maharaj Nakorn Chiang Mai Hospital [Chiang Mai, Thailand] | GI ""V. T. Zaycev Institute General and Urgent Surgery of NAMS of Ukraine "" [Kharkiv, Ukraine]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial compares HD201, a biosimilar to Herceptin, in patients with HER2+ early breast cancer, indicating an extension of indication for a similar treatment rather than a new medicine.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03025711,Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine,Use Of Pertuzumab And Trastuzumab Emtansine In Adult Patients With Her2-Positive Metastatic Or Locally Recurrent Unresectable Breast Cancer,COMPLETED,,BELEN RUIZ-ANTORAN,2017-12-01,2018-10-01,2020-01-31,2017-01-19,2020-03-05,['Overall survival.'],"['Progression free survival.', 'Best overall response rate', 'Duration of response (DOR)', 'Time to treatment failure', 'Time to Objective Response', 'Time to change treatment', 'Time to next treatment', 'All suspected Grade 3/4/5 adverse reactions', 'Adverse events of special interest to anti HER2 Mab (AESI)', 'AEs of scientific interest']",,,,,1,Spain,"Puerta de Hierro University Hospital [Madrid, Spain]",2017.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The text discusses the use of Pertuzumab and Trastuzumab Emtansine in a specific patient population (HER2-positive metastatic or locally recurrent unresectable breast cancer), indicating an extension of indication for these existing medications.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03027245,Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy,Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE),COMPLETED,,Eisai GmbH,2016-10-13,2022-05-31,2022-05-31,2017-01-23,2022-07-13,"['Number of participants experiencing eribulin-induced peripheral neuropathy (PN)', 'Percentage of participants experiencing eribulin-induced PN', 'Number of participants with the indicated grade of eribulin-induced PN, as determined by Common Terminology Criteria for Adverse Events (CTCAE), grade version 4.0', 'Percentage of participants who experienced dose modifications of eribulin treatment due to eribulin-induced PN', 'Percentage of participants who discontinued eribulin treatment due to eribulin-induced PN', 'Time to eribulin treatment discontinuation due to eribulin-induced PN', 'Number of resolved cases in participants who experience eribulin-induced PN', 'Percentage of resolved cases in participants who experience eribulin-induced PN', 'Time to resolution of eribulin-induced PN', 'Number of therapeutic interventions (e.g., analgesics) being used to treat eribulin-induced PN']","['Health-related quality of life scores measured using the Patient Neurotoxicity Questionnaire', 'Health-related quality of life scores measured using the EuroQOl-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire', 'Time to disease progression', 'Number of participants with any serious adverse event (SAE) and number of participants with any non-serious AE', 'Percentage of participants with any SAE and percentage of participants with any non-serious AE']",,,,,65,Germany,"Eisai Trial Site 1 [Amberg, Germany] | Eisai Trial Site 1 [Aschaffenburg, Germany] | Eisai Trial Site 2 [Aschaffenburg, Germany] | Eisai Trial Site 1 [Augsburg, Germany] | Eisai Trial Site 2 [Augsburg, Germany] | Eisai Trial Site 1 [Aurich, Germany] | Eisai Trial Site 1 [Berlin, Germany] | Eisai Trial Site 2 [Berlin, Germany] | Eisai Trial Site 3 [Berlin, Germany] | Eisai Trial Site 1 [Bonn, Germany] | Eisai Trial Site 2 [Bonn, Germany] | Eisai Trial Site 1 [Cologne, Germany] | Eisai Trial Site 2 [Cologne, Germany] | Eisai Trial Site 1 [Darmstadt, Germany] | Eisai Trial Site 1 [Donauwörth, Germany] | EISAI Trial Site 1 [Dresden, Germany] | Eisai Trial Site 1 [Düren, Germany] | Eisai Trial Site 1 [Essen, Germany] | Eisai Trial Site 1 [Esslingen am Neckar, Germany] | Eisai Trial Site 1 [Eutin, Germany] | Eisai Trial Site 1 [Freiburg im Breisgau, Germany] | Eisai Trial Site 1 [Fürstenwalde, Germany] | Eisai Trial Site 1 [Gelsenkirchen, Germany] | Eisai Trial Site 1 [Georgsmarienhütte, Germany] | Eisai Trial Site 1 [Greifswald, Germany] | Eisai Trial Site 1 [Hanover, Germany] | Eisai Trial Site 2 [Hanover, Germany] | Eisai Trial Site 1 [Hof, Germany] | Eisai Trial Site 1 [Homburg, Germany] | Eisai Trial Site 1 [Ilsede, Germany] | Eisai Trial Site 1 [Karlsruhe, Germany] | Eisai Trial Site 1 [Kassel, Germany] | Eisai Trial Site 1 [Kiel, Germany] | Eisai Trial Site 2 [Kiel, Germany] | Eisai Trial Site 1 [Koblenz, Germany] | Eisai Trial Site 1 [Lahr, Germany] | Eisai Trial Site 1 [Landshut, Germany] | Eisai Trial Site 1 [Lemgo, Germany] | Eisai Trial Site 1 [Lübeck, Germany] | Eisai Trial Site 1 [Magdeburg, Germany] | Eisai Trial Site 1 [Mainz, Germany] | Eisai Trial Site 1 [Mannheim, Germany] | Eisai Trial Site 1 [Marktredwitz, Germany] | Eisai Trial Site 1 [München, Germany] | Eisai Trial Site 2 [München, Germany] | Eisai Trial Site 3 [München, Germany] | Eisai Trial Site 1 [Münster, Germany] | Eisai Trial Site 1 [Naunhof, Germany] | Eisai Trial Site 1 [Nuremberg, Germany] | Eisai Trial Site 1 [Oberhausen, Germany] | Eisai Trial Site 1 [Offenbach, Germany] | Eisai Trial Site 1 [Offenburg, Germany] | Eisai Trial Site 1 [Oldenburg, Germany] | Eisai Trial Site 1 [Potsdam, Germany] | Eisai Trial Site 1 [Püttlingen, Germany] | Eisai Trial Site 1 [Quedlinburg, Germany] | Eisai Trial Site 1 [Rodgau, Germany] | Eisai Trial Site 1 [Rotenburg (Wümme), Germany] | Eisai Trial Site 1 [Saarlouis, Germany] | Eisai Trial Site 1 [Stolberg, Germany] | Eisai Trial Site 1 [Stuttgart, Germany] | Eisai Trial Site 2 [Stuttgart, Germany] | Eisai Trial Site 1 [Tübingen, Germany] | Eisai Trial Site 1 [Villingen-Schwenningen, Germany] | Eisai Trial Site 1 [Worms, Germany]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,"[""Overall Survival"",""Time to Progression""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT03036943,Fluciclovine (18F) Imaging of Breast Cancer,An Open-labelled Study to Characterise Fluciclovine (18F) Uptake Measured by positRon emissiON Tomography In Breast cancER,COMPLETED,,University of Oxford,2017-02-15,2018-12-04,2018-12-04,2017-01-31,2018-12-19,"['Tumour standardised uptake values (SUV) in invasive breast cancer, classified by molecular type, on fluciclovine (18F) PET imaging.']","['Amino acid transporter (AAT) and related growth pathway expression levels quantitatively assessed by immunohistochemistry using the H-score method, and correlated to fluciclovine (18F) uptake (SUV).', 'Tumour metabolite levels characterized by fold change compared to metabolite levels in the adjacent normal tissue, and correlated to fluciclovine (18F) uptake.']",,,,,1,United Kingdom,"Churchill Hospital [Oxford, United Kingdom]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the imaging of breast cancer using Fluciclovine (18F), which suggests an extension of its indication for use in a specific type of cancer rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03045289,"A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer","Whole-Food, Plant-Based Nutrition Among Women With Metastatic Breast Cancer: A Pilot Study of Recruitment, Retention, and Preliminary Changes in Biomarkers and Symptoms.",COMPLETED,,University of Rochester,2018-07-05,2022-07-01,2022-07-01,2017-02-07,2022-07-13,"['Recruitment', 'Retention', 'Compliance']","['FACT-B', 'EORTC QLQ-C30', 'FACT-COG', 'Brief Fatigue Inventory (BFI)', 'Symptom Inventory', 'Serum breast cancer biomarkers', 'Tumor Metabolic Activity as assessed by Positron Emission Tomography/ Computer Tomography (PET/CT)', 'Changes in nutrient intakes based on 3 day food diaries', 'Weight', 'Blood Pressure', 'Inflammatory Markers', 'Hormonal Levels', 'Metabolic Markers', 'Tumor Metabolic Activity', 'Circulating Tumor Cells', 'cell-free DNA']",,,,,1,United States,"University of Rochester [Rochester, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a nutritional intervention study rather than a clinical trial for a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03046004,Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making,The Effect of Receiving Information About the Benefits and Harms of Mammography Screening on Women's Decision Making,COMPLETED,,Institut de Recerca Biomèdica de Lleida,2016-07-01,2017-09-14,2018-06-20,2017-02-08,2021-04-06,['Informed choice'],"['Breast screening attitudes', 'Breast screening intention', 'Decisional conflict', 'Confidence in the decision made', 'Anxiety about screening participation', 'Worry about breast cancer', 'Anticipated regret', 'Time perspective', 'Perceived importance of benefit/harms of screening', 'Perceived risk of breast cancer']",,,,,1,Spain,"Lleida Biomedical Research Institute (IRBLLEIDA) [Lleida, Spain]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of information on decision-making regarding mammography screening, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03054025,Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors,Facilitating Motivational Readiness and Adoption of Physical Activity by Breast Cancer Survivors With a Smart Phone Application,TERMINATED,,Sidney Kimmel Cancer Center at Thomas Jefferson University,2015-09-02,2016-08-31,2018-05-17,2017-02-15,2025-04-29,['Features of the mobile application that were most used by participants'],[],,,,,1,United States,"Sidney Kimmel Cancer Center at Thomas Jefferson University [Philadelphia, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a smart phone application aimed at increasing physical activity among breast cancer survivors, which does not pertain to a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03055312,Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer,"A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer",TERMINATED,PHASE3,Sun Yat-sen University,2016-12-20,2020-11-15,2020-11-15,2017-02-16,2021-01-28,['Clinical benefit rate for 16 weeks'],['progression-free survival'],,,,,2,China,"Sun Yat-sen University Cancer Center [Guangzhou, China] | Sun Yat-sen University, Cancer Center [Guangzhou, China]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of Bicalutamide, which is an existing medication, in a new patient population (AR Positive Metastatic Triple Negative Breast Cancer), indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,Phase 3
NCT03057743,Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer,Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer,TERMINATED,,Abramson Cancer Center at Penn Medicine,2016-04-05,2021-11-01,2021-11-01,2017-02-20,2021-11-18,['Progression free survival'],[],,,,,1,United States,"Abramson Cancer Center of the University of Pennsylvania [Philadelphia, United States]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses imaging techniques and does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03060356,Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET),Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma,TERMINATED,EARLY_PHASE1,University of Pennsylvania,2016-12-21,2020-03-27,2020-03-27,2017-02-23,2023-06-22,['Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 in melanoma and breast cancer subjects'],"['Objective overall response rate by clinical exam for visible cutaneous tumors', 'Objective overall response rate by radiologic imaging using RECIST 1.1', 'Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using RECIST 1.1 criteria', 'Estimate the activity of RNA CART-cMET in subjects who receive at least 1 dose of cells by objective response rate using pathological evaluation of resected or biopsied tissue']",,,,,1,United States,"University of Pennsylvania [Philadelphia, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new treatment using autologous T cells expressing a specific CAR (chimeric antigen receptor) targeting cMET, indicating it is a new medicine.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03061773,Physical Training on Patients With Breast Cancer,Benefits of Physical Exercise in Patients With Breast Cancer,COMPLETED,,Federal University of Maranhao,2014-03-01,2015-09-01,2015-09-30,2017-02-23,2017-02-23,"['Measure the pain, The Brief Pain Inventory (BPI).']",['Measure the Fatigue; The revised piper fatigue scale (PFS-R).'],,,,,0,,,2014.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses physical training and exercise benefits for breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2015.0,10.0,0,NA/Other
NCT03066856,Dietary Intervention and BRCA Penetrance,Lifestyle and the Penetrance of BRCA Mutation,COMPLETED,,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",2015-12-01,2018-12-31,2018-12-31,2017-03-01,2021-10-04,"['Reduction of serum levels of IGF-I (ng/mL) (intervention trial).', 'Case-control analysis: comparison of the affected versus the unaffected BRCA mutation carriers for the baseline IRm levels baseline serum levels of IGF-I and IRm.']",['Survival analysis: evaluation of the association between IGF-I and IGF-I changes and subsequent BC incidence and BC prognosis (BC incidence for unaffected women and ipsilateral or contralateral BC and BC recurrences for affected women).'],,,,,1,Italy,"Fondazione IRCCS Istituto Nazionale dei Tumori [Milan, Italy]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a dietary intervention and its effects on BRCA mutation penetrance, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03071757,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors","A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,AbbVie,2017-03-21,2022-04-13,2022-04-13,2017-03-07,2022-04-28,"['Terminal half-life (t1/2) of ABBV-368', 'Area under the serum concentration-time curve (AUC) of ABBV-368', 'Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181', 'Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181', 'Time to Cmax (Tmax) of ABBV-368', 'Terminal phase elimination rate constant (β) of ABBV-368', 'Number of Participants With Adverse Events', 'Maximum observed serum concentration (Cmax) of ABBV-368']","['Objective Response Rate (ORR)', 'Clinical benefit rate (CBR)', 'Duration of Objective Response (DOR)', 'Progression-Free Survival (PFS)']",,,,,27,France; Japan; Puerto Rico; Spain; Taiwan; United States,"Moores Cancer Center at UC San Diego /ID# 201334 [La Jolla, United States] | University of California, Davis Comprehensive Cancer Center /ID# 201342 [Sacramento, United States] | Stanford University /ID# 206949 [Stanford, United States] | Yale University /ID# 207895 [New Haven, United States] | Carolina BioOncology Institute /ID# 160786 [Huntersville, United States] | Greenville Hospital System /ID# 160785 [Greenville, United States] | University of Texas Southwestern Medical Center /ID# 201934 [Dallas, United States] | South Texas Accelerated Research Therapeutics /ID# 160788 [San Antonio, United States] | University of Virginia /ID# 212895 [Charlottesville, United States] | Virginia Cancer Specialists - Fairfax /ID# 160787 [Fairfax, United States] | AP-HM - Hopital de la Timone /ID# 165036 [Marseille, France] | Centre Leon Berard /ID# 165037 [Lyon, France] | Institut Gustave Roussy /ID# 165035 [Villejuif, France] | Institut Curie /ID# 165038 [Paris, France] | National Cancer Center Hospital East /ID# 214530 [Kashiwa-shi, Japan] | National Cancer Center Hospital /ID# 214531 [Chuo-ku, Japan] | Pan American Center for Oncology Trials, LLC /ID# 213809 [Rio Piedras, Puerto Rico] | Hospital Duran i Reynals /ID# 205997 [L'Hospitalet de Llobregat, Spain] | Hospital Universitario Puerta de Hierro, Majadahonda /ID# 206973 [Majadahonda, Spain] | CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 208879 [Pamplona, Spain] | Hospital General Universitario Gregorio Maranon /ID# 205999 [Madrid, Spain] | CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 205996 [Madrid, Spain] | Hospital Universitario Fundacion Jimenez Diaz /ID# 211500 [Madrid, Spain] | Hospital Clinico Universitario de Valencia /ID# 211499 [Valencia, Spain] | National Cheng Kung University Hospital /ID# 164002 [Tainan City, Taiwan] | National Taiwan University Hospital /ID# 164000 [Taipei, Taiwan] | Taipei Medical University Hospital /ID# 164001 [Taipei, Taiwan]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03072992,"""Curcumin"" in Combination With Chemotherapy in Advanced Breast Cancer","Study of Efficacy of Curcumin in Combination With Chemotherapy in Patients With Advanced Breast Cancer: Randomized, Double Blind, Placebo Controlled Clinical Trial",COMPLETED,PHASE2,"National Center of Oncology, Armenia",2017-03-20,2018-11-20,2019-06-30,2017-03-08,2019-11-27,['Objective response rate'],"['Adverse events', 'Global Health Status/QoL scale', 'Progression free survival', 'Time to Treatment Failure', 'Time to Tumour Progression']",,,,,1,Armenia,"National Center of Oncology [Yerevan, Armenia]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the efficacy of curcumin in combination with chemotherapy for advanced breast cancer, suggesting an extension of indication for curcumin rather than introducing a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03073473,Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers,Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers,TERMINATED,,Cota Inc.,2017-02-28,2018-06-13,2018-06-13,2017-03-08,2018-07-20,['Time on original treatment strategy for advanced cancer'],['Total cost of care'],,,,,10,United States,"RCCA - Central Jersey Division [East Brunswick, United States] | RCCA - Freehold Division [Freehold, United States] | Hackensack Meridian Health System [Hackensack, United States] | RCCA - Hackettstown Division [Hackettstown, United States] | RCCA - Howell Division [Howell Township, United States] | RCCA - Little Silver Division [Little Silver, United States] | RCCA - Marmora Division [Marmora, United States] | RCCA - Mount Holly Division [Mount Holly, United States] | RCCA - Pompton Plains Division [Pompton Plains, United States] | RCCA - Sparta Division [Sparta, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a cancer test and its evaluation in patients with advanced cancers, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT03075462,A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,"An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer",COMPLETED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2017-03-09,2021-08-22,2021-12-13,2017-03-09,2022-07-01,['The type and incidence of adverse events [safety and tolerability]'],"['Objective Response Rate (ORR)', 'Disease Control Rate (DOR)', 'Time to Progression (TTP)', 'Overall Survival (OS)', 'Cmax', 'T1/2 (Half-life)', 'Area under curve (AUC)', 'V/F', 'CL/F']",,,,,1,China,"Beijing Cancer Hosptial [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03078036,"International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study","BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study",COMPLETED,,AstraZeneca,2017-03-13,2019-05-20,2019-05-20,2017-03-13,2020-05-20,['BRCA Mutational status (BRCA1 mutated and/or BRCA2 mutated or BRCA wild type).'],"['Descriptive statistics for treatments administered by line of therapy from 1st line metastatic breast cancer.', 'Progression free survival by line of therapy', 'Overall survival by line of therapy']",,,,,98,Australia; Bulgaria; Canada; Germany; Hungary; Italy; Japan; Poland; Russia; South Korea; Spain; Taiwan; Turkey (Türkiye); United Kingdom; United States,"Research Site [Santa Barbara, United States] | Research Site [Denver, United States] | Research Site [Hialeah, United States] | Research Site [Dallas, United States] | Research Site [Denton, United States] | Research Site [Flower Mound, United States] | Research Site [Houston, United States] | Research Site [Houston, United States] | Research Site [Paris, United States] | Research Site [San Antonio, United States] | Research Site [The Woodlands, United States] | Research Site [Newport News, United States] | Research Site [Vancouver, United States] | Research Site [Wenatchee, United States] | Research Site [Redcliffe, Australia] | Research Site [Kurralta Park, Australia] | Research Site [Ballarat, Australia] | Research Site [Dobrich, Bulgaria] | Research Site [Rousse, Bulgaria] | Research Site [Sofia, Bulgaria] | Research Site [Kingston, Canada] | Research Site [Kitchener, Canada] | Research Site [Chicoutimi, Canada] | Research Site [Québec, Canada] | Research Site [Tübingen, Germany] | Research Site [Budapest, Hungary] | Research Site [Szeged, Hungary] | Research Site [Szekszárd, Hungary] | Research Site [Szolnok, Hungary] | Research Site [Carpi, Italy] | Research Site [Castellanza, Italy] | Research Site [Milan, Italy] | Research Site [Pavia, Italy] | Research Site [Reggio Emilia, Italy] | Research Site [Kamogawa-shi, Japan] | Research Site [Matsuyama, Japan] | Research Site [Fukuoka, Japan] | Research Site [Sapporo, Japan] | Research Site [Sendai, Japan] | Research Site [Osaka, Japan] | Research Site [Chūōku, Japan] | Research Site [Brzozów, Poland] | Research Site [Opole, Poland] | Research Site [Warsaw, Poland] | Research Site [Wałbrzych, Poland] | Research Site [Wieliszew, Poland] | Research Site [Wroclaw, Poland] | Research Site [Żory, Poland] | Research Site [Chelyabinsk, Russia] | Research Site [Krasnodar, Russia] | Research Site [Novosibirsk, Russia] | Research Site [Omsk, Russia] | Research Site [Pyatigorsk, Russia] | Research Site [Ryazan, Russia] | Research Site [Tomsk, Russia] | Research Site [Goyang-si, South Korea] | Research Site [Seongnam-si, South Korea] | Research Site [Busan, South Korea] | Research Site [Seoul, South Korea] | Research Site [Ulsan, South Korea] | Research Site [Terrassa, Spain] | Research Site [A Coruña, Spain] | Research Site [Alcorcón, Spain] | Research Site [San Sebastián de los Reyes, Spain] | Research Site [Barcelona, Spain] | Research Site [Burgos, Spain] | Research Site [Girona, Spain] | Research Site [Huelva, Spain] | Research Site [Changhua, Taiwan] | Research Site [Kaohsiung City, Taiwan] | Research Site [Taichung, Taiwan] | Research Site [Tainan City, Taiwan] | Research Site [Taipei, Taiwan] | Research Site [Adana, Turkey (Türkiye)] | Research Site [Ankara, Turkey (Türkiye)] | Research Site [Antalya, Turkey (Türkiye)] | Research Site [Diyarbakır, Turkey (Türkiye)] | Research Site [Istanbul, Turkey (Türkiye)] | Research Site [Izmir, Turkey (Türkiye)] | Research Site [Kocaeli, Turkey (Türkiye)] | Research Site [Sakarya, Turkey (Türkiye)] | Research Site [Samsun, Turkey (Türkiye)] | Research Site [Tekirdağ, Turkey (Türkiye)] | Research Site [Trabzon, Turkey (Türkiye)] | Research Site [Van, Turkey (Türkiye)] | Research Site [Huntingdon, United Kingdom] | Research Site [Peterborough, United Kingdom] | Research Site [Truro, United Kingdom] | Research Site [Derby, United Kingdom] | Research Site [Exeter, United Kingdom] | Research Site [Worthing, United Kingdom] | Research Site [London, United Kingdom] | Research Site [Blackpool, United Kingdom] | Research Site [Lancaster, United Kingdom] | Research Site [Stoke-on-Trent, United Kingdom] | Research Site [Warwick, United Kingdom] | Research Site [Wolverhampton, United Kingdom] | Research Site [Huddersfield, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,1,0,1,,INDUSTRY,False,2019.0,6.0,1,NA/Other
NCT03082456,Molecular Breast Imaging in Screening Breast Cancer,Molecular Breast Imaging in Screening Breast Cancer,COMPLETED,,Chang Gung Memorial Hospital,2015-06-01,2018-12-31,2019-06-01,2017-03-17,2020-05-13,['Recall rate'],['Diagnostic efficacy'],,,,,1,Taiwan,"TzuPei Su [Keelung, Taiwan]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Molecular Breast Imaging in the context of screening for breast cancer, which suggests an extension of indication for an existing diagnostic method rather than introducing a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03083782,Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus,"A Phase I, Open-Label, Crossover, Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus in Healthy Volunteers",COMPLETED,PHASE1,Thomas Jefferson University,2017-04-18,2017-06-05,2017-06-30,2017-03-20,2017-10-11,"['Apixaban area under the plasma concentration curve between 0 and 72 hours (AUC(0-72)).', 'Apixaban peak plasma concentration (Cmax)']","['Safety and tolerability of apixaban when co-administered with cyclosporine assessed by capturing adverse events and laboratory safety tests', 'Safety and tolerability of apixaban when co-administered with tacrolimus assessed by capturing adverse events and laboratory safety tests']",,,,,1,United States,"Thomas Jefferson University [Philadelphia, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2017.0,8.0,0,Phase 1
NCT03088527,"Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer","A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer",COMPLETED,PHASE1,"Stemline Therapeutics, Inc.",2017-10-23,2020-08-28,2020-09-24,2017-03-23,2022-08-18,"['Incidence rate of dose-limiting toxicities (DLTs) RAD140 treatment', 'Number of adverse events related to study treatment', 'Number participants with dose interruptions and dose adjustments']","['Maximum plasma concentration (Cmax)', 'Time to maximum plasma concentration (Tmax)', 'Area under the plasma concentration versus time curve (AUC)', 'Tumor response']",,,,,5,United States,"Yale Cancer Center [New Haven, United States] | Cancer Center Protocol Office [Boston, United States] | Barbara Ann Karmanos Cancer Center [Detroit, United States] | Washington University School of Medicine [St Louis, United States] | Sarah Cannon Research Institute [Nashville, United States]",2017.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03089918,A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,An Open-Label Microdosing Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain,COMPLETED,PHASE1,"Janssen Research & Development, LLC",2017-05-17,2018-08-24,2018-08-24,2017-03-24,2025-04-27,"['Effective Radiation Dose Following Injection of 11C-JNJ-63779586 (Part A)', 'Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 (Part B)', 'Percent Intact Tracer of 11C-JNJ-63779586 in Blood Samples (Part B)', 'Radiometabolite Fraction of 11C-JNJ-63779586 in Blood Samples (Part B)']",['Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Part A and Part B)'],,,,,2,Belgium,"UZ Leuven [Leuven, Belgium] | University of Antwerpen [Wilrijk, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,The text describes a study involving a specific drug (11C-JNJ-63779586) which indicates it is a new medicine being investigated for its effects on brain drug transporters.,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03092635,AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy,"Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy",TERMINATED,PHASE1,Medical University of South Carolina,2017-06-06,2021-11-10,2022-04-22,2017-03-28,2025-01-06,['AGE level reduction'],"['Correlation between AGE level and changes to BMI', 'Correlation between AGE level and insulin resistance (HOMA-IR)', 'Correlation between AGE level and A1C', 'Correlation between AGE level and lipids', 'Correlation between AGE level and diet', 'Correlation between AGE level and quality of life', 'Correlation between AGE level and plasma IL6', 'Correlation between AGE level and leptin', 'Correlation between AGE level and c-reactive protein (CRP)', 'Correlation between AGE level and malondialdehyde (MDA)', 'Correlation between AGE level and oxLDLs (low density lipoprotein)', 'Correlation between AGE level and sRAGE (soluble receptor for AGE)', 'Frequency of adverse events as assessed by CTCAE v. 4', 'Tumor response to treatment as assessed by RECIST 1.1 or MD Anderson criteria']",,,,,1,United States,"Medical University of South Carolina [Charleston, United States]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the effects of manipulating AGE levels in patients already receiving endocrine therapy for ER+ metastatic breast cancer, indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 1
NCT03100981,Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer,"Internet-delivered Mindfulness-Based Cognitive Therapy for Symptoms of Depression, Anxiety, and Stress Among Women Treated for Breast Cancer and Men Treated for Prostate Cancer - Effects and Mechanisms",COMPLETED,,University of Aarhus,2016-02-24,2017-11-27,2018-06-27,2017-04-04,2019-01-08,"['Symptoms of Depression', 'Symptoms of Anxiety']","['Symptoms of Stress', 'Cost-Effectiveness']",,,,,1,Denmark,"Department of Psychology, Aarhus University [Aarhus, Denmark]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2018.0,7.0,0,NA/Other
NCT03101280,A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,COMPLETED,PHASE1,Hoffmann-La Roche,2017-04-27,2020-08-11,2020-08-11,2017-04-05,2020-10-22,"['Percentage of Participants With Adverse Events', 'Percentage of Participants With Dose-Limiting Toxicities (DLTs) [Part 1]', 'Recommended Phase II Dose (RP2D) of Rucaparib for the Combination [Part 1]', 'Number of Dose Modifications due to Adverse Events [Part 2]']","['Percentage of Participants With Objective Response of Complete Response (CR) or Partial Response (PR) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)', 'Percentage of Participants With Objective Response of CR or PR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (Cancer Antigen 125 [CA125] Response) Considerations', 'Duration of Response (DOR) as Determined by Investigator Assessment Using RECIST v1.1', 'DOR as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations', 'Progression-Free Survival (PFS) as Determined by Investigator Assessment Using RECIST v1.1', 'PFS as Determined by Investigator Assessment Using Immune-Modified RECIST Incorporating Immune-Response (CA125 Response) Considerations', 'Overall Survival', 'Steady State Maximum Plasma Concentration Observed (Cmax) for Rucaparib [Part 1]', 'Time to Maximum Plasma Concentration (tmax) for Rucaparib [Part 1]', 'Area Under the Plasma Concentration-Time Curve (AUC) for Rucaparib [Part 1]', 'Apparent Clearance (CL/F) for Rucaparib [Part 1]', 'Minimum Plasma Concentration During the Dosing Interval (Cmin) for Rucaparib [Part 2]', 'Serum Concentration of Atezolizumab [Parts 1 and 2]', 'Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab']",,,,,11,Australia; France; Spain; United Kingdom,"Peter Maccallum Cancer Centre [Melbourne, Australia] | Centre Leon Berard [Lyon, France] | Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale [Pierre-Bénite, France] | Gustave Roussy [Villejuif, France] | Clínica Universidad de Navarra [Pamplona, Spain] | Hospital Universitario Vall d'Hebron [Barcelona, Spain] | La Paz University Hospital [Madrid, Spain] | Royal Marsden Hospital - London [London, United Kingdom] | University College London Hospitals NHS Foundation Trust - University College Hospital [London, United Kingdom] | Lancashire Teaching Hospitals NHS Foundation Trust [Preston, United Kingdom] | Royal Marsden NHS Foundation Trust [Sutton, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves a combination study of Rucaparib and Atezolizumab, which are already approved drugs, indicating an extension of indication for their use in advanced gynecologic cancers and triple-negative breast cancer.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03105076,Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial,Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial,COMPLETED,,Taipei Medical University Shuang Ho Hospital,2017-04-01,2019-11-30,2020-01-31,2017-04-07,2020-03-18,"['Decisional conflict', 'Knowledge']","['Decision regret', 'Postsurgical depression']",,,,,1,Taiwan,"Shuang Ho Hospital, Taipei Medical University [New Taipei City, Taiwan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a randomized controlled trial focused on decision aids for breast cancer surgery choice, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03107663,⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma,"A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Selected Solid Malignancies (Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma Head and Neck (SqCCHN), Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma",COMPLETED,PHASE1,"ImaginAb, Inc.",2017-06-19,2018-08-16,2018-08-16,2017-04-11,2018-09-18,"['Safety and tolerability of ⁸⁹Zr-Df-IAB22M2C assessed by local and systemic signs and symptoms of infusion reactions,incidence of adverse events,changes in laboratory test results,dose limiting toxicities,vital signs and 12-lead electrocardiogram findings']","['Evaluate imaging time window with ⁸⁹Zr-Df-IAB22M2C', 'Evaluate protein dose for imaging with ⁸⁹Zr-Df-IAB22M2C', 'Evaluate the radioactive pharmacokinetics of ⁸⁹Zr-Df-IAB22M2C by determining the time-activity curves for serum (% injected dose/liter), AUC, clearance, volume of distribution, Tmax and Cmax.', 'Evaluate the dosimetry of a single dose of ⁸⁹Zr-Df-IAB22M2C']",,,,,3,United States,"Honor Health and Imaging Endpoints [Scottsdale, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of Pennsylvania [Philadelphia, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03109080,Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC),"A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease",COMPLETED,PHASE1,Institut Curie,2017-07-24,2020-02-17,2021-11-29,2017-04-12,2024-01-31,['Determination of the Maximal Tolerated Dose of Olaparib administered with concurrent loco regional radiotherapy'],"['Incidence of Serious Adverse Events (SAEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence and severity of Adverse Events (AEs), graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence and severity of laboratory abnormalities, graded according to NCI-CTCAE version 4.03 criteria to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of acute toxicity 2 weeks and 6 weeks after the end of radiotherapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of late toxicity at 1 year and at 2 years as of initiation of radiation therapy to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Incidence of treatment discontinuations and treatment modifications due to AEs to assess the safety profile of Olaparib administered with concurrent loco-regional radiotherapy.', 'Evaluation of the Objective Response Rate (ORR) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the Complete Response Rate to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of Pathological Response Rate (pRR) after salvage surgery to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the loco-regional Progression Free Survival (l-PFS) to evaluate Olaparib administered with concurrent loco regional radiotherapy efficacy profile', 'Evaluation of the Progression Free Survival (PFS) or Disease Free survival (DFS) according to stage of disease to evaluate patient outcome', 'Evaluation of the distant relapse rate to evaluate patient outcome', 'Evaluation of patient outcome by evaluation of the Overall Survival (OS).', 'Evaluation of patient outcome by evaluate disease specific survival rate.', 'Explore biomarkers of Olaparib activity in combination with concurrent radiotherapy.']",,,,,1,France,"Institut Curie [Paris, France]",2017.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT03113825,"Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery","An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery",COMPLETED,PHASE2,"Avelas Biosciences, Inc.",2017-07-05,2020-04-08,2020-11-18,2017-04-14,2021-06-11,['Determine the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.'],"['Safety of AVB-620 as assessed by incidence of adverse events and abnormal laboratory values.', 'Identify malignant tissue types that provide the most robust fluorescence response compared to non-malignant tissue.', 'Evaluate timing of AVB-620 administration on optical fluorescence characteristics']",,,,,13,United States,"UCSD [San Diego, United States] | Medstar Washington Hospital [Washington D.C., United States] | Mayo Clinic Jacksonville -- Center for Breast Health [Jacksonville, United States] | Moffitt Cancer Center [Tampa, United States] | Advocate Good Shepherd Hospital [Barrington, United States] | William Beaumont Hospital [Royal Oak, United States] | UNLV School of Medicine [Las Vegas, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Montefiore Einstein Center for Cancer Care [The Bronx, United States] | University Hospitals Cleveland Medical Center [Cleveland, United States] | Ohio State University, James Cancer Center [Columbus, United States] | Roper St. Francis Hospital [Charleston, United States] | Swedish Cancer Institute [Seattle, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is studying AVB-620, which appears to be a new treatment or imaging agent for breast cancer, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 2
NCT03116048,Evaluation of Persistent Postsurgical Pain After Breast Surgery With a Pectoral Nerves Block (Pecs) Type II,Evaluation of Persistent Postsurgical Pain After Breast Surgery With a Pectoral Nerves Block (Pecs) Type II: a Prospective Follow-up After a Prospective Double Blind Placebo-controlled Randomized Controlled Trail,COMPLETED,,GZA Ziekenhuizen Campus Sint-Augustinus,2017-05-02,2017-06-12,2018-04-24,2017-04-14,2019-02-15,['Chronic post- procedural pain evaluation through questionaire'],[],,,,,1,Belgium,"GZA Sint Augustinus [Wilrijk, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study evaluating pain management techniques (Pectoral Nerves Block) after breast surgery, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03117894,PECS-2 for Breast Surgery,"Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.",COMPLETED,,Umeå University,2017-05-23,2020-10-22,2020-10-22,2017-04-18,2021-06-04,"['Opiate consumption', 'All cause mortality']","['Postoperative Nausea and Vomiting (PONV)', 'Actual pain score', 'Recurrence of breast neoplasm', 'Chronic Pain']",,,,,1,Sweden,"Östersund Hospital [Östersund, Sweden]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the effects of a regional anesthesia technique (PECS-2) on postoperative outcomes in breast cancer surgery, indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03128619,"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer","A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer",TERMINATED,PHASE1,Jonsson Comprehensive Cancer Center,2017-08-02,2022-03-31,2022-03-31,2017-04-25,2022-09-26,"['Change in Ki-67 expression defined as the percent of cells staining positive by validated central assay (Phase II)', 'Incidence of dose-limiting toxicities (DLT) evaluated according to National Cancer Institute (NCI) CTCAE version 4.0 to determine MTD (Phase Ib)']","['Clinical objective response rate (ORR) evaluated by RECIST 1.1 using caliper measurements', 'Gene expression and/or biomarker changes', 'Incidence of adverse events (AEs) evaluated according to NCI CTCAE version 4.0', 'pCR rate defined as the percentage of randomized patients with a pCR', 'The pharmacokinetic (PK) parameter - area under the plasma concentration-time curve (AUC) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Elimination half-life (t½) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Maximum plasma concentration (Cmax) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Minimum plasma concentration of BAY 80-694 will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Time when Cmax occurs (Tmax) will be determined for copanlisib in arms A, B, and escalation dose levels.', 'The pharmacokinetic (PK) parameter - Average plasma concentration at steady state (Cavg) will be determined for copanlisib in arms A, B, and escalation dose levels.']",,,,,1,United States,"UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 1
NCT03134638,A Study of SY-1365 in Adult Patients With Advanced Solid Tumors,"A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors",TERMINATED,PHASE1,Syros Pharmaceuticals,2017-05-12,2020-05-15,2020-06-24,2017-05-01,2021-03-09,"['(Part 1) First-cycle dose-limiting toxicities (DLTs)', '(Part 1) ECG QTc Interval', '(Part 1 and 2) Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]']","['Peak Plasma Concentration (Cmax) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', 'Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-last) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', 'Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-INF) of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin (Part 2 only)', '(Part 1 and 2) Terminal elimination half life (t1/2)', '(Part 1 and 2) Evaluate the PD effects of SY-1365 as a single agent (Part 1 and 2) and in combination with carboplatin or fulvestrant (Part 2 only)', '(Part 2) Evaluation of Objective Response Rate (ORR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1', '(Part 2) Evaluation of Duration of Response (DoR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1', '(Part 2) Evaluation of Disease Control Rate (DCR) in patients with ovarian cancer, breast cancer, and advanced solid tumors as measured by RECIST v1.1']",,,,,20,Canada; France; United States,"University of Alabama at Birmingham [Birmingham, United States] | Honor Health Research Institute [Scottsdale, United States] | Palo Alto Medical Foundation Group [San Francisco, United States] | University of Chicago Medical Center [Chicago, United States] | Massachusetts General Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States] | Columbia University Medical Center [New York, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Willamette Valley Cancer Institute and Research Center [Eugene, United States] | Women and Infants Hospital of Rhode Island [Providence, United States] | Tennessee Oncology [Nashville, United States] | Texas Oncology [Austin, United States] | University of Texas Southwestern Medical Center [Dallas, United States] | Texas Oncology [Fort Worth, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States] | Hamilton Health Sciences [Hamilton, Canada] | McGill University Health Center [Montreal, Canada] | Centre Léon Bérard [Lyon, France] | Institut de Cancérologie de l'Ouest [Saint-Herblain, France] | Institut Gustave Roussy [Villejuif, France]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03135171,Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,COMPLETED,PHASE1,University of Michigan Rogel Cancer Center,2017-07-26,2020-03-16,2020-03-20,2017-05-01,2021-09-10,['Recommended Phase II Dose of Tocilizumab'],['The Frequency of Adverse Events at Each Dose Level'],,,,,3,United States,"University of Chicago [Chicago, United States] | University of Michigan Comprehensive Cancer Center [Ann Arbor, United States] | Yale University [New Haven, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03139851,Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide,CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide,COMPLETED,PHASE2,Centre Leon Berard,2017-06-27,2018-09-26,2019-09-18,2017-05-04,2021-09-10,"['Severe Toxicities (ST) in Run-In Phase Part', '24-week Clinical Benefit Rate (CBR24w) in Phase II part']","['Overall response Rate (ORR) at 24 weeks', 'Duration of response (DoR)', 'Progression-Free Survival (PFS)', 'Overall Survival (OS)', 'Adverse events reporting']",,,,,5,France,"ICO - Paul Papin [Angers, France] | Centre Léon Bérard [Lyon, France] | Hôpital Privé Jean Mermoz [Lyon, France] | ICO - René Gauducheau [Saint-Herblain, France] | Institut de cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates Pembrolizumab, which is an existing drug, in a new patient population (lymphopenic metastatic breast cancer patients) and in combination with metronomic cyclophosphamide, indicating an extension of its indication.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03140553,TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer,TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer,COMPLETED,PHASE2,Guangdong Provincial People's Hospital,2016-09-01,2019-11-11,2019-11-11,2017-05-04,2020-07-28,['pCR'],[],,,,,1,China,"Guangdong General Hospital [Guangzhou, China]",2016.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,0,Phase 2
NCT03145909,"A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)","A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)",TERMINATED,PHASE1,AbbVie,2017-07-03,2018-11-27,2018-11-27,2017-05-09,2018-11-29,"['Dose Escalation Cohort: Tmax of ABBV-176', 'Dose Escalation Cohort: AUC∞ for ABBV-176', 'Dose Escalation Cohort: Terminal phase elimination rate constant (β) for ABBV-176', 'Dose Escalation Cohort: Recommended Phase 2 dose (RPTD) for ABBV-176', 'Dose Escalation Cohort: Cmax of ABBV-176', 'Dose Escalation Cohort: Maximum tolerated dose (MTD) of ABBV-176', 'Expanded Recommended Phase Two Dose (RPTD) Cohort: Objective Response Rate (ORR)', 'Dose Escalation Cohort: AUCt for ABBV-176', 'Dose Escalation Cohort: t1/2 for ABBV-176']","['Expanded RPTD Cohort: AUCt for ABBV-176', 'Expanded RPTD Cohort: Tmax of ABBV-176', 'Expanded RPTD Cohort: Overall Survival (OS)', 'Expanded RPTD Cohort: Cmax of ABBV-176', 'Expanded RPTD Cohort: Duration of Response (DOR)', 'Expanded RPTD Cohort: Terminal phase elimination rate constant (β) for ABBV-176', 'Expanded Recommended Phase Two Dose (RPTD) Cohort: Progression-Free Survival (PFS)', 'Expanded RPTD Cohort: Change in ECOG Performance Status', 'Expanded RPTD Cohort: AUC∞ for ABBV-176', 'Expanded RPTD Cohort: t1/2 for ABBV-176', 'Dose Escalation Cohort: Change from Baseline in QTcF']",,,,,11,Australia; Denmark; Spain; United States,"HonorHealth Research Institute - Pima /ID# 161078 [Scottsdale, United States] | City of Hope /ID# 161079 [Duarte, United States] | Yale University /ID# 201357 [New Haven, United States] | St. Lukes Cancer Institute /ID# 201353 [Kansas City, United States] | Washington University-School of Medicine /ID# 162745 [St Louis, United States] | Rutgers Cancer Institute of NJ /ID# 161080 [New Brunswick, United States] | University of Utah /ID# 161606 [Salt Lake City, United States] | Sydney Children's Hospital /ID# 162917 [Randwick, Australia] | Mater Misericordiae /ID# 162918 [South Brisbane, Australia] | Rigshospitalet /ID# 159707 [Copenhagen Ø, Denmark] | Hosp Univ Madrid Sanchinarro /ID# 161644 [Madrid, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2018.0,7.0,1,Phase 1
NCT03147040,AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer,AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial,TERMINATED,PHASE2,The Netherlands Cancer Institute,2017-11-02,2022-05-01,2022-07-01,2017-05-10,2022-07-19,['Number of patients free of progression at 6 months'],"['Number of patients free of progression at 6 months in the IR profile subgroup', 'Number of patients free of progression at 6 months in the non- IR profile subgroup', 'Number of patients free of progression at 12 months', 'Objective Response Rate', 'Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)', 'Overall Survival']",,,,,4,Netherlands,"Antoni van Leeuwenhoek [Amsterdam, Netherlands] | UMCG [Groningen, Netherlands] | Maastricht University Medical Center [Maastricht, Netherlands] | Erasmus Medical Center Cancer Institute [Rotterdam, Netherlands]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial assesses the efficacy of Carboplatin and Atezolizumab in a specific cancer type (metastatic lobular breast cancer), indicating an extension of indication for these existing drugs rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT03153163,Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer,A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy,COMPLETED,PHASE1,Hoffmann-La Roche,2017-06-20,2018-09-27,2018-09-27,2017-05-15,2018-11-23,"[""Area Under the Concentration-Time Curve [AUC] of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Maximum Serum Concentration (Cmax) Immediately After Dosing of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Minimum (Trough) Concentration (Cmin) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Clearance (CL) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Volume of Distribution at Steady-State (Vss) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1"", ""Half-Life (t1/2) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1""]","['Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.03 (NCI CTCAE V4.03)']",,,,,1,China,"Fudan University Shanghai Cancer Center; Medical Oncology [Shanghai, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03154749,DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer,"Neoadjuvant Docetaxel + Carboplatin Versus Epirubicin+Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Study Protocol for a Multicenter, Randomized Controlled, Open-Label, Phase 2 Trial",COMPLETED,PHASE2,Guangdong Provincial People's Hospital,2016-09-01,2019-12-31,2019-12-31,2017-05-16,2022-09-01,['PCR'],"['Breast-conserving surgery rate', 'EFS', 'OS', 'Adverse events']",,,,,1,China,"Guangdong General Hospital [Guangzhou, China]",2016.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,Phase 2
NCT03159572,Homologous Recombination Inquiry Through Ovarian Malignancy Investigations,Homologous Recombination Inquiry Through Ovarian Malignancy Investigations,COMPLETED,,"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan",2017-03-28,2022-02-16,2022-02-16,2017-05-18,2024-11-21,['Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)'],"['Association between Progression Free Survival (PFS) / Response Rate and HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)', 'Association between Progression Free Survival (PFS) / Response Rate and germline mutation in BRCA1/2 gene in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)']",,,,,1,Japan,"Niigata University Graduate School of Medical and Dental Sciences [Niigata, Japan]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,1,0,1,"The text discusses investigations related to ovarian cancer and associations with genetic factors, indicating an extension of indication for existing treatments rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03159585,To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors,"Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Except Non Small Cell Lung Cancer,Including Liver Cancer,Gastric Cancer,Esophageal Cancer and so on.",COMPLETED,PHASE1,Zhujiang Hospital,2017-04-14,2019-06-04,2019-06-04,2017-05-18,2020-01-22,['treatment-related adverse events as assessed by CTCAE v4.03'],"['assess overall response rate', 'assess duration of response', 'assess time to progress', 'assess progression free survival', 'assess overall survival', 'assess the expression of tumor markers']",,,,,1,China,"Zhujiang Hospital of Southern Mediacl University [Guangzhou, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text describes the application of an existing therapy (NY-ESO-1-specific TCR therapy) to new types of solid tumors, indicating an extension of indication rather than a new medicine.",OTHER,False,2019.0,6.0,0,Phase 1
NCT03165006,Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer,CAMISS Retrospective Cohort - Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer,COMPLETED,,Parc de Salut Mar,2013-01-01,2014-06-30,2015-12-31,2017-05-24,2017-05-24,['Mortality'],"['Recurrences and second breast neoplasms', 'Treatment-related complications', 'Readmissions to hospital for reasons related to breast cancer']",,,,,0,,,2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effects of interval cancer and screening processes on survival and disease-free periods in breast cancer, but does not mention a new medicine or an extension of indication for an existing treatment.",OTHER,False,2015.0,10.0,0,NA/Other
NCT03166085,PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer,COMPLETED,PHASE1,Memorial Sloan Kettering Cancer Center,2017-05-23,2021-12-14,2021-12-14,2017-05-24,2021-12-20,['Maximum Tolerated Dose (MTD)'],[],,,,,1,United States,"Memorial Sloan Kettering Cancer Center [New York, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves PU-H71, which is a new medicine being tested in combination with an existing treatment (Nab-paclitaxel) for a specific type of cancer.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03166384,ELectrosurgical Bipolar Devices VS Conventional Electro-cauterization in Breast Surgery,A Prospective Randomized Study Comparing Surgery Using Electrosurgical Bipolar Sealing Devices and Surgery Using Conventional Electro-cautery,COMPLETED,,Severance Hospital,2017-05-01,2020-03-01,2022-06-27,2017-05-25,2023-09-08,['Total drainage volume after surgery: mL'],"['Total exact drainage volume', 'Drainage volume In hospital: mL', 'Total operation running time', 'Complication ratio within a month after surgery', 'Frequency of seroma aspiration']",,,,,1,South Korea,"Yonsei University College of Medicine [Seoul, South Korea]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial compares two surgical techniques (electrosurgical bipolar devices vs conventional electro-cauterization) rather than testing a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03180086,Breast Cancer Risk Assessment in Women Aged 40-49,Breast Cancer Risk Assessment in Women Aged 40-49,COMPLETED,,Beth Israel Deaconess Medical Center,2017-07-01,2019-11-25,2019-11-25,2017-06-08,2023-11-14,['Screening intentions'],"['Screening intentions within risk groups', 'Knowledge of the pros and cons of mammography screening', 'Decisional conflict scale', 'Difference in PCP discussion of breast cancer risk', 'Difference in PCP discussion of pros/cons of mammography screening', 'PCP discussion of breast cancer prevention medications', 'PCP documentation of discussions of breast cancer medications', 'Prescription of breast cancer prevention medications', 'Time until breast screening MRI', 'Referral to genetic counseling', 'Attended genetic counseling', 'Time until next mammogram after intervention', 'Date of mammogram(s) after intervention', 'Type of mammogram(s) after intervention', 'No mammogram after intervention', 'Risk report acceptability', 'PCP facilitators and barriers', 'PCP risk of malpractice/litigation']",,,,,1,United States,"Beth Israel Deaconess Medical Center [Boston, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses breast cancer risk assessment and screening intentions but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03181139,Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy,Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy,COMPLETED,,Monica Harbell,2013-07-01,2016-04-30,2016-04-30,2017-06-08,2017-06-08,['perioperative opioid consumption'],"['Post-operative nausea and vomiting (PONV)', 'postoperative benzodiazepine use', 'Length of stay (LOS)', 'Pain score', 'Surgery duration']",,,,,0,,,2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the efficacy of a surgical recovery pathway rather than a new medicine or an extension of indication for an existing medicine.,OTHER,False,2016.0,9.0,0,NA/Other
NCT03183206,Safety and Efficiency of γδ T Cell Against Breast Cancer,γδ T Cell Immunotherapy for Treatment of Breast Cancer,COMPLETED,PHASE1; PHASE2,"Fuda Cancer Hospital, Guangzhou",2017-06-15,2018-06-15,2019-06-15,2017-06-12,2020-07-13,"['Relief degree of tumors', 'Progress free survival（PFS）', 'Overall survival（OS）']",[],,,,,1,China,"Biotherapy center in Fuda cancer hospital [Guangzhou, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text discusses a new immunotherapy approach using γδ T cells specifically for the treatment of breast cancer, indicating it is a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03184090,Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC,"An International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer Patients",COMPLETED,PHASE2,MedSIR,2017-06-28,2020-10-27,2020-10-27,2017-06-12,2022-06-21,"['molecular patterns of resistance [with a special focus on retinoblastoma (Rb) status] upon progression to palbociclib plus endocrine therapy in patients who previously achieved clinical benefit with the combination', 'clinical activity of the combination of palbociclib and endocrine therapy after prior progression to palbociclib in endocrine-sensitive patients.']","['Compare clinical activity with molecular patterns of resistance.', 'Measure changes of immunostaining of Rb targets (E2F, DNMT, HIF1alpha, and SKP2) as a result of CDK4 and CDK6 inhibition and the potential predictive value of cyclin D, cyclin E, p16, p18, p21, and p27, in CDK4, and CDK6 inhibition']",,,,,15,Italy; Spain,"Istituto Europeo di Oncologia [Milan, Italy] | Azienda Sanitaria Universitaria Integrata di Udine [Udine, Italy] | ICO Badalona [Badalona, Spain] | ICO l'Hospitalet [L'Hospitalet de Llobregat, Spain] | Clinico Universitario A Coruña [A Coruña, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Provincial de Castellón [Castellon, Spain] | Hospital Reina Sofia [Córdoba, Spain] | Hospital La Paz [Madrid, Spain] | Hospital Sant Joan de Reus [Reus, Spain] | Hospital Virgen del Rocío [Seville, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain] | Hospital Universitari i Politecnic La Fe [Valencia, Spain] | Instituto Valenciano de Oncología - IVO [Valencia, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on the re-challenge of Palbociclib in patients who have previously been treated with it, indicating an extension of its indication for use in a specific patient population (ER-positive metastatic breast cancer) rather than testing a new medicine.",OTHER,False,2020.0,5.0,1,Phase 2
NCT03186937,A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer,A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer,TERMINATED,PHASE2,"University of Wisconsin, Madison",2017-08-10,2019-06-21,2019-06-21,2017-06-14,2021-08-18,['Change in cell surface expression of TRAIL receptor-2'],"['Safety and tolerability of methionine measured by number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'Effect of methionine restriction on cancer stem cell markers CD44 and CD24', 'Change in plasma concentrations', 'Change in subject weight', 'Change in subject BMI', 'Change in subject waist circumference', 'Change in subject metabolic indices', 'Change in body composition']",,,,,1,United States,"University of Wisconsin Carbone Cancer Center [Madison, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study investigates the effects of methionine deprivation in a specific cancer type (Triple Negative Breast Cancer), indicating an extension of indication for an existing treatment approach rather than introducing a new medicine.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03188393,Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery,A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery,COMPLETED,PHASE2,NRG Oncology,2017-04-13,2019-07-05,2022-12-01,2017-06-15,2025-05-22,['Proportion of patients with pCR'],"['Improvement of negative predictive value', 'Incidence of adverse events associated with tumor bed biopsy', 'Number of needle cores performed', 'Proportion of clips retrieved', 'Residual cancer burden score', 'Trimodality imaging algorithm +/- biopsy as a predictor of pCR']",,,,,381,Canada; United States,"University of Alabama at Birmingham Cancer Center [Birmingham, United States] | University of South Alabama Mitchell Cancer Institute [Mobile, United States] | Cancer Center at Saint Joseph's [Phoenix, United States] | Banner University Medical Center - Tucson [Tucson, United States] | University of Arizona Cancer Center-North Campus [Tucson, United States] | Mercy Hospital Fort Smith [Fort Smith, United States] | Kaiser Permanente-Deer Valley Medical Center [Antioch, United States] | Sutter Auburn Faith Hospital [Auburn, United States] | Sutter Cancer Centers Radiation Oncology Services-Auburn [Auburn, United States] | Alta Bates Summit Medical Center-Herrick Campus [Berkeley, United States] | Mills-Peninsula Medical Center [Burlingame, United States] | Sutter Cancer Centers Radiation Oncology Services-Cameron Park [Cameron Park, United States] | Eden Hospital Medical Center [Castro Valley, United States] | Sutter Davis Hospital [Davis, United States] | Epic Care-Dublin [Dublin, United States] | Bay Area Breast Surgeons Inc [Emeryville, United States] | Epic Care Partners in Cancer Care [Emeryville, United States] | Kaiser Permanente-Fremont [Fremont, United States] | Palo Alto Medical Foundation-Fremont [Fremont, United States] | Fresno Cancer Center [Fresno, United States] | Kaiser Permanente-Fresno [Fresno, United States] | Los Angeles County-USC Medical Center [Los Angeles, United States] | USC / Norris Comprehensive Cancer Center [Los Angeles, United States] | Contra Costa Regional Medical Center [Martinez, United States] | Memorial Medical Center [Modesto, United States] | Kaiser Permanente-Modesto [Modesto, United States] | Palo Alto Medical Foundation-Camino Division [Mountain View, United States] | Palo Alto Medical Foundation-Gynecologic Oncology [Mountain View, United States] | Sutter Cancer Research Consortium [Novato, United States] | Alta Bates Summit Medical Center - Summit Campus [Oakland, United States] | Bay Area Tumor Institute [Oakland, United States] | Kaiser Permanente Oakland-Broadway [Oakland, United States] | Kaiser Permanente-Oakland [Oakland, United States] | Palo Alto Medical Foundation Health Care [Palo Alto, United States] | Stanford Cancer Institute Palo Alto [Palo Alto, United States] | Keck Medical Center of USC Pasadena [Pasadena, United States] | Kaiser Permanente-Rancho Cordova Cancer Center [Rancho Cordova, United States] | Kaiser Permanente-Redwood City [Redwood City, United States] | Kaiser Permanente-Richmond [Richmond, United States] | Rohnert Park Cancer Center [Rohnert Park, United States] | Kaiser Permanente-Roseville [Roseville, United States] | Sutter Cancer Centers Radiation Oncology Services-Roseville [Roseville, United States] | Sutter Roseville Medical Center [Roseville, United States] | The Permanente Medical Group-Roseville Radiation Oncology [Roseville, United States] | Kaiser Permanente Downtown Commons [Sacramento, United States] | Sutter Medical Center Sacramento [Sacramento, United States] | Kaiser Permanente-South Sacramento [Sacramento, United States] | South Sacramento Cancer Center [Sacramento, United States] | Kaiser Permanente - Sacramento [Sacramento, United States] | Naval Medical Center -San Diego [San Diego, United States] | California Pacific Medical Center-Pacific Campus [San Francisco, United States] | Kaiser Permanente-San Francisco [San Francisco, United States] | Kaiser Permanente-Santa Teresa-San Jose [San Jose, United States] | Kaiser Permanente San Leandro [San Leandro, United States] | Kaiser Permanente-San Rafael [San Rafael, United States] | Kaiser San Rafael-Gallinas [San Rafael, United States] | Kaiser Permanente Medical Center - Santa Clara [Santa Clara, United States] | Palo Alto Medical Foundation-Santa Cruz [Santa Cruz, United States] | Kaiser Permanente-Santa Rosa [Santa Rosa, United States] | Sutter Pacific Medical Foundation [Santa Rosa, United States] | Kaiser Permanente Cancer Treatment Center [South San Francisco, United States] | Kaiser Permanente-South San Francisco [South San Francisco, United States] | Kaiser Permanente-Stockton [Stockton, United States] | Palo Alto Medical Foundation-Sunnyvale [Sunnyvale, United States] | Sutter Cancer Centers Radiation Oncology Services-Vacaville [Vacaville, United States] | Kaiser Permanente Medical Center-Vacaville [Vacaville, United States] | Kaiser Permanente-Vallejo [Vallejo, United States] | Sutter Solano Medical Center/Cancer Center [Vallejo, United States] | Kaiser Permanente-Walnut Creek [Walnut Creek, United States] | Epic Care Cyberknife Center [Walnut Creek, United States] | Rocky Mountain Cancer Centers-Aurora [Aurora, United States] | University of Colorado Hospital [Aurora, United States] | Boulder Community Hospital [Boulder, United States] | Rocky Mountain Cancer Centers-Boulder [Boulder, United States] | Denver Health Medical Center [Denver, United States] | National Jewish Health-Main Campus [Denver, United States] | The Women's Imaging Center [Denver, United States] | Colorado Blood Cancer Institute [Denver, United States] | Presbyterian - Saint Lukes Medical Center - Health One [Denver, United States] | Rocky Mountain Cancer Centers-Midtown [Denver, United States] | SCL Health Saint Joseph Hospital [Denver, United States] | Rocky Mountain Cancer Centers-Rose [Denver, United States] | Rose Medical Center [Denver, United States] | Western Surgical Care [Denver, United States] | Mountain Blue Cancer Care Center - Swedish [Englewood, United States] | Swedish Medical Center [Englewood, United States] | Poudre Valley Hospital [Fort Collins, United States] | National Jewish Health-Western Hematology Oncology [Golden, United States] | Saint Mary's Hospital and Regional Medical Center [Grand Junction, United States] | Grand Valley Oncology [Grand Junction, United States] | North Colorado Medical Center [Greeley, United States] | Good Samaritan Medical Center [Lafayette, United States] | Rocky Mountain Cancer Centers-Littleton [Littleton, United States] | Rocky Mountain Cancer Centers-Sky Ridge [Lone Tree, United States] | McKee Medical Center [Loveland, United States] | National Jewish Health-Northern Hematology Oncology [Thornton, United States] | SCL Health Lutheran Medical Center [Wheat Ridge, United States] | Smilow Cancer Center/Yale-New Haven Hospital [New Haven, United States] | Yale University [New Haven, United States] | Beebe Medical Center [Lewes, United States] | Delaware Clinical and Laboratory Physicians PA [Newark, United States] | Helen F Graham Cancer Center [Newark, United States] | Medical Oncology Hematology Consultants PA [Newark, United States] | Christiana Care Health System-Christiana Hospital [Newark, United States] | Beebe Health Campus [Rehoboth Beach, United States] | TidalHealth Nanticoke / Allen Cancer Center [Seaford, United States] | Christiana Care Health System-Wilmington Hospital [Wilmington, United States] | John Fitzgerald Kennedy Medical Center [Atlantis, United States] | University of Florida Health Science Center - Gainesville [Gainesville, United States] | Memorial Regional Hospital/Joe DiMaggio Children's Hospital [Hollywood, United States] | Orlando Health Cancer Institute [Orlando, United States] | Memorial Hospital West [Pembroke Pines, United States] | Emory University Hospital Midtown [Atlanta, United States] | Piedmont Hospital [Atlanta, United States] | Emory University Hospital/Winship Cancer Institute [Atlanta, United States] | Emory Saint Joseph's Hospital [Atlanta, United States] | Dekalb Medical Center [Decatur, United States] | Piedmont Fayette Hospital [Fayetteville, United States] | Medical Center of Central Georgia [Macon, United States] | Hawaii Cancer Care Inc - Waterfront Plaza [Honolulu, United States] | Island Urology [Honolulu, United States] | Queen's Cancer Cenrer - POB I [Honolulu, United States] | Queen's Medical Center [Honolulu, United States] | Straub Clinic and Hospital [Honolulu, United States] | University of Hawaii Cancer Center [Honolulu, United States] | Hawaii Cancer Care Inc-Liliha [Honolulu, United States] | Kuakini Medical Center [Honolulu, United States] | Queen's Cancer Center - Kuakini [Honolulu, United States] | The Cancer Center of Hawaii-Liliha [Honolulu, United States] | Kaiser Permanente Moanalua Medical Center [Honolulu, United States] | Kapiolani Medical Center for Women and Children [Honolulu, United States] | Wilcox Memorial Hospital and Kauai Medical Clinic [Lihue, United States] | Hawaii Cancer Care - Westridge [‘Aiea, United States] | Pali Momi Medical Center [‘Aiea, United States] | Queen's Cancer Center - Pearlridge [‘Aiea, United States] | The Cancer Center of Hawaii-Pali Momi [‘Aiea, United States] | Saint Alphonsus Cancer Care Center-Boise [Boise, United States] | Saint Alphonsus Cancer Care Center-Caldwell [Caldwell, United States] | Kootenai Health - Coeur d'Alene [Coeur d'Alene, United States] | Walter Knox Memorial Hospital [Emmett, United States] | Idaho Urologic Institute-Meridian [Meridian, United States] | Saint Alphonsus Cancer Care Center-Nampa [Nampa, United States] | Kootenai Clinic Cancer Services - Post Falls [Post Falls, United States] | Kootenai Cancer Clinic [Sandpoint, United States] | Rush - Copley Medical Center [Aurora, United States] | Northwestern University [Chicago, United States] | John H Stroger Jr Hospital of Cook County [Chicago, United States] | Rush University Medical Center [Chicago, United States] | University of Chicago Comprehensive Cancer Center [Chicago, United States] | Carle at The Riverfront [Danville, United States] | Carle Physician Group-Effingham [Effingham, United States] | Northwestern Medicine Lake Forest Hospital [Lake Forest, United States] | Carle Physician Group-Mattoon/Charleston [Mattoon, United States] | Loyola University Medical Center [Maywood, United States] | Marjorie Weinberg Cancer Center at Loyola-Gottlieb [Melrose Park, United States] | Trinity Medical Center [Moline, United States] | Good Samaritan Regional Health Center [Mount Vernon, United States] | UC Comprehensive Cancer Center at Silver Cross [New Lenox, United States] | University of Chicago Medicine-Orland Park [Orland Park, United States] | Carle Cancer Center [Urbana, United States] | The Carle Foundation Hospital [Urbana, United States] | Rush-Copley Healthcare Center [Yorkville, United States] | Deaconess Clinic Downtown [Evansville, United States] | Parkview Hospital Randallia [Fort Wayne, United States] | Parkview Regional Medical Center [Fort Wayne, United States] | Goshen Center for Cancer Care [Goshen, United States] | Chancellor Center for Oncology [Newburgh, United States] | University of Iowa/Holden Comprehensive Cancer Center [Iowa City, United States] | Coffeyville Regional Medical Center [Coffeyville, United States] | Central Care Cancer Center - Garden City [Garden City, United States] | Central Care Cancer Center - Great Bend [Great Bend, United States] | HaysMed University of Kansas Health System [Hays, United States] | University of Kansas Cancer Center [Kansas City, United States] | Kansas Institute of Medicine Cancer and Blood Center [Lenexa, United States] | Minimally Invasive Surgery Hospital [Lenexa, United States] | Olathe Health Cancer Center [Olathe, United States] | Menorah Medical Center [Overland Park, United States] | University of Kansas Cancer Center-Overland Park [Overland Park, United States] | University of Kansas Hospital-Indian Creek Campus [Overland Park, United States] | Ascension Via Christi - Pittsburg [Pittsburg, United States] | Salina Regional Health Center [Salina, United States] | University of Kansas Health System Saint Francis Campus [Topeka, United States] | University of Kansas Hospital-Westwood Cancer Center [Westwood, United States] | Louisiana State University Health Science Center [New Orleans, United States] | University Medical Center New Orleans [New Orleans, United States] | Anne Arundel Medical Center [Annapolis, United States] | Greater Baltimore Medical Center [Baltimore, United States] | UM Upper Chesapeake Medical Center [Bel Air, United States] | Lahey Hospital and Medical Center [Burlington, United States] | Winchester Hospital [Winchester, United States] | Henry Ford Cancer Institute-Downriver [Brownstown, United States] | Henry Ford Macomb Hospital-Clinton Township [Clinton Township, United States] | Henry Ford Medical Center-Fairlane [Dearborn, United States] | Henry Ford Hospital [Detroit, United States] | Allegiance Health [Jackson, United States] | Henry Ford Medical Center-Columbus [Novi, United States] | Henry Ford West Bloomfield Hospital [West Bloomfield, United States] | Sanford Joe Lueken Cancer Center [Bemidji, United States] | Fairview Ridges Hospital [Burnsville, United States] | Cambridge Medical Center [Cambridge, United States] | Mercy Hospital [Coon Rapids, United States] | Fairview Southdale Hospital [Edina, United States] | Unity Hospital [Fridley, United States] | Fairview Clinics and Surgery Center Maple Grove [Maple Grove, United States] | Minnesota Oncology Hematology PA-Maplewood [Maplewood, United States] | Saint John's Hospital - Healtheast [Maplewood, United States] | Abbott-Northwestern Hospital [Minneapolis, United States] | Hennepin County Medical Center [Minneapolis, United States] | Health Partners Inc [Minneapolis, United States] | Monticello Cancer Center [Monticello, United States] | New Ulm Medical Center [New Ulm, United States] | North Memorial Medical Health Center [Robbinsdale, United States] | Mayo Clinic in Rochester [Rochester, United States] | Park Nicollet Clinic - Saint Louis Park [Saint Louis Park, United States] | Regions Hospital [Saint Paul, United States] | United Hospital [Saint Paul, United States] | Saint Francis Regional Medical Center [Shakopee, United States] | Lakeview Hospital [Stillwater, United States] | Ridgeview Medical Center [Waconia, United States] | Rice Memorial Hospital [Willmar, United States] | Minnesota Oncology Hematology PA-Woodbury [Woodbury, United States] | Fairview Lakes Medical Center [Wyoming, United States] | Saint Louis Cancer and Breast Institute-Ballwin [Ballwin, United States] | Central Care Cancer Center - Bolivar [Bolivar, United States] | Cox Cancer Center Branson [Branson, United States] | Siteman Cancer Center at Saint Peters Hospital [City of Saint Peters, United States] | Siteman Cancer Center at West County Hospital [Creve Coeur, United States] | Centerpoint Medical Center LLC [Independence, United States] | Freeman Health System [Joplin, United States] | Mercy Hospital Joplin [Joplin, United States] | Truman Medical Centers [Kansas City, United States] | The University of Kansas Cancer Center-South [Kansas City, United States] | Research Medical Center [Kansas City, United States] | University of Kansas Cancer Center - North [Kansas City, United States] | University of Kansas Cancer Center - Lee's Summit [Lee's Summit, United States] | Delbert Day Cancer Institute at PCRMC [Rolla, United States] | Mercy Clinic-Rolla-Cancer and Hematology [Rolla, United States] | Heartland Regional Medical Center [Saint Joseph, United States] | Mercy Hospital Springfield [Springfield, United States] | CoxHealth South Hospital [Springfield, United States] | Saint Louis Cancer and Breast Institute-South City [St Louis, United States] | Washington University School of Medicine [St Louis, United States] | Mercy Hospital South [St Louis, United States] | Siteman Cancer Center-South County [St Louis, United States] | Siteman Cancer Center at Christian Hospital [St Louis, United States] | Mercy Hospital Saint Louis [St Louis, United States] | Mercy Hospital Washington [Washington, United States] | Community Hospital of Anaconda [Anaconda, United States] | Billings Clinic Cancer Center [Billings, United States] | Saint Vincent Healthcare [Billings, United States] | Saint Vincent Frontier Cancer Center [Billings, United States] | Bozeman Deaconess Hospital [Bozeman, United States] | Saint James Community Hospital and Cancer Treatment Center [Butte, United States] | Benefis Healthcare- Sletten Cancer Institute [Great Falls, United States] | Great Falls Clinic [Great Falls, United States] | Saint Peter's Community Hospital [Helena, United States] | Kalispell Regional Medical Center [Kalispell, United States] | Community Medical Hospital [Missoula, United States] | The Cancer Institute of New Jersey Hamilton [Hamilton, United States] | Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital [New Brunswick, United States] | Rutgers Cancer Institute of New Jersey [New Brunswick, United States] | University of New Mexico Cancer Center [Albuquerque, United States] | Roswell Park Cancer Institute [Buffalo, United States] | Mount Sinai Union Square [New York, United States] | Mount Sinai West [New York, United States] | Mount Sinai Hospital [New York, United States] | State University of New York Upstate Medical University [Syracuse, United States] | SUNY Upstate Medical Center-Community Campus [Syracuse, United States] | Montefiore Medical Center-Einstein Campus [The Bronx, United States] | Montefiore Medical Center-Weiler Hospital [The Bronx, United States] | Montefiore Medical Center - Moses Campus [The Bronx, United States] | UNC Lineberger Comprehensive Cancer Center [Chapel Hill, United States] | Carolinas Medical Center/Levine Cancer Institute [Charlotte, United States] | Atrium Health Pineville/LCI-Pineville [Charlotte, United States] | Duke University Medical Center [Durham, United States] | Wake Forest University at Elkin [Elkin, United States] | Wake Forest University at Lexington [Lexington, United States] | Atrium Health Union/LCI-Union [Monroe, United States] | Wake Forest University at Mount Airy [Mount Airy, United States] | Wake Forest University Health Sciences [Winston-Salem, United States] | Sanford Bismarck Medical Center [Bismarck, United States] | Sanford Broadway Medical Center [Fargo, United States] | Sanford Roger Maris Cancer Center [Fargo, United States] | UHHS-Chagrin Highlands Medical Center [Beachwood, United States] | Case Western Reserve University [Cleveland, United States] | Ohio State University Comprehensive Cancer Center [Columbus, United States] | UH Seidman Cancer Center at Saint John Medical Center [Westlake, United States] | UHHS-Westlake Medical Center [Westlake, United States] | University of Oklahoma Health Sciences Center [Oklahoma City, United States] | Mercy Hospital Oklahoma City [Oklahoma City, United States] | Saint Alphonsus Medical Center-Baker City [Baker City, United States] | Saint Alphonsus Medical Center-Ontario [Ontario, United States] | Jefferson Abington Hospital [Abington, United States] | UPMC-Heritage Valley Health System Beaver [Beaver, United States] | Christiana Care Health System-Concord Health Center [Chadds Ford, United States] | Ephrata Cancer Center [Ephrata, United States] | Ephrata Community Hospital [Ephrata, United States] | Adams Cancer Center [Gettysburg, United States] | UPMC Cancer Centers - Arnold Palmer Pavilion [Greensburg, United States] | Cherry Tree Cancer Center [Hanover, United States] | UPMC Pinnacle Harrisburg [Harrisburg, United States] | UPMC Pinnacle Cancer Center/Community Osteopathic Campus [Harrisburg, United States] | UPMC-Johnstown/John P. Murtha Regional Cancer Center [Johnstown, United States] | Sechler Family Cancer Center [Lebanon, United States] | UPMC Cancer Center at UPMC McKeesport [McKeesport, United States] | UPMC Hillman Cancer Center in Coraopolis [Moon Township, United States] | Allegheny General Hospital [Pittsburgh, United States] | UPMC-Magee Womens Hospital [Pittsburgh, United States] | UPMC-Presbyterian Hospital [Pittsburgh, United States] | UPMC-Saint Margaret [Pittsburgh, United States] | University of Pittsburgh Cancer Institute (UPCI) [Pittsburgh, United States] | UPMC-Shadyside Hospital [Pittsburgh, United States] | UPMC-Passavant Hospital [Pittsburgh, United States] | UPMC-Saint Clair Hospital Cancer Center [Pittsburgh, United States] | UPMC Cancer Center at UPMC Northwest [Seneca, United States] | UPMC Uniontown Hospital Radiation Oncology [Uniontown, United States] | UPMC Washington Hospital Radiation Oncology [Washington, United States] | Reading Hospital [West Reading, United States] | Wexford Health and Wellness Pavilion [Wexford, United States] | WellSpan Health-York Cancer Center [York, United States] | WellSpan Health-York Hospital [York, United States] | Women and Infants Hospital [Providence, United States] | Prisma Health Cancer Institute - Spartanburg [Boiling Springs, United States] | Prisma Health Cancer Institute - Easley [Easley, United States] | Prisma Health Cancer Institute - Butternut [Greenville, United States] | Prisma Health Cancer Institute - Faris [Greenville, United States] | Prisma Health Greenville Memorial Hospital [Greenville, United States] | Prisma Health Cancer Institute - Eastside [Greenville, United States] | Prisma Health Cancer Institute - Greer [Greer, United States] | Prisma Health Cancer Institute - Seneca [Seneca, United States] | Sanford Cancer Center Oncology Clinic [Sioux Falls, United States] | Avera Cancer Institute [Sioux Falls, United States] | Sanford USD Medical Center - Sioux Falls [Sioux Falls, United States] | Vanderbilt-Ingram Cancer Center Cool Springs [Franklin, United States] | Baptist Memorial Hospital and Cancer Center-Memphis [Memphis, United States] | Vanderbilt Breast Center at One Hundred Oaks [Nashville, United States] | Vanderbilt University/Ingram Cancer Center [Nashville, United States] | Houston Methodist Hospital [Houston, United States] | M D Anderson Cancer Center [Houston, United States] | Doctor's Hospital of Laredo [Laredo, United States] | Scott and White Healthcare Round Rock [Round Rock, United States] | Houston Methodist Sugar Land Hospital [Sugar Land, United States] | Scott and White Memorial Hospital [Temple, United States] | Farmington Health Center [Farmington, United States] | Huntsman Cancer Institute/University of Utah [Salt Lake City, United States] | South Jordan Health Center [South Jordan, United States] | Sentara Cancer Institute at Sentara CarePlex Hospital [Hampton, United States] | Sentara Leigh Hospital [Norfolk, United States] | Sentara Norfolk General Hospital [Norfolk, United States] | Virginia Commonwealth University/Massey Cancer Center [Richmond, United States] | Sentara Virginia Beach General Hospital [Virginia Beach, United States] | Sentara Princess Anne Hospital [Virginia Beach, United States] | United Hospital Center [Bridgeport, United States] | WVUH-Berkely Medical Center [Martinsburg, United States] | West Virginia University Healthcare [Morgantown, United States] | Camden Clark Medical Center [Parkersburg, United States] | Aurora Cancer Care-Southern Lakes VLCC [Burlington, United States] | Aurora Health Center-Fond du Lac [Fond du Lac, United States] | Aurora Health Care Germantown Health Center [Germantown, United States] | Aurora Cancer Care-Grafton [Grafton, United States] | Aurora BayCare Medical Center [Green Bay, United States] | Aurora Cancer Care-Kenosha South [Kenosha, United States] | Aurora Bay Area Medical Group-Marinette [Marinette, United States] | Aurora Cancer Care-Milwaukee [Milwaukee, United States] | Aurora Saint Luke's Medical Center [Milwaukee, United States] | Aurora Sinai Medical Center [Milwaukee, United States] | Cancer Center of Western Wisconsin [New Richmond, United States] | Vince Lombardi Cancer Clinic - Oshkosh [Oshkosh, United States] | Aurora Cancer Care-Racine [Racine, United States] | Vince Lombardi Cancer Clinic-Sheboygan [Sheboygan, United States] | Aurora Medical Center in Summit [Summit, United States] | Vince Lombardi Cancer Clinic-Two Rivers [Two Rivers, United States] | Aurora Cancer Care-Milwaukee West [Wauwatosa, United States] | Aurora West Allis Medical Center [West Allis, United States] | Cheyenne Regional Medical Center-West [Cheyenne, United States] | Billings Clinic-Cody [Cody, United States] | Welch Cancer Center [Sheridan, United States] | University Health Network-Princess Margaret Hospital [Toronto, Canada] | CHUM - Centre Hospitalier de l'Universite de Montreal [Montreal, Canada] | The Research Institute of the McGill University Health Centre (MUHC) [Montreal, Canada] | Jewish General Hospital [Montreal, Canada]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,1,Phase 2
NCT03194997,Pilates and Dance to Breast Cancer Patients Undergoing Treatment,Pilates and Dance to Breast Cancer Patients Undergoing Treatment: MoveMama Project,COMPLETED,,Laboratório de Pesquisa em Lazer e Atividade Física,2018-01-01,2019-12-10,2020-12-30,2017-06-22,2021-06-14,['Perception of Quality of life'],"['Depressive Symptoms', 'Body image', 'Self-Esteem', 'Optimism', 'Stress', 'Fatigue', 'Sexual function', 'Sleep Quality', 'Pain level', 'Cardiorespiratory fitness', 'Physical Activity', 'Upper limb function', 'Muscular Strength', 'Range of motion', 'Posture', 'Flexibility', 'Balance', 'Lymphedema', 'Cardiorrespiratory fitness']",,,,,1,Brazil,"Santa Catarina State University [Florianópolis, Brazil]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a project involving Pilates and dance for breast cancer patients, focusing on quality of life and various health metrics, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03195192,Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer,Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer,COMPLETED,,Side-Out Foundation,2017-03-09,2020-06-30,2020-06-30,2017-06-22,2020-07-01,['Evaluate baseline phosphorylated RB levels in tumor tissue as a predictive marker of response to palbociclib or ribociclib as first line treatment for ER+/HER2- metastatic breast cancer'],"['Evaluate baseline biomarkers which are direct substrates of CDK 4/6 or controlled secondarily by CDK 4/6 kinase activity as qualifying predictive markers of response to CDK 4/6 inhibitors as first line treatment for ER+/HER2- metastatic breast cancer', 'Evaluate tumor tissue collected at time of disease progression, for post CDK 4/6 inhibitor treatment changes in biomarkers which are either direct substrates of Cyclin Dependent (CDK) 4/6 kinase or controlled secondarily by CDK 4/6 kinase activity.', 'Evaluate tumor tissue collected at time of disease progression for measurement of the activation state signaling pathways that are known markers for endocrine resistance (e.g. AKT-mTOR signaling).', 'Determine frequency when ""multi-omic"" profiling: proteomic and genomic profiling analysis of patient\'s tumor yields a target against which there is an FDA-approved agent or therapeutic regimen.', ""Determine percent of time multiomic profiling based treatment recommendation is different than treatment selected by the patient's physician once a patient shows progression after first line treatment with palbociclib or ribociclib""]",,,,,8,United States,"University of Alabama at Birmingham [Birmingham, United States] | Cedars-Sinai Medical Center [Los Angeles, United States] | UHealth/Sylvester Comprehensive Cancer Center [Miami, United States] | Abramson Cancer Center Perelman Center for Advanced Medicine [Philadelphia, United States] | Thomas Jefferson University Sidney Kimmel Cancer Center [Philadelphia, United States] | Women & Infants Hospital of Rhode Island [Providence, United States] | Virginia Cancer Specialists [Fairfax, United States] | University of Washington [Seattle, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03195322,Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction,The Use of Complete AlloDerm® Coverage in Two-stage Tissue Expansion and Implant Placement in the Subcutaneous (Pre-pectoral) Plane: a Prospective Pilot,COMPLETED,,Johns Hopkins University,2017-10-01,2021-11-30,2021-12-10,2017-06-22,2021-12-16,['Evaluation of Postoperative Static Pain Score in patients receiving pre-pectoral Tissue Expander placement for Breast Reconstruction using Visual Analog Scale (VAS)'],"['Evaluation of Postoperative Dynamic Pain Score in patients receiving pre-pectoral Tissue Expander placement for Breast Reconstruction using VAS', 'Evaluation of Postoperative Static Pain Score in patients receiving pre-pectoral Tissue Expander placement for Breast Reconstruction using VAS', 'Evaluation of Postoperative Static Pain Score in patients receiving pre-pectoral Tissue Expander placement for Breast Reconstruction using ""BPI-SF"" questionnaire', 'Level of Postoperative opioid use after Mastectomy and Tissue Expander', 'Number of participants with postoperative vomiting after Mastectomy and Tissue Expander placement using the PONV Intensity Scale', 'Number of participants with postoperative nausea after Mastectomy and Tissue Expander placement using the PONV Intensity Scale', 'Evaluation of Postoperative Quality of Life scores of patients receiving tissue expander placement by using Breast-Q questionnaire', 'Evaluation of Changes in Postoperative Quality of Life scores of patients receiving tissue expander placement by using Breast-Q questionnaire', 'Evaluation of Postoperative Quality of Life scores of patients receiving tissue expander placement by using SF-36 questionnaire', 'Evaluation of Changes in Postoperative Quality of Life scores of patients receiving tissue expander placement by using SF-36 questionnaire', 'Number of participants with any postoperative complication following mastectomy and tissue expander placement based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0', 'Level of Postoperative opioid use after final breast reconstruction', 'Number of participants with postoperative vomiting after final breast reconstruction using the PONV Intensity Scale', 'Number of participants with postoperative nausea after final breast reconstruction using the PONV Intensity Scale', 'Evaluation of Postoperative Quality of Life scores of patients receiving final breast reconstruction with permanent implant by using Breast-Q questionnaire', 'Evaluation of Changes in Postoperative Quality of Life scores of patients receiving final breast reconstruction by using Breast-Q questionnaire', 'Evaluation of Postoperative Quality of Life scores of patients receiving final breast reconstruction by using SF-36 questionnaire', 'Evaluation of Changes in Postoperative Quality of Life scores of patients receiving final breast reconstruction by using SF-36 questionnaire', 'Number of participants with any postoperative complication following final breast reconstruction based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0', 'Number of participants with postoperative breast animation deformity assessed by Spear grading system and ""VECTRA XT 3D""', 'Evaluation of Hospital Length of Stay after final reconstruction in days', 'Evaluation of Postoperative Static Pain Score in patients receiving final Breast Reconstruction using Visual Analog Scale (VAS)', 'Evaluation of Postoperative Dynamic Pain Score in patients receiving final Breast Reconstruction using Visual Analog Scale (VAS)', 'Evaluation of Postoperative Static Pain Score in patients receiving final Breast Reconstruction using BPI-SF']",,,,,1,United States,"The Johns Hopkins University [Baltimore, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT03196037,Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors,Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors,COMPLETED,,UNC Lineberger Comprehensive Cancer Center,2017-12-05,2018-12-07,2018-12-07,2017-06-22,2019-03-07,"['Feasibility - Attendance', 'Feasibility Pre-Test Completion', 'Feasibility Post-Test Completion']","['Recruitment - Frequency Approached for Screening', 'Recruitment - Proportion of Completed Screening', 'Recruitment - Screened Eligible', 'Retention Rate', 'Recruitment - Enrollment Refusal', 'Retention - Withdrawals', 'Feasibility of the Different Recruitment Strategies - Screened', 'Feasibility of the Different Recruitment Strategies - Screened Eligible', 'Feasibility of the Different Recruitment Strategies - Enrolled', 'Expectancy/Credibility', 'Acceptability', 'Intervention Satisfaction Questionnaire']",,,,,1,United States,"UNC Chapel Hill Program on Integrative Medicine [Chapel Hill, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a feasibility study of a Tai Chi Chuan intervention for breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03199586,Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies,"First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies",COMPLETED,PHASE1,"Novita Pharmaceuticals, Inc.",2017-12-21,2020-05-07,2020-05-07,2017-06-27,2025-07-20,['Establish the safe recommended phase 2 dose'],"['Identify and characterize preliminary anti tumor activity', 'Characterize the pharmacokinetics of NP-G2-044', 'Tmax', 'Cmax']",,,,,3,United States,"HonorHealth Research Institute [Scottsdale, United States] | City of Hope National Medical Center [Duarte, United States] | Memorial Sloan Kettering Hospital [New York, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03200639,Cachexia in Gynecological Cancer and the Preventive Role of Weight Training,"Comparison of High Intensity Interval Body Weight Training Versus Combined Training on Body Composition, Physical Function, Metabolic Risk and Inflammation in Postmenopausal Women With and Without Gynecological Cancer",COMPLETED,,Universidade Federal do Triangulo Mineiro,2015-05-30,2015-12-01,2015-12-10,2017-06-27,2017-06-27,"['Body composition', 'Muscle strength', 'Rate of force development (a critical component of muscle power)', 'Cardiorespiratory fitness', 'Short physical performance battery (SPPB)']","['Citokines', 'Quality of life', 'Hormones', 'Metabolic markers', 'Electromyography', 'Physical activity level', 'Nutrition habits', 'Functional capacity']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effects of weight training on various health parameters in postmenopausal women with and without gynecological cancer, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2015.0,10.0,0,NA/Other
NCT03202446,Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer,Phase 3 Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT) System in Advanced Breast Cancer,TERMINATED,PHASE3,Eske Corporation S.A.C,2016-06-13,2018-01,2018-01,2017-06-28,2018-02-23,['Overall Response Rate'],"['Overall Survival', 'Relative change in overall tumor burden', 'Health Related Quality of Life (HRQOL)']",,,,,4,Peru,"Clinica Ricardo Palma [Lima, Peru] | Hospital Maria Auxiliadora [Lima, Peru] | Hospital Nacional Arzobispo Loayza [Lima, Peru] | Hospital Nacional Guillermo Almenara Irigoyen [Lima, Peru]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial evaluates a new treatment method (Laser-Assisted Immunotherapy) for advanced breast cancer, indicating it is a new medicine.",INDUSTRY,False,2018.0,7.0,0,Phase 3
NCT03205176,"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas",COMPLETED,PHASE1,AstraZeneca,2017-06-30,2021-03-01,2021-04-08,2017-07-02,2021-05-06,['Incidence of dose-limiting toxicity (DLT).'],"['Peak plasma concentration (Cmax)', 'The urine concentration of AZD5153 and its co-former (if appropriate).', 'The effect of AZD 5153 on QTc interval.', 'Antitumor activity of AZD5153 in patients by assessing the disease control rate (DCR).', 'Antitumor activity of AZD5153 in patients by assessing progression free survival (PFS).', 'Antitumor activity of AZD5153 in patients by assessing overall response rate (ORR).', 'Antitumor activity of AZD5153 in patients by assessing duration of response (DoR).', 'Area under the plasma concentration versus time curve (AUC).', 'Time to reach peak plasma concentration (tmax).', 'Elimination half-lfe (t1/2).', 'Volume of distribution (Vd).', 'Clearance (CL).']",,,,,4,Canada; United States,"Research Site [Sarasota, United States] | Research Site [Oklahoma City, United States] | Research Site [Nashville, United States] | Research Site [Toronto, Canada]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03207594,Improving Evidence-Based Care for Cancer Patients,Improving Evidence-Based Care for Cancer Patients,COMPLETED,,Medical University of South Carolina,2016-09-01,2019-05-01,2020-03-01,2017-07-05,2025-01-31,"['Number of patients with biochemically confirmed smoking cessation', 'Number of patient who self-report smoking cessation']","['Average weekly smoke exposure', 'Number of patients who participate in smoking cessation', 'Compliance with smoking cessation']",,,,,1,United States,"Medical University of South Carolina [Charleston, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses improving evidence-based care for cancer patients with a focus on smoking cessation metrics, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03210129,Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients,"Motivational Interviewing to Increase Physical Activity Behaviour in Breast, Endometrial and Colorectal Cancer Patients in the Grand-Duchy of Luxembourg: a Pilot Randomized Controlled Trial",COMPLETED,,Luxembourg Institute of Health,2017-07-06,2019-02-28,2019-02-28,2017-07-06,2019-03-14,['Change in physical activity behavior'],"['Body mass index', 'Ramped Bruce Protocol test', '30 seconds chair test', 'Southampton protocol', 'Cost-effectiveness of the intervention']",,,,,1,Luxembourg,"Luxembourg Institute for Health [Luxembourg, Luxembourg]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial focused on a behavioral intervention (Motivational Interviewing) to increase physical activity in cancer patients, rather than testing a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2019.0,6.0,0,NA/Other
NCT03210974,Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM Group,Retrospective Observational Study About the Evolution of Patients With Breast Cancer in Hospitals From the GEICAM Group (2002 - 2005). ALAMO IV,COMPLETED,,Spanish Breast Cancer Research Group,2016-06-03,2021-03-01,2021-03-01,2017-07-07,2023-03-06,"['Study demographic', 'Study clinical and anatomic-pathological']","['Evolution of Breast Cancer in terms of frequency', 'Evolution of Breast Cancer in terms of type', 'Evolution of Breast Cancer in terms of location of relapse', 'Family history of Breast Cancer', 'Characteristics of family history of Breast Cancer', 'Differences in Breast Cancer between sex', 'Quantify the influence of type of surgery conducted on primary tumor', 'Number of patients with metastatic disease as first diagnosis', 'Quantify the prevalence of breast cancer related to pregnancy']",,,,,41,Spain,"Hospital General Universitario de Elche [Elche, Spain] | Hospital General Universitario de Elda - Virgen de la Salud [Elda, Spain] | Hospital Universitario Germans Trias i Pujol [Badalona, Spain] | Hospital General de Granollers [Granollers, Spain] | Hospital de Mataró-Consorci Sanitari del Maresme [Mataró, Spain] | Corporació Sanitaria Parc Taulí [Sabadell, Spain] | Consorci Sanitari de Terrassa [Terrassa, Spain] | Onkologikoa [Donostia / San Sebastian, Spain] | Hospital Universitario de Donostia [Donostia / San Sebastian, Spain] | Hospital Universitario de Gran Canaria Doctor Negrín [Las Palmas de Gran Canaria, Spain] | Hospital Universitario Fundación Alrcorcón [Alcorcón, Spain] | Hospital Universitario de Fuenlabrada [Fuenlabrada, Spain] | Hospital Universitario Puerta de Hierro de Majadahonda [Majadahonda, Spain] | Clínica Universidad de Navarra [Pamplona, Spain] | Hospital Universitario Central de Asturias [Oviedo, Spain] | Hospital Universitario Canarias [San Cristóbal de La Laguna, Spain] | Hospital Virgen de los Lirios [Alcoy, Spain] | Hospital Universitario de Basurto [Bilbao, Spain] | Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] | Centro Oncológico de Galicia [A Coruña, Spain] | Complejo Hospitalario de Albacete [Albacete, Spain] | Hospital General Universitario de Alicante [Alicante, Spain] | Hospital Nuestra Señora de Sonsoles [Ávila, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Clinic i Provincial [Barcelona, Spain] | Hospital Universitario Puerta del Mar [Cadiz, Spain] | Hospital General Virgen de la Luz [Cuenca, Spain] | Hospital Josep Trueta [Girona, Spain] | Hospital Universitario Lucus Augusti [Lugo, Spain] | Hospital Universitario La Prinesa [Madrid, Spain] | Hospital General Universitario Gregorio Marañón [Madrid, Spain] | Hospital Clínico Universitario Virgen de la Arrixaca [Murcia, Spain] | Complejo Hospitalario Universitario de Ourense [Ourense, Spain] | Hospital Universitario Virgen de la Salud [Toledo, Spain] | Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Hospital General Universitario de Valencia [Valencia, Spain] | Hospital Universitario Dr. Peset [Valencia, Spain] | Hospital Universitari i Politécnic La Fe [Valencia, Spain] | Hospital Clínico Universitario de Zaragoza Lozano Blesa [Zaragoza, Spain] | Hospital Universitario Miguel Servet [Zaragoza, Spain]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a retrospective observational study focused on the evolution of breast cancer in patients, without indicating the introduction of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03220178,Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy,"PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant",TERMINATED,PHASE4,Palleos Healthcare GmbH,2017-07-24,2021-12-07,2021-12-07,2017-07-18,2022-01-06,['DQoL'],"['Progression-free survival', 'Overall survival', 'Drug intake', 'Global health status']",,,,,1,Germany,"University Hospital Mainz [Mainz, Germany]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the impact of eHealth support on quality of life in patients already treated with Palbociclib, indicating it is an extension of indication rather than a new medicine.",INDUSTRY,False,2021.0,4.0,0,Other
NCT03222258,Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients,"Change of Quality of Life, Treatment Decision and Utilization of Health Care Depending on the Use of Palliative Care in Adult and Pediatric Patients With Advanced Stage of Cancer: a Prospective Cohort Study",COMPLETED,,Seoul National University Hospital,2016-12-17,2019-10-31,2020-04-30,2017-07-19,2021-03-17,['Change from baseline Overall QOL of EORTC QLQ - Core 15 at 6 months items'],"['Patients survival and Physicians Orders for Life Sustaining Treatment (POLST) documentation', 'Patient Health Questionnaire-9', 'Decision Conflict Scale', 'Understanding the illness', 'Self-reported Health Status', 'KG-7(The Korean Cancer Study Group Geriatric Score)', 'Medical cost in KRW/person/month', 'Utilization of healthcare services', 'Preference of Advance care and Palliative care', 'Mcgill Quality of Life (MQOL)', 'Pediatric Quality of Life Inventory']",,,,,15,South Korea,"National Cancer Center, Korea [Goyang-si, South Korea] | Seoul National University Bundang Hospital [Seongnam-si, South Korea] | Gyeongsang National University Hospital [Jinju, South Korea] | Chonbuk National University Hospital [Jeonju, South Korea] | Chonnam National University Hwasun Hospital [Hwasun, South Korea] | Daegu Fatima Hospital [Daegu, South Korea] | Keimyung University Dongsan Medical Center [Daegu, South Korea] | Chungnam National University Hospital [Daejeon, South Korea] | Kyunghee University Medical Center [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital [Seoul, South Korea] | Kangdong Sacred Heart Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Ewha Womans University Mokdong Hospital [Seoul, South Korea] | Ulsan University Hospital [Ulsan, South Korea]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on the use of palliative care for advanced stage cancer patients, focusing on quality of life and healthcare utilization, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03227328,"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer.",COMPLETED,PHASE2,Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS,2017-08-02,2022-02-01,2022-07-01,2017-07-24,2024-11-07,['Progression Free Survival (PFS)'],"['EORTC QLQ-C30 quality of life between the 2 arms', 'QLQ-BR23 quality of life between the 2 arms', 'toxicity', 'time to treatment failure (TTF)', 'best objective response rate', 'duration of response', 'clinical benefit rate (CBR)', 'overall survival (OS)', 'Progression free survival (PFS)', 'correlative biomarkers of response to chemotherapy and endocrine therapy']",,,,,20,Italy,"U.O. Oncologia Medica, P.O. Bellaria-Maggiore [Bologna, Italy] | UO Oncologia Medica IRST IRCCS [Meldola, Italy] | Dip. Medicina Interna e Riabilitazione - U.O. Medicina Interna Oncologica, Ospedale Ramazzini [Carpi, Italy] | Dip. Oncologia-Ematologia - U.O. Oncologia Medica,Azienda USL di Piacenza - Ospedale Civile [Piacenza, Italy] | UOC Oncologia Medica AUSL Romagna-Ravenna [Ravenna, Italy] | UO Oncologia Medica AUSL Romagna-Rimini [Rimini, Italy] | A.O.U. Ospedali Riuniti Umberto I - GM Lancisi - G Salesi [Ancona, Italy] | U.O. Oncologia Medica; Ist. Tumori Giovanni Paolo II - IRCCS Osp. Oncologico di Bari [Bari, Italy] | Terapia Molecolare e Farmaco Genomica, Azienda Socio-Sanitaria Territoriale di Cremona [Cremona, Italy] | A.O.U. di Ferrara Arcispedale Sant'Anna [Ferrara, Italy] | Ospedale Civile di Guastalla - AUSL di Reggio Emilia [Guastalla, Italy] | AUSL Imola [Imola, Italy] | Ospedale Mater Salutis - Azienda ULSS9 Scaligera [Legnago, Italy] | Ospedale di Macerata, ASUR AV3 [Macerata, Italy] | A.O.U. Policlinico di Modena [Modena, Italy] | A.O.U. Maggiore della Carità di Novara [Novara, Italy] | U.O. Oncologia Medica, AOU di Parma [Parma, Italy] | A.O. Santa Maria della Misericordia di Perugia [Perugia, Italy] | A.O. Arcispedale S. Maria Nuova IRCCS di Reggio Emilia [Reggio Emilia, Italy] | Ospedale di Sondrio - ASST Valtellina e Alto Lario [Sondrio, Italy]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial compares existing treatments (CDK4/6 inhibitors and chemotherapy) in combination with endocrine therapy for a specific type of advanced breast cancer, indicating an extension of indication for these therapies rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT03229824,Use of Clorhexidine Dressings to Reduce Surgical Site Infections in Breast Cancer Surgery. A Controlled Clinical Trial,Randomized Controlled Trial to Reduce Surgical Site Infections in Breast Cancer Surgery With Clorhexidine Gluconate Securement Dressing (Tegaderm CHG),COMPLETED,,National Institute of Cancerología,2016-10-03,2018-04-30,2018-05-30,2017-07-26,2018-11-13,"['Number of subjects with drain bulb fluid bacterial colonization at the first and second week postoperative.', 'Number of subjects with drain tip bacterial colonization at removal.']",['Number of Subjects With Surgical Site Infection Within 30 Days'],,,,,1,Mexico,"Instituto Nacional de Cancerología [Mexico City, Mexico]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the use of Clorhexidine Dressings, which is an existing product, in a new context (breast cancer surgery) to reduce surgical site infections, indicating an extension of its indication.",OTHER_GOV,False,2018.0,7.0,0,NA/Other
NCT03233334,Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study),Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study),COMPLETED,,Allina Health System,2017-08-01,2018-08-01,2019-01-31,2017-07-28,2019-07-02,['Change in psychological well-being'],"['Recruitment', 'Time of pre-testing session', 'Time of testing session', 'Time of post-testing session', 'Homework completion', 'Intervention fidelity', 'Change in Meaning in life', 'Change in Satisfaction with Participation in Discretionary Social Activities', 'Engagement in Meaningful Activities', 'Purpose Status and Expectations', 'Participant Experience of Purpose Project']",,,,,1,United States,"Abbott Northwestern Hospital [Minneapolis, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study focused on psychological well-being and life purpose after breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03240224,Bioinformation Therapy for Breast Cancer,Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Breast Cancer,COMPLETED,PHASE2; PHASE3,"Fuda Cancer Hospital, Guangzhou",2017-09-02,2018-09-02,2018-09-02,2017-08-07,2019-01-25,['Relief degree of tumors'],"['Progress free survival（PFS）', 'Overall survival（OS）']",,,,,1,China,"Fuda cancer institute of Fuda cancer hospital [Guangzhou, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a new therapy approach (Bioinformation Therapy) for treating breast cancer, indicating it is a new medicine rather than an extension of an existing indication.",OTHER,False,2018.0,7.0,0,Phase 3
NCT03242239,A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects,"A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers",COMPLETED,PHASE1,"Alteogen, Inc.",2016-02-09,2016-08-04,2016-09-30,2017-08-08,2017-08-21,['AUC0-inf: area under the concentration-time curve from time zero to infinity'],"['AUC0-t: area under the concentration-time curve from time zero to the last non-zero concentration', 'Cmax: maximum observed concentration', 'Tmax: time of observed Cmax', 'Kel: apparent terminal elimination rate constant', 'T½ el: apparent terminal half-life', 'CL: apparent body clearance, calculated as Dose/AUC0-inf', 'Vd: apparent volume of distribution, calculated as Dose/(kel x AUC0-inf)']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2016.0,9.0,0,Phase 1
NCT03243331,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,COMPLETED,PHASE1,Kathy Miller,2018-01-19,2020-05-27,2020-05-27,2017-08-09,2021-01-07,['Safety of Gedatolisb + PTK7-ADC using NCI CTCAE v4.0'],"['Efficacy in all enrolled subjects', 'Overall response rate in all enrolled subjects', 'Progression free survival in all enrolled subjects', 'Pharmacodynamic determination of inhibition of PI3k signaling', 'Pharmacodynamic determination modulation of Wnt pathway', 'Pharmacodynamic determination modulation of Wnt pathway']",,,,,1,United States,"IU Simon Cancer Center [Indianapolis, United States]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Gedatolisib, which is being tested in combination with PTK7-ADC for a specific cancer type, indicating it is a new medicine being evaluated for safety and efficacy.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03243786,Stay on Track: A Study of Exercise Effects During Radiation,Stay on Track: A Pilot Study of the Effects of Exercise on Mitigating Side Effects and Altering Inflammatory Biomarker Profiles During Radiation Therapy for Breast Cancer,COMPLETED,,Medical College of Wisconsin,2017-04-12,2018-09-01,2018-10-31,2017-08-09,2021-11-30,['Percent time of personal fitness tracker use during the intervention period for the Stay on Track intervention arm'],"['Percent of participant retention thoughout the 12-week intervention through the six month follow-up', 'The percent of eligible patient who choose to take part in the study', 'Number of personal exercise sessions were attended by members in the Stay on Track Intervention Arm', 'Changes in lean soft tissue over the study period associated with intervention and activity', 'Changes in BMI (weight and height will be combined to report BMI in kg/m^2) over the study period associated with intervention and activity', 'Measures of physical activity (self-report and objective)', 'Dietary intake (assessed via Full Length Block Questionnaire)', 'Measures of fatigue (Piper Fatigue Scale Score and physician CTCAE v4.0 Scoring)', 'Measures of skin side effects (CTCAE v4.0 Scoring)', 'Quality of life (FACT-B Questionnaire) over the study period associated with intervention and activity', 'Measures of pain (PROMIS Scale v1.0- Pain Intensity 3a Questionnaire) over the study period associated with intervention and activity', 'Changes in biomarker (GM-CSF) associated with intervention and activity', 'Changes in biomarker (IFN-gamma) associated with intervention and activity', 'Changes in biomarker (IL-1alpha) associated with intervention and activity', 'Changes in biomarker (IL-1beta) associated with intervention and activity', 'Changes in biomarker (IL-4) associated with intervention and activity', 'Changes in biomarker (IL-6) associated with intervention and activity', 'Changes in biomarker (IL-8) associated with intervention and activity', 'Changes in biomarker (IL-10) associated with intervention and activity', 'Changes in biomarker (IL-12) associated with intervention and activity', 'Changes in biomarker (MCP-1) associated with intervention and activity', 'Changes in biomarker (TNF-alpha) associated with intervention and activity', 'Changes in biomarker (adiponectin) associated with intervention and activity', 'Changes in biomarker (leptin) associated with intervention and activity', 'Changes in biomarker (CRP) associated with intervention and activity', 'Changes in blood insulin level associated with intervention and activity', 'Changes in blood hemoglobin A1C level associated with intervention and activity', 'Changes in blood glucose level associated with intervention and activity']",,,,,1,United States,"Medical College of Wisconsin [Milwaukee, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the effects of exercise during radiation therapy for breast cancer, indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03243838,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,"Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET): A Multicenter, Single-arm, Phase II Trial",COMPLETED,PHASE2,Guangdong Provincial People's Hospital,2018-08-01,2021-10-13,2021-12-31,2017-08-09,2022-02-02,['The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0)'],"['Objective response rate (ORR)', 'Event-free survival (EFS)', 'Overall survival (OS)', 'Adverse events']",,,,,2,China,"Guangdong general hospital [Guangzhou, China] | Guangdong General Hospital [Guangzhou, China]",2018.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,Phase 2
NCT03244358,Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer,"Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phase II Study",TERMINATED,PHASE2,Sun Yat-sen University,2017-03-01,2020-12-01,2020-12-01,2017-08-09,2021-01-29,['Progression-free survival (PFS)'],"['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'Overall Survival']",,,,,1,China,"Sun Yat-sen University, Cancer Center [Guangzhou, China]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates Epalrestat, which is likely an existing drug, in a new context (metastatic triple-negative breast cancer), indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,Phase 2
NCT03244943,Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy,Effects of Non-surgical Periodontal Treatment on the Gingival Crevicular Fluid Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy,COMPLETED,,University of Sao Paulo,2015-08-01,2016-12-12,2017-07-31,2017-08-10,2020-06-22,['Cytokines'],['Correlation of cytokines'],,,,,0,,,2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses cytokine profiles in breast cancer patients undergoing chemotherapy and the effects of periodontal treatment, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03245788,Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study,Pilot Project to Better Understand Non-Clinical Needs of Cancer Patients,COMPLETED,,Stanford University,2017-02-15,2018-07-31,2018-12-31,2017-08-10,2019-04-08,"['Patient Experience/Satisfaction: Difference in topbox scores', 'Rates of unplanned hospitalization and ER visits']",['Utilization of non-treatment-related cancer services'],,,,,1,United States,"Stanford Cancer Center [Palo Alto, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a pilot study focused on non-clinical needs of cancer patients and does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2018.0,7.0,0,NA/Other
NCT03247478,Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure,Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure: a Prospective Observational Study Evaluating Response in Axillary Lymph Nodes of Breast Cancer After Neoadjuvant Chemotherapy,COMPLETED,,Peking University,2017-08-25,2019-06-19,2019-08-30,2017-08-11,2019-09-06,"['Sensitivity, specificity, positive-predictive value (PPV) and negative-predictive value (NPV) of Computed tomography (CT) reconstruction for axillary lymph node status after neoadjuvant chemotherapy.']",['Rreceiver operating characteristic (ROC) curve analysis'],,,,,1,China,"Peking University Cancer Hospital [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03248427,Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.,CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.,COMPLETED,PHASE2,SOLTI Breast Cancer Research Group,2017-07-13,2019-06-10,2019-07-20,2017-08-14,2021-03-17,['Rate of ROR-low according to the Prosigna test.'],"['Tumor Overall response rate (ORR)', 'pCR in the breast and axillary lymph nodes', 'PEPI Score', 'Residual Cancer Burden (RCB)', 'Rate of breast conserving surgery (BCS)', 'Decrease in Ki67 in both treatment arms.', 'Incidence, duration and severity of Adverse Events (AEs)']",,,,,21,Spain,"Hospital Clinic de Barcelona [Barcelona, Spain] | Hospital General de Catalunya [Barcelona, Spain] | Hospital Universitari Vall d' Hebron [Barcelona, Spain] | Institut Català d'Oncologia l'Hospitalet [Barcelona, Spain] | Consorcio Hospitalario Provincial de Castellón [Castelló, Spain] | Hospital San Pedro de Alcántara [Cáceres, Spain] | Fundació Privada Hospital Asil de Granollers [Granollers, Spain] | Centro Integral Oncologico Clara Campal [Madrid, Spain] | Centro Oncológico MD Anderson International España [Madrid, Spain] | Hospital Quirón Madrid [Madrid, Spain] | Hospital Rey Juan Carlos [Madrid, Spain] | Hospital Universitario 12 de octubre [Madrid, Spain] | Hospital Universitario Fundación de Alcorcón [Madrid, Spain] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hospital Universitari Son Espases [Palma, Spain] | Complexo Hospitalario Universitario de Santiago [Santiago de Compostela, Spain] | Hospital Virgen del Rocío [Seville, Spain] | Hospital Virgen Macarena [Seville, Spain] | Fundación Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Hospital Universitari Arnau de Vilanova de València [Valencia, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,0,Phase 2
NCT03250130,Hypnosis for Patients Treated With Adjuvant Chemotherapy for Breast Cancer(HYPNOVAL),Medical Ericksonian Hypnosis on Patients Treated With Adjuvant Chemotherapy for Breast Cancer at the ICM Val d'Aurelle - Montpellier: a Feasibility Study,COMPLETED,,Institut du Cancer de Montpellier - Val d'Aurelle,2015-07-01,2016-09-01,2017-06-06,2017-08-15,2020-08-10,['proportion of patients rated as being compliant to self-hypnosis'],['Impact of hypnosis on the tolerance of the CT'],,,,,1,France,"Institut régional du Cancer de montpellier [Montpellier, France]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2017.0,8.0,0,NA/Other
NCT03254654,Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer,"A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer (NAN Trail)",COMPLETED,PHASE2,Fudan University,2017-08-16,2021-08-01,2021-08-01,2017-08-18,2022-04-20,['PFS'],"['OS', 'ORR', 'Safety: Number of Participants with Adverse Events']",,,,,1,China,"Fudan University Cancer Hospital [Shanghai, China]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the combination of Vinorelbine and Apatinib in a specific patient population (advanced triple-negative breast cancer) as a treatment option, which suggests an extension of indication for existing drugs rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03254875,Rehabilitation After Breast Cancer,Individually Tailored Rehabilitation After Breast Cancer,COMPLETED,,Danish Cancer Society,2017-08-15,2021-03-31,2021-03-31,2017-08-21,2021-08-27,['Distress'],"['Distress', 'Distress', 'Distress', 'Depression', 'Depression', 'Depression', 'Depression', 'Anxiety', 'Anxiety', 'Anxiety', 'Anxiety', 'Health related quality of life summary index', 'Health related quality of life summary index', 'Health related quality of life summary index', 'Health related quality of life summary index', 'Breast cancer related quality of life summary index', 'Breast cancer related quality of life summary index', 'Breast cancer related quality of life summary index', 'Breast cancer related quality of life summary index', 'Functional related quality of life summary index', 'Functional related quality of life summary index', 'Functional related quality of life summary index', 'Functional related quality of life summary index', 'Physical health related quality of life', 'Physical health related quality of life', 'Physical health related quality of life', 'Physical health related quality of life', 'Social health related quality of life', 'Social health related quality of life', 'Social health related quality of life', 'Social health related quality of life', 'Emotional health related quality of life', 'Emotional health related quality of life', 'Emotional health related quality of life', 'Emotional health related quality of life', 'Self-efficacy', 'Self-efficacy', 'Self-efficacy', 'Self-efficacy', 'Fear of recurrence', 'Fear of recurrence', 'Fear of recurrence', 'Pain in the breast surgery area (side of chest, armpit or arm)', 'Pain in the breast surgery area (side of chest, armpit or arm)', 'Pain in the breast surgery area (side of chest, armpit or arm)', 'Pain in the breast surgery area (side of chest, armpit or arm)', 'Neuropathy in the breast surgery area (side of chest, armpit or arm)', 'Neuropathy in the breast surgery area (side of chest, armpit or arm)', 'Neuropathy in the breast surgery area (side of chest, armpit or arm)', 'Neuropathy in the breast surgery area (side of chest, armpit or arm)', 'Sleep quality', 'Sleep quality', 'Sleep quality', 'Sleep quality', 'Cognitive function - Perceived cognitive impairments', 'Cognitive function - Perceived cognitive impairments', 'Cognitive function- Perceived cognitive impairments', 'Cognitive function - Perceived cognitive impairments', 'Cognitive function - Impact of Perceived cognitive impairments on quality of life', 'Cognitive function - Impact of Perceived cognitive impairments on quality of life', 'Cognitive function - Impact of Perceived cognitive impairments on quality of life', 'Cognitive function - Impact of Perceived cognitive impairments on quality of life', 'Cognitive function - Perceived cognitive abilities', 'Cognitive function - Perceived cognitive abilities', 'Cognitive function - Perceived cognitive abilities', 'Cognitive function - Perceived cognitive abilities', 'Need for support', 'Need for support', 'Need for support', 'Need for support', 'Health care costs', 'Acceptability']",,,,,1,Denmark,"Rigshospitalet [Copenhagen, Denmark]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses rehabilitation after breast cancer and various quality of life indices but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03257917,Understanding Value in Metastatic Breast Cancer,Understanding Out-of-pocket Expenses and Patient Time Spent on Healthcare in Metastatic Breast Cancer Patients (Understanding Value in Metastatic Breast Cancer),COMPLETED,,University of Alabama at Birmingham,2017-06-13,2019-06-24,2019-07-12,2017-08-22,2019-08-26,['Post-cancer diagnosis cost'],"['Time loss experienced by patients with metastatic breast cancer.', 'Do patient characteristics (sociodemographics, cancer characteristics, health status, healthcare utilization) influence the total cost of care or financial burden?', 'Does treatment type (chemotherapy vs. hormone therapy) influence the total cost of care or financial burden?', 'What is the trajectory of financial burden or total cost of care over time (year pre-MBC diagnosis vs. post-MBC diagnosis)?', 'Does financial burden or total cost of care influence treatment adherence?', 'Does clinical trial participation influence the total cost of care or financial burden?', 'Does financial burden or total cost of care influence perception of or preference for shared decision-making?', 'Describe the cost experienced by patients with metastatic breast cancer.', 'Describe the productivity loss experienced by patients with metastatic breast cancer.']",,,,,1,United States,"University of Alabama at Birmingham [Birmingham, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses understanding value and costs associated with metastatic breast cancer but does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03262831,Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer,The Role of Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer,COMPLETED,,Washington University School of Medicine,2018-01-10,2019-06-26,2019-06-26,2017-08-25,2019-09-03,"['Feasibility of enrolling patients to larger randomized controlled trial using yoga and mindful movement as measured the number of eligible patients enrolled', 'Feasibility of conducting a larger randomized trial using yoga and mindful movement', 'Efficacy of yoga exercise as measured by weight change from baseline to completion']","['Effect of yoga exercise as measured by rate of pathologic response (partial and complete) (neoadjuvant subset only)', 'Effect of yoga exercise as measured by inflammatory markers', 'Effect of yoga exercise as measured by fatigue index', 'Effect of yoga exercise as measured by quality of life']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03266185,Shorter Scalp Cooling Time in Paclitaxel,"Prospective, Multi-centre Trial to Evaluate Effectiveness of 45-min and 20-min Post-infusion Cooling Time for Patients Treated With Scalp Cooling to Prevent Paclitaxel-induced Alopecia",COMPLETED,,Leiden University Medical Center,2017-12-20,2020-08-28,2020-08-28,2017-08-30,2021-04-01,"[""To determine the efficacy of scalp cooling in patients treated with paclitaxel-containing chemotherapy with a 45- and 20-minutes post-infusion cooling time, defined by the patient's self-determined need to wear a wig or other head covering""]","['To determine the degree of chemotherapy-induced alopecia (CIA), assessed with the DEAN scale for assessment of hair loss', 'To determine the grade of chemotherapy-induced alopecia (CIA), according to NCI-CTCAEv4.03', 'To determine the tolerance of scalp cooling, assessed by a (self-adapted) visual analogue scale (VAS)', 'To determine the added value of scalp cooling for weekly paclitaxel; what is the incidence of severe alopecia with and without scalp cooling', 'Assessing the amount of distress experienced by CIA in patients, assessed with the chemotherapy-induced alopecia distress scale (CADS)']",,,,,1,Netherlands,"LUMC [Leiden, Netherlands]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03266718,Move 2 Health: A Couple-Based Physical Activity Intervention for Cancer Survivors,A Couple-Based Physical Activity Intervention for Cancer Survivors,COMPLETED,,Duke University,2015-07-01,2016-09-26,2016-12-11,2017-08-30,2017-08-30,"['Feasibility of a couple-based physical activity intervention for cancer survivors as measured by a composite score of total number of couples screened and rates for non-eligibility.', 'Feasibility of a couple-based physical activity intervention for cancer survivors as measured by a composite score of total number of couples screened and rates of refusal.', 'Acceptability of a couple-based physical activity intervention for cancer survivors as measured by a composite score of total number of couples screened and rates for non-eligibility.', 'Acceptability of a couple-based physical activity intervention for cancer survivors as measured by a composite score of total number of couples screened and rates of refusal.']","['Efficacy as measured by steps taken', 'Quality of life as measured by surveys', 'Self -efficacy for achieving and maintaining physical activity goals as measured by surveys', 'Perceived partner support for physical activity as measured by surveys', 'Quality of the survivor-partner relationship as measured by surveys']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a physical activity intervention for cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine. It focuses on feasibility and acceptability of a behavioral intervention rather than pharmacological treatment.",OTHER,False,2016.0,9.0,0,NA/Other
NCT03266809,CARdiac Function Evaluation in Breast Cancer Patients,Longitudinal Characterisation of Cardiac Function in Recently-diagnosed Breast Cancer Patients,COMPLETED,,Swansea University,2017-08-01,2019-09-28,2020-04-01,2017-08-30,2022-12-01,"['Cardiac Function (stroke volume or ejection fraction)', 'Cardiac Rhythm (heart rate variability)']","[""Physical activity level (accelerometer-based activity level 'counts')"", 'Cardiorespiratory function (rate of respiratory oxygen uptake)', 'Body mass composition (from DEXA scan)']",,,,,1,United Kingdom,"Singleton Hospital [Swansea, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study focused on evaluating cardiac function in breast cancer patients, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03272919,Chemotherapy Induced Peripheral Neuropathy (CIPN),Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy,COMPLETED,,Loma Linda University,2017-09-28,2022-05-25,2022-05-25,2017-09-06,2023-05-10,"['Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on the PQAS score.', 'Descriptive Statistics to measure the degree of distress in the two arms based on NCCN- DT', 'Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on MSNI scores', 'Descriptive Statistics to measure the degree of peripheral neuropathy in the two arms based on CTCAE grading']","['Measure the peak systolic velocity on ultrasound imaging in the popliteal and posterior tibia artery in the two arms.', 'Measure the rate of premature chemotherapy discontinuation due to peripheral neuropathy by treatment group', 'Measure the rate of dose reductions in chemotherapy due to peripheral neuropathy by treatment group', 'Questionnaire to survey patients on acceptability, satisfaction and burden of treatment']",,,,,1,United States,"Loma Linda Medical Center [Loma Linda, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses a pilot study for managing an existing condition (Chemotherapy Induced Peripheral Neuropathy) using a specific intervention (Intraneural Facilitation), indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03275987,Promoting Cancer Screening Among Medicaid Recipients in Minnesota,A Population-based Randomized Trial to Promote Cancer Screening Among Unscreened Medicaid Recipients in Minnesota,COMPLETED,,Minnesota Department of Health,2014-04-23,2014-09-30,2017-05-10,2017-09-08,2017-09-11,['screening mammography or colonoscopy'],[],,,,,1,United States,"Minnesota Department of Health [Saint Paul, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial focuses on promoting cancer screening among Medicaid recipients and does not involve a new medicine or an extension of indication for an existing medicine.,OTHER_GOV,False,2017.0,8.0,0,NA/Other
NCT03279198,Increasing Colorectal and Breast Cancer Screening in Women,Increasing Colorectal and Breast Cancer Screening in Women,COMPLETED,,Indiana University,2010-07-22,2015-09-15,2017-05-31,2017-09-12,2017-09-12,"['Primary Outcome -differences in CRC screening adherence, when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.', 'Primary Outcome:differences in stage of adoption (precontemplation, contemplation, action) when controlling for adherence to BC screening at baseline, among women who are randomized to 1) usual care; 2) a TIWeb; 3) a CSC, and 4) a TIWeb plus a CSC.']",['Secondary outcome:Intervention Costs'],,,,,0,,,2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study focused on increasing cancer screening adherence rather than introducing a new medicine or extending the indication of an existing medicine.,OTHER,False,2017.0,8.0,0,NA/Other
NCT03280719,Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions,Whole Breast (WB) + Lymph Node Irradiation (LNI): Prone Compared to Supine Position in a Randomized Study with 15 or 5 Fractions,COMPLETED,,"University Hospital, Ghent",2017-09-15,2020-07-07,2021-06-09,2017-09-12,2024-09-19,['Breast retraction'],"['Acute toxicity - Dermatitis', 'Acute toxicity - Desquamation', 'Acute toxicity - Breast oedema', 'Acute toxicity - Shoulder range of motion', 'Acute toxicity - Arm circumference', 'Acute toxicity - Breast symptoms - pain', 'Acute toxicity - Breast symptoms - sense of heaviness', 'Acute toxicity - Breast symptoms - itching', 'Acute toxicity - Arm Symptoms - Pain', 'Acute toxicity - Arm Symptoms - Sense of heaviness', 'Acute toxicity - Shoulder symptoms - Pain', 'Acute toxicity - Shoulder symptoms - Impaired shoulder mobility', 'Acute toxicity - Pain not in arm/shoulder/breast', 'Acute toxicity - Dysphagia', 'Acute toxicity - Dyspnea', 'Acute toxicity - Cough', 'Acute toxicity - Cardiac toxicity', 'Non-breast retraction late treatment related toxicity', 'Cosmesis', 'Quality of life - General', 'Quality of life - Breast specific questionnaire', 'Locoregional and distant tumor control', 'Treatment duration', 'Dose parameters of target tissues/organs at risk', 'Volume parameters of targets/organs at risk/hot spots - volume of the structures', 'Volume parameters of targets/organs at risk - relative volume receiving a certain dose', 'Setup accuracy', 'Treatment cost']",,,,,1,Belgium,"Radiotherapy department, UZ Ghent [Ghent, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares different positions for irradiation in breast cancer treatment, indicating an extension of indication for existing treatment methods rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03282214,A Self-Management Energy Conservation Program for Cancer-Related Fatigue,A Self-Management Energy Conservation Program for Cancer-Related Fatigue in Thai Women With Breast Cancer Receiving Chemotherapy: A Pilot Study,COMPLETED,PHASE2,University of Michigan,2017-10-01,2018-02-14,2018-05-09,2017-09-13,2018-05-22,['Cancer-related fatigue (CRF)'],"['Acceptability', 'Satisfaction', 'The General Sleep Disturbance (GSD)', 'Physical Activity (subjective measure)', 'Physical Activity (objective measure)', 'Hospital Anxiety and Depression Scale (HADS)', 'Self-Efficacy for Managing Chronic Disease Scale (SEMCDS)', 'Fatigue Belief Questions (FBQ)']",,,,,2,Thailand,"Saraburi Hospital [Changwat Sara Buri, Thailand] | Lopburi Cancer Hospital [Lopburi, Thailand]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study on a self-management program for cancer-related fatigue, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,Phase 2
NCT03284346,Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors,"Circuit, Interval-Based Aerobic and Resistance Exercise to Target Metabolic Dysregulation: The CARE Study for Breast and Prostate Cancer Survivors",TERMINATED,,University of Southern California,2017-08-17,2019-07-15,2019-07-15,2017-09-15,2025-09-29,"['Change in insulin resistance', 'Change in metabolic syndrome (Blood Pressure)', 'Change in metabolic syndrome (Waist Circumference)', 'Change in metabolic syndrome (Fasting Plasma Levels of Glucose)', 'Change in metabolic syndrome (High-Density Lipoprotein-Cholesterol)', 'Change in metabolic syndrome (Triglycerides)']",[],,,,,1,United States,"USC / Norris Comprehensive Cancer Center [Los Angeles, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study focused on exercise interventions for cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03284567,Football Fitness After Breast Cancer,A Randomized Controlled Trial to Investigate the Health Promoting Effects of a Football Fitness Intervention for Women After Treatment for Breast Cancer,COMPLETED,,University of Copenhagen,2017-03-20,2019-11-30,2020-01-20,2017-09-15,2021-10-01,['Mean change in fitness level (maximal oxygen uptake) from baseline to month 6 and month 12.'],"['Mean change in whole-body fat mass from baseline to month 6 and month 12.', 'Mean change in whole-body weight from baseline to month 6 and month 12.', 'Mean change in whole-body muscle mass from baseline to month 6 and month 12.', 'Mean change in muscle strength from baseline to month 6 and month 12.', 'Mean change in balance from baseline to month 6 and month 12.', 'Mean change in blood pressure from baseline to month 6 and month 12.', 'Mean change in markers of bone mineral metabolism from baseline to month 6 and month 12.', 'Mean change in cholesterol from baseline to month 6 and month 12.', 'Self-reported physical activity from baseline to month 6 and month 12.', 'Self-reported diagnosis-specific symptoms and side-effects from baseline to month 6 and month 12.', 'Self-reported health-related quality of life outcomes from baseline to month 6 and month 12.', 'Self-reported functional level in upper extremities from baseline to month 6 and month 12.', 'Self-reported health related quality of life from baseline to month 6 and month 12.', 'Mean change in bone mineral density (BMD) of the spine (L2-L4), Total hip and Femoral Neck.', 'Mean change in total body and leg bone mineral content (BMC).']",,,,,1,Denmark,"University Hospital of Copenhagen, Rigshospitalet [Copenhagen, Denmark]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on a fitness intervention for women after breast cancer treatment, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03285568,Patterns of Prescribing and Monitoring of Palbociclib,Patterns of Prescribing and Monitoring of Palbociclib,COMPLETED,,Rush University Medical Center,2015-02-03,2016-12-30,2016-12-30,2017-09-18,2023-03-31,['Palbociclib dose according to the package insert recommendations.'],"['Dose adjustment for hematologic toxicities', 'Number of patients who experienced neutropenia.', 'Duration of therapy', 'Progression free survival (PFS)', 'Adherence to manufacturer monitoring recommendations']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses prescribing patterns and monitoring for Palbociclib, which suggests it is being used in a context that may indicate an extension of its indication rather than introducing a new medicine.",OTHER,False,2016.0,9.0,0,NA/Other
NCT03289819,Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC,A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer,COMPLETED,PHASE2,Institut fuer Frauengesundheit,2018-03-23,2020-08-27,2021-01-22,2017-09-21,2021-04-08,['Pathological Complete Response (pCR) rate'],"['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'Clinical Response', 'EORTC QLQ-BR23', 'EORTC QLQ-C30']",,,,,4,Germany,"Department of Gynecology, Tübingen University Hospital [Tübingen, Germany] | Department of Gynecology and Obstetrics, Erlangen University Hospital [Erlangen, Germany] | Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH [Bottrop, Germany] | Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH [Berlin, Germany]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,Phase 2
NCT03291886,Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer,COMPLETED,PHASE2,"Kyowa Kirin Co., Ltd.",2017-09-22,2019-04-04,2021-03-26,2017-09-25,2022-06-21,['Progression Free Survival(PFS) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1)'],"['Overall survival (OS)', 'Antitumor effect']",,,,,28,Japan,"Aichi Cancer Center Hospital [Nagoya, Japan] | Nagoya City University Hospital [Nagoya, Japan] | Shikoku Cancer Center [Matsuyama, Japan] | Kitakyushu Municipal Medical Center [Kitakyushu, Japan] | Gunma Cancer Center [Ōta, Japan] | Hokkaido Cancer Center [Sapporo, Japan] | Hokkaido University Hospital [Sapporo, Japan] | The Hospital of Hyogo College of Medicine [Nishinomiya, Japan] | Tsukuba University Hospital [Tsukuba, Japan] | Tokai University Hospital [Isehara, Japan] | Kanagawa Cancer Center [Yokohama, Japan] | Nahanishi Clinic [Naha, Japan] | Kindai University Hospital [Sayama, Japan] | Osaka University Hospital [Suita, Japan] | Saitama Medical University International Medical Center [Hidaka, Japan] | Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital [Bunkyo, Japan] | National Cancer Center Hospital [Chūō, Japan] | The Cancer Institute Hospital of JFCR [Koto, Japan] | Toranomon Hospital [Minato, Japan] | Showa University Hospital [Shinagawa, Japan] | Chiba Cancer Center [Chiba, Japan] | Kyushu Cancer Center [Fukuoka, Japan] | Sagara Hospital [Kagoshima, Japan] | Kumamoto University Hospital [Kumamoto, Japan] | Kyoto University Hospital [Kyoto, Japan] | Niigata Cancer Center Hospital [Niigata, Japan] | Okayama University Hospital [Okayama, Japan] | Osaka National Hospital [Osaka, Japan]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on KHK2375, which is being studied in a specific patient population (advanced or recurrent breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",INDUSTRY,False,2021.0,4.0,0,Phase 2
NCT03291938,IACS-010759 in Advanced Cancers,A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,COMPLETED,PHASE1,M.D. Anderson Cancer Center,2017-11-13,2020-11-23,2020-11-23,2017-09-25,2020-11-24,"['Incidence of adverse events', 'Maximum tolerated dose']","['Maximum Plasma concentration of IACS-010759 [Cmax]', 'Overall response rate', 'Duration of response']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03292172,"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer","Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer",TERMINATED,PHASE1,Hoffmann-La Roche,2017-11-08,2019-02-26,2019-02-26,2017-09-25,2020-11-06,"['Group 1: Percentage of Participants With Dose Limiting Toxicities (DLT)', 'Groups 1 to 4: Percentage of Participants With Adverse Events (AEs)', 'Groups 1 to 4: Percentage of Participants With Change in Vital Signs, Physical Findings, Electrocardiogram (ECG) and Laboratory Parameters', 'Groups 3 and 4: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.']","['Groups 1 to 4: Maximum concentration (Cmax) of RO6870810 (RO) and Atezolizumab (Ate)', 'Groups 1 to 4: Time of maximum concentration (tmax) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Clearance (CL) or Apparent Clearance (CL/F) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Volume of Distribution (Vd) or Apparent Volume of Distribution (Vd/F) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Area Under the Plasma Concentration-Time Curve From Time Zero to End of the Dosing Interval (AUC0-tau) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Half life (t1/2) of RO6870810 and Atezolizumab', 'Groups 1 to 4: Trough concentration (Ctrough) of RO6870810 and Atezolizumab', 'Groups 1 and 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.', 'Groups 1 to 4: Objective Response (OR) as per Immune-Modified RECIST', 'Groups 1 to 4: Duration of Response (DoR) as per RECIST v1.1 and Immune-Modified RECIST', 'Groups 1 to 4: Progression-Free Survival (PFS) per RECIST v1.1 and Immune-Modified RECIST', 'Groups 1 to 4: Overall Survival (OS)', 'Groups 1 to 4: Tumor Marker Assessments (CA-125, According to Modified Gynecologic Cancer InterGroup [GCIG] Guidelines,CEA, CA15-3 Changes)', 'Groups 1 to 4: Changes in CD11b Expression Levels Measurement in CD14+ Monocytes From Blood Association with Steady-State RO6870810 PK Drug Exposure', 'Groups 1 to 4: Changes in Markers (e.g., PD-L1, CD8/Ki 67) in Tissue Biopsy Specimens by Immunohistochemistry (IHC)', 'Groups 1 to 4: Percentage of Participants With Transcript Profiling Assessment Receiving Combination Study Treatment']",,,,,11,Australia; Canada; Denmark; United Kingdom; United States,"Dana Farber Cancer Institute [Boston, United States] | Oklahoma University Health Sciences Center [Oklahoma City, United States] | Sarah Cannon Res Inst; TN Onc [Nashville, United States] | St Vincent's Hospital Sydney [Darlinghurst, Australia] | Peter MacCallum Cancer Centre; Medical Oncology [Melbourne, Australia] | University Health Network; Princess Margaret Hospital; Medical Oncology Dept [Toronto, Canada] | Rigshospitalet; Onkologisk Klinik [København Ø, Denmark] | Western General Hospital [Edinburgh, United Kingdom] | Guys and St Thomas NHS Foundation Trust, Guys Hospital [London, United Kingdom] | The Christie [Manchester, United Kingdom] | Churchill Hospital [Oxford, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2019.0,6.0,1,Phase 1
NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer,TERMINATED,PHASE1,Dana-Farber Cancer Institute,2017-11-08,2020-10-14,2020-10-14,2017-09-27,2025-05-31,"['Cohort A: MTD/RP2D of the Combination of Ribociclib + PDR001', 'Cohort B: MTD/RP2D of the Combination of Ribociclib + PDR001 + Fulvestrant']","['Number of Participants with Adverse Events', 'Objective Response Rate']",,,,,3,United States,"Massachusetts General Hospital [Boston, United States] | Brigham and Women's Hospital [Boston, United States] | Dana-Farber Cancer Institute [Boston, United States]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,Phase 1
NCT03295552,Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC,Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer,TERMINATED,PHASE2,Shanghai Jiao Tong University School of Medicine,2017-11-15,2021-06-01,2021-06-01,2017-09-28,2022-04-06,['Overall response rate'],[],,,,,1,China,"Ruijin Hospital, Shanghai Jiaotong University School of Medicine [Shanghai, China]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text suggests the use of Decitabine in combination with Carboplatin for a specific type of cancer (metastatic triple negative breast cancer), indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03305757,Seroma Reduction After Mastectomy,"A Multi-center, Double Blinded Randomized Controlled Trial Evaluating Closure of the Dead Space After Mastectomy Using Sutures or Tissue Glue Versus Conventional Closure. Protocol for the Seroma Reduction After Mastectomy (SAM) Trial",COMPLETED,PHASE4,Zuyderland Medisch Centrum,2014-06-01,2019-08-31,2019-08-31,2017-10-10,2019-12-03,['Number of seroma aspirations'],"['Number of out patient clinic visits', 'Infection rate', 'Shoulder function', 'Cosmesis', 'Impact on Quality of life', 'Cost effectiveness']",,,,,1,Netherlands,"Zuyderland Medisch Centrum [Sittard, Netherlands]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial focuses on evaluating surgical techniques for seroma reduction after mastectomy rather than testing a new medicine or extending the indication of an existing medicine.,OTHER,False,2019.0,6.0,0,Other
NCT03314805,PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy,COMPLETED,PHASE2,PhytoHealth Corporation,2018-03-01,2021-05-26,2021-08-27,2017-10-19,2025-06-04,"['Change in chemotherapy-related fatigue by brief fatigue Inventory', 'Incidence of Grade 3/4 neutropenia']","['Incidence of other Grade 3/4 Hematologic Toxicities', 'Chemotherapy Dose Reductions', 'Days of chemotherapy delay', 'Cumulative Doses of G-CSF consumption', 'Health-related Quality of Life by EORTC QLQ-C30 & Br23', 'ECOG']",,,,,5,Taiwan,"E-Da Cancer Hospital [Kaohsiung City, Taiwan] | Chang Gung Memorial Hospital, Kaohsiung Branch [Kaohsiung City, Taiwan] | Chang Gung Memorial Hospital, Lovers Lake branch [Keelung, Taiwan] | Chang Gung Memorial Hospital, Taipei Branch [Taipei, Taiwan] | Chang Gung Memorial Hospital, Linkou Branch [Taoyuan, Taiwan]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2021.0,4.0,0,Phase 2
NCT03316794,A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC),TERMINATED,PHASE1,AbbVie,2018-01-04,2018-10-05,2018-10-05,2017-10-20,2018-12-17,['Number of Participants with Dose-limiting Toxicities (DLTs)'],"['QTcF Change from Baseline', 'Area Under the Plasma Concentration-time Curve (AUC)', 'Clinical benefit rate (CBR)', 'Maximum plasma concentration observed (Cmax)', 'Overall Survival (OS)', 'Observed Plasma Concentrations at Trough', 'Duration of Clinical Benefit (DOCB)', 'Objective Response Rate (ORR)Up to approximately 4 years', 'Time of Cmax (Tmax)', 'Progression Free Survival (PFS)', 'Duration of Response (DOR)']",,,,,8,United States,"University of Chicago /ID# 169231 [Chicago, United States] | Washington University School /ID# 169177 [St Louis, United States] | Memorial Sloan Kettering /ID# 201016 [New York, United States] | Gabrail Cancer Center Research /ID# 168756 [Canton, United States] | Oklahoma University /ID# 200937 [Oklahoma City, United States] | Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233 [Nashville, United States] | Baylor University /ID# 169860 [Houston, United States] | MD Anderson Cancer Center /ID# 169232 [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study involves SC-005, which is being tested in subjects with Triple Negative Breast Cancer (TNBC), indicating it is a new medicine being evaluated for this specific condition.",INDUSTRY,False,2018.0,7.0,0,Phase 1
NCT03318263,CIrCuLAting Dna ESr1 Gene Mutations Analysis,"Monitoring of ESR1, PIK3CA and AKT ctDNA Mutations During Real-life Followup of Patients With Metastatic Breast Cancer Treated With Aromatase Inhibitors",COMPLETED,,Institut de Cancérologie de Lorraine,2017-12-07,2022-12-22,2022-12-22,2017-10-23,2023-08-04,['incidence of ESR1 mutations'],"['incidence of PIK3CA and AKT1 mutations', 'prevalence of ESR1, PIK3CA and AKT1 mutations in patients with and without endocrine resistance at enrolment', 'prevalence of ESR1, PIK3CA and AKT1 mutations in patients according to mono vs combo therapy.', 'prevalence of mutations of other genes of interest included in the panel from the start of treatment to progression or end of follow-up', 'ESR1, PIK3CA and AKT1 mutations predictor of progression free survival']",,,,,10,France,"Hôpital Claude Bernard [Metz, France] | CHR Metz-Thionville [Metz, France] | Centre d'oncologie Gentilly [Nancy, France] | Institut Jean Godinot [Reims, France] | Polyclinique de Courlancy [Reims, France] | Centre Henri Becquerel [Rouen, France] | Polyclinique de l'Orangerie [Strasbourg, France] | Clinique Saint Anne [Strasbourg, France] | CHU Strasbourg [Strasbourg, France] | Institut de cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses monitoring of mutations in patients with metastatic breast cancer treated with existing aromatase inhibitors, indicating an extension of indication for the use of these treatments in the context of mutation analysis and resistance.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03318562,A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC,A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma,TERMINATED,PHASE2,Effector Therapeutics,2017-11-21,2018-07-05,2019-01-22,2017-10-24,2019-07-18,['Level of biomarkers of antitumor activation'],"['Molecular profiling of circulating lymphocytes and tumor-infiltrating lymphocytes (TILs)', 'Levels of eIF4E and phospho-eIF4E', 'Number of mutations', 'Objective tumor response', 'Progression Free Survival', 'Proportion of subjects with TEAEs and SAEs', 'PK plasma concentrations']",,,,,2,United States,"City of Hope [Duarte, United States] | Kansas City Research Institute [Kansas City, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a pharmacodynamic study of oral eFT508, which suggests it is a new medicine being tested for advanced triple negative breast cancer and hepatocellular carcinoma.",INDUSTRY,False,2019.0,6.0,0,Phase 2
NCT03319342,Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors,Kindness to Others or to Oneself: A Pilot Randomized Controlled Trial of Kindness Interventions to Enhance Well-Being in Breast Cancer Survivors,COMPLETED,,Jonsson Comprehensive Cancer Center,2017-07-11,2019-12-03,2019-12-03,2017-10-24,2020-07-24,"['Depressive symptoms (Center for Epidemiologic Studies Depression Scale)', 'Psychological well-being measured by the Mental Health Continuum-Short Form']","['Big-5 Personality Dimensions measured by the Ten-Item Personality Inventory (TIPI)', 'Empathy measured by the Perspective Taking & Empathic Concern Subscales of the Interpersonal Reactivity Index', 'Fatigue measured by the Severity items of the Fatigue Symptom Inventory', 'Fulfillment of psychological needs measured by the Balanced Measure of Psychological Needs', 'Life satisfaction measured by the Satisfaction with Life Scale', 'Pain measured by the Pain Subscale of the Rand Health 36-item Short Form Survey', 'Positive and negative affect measured by the Affect-Adjective Scale', 'Qualitative assessment of acts performed', 'Self-kindness measured by the Self-Compassion Scale', 'Sleep disturbance measured by the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Scale', 'Social connection measured by the Attachment Subscale of the Social Provisions Scale', 'Social support measured by the 2-way Social Support Scale']",,,,,2,United States,"UCLA / Jonsson Comprehensive Cancer Center [Los Angeles, United States] | University of California-Riverside [Riverside, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text describes a pilot study on kindness interventions aimed at enhancing well-being in breast cancer survivors, focusing on psychological and emotional outcomes rather than testing a new medicine or an extension of an existing treatment's indication.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03319459,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors,COMPLETED,PHASE1,Fate Therapeutics,2018-01-18,2020-05-29,2020-12-15,2017-10-24,2021-11-22,['Incidence of dose-limiting toxicity (DLT)'],"['Objective-response rate (ORR)', 'Pharmacokinetics (PK) of FATE-NK100']",,,,,4,United States,"UCSD Moores Cancer Center [San Diego, United States] | University of Minnesota [Minneapolis, United States] | The Ohio State University James Cancer Hospital [Columbus, United States] | Baylor Scott & White Research Institute [Dallas, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is testing FATE-NK100, which is a new medicine being evaluated for its efficacy and safety in subjects with advanced solid tumors.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03319511,Thoracic Spinal Anesthesia in Awake Breast Surgery,Comparison Between Thoracic Para-vertebral Block and Segmental Thoracic Spinal Anesthesia in Breast Cancer Surgery,COMPLETED,,Alaa Mazy,2014-11-24,2016-11-12,2016-11-12,2017-10-24,2017-10-24,['the block success rate.'],"['The paravertebral onset of sensory block', 'The spinal onset of sensory block', 'The power of hand grip (T1/ C8)', 'The power of wrist flexion (C8/C7)', 'The power of elbow flexion (C6/ C5)', 'The onset time of lower limb motor block (Bromage 3)', 'The duration of lower limb motor block (Bromage 0)', 'Ramsey sedation scale', 'Heart rate', 'Systolic blood pressure', 'Mean blood pressure', 'Total ephedrine consumption', 'Total atropine consumption', 'Total Midazolam consumption', 'Hypotension episodes', 'Bradycardia episodes', 'Hypoxia episodes', 'incidence of nausea', 'incidence of vomiting', 'the incidence of pneumothorax.', 'The incidence of post-dural puncture headache.', 'The duration of upper limb motor block,', 'Visual analog scale', 'The total mepridine consumption.', 'satisfaction of the patient', 'satisfaction of the surgeon']",,,,,1,Egypt,"Oncolgy Center, Mansoura University, [Al Mansurah, Egypt]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a comparison of anesthesia techniques in breast cancer surgery but does not introduce a new medicine or an extension of indication for an existing medicine.,OTHER,False,2016.0,9.0,0,NA/Other
NCT03320421,Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery,Phase II Trial of Hypofractionated Whole-breast Radiation and Concomitant Boost to the Surgical Bed After Breast Conserving Surgery,COMPLETED,,Chinese Academy of Medical Sciences,2017-01-01,2019-01-01,2019-01-01,2017-10-25,2019-01-31,['acute radiation induced dermatitis by CTCAE within 3 months'],"['late radiation toxicity by CTCAE every 3 months to 1 years after 3 months of completion of radiation', 'breast cosmetic result as measured by Harvard scale of breast cosmesis (excellent, good, fair, poor) every 3 months for 1year', 'quality of life as measured by Functional Assessment of Cancer Therapy-Breast Scale (FACT-B) every 3 months for 1 year', 'quality of life as measured by Breast Cancer Treatment Outcome Scale(BCTOS) every 3 months for 1 year', 'in-breast recurrence rate at 1 year of radiation completion']",,,,,1,China,"National Cancer Center/Cancer Hosptial, Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating a specific radiation therapy approach (hypofractionated radiation therapy with concomitant boost) in a specific patient population (women after breast conserving surgery), indicating an extension of indication for an existing treatment rather than testing a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03326102,Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer,"A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)",COMPLETED,PHASE2,"Daehwa Pharmaceutical Co., Ltd.",2018-07-06,2022-12-13,2022-12-13,2017-10-30,2024-02-16,['Objective Response Rate(ORR)'],"['Progression free survival(PFS)', 'Overall survival(OS)', 'Time to treatment failure(TTF)', 'Duration of response(DOR)', 'Disease control rate(DCR)', 'Quality of life(QoL)', 'PK']",,,,,15,Czechia; United States,"California Research Institute (CRI) [Los Angeles, United States] | University of California San Francisco (UCSF) [San Francisco, United States] | Boca Raton Regional Hospital (BRRH) [Boca Raton, United States] | ASCLEPES Research Center(ARC) [Weeki Wachee, United States] | Saint Luke's Cancer Institute(SLCI) [Kansas City, United States] | University of Kansas Medical Center(KUMC) [Kansas City, United States] | Anne Arundel Health System Research Institute (AAHS) [Annapolis, United States] | Massachusetts General Hospital(MGH) [Boston, United States] | Michigan Center of Medical Research(MCMR) [Farmington Hills, United States] | Metro-Minnesota Community Oncology Research Consortium (MMCORC) [Minneapolis, United States] | Nevada Cancer Research Foundation (NCRF) [Las Vegas, United States] | University of Pittsburgh Medical Center (UPMC) [Pittsburgh, United States] | Onkologicka klinika, Fakultni nemocnice Olomouc (OUH) [Olomouc, Czechia] | Onkologicky stacionar, NH Hospital a.s., nemocnice Horovice (NHH) [Hořovice, Czechia] | Onkologicka klinika, Vseobecna fakultni nemocnice v Praze (VFN) [Prague, Czechia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,,INDUSTRY,False,2022.0,3.0,1,Phase 2
NCT03326674,"Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC","A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane",TERMINATED,PHASE3,"Odonate Therapeutics, Inc.",2017-12-21,2020-08-24,2021-06-28,2017-10-31,2021-07-30,['PFS as assessed by the IRC'],"['OS', 'ORR as assessed by the IRC', 'DCR as assessed by the IRC', 'Central nervous system (CNS) ORR as assessed by the CNS IRC in patients with CNS metastases at baseline', 'CNS PFS as assessed by the CNS IRC in patients with CNS metastases at baseline or a history of CNS metastases and in the intent-to-treat (ITT) population', 'CNS OS in patients with CNS metastases at baseline or a history of CNS metastases']",,,,,207,Australia; Austria; Belgium; Canada; Czechia; France; Germany; Hungary; Italy; Poland; Russia; Singapore; South Korea; Spain; Taiwan; Thailand; Ukraine; United Kingdom; United States,"Ironwood Cancer and Research Centers [Chandler, United States] | Cancer Treatment Centers of America - Western Regional Medical Center [Goodyear, United States] | Arizona Oncology Associates, P.C. - HOPE [Tucson, United States] | Genesis Cancer Center [Hot Springs, United States] | Carti Cancer Center [Little Rock, United States] | Pacific Cancer Medical Center [Anaheim, United States] | CBCC Global Research, Inc. [Bakersfield, United States] | Compassionate Care Research Group [Fountain Valley, United States] | California Cancer Associates for Research and Excellence [Fresno, United States] | St. Joseph Heritage Healthcare [Fullerton, United States] | UCLA Medical Center [Los Angeles, United States] | Cancer Care - Torrance Memorial Physician Network [Redondo Beach, United States] | Sharp Memorial Hospital [San Diego, United States] | University of California San Francisco - Helen Diller Family Comprehensive Cancer Center [San Francisco, United States] | San Luis Obispo Oncology & Hematology Health Center [San Luis Obispo, United States] | California Cancer Associates for Research and Excellence [San Marcos, United States] | Cancer Research Collaboration and Breast Link [Santa Ana, United States] | Stanford Cancer Center / Cancer Clinical Trials [Stanford, United States] | Innovative Clinical Research Institute [Whittier, United States] | Rocky Mountain Cancer Center [Lakewood, United States] | Western Connecticut Health Network [Danbury, United States] | Hartford Healthcare [Hartford, United States] | Sarah Cannon Research Institute - Florida Cancer Specialists [Fort Myers, United States] | Memorial Healthcare System [Hollywood, United States] | Cancer Specialists of North Florida [Jacksonville, United States] | Miami Cancer Institute [Miami, United States] | Florida Cancer Affiliates - Ocala [Ocala, United States] | Orlando Health [Orlando, United States] | University of Miami Sylvester Comprehensive Cancer Center / Sylvester at Plantation [Plantation, United States] | Florida Cancer Specialists and Research Institute [St. Petersburg, United States] | Florida Cancer Specialists and Research Institute - Panhandle Region [Tallahassee, United States] | Florida Cancer Specialists and Research Institute [West Palm Beach, United States] | University Cancer and Blood Center [Athens, United States] | Cancer Treatment Centers of America [Newnan, United States] | University of Chicago Medical Center - Duchossois Center for Advanced Medicine (DCAM) [Chicago, United States] | Orchard Healthcare Research [Skokie, United States] | American Health Network [Indianapolis, United States] | Baptist Health Lexington [Lexington, United States] | SMHC Cancer Care and Blood Disorders [Biddeford, United States] | University of Maryland - Greenebaum Comprehensive Cancer Center [Baltimore, United States] | GBMC Cancer Center [Baltimore, United States] | Chevy Chase Health Care Center/ RCCA [Chevy Chase, United States] | James M. Stockman Cancer Institute [Frederick, United States] | Maryland Oncology Hematology, P.A. [Rockville, United States] | Dana-Farber Cancer Institute [Boston, United States] | Henry Ford Hospital [Detroit, United States] | Cancer and Hematology Centers of Western Michigan [Grand Rapids, United States] | Virginia Piper Cancer Institute, Allina Health [Minneapolis, United States] | Forrest General Cancer Center/Hattiesburg Clinic [Hattiesburg, United States] | Jackson Oncology Associates [Jackson, United States] | Mercy Cancer Center [Joplin, United States] | HCA Midwest Health [Kansas City, United States] | Washington University School of Medicine [St Louis, United States] | Mercy Hospital St. Louis, David C. Pratt Cancer Center [St Louis, United States] | St. Vincent Frontier Cancer Center [Billings, United States] | Oncology Hematology West, P.C. dba Nebraska Cancer Specialists [Papillion, United States] | New Jersey Hematology Oncology Associates [Brick, United States] | Regional Cancer Care Associates [East Brunswick, United States] | The Valley Hospital [Ridgewood, United States] | Regional Cancer Care Associates, LLC-Sparta [Sparta, United States] | New Mexico Cancer Care Alliance - Southwest Gynecology Oncology [Albuquerque, United States] | New York Oncology Hematology, P.C. [Albany, United States] | New York Cancer and Blood Specialists [East Setauket, United States] | Hematology Oncology Associates of Central New York, P.C. [East Syracuse, United States] | Broome Oncology, LLC [Johnson City, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | University of North Carolina Lineberger Cancer Center [Chapel Hill, United States] | Ohio State University Comprehensive Cancer Center, Stephanie Spielman Comprehensive Breast Center [Columbus, United States] | Mercy Clinic Oncology and Hematology [Oklahoma City, United States] | Oklahoma Cancer Specialists and Research Institute, LLC [Tulsa, United States] | Lehigh Valley Health Network [Allentown, United States] | Cancer Treatment Centers of America - Philadelphia [Philadelphia, United States] | Magee-Women's Hospital of UPMC [Pittsburgh, United States] | West Cancer Center [Germantown, United States] | Sarah Cannon Research Institute at Tennessee Oncology [Nashville, United States] | Texas Oncology - Bedford [Bedford, United States] | Texas Oncology - Medical City Dallas [Dallas, United States] | Texas Oncology - Dallas Presbyterian Hospital [Dallas, United States] | Texas Oncology - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Texas Oncology - Memorial City [Houston, United States] | Westside Surgical Hospital and Breast Center [Houston, United States] | Oncology Consultants [Houston, United States] | Hope Cancer Center of East Texas [Tyler, United States] | Bon Secours St. Francis [Midlothian, United States] | Virginia Oncology Associates [Norfolk, United States] | Virginia Cancer Institute [Richmond, United States] | Overlake Medical Center [Bellevue, United States] | Kadlec Regional Medical Center [Kennewick, United States] | Swedish Cancer Center [Seattle, United States] | Northwest Medical Specialties [Tacoma, United States] | Border Medical Oncology [Albury, Australia] | Sydney Adventist Hospital [Wahroonga, Australia] | Mater Cancer Care Centre [South Brisbane, Australia] | Princess Alexandra Hospital [Woolloongabba, Australia] | Monash Medical Centre [Clayton, Australia] | Peninsula and South Eastern Haematology and Oncology Group [Frankston, Australia] | Breast Cancer Research Centre [Nedlands, Australia] | St. John of God Subiaco Hospital [Perth, Australia] | Flinders Medical Centre [Bedford Park, Australia] | Universitätsklinik Onkologie Landeskkrankenhaus [Salzburg, Austria] | Facharzt für Frauenheilkunde und Geburtshilfe Spezialist für Brustchirurgie und Brustkrebs [Schwaz, Austria] | Ludwig Boltzmann Institut fur Klinische Onkologie und Photodynamische Therapie [Vienna, Austria] | AKH-Frauenheilkunde [Vienna, Austria] | AZ Klina AUGUSTIJNSLEI [Antwerp, Belgium] | Institut Jules Bordet [Brussels, Belgium] | UZA [Edegem, Belgium] | UZ Leuven [Leuven, Belgium] | CHC-Sant Joseph Oncology-Hematology [Liège, Belgium] | The Moncton Hospital [Moncton, Canada] | QEII Health Sciences Centre - Nova Scotia Cancer Centre [Halifax, Canada] | St. Michael's Hospital [Toronto, Canada] | Hopital Maisonneuve-Rosemont [Montreal, Canada] | Center Hospitalier de Montreal CHUM McPeak Sirois [Montreal, Canada] | CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital [Montreal, Canada] | McGill University Health Center [Montreal, Canada] | Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre [Sherbrooke, Canada] | CHU de Quebec-University Laval [Québec, Canada] | NH Hospital a.s. Nemocnice Hořovice Onkologie [Hořovice, Czechia] | Onkologicka Klinika FN Olomouc [Olomouc, Czechia] | Onkologicka Klinika (Vseobecna Fakultni Nemocnici v Praze ) [Prague, Czechia] | Onkologicka Klinika (Fakultni Nemocnice v Motole) [Prague, Czechia] | CHRU J. Minjoz Service Oncologie [Besançon, France] | Centre François Baclesse Service the Recherche Clinique [Caen, France] | Hospices Civils de Lyon Sud Oncologie Medicale [Pierre-Bénite, France] | Centre Eugène Marquis [Rennes, France] | Institut Curie - Hopital Rene Huguenin [Saint-Cloud, France] | Clinique Sainte Anne - Strasbourg Oncologie Liberale [Strasbourg, France] | Centre Hospitalier Regional et Universitaire de Tours CHRU [Tours, France] | St. Elisabeth-Krankenhaus GmbH [Cologne, Germany] | InVO - Institut für Versorgungsforschung [Koblenz, Germany] | St. Elisabethgruppe GmbH Marien Hospital Witten Brustzentrum [Witten, Germany] | Arzt der Studienzentrale Universitätsklinikum Erlangen [Erlangen, Germany] | Charité Universitätsmedizin Berlin-Campus Benjamin Franklin Klinik für Hämatologie, Onkologie und Tumorimmunologie [Berlin, Germany] | Helios Klinikum Berlin-Buch [Berlin, Germany] | Mammazentrum HH am Krankenhaus Jerusalem [Hamburg, Germany] | UKSH, Campus Kiel Klinik für Gynäkologie und Geburtshilfe [Kiel, Germany] | Staedtisches Klinikum Lueneburg gGmbH Brustzentrum und gynaekologisches Krebszentrum der Frauenklinik [Lüneburg, Germany] | LMU Klinikum der Universität München Breast Cancer [München, Germany] | Technische Universität München Klinikum rechts der Isar Klinik und Poliklinik für Frauenheilkunde [München, Germany] | Military Hospital State Health Center [Budapest, Hungary] | Országos Onkológiai Intézet [Budapest, Hungary] | Semmelweis University [Budapest, Hungary] | Uzsoki utcai kórház [Budapest, Hungary] | Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz [Nyíregyháza, Hungary] | University of Pécs Department of Oncotherapy [Pécs, Hungary] | Ospedale San Raffaele - Medical Oncology Dept. [Milan, Italy] | Istituto Europeo di Oncologia (IEO) [Milan, Italy] | Centro Oncologico Modenese [Modena, Italy] | S.C. Oncologia/Az. Osp.Ra. S Maria Terni [Terni, Italy] | Szpitale Pomorskie Oddział Onkologii i Radioterapii Powstania [Gdynia, Poland] | Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Oddzial Onkologii z Pododdzialem Chemoioterapii [Olsztyn, Poland] | Mrukmed [Rzeszów, Poland] | Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej Centrum Onkologii-Instytut [Warsaw, Poland] | Wilmed [Warsaw, Poland] | Onko-Dent G.L.Slomian [Żory, Poland] | State Oncology Clinical Dispansery [Saint Petersburg, Russia] | Federal State Budgetary Institution Research Institute of Oncology named after N.N. Petrov of the Ministry of Health of the Russian Federation [Saint Petersburg, Russia] | John Hopkins Singapore International Medical Centre [Singapore, Singapore] | National Cancer Centre Singapore [Singapore, Singapore] | National University Hospital [Singapore, Singapore] | Dong-A University Hospital [Busan, South Korea] | Kyungpook National University Hospital [Daegu, South Korea] | National Cancer Center [Goyang, South Korea] | Gachon University Gil Medical Center [Incheon, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Samsung Medical Center [Seoul, South Korea] | Seoul National University Hospital [Seoul, South Korea] | Severance Hospital [Seoul, South Korea] | Ajou University Hospital [Suwon, South Korea] | St. Vincents Hospital [Suwon, South Korea] | Onkologikoa [San Sebastián, Spain] | Althaia Hospital Sant Joan de Deu [Barcelona, Spain] | Hospital Teresa Herrera Materno-Infantil (CHUAC) [A Coruña, Spain] | Centro Oncológico de Galicia [A Coruña, Spain] | Hospital Quironsalud Barcelona [Barcelona, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Institut Catala d'Oncologia [Barcelona, Spain] | HU San Pedro de Alcantara [Cáceres, Spain] | Hospital Universitario Ramon y Cajal Servicio de Oncologia [Madrid, Spain] | IOB_Hospital Ruber Internacional [Madrid, Spain] | Fundacion Jimenez Diaz [Madrid, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Universitario Virgen de la Victoria [Málaga, Spain] | Hospital Universitario Miguel Servet Paseo Isabel la Catolica 1-3 Edificio de Maternidad [Zaragoza, Spain] | Changhua Christian Hospital [Taichung, Taiwan] | Chi Mei Medical Center [Tainan City, Taiwan] | National Cheng Kung University Hospital [Tainan City, Taiwan] | Koo Foundation Sun Yat-Sen Cancer Center [Taipei, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | Taipei Veterans General Hospital [Taipei, Taiwan] | Chang Gung Memorial Hospital Linkou Branch [Taoyuan District, Taiwan] | Chulabhorn Hospital [Bangkok, Thailand] | King Chulalongkorn Memorial Hospital [Bangkok, Thailand] | Buddhachinaraj Hospital [Phitsanulok, Thailand] | Dnipropetrovsk City Multifield Clinical Hospital #4 [Dnipro, Ukraine] | Communal Non-Profit Enterprise ""Regional Center of Oncology"" [Kharkiv, Ukraine] | Kryviy Rih Onkology Dispensary [Kryvyi Rih, Ukraine] | National Cancer Institute [Kyiv, Ukraine] | Municipal Institution of Lviv Regional Council - Lviv Oncology Regional Treatment Diagnostic Center [Lviv, Ukraine] | Central City Clinical Hospital, City Oncology Center [Uzhhorod, Ukraine] | Podilskiy Regional Center of Oncology [Vinnytsia, Ukraine] | Communal Institution ""Zaporizhzhia Regional Clinical Oncological Dispensary"" [Zaporizhzhia, Ukraine] | Royal Cornwall Hospital Oncology Trials, Sunrise Centre [Truro, United Kingdom] | Hertford County Hospital [Hertford, United Kingdom] | Cancer Centre, Guy's Hospital [London, United Kingdom] | Nottingham University Hospitals NHS Trust [Nottingham, United Kingdom]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2021.0,4.0,1,Phase 3
NCT03328494,Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies,"A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies",COMPLETED,PHASE1,Boston Pharmaceuticals,2017-10-13,2021-03-16,2021-03-16,2017-11-01,2021-04-15,"['Incidence of adverse events (AEs)', 'Number of participants with a dose-limiting toxicity (DLT)']","['Part A Monotherapy: Plasma concentration of BOS172722 measured over 24 hours when administered alone', 'Part A Combination: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered either individually or in combination', 'Part B Expansion: Plasma concentration of BOS172722 and paclitaxel measured over 24 hours when administered in combination', 'Objective response rate (ORR)', 'Duration of response (DOR)', 'Time to response (TTR)', 'Time to progression on study']",,,,,3,United Kingdom,"Addenbrooks Hospital [Cambridge, United Kingdom] | Edinburgh Cancer Centre - Western General Hospital [Edinburgh, United Kingdom] | Royal Marsden [London, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves BOS172722, a new drug being tested in combination with Paclitaxel for advanced nonhaematologic malignancies, indicating it is a new medicine.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03329950,A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies,A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies,COMPLETED,PHASE1,Celldex Therapeutics,2017-12-01,2022-09-13,2022-09-13,2017-11-06,2024-03-28,['Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0'],"['Objective Response Rate', 'Clinical benefit rate', 'Duration of Response', 'Progression-free survival', 'Overall survival', 'Immunogenicity evaluation', 'Pharmacokinetic evaluation']",,,,,11,United States,"HonorHealth Research Insititute [Scottsdale, United States] | Northside Hospital, Inc. [Atlanta, United States] | Georgia Cancer Center at Augusta University [Augusta, United States] | Oncology Hematology West, PC dba Nebraska Cancer Specialists [Omaha, United States] | Icahn School of Medicine at Mount Sinai [New York, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Gabrail Cancer Center Research LLC [Canton, United States] | Providence Portland Medical Center [Portland, United States] | Abramson Cancer Center at the University of Pennsylvania [Philadelphia, United States] | Rhode Island Hospital (RIH) The Miriam Hospital (TMH) [Providence, United States] | Houston Methodist [Houston, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03330717,Interventional Study on the Impact of the Hypnosis Used as Sedation or Relaxation in the Breast Oncologic Surgery,Interventional Study on the Impact of the Hypnosis Used as Sedation or Relaxation (Virtual Reality) in the Breast Oncologic Surgery,COMPLETED,,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,2017-11-15,2019-12-31,2019-12-31,2017-11-06,2021-06-24,"['Number of the days spent at the hospital post-surgery between the three groups', 'Comparaison of inflammatory parameters measured on day 0,1,8: CRP ( c reactive protein) and NLR ( neutrophils to lymphocyte ratio)']",['Substudy evaluation of salivary immunoglobulins and endocannabinoids among 50 patients (25 under general anesthesia and 25 under hypnosis sedation'],,,,,2,Belgium,"Hôpital de Jolimont [Haine-Saint-Paul, Belgium] | Cliniques Universitaires Saint-Luc [Brussels, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses an interventional study on the use of hypnosis as a method of sedation or relaxation during breast oncologic surgery, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03333785,Randomized Trial of eOncoNote,Improving Cancer Care Together Through eOncoNote,COMPLETED,,University of Toronto,2018-02-05,2020-08-31,2021-02-17,2017-11-07,2021-04-29,['Team/Cross Boundary Continuity subscale of the Nijmegen Continuity Questionnaire'],"['Anxiety', 'Depression', 'Patient experience of the care process']",,,,,1,Canada,"The Ottawa Hospital Research Institute [Ottawa, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text does not mention a new medicine or an extension of indication for an existing medicine. It focuses on a trial related to improving cancer care and patient experience.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03336827,Improving Emotion Regulation at the End of Breast Cancer Treatment,Improving Emotion Regulation at the End of Breast Cancer Treatment: A Randomized Controlled Study Assessing the Impact of a Multi-Component Psychological Group Intervention,COMPLETED,,Université Libre de Bruxelles,2017-01-01,2020-02-28,2020-02-28,2017-11-08,2020-12-08,"[""Change in Patients' Subjective Emotion Regulation through six 10-cm visual analog scales assessing anxiety, sadness, fear of cancer recurrence, physical fatigue, psychological fatigue, and energy state-levels"", ""Change in Patients' Objective Emotion Regulation through an ambulatory digital Holter recording heart rate (beats per minute)"", ""Change in Patients' Emotion Regulation in their Everyday Life through an ecological momentary assessment"", ""Change in Patients' Anxiety State through the Hospital Anxiety Depression Scale (HADS) - anxiety subscale and the Penn State Worry Questionnaire (PSWQ)"", ""Change in Patients' Depression State through the Hospital Anxiety Depression Scale (HADS)"", ""Change in Patients' Fear of Cancer Recurrence State through the Fear of Cancer Recurrence Inventory (FCRI)""]","['Change in an adapted Emotion Symptom Assessment Scale (ESAS)', 'Change in the Hospital Anxiety and Depression Scale (HADS) Questionnaire', 'Change in the Fear of Cancer Recurrence Inventory (FCRI) Questionnaire', 'Change in the White Bear Suppression Inventory (WBSI)', 'Change in the Mental Adjustment to Cancer Scale (MAC)', 'Change in Penn State Worry Questionnaire (PSWQ)', 'Change in the Five Facet of Mindfulness Questionnaire (FFMQ)', 'Change in the Metacognitions About Health Anxiety Questionnaire (MCQ-30)', 'Change in the Insomnia Severity Index (ISI)', 'Change in the Impact of Cancer Scale (IOCv2)', 'Change in the Cognitive Emotion Regulation Questionnaire (CERQ)', 'Change in the Multidimensional Fatigue Inventory (MFI-20)', 'Change in a Life Event Questionnaire', 'Change in Ecological Momentary Assessment through the use of a pedometer and a measure of cardio frequency (Garmin vívoactive® HR)', 'Change in Attentional Bias through a dot probe task']",,,,,1,Belgium,"Institut Jules Bordet [Brussels, Belgium]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a psychological intervention aimed at improving emotion regulation in breast cancer patients, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03339765,Self-Advocacy Serious Game in Advanced Cancer,Piloting a Serious Game to Improve Self-Advocacy Among Women With Advanced Cancer,COMPLETED,,University of Pittsburgh,2018-12-13,2021-03-18,2021-03-18,2017-11-13,2023-07-05,"['Number of participants who engage in at least 8 out of the 12 serious game sessions', 'Number of participants who find the intervention acceptable based on ratings of the Post Study System Usability Questionnaire and qualitative interviews.']","['Change in patient self-advocacy as assessed by the Female Self-Advocacy in Cancer Survivorship Scale.', 'Change in symptom burden as assessed by the MD Anderson Symptom Inventory scale.', ""Change in healthcare utilization as assessed by participants' number of hospital admissions, emergency room visits, and primary care visits in the past three months."", 'Change in quality of life as assessed by the Functional Assessment of Cancer Therapy-General scale.']",,,,,1,United States,"University of Pittsburgh Medical Center [Pittsburgh, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study for a serious game aimed at improving self-advocacy among women with advanced cancer, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03342417,"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients","Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients",TERMINATED,PHASE2,ExcellaBio LLC,2018-02-14,2019-05-29,2019-05-29,2017-11-17,2021-11-09,"['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'Clinical Response']","['Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BCT', 'Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Possible predictive biomarkers', 'Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Status of PD-L1, PDL-2, and PD-1 in tumor tissues before vs. after investigational neoadjuvant therapy', 'Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Possible transition of Th2 to Th1 in the tumor', 'Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BOR and ORR', 'Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - PFS', 'Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - DOR', 'Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - OS', 'Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate']",,,,,1,United States,"Hoffman Oncology [The Bronx, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,INDUSTRY,False,2019.0,6.0,0,Phase 2
NCT03343613,A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors,A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors,TERMINATED,PHASE1,Eli Lilly and Company,2017-11-17,2020-02-07,2020-05-04,2017-11-17,2020-06-09,['Number of Participants with Dose Limiting Toxicities (DLTs)'],"['Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY3381916', 'PK: Area Under the Plasma Concentration Curve (AUC) of LY3381916', 'PK: Cmax of LY3381916 Administered in Combination with LY3300054', 'PK: AUC of LY3381916 Administered in Combination with LY3300054', 'PK: Cmax of LY3300054 Administered in Combination with LY3381916', 'PK: Minimum Plasma Concentration (Cmin) of LY3300054 Administered in Combination with LY3381916', 'Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)', 'Time to Response (TTR)', 'Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR', 'Duration of Response (DOR)', 'Progression Free Survival (PFS)']",,,,,12,Belgium; Denmark; France; Italy; Spain; United States,"IU Simon Cancer Center [Indianapolis, United States] | Sarah Cannon Research Institute SCRI [Nashville, United States] | Tennessee Oncology PLLC [Nashville, United States] | Institut Jules Bordet [Brussels, Belgium] | Universitair Ziekenhuis Antwerpen [Edegem, Belgium] | Universitair Ziekenhuis Gent [Ghent, Belgium] | Finsen Institute [Copenhagen, Denmark] | Gustave Roussy [Villejuif, France] | Azienda Ospedaliera San Gerardo [Monza, Italy] | Azienda Ospedaliera Umberto I [Ancona, Italy] | Hospital Clinico Universitario Virgen de la Victoria [Málaga, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain]",2017.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves LY3381916, which is identified as a new anti-IDO-1 agent being tested for the first time in combination with another agent (LY3300054) in participants with solid tumors, indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03348696,Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients,A Multi-Centre Randomised Study Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for Taxane- Associated Pain Syndrome (TAPS) in Breast Cancer Patients (OTT 17-02 REaCT-TAPS),COMPLETED,PHASE4,Ottawa Hospital Research Institute,2018-02-28,2019-04-02,2019-04-02,2017-11-21,2020-01-09,['Evaluation of TAPS'],"['Quality of Life', 'Quality of Life', 'Pain scores', 'Use of rescue analgesic', 'Symptoms and signs associated with dexamethasone', 'Cost effectiveness']",,,,,2,Canada,"Southlake Regional Cancer Centre [Newmarket, Canada] | The Ottawa Hospital Cancer Centre [Ottawa, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the use of low dose dexamethasone for a specific condition (Taxane-Associated Pain Syndrome) in breast cancer patients, which indicates an extension of indication for an existing medication.",OTHER,False,2019.0,6.0,0,Other
NCT03351140,Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function,Qualitative Interviews to Evaluate the PROMIS Physical Function Item Bank for Use in Oncology Clinical Trials,COMPLETED,,GlaxoSmithKline,2017-12-20,2020-05-08,2020-05-08,2017-11-22,2021-07-14,['Conduct qualitative patient interviews with a range of cancer patients across multiple tumor types to identify a subset of relevant PROMIS Physical Function items that can be utilized in future clinical trials'],"['Number of subject expressions of a given concept', 'Number of interviews to reach saturation of concept']",,,,,1,United States,"GSK Investigational Site [Mountlake Terrace, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses qualitative interviews to evaluate a measurement system (PROMIS) for physical function in oncology clinical trials, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT03355261,Positive Node Traced Before Neoadjuvant Chemotherapy (NAC),Long-term Tracing for Axillary Lymph Nodes Dissection in the Patients With Fusion Lymph Node Before Neo-adjuvant Chemotherapy,COMPLETED,,Shengjing Hospital,2014-07-01,2018-07-01,2018-07-01,2017-11-28,2020-02-20,['The spatial distribution of positive nodes in axillary after neoadjuvant chemotherapy based on pectoralis minor location'],"['The spatial distribution of black-stained in axillary after neoadjuvant chemotherapy based on pectoralis minor location', 'The spatial distribution of positive nodes in axillary after neoadjuvant chemotherapy based on intercostobrachiales nerves (ICBN) location']",,,,,3,China,"The Second Hospital of Jilin University [Changchun, China] | the First Affiliated Hospital of China Medical University [Shenyang, China] | Shengjing Hospital of China Medical University [Shenyang, China]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2018.0,7.0,0,NA/Other
NCT03358004,the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment,"An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment",TERMINATED,PHASE2,Mario Negri Institute for Pharmacological Research,2017-06-14,2018-09-13,2018-09-13,2017-11-30,2018-10-05,['PFS-12 weeks'],"['OS', 'PFS', 'Incidence of Adverse Events']",,,,,30,Italy; Portugal; Spain,"AOU Ospedali riuniti di Ancona [Torrette, Italy] | ASST Monza [Monza, Italy] | Azienda Ospedaliero-Universitaria Pisana [Pisa, Italy] | Azienda Ospedaliero Universitaria di Parma [Parma, Italy] | Ospedale Civile di Guastalla [Reggio Emilia, Italy] | Ospedale Martini ASL Torino 1 [Torino, Italy] | Istituto Tumori Giovanni Paolo II [Bari, Italy] | ASST Papa Giovanni XXIII [Bergamo, Italy] | A. Ospedaliero universitaria di Bologna [Bologna, Italy] | Azienda Sanitaria Locale Brindisi [Brindisi, Italy] | ASST - Cremona [Cremona, Italy] | A.O. San Croce e Carle [Cuneo, Italy] | Ospedale Vito Fazzi [Lecce, Italy] | Istituto Europeo di Oncologia [Milan, Italy] | Policlinico di Modena [Modena, Italy] | Policlinico Paolo Giaccone [Palermo, Italy] | Casa di Cura La Maddalena [Palermo, Italy] | Ospedale Felice Lotti [Pontedera, Italy] | Istituto Nazionale Regina Elena [Roma, Italy] | Azienda Ospedaliero Universitaria di Sassari [Sassari, Italy] | Instituto Portugues Oncologia de Coimbra [Coimbra, Portugal] | CHLN Hospital Santa Maria [Lisbon, Portugal] | Hospital de S. Francisco Xavier [Lisbon, Portugal] | Hospital Beatriz Angelo [Loures, Portugal] | Centro Hospitalar Do Porto [Porto, Portugal] | Centro Hospitalar De Sao Joao EPE [Porto, Portugal] | Instituto Portugues Oncologia de Porto [Porto, Portugal] | Hospital Vall d'Hebron [Barcelona, Spain] | Hospital Virgen de la Salud [Toledo, Spain] | Hospital Clinico Universitario Lozano Blesa [Zaragoza, Spain]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2018.0,7.0,1,Phase 2
NCT03361800,"Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC","A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)",TERMINATED,EARLY_PHASE1,UNC Lineberger Comprehensive Cancer Center,2018-11-28,2019-09-18,2019-10-11,2017-12-05,2024-03-25,['Decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers'],"['mRNA gene expression changes following treatment with entinostat, across TNBC', 'Changes in the proliferation signature by mRNA expression following treatment with entinostat across TNBC', 'Differential kinome activation before and after treatment with entinostat across TNBC', 'Correlation of mutation and/or copy number variations by whole exome sequencing (WES) with mRNA gene expression changes and reduction of proliferation signature following treatment with entinostat across TNBC.', 'Correlation of protein lysine hyperacetylation in peripheral blood and tumor from pre- and post-entinostat treated TNBCs', 'Percentage of participants with treatment related adverse events']",,,,,1,United States,"Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill [Chapel Hill, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating the use of Entinostat, which is not previously approved for the specific patient population of newly diagnosed Stage I-IIIC TNBC, indicating it is a new medicine trial.",OTHER,False,2019.0,6.0,0,Phase 1
NCT03367208,Study of Metabolites Markers in Adjuvant Breast Cancer,Study of Metabolites Markers in Adjuvant Breast Cancer,COMPLETED,,Centre Antoine Lacassagne,2017-04-12,2017-05-23,2017-05-23,2017-12-08,2025-09-30,['Metabolomic profil diagnosis value'],"['correlation coefficient between glycolysis pathway metabolic concentration and 18FDG uptake', 'qualitative profile of tumor metabolic in serum', 'quantitative profile of tumor metabolic in serum', 'PFS comparisons at 2 years regarding the presence or absence of some metabolites (serum or tissue)', 'Test of concordance between metabolites found in tissues and serum sample']",,,,,1,France,"Centre Antoine Lacassagne [Nice, France]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2017.0,8.0,0,NA/Other
NCT03367689,A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent,A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Homologous Recombination Deficiency Treated With OLAparib Single Agent,TERMINATED,PHASE2,MedSIR,2018-04-17,2021-07-31,2021-12-31,2017-12-11,2023-02-22,"['To assess the efficacy of olaparib single agent in non-BRCA MBC patients whose tumours exhibit an homologous recombination deficiency (HRD) signature, as determined by Clinical Benefit Rate (CBR) using RECIST 1.1 criteria']","[""To assess the accuracy of Foundation One's HRR assay in predicting the proportion of patients with response to olaparib."", 'To assess incidence of Treatment-Emergent Adverse Events (Safety profile) of olaparib in this population', ""To investigate the prevalence of HRD signature within triple negative and luminal non-BRCA patients' cohorts"", 'To explore the efficacy of olaparib in terms of Progression-free survival (PFS)', 'To explore the efficacy of olaparib in terms of objective response rate (ORR)', 'To explore the efficacy of olaparib in terms of overall survival (OS)']",,,,,5,Spain,"Hospital del Mar [Barcelona, Spain] | Onkologikoa [Donostia / San Sebastian, Spain] | Institut Català d' Oncologia L'Hospitalet (ICO) [L'Hospitalet de Llobregat, Spain] | Hospital Ramón y Cajal [Madrid, Spain] | Hospital Arnau de Vilanova de Valencia [Valencia, Spain]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is assessing the efficacy of olaparib in a specific patient population (non-BRCA MBC patients with HRD), indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03373474,Warm Acupuncture for Breast Cancer Related Lymphedema,"Comparison of Effectiveness Between Warm Acupuncture With Local-Distal Points Association and Local Distribution Points Association in Breast Cancer Related Lymphedema Patients: A Multicenter, Randomized, Controlled Clinical Trial",COMPLETED,,Tianjin University of Traditional Chinese Medicine,2018-01-18,2020-05-26,2020-12-26,2017-12-14,2021-05-06,['Upper extremity circumference'],"['Upper extremity volume', 'Common terminology criteria for adverse events (CTCAE 4.03) - edema limbs criteria', 'Stages of lymphedema from the international society of lymphology', 'The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure', 'The MOS 36-Item Short-Form Health Survey (SF-36)']",,,,,1,China,"Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine [Tianjin, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the effectiveness of warm acupuncture, which is an existing treatment, specifically for breast cancer-related lymphedema, indicating an extension of indication for this therapy.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03375801,Implementing a Decision Aid for Breast Cancer and DCIS Patients Deciding on Their Radiation Treatment.,Implementing a Decision Aid for Breast Cancer and DCIS Patients Deciding on Their Radiation Treatment: A Pre- and Post-intervention Study.,COMPLETED,,Maastricht University,2017-10-01,2019-10-30,2020-07-27,2017-12-18,2020-07-28,['Decisional conflict'],"['Improvement on the perceived level of shared decision making.', 'Improvement on the perceived level of shared decision making.', 'Patient knowledge', 'Decisional conflict', 'Prospective process evaluation']",,,,,5,Netherlands,"Radboud UMC [Nijmegen, Netherlands] | MAASTRO-clinic [Maastricht, Netherlands] | Maastricht University [Maastricht, Netherlands] | Academisch Medisch Centrum (AMC) [Amsterdam, Netherlands] | NKI-AVL [Amsterdam, Netherlands]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a decision aid for patients regarding radiation treatment for breast cancer and DCIS, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03383107,Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome,Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome,COMPLETED,,Weill Medical College of Cornell University,2018-01-22,2021-07-31,2021-07-31,2017-12-26,2022-08-12,"['prospectively collecting blood specimens to assess peripheral immune mediatiors in 4 distinct clinical settings', 'distribution and frequency of peripheral immune mediators before, during and after radiotherapy will be assessed from blood samples that are collected at various time points']",['microbiome changes associated with different radiation treatments through collection of stool microbiome samples at different time points'],,,,,1,United States,"Weill Cornell Medical College [New York, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the effects of radiotherapy on immune response and microbiome but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03383679,Study on Androgen Receptor and Triple Negative Breast Cancer,A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine,COMPLETED,PHASE2,UNICANCER,2018-03-14,2021-11-30,2022-07-20,2017-12-26,2022-11-21,['clinical benefit rate'],"['clinical benefit rate', 'Objective response rate', 'Duration of overall response', 'Overall survival', 'Progression-free survival', 'Safety: Evaluation of toxicity in each arm according to CTCAE V4.03']",,,,,1,France,"Centre François Baclesse [Caen, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the use of Darolutamide in a specific patient population (triple-negative androgen receptor positive breast cancer), indicating an extension of indication for an existing drug.",OTHER,False,2022.0,3.0,0,Phase 2
NCT03386162,SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer,A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer,TERMINATED,PHASE2,UNICANCER,2018-03-15,2022-11-18,2022-11-18,2017-12-29,2022-11-28,['progression-free survival'],[],,,,,14,France,"Institut de Cancérologie de l'Ouest/Paul Papin [Angers, France] | Institut Sainte-Catherine [Avignon, France] | Institut Bergonié [Bordeaux, France] | Centre François Baclesse [Caen, France] | Chd Vendee [La Roche-sur-Yon, France] | CHU Dupuytren [Limoges, France] | Centre Leon Berard [Lyon, France] | Institut Paoli Calmettes [Marseille, France] | CInstitut Regional du cancer-Centre Val D'Aurelle [Montpellier, France] | Centre Eugène Marquis [Rennes, France] | Centre Rene Huguenin [Saint-Cloud, France] | Hôpitaux du Léman [Thonon-les-Bains, France] | Institut Claudius Regaud [Toulouse, France] | Institut Gustave Roussy [Villejuif, France]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 2
NCT03394287,A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC,"A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer",COMPLETED,PHASE2,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2018-01-10,2019-12-30,2020-09-30,2018-01-09,2020-10-23,['ORR'],"['Incidence of Treatment-Emergent Adverse Events', 'DCR', 'DoR', 'PFS', 'One year-OS', 'CBR', 'TTR', 'Frequencies Of Biomarkers']",,,,,1,China,"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University [Guangzhou, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves SHR-1210, which is an Anti-PD-1 antibody being tested in combination with Apatinib for a specific patient population (advanced TNBC), indicating it is a new medicine.",OTHER,False,2020.0,5.0,0,Phase 2
NCT03402997,Tissue Resistivity in Breast Cancer Patients,Minimally Invasive Procedure for the Discrimination of Tissue Resistivity in Breast Cancer Patients,COMPLETED,,"Ente Ospedaliero Cantonale, Bellinzona",2017-12-15,2019-09-25,2019-09-25,2018-01-18,2019-12-12,['Breat tissue characterization'],"['Evaluation of the precision of each EIS measurement', 'Correlation between electrical and biological results']",,,,,1,Switzerland,"Ospedale Regionale di Mendrisio [Mendrisio, Switzerland]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a procedure for tissue characterization in breast cancer patients but does not indicate the introduction of a new medicine or an extension of an existing medicine's indication.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03405168,Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer,Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer,COMPLETED,PHASE2,Sun Yat-sen University,2018-01-01,2018-07-30,2018-07-30,2018-01-19,2018-11-16,['progression-free survival (PFS)'],"['objective response rate (ORR)', 'clinical benefit rate (CBR)', 'overal survival(OS)']",,,,,1,China,"Zhongyu Yuan [Guangzhou, China]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text suggests the use of Moxifloxacin in combination with routine therapy for advanced breast cancer, indicating an extension of indication for an existing treatment rather than the introduction of a new medicine.",OTHER,False,2018.0,7.0,0,Phase 2
NCT03405519,MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs,MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs,COMPLETED,,Royal Marsden NHS Foundation Trust,2017-12-18,2019-12-12,2019-12-12,2018-01-23,2020-08-17,['The number of patients in whom a higher dose can be delivered to the level IV (SCF) nodes without breaching brachial plexus constraints on the radiotherapy plans created using MR images compared with CT images'],[],,,,,1,United Kingdom,"The Royal Marsden NHS Foundation Trust [Sutton, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses MR-guided radiotherapy with dose escalation to regional lymph nodes, indicating an extension of indication for an existing treatment rather than a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03408769,Metastatic Breast Carcinoma and Women Sexual Quality of Life,Metastatic Breast Carcinoma: Evaluation of Women Sexual Quality of Life,COMPLETED,,Institut de Cancérologie de Lorraine,2018-03-12,2018-04-04,2018-04-04,2018-01-24,2018-08-08,['Quality of sexual life of postmenopausal women with metastatic breast carcinoma living in couples'],"['Quality of life', 'Quality of Relationship of the couple', 'Sexual and emotional intimacy']",,,,,1,France,"Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the quality of life and sexual quality of life in postmenopausal women with metastatic breast carcinoma, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03409198,Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer,A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Patients with Metastatic Hormone Reseptor Positive Breast Cancer,COMPLETED,PHASE2,Oslo University Hospital,2018-01-21,2022-05-11,2022-05-11,2018-01-24,2024-10-15,"['Toxicity: CTCAE v4.0', 'Progression-free survival (PFS)']","['Duration of Response (DR)', 'Overall Survival (OS)', 'Duration of Response (DR) in cross-over arm', 'Overall Suvival (OS) in cross-over arm', 'Toxicity, cross-over arm, CTCAE v4.0', 'Objective tumor Response Rate (ORR)', 'Durable tumor Response Rate (DRR)', 'Objective tumor Response Rate (ORR) in cross-over arm', 'Durable tumor Response Rate (DRR) in cross-over arm', 'Clinical Benefit Rate (CBR)', 'Clinical Benefit Rate (CBR) in cross-over arm', 'PD-L1 expression', 'Chalder Fatigue Questionnaire (FQ)', 'Pain intensity', 'EORTC QLQ-C15-PAL', 'Biological response in molecular subtypes of breast cancer']",,,,,6,Belgium; Norway,"Institut Jules Bordet [Brussels, Belgium] | Cliniques universitaires Saint-Luc [Brussels, Belgium] | CHU UCL Namur [Namur, Belgium] | Soerlandet Hospital HF Kristiansand [Kristiansand, Norway] | Oslo University Hospital [Oslo, Norway] | Stavanger University Hospital [Stavanger, Norway]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the combination of existing drugs (Ipilimumab and Nivolumab) with a new chemotherapy regimen in a specific patient population (metastatic hormone receptor positive breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,1,Phase 2
NCT03411161,S 81694 Plus Paclitaxel in Metastatic Breast Cancer,"Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer",COMPLETED,PHASE1; PHASE2,Institut de Recherches Internationales Servier,2018-01-04,2020-06-08,2020-06-08,2018-01-26,2021-05-25,"['Incidence of DLTs (dose-limiting toxicities)', 'Safety and tolerability assessed by incidence of Adverse Events', 'Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis)', 'Abnormalities in physical examination and performance status (ECG) (mm/s)', 'Abnormalities in blood pressure (mmHg)', 'Abnormalities in heart rate (BPM (beat per minute))', 'Abnormalities in body temperature (C°degree celsius)', 'Abnormalities in respiration rate (cycles per minute)', 'Abnormalities in body weight (Kg)', 'Progression free survival (PFS) [based on Investigator review of the images according to RECIST 1.1]']","['The PK (pharmacokinetic) profile of S 81694 and paclitaxel plasma concentration : Area under the plasma concentration-time curve (AUC)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Elimination half-life (T½)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Maximum plasma concentration (Cmax)', 'The PK profile of S 81694 and paclitaxel plasma concentration : Minimum plasma concentration (Cmin)', 'Overall Response Rate (ORR) [ based on Investigator review of the images according to RECIST 1.1]', 'Incidence of treatment-emergent adverse events (AEs) graded according to NCI CTCAE v4.03']",,,,,6,Belgium; France; Japan; Netherlands,"Institut Jules Bordet Clinique Oncologie Médicale [Brussels, Belgium] | UZ Leuven Campus Gasthuisberg Dept. of General Medical [Leuven, Belgium] | Institut de Cancérologie de l'Ouest site Saint Herblain [Saint-Herblain, France] | Chiba cancer center Breast surgery [Chiba, Japan] | Osaka International Cancer Institute [Osaka, Japan] | Erasmus MC Section Clinical Pharmacology [Rotterdam, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,1,Phase 2
NCT03419026,Pregnant Exposure to Persistent Organic Pollutants,Pregnant Exposure to Persistent Organic Pollutants With Endocrine Disrupting Activity and Development of Breast Cancer in the Next 15 Years: Longitudinal Prospective Cohort Nested Case-control Study,COMPLETED,,Centre Hospitalier Universitaire de Nice,2016-05-01,2017-05-01,2017-05-01,2018-02-01,2018-02-01,['the Number of blood samples usable by return of patient non-opposition'],[],,,,,1,France,"Nice Hospital [Nice, France]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effects of persistent organic pollutants on pregnant women and breast cancer development, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03420105,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep,COMPLETED,,Centre Francois Baclesse,2018-01-05,2020-03-06,2020-03-06,2018-02-05,2020-03-09,['The memory components and memory loss mechanisms by questionnaires'],"['The effect of sleep quality on the recovery of intentions in prospective memory by questionnaires', 'The impact of adjuvant hormone therapy on the functioning of prospective memory by questionnaires', 'The influence of anxio-depressive factors and fatigue on prospective memory by questionnaires']",,,,,2,France,"Centre François Baclesse [Caen, France] | Inserm-Ephe-Unicaen U1077 ( [Caen, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03425773,Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care,"Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care",COMPLETED,PHASE1,"Cellid Co., Ltd.",2018-02-26,2019-05-13,2019-05-13,2018-02-08,2020-02-20,"['Evaluate Maximum tolerated dose(MTD) for phase 2 trial', 'Incidence of Serious Adverse Events assessed with CTCAE v4.03']","['Serum cytokine', 'HER2/neu specific antibody', 'NKT/NK cell assay', 'CD4/CD8 assay', 'Lymphocyte subset', 'Change of tumor burden']",,,,,1,South Korea,"Severance Hospital [Seoul, South Korea]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating a new treatment (BVAC-B) for patients with HER2/Neu positive gastric cancer, indicating it is a new medicine.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03429101,A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer,A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer,TERMINATED,PHASE1,"Spectrum Pharmaceuticals, Inc",2018-07-13,2019-04-17,2019-04-17,2018-02-12,2021-01-15,['Objective Response Rate (ORR)'],"['Disease Control Rate (DCR)', 'Progression-free Survival (PFS)']",,,,,2,United States,"Pacific Cancer Medical Center, Inc. [Anaheim, United States] | Los Angeles Hematology Oncology Medical Group [Glendale, United States]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Poziotinib, which is being studied in combination with T-DM1 for a specific patient population (HER2-positive breast cancer), indicating it is a new medicine being evaluated for efficacy in this context.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03429296,Autohypnosis and Cancerology,"Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.",COMPLETED,,Groupe Hospitalier Mutualiste de Grenoble,2018-05-23,2022-01-21,2022-07-01,2018-02-12,2023-03-07,['>20% increase of the EORTC QLQC30 score (annexe 1) at the third week after the last chemotherapy session in the auto-hypnosis arm compared to the standard care arm.'],"['Evaluation of auto-hypnosis effects on the life quality and global health of patients at short, mid, and long term.', 'Evaluation of auto-hypnosis effects on different components of quality of life.', 'Evaluation of auto-hypnosis effects on different components of quality of life specific to breast cancer', 'Evaluation of auto-hypnosis effects on different components of quality of life specific to colorectal cancer.', 'Evaluation of auto-hypnosis effects on drug consumption.', 'Evaluation of auto-hypnosis effects on fatigue.', 'Evaluation of auto-hypnosis impact on anxiety and/or depression.', 'Evaluation of auto-hypnosis impact on the global medical handling of their cancer.', ""Evaluation of patient's satisfaction about auto-hypnosis therapies.""]",,,,,1,France,"Groupe hospitalier Mutualiste de Grenoble [Grenoble, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,NA/Other
NCT03430466,Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer,"Phase II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer",TERMINATED,PHASE2,Kyoto Breast Cancer Research Network,2017-06-22,2018-01-30,2018-07-31,2018-02-13,2020-08-12,['Response rate based on RECIST1.1'],[],,,,,1,Japan,"Kyoto University Hospital [Kyoto, Japan]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text describes a combination therapy involving existing treatments (Anti PD-L1 and Anti CTLA-4 antibodies) with hormone therapy for a specific patient population, indicating an extension of indication rather than a new medicine.",OTHER,False,2018.0,7.0,0,Phase 2
NCT03430479,Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer,"Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer",COMPLETED,PHASE1; PHASE2,Kyoto Breast Cancer Research Network,2017-06-22,2018-11-30,2021-04-01,2018-02-13,2023-01-19,['Phase Ib : dose-limiting toxicity rate'],[],,,,,1,Japan,"Kyoto University Hospital [Kyoto, Japan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves an anti PD-1 antibody, which is a new medicine being tested in combination with radiation therapy for a specific type of cancer (HER2-negative metastatic breast cancer).",OTHER,False,2021.0,4.0,0,Phase 2
NCT03430518,Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer,COMPLETED,PHASE1,Amy Tiersten,2018-05-17,2020-02-10,2020-02-10,2018-02-13,2020-08-05,['The dose-limiting toxicity (DLT) rate'],"['Number of Adverse events', 'Objective response rate (ORR)', 'Progression free survival (PFS)', 'Overall survival (OS)', 'ECOG performance status']",,,,,1,United States,"Icahn School of Medicine at Mount Sinai [New York, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the combination of Durvalumab, which is already an approved medication, with Eribulin in specific cancer types, indicating an extension of indication for these existing drugs.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03432429,Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study,Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins,COMPLETED,,Imperial College London,2017-09-05,2021-12-08,2021-12-08,2018-02-14,2022-03-31,['Diagnostic accuracy'],"['Assessment of procedure duration using REIMS', 'REIMS technology user satisfaction', 'Accuracy of predicting oncological status']",,,,,3,United Kingdom,"Royal Marsden NHS Foundation Trust (Chelsea) [London, United Kingdom] | Imperial College NHS Foundation Trust, Charing Cross Hospital [London, United Kingdom] | The Royal Marsden NHS Foundation Trust (Sutton) [Sutton, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a study focused on diagnostic accuracy and procedural assessment using existing technology (REIMS) rather than introducing a new medicine or extending the indication of an existing one.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03433313,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,"A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer",COMPLETED,PHASE3,"EirGenix, Inc.",2018-10-16,2022-01-20,2022-01-20,2018-02-14,2023-01-20,['Determination of pathologic complete response (pCR) at time of surgery'],"['pCR at the time of surgery', 'pCR at the time of surgery', 'Event-free survival (EFS) up to end of study (EOS)', 'Overall response (OR) prior to surgery', 'Overall survival (OS) up to End of Study (EOS)', 'Incidence of AEs', 'Evaluation of Immunogenicity of EG12014 and Herceptin', 'Measure serum trastuzumab concentration']",,,,,91,Belarus; Chile; Colombia; Georgia; India; Russia; South Africa; South Korea; Taiwan; Ukraine; United States,"Detroit Clinical Research Center [Farmington Hills, United States] | Aultman Hospital, Cancer Center [Canton, United States] | Brest Regional Oncology Center [Brest, Belarus] | Gomel Regional Clinical Oncology Center [Homyel, Belarus] | N.N. Aleksandrov Republican Research Oncology and Medical Radiology Center [Lesnoy, Belarus] | Minsk City Clinical Oncology Center [Minsk, Belarus] | Mogilev Regional Oncology Center [Mogilev, Belarus] | Vitebsk Regional Clinical Oncology Center [Vitebsk, Belarus] | Medical Research Limited Society [Temuco, Chile] | Oncocentro Apys [Viña del Mar, Chile] | Clinic Life Foundation [Medellín, Colombia] | Rodrigo Botero SAS [Medellín, Colombia] | LTD High-Tech Hospital MedCenter [Batumi, Georgia] | JSC ""Evex Hospitals [Kutaisi, Georgia] | LTD Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine [Tbilisi, Georgia] | LTD Aversi Clinic [Tbilisi, Georgia] | LTD Cancer Research Centre [Tbilisi, Georgia] | LTD Health House [Tbilisi, Georgia] | LTD Institute of Clinical Oncology [Tbilisi, Georgia] | LTD S.Khechinashvili University Hospital [Tbilisi, Georgia] | Malkhaz Katsiashvili Multiprofile Emergency Medicine Center [Tbilisi, Georgia] | Cytecare Cancer Hospitals [Bengaluru, India] | King George's Medical University, Department of Endocrine surgery, Shatabdi Phase II [Lucknow, India] | Tata Memorial Centre [Mumbai, India] | HCG NCHRI Cancer Centre [Nagpur, India] | Christian Medical College, Department of Medical Oncology [Vellore, India] | Arkhangelsk Clinical Oncology Center [Arkhangelsk, Russia] | Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center [Chelyabinsk, Russia] | Evimed, LLC [Chelyabinsk, Russia] | Ivanovo Regional Oncology Center [Ivanovo, Russia] | Republican Clinical Oncology Center [Kazan', Russia] | Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center [Krasnoyarsk, Russia] | Kursk Regional Clinical Oncology Center [Kursk, Russia] | N.N. Blokhin National Medical Oncology Research Center [Moscow, Russia] | National Medical Research Center for Radiology [Moscow, Russia] | Vitamed"" LLC [Moscow, Russia] | A.F.Tsyb Medical Radiology Research Center [Obninsk, Russia] | Clinical Oncology Center [Omsk, Russia] | Pyatigorsk Interdistrict Oncology Center [Pyatigorsk, Russia] | Rostov Oncology Research Institute [Rostov-on-Don, Russia] | Regional Clinical Oncology Center [Ryazan, Russia] | AV Medical Group [Saint Petersburg, Russia] | City Clinical Oncology Center [Saint Petersburg, Russia] | Clinic ""Mart"" [Saint Petersburg, Russia] | I.I. Mechnikov North-Western State Medical University [Saint Petersburg, Russia] | Leningrad Regional Oncology Center (Outpatient Department) [Saint Petersburg, Russia] | Leningrad Regional Oncology Center (Surgery Department) [Saint Petersburg, Russia] | N.N. Petrov National Medical Research Center of Oncology [Saint Petersburg, Russia] | Oncology Center of Moskovskiy District [Saint Petersburg, Russia] | Private Medical Institution ""EVROMEDSERVIS"", Department of Oncology [Saint Petersburg, Russia] | St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncology) [Saint Petersburg, Russia] | Republican Oncology Center [Saransk, Russia] | Oncology Center #2 [Sochi, Russia] | Tomsk National Research Medical Center [Tomsk, Russia] | Regional Clinical Oncology Center [Veliky Novgorod, Russia] | Volgograd Regional Clinical Oncology Center [Volgograd, Russia] | GVI Oncology, Cape Gate Oncology Centre [Cape Town, South Africa] | The Oncology Centre [Durban, South Africa] | Medical Oncology Centre of Rosebank [Johannesburg, South Africa] | Little Company of Mary Medical Center, Department of Oncology [Pretoria, South Africa] | University of Pretoria, Department of Medical Oncology [Pretoria, South Africa] | Keimyung University - Dongsan Medical Center [Daegu, South Korea] | Kaohsiung Medical University Chung-Ho Memorial Hospital [Kaohsiung City, Taiwan] | China Medical University Hospital [Taichung, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | Taipei Veterans General Hospital [Taipei, Taiwan] | Tri-Service General Hospital [Taipei, Taiwan] | Linkou Chang Gung Memorial Hospital [Taoyuan District, Taiwan] | Chernihiv Regional Oncology Center [Chernihiv, Ukraine] | Chernivtsi Regional Clinical Oncology Center [Chernivtsi, Ukraine] | Clinical Oncology Center [Dnipro, Ukraine] | Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy [Dnipro, Ukraine] | Prikarpattia Clinical Oncology Center [Ivano-Frankivsk, Ukraine] | Communal Non-profit enterprise ""Regional Center of Oncology"" [Kharkiv, Ukraine] | State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Department of Clinical Oncology and Hematology [Kharkiv, Ukraine] | Khmelnytskyi Regional Oncology Center [Khmelnytskyi, Ukraine] | Kryvyi Rih Oncology Center, Department of Chemotherapy [Kryvyi Rih, Ukraine] | Kyiv City clinical Hospital #2 [Kyiv, Ukraine] | Kyiv Regional Oncology Center, Department of Mastology [Kyiv, Ukraine] | Medical Center ""Verum"" [Kyiv, Ukraine] | Medical Center of First Private Clinic [Kyiv, Ukraine] | Volyn Regional Oncology Center, Department of Chemotherapy [Lutsk, Ukraine] | Public Institution under Lviv Regional Council: Lviv Regional Treatment and Diagnostics Oncology Center, Department of Chemotherapy [Lviv, Ukraine] | Mariupol Oncology Center [Mariupol, Ukraine] | Odesa Regional Clinical Hospital, Center for Mastology, Department of Thoracic Surgery [Odesa, Ukraine] | Odesa Regional Oncology Center [Odesa, Ukraine] | Ternopil Regional Clinical Oncology Center, Department of Chemotherapy [Ternopil, Ukraine] | Central City Clinical Hospital, Department of Oncology and Radiology [Uzhhorod, Ukraine] | Zakarpattia Regional Clinical Oncology Center, Department of Chemotherapy [Uzhhorod, Ukraine] | Podillia Regional Oncology Center [Vinnytsia, Ukraine] | Zhytomyr Regional Oncology Center [Zhytomyr, Ukraine]",2018.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03433560,An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®),"An Observational, Prospective, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.",COMPLETED,,"Kyowa Kirin Korea Co., Ltd.",2018-01-18,2021-06-30,2021-06-30,2018-02-14,2024-05-14,['The incidence of febrile neutropenia after secondary prophylaxis with pegfilgrastim'],"['The incidence of bone pain, or percentage of patients with relative dose intensity (RDI) or all adverse events as assessed by CTCAE']",,,,,3,South Korea,"Wonju Severance Christian Hospital [Wŏnju, South Korea] | Bucheon Soonchunhyang University Hospital [Bucheon-si, South Korea] | Pusan National University Yangsan Hospital [Yangsan, South Korea]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,The study evaluates the use of Pegfilgrastim (Neulasta®) for a new indication (secondary prophylaxis to decrease febrile neutropenia in a specific patient population) rather than introducing a new medicine.,INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT03437083,A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants,"A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients",COMPLETED,,Eisai Korea Inc.,2018-01-25,2018-06-30,2018-06-30,2018-02-19,2019-01-25,['Progression-free survival (PFS) rate at 6 months'],"['Progression-Free Survival (PFS)', 'Overall Survival (OS)', 'Time to treatment failure (TTF)', 'Tumor response rate (TRR)', 'Number of participants with any treatment-emergent adverse event (TEAE)', 'PFS in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)', 'OS in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)', 'TTF in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)', 'TRR in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)', 'PFS rate in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use', 'OS in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use', 'TTF in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use', 'TRR in eribulin-treated breast cancer participants comparing early (≤third line) to late (≥ fourth line) use', 'Number of participants with the indicated action to TEAEs', 'Number of participants with TEAEs resulting in discontinuation of eribulin', 'Number of participants using supportive drugs to treat AEs', 'Median number of eribulin cycles', 'Number of participants experiencing a dose reduction', 'Mean duration of treatment', 'Mean duration of response', 'Mean dose intensity', 'Number of participants with the indicated reason for treatment discontinuation']",,,,,14,South Korea,"Eisai Trial site_03 [Ansan, South Korea] | Eisai Trial site_04 [Busan, South Korea] | Eisai Trial site_05 [Busan, South Korea] | Eisai Trial site_06 [Busan, South Korea] | Eisai Trial site_09 [Daegu, South Korea] | Eisai Trial site_13 [Daejeon, South Korea] | Eisai Trial site_14 [Gwangju, South Korea] | Eisai Trial site_01 [Seoul, South Korea] | Eisai Trial site_02 [Seoul, South Korea] | Eisai Trial site_07 [Seoul, South Korea] | Eisai Trial site_10 [Seoul, South Korea] | Eisai Trial site_11 [Seoul, South Korea] | Eisai Trial site_12 [Seoul, South Korea] | Eisai Trial site_08 [Suwon, South Korea]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study investigates the efficacy and safety of Eribulin specifically in Korean breast cancer patients, suggesting it is an extension of indication for an existing treatment rather than a new medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT03442686,Compass Course: Efficacy Study,Compass Course: Efficacy Study,COMPLETED,,Allina Health System,2018-03-02,2021-05-01,2021-05-01,2018-02-22,2021-05-12,['Change in psychological well-being'],"['Recruitment', 'Time of pre-testing session', 'Time of testing session', 'Time of post-testing session', 'Homework completion', 'Intervention fidelity', 'Change in Meaning in life', 'Engagement in Meaningful Activities', 'Purpose Status and Expectations', 'Participant Experience of Compass Course']",,,,,3,United States,"Courage Kenny Rehabilitation Institute [Golden Valley, United States] | Abbott Northwestern Hospital [Minneapolis, United States] | Allina Health Shoreview Clinic [Shoreview, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes an efficacy study related to a course focused on psychological well-being and does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03447132,Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant,"Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®",COMPLETED,PHASE3,"International Cancer Research Group, United Arab Emirates",2017-12-20,2021-04-12,2021-07-20,2018-02-27,2023-03-10,"[""pCR according to Le Chevalier's classification""]","[""pCR according to Sataloff's classification"", 'radiological response', 'Rate of breast conservative surgery', 'Safety /Tolerability of the combination Fulvestrant + Palbociclib', 'DFS and OS']",,,,,14,Algeria; Egypt; Jordan; Lebanon; Morocco; Saudi Arabia; Tunisia; United Arab Emirates,"Center Pierre et Marie Curie [Algiers, Algeria] | Cancer Center - Blida [Blida, Algeria] | CHU - Oran [Oran, Algeria] | University of Alexandria [Alexandria, Egypt] | National Cancer Institut (NCI) [Cairo, Egypt] | King Hussein Cancer Center (KHCC) - Amman [Amman, Jordan] | Hotel Dieu de France [Beirut, Lebanon] | Hopital Cheikh Khalifa Ibn Zaid [Casablanca, Morocco] | Department of Oncology - Institut National d'Oncologie [Rabat, Morocco] | King Abdul Aziz Medical City-National Guard Health Affairs (NGHA) [Riyadh, Saudi Arabia] | Oncology Center- King Fahad Medical City (KFMC) [Riyadh, Saudi Arabia] | Oncology Center- King Saud University Medical City (KSUMC) [Riyadh, Saudi Arabia] | Oncologie Medicale de l'Ariana (SOMA) [Tunis, Tunisia] | Tawam Hospital [Al Ain City, United Arab Emirates]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,1,Phase 3
NCT03448250,Evaluating a Novel Web-based Intervention for Breast Cancer Survivors,"Evaluation of a Web-based Psychological Intervention as add-on to Care as Usual in Breast Cancer Survivors: Effect on Immune Status, Inflammation and Psychometric Outcome",TERMINATED,,Technical University of Dortmund,2018-03-16,2021-09-30,2022-04-30,2018-02-28,2022-05-05,"['concentration of C-reactive protein (CRP)', 'circulating Interleukin (IL) 6', 'circulating Tumor necrosis factor (TNF)-α', 'stimulated IL-6', 'stimulated TNF-α']","['Plasma Concentrations of Cytokines', 'Concentration of secreted Cytokines after Phorbol-12-myristate-13-acetate (PMA) stimulation of peripheral blood mononuclear cells', 'Concentration of secreted Cytokines after Lipopolysaccharide (LPS) Stimulation of peripheral blood mononuclear cells', 'Circulating numbers of Lymphocytes, Monocytes, Granulocytes', 'Phenotypic analysis of T and NK cell subsets', 'Cortisol awakening response (CAR)', 'Determination of cancer-related fatigue using the Brief Fatigue Inventory Questionnaire', 'Determination of cancer-related emotional stress', 'Determination of depression', 'Determination of anxiety', 'Determination of fear of progression', 'Determination of usefulness of the program', 'Determination of Negative Effects']",,,,,2,Germany,"Technical University of Dortmund, Leibniz Research Centre for Working Environment and Human Factors [Dortmund, Germany] | University Medical Center Leipzig, Department of Medical Psychology and Medical Sociology, Section Psychosocial Oncology [Leipzig, Germany]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT03455270,"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer","A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer",COMPLETED,PHASE1,"G1 Therapeutics, Inc.",2018-05-09,2022-09-29,2022-09-29,2018-03-06,2022-12-15,"['Dose Limiting Toxicity', 'Recommended Phase 2 dose', 'Number of Treatment Related Adverse Event, including Abnormal Laboratory Events']","['Tumor response based on RECIST, Version 1.1', 'Effect of food on bioavailability of G1T48', 'Pharmacokinetics of G1T48 and metabolites: Maximum Plasma Concentration (Cmax)', 'Pharmacokinetics of G1T48 and metabolites: Area under Curve - plasma concentration (AUC)', 'Pharmacokinetics of G1T48 and metabolites: Plasma: terminal half life (T1/2)', 'Pharmacokinetics of G1T48 and metabolites: Plasma - Volume of distribution', 'Pharmacokinetics of palbociclib: Plasma - Trough concentration']",,,,,15,Belgium; Bulgaria; Georgia; Moldova; Netherlands; Ukraine; United States,"Beverly Hills Cancer Center [Beverly Hills, United States] | Stanford Women Cancer Center [Stanford, United States] | Northwestern University - Feinberg School of Medicine [Chicago, United States] | University of North Carolina at Chapel Hill [Chapel Hill, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Sarah Cannon Research Institute at Tennessee Oncology [Nashville, United States] | Institut Jules Bordet [Brussels, Belgium] | UZ Leuven [Leuven, Belgium] | MHAT for Womens Health - Nadezhda OOD [Sofia, Bulgaria] | ARENSIA Exploratory Medicine LLC [Tbilisi, Georgia] | ARENSIA Exploratory Medicine Phase I Unit, The Institute of Oncology [Chisinau, Moldova] | VU University Medical Center [Amsterdam, Netherlands] | University Medical Center Groningen [Groningen, Netherlands] | Erasmus Medical Center [Rotterdam, Netherlands] | Spizhenko Clinic [Kiev, Ukraine]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03456167,Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery,Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery,COMPLETED,,"Alberta Health Services, Calgary",2019-06-10,2021-04-16,2021-04-16,2018-03-07,2021-04-21,"['Patient Satisfaction Questionnaire (PSQ-III) - Select Subscales', 'Quality of Recovery 15']","['Patient-borne Financial Costs of Followup Appointments', 'Total Number of Contacts with Medical System Postoperatively', 'Postoperative Complications', 'Adverse events NCI Version 3 / EORTC', ""Healthcare Professionals' Contact with Study Patients"", 'Healthcare Professional Response to Virtual versus Traditional FollowUp Care']",,,,,1,Canada,"Tom Baker Cancer Centre [Calgary, Canada]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a mobile app for postoperative monitoring and does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT03456661,Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block,"Comparison Between Levobupivacaine 0.25% and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Modified Pectoral Nerve Block, a Double Blind Randomised Controlled Trial.",TERMINATED,PHASE4,"University Hospital, Antwerp",2014-05-19,2018-01-12,2018-01-12,2018-03-07,2019-09-20,['Total postoperative opioid (morphine) consumption'],"['Onset of postoperative pain', 'Number of boluses morphine the patient asked for in the first 24 hours postoperative', 'Number of effectively delivered morphine boluses in the first 24 hours postoperatively']",,,,,1,Belgium,"University Hospital Antwerp [Edegem, Belgium]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares the use of Levobupivacaine with and without Dexmedetomidine, indicating an extension of indication for Levobupivacaine in combination with another agent.",OTHER,False,2018.0,7.0,0,Other
NCT03457506,Intra-individual Comparison of Conventional and Digital PET/CT Scanners,Intra-individual Patient-based Comparison of Conventional and Digital PET/CT Scanners,COMPLETED,,Isala,2018-01-08,2019-09-13,2019-09-13,2018-03-07,2019-09-19,['Diagnostic outcome of the PET/CT study'],['PET image quality'],,,,,1,Netherlands,"Isala [Zwolle, Netherlands]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a comparison of imaging technologies (Conventional and Digital PET/CT Scanners) rather than introducing a new medicine or extending the indication of an existing treatment.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03457779,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer,Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative (TN) Breast Cancer and Associated Genomic Alterations,COMPLETED,,Baylor Research Institute,2018-02-08,2020-04-08,2020-12-31,2018-03-08,2021-10-08,"['Amount of glucose, amino acid, and lipid metabolites in TNBC.']",['Correlation of signaling pathways in TNBC with response and metabolites.'],,,,,1,United States,"Baylor University Medical Center [Dallas, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study investigating metabolic pathways and genomic alterations in triple negative breast cancer, but does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03459898,Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control,Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control,COMPLETED,,Sunnybrook Health Sciences Centre,2018-05-19,2021-12-31,2022-01-30,2018-03-09,2022-05-05,"['Reproducibility of ABC or vDIBH set-up as measured by Align RT.', 'Mean heart dose as determined using Align RT.']",['The impact of Align RT with vDIBH as compared to vDIBH without AlignRT on quality of life as assessed by the EORTC core QoL questionnaire.'],,,,,1,Canada,"Sunnybrook Health Sciences Centre [Toronto, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a method for cardiac sparing during treatment but does not introduce a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03462251,Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line,"A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line",COMPLETED,PHASE3,iOMEDICO AG,2018-05-24,2021-11-30,2022-11-30,2018-03-12,2023-01-19,['Efficacy in terms of PFS'],"['Overall Survival (OS)', 'Overall Response Rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Time To Response (TTR)', 'Number of participants with Adverse Events', 'Time to deterioration of ECOG performance status', 'Tolerability of treatment', 'corrected QT interval (QTc) time', 'Health-related quality of life (QoL)', 'Side effects of treatment', 'Time spent on treatment']",,,,,27,Germany,"Gemeinschaftspraxis für Hämatologie und Onkologie [Ravensburg, Germany] | Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin [Aachen, Germany] | Klinikum Mittelbaden Baden-Baden Balg [Baden-Baden, Germany] | Gynäkologisches Zentrum Bonn [Bonn, Germany] | St.-Johannes-Hospital Gynäkologie und Geburtshilfe [Dortmund, Germany] | BAG / Onkologische Gemeinschaftspraxis [Dresden, Germany] | Universitätsklinikum Essen [Essen, Germany] | Praxis für interdisziplinäre Onkologie & Hämatologie [Freiburg im Breisgau, Germany] | Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz [Goslar, Germany] | Gemeinschaftspraxis für Innere Medizin, Hämatologie, Onkologie, Gastroenterologie [Halle, Germany] | OncoResearch Lerchenfeld GmbH [Hamburg, Germany] | Onkologische Schwerpunktpraxis [Heidelberg, Germany] | IDGGQ GbR [Kaiserslautern, Germany] | Hämato-Onkologisches Zentrum Kassel MVZ GmbH [Kassel, Germany] | Praxis Dr. med. Bettina Peuser [Leipzig, Germany] | Gemeinschaftspraxis für Hämatologie und Onkologie [Mühlheim, Germany] | Hämatologisch-onkologische Gemeinschaftspraxis [Münster, Germany] | Praxis Dr. med. Jens Uhlig [Naunhof, Germany] | Klinikum Neumarkt [Neumarkt, Germany] | Onkologie Offenburg [Offenburg, Germany] | Praxis und Tagesklinik für Onkologie und Hämatologie [Recklinghausen, Germany] | Tumorzentrum und Hausarztpraxis Rötha Leipziger-Land [Rötha, Germany] | Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie [Singen, Germany] | Onkologische Schwerpunktpraxis [Speyer, Germany] | g.SUND Gynäkologie Kompetenzzentrum Stralsund [Stralsund, Germany] | Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH [Villingen-Schwenningen, Germany] | Gemeinschaftspraxis für Hämatologie und Onkologie [Westerstede, Germany]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the efficacy of Ribociclib in combination with existing therapies (Endocrine Therapy or Chemotherapy) for a specific patient population, indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT03470935,Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger,A Non-interventional Study Evaluating the Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger Than 40 Years (ARTEMIS),COMPLETED,,Hôpital Privé des Côtes d'Armor (HPCA),2017-09-15,2018-09-30,2018-09-30,2018-03-20,2019-01-16,['Describe the impact of diagnosis and the breast cancer care on fertility in patients younger than 40 years'],[],,,,,1,France,"Centre investigateur CARIO-HPCA [Plérin, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a non-interventional study focused on the impact of breast cancer diagnosis and treatment on fertility, but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03471494,GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery,GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery,COMPLETED,,University of Edinburgh,2018-04-01,2018-10-31,2019-04-23,2018-03-20,2024-06-07,"['30-day mortality rate', '30-day complication rate']","['Availability/performance of pre-operative fine needle aspiration/core biopsy to diagnose breast cancer.', 'Availability/performance of breast/axillary MRI for staging.', 'Availability/performance of breast conservation surgery for AJCC stage 0/I/II breast cancer.', 'Availability/ performance of axillary/breast radiotherapy and axillary lymph node clearance.', 'Availability/performance of sentinel lymph-node biopsy for early invasive breast cancer.', 'Availability/performance of progesterone receptor (PR), oestrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) receptor and Ki67 status for invasive cancers.', 'Availability/treatment with adjuvant treatment where appropriate within 31 days of completion of surgery.', 'Availability/plan for radiotherapy for all with breast conserving surgery with clear margins (including DCIS).', 'Margin involvement. ""Tumour on inked margin"" is considered positive (SSO/ASTRO consensus guidelines) in surgery for early stage breast cancer or a margin <2 mm in DCIS [or ability to measure this locally].', 'Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging.', 'Availability/treatment with pre- or post-operative chemotherapy for gastric cancer.', 'Treatment decisions made within multidisciplinary team meeting / tumour board.', 'At least 15 regional lymph nodes removed and pathologically examined for resected gastric cancer [or ability to measure this locally].', 'Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging.', 'Availability/performance of pre-operative MRI for rectal cancer.', 'Availability/planning/treatment with post-operative chemotherapy following resection for lymph node positive colon cancer.', 'Availability/treatment with pre-operative chemotherapy/radiotherapy.', 'Treatment decisions made within multidisciplinary team meeting / tumour board.', 'Stoma formation rate.', 'Circumferential resection margin (CRM) >1mm [or ability to measure this locally].', 'At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer [or ability to measure this locally].']",,,,,1,United Kingdom,"University of Edinburgh [Edinburgh, United Kingdom]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03472794,Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women,Adaptation of a Knowledges Exchange Portal (KEP) Between Healers and Patients : Study of Obstacles and Sources to the Use of a KEP in the Case of Women Affected by a Breast Cancer in Nouvelle Aquitaine(Sav-AQ),COMPLETED,,"University Hospital, Bordeaux",2018-03-16,2019-06-17,2019-06-17,2018-03-21,2019-09-04,['Feasability of the web portal'],"['Number of the portal connections realized each month', 'Number of webpages used', 'Number of status posted', 'Number of comments/questions posted', 'Number of ""like"" emoticon posted', 'Number of ""comfort"" emoticon posted', 'Number of ""favorites"" emoticon posted', 'Number of ""mood"" posted', 'Number of private posts posted', 'Number of webpages consulted', 'Number of leaflets consulted', 'Headings of leaflets consulted', 'Number of cards consulted', 'Headings of cards consulted', 'Number of videos consulted', 'Headings of videos consulted', 'Number of address consulted in the address list', 'Number of upcoming events consulted']",,,,,1,France,"Institut Bergonié [Bordeaux, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the adaptation of a knowledge exchange portal for breast cancer patients, focusing on obstacles and usage metrics, rather than introducing a new medicine or extending the indication of an existing one.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03473639,A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy,COMPLETED,PHASE1,University of Virginia,2019-01-29,2021-09-02,2022-11-01,2018-03-22,2022-11-01,"['Identification of a maximum tolerated dose combination (MTDC) of entinostat and capecitabine', 'Frequency of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy', 'Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy']","['Frequency of adverse events (AEs) in MBC participants at the determined MTDC.', 'Disease-free survival (DFS)', 'Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in MBC participants', 'Frequency of adverse events (AEs) and dose-limiting toxicities (DLTs) in participants on both arms of the study at the determined MTDC.', 'Severity (as graded with the CTCAE) of adverse events (AEs) in participants on both arms of the study at the determined MTDC']",,,,,2,United States,"University of Rochester Medical Center [Rochester, United States] | University of Virginia [Charlottesville, United States]",2019.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 1
NCT03475433,An Observational Prospective Cohort Study Using an Actigraphy Device.,An Observational Prospective Cohort Study About Quality of Life in Relation to the Physical Activity of Taiwanese Breast and Prostate Cancer Patients.,COMPLETED,,Taipei Medical University,2018-05-15,2018-07-31,2018-08-31,2018-03-23,2019-04-10,"['Change will be assessed on the quality of life of breast and prostate cancer patients.', 'Change will be assessed for the influence of physical activity on the Quality of Life of breast and prostate cancer patients.']",['Study whether sleep quality and the quality of life scores of breast and prostate cancer patients are correlated'],,,,,2,Taiwan,"Taipei Medical University Hospital [Taipei, Taiwan] | Taipei Municipal Wanfang Hospital [Taipei, Taiwan]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an observational study focusing on quality of life and physical activity in cancer patients, without introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03480659,"Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC","Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA.",TERMINATED,,HKGepitherapeutics,2018-06-01,2021-08-01,2021-09-01,2018-03-29,2023-12-21,['DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of breast cancer'],[],,,,,1,Kazakhstan,"Kazakh Institute of Oncology and Radiology [Almaty, Kazakhstan]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses a non-invasive method for detecting breast cancer using DNA methylation changes, which suggests an extension of indication for existing diagnostic methods rather than introducing a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT03480958,Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery,Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery,COMPLETED,,Kocaeli University,2018-03-28,2018-08-20,2018-08-20,2018-03-29,2018-08-28,['Morphine consumption'],"['Numering Rating Scale scores for pain', 'Postoperative nausea and vomiting']",,,,,1,Turkey (Türkiye),"Kocaeli University Hospital [Kocaeli, Turkey (Türkiye)]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a comparison of two existing anesthesia techniques (Erector Spinae Plane Block and Thoracic Paravertebral Block) for breast surgery, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03481998,A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer,A Phase IB/II to Evaluate Efficacy and Safety of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer,COMPLETED,PHASE1; PHASE2,"Jiangsu HengRui Medicine Co., Ltd.",2018-03-22,2022-07-30,2022-07-30,2018-03-29,2023-11-21,['Number of Participants With adverse events (AEs) and serious adverse events (SAEs) at Phase 1'],"['Area under the plasma concentration versus time curve (AUC) of SHR6390', 'Peak Plasma Concentration (Cmax) of SHR6390', 'The time of SHR6390 to reach the maximum concentration (Tmax)', 'Half-time (t1/2) of SHR6390', 'Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', 'Progression-free Survival (PFS) per RECIST 1.1', 'Disease Control Rate (DCR) per RECIST 1.1', 'Number of Participants With adverse events (AEs) and serious adverse events (SAEs)']",,,,,4,China,"Ha'erbin Tumor Hospital [Harbin, China] | Henan Cancer Hospital [Zhengzhou, China] | Sir Run Run Shaw Hospital of Zhejiang University [Hangzhou, China] | Cancer Hospital, Chinese Academy of Medical Sciences [Beijing, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03494400,Aerobic Training in Treatment for Breast Cancer,Effects of Aerobic Training in Treatment for Breast Cancer,COMPLETED,,Universidade Estadual Paulista Júlio de Mesquita Filho,2018-07-01,2019-06-23,2020-11-30,2018-04-11,2021-04-30,['Evaluation of body composition by Bone Densitometry (DEXA) equipment'],"['Evaluation of quality of life by questionnarie EORTC-QLQ-30', 'Evaluation inflammatory response by ELISA equipment', 'Evaluation of pain by questionnarie BPI.', 'Evaluation of level of physical activity by triaxial accelerometer equipment', 'Nutritional evaluation by food register']",,,,,1,Brazil,"Faculdade de Ciências e Tecnologia, Universidade Estadual Paulista Júlio de Mesquita Filho [Presidente Prudente, Brazil]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the effects of aerobic training as a treatment for breast cancer, indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03505528,An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer,A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer,COMPLETED,PHASE1,EpiAxis Therapeutics,2017-08-17,2019-10-30,2019-10-30,2018-04-23,2019-11-13,['Dose-Limiting Toxicity (DLT) events'],"['Abraxane Cmax', 'Abraxane Tmax', 'Abraxane Half-life', 'Abraxane AUC', 'Nardil Cmax', 'Nardil Tmax', 'Nardil Half-life', 'Nardil AUC', 'Circulating Tumour Cell (CTC) burden', 'PDL1 expressing Circulating Tumour Cell (CTC) burden', 'HER2 expressing Circulating Tumour Cell (CTC) burden', 'FFPE Tumour cells burden', 'FFPE Stoma cells burden', 'FFPE Cancer Stem Cells (CSC) burden']",,,,,3,Australia,"Canberra Region Cancer Centre [Canberra, Australia] | Liverpool Cancer Therapy Centre [Sydney, Australia] | Southern Medical Day Care Centre [Wollongong, Australia]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study involves the combination of Abraxane, which is an existing medication, with Phenelzine Sulfate to treat metastatic or advanced breast cancer, indicating an extension of indication for Abraxane.",INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03505736,Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer,The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer,COMPLETED,,Wake Forest University Health Sciences,2018-06-21,2020-03-05,2020-03-05,2018-04-23,2020-03-26,['Myocardial perfusion reserve index (MPRI)'],"['Myocardial rest myocardial fibrosis burden (T1) and left ventricular ejection fraction (LVEF)', 'Change in MPRI measures', 'Accrual rate defined as based on the number of patients who participate compared to the total number of patients approached', 'Retention rate defined the number of patients who are enrolled and complete both assessments']",,,,,1,United States,"Wake Forest University Health Sciences [Winston-Salem, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the effects of aromatase-inhibitor treatment in a specific population (premenopausal women with breast cancer), indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03507088,Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer,Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?,COMPLETED,,Zhimin Shao,2015-09-01,2018-07-01,2018-07-01,2018-04-24,2019-05-08,['To evaluate the accuracy of the change of FES uptake in predicting progression-free survival(PFS) in patients treated with fulvestrant 500 mg'],['Evaluate the heterogeneity of ER among different metastatic sites in breast cancer patients in vivo'],,,,,2,China,"Cancer Hospital/ Institute, Fudan University [Shanghai, China] | Department of Breast Surgery, Cancer Hospital, Fudan University [Shanghai, China]",2015.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the use of Fulvestrant, which is an existing medication, in a specific patient population (women with estrogen positive metastatic breast cancer) and aims to predict response to this treatment, indicating an extension of its indication.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03507543,The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors,"A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Impact Therapeutics, Inc.",2017-02-03,2020-09-24,2021-03-17,2018-04-25,2021-03-30,"['The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.', 'The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297.']","['Area Under Curve [AUClast, AUCINF and AUCtau]', 'Area Under Curve [AUClast, AUCINF and AUCtau]', 'Maximum plasma concentration (Cmax)', 'Maximum plasma concentration (Cmax)', 'Time at which Cmax occurred (Tmax)', 'Time at which Cmax occurred (Tmax)', 'Trough Concentrations (Ctrough)', 'Trough Concentrations (Ctrough)', 'Clearance (CL/F)', 'Clearance (CL/F)', 'Volume of distribution (Vd/F)', 'Volume of distribution (Vd/F)']",,,,,3,Australia,"Blacktown Hospital [Blacktown, Australia] | St George Private Hospital [Kogarah, Australia] | Nucleus Network [Melbourne, Australia]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03508011,A Study of IMP4297 in Patients With Advanced Solid Tumors,"A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Impact Therapeutics, Inc.",2017-08-23,2020-12-16,2020-12-16,2018-04-25,2021-03-30,"['The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors.', 'The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297']","['Area Under Curve [AUClast, AUCINF]', 'Area Under Curve [AUClast, AUCINF]', 'Maximum plasma concentration (Cmax)', 'Maximum plasma concentration (Cmax)', 'Time at which Cmax occurred (Tmax)', 'Time at which Cmax occurred (Tmax)', 'Trough Concentrations (Ctrough)', 'Trough Concentrations (Ctrough)', 'Clearance (CL/F)', 'Clearance (CL/F)', 'Volume of distribution (Vd/F)', 'Volume of distribution (Vd/F)']",,,,,2,China,"Cancer Hospital Chinese Academy of Medical Sciences [Beijing, China] | Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03511690,Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment,Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer,COMPLETED,,Georgetown University,2017-07-01,2022-02-20,2022-02-20,2018-04-30,2022-04-25,"['Breast Cancer Genetics Knowledge', 'Intentions to participate in genetic counseling', 'Perceived pros and cons of genetic counseling and testing']","['Uptake of Genetic Counseling', 'Self-efficacy about participating in genetic counseling', 'Emotions about developing breast cancer and about participating in genetic counseling', 'Health Literacy and Numeracy', 'Mistrust about the medical system', 'Declarative Knowledge of Breast Cancer, Genetic Testing, and Genetic Risk', 'Gist Comprehension of Genetic Cancer Risk']",,,,,4,United States,"Capital Breast Care Center [Washington D.C., United States] | Georgetown University [Washington D.C., United States] | Nueva Vida [Alexandria, United States] | Virginia Commonwealth University [Richmond, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses an intervention related to genetic counseling and education rather than a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03517813,CESM ABMR Breast Cancer Screening Trial,Comparative Performance of Contrast-enhanced Spectral Mammography (CESM) and Abbreviated Breast MRI (ABMR) With Standard Breast MRI for Breast Cancer Screening,COMPLETED,,University of Washington,2018-01-03,2021-06-22,2022-12-31,2018-05-07,2023-01-06,['Abnormal interpretation rate'],"['Biopsy rate', 'Positive predictive value for biopsy recommendation (PPV2)', 'Negative predictive value', 'Cancer detection rate', 'Sensitivity', 'Specificity']",,,,,1,United States,"Seattle Cancer Care Alliance [Seattle, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial text discusses a comparative performance study of imaging techniques for breast cancer screening rather than testing a new medicine or an extension of indication for an existing treatment.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03518242,Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer,Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications,COMPLETED,PHASE1,Fred Hutchinson Cancer Center,2018-06-06,2022-05-04,2022-05-04,2018-05-08,2022-06-08,"['Distribution of molecular subtypes', 'Sensitivity to polymerase chain reaction (PCR)', 'Specificity of PCR', 'Patient adherence to treatment', 'Incidence of adverse events', 'Overall Survival']",[],,,,,2,Uganda,"New Mulago Hospital [Kampala, Uganda] | Uganda Cancer Institute [Kampala, Uganda]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the molecular profile of breast cancer and its clinical implications but does not indicate the introduction of a new medicine or an extension of indication for an existing treatment.,OTHER,False,2022.0,3.0,0,Phase 1
NCT03523195,Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors,Physical Activity After Cancer Treatment (PACT): Pilot Study of Exercise in Stage II-III Breast Cancer Survivors,COMPLETED,,Fred Hutchinson Cancer Center,2018-04-18,2019-07-15,2019-07-15,2018-05-14,2019-07-22,"['Adherence', 'Differential micro ribonucleic acid expression']",['Percent of expected home exercise sessions completed as determined by the home exercise logs for those choosing to not come in for a third weekly session'],,,,,1,United States,"Fred Hutch/University of Washington Cancer Consortium [Seattle, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses an exercise intervention aimed at improving health in breast cancer survivors, which suggests an extension of indication for existing treatments rather than a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03524170,"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","RACHEL1: A Phase I Radiation and Checkpoint Blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",COMPLETED,PHASE1,M.D. Anderson Cancer Center,2018-04-30,2022-02-10,2022-02-10,2018-05-14,2022-03-07,"['Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer', 'Safety and tolerability in patients with metastatic HR+/HER2- breast cancer']","['Progression-free survival (PFS)', 'Overall survival (OS)', 'Immunologic/molecular response', 'Evaluation of the size of metastasis after treatment with M7824 with radiation (in-field) and non-irradiated (abscopal) sites']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT03524248,Development of Real-time Image-guided Radiotherapy,Development of Real-time Image-guided Radiotherapy,TERMINATED,,Fox Chase Cancer Center,2012-05-17,2018-07-16,2018-07-19,2018-05-14,2020-03-02,['Develop real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).'],['To correlate real-time 4D surface images with the internal structures shown in daily XVI volumetric images'],,,,,1,United States,"Temple University Hospital [Philadelphia, United States]",2012.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the development of imaging technology for radiotherapy but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2018.0,7.0,0,NA/Other
NCT03529383,Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer,Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer,COMPLETED,,Centre Leon Berard,2018-05-18,2022-03-04,2022-09-23,2018-05-18,2023-03-22,['Number of patients achieving the internationally recommended level of physical activity of at least 150 minutes per week of moderate-to-vigorous physical activity (intensity ≥3 METs)'],"['Number of patients achieving the internationally recommended level of physical activity of at least 150 minutes per week of moderate-to-vigorous physical activity (intensity ≥3 METs)', 'Proportion of patients who are compliant to the programs', 'Proportion of patients who change their physical activity profile (Time spent in different intensities of physical activity, time spent in sedentary activities)', 'Proportion of patients who change their physical condition (6-min walking test)', 'Proportion of patients who change their physical condition (Sit to stand test)', 'Proportion of patients who change their physical condition (Hand-grip test)', 'Proportion of patients who change their physical condition (sit-and-reach flexibility test)', 'Proportion of patients who change their physical condition', 'Proportion of patients who change their weight', 'Proportion of patients who change their waist circumference', 'Proportion of patients who change their hip circumference', 'Proportion of patients who change their BMI', 'Proportion of patients who change their fat mass in body composition', 'Proportion of patients who change their lean body mass in body composition', 'Proportion of patients who change their fat free mass in body composition', 'Proportion of patients who change their water in body composition', 'Proportion of patients who change their tobacco use', 'Proportion of patients who change their alcohol intake', 'Proportion of patients with a change in quality of life', 'Proportion of patients with a change in fatigue condition', 'Proportion of patients with a change in health-related quality of life', 'Proportion of patients who modify their professional status', 'Proportion of patients with a modification on serum circulating levels of endocrine factors (insulin, IGF1, estradiol)', 'Proportion of patients with a modification on plasma circulating levels of cytokines (inflammatory cytokines: IL-6, TNF, and CRP; adipokines: adiponectin and leptin)', 'Proportion of patients with a modification on vitamin D status', 'Number of patients who accept the connected device', 'Number of patients who accept the therapeutic program', 'Proportion of patients who refuse to participate']",,,,,3,France,"Institut Sainte-Catherine [Avignon, France] | CHRU Besançon [Besançon, France] | Centre Léon Bérard [Lyon, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on the efficacy of an exercise program and therapeutic education for women with localized breast cancer, rather than testing a new medicine or extending the indication of an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03530722,Ex-vivo Performance Evaluation of the Histolog™ Scanner for Human Breast Carcinoma Detection on Fresh Breast Core Biopsies,Ex-vivo Performance Evaluation of the Histolog™ Scanner for Human Breast Carcinoma Detection on Fresh Breast Core Biopsies,COMPLETED,,Brust-Zentrum AG,2017-07-04,2017-11-15,2017-12-11,2018-05-21,2018-05-21,['Correspondence of pathologic assessment in specimen suspicious for breast cancer'],"['Usability of the HistologTM Scanner confocal device', 'Acceptance of the HistologTM Scanner confocal device']",,,,,1,Switzerland,"Brust-Zentrum AG [Zurich, Switzerland]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the evaluation of a diagnostic device (Histolog™ Scanner) for detecting breast carcinoma, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03535701,Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer,Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study),COMPLETED,PHASE1,Ohio State University Comprehensive Cancer Center,2017-10-20,2020-03-01,2020-05-01,2018-05-24,2025-06-08,"['Adherence and compliance to the ketogenic diet', 'Changes in psychosocial measures', 'Changes in physiologic outcomes']",[],,,,,1,United States,"Ohio State University Comprehensive Cancer Center [Columbus, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study investigates the effects of a ketogenic diet in conjunction with chemotherapy for patients with stage IV breast cancer, indicating an extension of indication for the ketogenic diet in this specific patient population.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03535961,Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer,Phase II Single Arm Study of Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer,COMPLETED,PHASE2,Chinese Academy of Medical Sciences,2017-05-01,2019-05-01,2019-05-01,2018-05-24,2020-12-02,['objective response rate(ORR)'],"['disease control rate(DCR)', 'Progression free survival (PFS)', 'overall survival(OS)', 'Incidence of Treatment-Emergent Adverse Events']",,,,,1,China,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Apatinib, which is being tested in combination with Oral Etoposide for a specific indication (metastatic HER2 negative breast cancer), indicating it is a new medicine trial.",OTHER,False,2019.0,6.0,0,Phase 2
NCT03539835,Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors,Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors,COMPLETED,,Emory University,2018-12-10,2020-03-09,2020-03-12,2018-05-29,2020-07-27,['Change in fatigue assessed by Multidimensional Fatigue Inventory (MFI) score'],"['Change in depression assessed by Hamilton Depression Rating Scale (HAM-D) score', 'Change in balance test score', 'Change in muscle function assessed by Isometric Handgrip test.', 'Change in muscle function assessed by Lower Extremity Endurance test', 'Change in muscle function assessed by Lower Extremity Strength test', 'Change in Timed Up and Go (TUG) completion time', 'Change in 30 meter walk velocity', 'Change in Functional Gait Assessment score', 'Change in 6 min walk distance', 'Change in Resting Metabolic Rate (RMR)', 'Change in peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) level', 'Change in kynurenic acid level', 'Change in interleukin-6 (IL-6) level', 'Change in tumor necrosis factor-α (TNF-α) protein level']",,,,,1,United States,"Winship Cancer Institute [Atlanta, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a trial focused on resistance training as an intervention for improving fatigue and physical function in a specific population (postmenopausal breast cancer survivors). It does not indicate the testing of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2020.0,5.0,0,NA/Other
NCT03539965,Triple-negative Breast Cancer: a New Perspective on Biomarkers,Triple-negative Breast Cancer: a New Perspective on Predictive and Prognostic Biomarkers,COMPLETED,,"Instituto Nacional de Cancer, Brazil",2010-01-01,2014-12-31,2014-12-31,2018-05-30,2018-05-31,['Progression Free Survival (PFS)'],"['Clinical Response Rate', 'Objective response rate', 'Determine predictive markers', 'Determine prognostic markers']",,,,,1,Brazil,"Instituto Nacional do Cancer - CPQ [Rio de Janeiro, Brazil]",2010.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses biomarkers and clinical response rates in the context of triple-negative breast cancer but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.,OTHER_GOV,False,2014.0,11.0,0,NA/Other
NCT03541863,Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients,What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China,COMPLETED,,Fudan University,2017-10-10,2018-12-15,2018-12-20,2018-05-31,2019-02-15,['PFS'],"['OS', 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses treatment options after progression on Fulvestrant, indicating an extension of indication for existing treatments in the context of metastatic breast cancer.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03542604,"Cancer, Obesity/Overweight and Insomnia Study",The Effects of Treating Insomnia Prior to a Weight Loss Intervention in Women With Early Stage Breast Cancer,COMPLETED,,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,2018-06-12,2020-11-30,2020-11-30,2018-05-31,2020-12-16,['Percent Weight loss'],"['Sleep continuity as measured by wake after sleep onset (WASO)', 'Sleep continuity as measured by total sleep time (TST)', 'Sleep continuity as measured by sleep efficiency (SE)', 'Sleep continuity as measured by sleep latency (SL)']",,,,,1,United States,"Johns Hopkins University, Bayview Medical Campus [Baltimore, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on treating insomnia in women with early stage breast cancer, indicating an extension of indication for an existing treatment to a new patient population.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03544125,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE1,OHSU Knight Cancer Institute,2018-05-03,2018-08-07,2020-11-18,2018-06-01,2020-11-20,['Proportion of completion of Clinical Laboratory Improvement Act (CLIA) analytics on pre-treatment biopsy before the planned for 4-week biopsy'],"['Incidence of >= grade 3 adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.03', 'Overall response rate (ORR) for olaparib in combination with durvalumab', 'Clinical benefit rate (CBR) for olaparib in combination with durvalumab', 'Duration of response (DOR) for olaparib in combination with durvalumab', 'Progression-free survival (PFS) for olaparib in combination with durvalumab', 'Overall survival (OS) olaparib in combination with durvalumab']",,,,,1,United States,"OHSU Knight Cancer Institute [Portland, United States]",2018.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the combination of Olaparib and Durvalumab for treating metastatic triple negative breast cancer, which suggests an extension of indication for these existing drugs rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03549000,A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.,"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.",TERMINATED,PHASE1,Novartis Pharmaceuticals,2018-07-18,2022-10-17,2022-10-17,2018-06-07,2024-12-13,['Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178'],"['Overall response rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Progression Free Survival (PFS)', 'Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.', 'Plasma concentration vs. time profiles for NIR178 and derived PK parameters', 'To assess the immunogenicity of NZV930 and PDR001']",,,,,10,Australia; Canada; Japan; Singapore; Spain; United Kingdom; United States,"H Lee Moffitt Cancer Center and Research Institute Inc [Tampa, United States] | University of Texas MD Anderson Cancer Center MD Anderson PSC [Houston, United States] | Novartis Investigative Site [Melbourne, Australia] | Novartis Investigative Site [Toronto, Canada] | Novartis Investigative Site [Montreal, Canada] | Novartis Investigative Site [Chuo Ku, Japan] | Novartis Investigative Site [Singapore, Singapore] | Novartis Investigative Site [Valencia, Spain] | Novartis Investigative Site [Madrid, Spain] | Novartis Investigative Site [Sutton, United Kingdom]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT03555227,USG PECS vs LIA for Breast Cancer Surgery,Ultrasound Guided (USG) PECS Versus Local Infiltration Anaesthesia (LIA) for Breast Cancer Surgery - A Randomized Quadruple Blinded Efficacy and Safety Study,COMPLETED,,"National Health Service, United Kingdom",2017-09-25,2018-11-25,2018-11-25,2018-06-13,2018-11-29,"['Morphine consumption in Recovery', 'Numeric Rating Scale (NRS) Pain scores']","['PONV (Post operative nausea and vomiting) Impact Scale Score', 'S -LANNS (Self- administered Leeds Assessment of Neuropathic Symptoms and Signs) questionnaire for chronic post surgical pain', 'Cancer recurrence or metastasis']",,,,,1,United Kingdom,"Craigavon Area Hospital [Portadown, United Kingdom]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses a comparison between two anesthesia techniques (USG PECS and LIA) for breast cancer surgery, which does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2018.0,7.0,0,NA/Other
NCT03555877,Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer,Anti-hormonal Maintenance Treatment With the CDK4/6 Inhibitor Ribociclib After 1st Line Chemotherapy in Hormone Receptor Positive / HER2 Negative Metastatic Breast Cancer: A Phase II Trial,COMPLETED,PHASE2,GBG Forschungs GmbH,2018-03-15,2022-07-21,2022-07-21,2018-06-14,2023-07-07,['Locally-assessed progression-free survival (PFS)'],"['The impact on overall survival', 'The clinical benefit rate', 'Patient reported outcomes', 'Number of participants with adverse events, serious adverse events and adverse events of special interest as assessed by CTCAE v4.03.', 'The number of patients who reduced, interrupted or permanently discontinued treatment and the reasons for that.']",,,,,1,Germany,"Studienzentrum Onkologie Ravensburg [Ravensburg, Germany]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 2
NCT03557554,Investigating the Preventative Ability of Massage Therapy on Paclitaxel Induced Peripheral Neuropathy,A Prospective Feasibility Study Investigating Primary Preventive Ability of Massage Therapy of Paclitaxel-Induced Peripheral Neuropathy in Patients With Newly Diagnosed Breast Cancer Scheduled to Undergo a Paclitaxel Based Regimen,TERMINATED,,Bryan Schneider,2018-02-08,2018-10-15,2018-10-15,2018-06-15,2019-08-26,"['Feasibility of Recruitment', 'Feasibility of Retention']","['Incidence of paclitaxel induced peripheral neuropathy', 'Severity of paclitaxel induced peripheral neuropathy', 'Rate of pharmacological interventions', 'Paclitaxel dose modification']",,,,,1,United States,"Indiana University Melvin & Bren Simon Cancer Center [Indianapolis, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study on the preventative ability of massage therapy for a specific condition (paclitaxel-induced peripheral neuropathy) but does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2018.0,7.0,0,NA/Other
NCT03559387,"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","A Randomized and Open-label Dose-finding, Ph. 2, Efficacy, Safety, and Pharmacokinetic Study of Once-per-cycle Prophylactic Injections of ANF-RHO™ Versus Pegfilgrastim (Neulasta®) in Non-metastatic Breast Cancer Patients at High-risk of Chemotherapy-induced Neutropenia",TERMINATED,PHASE2,Prolong Pharmaceuticals,2017-08-03,2018-04-18,2018-05-22,2018-06-18,2019-02-12,['Duration of neutropenia grade 1 or worse (absolute neutrophil count [ANC] ≤ 2.0 x 10^9/L) in the first cycle of chemotherapy (FE100C).'],"['Duration of neutropenia grade 1 or worse (absolute neutrophil count [ANC] ≤ 2.0 x 10^9/L) in the fourth cycle of chemotherapy (docetaxel).', 'Duration of severe neutropenia (ANC < 0.5 x 10^9/L) during the first chemotherapy cycle (21-day cycle FE100C)', 'Duration of severe neutropenia (ANC < 0.5 x 10^9/L) during the fourth chemotherapy cycle (21-day cycle docetaxel)', 'Incidence of severe neutropenia (ANC < 0.5 x 10^9/L) during all chemotherapy cycles', 'Incidence and duration of febrile neutropenia defined as peak temperature ≥38.5°C and ANC < 0.5 x 10^9/L, during all chemotherapy cycles', 'Incidence and duration of febrile neutropenia defined as peak temperature ≥38.0°C for two readings over two hours and ANC < 0.5 x 10^9/L, during all chemotherapy cycles', 'Incidence and duration of infection and infection-related events based on use of antibiotics during all chemotherapy cycles', 'Incidence and duration of infection and infection-related events based on the need for hospitalization during all chemotherapy cycles', 'Incidence and duration of moderate (ANC ≥ 50 x 10^9/L) leukocytosis during all chemotherapy cycles', 'Incidence and duration of severe (ANC ≥ 100 x 10^9/L) leukocytosis during all chemotherapy cycles', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Blood pressure', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Heart rate', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Respiratory rate', 'Clinically meaningful changes in vital signs during all chemotherapy cycles - Assessment of Body Temperature', 'Incidence of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Duration of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Severity of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Site of bone pain, determined by a numerical rating scale, as well as other reported adverse events', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of Maximum Plasma Concentration (Cmax)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of Time taken to reach the maximum concentration (Tmax)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Measurement of half-life (T1/2)', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-t])', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-∞])', 'Pharmacokinetic profile of ANF-RHO and Neulasta - Area Under the Curve (AUC[0-t]/AUC[0-∞])', 'Incidence of anti-drug antibodies to ANF-RHO and Neulasta']",,,,,8,France; Netherlands,"Hôpital Saint Louis - Center des Maladies du Sein [Paris, France] | Institut de cancérologie Jean Godinot [Reims, France] | Strasbourg Oncologie Libérale [Strasbourg, France] | CHU de Tours [Tours, France] | Erasmus Medical Center [Rotterdam, Netherlands] | Ikazia Ziekenhuis [Rotterdam, Netherlands] | Maasstad Ziekenhuis [Rotterdam, Netherlands] | Franciscus Gasthuis & Vlietland [Schiedam, Netherlands]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating a new medicine (ANF-RHO™) against an existing treatment (Neulasta®) for a specific condition (chemotherapy-induced neutropenia), indicating it is a new medicine rather than an extension of indication.",INDUSTRY,False,2018.0,7.0,1,Phase 2
NCT03564899,The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study,The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study,COMPLETED,,AHS Cancer Control Alberta,2017-02-13,2018-07-31,2018-12-31,2018-06-21,2021-01-12,"['Change in sedentary time, light intensity physical activity time and moderate-vigorous intensity physical activity time (hours/day)']","['Change in body weight (kg)', 'Change in height (cm)', 'Change in waist and hip circumference (cm)', 'Change in body composition (fat and lean mass in kg)', 'Change in cardiorespiratory fitness (VO2max)', 'Change in body mass index (BMI in kg/m2)']",,,,,1,Canada,"The Rehabilitation, Exercise and Complementary (REACH) center within the Holy Cross Center [Calgary, Canada]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focused on physical activity levels and body composition changes in breast cancer patients, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03566485,Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer,BRE 17107: A Phase Ib/II Trial of Atezolizumab (an Anti-PD-L1 Monoclonal Antibody) With Cobimetinib (a MEK1/2 Inhibitor) or Idasanutlin (an MDM2 Antagonist) in Metastatic ER+ Breast Cancer,TERMINATED,PHASE1; PHASE2,Vanderbilt-Ingram Cancer Center,2018-07-10,2020-12-10,2020-12-10,2018-06-25,2021-08-11,"['Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)', 'Maximum Tolerated Dose (Phase I)', 'Recommended Phase II Dose (Phase I)', 'Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)']","['Clinical Benefit Rate (CBR) (Phase II)', 'Immune Related Response Criteria (irRC) (Phase II)', 'Progression-free Survival (PFS) (Phase II) in Days', 'Overall Survival (OS) (Phase II) in Days', 'Number of Adverse Events (Phase II)']","[{""type"":""PRIMARY"",""title"":""Number of Participants With a Dose Limiting Toxicity (DLT) (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""1"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Maximum Tolerated Dose (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""mg"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""NA"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Recommended Phase II Dose (Phase I)"",""timeFrame"":""At 28 days"",""unit"":""mg"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""NA"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""PRIMARY"",""title"":""Overall Response Rate (ORR; by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""NA"",""spread"":null,""lower"":""NA"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Clinical Benefit Rate (CBR) (Phase II)"",""timeFrame"":""At 6 months"",""unit"":""percentage of participants"",""paramType"":""NUMBER"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""NA"",""spread"":null,""lower"":""NA"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Immune Related Response Criteria (irRC) (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":null,""paramType"":null,""dispersionType"":null,""groups"":[]},{""type"":""SECONDARY"",""title"":""Progression-free Survival (PFS) (Phase II) in Days"",""timeFrame"":""At 12 months"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""56"",""spread"":null,""lower"":""51"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Overall Survival (OS) (Phase II) in Days"",""timeFrame"":""At 12 months"",""unit"":""days"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""161"",""spread"":null,""lower"":""136"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Number of Adverse Events (Phase II)"",""timeFrame"":""Up to 28 days after completion of study treatment, for a total of 2 years"",""unit"":""events"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""99"",""spread"":null,""lower"":null,""upper"":null}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""7""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""0""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""7""}]}],""dropWithdraws"":[{""type"":""Disease progression"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""5""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""4""}]},{""type"":""Clinical progression"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""1""}]},{""type"":""Toxicity"",""reasons"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""n"":""0""},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""n"":""2""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""5"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""7"",""spread"":null},{""group"":""Total"",""value"":""12"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""4"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""5"",""spread"":null},{""group"":""Total"",""value"":""9"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""0"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""0"",""spread"":null},{""group"":""Total"",""value"":""0"",""spread"":null},{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""1"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""2"",""spread"":null},{""group"":""Total"",""value"":""3"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""participants"",""paramType"":""NUMBER"",""dispersionType"":null,""groups"":[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""value"":""5"",""spread"":null},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""value"":""7"",""spread"":null},{""group"":""Total"",""value"":""12"",""spread"":null}]}]","[{""group"":""Phase 2 (Atezolizumab, Cobimetinib)"",""serious_affected"":2,""serious_at_risk"":5,""other_affected"":5,""other_at_risk"":5},{""group"":""Phase 1b - (Atezolizumab, Idasanutlin)"",""serious_affected"":4,""serious_at_risk"":7,""other_affected"":7,""other_at_risk"":7}]",1,United States,"Vanderbilt-Ingram Cancer Center [Nashville, United States]",2018.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Survival"",""Overall Response""]",2,1,1,1,1,0,1,0,1,5,0,0,1,0,,OTHER,True,2020.0,5.0,0,Phase 2
NCT03568526,Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer,The Effects of a Sensorimotor Rehabilitation Program on the Upper and Lower Limbs of Persons With Cancer Following Taxane-Based Chemotherapy for Early Stage Breast Cancer,COMPLETED,,Ohio State University Comprehensive Cancer Center,2015-07-02,2018-02-08,2022-09-14,2018-06-26,2022-10-12,"['Identify differences in patients scores using post-test scores on the McGill Pain Questionnaire', 'Evaluate patients using post-test scores on the CIPN-20', 'Assess the differences in patients post-test scores on the Disability of Arm Hand and Shoulder scores']",[],,,,,1,United States,"Ohio State University Comprehensive Cancer Center [Columbus, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a rehabilitation program and its effects on quality of life and pain management in patients with early-stage breast cancer, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03571984,Moving on After Breast Cancer Plus- for Breast Cancer Survivors,A Culturally Adapted Positive Health Programme - Moving on After Breast Cancer Plus- for Breast Cancer Survivors: A Feasibility Randomized Controlled Trial,COMPLETED,,Pakistan Institute of Living and Learning,2019-03-10,2021-12-30,2022-07-05,2018-06-28,2023-04-12,['Patient Health Questionnaire-9 (PHQ-9)'],"['Generalized Anxiety Disorder - 7', 'EuroQol-5D (EQ-5D)', 'Multidimensional Scale for Perceived Social Support (MSPSS)', 'Intrusive Thoughts Scale', 'Rosenberg Self Esteem Scale', 'The Functional Assessment of Cancer Therapy - Breast (FACT-B)', 'Client Satisfaction Questionnaire']",,,,,1,Pakistan,"Civil Hospital [Karachi, Pakistan]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility randomized controlled trial for a health program aimed at breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03574194,Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy,Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy,TERMINATED,,West Virginia University,2018-06-12,2021-12-31,2021-12-31,2018-06-29,2023-04-25,"['Safety of combined MRD plus RT will be assessed by measuring the rate of 1-year grade 3 or higher adverse events definitely, probably, or possibly related to MRD and RT, using CTCAE version 5.0.']",['Patient adherence to the MRD will be assessed by measuring plasma methionine levels 2 weeks and 6 weeks after starting the MRD'],,,,,1,United States,"WVU Cancer Institute - Mary Babb Randolph Cancer Center [Morgantown, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses a methionine-restricted diet (MRD) being used in conjunction with radiation therapy (RT), indicating an extension of indication for the diet rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03575260,500mg Fulvestrant Versus Exemestane in MBC,500mg Fulvestrant Versus Exemestane in Metastatic Breast Cancer (MBC) Resistant to Adjuvant Non-steroidal Aromatase Inhibitors in Clinical Practice- a Multicenter Retrospective Study,COMPLETED,,Fudan University,2017-07-01,2019-01-10,2019-01-15,2018-07-02,2019-07-30,['PFS'],['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'],,,,,1,China,"Biyun Wang, MD [Shanghai, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03575520,Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients,A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-dense Doxorubicin/Cyclophosphamide,COMPLETED,PHASE2,Yonsei University,2016-06-07,2017-02-15,2017-03-15,2018-07-02,2018-07-02,['the incidence of febrile neutropenia (FN)'],"['the incidences of febrile neutropenia during the first cycle of chemotherapy', 'the incidences of hospitalization for FN', 'number of grade 3 or 4 neutropenia in the first cycle of DD-AC', 'the incidences of dose delay or reduction of chemotherapy']",,,,,1,South Korea,"Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System [Seoul, South Korea]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the safety and efficacy of Pegteograstim in a specific patient population (Korean breast cancer patients) and in the context of a specific chemotherapy regimen, indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2017.0,8.0,0,Phase 2
NCT03575624,Changing Health Behaviors to Manage Chronic Conditions in Community-dwelling African American Breast Cancer Survivors,Changing Health Behaviors to Manage Chronic Conditions in Community-dwelling African American Breast Cancer Survivors,COMPLETED,,Mount Mary University,2017-01-26,2017-06-15,2017-06-15,2018-07-02,2018-07-02,['Change in central adiposity'],"['Independent yoga posture series', 'Change in body weight', 'Change in balance', 'independent healthy meal preparation', 'Goal setting']",,,,,1,United States,"Mount Mary University [Milwaukee, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses health behavior changes and interventions for managing chronic conditions in breast cancer survivors, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03577743,Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer,COMPLETED,PHASE2,Assiut University,2018-07-01,2020-03-15,2021-02-15,2018-07-05,2021-03-09,['- progression free survival'],"['- Response rate (R.R) :', '- Over all survival.']",,,,,1,Egypt,"Clinical Oncology Departement Assuit University Hospital [Asyut, Egypt]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effect of Bevacizumab, which is an existing drug, in a new patient population (metastatic triple negative breast cancer), indicating an extension of indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03579472,M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer,A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC),TERMINATED,PHASE1,M.D. Anderson Cancer Center,2018-05-30,2022-09-21,2022-09-21,2018-07-06,2022-10-31,"['Recommended phase II dose (RP2D)', 'Incidence of adverse events']",[],,,,,2,United States,"Lyndon Baines Johnson General Hospital [Houston, United States] | M D Anderson Cancer Center [Houston, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves M7824, which is a new medicine being tested in combination with Eribulin Mesylate for a specific type of cancer, indicating it is a new treatment approach.",OTHER,False,2022.0,3.0,0,Phase 1
NCT03579524,Comparison of Erector Spinae Plane Block With Serratus Anterior Plane Block for Breast Surgery,The Effectiveness of Pain Relieve of Ultrasound-guided Erector Spinae Plane Block Versus Serratus Anterior Plane Block With General Anesthesia in Modified Radical Mastectomy Patient (Randomized Double-Blinded Controlled Clinical Trial),COMPLETED,,Fayoum University Hospital,2018-08-01,2019-08-15,2019-09-15,2018-07-06,2020-11-09,['The duration of analgesia of the two blocks'],"['The cumulative opioids (morphine) consumption', 'The cumulative opioids (morphine) consumption', 'The intervals between opioid (morphine) doses', 'The intervals between opioid (morphine) doses', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at rest', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'The quality of analgesia based on visual analogue scale (VAS) pain score at arm abduction', 'Incidences of complications related to both techniques', 'Nausea', 'Nausea', 'Nausea', 'Nausea', 'Nausea', 'Nausea', 'Vomiting', 'Vomiting', 'Vomiting', 'Vomiting', 'Vomiting', 'Vomiting', 'Pruritus', 'Pruritus', 'Pruritus', 'Pruritus', 'Pruritus', 'Pruritus', 'Over-sedation', 'Over-sedation', 'Over-sedation', 'Over-sedation', 'Over-sedation', 'Over-sedation', 'Urine retension', 'Urine retension', 'Urine retension', 'Urine retension', 'Urine retension', 'Urine retension', 'The duration of surgery', 'Intraoperative fentanyl needed', ""Patients' satisfaction with postoperative analgesia"", 'Age', 'weight', 'Height', 'BMI']",,,,,1,Egypt,"Fayoum University hospital [El Fayoum Qesm, Egypt]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a comparison of two existing pain management techniques (Erector Spinae Plane Block and Serratus Anterior Plane Block) rather than introducing a new medicine or extending the indication of an existing one.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03581630,Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients,Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment on Body Weight and Metabolic Risk Factors in Obese Breast Cancer Patients After Breast Cancer Treatment,COMPLETED,,Gangnam Severance Hospital,2017-07-29,2018-07-22,2018-07-22,2018-07-10,2018-08-29,"['Change in body weight', 'Change in fat mass', 'Change in muscle mass', 'Change in fasting glucose', 'Change in insulin', 'Change in triglyceride', 'Change in high-density lipoprotein cholesterol (HDL-cholesterol)', 'Change in leukocyte count']",[],,,,,1,South Korea,"GangnamSeverance Hospital [Seoul, South Korea]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves the use of Naltrexone/Bupropion, which is an existing medication, in a new patient population (obese breast cancer patients) to assess its effects on weight and metabolic risk factors, indicating an extension of indication.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03583463,ALEXANDRIA Study Egypt,"A Prospective Non-InterventionaL Study To EXplore the Real-Life MAnagement Of Postmenopausal womeN With Hormone Receptor- Positive, Human EpiDermal Growth Factor Receptor 2-Negative Locally Advanced/ MetastatIc BreAst Cancer In Egypt",COMPLETED,,AstraZeneca,2018-10-29,2021-01-24,2021-01-24,2018-07-11,2022-02-07,"['Proportion of patients with ER positive, HER2 negative locally advanced or metastatic breast cancer assigned to each treatment modality used as the first line of treatment.', 'Characteristics of patients in each treatment modality according to their histologic diagnosis, Hormone sensitivity, visceral vs non-visceral disease proportion, reason for selecting the treatment.']","['Progression-free survival of patients receiving first line treatment for ER positive, HER2 negative locally advanced or metastatic breast cancer, for all patients.', 'Response Rate (RR) of patients receiving first line treatment for ER positive, HER2 negative locally advanced or metastatic breast cancer.', 'Proportions of patients on each second line treatment modality in patients diagnosed with ER positive, HER2 negative locally advanced or metastatic breast cancer.']",,,,,8,Egypt,"Research Site [Alexandria, Egypt] | Research Site [Cairo, Egypt] | Research Site [El Gharbia, Egypt] | Research Site [El Menofia, Egypt] | Research Site [Gharbia, Egypt] | Research Site [Giza, Egypt] | Research Site [Luxur, Egypt] | Research Site [Zagazig, Egypt]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on the management of a specific type of breast cancer (ER positive, HER2 negative) and evaluates treatment modalities, indicating an extension of indication for existing treatments rather than testing a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT03583944,"A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer","Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer",COMPLETED,PHASE4,Eisai Inc.,2018-03-28,2019-06-28,2019-06-28,2018-07-12,2019-11-27,"['Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'Number of Participants with TEAEs Related to Laboratory Parameters']","['Objective Tumor Response', 'Objective Response Rate (ORR)']",,,,,18,India,"HEMATO-ONCOLOGY CLINIC Vedanta Institute of Medical Sciences [Ahmedabad, India] | HealthCare Global Enterprises Ltd [Bangalore, India] | Srinivasam Cancer Care Multispecialty Hospitals India Pvt Ltd [Bangalore, India] | KR Hospital Mysore Medical College [Mysore, India] | Tata Memorial Hospital Department of Oncology [Mumbai, India] | HCG NCHRI Cancer Centre [Nagpur, India] | Lokmanya Hospital [Pune, India] | Sir Ganga Ram Hospital [New Delhi, India] | All India Institute of Medical Sciences [Bhubaneswar, India] | Deep Hospital [Ludhiana, India] | Sawai Man Singh Hospital [Jaipur, India] | MNJ Institute of Oncology and Regional Cancer Centre [Hyderabad, India] | J.K.Cancer Institute [Kanpur, India] | King George's Medical University,(Erstwhile Chhatrapati Shahuji Maharaj Medical University) [Lucknow, India] | Ajanta Research Centre, Ajanta Hospital & IVF Centre [Lucknow, India] | Nilratan Sircar Medical College and Hospital [Kolkata, India] | Netaji Subhash Chandra Bose Cancer Institute [Kolkata, India] | IPGME&R S.S.K.M Hospital [Kolkata, India]",2018.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,"[""Best Overall Response"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the safety and efficacy of Eribulin Mesylate in a specific patient population (adult females with locally advanced or metastatic breast cancer), indicating it is an extension of indication for an existing treatment.",INDUSTRY,False,2019.0,6.0,0,Other
NCT03596658,SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer,"Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of SHR9549 in Women With ER Positive HER2 Negative Advanced Breast Cancer",TERMINATED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2018-07-25,2019-10-14,2019-10-14,2018-07-24,2022-09-01,"['Dose Limited Toxicity (DLT)', 'Maximum Tolerated Dose (MTD)']","['Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC)', 'overall response rate (ORR)', 'progression free survival (PFS)', 'Incidence of Treatment-Emergent Adverse Events']",,,,,1,China,"The 307th Hospital of Military Chinese People's Liberation Army [Beijing, China]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2019.0,6.0,0,Phase 1
NCT03600090,Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer,"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer",COMPLETED,PHASE1,"Taizhou EOC Pharma Co., Ltd.",2018-10-16,2021-12-25,2021-12-25,2018-07-26,2022-03-31,['DLT'],"['PFS', 'Cmax', 'Tmax', 'AUC 0-inf', 'T1/2']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03602079,Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene,"A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies",COMPLETED,PHASE1; PHASE2,Klus Pharma Inc.,2018-07-16,2022-01-12,2022-01-12,2018-07-26,2023-08-03,['Phase I: Maximum Tolerated Dose'],"['Phase I: Number of patients with Dose Limiting Toxicities', 'Phase I: Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.', 'Phase I: Number of participants who developed measurable anti-drug antibodies', 'Phase I Maximum observed serum or plasma concentration (Cmax).', 'Phase I Clearance (CL).', 'Phase I Area under the serum or plasma concentration time curve from 0 to infinity (AUC[0-∞]).', 'Phase I Terminal phase elimination half life (t½).', 'Phase I Volume of distribution at terminal phase (Vz).', 'Phase I Volume of distribution at steady state (Vss).']",,,,,10,United States,"Florida Cancer Specialists & Research Institute [Sarasota, United States] | Beth Israel Deaconess Medical Center Cancer Center [Boston, United States] | Karmanos Cancer Institute [Detroit, United States] | Clinical Research Alliance, Inc. [Lake Success, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Providence Cancer Institute [Portland, United States] | Mary Crowley Cancer Research Centers - Medical City [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | South Texas Accelerated Research Therapeutics, LLC (START) [San Antonio, United States] | Virginia Cancer Specialist [Fairfax, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03604939,Improving Access to Control of Diseases for Women,Improving Access to Control of Diseases for Women,COMPLETED,,International Agency for Research on Cancer,2017-01-01,2018-08-01,2019-07-01,2018-07-30,2021-09-05,"['Outcomes of the questionnaire survey 1/5', 'Outcomes of the questionnaire survey 2/5', 'Outcomes of the questionnaire survey 3/5', 'Outcomes of the questionnaire survey 4/5', 'Outcomes of the questionnaire survey 5/5', 'NCD Screening study 1/11', 'NCD Screening study 2/11', 'NCD Screening study 3/11', 'NCD Screening study 4/11', 'NCD Screening study 5/11', 'NCD Screening study 6/11', 'NCD Screening study 7/11', 'NCD Screening study 8/11', 'NCD Screening study 9/11', 'NCD Screening study 10/11', 'NCD Screening study 11/11']",['effect of different participant characteristics on the final diagnosis of hypertension and diabetes using multivariate analysis'],,,,,1,India,"GBH Cancer Memorial Hospital [Udaipur, India]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses outcomes of surveys and studies related to disease control and screening, but does not mention any new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03606616,Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients,A Prospective Feasibility Study Applying the ACOSOG Z0011 Criteria to Chinese Patients With Early Breast Cancer Undergoing Breast-conserving Surgery,COMPLETED,,Peking University People's Hospital,2014-11-01,2019-11-30,2019-11-30,2018-07-31,2022-10-18,['overall survival'],"['disease-free survival', 'occurrence of surgical morbidities']",,,,,1,China,"Peking university people's hospital [Beijing, China]",2014.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study applying existing criteria to a specific patient population, rather than testing a new medicine or extending the indication of an existing treatment.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03608865,"Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing","Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing",COMPLETED,PHASE2,Yonsei University,2017-09-19,2021-11-24,2021-11-24,2018-08-01,2022-01-03,['Objective response rate (ORR) by RECIST 1.1'],"['Clinical benefit rate (CBR) by RECIST 1.1 defined by complete or partial response or stable disease for at least 24 weeks', 'Duration of response (DoR)', 'Disease control rate (DCR) by RECIST 1.1', 'Progression-free survival (PFS) by RECIST 1.1']",,,,,1,South Korea,"Yonsei Cancer Center, Severance Hospital, Yonsei University Health System [Seoul, South Korea]",2017.0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial involves Durvalumab and Tremelimumab, which are already approved drugs, being tested in a new patient population (hormone receptor-positive, hypermutated metastatic breast cancer), indicating an extension of indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03609671,Emotions Immunology and Breast Cancer,A Pilot Study: Emotions Immunology and Breast Cancer,COMPLETED,,"Luz A. Venta, MD",2015-11-23,2019-03-18,2019-03-18,2018-08-01,2019-08-28,"['Questionnaire#1, Adverse Childhood Experience (ACE).', 'Questionnaire#2, Depression, Anxiety, and Stress Scale (DASS).', 'Questionnaire#3, Experiences in Close Relationships-Revised (ECR-R).', 'Questionnaire#4, Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B, version 4).', 'Questionnaire#5, Benefit Finding Scale (BFS).', 'Questionnaire#6, Acceptance and Action Questionnaire - II (AAQ-II)']",[],,,,,2,United States,"Houston Methodist Hospital Cancer Center [Houston, United States] | Houston Methodist Hospital [Houston, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focusing on emotional and psychological assessments related to breast cancer, but does not mention any new medicine or an extension of indication for an existing treatment.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03619044,The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.,The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.,TERMINATED,,Institut Claudius Regaud,2020-08-28,2021-06-11,2021-07-09,2018-08-07,2022-02-10,['The rate of patients with conversion of FES negative lesions in FES positive lesions.'],"['The rate of patients with FES positive lesions before treatment.', 'The adverse events due to FES-PET imaging evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.']",,,,,6,France,"Clinique Claude Bernard [Albi, France] | Centre Hospitalier Auch [Auch, France] | Clinique Capio La Croix Du Sud [Quint-Fonsegrives, France] | Centre Hospitalier de Rodez [Rodez, France] | IUCT-O [Toulouse, France] | Clinique Pasteur [Toulouse, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2021.0,4.0,0,NA/Other
NCT03619681,Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer,"A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer",COMPLETED,PHASE1,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2018-09-17,2022-06-30,2022-08-26,2018-08-08,2024-03-12,['The proportion of patients experiencing dose limiting toxicities.'],"['Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest.', 'Percentage of participants who experience laboratory abnormalities and/or adverse events as defined by CTCAE that are related to treatment', 'Maximum observed serum concentration (Cmax) of KN026.', 'Time of Maximum observed serum concentration (Tmax) of KN026.', 'Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) for KN026.', 'Serum Half-life (T-HALF) of KN026.', 'Serum clearance (CL) of KN026.', 'Volume of distribution at steady state (VSS) of KN026.', 'Frequency and titer of anti-KN026 antibody.', 'The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria.', 'Progression free survival according to RECIST 1.1 criteria.']",,,,,1,China,"Fudan University Shanghai Cancer Hospital [Shanghai, China]",2018.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03619993,Patient Preference for Pegfilgrastim (Neulasta®) Application Forms,A Comparison of Pegfilgrastim (Neulasta®) Application Via Manual Injection Versus Injection Via an On-body Injector Regarding Patient Preference and Health Economics,COMPLETED,,iOMEDICO AG,2018-06-25,2019-09-10,2019-09-10,2018-08-08,2019-12-17,['Patient preference for type of pegfilgrastim application assessed via project specific survey answered after 4 applications.'],"['Time point of pegfilgrastim application within a chemotherapy cycle', 'Patient preference for pegfilgrastim application assessed via project specific survey answered at time of enrollment', 'Impact of type of pegfilgrastim application on daily life of the patient assessed by direct questioning using project specific patient survey.', 'Percentage of nurses favoring pegfilgrastim application via On-body injector at study start and at end of study as stated via a project specific nurse survey', 'Preference of investigators for either type of pegfilgrastim application at study start und at end of study assessed via project specific investigator survey', 'Cost factors for the health care system for both types of application of pegfilgrastim']",,,,,48,Germany,"Research Site [Aschaffenburg, Germany] | Research Site [Augsburg, Germany] | Research Site [Berlin, Germany] | Research Site [Bonn, Germany] | Research Site [Celle, Germany] | Research Site [Dresden, Germany] | Research Site [Dresden, Germany] | Research Site [Erfurt, Germany] | Research Site [Flensburg, Germany] | Research Site [Frankfurt (Oder), Germany] | Research Site [Freiburg im Breisgau, Germany] | Research Site [Georgsmarienhütte, Germany] | Research Site [Goslar, Germany] | Research Site [Göttingen, Germany] | Research Site [Halberstadt, Germany] | Research Site [Halle, Germany] | Research Site [Hanover, Germany] | Research Site [Heidelberg, Germany] | Research Site [Herne, Germany] | Research Site [Hildburghausen, Germany] | Research Site [Hildesheim, Germany] | Research Site [Kaiserslautern, Germany] | Research Site [Kassel, Germany] | Research Site [Köthen, Germany] | Research Site [Krefeld, Germany] | Research Site [Mannheim, Germany] | Research Site [Mayen, Germany] | Research Site [Moers, Germany] | Research Site [Mühlhausen, Germany] | Research Site [Mülheim, Germany] | Research Site [München, Germany] | Research Site [Naunhof, Germany] | Research Site [Neunkirchen, Germany] | Research Site [Neustadt in Sachsen, Germany] | Research Site [Nordhorn, Germany] | Research Site [Offenbach, Germany] | Research Site [Oldenburg, Germany] | Research Site [Ostfildern, Germany] | Research Site [Passau, Germany] | Research Site [Plauen, Germany] | Research Site [Ratingen, Germany] | Research Site [Rostock, Germany] | Research Site [Singen, Germany] | Research Site [Sömmerda, Germany] | Research Site [Spremberg, Germany] | Research Site [Stolberg, Germany] | Research Site [Stralsund, Germany] | Research Site [Würselen, Germany]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses patient preferences and application methods for an existing medication (pegfilgrastim), rather than introducing a new medicine or extending the indication of an existing one.",INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT03629717,RANKL Inhibition and Breast Tissue Biomarkers,RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts,COMPLETED,EARLY_PHASE1,Washington University School of Medicine,2018-06-01,2018-12-03,2018-12-03,2018-08-14,2024-10-16,"['Effect of denosumab on breast tissue gene pathway gene expression', 'Effect of denosumab on pathways that may influence breast cancer development as measured by spatial transcriptomic analysis', 'Effect of denosumab on pathways that may influence breast cancer development as measured by metabolomic analysis']",['Correlation of breast tissue gene expression with circulating biomarker levels'],,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the effects of denosumab, which is already an approved medication, on breast tissue biomarkers and pathways related to breast cancer development. This suggests an investigation into a new indication for an existing drug rather than a new medicine.",OTHER,False,2018.0,7.0,0,Phase 1
NCT03629756,A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,COMPLETED,PHASE1,"Arcus Biosciences, Inc.",2018-07-24,2021-08-18,2021-09-03,2018-08-14,2024-05-24,"['Percentage of participants with Adverse Events', 'Percentage of participants who experience a Dose Limiting Toxicity']","['Etrumadenant Peak Serum Concentration: Cmax', 'Zimberelimab Peak Serum Concentration: Cmax', 'Etrumadenant Time of Peak Concentration: Tmax', 'Zimberelimab Time of Peak Concentration: Tmax', 'Percentage of participants with anti-drug antibodies to zimberelimab', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Duration of Response (DOR)', 'Percentage of Participants with Disease Control', 'Percentage of participants with Objective Response']",,,,,15,Australia; United States,"Scottsdale Healthcare Hospitals dba HonorHealth [Scottsdale, United States] | University of California, Los Angeles [Los Angeles, United States] | The Angeles Clinic and Research Institute [Los Angeles, United States] | Rocky Mountain Cancer Centers (Midtown) [Denver, United States] | University of Michigan [Ann Arbor, United States] | QUEST Research Institute [Royal Oak, United States] | Carolina BioOncology Institute [Huntersville, United States] | Prisma Health [Greenville, United States] | Texas Oncology, P.A. - Fort Worth Cancer Center [Fort Worth, United States] | Texas Oncology, P.A. - San Antonio Medical Center [San Antonio, United States] | Texas Oncology, P.A. - Tyler [Tyler, United States] | Medical Oncology Associates dba Summit Cancer Centers [Spokane, United States] | St. George Private Hospital [Kogarah, Australia] | Gallipoli Medical Research Foundation [Greenslopes, Australia] | Cabrini Health Limited [Malvern, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03638219,Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer,Prognostic Significance of Bioscore in Nonmetastatic Cancer,COMPLETED,,Assiut University,2018-01-01,2020-09-30,2020-10-16,2018-08-20,2021-03-18,"['the correlation between pathological stage, T stage (T), nodal stage (N), grade (G), estrogen receptor (ER) status (E) and human epidermal growth factor receptor (HER2) status combined score and the disease specific survival (DSS)']",[],,,,,1,Egypt,"Assiut University hospital [Asyut, Egypt]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,The text discusses the prognostic significance of a bioscore in nonmetastatic breast cancer but does not indicate the introduction of a new medicine or an extension of indication for an existing treatment.,OTHER,False,2020.0,5.0,0,NA/Other
NCT03650348,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,"A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors",COMPLETED,PHASE1,"Pieris Pharmaceuticals, Inc.",2018-08-21,2022-08-11,2022-08-11,2018-08-28,2024-04-22,['Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab'],"['Overall response rate (ORR) per RECIST v1.1', 'Duration of response (DOR) per RECIST v1.1', 'Rate of complete response (CR) per RECIST v1.1', 'Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, and changes in clinical laboratory parameters', 'Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC)', 'Time to maximum dose concentration (Tmax)', 'Terminal half life (t1/2)', 'Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])']",,,,,8,United States,"USC Norris Comprehensive Cancer Center [Los Angeles, United States] | Hoag Memorial Hospital Presbyterian [Newport Beach, United States] | UCLA Health [Santa Monica, United States] | Ochsner Cancer Institute [New Orleans, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | The Ohio State University Comprehensive Cancer Center [Columbus, United States] | M.D. Anderson Cancer Center [Houston, United States] | NEXT Oncology [San Antonio, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating PRS-343, which is a new medicine being tested in combination with atezolizumab for HER2-positive solid tumors, indicating it is a new medicine rather than an extension of indication.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03652077,A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies,"A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies",COMPLETED,PHASE1,Incyte Corporation,2018-09-24,2021-08-18,2021-08-18,2018-08-29,2021-11-15,"['Number of treatment-emergent adverse events', 'Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only)']","['Cmax of INCAGN02390', 'Tmax of INCAGN02390', 'Cmin of INCAGN02390', 'AUC0-t of INCAGN02390', 'Objective response rate', 'Duration of response', 'Disease control rate', 'Progression-free survival', 'Level of binding of INCAGN02390 to TIM-3', 'Immunogenicity of INCAGN02390']",,,,,4,United States,"The Angeles Clinical and Research Institute [Los Angeles, United States] | University of Mississippi [Jackson, United States] | Hackensack Medical Center [Hackensack, United States] | Carolina BioOncology [Huntsville, United States]",2018.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03655600,Acupressure for Pain and Opioid Use Among Breast Cancer Patients,Acupressure for Preventing Post-Operative Pain and Opioid Use Among Breast Cancer Patients Receiving Surgery,TERMINATED,,University of Michigan,2018-09-17,2019-10-17,2019-10-17,2018-08-31,2019-10-25,"['Feasibility of recruitment for self-acupressure: Measure screening to on-study ratio of participants', 'Feasibility of training, as measured by number of participants who complete the daily self-reported logbook', 'Feasibility of training for self-acupressure: Measure the fidelity (accuracy) of participants using training application via instrument administered by study team']","['Pain mitigation in acute postoperative period measured using the Brief Pain Inventory', 'Opioid use mitigation in acute postoperative period']",,,,,1,United States,"Chronic Pain and Fatigue Research Center, University of Michigan [Ann Arbor, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the feasibility of acupressure as a method for pain management and opioid use reduction among breast cancer patients, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03660137,Magnetic Occult Lesion Localization and Imaging (MOLLI),Magnetic Occult Lesion Localization and Imaging (MOLLI) for Non-palpable Breast Lesions: a Phase 0 Pilot Feasibility Trial,COMPLETED,,Sunnybrook Health Sciences Centre,2018-05-28,2019-06-01,2020-01-01,2018-09-06,2020-03-17,['MOLLI Localization Success Rate'],"['Duration of Implantation', 'Specimen Margin Positivity', 'Re-excision rates at 30 days', 'European Quality-of-Life Questionnaire - 5 Dimensions (EQ5D) questionnaire to evaluate quality-of-life', 'Duration of Excision', 'European Quality-of-Life Visual Analogue Scale (EQVAS) questionnaire to evaluate quality-of-life']",,,,,1,Canada,"Sunnybrook Health Sciences Centre [Toronto, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility trial for a localization and imaging technique (MOLLI) for breast lesions, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03661424,BATs in Patients With Breast Cancer and Leptomeningeal Metastases,A Phase I Study of Anti-CD3 x Anti-Her2/Neu (Her2Bi) Armed Activated T Cells (ATC) in Patients With Breast Cancer Leptomeningeal Metastases,TERMINATED,PHASE1,University of Virginia,2019-02-26,2021-12-14,2021-12-14,2018-09-07,2022-12-20,"['Types of adverse events (AEs)', 'Frequency of adverse events (AEs)', 'Severity of adverse events (AEs)', 'Timing of onset of adverse events', 'Duration of adverse events', 'Relationship to study therapy of any adverse events or abnormalities of laboratory tests as determined by CTCAE v5.0 will be assessed based on protocol-defined relationships of definitely, probably, possibly, unlikely and unrelated to study therapy.', 'Number of participants achieving at least 80% of the planned HER2 BATs dose.']","['Immune shift: in vitro cytotoxicity assays and/or IFN-y EliSpots against breast cancer cell lines', 'Immune shift: Phenotyping of activating and regulatory immune cells', 'Immune shift: Measurement of cytokine patterns', 'Immune shift: Determination of anti-Her2 antibodies', 'Correlation of clinical and immune response characteristics to progression-free survival', 'Correlation of clinical and immune response characteristics to overall survival', 'Objective response rate (ORR)', 'Progression-free survival (PFS)', 'Overall survival (OS)', 'MD Anderson Symptom Inventory for Spinal Tumors (MDASI - SP)', 'MD Anderson Symptom Inventory for Brain Tumors (MDASI- BT)']",,,,,1,United States,"University of Virginia [Charlottesville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 1
NCT03673150,Peri-gravidic Exposure to Endocrine Disrupting Persistent Organic Pollutants,Peri-gravidic Exposure to Endocrine Disrupting Persistent Organic Pollutants Dioxins and Dioxin-like Dioxins and the Development of Breast Cancer Within 15 Years: Prospective Longitudinal Case-control Study,COMPLETED,,Centre Hospitalier Universitaire de Nice,2018-08-10,2021-03-03,2021-03-03,2018-09-17,2024-05-17,['Number of women who had pre- and per-gravidic exposure and who developped a breast cancer'],[],,,,,1,France,"University Nice Hospital [Nice, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effects of environmental exposure to pollutants on breast cancer development, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03674242,Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2),A Randomized Phase 2/3 Study of Eryaspase in Combination With Gemcitabine and Carboplatin Chemotherapy Versus Chemotherapy Alone for the Treatment of Patients With Metastatic or Locally Recurrent Triple-Negative Breast Cancer,TERMINATED,PHASE2; PHASE3,ERYtech Pharma,2019-06-13,2022-03-31,2022-03-31,2018-09-17,2022-08-01,['Disease Control Rate (DCR)'],"['Disease Control Rate (DCR)', 'Objective response rate (ORR)', 'Progression-Free Survival (PFS)', 'Duration of Response (DoR)', 'Overall Survival (OS)', 'Incidence of treatment emergent adverse events as assessed by CTCAE v5.0', 'Clinical response assessed by F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging', 'Eryaspase induced immunogenecity', 'Biomarkers potentials in predicting eryaspase activity.', 'Pharmacokinetics of eryaspase', 'Pharmacodynamics of eryaspase']",,,,,16,Belgium; Hungary; Spain,"ZNA Middelheim [Antwerp, Belgium] | Institut Jules Bordet [Brussels, Belgium] | UZ Brussel [Brussels, Belgium] | Grand Hôpital de Charleroi asbl [Charleroi, Belgium] | Clinique Sainte-Elisabeth [Namur, Belgium] | Debreceni Egyetem - Klinikai Kozpont - Onkologiai Klinika [Debrecen, Hungary] | Bacs Kiskun Megyei Korhaz [Kecskemét, Hungary] | Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet [Szolnok, Hungary] | Complejo Hospitalario Universitario A Coruña [A Coruña, Spain] | Hospital Universitario Germans Trias i Pujol [Badalona, Spain] | Hospital Universitario Arnau Vilanova [Lleida, Spain] | Fundacion Jimenez Diaz [Madrid, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Universitario Quirón Madrid [Madrid, Spain] | Hospital Universitario Ramon y Cajal [Madrid, Spain] | Hospital Universitario Virgen del Rocio [Seville, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Eryaspase, which is being studied in combination with chemotherapy for a specific cancer type, indicating it is a new medicine being evaluated for efficacy in treating triple-negative breast cancer.",INDUSTRY,False,2022.0,3.0,1,Phase 3
NCT03680560,Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers,"A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies",TERMINATED,PHASE1,"Cogent Biosciences, Inc.",2019-03-13,2020-03-12,2020-03-12,2018-09-21,2020-03-31,"['Safety and tolerability of ACTR T cell product with trastuzumab as assessed by committee review of dose limiting toxicities (DLTs), incidence and severity of adverse events (AEs) and clinically significant abnormalities of laboratory values', 'Determination of recommended phase 2 dose (RP2D) regimen']","['Anti-tumor activity as measured by overall response rate (ORR) per iRECIST', 'Anti-tumor activity as measured best overall response (BOR)', 'Anti-tumor activity as measured by duration of response (DOR)', 'Anti-tumor activity as measured by progression-free survival (PFS)', 'Anti-tumor activity as measured by overall survival (OS)', 'Assessment of persistence of ACTR as measured by flow cytometry', 'Assessment of persistence of ACTR as measured by quantitative polymerase chain reaction (qPCR)', 'Assessment of ACTR phenotype and function as measured by flow cytometry', 'Assessment of induction of inflammatory markers and cytokines/chemokines after ACTR T cell product administration', 'Trastuzumab pharmacokinetics (PK)']",,,,,6,United States,"Yale Smilow Cancer Hospital [New Haven, United States] | Miami University Cancer Center [Miami, United States] | The Ohio State University [Columbus, United States] | Sarah Cannon Research Institute/Tennessee Oncology, PLLC [Nashville, United States] | Baylor Scott & White Medical Center [Dallas, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03684135,Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure,Satisfaction Assessment of Patients With Local Breast Cancer When Using Cosmetics During Chemotherapy and Post-treatment Thermal Cure,COMPLETED,,Centre Jean Perrin,2018-08-03,2020-11-26,2020-11-30,2018-09-25,2021-01-13,"['Mean satisfaction related to the use of cosmetics during chemotherapy using a visual analog score (VAS) ranging from 0 (not satisfied) to 10 (satisfied).', 'Mean compliance related to the use of cosmetics during chemotherapy by asking if yes or no the products was stopped.', 'Percentage of patients declaring skin problems after the use of these 2 cosmetics', 'Qualitative assessment of cosmetics : percentage of patients feeling that the products texture/oiliness/application/absorption is good/not good', 'Patient expectations related to the use of cosmetics during chemotherapy']","['Mean satisfaction related to the use of cosmetics during post-treatment thermal cure using a visual analog score (VAS) ranging from 0 (not satisfied) to 10 (satisfied).', 'Mean compliance related to the use of cosmetics during post-treatment thermal cure by asking if yes or no the products was stopped', 'Percentage of patients declaring skin problems after the use of these 2 cosmetics', 'Qualitative assessment of cosmetics : percentage of patients feeling that the products texture/oiliness/application/absorption is good/not good', 'Patient expectations related to the use of cosmetics during post-treatment thermal cure']",,,,,1,France,"Centre Jean Perrin [Clermont-Ferrand, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a satisfaction assessment related to the use of cosmetics during chemotherapy and post-treatment, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03691493,"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients",COMPLETED,PHASE2,Emory University,2019-02-08,2022-10-13,2022-10-13,2018-10-01,2025-02-17,['Response Rate'],"['Response Rate Incorporating BPI and Analgesic Measures According to International Bone Consensus Guideline Criteria', 'Number of Participants With Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0', 'Progression-free Survival (PFS)', 'Overall Survival (OS)', 'Fatigue as Measured by The Multidimensional Fatigue Inventory (MFI)', 'Quality of Life as Measured by Short Form Health Survey (SF-36)', 'Quality of Life as Measured by European Organization for Research and Treatment of Cancer Metastases Module (EORTC QLQ-BM22)', 'Quality of Life as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 for Palliative Care (EORTC QLQ-C15-PAL)', 'Depression as Measured by Hospital Anxiety and Depression Scale (HADS)', 'Number of Participants With Adherence as Measured by Drug Diary']","[{""type"":""PRIMARY"",""title"":""Response Rate"",""timeFrame"":""Up to 3 months post radiation"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""29"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""6"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Response Rate Incorporating BPI and Analgesic Measures According to International Bone Consensus Guideline Criteria"",""timeFrame"":""Up to 3 months post radiation"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""18"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""2"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""7"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Number of Participants With Adverse Events Graded According to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0"",""timeFrame"":""Up to 3 months post radiation"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""31"",""spread"":null,""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Progression-free Survival (PFS)"",""timeFrame"":""Up to 44 months post radiation"",""unit"":""Months, estimated using the Kaplan-Meier"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""30.4"",""spread"":null,""lower"":""17.7"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Overall Survival (OS)"",""timeFrame"":""Up to 44 months post radiation"",""unit"":""Months, estimated using the Kaplan-Meier"",""paramType"":""MEDIAN"",""dispersionType"":""95% Confidence Interval"",""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""37.9"",""spread"":null,""lower"":""25.4"",""upper"":""NA""}]},{""type"":""SECONDARY"",""title"":""Fatigue as Measured by The Multidimensional Fatigue Inventory (MFI)"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""Scores on a scale"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""55"",""spread"":""16.4"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""53.6"",""spread"":""13.8"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""54.0"",""spread"":""16.6"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""52.3"",""spread"":""15.9"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0.1"",""spread"":""11.5"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""-0.4"",""spread"":""15.2"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""-1.4"",""spread"":""12.7"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Quality of Life as Measured by Short Form Health Survey (SF-36)"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""Scores on a scale"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""41.8"",""spread"":""8.8"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""42.0"",""spread"":""8.2"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""44.0"",""spread"":""8.1"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""44.0"",""spread"":""8.2"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0.2"",""spread"":""4.7"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""2.1"",""spread"":""6.6"",""lower"":null,""upper"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""1.9"",""spread"":""7.3"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Quality of Life as Measured by European Organization for Research and Treatment of Cancer Metastases Module (EORTC QLQ-BM22)"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""EORT QLQ-BM22 score"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Treated, Painful Site"",""value"":""28.0"",""spread"":""21.0"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""31.2"",""spread"":""26.5"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""63.6"",""spread"":""30.9"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""61.0"",""spread"":""20.9"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""21.5"",""spread"":""20.0"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""25.0"",""spread"":""23.7"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""73.4"",""spread"":""25.8"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""68.4"",""spread"":""19.8"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""18.5"",""spread"":""15.1"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""22.2"",""spread"":""24.6"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""74.1"",""spread"":""26.6"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""69.9"",""spread"":""21.7"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""17.7"",""spread"":""14.4"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""18.1"",""spread"":""16.6"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""74.8"",""spread"":""21.0"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""68.1"",""spread"":""23.3"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""-6.5"",""spread"":""14.1"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""-6.2"",""spread"":""19.4"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""9.8"",""spread"":""18.7"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""7.4"",""spread"":""18.7"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""-9.4"",""spread"":""15.7"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""-9.0"",""spread"":""25.9"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""10.5"",""spread"":""29.8"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""9.0"",""spread"":""17.1"",""lower"":null,""upper"":null},{""group"":""Treated, Painful Site"",""value"":""-10.7"",""spread"":""15.8"",""lower"":null,""upper"":null},{""group"":""Treated, Pain Characteristics"",""value"":""-13.7"",""spread"":""20.0"",""lower"":null,""upper"":null},{""group"":""Treated, Functional Interference"",""value"":""11.9"",""spread"":""23.1"",""lower"":null,""upper"":null},{""group"":""Treated, Psychological Aspects"",""value"":""6.7"",""spread"":""19.0"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Quality of Life as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 for Palliative Care (EORTC QLQ-C15-PAL)"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""EORTC QLQ-C15-PAL score"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Evaluable, Global Health"",""value"":""72.7"",""spread"":""19.6"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""42.6"",""spread"":""28.9"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""68.1"",""spread"":""20.5"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""32.4"",""spread"":""28.4"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""72.7"",""spread"":""20.4"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""28.7"",""spread"":""23.8"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""71.9"",""spread"":""20.5"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""28.6"",""spread"":""23.8"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""-4.6"",""spread"":""21.3"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""-10.2"",""spread"":""25.3"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""0.0"",""spread"":""22.9"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""-13.9"",""spread"":""27.7"",""lower"":null,""upper"":null},{""group"":""Evaluable, Global Health"",""value"":""-0.5"",""spread"":""19.6"",""lower"":null,""upper"":null},{""group"":""Evaluable, Pain"",""value"":""-13.8"",""spread"":""26.0"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Depression as Measured by Hospital Anxiety and Depression Scale (HADS)"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""HADS score, both depression and anxiety"",""paramType"":""MEAN"",""dispersionType"":""Standard Deviation"",""groups"":[{""group"":""Evaluable Depression"",""value"":""4.9"",""spread"":""3.5"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""6.1"",""spread"":""3.6"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""4.6"",""spread"":""3.5"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""5.3"",""spread"":""3.8"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""4.3"",""spread"":""3.5"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""5.2"",""spread"":""3.6"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""4.1"",""spread"":""3.5"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""5.3"",""spread"":""4.0"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""-0.3"",""spread"":""2.0"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""-0.8"",""spread"":""1.9"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""-0.6"",""spread"":""2.6"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""-0.8"",""spread"":""2.3"",""lower"":null,""upper"":null},{""group"":""Evaluable Depression"",""value"":""-0.7"",""spread"":""3.5"",""lower"":null,""upper"":null},{""group"":""Evaluable Anxiety"",""value"":""-0.8"",""spread"":""3.0"",""lower"":null,""upper"":null}]},{""type"":""SECONDARY"",""title"":""Number of Participants With Adherence as Measured by Drug Diary"",""timeFrame"":""Pre-radiation on day 1, Last Day of radiation (5-10 days), 1 month post radiation, and 3 months post radiation, change last day of radiation, change 1 month post radiation, change 3 months post radiation"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Evaluable Palbo"",""value"":""36"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Hormone"",""value"":""36"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Palbo"",""value"":""33"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Hormone"",""value"":""35"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Palbo"",""value"":""25"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Hormone"",""value"":""29"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Palbo"",""value"":""26"",""spread"":null,""lower"":null,""upper"":null},{""group"":""Evaluable Hormone"",""value"":""30"",""spread"":null,""lower"":null,""upper"":null}]}]","{""periods"":[{""title"":""Overall Study"",""milestones"":[{""type"":""STARTED"",""achievements"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""n"":""36""}]},{""type"":""COMPLETED"",""achievements"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""n"":""35""}]},{""type"":""NOT COMPLETED"",""achievements"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""n"":""1""}]}],""dropWithdraws"":[{""type"":""Withdrawal by Subject"",""reasons"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""n"":""1""}]}]}]}","[{""title"":""Age, Categorical"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""26"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""10"",""spread"":null}]},{""title"":""Sex: Female, Male"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""35"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""1"",""spread"":null}]},{""title"":""Ethnicity (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""1"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""33"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""2"",""spread"":null}]},{""title"":""Race (NIH/OMB)"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""3"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""9"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""24"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0"",""spread"":null},{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""0"",""spread"":null}]},{""title"":""Region of Enrollment"",""unit"":""Participants"",""paramType"":""COUNT_OF_PARTICIPANTS"",""dispersionType"":null,""groups"":[{""group"":""Radiation, Palbociclib, Hormone Therapy"",""value"":""36"",""spread"":null}]}]","[{""group"":""Grade 1 Adverse Event"",""serious_affected"":0,""serious_at_risk"":36,""other_affected"":31,""other_at_risk"":36},{""group"":""Grade 2 Adverse Event"",""serious_affected"":0,""serious_at_risk"":36,""other_affected"":30,""other_at_risk"":36},{""group"":""Grade 3 Adverse Event"",""serious_affected"":0,""serious_at_risk"":36,""other_affected"":17,""other_at_risk"":36},{""group"":""Grade 4 Adverse Event"",""serious_affected"":0,""serious_at_risk"":36,""other_affected"":2,""other_at_risk"":36},{""group"":""Grade 5 Adverse Event"",""serious_affected"":0,""serious_at_risk"":36,""other_affected"":0,""other_at_risk"":36}]",10,United States,"Grady Health System [Atlanta, United States] | Emory University Hospital Midtown [Atlanta, United States] | Piedmont Hospital [Atlanta, United States] | Emory University Hospital/Winship Cancer Institute [Atlanta, United States] | Emory Saint Joseph's Hospital [Atlanta, United States] | Northside Hospital [Atlanta, United States] | Augusta University Medical Center [Augusta, United States] | John B. Amos Cancer Center [Columbus, United States] | Lewis Cancer and Research Pavilion at Saint Joseph's/Candler [Savannah, United States] | Maine Medical Center-Bramhall Campus [Portland, United States]",2019.0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,"[""Overall Response"",""Overall Survival""]",2,1,1,1,1,0,1,0,1,5,0,0,0,1,"The study involves the use of Palbociclib, which is an existing medication, in combination with other therapies for a specific patient population (breast cancer patients with bone metastasis), indicating an extension of its indication rather than a new medicine.",OTHER,True,2022.0,3.0,0,Phase 2
NCT03695341,500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI,Fulvestrant Versus Everolimus Plus Exemestane for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitors: the Clinical Experience From Real -World,COMPLETED,,Fudan University,2018-05-14,2019-03-10,2019-05-15,2018-10-04,2019-06-18,['PFS'],['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares Fulvestrant with Everolimus plus Exemestane in patients with metastatic breast cancer who are refractory to previous aromatase inhibitors, indicating an extension of indication for existing treatments rather than testing a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03696056,Improving Brain Function After Breast Cancer Study,Improving Cognition in Breast Cancer Survivors Using Meditation: A Pilot Study,COMPLETED,,University of Texas at Austin,2018-09-28,2020-01-01,2020-01-30,2018-10-04,2020-11-09,"['Verbal learning and memory performance-Hopkins Verbal Learning Test Immediate and Delayed Recall', 'Verbal Fluency Performance-Controlled Oral Word Association Test', 'Executive Functioning Performance- Trail Making Test Parts A & B']","['Granulocyte-macrophage colony-stimulating factor concentration', 'Interferon gamma concentration', 'Interleukin-1 β concentration', 'Interleukin-2 concentration', 'Interleukin-4 concentration', 'Interleukin-5 concentration', 'Interleukin-6 concentration', 'Interleukin-7 concentration', 'Interleukin-8 concentration', 'Interleukin-10 concentration', 'Interleukin-12 concentration', 'Interleukin-13 concentration', 'Tumor necrosis factor alpha concentration', 'Self-reported cognitive function', 'Anxiety Symptoms', 'Feelings of depression', 'Perceived Fatigue', 'Perceived stress']",,,,,1,United States,"University of Texas at Austin [Austin, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on improving cognition in breast cancer survivors using meditation, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03696771,Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer,"A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies",COMPLETED,PHASE1,Novartis Pharmaceuticals,2018-12-27,2020-10-19,2020-10-19,2018-10-05,2022-02-04,"['Incidence and severity of dose limiting toxicities (DLTs)', 'Number of participants with Adverse Events']","['Concentration versus time profiles for NJH395 and its catabolite', 'PK parameter (Cmax) for NJH395', 'Pharmacokinetic (PK) parameter (AUC) for NJH395', 'Incidence of anti-NJH395 antibodies and neutralizing antibodies to trastuzumab', 'Overall Response Rate', 'Clinical Benefit Rate (CBR)', 'Progression Free Survival (PFS)', 'Duration of Response (DOR)', 'Characterization of tumor-infiltrating lymphocytes by IHC']",,,,,4,Italy; Japan; South Korea; United States,"University of Texas MD Anderson Cancer Center [Houston, United States] | Novartis Investigative Site [Milan, Italy] | Novartis Investigative Site [Kashiwa, Japan] | Novartis Investigative Site [Seoul, South Korea]",2018.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03697200,Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings,Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings,COMPLETED,,Johns Hopkins University,2018-11-11,2020-12-01,2020-12-30,2018-10-05,2021-07-28,"['Change in Pain Intensity as assessed by the Brief Pain Inventory-short form', 'Change in Physical Function as assessed by the Western Ontario and McMaster Osteoarthritis Index', 'Change in Physical disability as assessed by the QuickDASH', 'Change in Physical Strength as assessed by Handgrip']",['Change in medication use adherence as assessed by the Ecological Momentary Assessment'],,,,,1,United States,"Johns Hopkins School of Nursing [Baltimore, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Auricular Point Acupressure for managing symptoms related to Aromatase Inhibitors in breast cancer survivors, indicating an extension of indication for an existing treatment rather than a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03705429,A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,A Multi-Centre Randomized Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,COMPLETED,PHASE3,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,2019-05-01,2022-05-11,2022-05-11,2018-10-15,2022-08-19,['Feasibility of performing a pragmatic clinical trial with an Integrated Consent Model.'],"['Adverse events/ toxicity profile between the two different approaches.', 'Cost of each chemotherapy regimen and potential cost-effectiveness analysis.', 'Cost-effectiveness analysis.', 'Cost-effectiveness analysis.', 'Quality of life as reflected by self-reported fatigue using FACIT-Fatigue scores.', 'Quality of life as reflected by self-reported pain using FACT-Taxane scores']",,,,,3,Canada,"London Health Sciences Centre [London, Canada] | The Ottawa Hospital [Ottawa, Canada] | Thunder Bay Regional Health Sciences Centre [Thunder Bay, Canada]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 3
NCT03708432,500mg Fulvestrant in HR+ MBC,"An Observational, Retrospective Study of 500mg Fulvestrant in Hormone Receptor+/HER2- Advanced Breast Cancer",COMPLETED,,Fudan University,2017-07-15,2018-06-15,2018-08-15,2018-10-17,2024-02-26,['PFS'],['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text discusses the use of Fulvestrant, which is an existing medication, in a specific patient population (HR+/HER2- Advanced Breast Cancer), indicating an extension of its indication rather than a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03708978,Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography,Development of Artificial Intelligence System for Detection and Diagnosis of Breast Lesion Using Mammography,COMPLETED,,Peking University Cancer Hospital & Institute,2018-04-05,2020-05-04,2020-05-04,2018-10-17,2021-07-27,"['benign-malignant diagnosis accuracy', 'benign-malignant diagnosis accuracy']",['lesion detection accuracy'],,,,,8,China,"Beijing Cancer Hospital [Beijing, China] | Beijing Chao Yang Women and Children's Health Hospital [Beijing, China] | Beijing Da Xing People's Hospital [Beijing, China] | Beijing Hang Tian Centre Hospital [Beijing, China] | Beijing Nan Jiao Cancer Hospital [Beijing, China] | Beijing Shi Jing Shan Hospital [Beijing, China] | Beijing Shun Yi Qu Hospital [Beijing, China] | Beijing Shun Yi Woman and Children Health Hospital [Beijing, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes the development of an artificial intelligence system for diagnosis and detection, which does not pertain to a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03709082,Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer,"A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,University of Kansas Medical Center,2018-10-15,2020-03-12,2021-02-03,2018-10-17,2024-03-05,['Rate of Overall Response'],"['Proportion of participants with complete response (CR).', 'Proportion of participants with partial response (PR).', 'Proportion of participants with stable disease (SD).', 'Proportion of participants with Grade 3 or higher adverse event.', 'Number of patients with adverse events', 'Number of participants with a worsening Patient Reported Outcomes of Adverse Events (PRO-AE) score', 'Peak observed plasma concentration']",,,,,5,United States,"The University of Kansas Cancer Center, West Clinic [Kansas City, United States] | The University of Kansas Cancer Center, Westwood Campus [Kansas City, United States] | The University of Kansas Cancer Center, Overland Park Clinic [Overland Park, United States] | The University of Kansas Cancer Center, North Clinic [Kansas City, United States] | The University of Kansas Cancer Center, Lee's Summit Clinic [Lee's Summit, United States]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,OTHER,False,2021.0,4.0,0,Phase 2
NCT03712696,Efficacy and Safety of DIGNICAP™ System,A Study on the Efficacy and Safety of DIGNICAP™ System for Preventing Chemotherapy Induced Alopecia,COMPLETED,,European Institute of Oncology,2014-07-18,2018-04-30,2018-09-20,2018-10-19,2018-10-19,['Reduction of hair loss'],"['Hair loss assessed by physician', 'Assessment of head/scalp pain', 'Assessment of feeling chilled', 'Assessment of patient satisfaction', 'Assessment of patient symptoms', 'Assessment of patient health status']",,,,,1,Italy,"European Institute of Oncology [Milan, Italy]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,The trial text indicates an extension of indication as it studies the efficacy and safety of an existing system (DIGNICAP™) for a new use (preventing chemotherapy-induced alopecia).,OTHER,False,2018.0,7.0,0,NA/Other
NCT03719326,A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies,A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies,COMPLETED,PHASE1,"Arcus Biosciences, Inc.",2018-10-15,2021-07-01,2021-07-02,2018-10-25,2024-05-24,"['Incidence of Adverse Events (AEs)', 'Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase']","['Plasma concentration of etrumadenant', 'Plasma concentration of IPI-549', 'Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1', 'Percentage of participants with Disease Control (complete response, partial response, or stable disease) for > 6 months as determined by RECIST v1.1', 'Duration of Response as determined by the Investigator according to RECIST v1.1', 'Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1', 'Overall Survival (OS) as determined by the Investigator according to RECIST v1.1', 'Percentage of etrumadenant target inhibition in peripheral blood', 'Immunophenotyping activity in select immune subsets for etrumadenant and IPI-549 in peripheral blood']",,,,,27,Australia; United States,"Scottsdale Healthcare Hospitals dba Honor Health Research Institute [Scottsdale, United States] | Arizona Clinical Research Center [Tucson, United States] | University of California, Los Angeles [Los Angeles, United States] | Rocky Mountain Cancer Centers (Aurora) [Aurora, United States] | Miami Cancer Institute at Baptist Health [Miami, United States] | Maryland Oncology Hematology, PA [Rockville, United States] | HealthPartners Institute Cancer Care Center [Saint Paul, United States] | Comprehensive Cancer Centers of Nevada [Las Vegas, United States] | Carolina BioOncology Institute [Huntersville, United States] | Willamette Valley Cancer Institute and Research Center [Eugene, United States] | Texas Oncology, P.A. - Austin (Midtown) [Austin, United States] | Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Texas Oncology, P.A. - Fort Worth Cancer Center [Fort Worth, United States] | Texas Oncology, P.A. - San Antonio Northeast [San Antonio, United States] | Texas Oncology, P.A. - San Antonio Medical Center [San Antonio, United States] | Texas Oncology, P.A. - Tyler [Tyler, United States] | Virginia Cancer Specialists, PC [Fairfax, United States] | Virginia Oncology Associates [Norfolk, United States] | Medical Oncology Associates dba Summit Cancer Centers [Spokane, United States] | MultiCare Regional Cancer Center [Tacoma, United States] | Chris O'Brien Lifehouse [Camperdown, Australia] | The Kinghorn Cancer Centre [Darlinghurst, Australia] | St. George Private Hospital [Kogarah, Australia] | Macquarie University [Macquarie, Australia] | Pindara Private Hospital [Benowa, Australia] | Peninsula & South Eastern Haematology and Oncology Group [Frankston, Australia] | Cabrini Hospital [Malvern, Australia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03726801,Prevention of Body Image Disorder by Nurse Intervention on the Patient and Family Prior to Breast and Colon Surgery,Prevention of Body Image Disorder by Nurse Intervention on the Patient and Family Prior to Breast and Colon Surgery,COMPLETED,,Universidad Complutense de Madrid,2017-04-24,2018-08-30,2018-08-30,2018-11-01,2018-11-05,['Average result in patients who have a body image disorder accompanied with or without a direct family member evaluated by the BIS Scale.'],"['Average body image in all patients, to check the alterations that refer to perform a nursing intervention prior to surgery.', 'Percentage of the self-esteem of the patients, differentiating whether or not they go with a direct family member, evaluated by the Rosenberg Scale.', 'Percentage of the Rosenberg scale in all patients, to check the self-esteem that patients refer to when performing a nursing intervention prior to surgery.', 'Average of the quality of life that patients have, differentiating whether or not they go with a direct family member, evaluated by the QLQBR23 Scale', 'Percentages of the Rosenberg Scale and average of the Bis Scale in all patients, to check whether the body image is related to self-esteem.', 'Percentages in the Bis Scale and in the QLQ BR23 scale in all patients, to check if the body image is related to the quality of life.']",,,,,1,Spain,"Natalia Mudarra Garcia [Madrid, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a nursing intervention aimed at preventing body image disorders prior to surgery, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03730428,Everolimus Related Pneumonitis in MBC,Drug-related Pneumonitis During mTOR Inhibitor Therapy in Patients With Metastatic Breast Cancer: A Radiographic Patternbased Approach,COMPLETED,,Fudan University,2017-07-15,2020-05-15,2020-06-15,2018-11-05,2020-08-18,"['radiographic pattern', 'PFS']",[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses drug-related pneumonitis during therapy with an existing drug (mTOR inhibitor) in a specific patient population (metastatic breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03732339,"CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial","Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemotherapy Among Locally Advanced Breast Cancer Patients: a Single-center, Prospective, Exploratory Clinical Trial",COMPLETED,,RenJi Hospital,2018-08-24,2019-03-11,2019-06-30,2018-11-06,2022-04-29,['Predictive value of CTC in ypT0 ypN0'],"['Predictive value of CTC in ypT0, ypT0/is ypN0, near pCR', 'hypersensitivity', 'Detection rate of GILUPI CellCollector®']",,,,,1,China,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University [Shanghai, China]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03735966,Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.,"Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer : a Single-arm,Ahead , Open-label Study",COMPLETED,PHASE2,Henan Cancer Hospital,2018-11-20,2020-10-20,2020-10-20,2018-11-08,2022-12-01,['Pathological Complete Response (pCR)'],"['EFS', 'DFS', 'DDFS', 'ORR']",,,,,1,China,"Henan cancer hospital [Zhengzhou, China]",2018.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER_GOV,False,2020.0,5.0,0,Phase 2
NCT03737500,Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer,Standard Silicone-based Breast Implant vs. B-Lite® Light Weight Breast Implant for Reconstructive Surgery After Total Mastectomy and Post-Mastectomy Radiotherapy for Breast Cancer: a Randomized Clinical Trial,COMPLETED,,Istituti Clinici Scientifici Maugeri SpA,2018-06-01,2021-04-30,2021-06-30,2018-11-09,2023-03-20,['Failure rate of breast reconstruction'],"['Overall complications rate', 'Magnetic resonance imaging (MRI) of breast implant and surrounding tissues', 'Change in cosmetic outcome', 'Change in Quality of life (QoL) measured with BIBCQ', 'Change in Quality of life (QoL) measured with BREAST-Q']",,,,,1,Italy,"Breast Unit - Istituti Clinici Scientifici Maugeri Spa SB [Pavia, Italy]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares two types of breast implants (Standard Silicone-based vs. B-Lite®) for reconstructive surgery after mastectomy, indicating an extension of indication for the B-Lite® implant in this specific context.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03742401,Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU),Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) vs Surgery: A Prospective Randomized Study,TERMINATED,,Theraclion,2018-06-11,2019-04-30,2019-04-30,2018-11-15,2020-03-16,['Evaluation of the treatment of breast fibroadenoma by HIFU compared to surgery assessing the total induced cost in both study arms'],"['Evaluation of the clinical effectiveness in both arms : Pain level assessment', 'Evaluation of the clinical effectiveness in both arms: Anxiety level assessment', 'Evaluation of the clinical effectiveness in both arms: Volume assessment', 'Number of cases needing corrective surgery in case of lack of effectiveness of the primary HIFU treatment.', 'Safety of the procedures in both arms: Number of and severity of adverse events in both arms']",,,,,12,France,"Hopital Européen [Marseille, France] | CHU de Montpellier [Montpellier, France] | Polyclinique Majorelle [Nancy, France] | Polyclinique de l'Atlantique [Nantes, France] | American Hospital of Paris [Neuilly-sur-Seine, France] | Hopital Saint Louis [Paris, France] | Groupe Hospitaliler Diaconesses [Paris, France] | Hopital Pitié-salpêtrière [Paris, France] | Hopital TENON [Paris, France] | Clinique Mutualiste LA SAGESSE [Rennes, France] | CHU Strasbourg [Strasbourg, France] | Centre Hospitalier [Valenciennes, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effectiveness of High Intensity Focused Ultrasound (HIFU) for treating breast fibroadenoma, which suggests it is an extension of indication for an existing treatment rather than a new medicine.",INDUSTRY,False,2019.0,6.0,0,NA/Other
NCT03754816,The Combination of PECS II Block and Parasternal Block for Radical Mastectomy,The Combination of PECS II Block and Parasternal Block Provide Useful Analgesia After Radical Mastectomy With Axillary Dissection and Implant Breast Reconstruction,COMPLETED,,San Salvatore Hospital of L'Aquila,2018-12-01,2019-03-31,2019-04-12,2018-11-27,2019-04-18,['Postoperative pain: Numeric Rate Scale'],"['Intraoperative opiates', 'Postoperative opiates', 'Side effects']",,,,,1,Italy,"San Salvatore Academic Hospital [Coppito, Italy]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a combination of existing analgesic techniques (PECS II Block and Parasternal Block) for postoperative pain management in a specific surgical context, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03760536,Get REAL and HEEL Research Program,Get REAL and HEEL Research Program,COMPLETED,,UNC Lineberger Comprehensive Cancer Center,2017-03-20,2019-03-09,2020-02-12,2018-11-30,2021-09-02,['Cardiopulmonary exercise test with NIRS and PWA (vascular function)'],"['Anthropometrics-Height', 'Anthropometrics-Weight', 'Anthropometrics-BMI', 'Anthropometrics-Blood Pressure', 'Anthropometrics-Resting Heart Rate', 'Body Composition', 'Measure of muscle composition -- proportion of body fat to lean muscle mass', 'Vascular Function', 'Resting ECG', 'Functional Tests', 'Functional Tests', 'Cognitive Testing', 'Cognitive Testing', 'Cognitive Testing', 'Cognitive Testing', 'Cognitive Testing', 'Cognitive Testing', 'Muscle Strength and Power', 'Blood Draw', 'Satisfaction with GR&H Questionnaire', 'Acute exercise bout with blood draw for immune/inflammatory parameters (subset group only)']",,,,,1,United States,"North Carolina Cancer Hospital [Chapel Hill, United States]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a research program focused on various tests and measurements related to health and fitness, but does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03761420,Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Adherence and Clinical Outcome,Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes,COMPLETED,,St. Olavs Hospital,2019-08-01,2021-04-01,2021-04-01,2018-12-03,2021-05-03,"['Medication Possession Ratio (MPR) as a proxy for medication adherence', 'Survival']",[],,,,,1,Norway,"St Olavs Hospital [Trondheim, Norway]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT03762642,Trends of Mastectomy and Breast-Conserving Surgery in Female Breast Cancer Patients,"Trends of Mastectomy and Breast-Conserving Surgery and Related Factors in Female Breast Cancer Patients Treated at King Abdulaziz University Hospital, Jeddah, Saudi Arabia, 2009-2017",COMPLETED,,King Abdulaziz University,2017-07-17,2018-08-02,2018-08-02,2018-12-04,2018-12-06,['Prevalence of each of mastectomy and breast-conserving surgery'],"[""The relationship between the choice of procedure and the patients' age (in years)"", 'The relationship between the choice of procedure and the use of preoperative chemotherapy (also called ""neoadjuvant chemotherapy"")', ""The relationship between the choice of procedure and the tumor's laterality (right versus left breast cancer)"", ""The relationship between the choice of procedure and the tumor's focality (whether it is composed of more than one mass)"", ""The relationship between the choice of procedure and the tumor's centricity (whether it involves more than one quadrant of the breast)"", ""The relationship between the choice of procedure and the tumor's size (in centimeters)"", 'The relationship between the choice of procedure and the tumor\'s stage (using the 7th ""American Joint Committee on Cancer""\'s staging guidelines)', ""The relationship between the choice of procedure and the tumor's histological grade (using the Nottingham Histologic Score system)"", ""The relationship between the choice of procedure and the tumor's receptor status (whether it is positive for estrogen, progesterone, and/or human epidermal growth factor receptor 2)"", 'The relationship between the choice of procedure and having preoperative magnetic resonance imaging of the breast and its findings']",,,,,1,Saudi Arabia,"Faculty of Medicine [Jeddah, Saudi Arabia]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2018.0,7.0,0,NA/Other
NCT03763851,Cannabis Oil and Radiation Therapy for the Management of Pain,"Cannabis Oil and Radiation Therapy for the Management of Pain: Assessment of Safety and Efficacy in a Randomized, Double-blind Placebo-controlled Phase II/III Clinical Trial",TERMINATED,PHASE2,Tetra Bio-Pharma,2018-03-14,2018-11-30,2018-11-30,2018-12-04,2020-03-12,"['Cancer pain intensity assessed by Pain Intensity (PI) measurement a numerical rating scale', 'Cancer pain quality using the Brief Pain Inventory-SF (BPI-SF)']","['Impact of medical cannabis oil combined with radiation treatment on HRQoL as measured by the EQ-5D-5L', 'Functional status assessed by the Functional Assessment of Cancer Therapy for Prostate patients (FACT-P).', 'Fatigue burden assessed by the Brief Fatigue Inventory (BFI).', 'Cognitive status assessed by the Mini-Cog']",,,,,1,Canada,"Sante Cannabis [Montreal, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is investigating the use of cannabis oil, which is considered a new medicine, in combination with radiation therapy for managing cancer pain.",INDUSTRY,False,2018.0,7.0,0,Phase 2
NCT03764943,Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction,Evaluating the Use of Enhanced Recovery Preoperative Immunonutrition and Carbohydrate Loading Strategies in Immediate Autologous and Alloplastic Breast Reconstruction,COMPLETED,PHASE3,"University of Wisconsin, Madison",2019-02-01,2021-08-01,2021-11-01,2018-12-05,2022-03-29,['Number of Incidents of Wound Complications 30-days Post-Op'],"['Number of Patients that Return to the Operating Room 30-days Post-Op', 'Average Length of Hospitalization for Autologous Reconstruction Patients', 'Rate of Wound Complications for Alloplastic Reconstruction Patients up to 90-days Post-Op', 'Number of Alloplastic Reconstruction Patients that Return to the Operating Room up to 90-days Post-Op']",,,,,1,United States,"University of Wisconsin Hospital and Clinics [Madison, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses strategies related to immunonutrition and carbohydrate loading in the context of breast reconstruction, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,Phase 3
NCT03769428,Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block,"Postoperative Analgesia in Breast Cancer Surgery: Safety and Efficiency of Ultrasound Guided Erector Spinae Plane Block, a Randomized Controlled Double Blinded Trial",COMPLETED,,Ben marzouk Sofiene,2018-12-17,2019-06-30,2019-06-30,2018-12-07,2019-12-24,['Comparing morphine consumption rates within 24h postoperative'],"['Assessment of pain in postoperative period via visual analogue scales (VAS) .', 'Total morphine demand', 'Time to first request for morphine', 'Requirement of rescue analgesia', 'Total intraoperative consumption of Fentanyl.', 'Postoperative nausea and vomiting', 'Morphine related side effects']",,,,,1,Tunisia,"Tunis maternity and neonatology center, [Tunis, Tunisia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial focuses on a specific analgesic technique (Erector Spinae Plane Block) rather than testing a new medicine or extending the indication of an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03771183,Loreline Study: Characterization of Long Responders Under Eribuline,National Retrospective Study to Characterize LOng REsponder Under EribuLINE (HALAVEN®) Metastatic Breast Cancer Patients,COMPLETED,,Centre Jean Perrin,2019-08-23,2020-11-30,2021-02-28,2018-12-11,2021-04-05,"[""Measure patient's age at the beginning of Halaven® treatment in patients who received Halaven® and who were in response since 6 months or more"", 'Characterize tumor of patients who received Halaven® and who were in response since 6 months or more', 'Characterize patients who received Halaven® and who were in response since 6 months or more, according to previous treatments (neoadjuvant and/or adjuvant treatments)', 'Characterize patients who received Halaven® and who were in response since 6 months or more, according to the number of lines of treatment received for metastatic disease', 'Characterize metastatic localizations of patients who received Halaven® and who were in response since 6 months or more', 'Characterize patients who received Halaven® and who were in response since 6 months or more', 'Measure the number of Halaven® injections to obtaine the ""best"" response in patients who received Halaven® and who were in response since 6 months or more', 'Measure the best response under Halaven® in patients who received Halaven® and who were in response since 6 months or more', 'Measure hormonal receptors tumours of patients who received Halaven® and who were in response since 6 months or more', 'Measure KI-67 tumours of patients who received Halaven® and who were in response since 6 months or more', 'Measure Scarff Bloom Richardson grade tumours of patients who received Halaven® and who were in response since 6 months or more']","['Measure Percentage of long responders patients under Halaven® among patients treated by Halaven® in second, third and fourth line of treatment', '-Evaluate the percentage of patients with hepatic metastases', '-Evaluate the specific response and/or stability in patients with hepatic metastases, that is measure percentage of liver metastatic patients in complete or partial response or in stability under Halaven®', '-Evaluate toxicities due to the use of Halaven®', '-Evaluation of percentage of patients in complete or partial response or in stability under Halaven® according to number of previous metastatic treatment lines', '-Evaluation of Progression Free Survival (PFS)', 'Evaluation of overall survival']",,,,,5,France,"CHRU Jean Minoz [Besançon, France] | Centre Jean Perrin [Clermont-Ferrand, France] | Institut de Cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France] | Centre Paul Strauss [Strasbourg, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2019.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Best Overall Response"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT03771833,M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid,"Comparison of M5 and M6 Versions of the MARIA Imaging System on Patients Attending Symptomatic Breast Clinic in Cheltenham, United Kingdom (UK), Including a Sub-study to Research the Dielectric Constant of Aspirated Cyst Fluid",COMPLETED,,"Micrima, Ltd.",2019-02-19,2019-08-19,2020-01-23,2018-12-11,2020-02-20,"['Establish the presence or absence of a difference in the MARIA(R) outputs obtained with M5 and M6 when the participants is not moved between scans and when they are moved between scans', 'Establish the presence or absence of a difference between MARIA(R) outputs on the same device when the participant is stationary between scans and when they are moved between scans', 'Measure the dielectric constant of aspirated cyst fluid and any variance between cyst type']","['Assess the diagnostic accuracy of both the M5 and M6 versions of the MARIA system in identifying lesions of the breast, including benign lesions such as cysts', 'Understand participant acceptability of the MARIA scan and obtain feedback on patient experience: questionnaire']",,,,,1,United Kingdom,"Thirlestaine Breast Centre, Gloucestershire Hospitals NHS Foundation Trust [Cheltenham, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study compares two versions of the MARIA imaging system (M5 and M6) for diagnostic accuracy in identifying breast lesions, indicating an extension of indication for the existing technology rather than a new medicine.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT03775850,"A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors","A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors",COMPLETED,PHASE1,"Evelo Biosciences, Inc.",2018-12-19,2021-06-30,2021-10-31,2018-12-14,2023-03-24,"['Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0', 'Safety and tolerability of EDP1503 alone and in combination with pembrolizumab', 'Evidence of anti-tumor activity of EDP1503 based on ORR']","['Progression Free Survival', 'Overall Survival']",,,,,8,Canada; United States,"Highlands Oncology Group [Rogers, United States] | Florida Cancer Specialists [Sarasota, United States] | Stephenson Cancer Center [Oklahoma City, United States] | Tennessee Oncology, PLLC [Chattanooga, United States] | Tennessee Oncology [Nashville, United States] | Centre de Recherche du CHUM [Montreal, Canada] | Jewish General Hospital [Montreal, Canada] | CHU de Québec - Université Laval [Québec, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT03776721,Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting,Treatment of Breast Cancer-related Lymphedema With Stem Cells and Fat Grafting,COMPLETED,PHASE2,Odense University Hospital,2018-12-18,2021-06-01,2021-06-01,2018-12-17,2021-06-25,['Change in arm volume'],"['Safety of treatments: Assessed by asking the patient at each visit', 'Subjective changes assessed using the LYMPH-ICF (Lymphoedema Functioning, Disability and Health) questionaire', 'Subjective changes assessed using DASH (DISABILITIES OF THE ARM, SHOULDER AND HAND) questionaire', 'Subjective changes assessed using SF-36 questionnaire', 'Change in lymph drainage', 'Change in conservative lymphedema treatment', 'Change in adverse lymphedema-related events', 'Change in L-DEX score (bioimpedance)', 'Change in weight and arm tissue composition']",,,,,1,Denmark,"Department of Plastic and Reconstructive Surgery [Odense, Denmark]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses a treatment approach (stem cells and fat grafting) for a specific condition (breast cancer-related lymphedema), indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03782896,The Effects of Anesthetics on Persistent Pain Following Breast Cancer Surgery,The Effects of Anesthetics on Persistent Pain Following Breast Cancer Surgery,COMPLETED,,Samsung Medical Center,2018-12-31,2019-12-05,2019-12-30,2018-12-20,2020-01-31,"['persistent pain', 'acute postoperative pain']","['inhalation agent', 'opioid consumption', 'surgical anxiety level', 'anticipate pain', 'anticipated pain medication need', 'surgery factor', 'The surgical pleth index', 'The pain score of discharge', 'the consumption of postoperative analgesia']",,,,,1,South Korea,"Samsung Medical Center [Seoul, South Korea]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the effects of anesthetics on pain management following surgery but does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03790423,18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer,Phase I: PET Imaging of Tissue Factor (TF) Expression in Patients With Primary and Metastastic Cancer Using 18F-ASIS.,COMPLETED,PHASE1,"Rigshospitalet, Denmark",2019-01-03,2019-11-18,2019-11-18,2018-12-31,2020-11-19,"['1.Biodistribution of the radiotracer 18F-ASIS estimated by PET', '2.Dosimetry of the radiotracer 18F-ASIS estimated by PET', '3. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]']",['1.Quantitative uptake of the radiotracer 18F-ASIS in tumor tissue'],,,,,1,Denmark,"Rigshospitalet [Copenhagen, Denmark]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT03791736,Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation,Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation In Patients With Breast Cancer,TERMINATED,,Institut Cancerologie de l'Ouest,2016-07-06,2018-07-06,2018-07-06,2019-01-03,2022-07-28,['A 50% decrease in the incidence of lymphocele (30% to 15% progression) following axillary clearance of patients operated for breast cancer (excluding mastectomy) pretreated with an injection of Sandostatin®.'],"['Evaluation of the volume of the punctures', 'Evaluation of the cost of this treatment']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,The trial evaluates the use of Sandostatin® in a new context (before axillary clearance in breast cancer patients) rather than testing a new medicine.,OTHER,False,2018.0,7.0,0,NA/Other
NCT03791840,The Value of High-resolution Ultrasound in the Detection of Lymph Node Metastasis: a Proposal of NI-RADS,The Accuracy of High-resolution Ultrasound in the Detection of Lymph Node Metastasis From Breast Cancer and the Proposal of Node Imaging Reporting and Data System,COMPLETED,,Peking University People's Hospital,2017-12-01,2019-01-01,2022-07-01,2019-01-03,2022-10-18,['Sensitivity of ultrasound'],"['Specificity of ultrasound', 'Diagnostic model of lymph node ultrasound']",,,,,1,China,"Peking University People's Hospital [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the use of high-resolution ultrasound for detecting lymph node metastasis and proposes a reporting system, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03795012,Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients,"A Multicenter, Randomized, Phase II Trial Evaluating the Efficacy of Eribulin Monotherapy and Eribulin Plus Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients After Progression on Endocrine Therapy (REVERT)",TERMINATED,PHASE2,MedSIR,2019-04-30,2021-03-31,2021-03-31,2019-01-07,2021-08-31,['The overall response rate (ORR)'],"['The progression-free survival (PFS)', 'PFS-2, in the eribulin and the eribulin + ET arms', 'Overall response rate (ORR) in the eribulin arm', 'The duration of response (DOR) in the eribulin and the eribulin + ET arms', 'The clinical benefit rate (CBR) in the eribulin and the eribulin + ET arms', 'The overall survival (OS) in the eribulin and the eribulin + ET arms', 'Maximum Tumor shrinkage']",,,,,9,Spain,"Hospital de Jaén [Jaén, Spain] | Hospital Quiron Dexeus [Barcelona, Spain] | Institut Català d'Oncologia [Girona, Spain] | Complejo Asistencial Universitario de León [León, Spain] | Hospital Ramón y Cajal [Madrid, Spain] | Hospital Universitario La Paz, [Madrid, Spain] | Hospital Son Llatzer [Palma de Mallorca, Spain] | Hospital Universitario Dr Peset [Valencia, Spain] | Hospital Miguel Servet [Zaragoza, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the efficacy of Eribulin, which is already an approved treatment, in a new patient population (locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy), indicating an extension of indication.",OTHER,False,2021.0,4.0,0,Phase 2
NCT03801850,Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D,Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: Monocentric Feasibility Study MorphoBreast3D,COMPLETED,,Centre Paul Strauss,2018-02-22,2020-05-07,2020-05-07,2019-01-14,2020-08-12,['Impact of breast morphology or volume changes during the breast irradiation on the total dose administered'],"['Preliminary quantitative assessment of breast volume changes (mL) during breast radiotherapy following breast cancer conservative surgery', 'Preliminary quantitative assessment of breast deformations (mm) during breast radiotherapy following breast cancer conservative surgery', 'Breast deformation and volume measurements reproducibility', 'Deviation between the breast volume calculated and the breast volume manually delineated', 'Required measurement time (surface scan)', 'Correlation between textural data and radio-induced erythema', 'Potential dose distribution alteration despite no variation of the 95Recalculated or the D2Recalculated']",,,,,1,France,"Centre paul Strauss [Strasbourg, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study on breast morphology during radiotherapy but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2020.0,5.0,0,NA/Other
NCT03809988,PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA),"International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.",COMPLETED,PHASE2,MedSIR,2019-04-05,2022-11-30,2022-11-30,2019-01-18,2023-09-07,['PFS (Progression-free survival)'],"['Safety AEs', 'Efficacy (ORR)', 'Efficacy (Quality of Life)', 'Efficacy of subgroup analysis', 'Compare efficacy', 'Exploratory objectives (molecular markers)', 'Exploratory objectives (intrinsic molecular subtypes)']",,,,,53,France; Germany; Italy; Slovenia; Spain; United Kingdom,"Hôpital Jean Minjoz [Besançon, France] | Polyclinique Bordeaux Nord Aquitaine [Bordeaux, France] | Centre Georges François Leclerc [Dijon, France] | CHD Vendee [La Roche-sur-Yon, France] | Hopital Europeen Georges Pompidou [Paris, France] | Hôpital Tenon AP-HP [Paris, France] | Centre Paul Strauss [Strasbourg, France] | University Hospital Dresden-GYN [Dresden, Germany] | Kliniken Essen Mitte [Essen, Germany] | Universitätsklinikum Essen Frauenklinik [Essen, Germany] | AGAPLESION Markus Krankenhaus [Frankfurt, Germany] | Technical University Munich [Munich, Germany] | UKM Brustzentrum [Münster, Germany] | Klinikum Ernst von Bergmann [Potsdam, Germany] | Klinikum Mutterhaus der Borromäerinnen Trier [Trier, Germany] | Ospedale Civili Brescia [Brescia, Italy] | Instituto Europeo di Oncologia [Milan, Italy] | Oncologia Medica Ospedale di Prato [Prato, Italy] | Policlinico Universitario Campus Bio-medico [Roma, Italy] | Onkološki Inštitut Ljubljana [Ljubljana, Slovenia] | Univerzitetni klinicni center Maribor Oddelek za onkologijo [Maribor, Slovenia] | ICO Badalona [Badalona, Spain] | Hospital Provincial de Castellón [Castelló, Spain] | Consorci Sanitari de Terrassa [Terrassa, Spain] | Centro Oncológico de Galicia [A Coruña, Spain] | Institut Català d'Oncologia Bellvitge [Barcelona, Spain] | H. Vall Hebrón [Barcelona, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital de Basurto [Bilbao, Spain] | Hospital San Pedro de Alcantara [Cáceres, Spain] | Institut Català d'Oncologia [Girona, Spain] | Hospital Arnau de Vilanova [Lleida, Spain] | Hospital Clinico San Carlos [Madrid, Spain] | Hospital Universitario Sanchinarro [Madrid, Spain] | Hospital La Paz [Madrid, Spain] | Hospital Regional Universitario de Malaga [Málaga, Spain] | Hospital Universitari Son Espases [Palma de Mallorca, Spain] | Hospital Sant Joan [Reus, Spain] | Hospital Universitario Virgen de la Macarena [Seville, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain] | Instituto Valenciano de Oncología IVO [Valencia, Spain] | Hospital General Universitari de Valencia [Valencia, Spain] | Hospital Arnau de Vilanova de Valencia [Valencia, Spain] | Hospital Universitari i Politecnic La Fe [Valencia, Spain] | Hospital Álvaro Cunqueiro [Vigo, Spain] | Hospital Lozano Blesa [Zaragoza, Spain] | Hospital Miguel Servet [Zaragoza, Spain] | Darent Valley Hospital by Dartford and Gravesham NHS Trust [Dartford, United Kingdom] | Beatson West of Scotland Cancer Center [Glasgow, United Kingdom] | Barts Cancer Institute [London, United Kingdom] | Kent Oncology Department [Maidstone, United Kingdom] | Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital [Swansea, United Kingdom] | Royal Cornwall Hospital NHS Trust [Truro, United Kingdom]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the continuation of an existing medication (Palbociclib) in a specific patient population, indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2022.0,3.0,1,Phase 2
NCT03817359,Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery,Use of a Remifentanil-propofol Mixture in Patients With Breast Cancer Undergoing Breast Cancer Surgery: a Prospective Pilot Study,COMPLETED,,Tri-Service General Hospital,2018-08-03,2018-12-27,2018-12-27,2019-01-25,2019-01-30,['Frequency of TCI device adjustments'],"['Mean blood pressure', 'Heart rate', 'Patient satisfaction', 'postoperative analgesia rescue', 'Total dose of remifentanil', 'Total dose of propofol']",,,,,1,Taiwan,"Tri-Service General hospital [Taipei, Taiwan]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the use of a combination of existing medications (Remifentanil and Propofol) in a specific patient population (breast cancer surgery), indicating an extension of indication rather than a new medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03819010,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -","Neoadjuvant Letrozole + Palbociclib in Patients With II-IIIB BC,HR+, HER2-, Phenotype and Pretreatment Recurrence Score(RS):18-25 or 26-100 by Oncotype DX Breast RS Assay.Analysis of RS and Pathological Changes at Surgery",COMPLETED,PHASE2,MedSIR,2019-05-07,2019-07-30,2019-12-31,2019-01-28,2020-11-27,['Difference on Recurrence Score between pre and post-treatment (molecular results)'],"['Molecular changes', 'Molecular induction', 'Global molecular reduction', 'increase RS result', 'Evaluate the concordance rate between the RCB score (0- I vs. II-III) and the post-treatment RS result in both cohorts of patients after treatment with palbociclib in com-bination with letrozole;', 'Evaluate the concordance rate between the pCR and the post-treatment RS re-sult in both cohorts of patients after treatment with palbociclib in combination with letro-zole;', 'Changes in RS']",,,,,18,Portugal; Spain,"Hospital da Luz [Lisbon, Portugal] | Hospital Fernando Fonseca [Lisbon, Portugal] | Portuguese Institute of Oncology of Oporto [Porto, Portugal] | ICO Badalona [Badalona, Spain] | ICO l'Hospitalet [L'Hospitalet de Llobregat, Spain] | Hospital de Jaén [Jaén, Spain] | Complejo Hospitalario Universitario A Coruña (CHUAC) [A Coruña, Spain] | H. Vall Hebrón [Barcelona, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Reina Sofia [Córdoba, Spain] | Onkologikoa [Donostia / San Sebastian, Spain] | Hospital Arnau de Vilanova [Lleida, Spain] | Hospital Ramón y Cajal [Madrid, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain] | Instituto Valenciano de Oncologia [Valencia, Spain] | Hospital Arnau de Vilanova de Valencia [Valencia, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain] | Hospital Miguel Servet [Zaragoza, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2019.0,6.0,1,Phase 2
NCT03829306,Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA),"""Unraveling KAdcyla (Trastuzumab Emtansine; T-DM1) Resistance In HER2-positive Advanced Breast Cancer (ABC): a Prospective GEICAM Study""",COMPLETED,,Spanish Breast Cancer Research Group,2018-06-12,2022-06-21,2022-06-21,2019-02-04,2023-01-13,"['Genomic alterations on tumor samples with Objective Response (OR) to Kadcyla', 'Tumor-specific mutation in plasma samples with OR to Kadcyla']","['Genomic alterations on tumor samples with progression-free survival (PFS)', 'Tumor-specific mutation in plasma samples with progression-free survival (PFS)', 'Genomic alterations on tumor samples with Progression-free survival', 'Genomic alterations on tumor samples with Time to Progression (TTP)', 'Tumor-specific mutation in plasma samples with Progression-free survival', 'Tumor-specific mutation in plasma samples Time to Progression (TTP)', 'Number of participants with treatment-related adverse events as assessed by CTCAE v5.0']",,,,,10,Spain,"Hospital Universitario Virgen Macarena [Seville, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Clínico Universitario ""Virgen de la Arrixaca"" [El Palmar, Spain] | Hospital Universitario Santa Creu i Sant Pau [Barcelona, Spain] | ICO L´Hospitalet [Barcelona, Spain] | Hospital General Universitario Gregorio Marañón [Madrid, Spain] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hopsital Clínico San Carlos [Madrid, Spain] | Hospital Universitario Virgen de la Victoria [Málaga, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial focuses on KAdcyla (Trastuzumab Emtansine) in the context of HER2-positive advanced breast cancer, indicating an extension of its indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03829436,TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers,"A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1,Tempest Therapeutics,2019-03-20,2022-09-07,2022-09-07,2019-02-04,2023-07-03,"['Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab.', 'Incidence of treatment-emergent adverse events as assessed by NCI-CTCAE v5.0 of TPST-1120 as a single agent and in combination with nivolumab.', 'Identify the maximum tolerated dose']","['Assess pharmacokinetics: Maximum serum concentration (Cmax)', 'Assess pharmacokinetics: Area under the curve (AUC)', 'Objective response rate']",,,,,11,United States,"University of California - San Francisco [San Francisco, United States] | Miami Cancer Institute [Miami, United States] | Johns Hopkins University [Baltimore, United States] | University of Michigan Rogel Cancer Center [Ann Arbor, United States] | Columbia University Medical Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Stephenson Cancer Center [Oklahoma City, United States] | University of Pennsylvania Perelman School of Medicine [Philadelphia, United States] | Thomas Jefferson University Hospital [Philadelphia, United States] | UPMC Hillman Cancer Center [Pittsburgh, United States] | Sarah Cannon Research Institute - TN [Nashville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating TPST-1120, which is a new agent being tested both as a monotherapy and in combination with nivolumab, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03830294,Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer,Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer During Rehabilitation: a Randomized Controlled Study,COMPLETED,,Fudan University,2016-10-10,2017-05-31,2017-06-30,2019-02-05,2019-02-05,"[""Participants' skin condition"", ""Participants' knowledge with regard to the breast prosthesis"", ""Participants' feeling of the comfort and practicality of breast prostheses"", 'Measurement of Quality of life of the participants', 'Measurement of Body Image of the participants']",[],,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on temperature-controlled breast prostheses for breast cancer patients, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03836872,Acupuncture for Joint Symptoms in Patients With Breast Cancer,Acupuncture for Joint Symptoms in Patients With Breast Cancer: A Randomised Controlled Trial,TERMINATED,,The Hong Kong Polytechnic University,2019-03-01,2022-01-10,2022-01-31,2019-02-11,2022-08-25,['Brief Pain Inventory'],"['Manchester Foot Pain Disability Questionnaire', 'Manchester Foot Pain Disability Questionnaire', 'Manchester Foot Pain Disability Questionnaire', 'Michigan Hand Outcomes Questionnaire', 'Michigan Hand Outcomes Questionnaire', 'Michigan Hand Outcomes Questionnaire', 'Western Ontario & McMaster Universities Osteoarthritis Index', 'Western Ontario & McMaster Universities Osteoarthritis Index', 'Western Ontario & McMaster Universities Osteoarthritis Index', 'Arthritis Impact Measurement Scale 2-Short Form', 'Arthritis Impact Measurement Scale 2-Short Form', 'Arthritis Impact Measurement Scale 2-Short Form', 'Functional Assessment of Cancer Therapy-Breast', 'Functional Assessment of Cancer Therapy-Breast', 'Functional Assessment of Cancer Therapy-Breast', 'Medical Outcomes Survey 36-item short form version', 'Medical Outcomes Survey 36-item short form version', 'Medical Outcomes Survey 36-item short form version', 'Brief Pain Inventory', 'Brief Pain Inventory']",,,,,1,China,"Xianliang Liu [Luzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the use of acupuncture, which is an existing treatment, for a specific new application (joint symptoms in breast cancer patients), indicating an extension of indication.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03838406,BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer,A Pilot Trial of Platinum Based Chemotherapy According to BRCA Expressions as First-line Chemotherapy in Patients With Metastatic Gastric Cancer,COMPLETED,,Chung-Ang University,2017-08-01,2019-12-31,2019-12-31,2019-02-12,2021-01-27,['Objective response rate'],"['Progression free survival', 'Overall survival']",,,,,1,South Korea,"Chung-Ang University College of Medicine [Seoul, South Korea]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of platinum-based chemotherapy in a new patient population (metastatic gastric cancer) based on BRCA expressions, which suggests an extension of indication for an existing treatment rather than a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03841110,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1),COMPLETED,PHASE1,Fate Therapeutics,2019-02-15,2022-11-15,2022-11-15,2019-02-15,2023-05-01,['The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.'],"['Objective-response rate (ORR)', 'Duration of FT500 persistence']",,,,,4,United States,"UCSD Moores Cancer Center [San Diego, United States] | University of Minnesota Masonic Cancer Center [Minneapolis, United States] | Hackensack University Medical Center/John Theurer Cancer Center [Hackensack, United States] | MD Anderson Cancer Center [Houston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT03841266,Recurrence Risk Evaluation by 21-gene Detection,"Postoperative Recurrence Risk Evaluation of Hormone Receptor Positive, Her-2 Negative Breast Cancer by Using Different 21-gene Detection Kits (REBCK)",COMPLETED,,Xijing Hospital,2019-01-01,2019-01-20,2019-02-01,2019-02-15,2019-02-15,['correlation analysis'],['consistency analysis'],,,,,1,China,"Xijing hoapital [Xi'an, China]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text indicates an evaluation of a specific gene detection method for assessing recurrence risk in a specific type of breast cancer, which suggests an extension of indication for existing treatments rather than the introduction of a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03852953,Under- and Overdiagnosis in BreastScreen Norway,Under- and Overdiagnosis in BreastScreen Norway,COMPLETED,,Norwegian Institute of Public Health,2018-07-01,2020-06-08,2020-06-08,2019-02-25,2024-08-28,"['Study 1: Prognostic and predictive histopathologic characteristics', 'Study 1: Prognostic and predictive histopathologic characteristics', 'Study 1: Prognostic and predictive histopathologic characteristics', 'Study 1: Prognostic and predictive histopathologic characteristics', 'Study 1: Prognostic and predictive histopathologic characteristics', 'Study 1: Prognostic and predictive histopathologic characteristics', 'Study 2: Crude and adjusted rate of overdiagnosis', 'Study 3: Agreement between awareness and knowledge of overdiagnosis']","['Study 1: Survival', 'Study 1: Survival']",,,,,1,Norway,"Cancer Registry of Norway [Oslo, Norway]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses studies related to overdiagnosis in breast cancer screening but does not mention a new medicine or an extension of indication for an existing medicine.,OTHER_GOV,False,2020.0,5.0,0,NA/Other
NCT03858738,A Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast Cancer,A Prospective Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast Cancer,COMPLETED,,Braster S.A.,2015-04-20,2016-06-08,2016-08-19,2019-03-01,2019-03-04,['Diagnostic efficacy of liquid crystal contact thermography using a manual assessment algorithm as compared with ultrasound and/or mammography and breast biopsy.'],[],,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focused on the diagnostic efficacy of a thermography technique for detecting breast cancer, which does not indicate a new medicine or an extension of indication for an existing treatment.",INDUSTRY,False,2016.0,9.0,0,NA/Other
NCT03858972,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC","Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane",TERMINATED,PHASE2,"Odonate Therapeutics, Inc.",2019-02-05,2021-06-11,2021-06-11,2019-03-01,2021-07-30,['ORR as assessed by the IRC'],"['DoR as assessed by the IRC', 'PFS as assessed by the IRC', 'DCR as assessed by the IRC', 'OS', 'Central nervous system (CNS) ORR as assessed by the CNS IRC in patients with CNS metastases at baseline', 'CNS DoR as assessed by the CNS IRC in patients with CNS metastases at baseline', 'CNS PFS as assessed by the CNS IRC in patients with CNS metastases at baseline or a history of CNS metastases and in the intent-to-treat (ITT) population', 'CNS OS in patients with CNS metastases at baseline or a history of CNS metastases']",,,,,25,Australia; Canada; South Korea; Spain; Taiwan; United States,"Innovative Clinical Research Institute [Whittier, United States] | Rocky Mountain Cancer Center [Lakewood, United States] | Sarah Cannon Research Institute - Florida Cancer Specialists [Fort Myers, United States] | Florida Cancer Specialists and Research Institute [St. Petersburg, United States] | Dana-Farber Cancer Institute [Boston, United States] | New York Cancer and Blood Specialists [East Setauket, United States] | West Cancer Center [Germantown, United States] | Texas Oncology - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Virginia Oncology Associates [Norfolk, United States] | Border Medical Oncology [Albury, Australia] | Hopital Maisonneuve-Rosemont [Montreal, Canada] | Center Hospitalier de Montreal CHUM McPeak Sirois [Montreal, Canada] | CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital [Montreal, Canada] | McGill University Health Center [Montreal, Canada] | CHU de Quebec-University Laval [Québec, Canada] | Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre [Sherbrooke, Canada] | Kyungpook National University Hospital [Daegu, South Korea] | National Cancer Center [Goyang, South Korea] | Gangnam Severance Hospital [Seoul, South Korea] | Asan Medical Center [Seoul, South Korea] | Ajou University Hospital [Suwon, South Korea] | Hospital Teresa Herrera Materno-Infantil (CHUAC) [A Coruña, Spain] | Fundacion Jimenez Diaz [Madrid, Spain] | Koo Foundation Sun Yat-Sen Cancer Center [Taipei, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2021.0,4.0,1,Phase 2
NCT03861403,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors,TERMINATED,PHASE1,"Leap Therapeutics, Inc.",2019-05-20,2020-07-14,2020-07-14,2019-03-04,2023-11-30,"['Phase 1b: Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)', 'Phase 1b: Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ± avelumab', 'Phase 2a: Efficacy in Breast and Ovarian Cancer Groups: objective response rate', 'Phase 2a: Efficacy in Prostate Cancer Group: objective response rate']","['To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 in breast and ovarian cancer groups', 'To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 and PCWG3 guidelines in prostate cancer group', 'To determine the duration of response according to modified RECIST 1.1 in breast and ovarian cancer groups', 'To determine the duration of response according to modified RECIST 1.1 and PCWG criteria in prostate cancer group', 'To determine the progression free survival according to RECIST 1.1 in breast and ovarian cancer groups', 'To determine the progression free survival according to RECIST 1.1 and PCWG3 criteria in prostate cancer group', 'To determine overall survival (OS) in all cancer groups', 'To determine the PSA response in prostate cancer group', 'Evaluate the effect of TRX518 in combination with cyclophosphamide and avelumab on lymphoid cell subset numbers and function', 'Time to peak concentration (Tmax)', 'TRX518 and avelumab peak concentration (Cmax)', 'Area under the curve (AUC)', 'Assess TRX518 and avelumab immunogenicity']",,,,,4,United States,"Horizon Oncology Research [Lafayette, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Cleveland Clinic [Cleveland, United States] | University of Virginia [Charlottesville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03868865,Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy,Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy: an Observational Study,COMPLETED,,Universität Duisburg-Essen,2012-08-07,2015-04-07,2015-04-07,2019-03-11,2019-03-11,"['European Organization for Research and Treatment of Cancer (EORTC) QoL questionnaire (QLQ-C30)', 'Hospital Anxiety and Depression Scale (HADS)', 'Brief Fatigue Inventory (BFI)', 'Perceived Stress Scale (PSS)', 'Satisfaction with the program', 'Patients and numbers of adverse events']",[],,,,,1,Germany,"Kliniken Essen-Mitte [Essen, Germany]",2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an observational study on the effects of a day-care clinic program for breast cancer patients during chemotherapy, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2015.0,10.0,0,NA/Other
NCT03872141,Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients,Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients,COMPLETED,,Yale University,2017-05-23,2021-02-25,2021-02-25,2019-03-13,2021-05-03,"['Verbal Memory Test', 'Information processing psychomotor function', 'Identification', 'Visual Working Memory', 'Visual Learning Memory', 'Verbal Memory Test - Delay']","['To correlate neuronal calcium sensor 1 (NCS1) levels with development of chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cognitive impairment (CICI) in human patients.', 'To correlate NCS1 levels with development of CIPN and/or CICI in human patients.', 'To correlate NCS1 levels with development of CIPN and/or CICI in human patients.']",,,,,1,United States,"Smilow Cancer Center [New Haven, United States]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the evaluation of chemotherapy-induced side effects (neuropathy and cognitive impairment) in breast cancer patients, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03872791,A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer,"A Phase Ib/II Study to Evaluate Efficacy, Safety and Tolerability of KN046 Monotherapy or in Combination With Nab-paclitaxel in Subjects With Triple-negative Breast Cancer",COMPLETED,PHASE1; PHASE2,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd",2019-05-30,2022-08-16,2022-10-27,2019-03-13,2023-06-08,"['IRC assessed objective response', 'IRC assessed duration of response']","['PFS rate at 6 and 12 months', 'Frequency and severity of treatment emergent adverse events', 'Percentage of subjects with anti-drug antibodies']",,,,,12,China,"National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China] | The First Affiliated Hospital of Xiamen University [Xiamen, China] | Sun Yat-sen Memorial Hospital, Sun Yat-sen University [Guangzhou, China] | Sun Yat-sen University Cancer Center [Guangzhou, China] | Harbin Medical University Cancer Hospital [Harbin, China] | Henan Cancer Hospital [Zhengzhou, China] | Hunan Cancer Hospital [Changsha, China] | Nantong Tumor Hospital [Nantong, China] | JiLin Cancer Hospital [Changchun, China] | Liaoning Cancer Hospital [Shenyang, China] | LiaoCheng People's Hospital [Liaocheng, China] | Zibo Municipal Hospital [Zibo, China]",2019.0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"[""Duration of Response"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating KN046, which is a new treatment being tested for triple-negative breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT03877146,Calming Alternatives Learned During MRI-Guided Breast Biopsy,Calming Alternatives Learned During MRI-Guided Breast Biopsy (CALM),COMPLETED,,Duke University,2018-10-16,2019-06-20,2019-06-20,2019-03-15,2020-09-25,"['Body pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale', 'Breast pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale', 'Body pain after positioning on the MRI table: Numerical rating scale (NRS)', 'Breast pain after local anesthetic injection: Numerical rating scale (NRS)', 'Breast pain after deeper local anesthetic injection: Numerical rating scale (NRS)', 'Body pain after introducer insertion: Numerical rating scale (NRS)', 'Breast pain after tissue sampling: Numerical rating scale (NRS)', 'Body pain after introducer sheath removal: Numerical rating scale (NRS)', 'Body pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale', 'Breast pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale', 'Body pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale', 'Breast pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale']","['Number of pre-biopsy body pain sites: Body map', 'Number of pre-biopsy breast pain sites: Breast map', 'Anticipated body pain: Anticipatory body pain scale', 'Anticipated breast pain: Anticipatory breast pain scale', 'Anxiety pre-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)', 'Likelihood of cancer pre-biopsy: Likelihood of cancer scale', 'Pain coping strategies pre-biopsy: Coping Strategies Questionnaire (CSQ)', 'Self-efficacy for pain and anxiety pre-biopsy: Self-efficacy for pain and anxiety scale', 'Blood pressure pre-biopsy', 'Pulse pre-biopsy', 'Blood pressure after positioning on the MRI table', 'Pulse after positioning on the MRI table', 'Blood pressure after introducer insertion', 'Pulse after after introducer insertion', 'Blood pressure after introducer sheath removal', 'Pulse after introducer sheath removal', 'Anxiety post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)', 'Likelihood of cancer post-biopsy: Likelihood of cancer scale', 'Distraction from pain during biopsy: Attention to pain scale', 'Distraction from pain during biopsy: Time spent thinking about pain scale', 'Relaxation during biopsy: Relaxation numerical rating scale (NRS)', 'Relaxation during biopsy: Tension Subscale of the Profile of Mood State Short-Form', 'Pain coping strategies post-biopsy: Coping Strategies Questionnaire (CSQ)', 'Self-efficacy for pain and anxiety during biopsy: Self-efficacy for pain and anxiety scale', 'Anxiety 24 hours post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)']",,,,,1,United States,"Duke Cancer Institute [Durham, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study related to pain management and anxiety during an MRI-guided breast biopsy, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03878524,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial,Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME,TERMINATED,PHASE1,OHSU Knight Cancer Institute,2020-04-01,2020-12-10,2020-12-10,2019-03-18,2024-03-04,['Feasibility of implementing an individualized treatment strategy (number of participants to receive first dose)'],"['Incidence of grade 3+ toxicities attributable to assigned study drug(s)', 'Time to treatment discontinuation', 'Overall survival (OS)', 'Time to decline (TTD)']",,,,,1,United States,"OHSU Knight Cancer Institute [Portland, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial focused on the feasibility of an individualized treatment strategy and various outcome measures, but does not indicate the testing of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,Phase 1
NCT03890744,ModraDoc006/r in Patients With Breast Cancer,"A Multicentre Phase IIa Study to Evaluate the Efficacy and Tolerability of ModraDoc006/r in Patients With Recurrent or Metastatic HER-2 Negative Breast Cancer, Suitable for Treatment With a Taxane",COMPLETED,PHASE2,Modra Pharmaceuticals,2019-01-30,2020-02-13,2020-11-09,2019-03-26,2021-10-19,['The objective response rate (ORR)'],"['The number of CTCAE v.4.03 toxicities during treatment with ModraDoc006/r', 'The activity data on progression-free survival (PFS) of ModraDoc006/r']",,,,,4,Belgium; Denmark; Spain,"Institut Jules Bordet [Brussels, Belgium] | Centre Hospitalier Universitaire de Liège [Liège, Belgium] | Odense University Hospital [Odense, Denmark] | Hospital Quiron Pozuelo [Madrid, Spain]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the efficacy and tolerability of ModraDoc006/r in a specific patient population, indicating it is a new medicine being tested for a specific condition (recurrent or metastatic HER-2 negative breast cancer).",INDUSTRY,False,2020.0,5.0,1,Phase 2
NCT03894410,Real World Study of Lapatinib Among Metastatic Breast Cancer Patients,"Real World Study of Lapatinib Among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study",COMPLETED,,Fudan University,2019-01-10,2019-11-15,2020-05-20,2019-03-28,2024-02-26,"['PFS', 'Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)']",[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the use of Lapatinib, which is an existing medication, in a specific patient population (metastatic breast cancer patients) and evaluates its effectiveness and safety in this context, indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03899545,Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery,Does Serratus Plane Plus Pectoral I Block Provide Better Perioperative Analgesia in Ambulatory Breast Cancer Surgery When Compared to Serratus Plane Block Alone,COMPLETED,,Bezmialem Vakif University,2019-04-06,2019-09-05,2019-09-20,2019-04-02,2020-02-25,['Pain intensity score'],"['İntraoperative fentanyl requirement', 'time to first analgesic request', 'Postoperative opioid consumption', 'Postoperative nausea and vomiting', 'Patient satisfaction: score']",,,,,1,Turkey (Türkiye),"Bezmialem Vakıf University [Istanbul, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2019.0,6.0,0,NA/Other
NCT03902964,Needs Assessment After Cancer in Patients Treated for Breast Cancer,Needs Assessment After Cancer in Patients Treated for Breast Cancer,COMPLETED,,Institut Jean-Godinot,2018-12-01,2019-02-01,2019-02-01,2019-04-04,2019-04-04,['Post-cancer needs analysis'],[],,,,,1,France,"Institut Jean Godinot [Reims, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text does not indicate the development of a new medicine or an extension of indication for an existing medicine. It focuses on a needs assessment for patients treated for breast cancer.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03902977,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection,Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection in Patients With Breast Cancer: a Single Blind Randomised Phase III Controlled Trial,TERMINATED,,Lindenhofgruppe AG,2019-02-19,2020-10-01,2020-10-01,2019-04-04,2020-10-23,['Total volume (ml) of axillary/breast drainage until drain removal.'],"['Total duration (days) of breast/axillary drainage', 'Duration of postoperative hospital stay', 'Number of patients with clinically relevant seroma', 'Number of patients with lymphedema', 'Adverse Events (AEs) due to surgical procedure', 'Surgical morbidity', 'Duration (number of days) of clinically relevant seroma aspiration period', 'Volume of axillary drainage per 24 hours in ml', 'Number of clinically relevant seroma aspirations', 'Total volume in ml of all clinically relevant seroma aspirations', 'Surgical morbidity', 'Surgical morbidity']",,,,,1,Switzerland,"Brustzentrum Bern [Bern, Switzerland]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial focuses on the effect of a surgical technique (Quilting Sutures) on post-operative outcomes rather than testing a new medicine or an extension of indication for an existing medicine.,INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT03905343,Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC,"Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.",TERMINATED,PHASE3,Swiss Cancer Institute,2019-06-25,2021-04-15,2021-04-15,2019-04-05,2021-06-16,"['Quality of life-adjusted early disease control', 'Quality of life-adjusted early disease control']","['Disease Control (DC) at 12 weeks', 'Objective response rate (ORR)', 'Time to objective response (OR)', 'Progression-free survival (PFS)', 'Time to treatment failure (TTF)', 'Overall survival (OS) at 3 years', 'Changes in overall QoL (FACT-B) until 24 months', 'Time to QoL deterioration', 'Time to QoL improvement', 'Time to pain improvement', 'Adverse events (AEs)']",,,,,35,Austria; Belgium; Switzerland,"Med. Univ. Klinik Graz [Graz, Austria] | Tirol Kliniken - BrustGesundheitZentrum Tirol [Innsbruck, Austria] | Salzburger Landeskliniken - Universitätsklinikum Salzburg [Salzburg, Austria] | Universitätsklinik für Frauenheilkunde [Vienna, Austria] | Algemeen Ziekenhuis Klina [Brasschaat, Belgium] | Grand Hôpital de Charleroi [Charleroi, Belgium] | Jessa Ziekenhuis [Hasselt, Belgium] | CHC Mont Légia [Liège, Belgium] | CHU de Liege [Liège, Belgium] | CHR de la Citadelle [Liége, Belgium] | CHU UCL Namur - Site Sainte Elisabeth [Namur, Belgium] | Clinique-Saint-Pierre [Ottignies, Belgium] | Kantonsspital Baden [Baden, Switzerland] | Kantonsspital Baden [Baden, Switzerland] | Universitaetsspital-Basel [Basel, Switzerland] | Brustzentrum Basel - Praxis für ambulante Tumortherapie [Basel, Switzerland] | Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli [Bellinzona, Switzerland] | Inselspital Bern [Bern, Switzerland] | Clinique des Grangettes [Chêne-Bougeries, Switzerland] | Kantonsspital Graubuenden [Chur, Switzerland] | Hôpital neuchâtelois [La Chaux-de-Fonds, Switzerland] | Centre Hospitalier Universitaire Vaudois [Lausanne, Switzerland] | Kantonsspital Liestal [Liestal, Switzerland] | Kantonsspital Luzern [Lucerne, Switzerland] | Hirslanden Klinik St. Anna Luzern [Lucerne, Switzerland] | Onkologie Zentrum Spital Männedorf [Männedorf, Switzerland] | Kantonsspital Olten [Olten, Switzerland] | Brustzentrum Ostschweiz [Sankt Gallen, Switzerland] | Kantonsspital - St. Gallen [Sankt Gallen, Switzerland] | Hôpital de Sion [Sion, Switzerland] | Spital STS AG [Thun, Switzerland] | Kantonsspital Winterthur, Brustzentrum [Winterthur, Switzerland] | Onkologie Bellevue [Zurich, Switzerland] | OnkoZentrum Zürich AG - Klinik im Park [Zurich, Switzerland] | Universitäts Spital Zürich [Zurich, Switzerland]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares ribociclib in combination with endocrine therapy to chemotherapy in a specific patient population (visceral metastatic breast cancer), indicating an extension of indication for ribociclib rather than testing a new medicine.",OTHER,False,2021.0,4.0,1,Phase 3
NCT03910595,Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients,An Efficacy Study of Mepitel Film in the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients Undergoing Adjuvant Radiotherapy,COMPLETED,,Sunnybrook Health Sciences Centre,2019-03-14,2020-04-28,2020-09-08,2019-04-10,2020-10-22,['Observable differences between treated and non-treated breasts/chest wall'],"['Patient reports of acute skin toxicity', 'Patient reports of late skin toxicity', 'Clinician reports of acute skin toxicity', 'Clinician reports of late skin toxicity', 'Clinician grading of acute skin toxicity', 'Clinician grading of late skin toxicity', 'Degree of acute skin toxicity and interference with daily functioning', 'Degree of late skin toxicity and interference with daily functioning', 'Long-term changes in skin pigmentation', 'Acute changes in breast cosmesis', 'Late changes in breast cosmesis', 'Film Integrity Assessment']",,,,,1,Canada,"Odette Cancer Centre, Sunnybrook Health Sciences Centre [Toronto, Canada]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03911453,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors",Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib,COMPLETED,EARLY_PHASE1,University of Arizona,2019-04-19,2021-07-16,2021-07-16,2019-04-11,2024-10-03,['Measurement of expression of PD-L1 by IHC via core biopsy.'],"['Measure change in expression of Ki67 by IHC after treatment with PARPi.', 'Measure and quantify change in number of tumor-infiltrating lymphocytes.', 'Measure levels of tumor PARylation in pre- and post-PARPi therapy by IHC.', 'Measure change in expression of programmed cell death-1 with ligand (PD-L1) pre- and post-PARPi therapy in circulating tumor cells (CTCs).', 'Measure cfDNA mutational expression for homologous recombination deficiency (HRD) and correlate with PD-L1 expression at baseline and change overtime.']",,,,,1,United States,"University of Arizona Cancer Center [Tucson, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the effects of the PARP inhibitor Rucaparib, indicating it is a new medicine being tested for its impact on PD-L1 expression in a specific cancer type.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03918668,Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women,Observational Study to Understand the Risk Factors Associated With Breast Cancer in Women With a Recent Diagnosis at the Community of Madrid,COMPLETED,,Instituto de Investigación Hospital Universitario La Paz,2018-07-01,2018-12-31,2019-12-31,2019-04-17,2021-07-20,['Dietary habits of a group of women with pre and post-surgical breast cancer'],[],,,,,1,Spain,"Institute for Health Research IdiPAZ [Madrid, Spain]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an observational study focused on understanding risk factors associated with breast cancer, rather than testing a new medicine or an extension of indication for an existing treatment.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03919682,Promoting Early Detection of Breast Cancer in Rural Rwanda: Impact of Community Health Worker and Nurse Training,Promoting Early Detection of Breast Cancer in Rural Rwanda: Impact of a Community Health Worker and Health Center Nurse Training Program,COMPLETED,,Brigham and Women's Hospital,2015-04-18,2017-04-17,2017-04-17,2019-04-18,2021-08-26,"['Health center nurse knowledge', 'Community health worker knowledge', 'Health center nurse clinical skills']","['Health center volume', 'District hospital referrals', 'Breast ultrasounds', 'Breast biopsy', 'Patient delays', 'System delays', 'Breast cancer detection rate', 'Breast cancer stage']",,,,,0,,,2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a training program for health workers aimed at improving breast cancer detection, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT03924609,Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients,Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients: A Multicenter Retrospective Study,COMPLETED,,Peking University People's Hospital,2018-03-01,2019-03-31,2019-03-31,2019-04-23,2019-04-23,['Overall survival'],"['disease-free survival', 'distant metastasis-free survival']",,,,,1,China,"Peking University People's Hospital [Beijing, China]",2018.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the impact of follow-up care for breast cancer patients with bone metastasis, which does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03931551,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer",Effectiveness of Olaparib Plus Trastuzumab in HER2-positive BRCA-mutated Advanced Breast Cancer Patients (The OPHELIA Study),TERMINATED,PHASE2,MedSIR,2019-04-30,2022-03-02,2022-03-02,2019-04-30,2023-02-22,['Assess the efficacy of olaparib in combination with trastuzumab'],"['ORR', 'PFS i', 'Clinical benefit rate (CBR', 'Duration of response (DoR)', 'Maximum Tumor Shrinkage', 'Overall survival (OS)', 'Health-Related Quality of Life (HRQoL) in cohorts A and B', 'Safety adverse events (AEs)']",,,,,4,Spain,"Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Complejo Hospitalario de Jaén [Jaén, Spain] | Hospital Clínico San Carlos [Madrid, Spain] | Hospital Virgen del Rocío [Seville, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the effectiveness of olaparib in combination with trastuzumab for a specific patient population (HER2-positive BRCA-mutated advanced breast cancer), indicating an extension of indication for olaparib rather than introducing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT03942575,The Risk of Postoperative Wound Complications Following the Use of Negative Pressure Wound Therapy in Patients Undergoing Mastectomy,The Risk of Postoperative Wound Complications Following the Use of Avelle Negative Pressure Wound Therapy in Patients Undergoing Mastectomy and Flap fiXation: a Pilot Study,COMPLETED,,Zuyderland Medisch Centrum,2019-05-31,2020-06-01,2020-06-01,2019-05-08,2020-07-02,['Number of patients with post-operative wound complications'],"['Number of unplanned visits to the ER or breast cancer clinic', 'Number of patients with clinically significant seroma']",,,,,1,Netherlands,"Zuyderland Medisch Centrum [Sittard, Netherlands]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Avelle Negative Pressure Wound Therapy in a specific patient population (mastectomy patients), indicating an extension of indication for an existing therapy rather than introducing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT03945604,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC,"A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer",COMPLETED,PHASE1,"Jiangsu HengRui Medicine Co., Ltd.",2019-06-04,2021-02-09,2021-02-09,2019-05-10,2022-08-12,['Dose Limiting Toxicity (DLT)'],"['Adverse Events and Serious Adverse Events', 'Overall Response Rate (ORR)', 'Duration of response (DoR)', 'Disease Control Rate', 'Progression-Free-Survival', '12-months overall survival rate']",,,,,1,China,"Beijing Cancer Hosptial [Beijing, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves SHR-1210, which is identified as an Anti-PD-1 inhibitor, indicating it is a new medicine being tested in combination with other agents for a specific cancer type.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT03947463,A Randomized Clinical Trial,"Pectoral Nerves I, II and Serratus Plane Blocks in Multimodal Analgesia for Mastectomies A Randomized Clinical Trial",COMPLETED,,Shaukat Khanum Memorial Cancer Hospital & Research Centre,2017-02-01,2017-12-19,2018-03-01,2019-05-13,2019-05-13,['Change in Pain score over 24 hours'],"['Post operative morphine (opioids) consumption in PACU', 'Antiemetic consumption for treatment of PONV']",,,,,1,Pakistan,"Shaukat Khanum Memorial Cancer Hospital and Research Center [Lahore, Pakistan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on the effectiveness of nerve blocks in pain management for mastectomies, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT03948568,Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT),"A Pragmatic Randomised, Multicentre Trial Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)",COMPLETED,PHASE4,Ottawa Hospital Research Institute,2019-09-17,2021-06-09,2022-04-09,2019-05-14,2022-09-30,['Endocrine toxicity'],"['Radiotherapy toxicity', 'Rates of starting endocrine therapy and compliance', 'Direct Estimation of Health Utility Values', 'Incremental cost-effectiveness ratios', 'Exploratory analyses on evaluating radiotherapy toxicity']",,,,,1,Canada,"Ottawa Hospital Research Institute [Ottawa, Canada]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial focuses on evaluating treatment timing and does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2022.0,3.0,0,Other
NCT03952325,Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC,"A Multicenter, Phase 2 Study of Tesetaxel Plus Three Different PD-(L)1 Inhibitors in Patients With Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly and Non-Elderly Adult Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer",TERMINATED,PHASE2,"Odonate Therapeutics, Inc.",2019-07-09,2021-06-23,2021-06-23,2019-05-16,2021-07-30,"['Cohort 1: ORR in patients with PD-L1 positive status', 'Cohort 1: PFS in patients with PD-L1 positive status', 'Cohort 2: ORR in patients with HR-positive, HER2-negative disease', 'Cohort 2: PFS in patients with HR-positive, HER2-negative disease', 'Cohort 3: ORR in patients with HR-positive, HER2-negative disease', 'Cohort 3: PFS in patients with HR-positive, HER2-negative disease']","['Cohort 1: ORR in all patients', 'Cohort 1: PFS in all patients', 'Cohort 1: DoR', 'Cohort 1: OS', 'Cohort 2: ORR in patients with triple-negative disease', 'Cohort 2: PFS in patients with triple-negative disease', 'Cohort 2: DoR', 'Cohort 2: OS', 'Cohort 3: ORR in patients with triple-negative disease', 'Cohort 3: PFS in patients with triple-negative disease', 'Cohort 3: DoR', 'Cohort 3: OS']",,,,,12,Singapore; South Korea; United States,"Sarah Cannon Research Institute - Florida Cancer Specialists [Fort Myers, United States] | Florida Cancer Specialists and Research Institute [St. Petersburg, United States] | Florida Cancer Specialists and Research Institute - Panhandle Region [Tallahassee, United States] | Florida Cancer Specialists and Research Institute [West Palm Beach, United States] | Dana-Farber Cancer Institute [Boston, United States] | New York Cancer and Blood Specialists [East Setauket, United States] | West Cancer Center [Germantown, United States] | Texas Oncology - Baylor Charles A. Sammons Cancer Center [Dallas, United States] | Virginia Oncology Associates [Norfolk, United States] | John Hopkins Singapore International Medical Centre [Singapore, Singapore] | National Cancer Centre Singapore [Singapore, Singapore] | Asan Medical Center [Seoul, South Korea]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,INDUSTRY,False,2021.0,4.0,1,Phase 2
NCT03954015,Comparison of Three Methods for Early Detection of Breast Cancer,"Contrast Enhanced Ultrasound (CEUS) With US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer",COMPLETED,EARLY_PHASE1,Mayo Clinic,2019-10-15,2020-06-30,2021-10-05,2019-05-17,2022-01-10,"['CEUS true positive diagnosis', 'CEUS false positive diagnosis', 'CEUS true negative diagnosis', 'CEUS false negative diagnosis']",[],,,,,1,United States,"Mayo Clinic [Rochester, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a comparison of diagnostic methods for breast cancer detection rather than introducing a new medicine or extending the indication of an existing treatment.,OTHER,False,2021.0,4.0,0,Phase 1
NCT03955939,A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body,A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 Erbumine in Monotherapy and Combination Therapy in Patients With Metastatic Breast Cancer Post CDK4/6 Inhibitor and Endocrine Therapy,COMPLETED,PHASE1,Eli Lilly and Company,2019-08-02,2020-05-14,2020-05-14,2019-05-20,2020-06-01,"['Number of Participants with Dose Reductions', 'Part II: Number of Participants with Dose Limiting Toxicities (DLTs)', 'Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)', 'Duration of Response (DoR)']","['Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve CR, PR or SD With a Duration of At Least 6 Months', 'Progression-Free Survival (PFS)', 'Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3295668', 'PK: AUC of LY3295668 in Combination with Endocrine Therapy', 'PK: AUC of Endocrine Therapy in Combination with LY3295668', 'PK: AUC of Midazolam', 'PK: AUC of Midazolam in Combination with LY3295668']",,,,,7,Belgium; United States,"City of Hope National Medical Center [Duarte, United States] | Dana Farber Cancer Institute [Boston, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | Cliniques Universitaires Saint-Luc [Brussels, Belgium] | Universitair Ziekenhuis Antwerpen [Edegem, Belgium] | Universitair Ziekenhuis Gent [Ghent, Belgium] | Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg [Leuven, Belgium]",2019.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on LY3295668 Erbumine, which is a new drug being tested in patients with metastatic breast cancer, indicating it is a New Medicine.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT03957096,A Safety Study of SGN-CD47M in Patients With Solid Tumors,A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors,TERMINATED,PHASE1,Seagen Inc.,2019-07-17,2020-09-14,2020-09-14,2019-05-21,2020-09-17,"['Number of patients with adverse events', 'Number of patients with laboratory abnormalities', 'Number of patients with dose-limiting toxicities (DLTs)']","['Objective response rate (ORR) per RECIST v1.1', 'ORR per iRECIST', 'Duration of objective response (DOR) per RECIST v1.1', 'DOR per iRECIST', 'Duration of complete response (CR) per RECIST v1.1', 'Duration of CR per iRECIST', 'Progression-free survival (PFS) per RECIST v1.1', 'PFS per iRECIST', 'Overall survival (OS)', 'Area under the concentration-time curve (AUC)', 'Maximum concentration (Cmax)', 'Time to Cmax (Tmax)', 'Trough concentration (Ctrough)', 'Incidence of antidrug antibodies (ADA)']",,,,,5,United States,"Case Western Reserve University / University Hospitals Cleveland Medical Center [Cleveland, United States] | Providence Portland Medical Center [Portland, United States] | Tennessee Oncology-Nashvilee/Sarah Cannon Research Institute [Nashville, United States] | MD Anderson Cancer Center / University of Texas [Houston, United States] | NEXT Oncology [San Antonio, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT03964896,Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy,Evaluating the Feasibility of a Nurse-Driven Telephone Triage Intervention for Cancer Patients Undergoing Chemotherapy in the Ambulatory Setting,COMPLETED,,M.D. Anderson Cancer Center,2016-10-17,2019-12-18,2019-12-18,2019-05-28,2019-12-24,['Feasibility of completing nurse-driven telephone triage calls'],"['Symptom experience', 'Patient Satisfaction', 'Number of emergency room visits', 'Number of hospital admissions']",,,,,1,United States,"M D Anderson Cancer Center [Houston, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a nurse-driven intervention aimed at improving patient care and managing side effects in cancer patients undergoing chemotherapy, but it does not introduce a new medicine or extend the indication of an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT03969121,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer","A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer",COMPLETED,PHASE3,Kyoto Breast Cancer Research Network,2019-07-16,2021-12-23,2021-12-23,2019-05-31,2023-03-10,"['Pre-operative Endocrine Prognostic Index (PEPI Score)', 'EndoPredict™ EPclin Score']","['Clinical Response Rate', 'Ki67 change', 'pathological response rate', 'Breast conserving rate', 'Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment as Assessed by CTCAE v4.03']",,,,,25,Australia; Hong Kong; Japan; South Korea; Taiwan,"Monash Health [Clayton, Australia] | Peter MacCallum Cancer Centre [Melbourne, Australia] | UNIMED Medical Institute [Hong Kong, Hong Kong] | Amagasaki General Medical Center [Amagasaki, Japan] | University of Tsukuba Hospital [Tsukuba, Japan] | Kyushu Cancer Center [Fukuoka, Japan] | Sagara Hospital [Kagoshima, Japan] | Kobe City Medical Center General Hospital [Kobe, Japan] | Kyoto University Hospital [Kyoto, Japan] | Aichi Cancer Center [Nagoya, Japan] | Tazuke Kofukai, Medical Research Institute, Kitano Hospital [Osaka, Japan] | Saitama Cancer Center [Saitama, Japan] | Toranomon Hospital [Tokyo, Japan] | Tokyo Metropolitan Komagome Hospital [Tokyo, Japan] | Cancer Institute Hospital Of JFCR [Tokyo, Japan] | Kyorin University Hospital [Tokyo, Japan] | Kanagawa Cancer Center [Yokohama, Japan] | National Cancer Center, Korea [Gyeonggi-do, South Korea] | Seoul National University Bundang Hospital [Seongnam, South Korea] | Korea Cancer Center Hospital [Seoul, South Korea] | Seoul National University College of Medicine [Seoul, South Korea] | Changhua Christian Hospital [Changhua, Taiwan] | Kaohsiung Medical University Chung-Ho Memorial Hospital [Kaohsiung City, Taiwan] | National Taiwan University Hospital [Taipei, Taiwan] | Sun Yat-Sen Cancer Center [Taipei, Taiwan]",2019.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2021.0,4.0,1,Phase 3
NCT03975621,Nurse AMIE: Addressing Metastatic Individuals Everyday,Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer (AMIE = Addressing Metastatic Individuals Everyday),COMPLETED,,Milton S. Hershey Medical Center,2019-03-01,2020-09-01,2020-09-01,2019-06-05,2022-01-21,"['Feasibility of the Application: The proportion of women who consent, take a tablet home, who actually interact with the tablet and participate at least one month of the program.']",['Acceptability of the Application: The proportion of patients who agree to participate among those deemed eligible and cleared by oncologist.'],,,,,1,United States,"Penn State Cancer Institute [Hershey, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a supportive care platform for metastatic breast cancer but does not indicate the development of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2020.0,5.0,0,NA/Other
NCT03979729,Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography,Breast Cancer Screening Among Medically Underserved Women in New Mexico: Comparing Outcomes and LOwering Recall Rates With Digital Breast Tomosynthesis (3D Mammography) VErsus Full-field Digital (2D) Mammography. The LOVE New Mexico Study,COMPLETED,,New Mexico Cancer Research Alliance,2016-09-22,2020-05-07,2021-06-03,2019-06-07,2022-10-05,['Recall rates using 3D + 2D- vs. 2D-mammogram in New Mexico women undergoing screening mammograms (Retrospective analysis)'],"['What psychosocial and cultural factors influence breast cancer screening among medically underserved patients, identified through interviews and questionnaires', ""What are primary care providers' knowledge, attitudes, beliefs, and preferences regarding 3D + 2D- vs. 2D-mammography, identified through interviews and questionnaires"", 'Breast cancer detection rate for 3D + 2D- vs. 2D-mammograms', 'Breast cancer biopsy positive predictive value for 3D + 2D- vs. 2D-mammograms', 'Screening outcome of women undergoing 3-D mammography', 'Compliance with recall recommendations of women undergoing 3-D mammography', 'Breast cancer detection rate in women undergoing 3-D mammography', 'Positive predictive value of women undergoing 3-D mammography']",,,,,1,United States,"University of New Mexico Comprehensive Cancer Center [Albuquerque, United States]",2016.0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares outcomes of 3D mammography versus 2D mammography in breast cancer screening, indicating an extension of indication for the use of 3D mammography in this context.",OTHER,False,2021.0,4.0,0,NA/Other
NCT03980093,The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors,COMPLETED,,"University of Colorado, Boulder",2019-04-01,2020-08-31,2020-08-31,2019-06-10,2022-11-03,['Medication adherence assessed by electronic pillbox (Wisepill box)'],"['Self-reported medication adherence', 'Positive and negative emotional associations with taking anti-hormonal medication', 'Intentions to adhere to anti-hormonal medication in the next year and next several years', 'Medication nonpersistence assessed by electronic pillbox (Wisepill box)']",,,,,1,United States,"Rocky Mountain Cancer Centers [Greenwood Village, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03981731,Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session,"Management of Perioperative Anxiety by the Fixed Rate Guided Breathing Technique (Cardiac Coherence) Coupled With a Hypnosis Session, as Part of the Improved Pre-habilitation After Surgery",COMPLETED,,Institut du Cancer de Montpellier - Val d'Aurelle,2020-02-14,2022-01-14,2022-01-14,2019-06-11,2023-09-28,['Proportion of patients who have enrolled in the pre-habilitation program'],"['The preoperative anxiety score by using the Amsterdam Preoperative Anxiety and Information Scale (APAIS)', 'Patient\'s satisfaction with perioperative period by using ""Evaluation of the Vecu of General Anesthesia"" questionnaire (EVAN-G)', 'Measurement of the Postoperative Quality of Recovery (QoR)', 'Measurement of anxiety level by using a visual analogue scale', 'Measurement of wake-up quality by using a visual analogue scale', 'Measurement of post-operative pain by using a visual analogue scale', 'Measurement of post-operative fatigue by using a visual analogue scale', 'Measurement of comfort and satisfaction with care by using a visual analogue scale', 'Number of patients taking anesthetic drugs at induction of anaesthesia', 'Number of patients taking anesthetic drugs during the post-interventional monitoring', 'Number of patients taking morphine in recovery room', 'Number of patients taking setrons (nausea and vomiting medication)', 'Rate of patients that consider continuing the program of cardiac coherence', 'Rate of patients willing to recommend the technique', 'Number of days of hospitalization', 'Number of patients taking morphine in peroperative', 'Measurement of pain at inclusion by using a visual analogue scale', 'The recruitment rate (proportion of patients consenting to participate in the study among eligible patients at the screening) and reasons for refusal.']",,,,,1,France,"Institut régional du cancer de Montpellier [Montpellier, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a study on techniques for managing perioperative anxiety but does not introduce a new medicine or extend the indication of an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT03982004,Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer,TERMINATED,PHASE1,Washington University School of Medicine,2020-09-14,2021-03-03,2021-03-03,2019-06-11,2021-06-21,['Safety and tolerability as measured by rate of treatment emergent grade 3 or higher toxicities'],"['Objective response rate (ORR) as measured by RECIST 1.1', 'Progression-free survival (PFS)', 'Change from baseline to week 3 in the number of tumor infiltrating lymphocytes after epicutaneous cryoimmunotherapy', 'Change from baseline to week 9 in the number of tumor infiltrating lymphocytes after epicutaenous cryoimmunotherapy plus pemrolizumab', 'Change from baseline to 18 weeks in the number of tumor cells', 'Change in quality of life as measured by the Dermatologic Quality of Life Index', 'Change in quality of life as measured by the Functional Assessment of Cancer Therapy (FACT)', 'Objective response rate as measured by measurement of 2 sentinel skin lesions', 'Objective response rate as measured by photography-based estimates of body surface area']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2020.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a new combination therapy (epicutaneous cryoimmunotherapy with pembrolizumab) for a specific condition (cutaneous metastatic breast cancer), indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT03983096,Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.,"Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer: an Real-world, Multicenter, Case Control Study.",COMPLETED,,Tianjin Medical University Cancer Institute and Hospital,2019-07-07,2020-05-01,2020-05-01,2019-06-12,2020-07-08,"['Pathological complete remission (pCR)', 'Disease-free survival （DFS）']","['Adverse event', 'Breast conserving rate']",,,,,1,China,"Jin Zhang [Tianjin, China]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03983395,Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer,"A Phase 1/2, Open-Label, Dose-Escalation Study of ISB 1302 in Subjects With HER2-Positive Metastatic Breast Cancer",TERMINATED,PHASE1; PHASE2,Ichnos Sciences SA,2020-04-08,2020-07-24,2020-07-24,2019-06-12,2021-05-24,"['MTD: Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug (i.e. Cycle 1) in each cohort.', 'RP2D: Incidence and severity of AEs, AESI, and SAEs, including but not limited to laboratory values, PK and biomarkers.', 'Anti-tumor Activity of ISB 1302 administered Q1W (Part 2)']","['Incidence, nature, and intensity of AEs according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.', 'Antitumor activity of ISB 1302 administered Q1W (Part 1)', 'Additional preliminary anti-tumor clinical activity of ISB 1302 administered (Part 2)', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) -Cmax', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2)-tmax', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) -AUC0-tau', 'Pharmacokinetics of ISB 1302 administered Q1W (Part 1 and Part 2) - AUC0-t', 'Immunogenicity of ISB 1302 administered Q1W (Part 1 and Part 2)', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-2', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-6', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IL-10', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- IFN-γ', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) - levels of pharmacodynamic cytokines- TNF-α', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD3', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD4', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD8', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD25', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers -CD69', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Pharmacodynamic Cellular Biomarkers - CD127', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include T cells', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include tumor microenvironment markers', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include apoptotic markers', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Tumor Mutational Burden (TMB)', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Epigenetic evaluation of Tregs', 'Exploratory: Pharmacodynamic biomarkers of ISB 1302 (Part 1 and Part 2) -Tumor tissue biopsy -Analyses of the tumor tissue include Epigenetic evaluation of T helper cells', 'Exploratory: Duration of treatment (Part 1 and Part 2)', 'Exploratory: Time to disease progression (Part 1 and Part 2)']",,,,,5,United States,"Ichnos Investigational Site 1 [Gilbert, United States] | Ichnos Investigational Site 5 [Los Angeles, United States] | Ichnos Investigational Site 4 [Louisville, United States] | Ichnos Investigational Site 2 [Detroit, United States] | Ichnos Investigational Site 3 [Philadelphia, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 2
NCT03983538,Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer,A Single Center Pilot Study Evaluating the Use of Mathematical Modeling to Predict Response to Neoadjuvant Anthracycline / Taxane Based Chemotherapy in Women With HER2 Negative Stage II and III Breast Cancer,COMPLETED,,New Mexico Cancer Research Alliance,2015-06-02,2018-01-28,2018-01-28,2019-06-12,2021-05-12,"['Feasibility of using diagnostic needle core biopsy to mathematically predict ƒkill-path in women with breast cancer undergoing neoadjuvant chemotherapy', 'Feasibility of calculating tumor BVF from pre-chemotherapy gadolinium enhanced MRI of the breast in women with breast cancer undergoing neoadjuvant chemotherapy', 'Feasibility of calculating ƒkill-rad from pre-chemotherapy gadolinium enhanced MRI of the breast in women with breast cancer undergoing neoadjuvant anthracycline / taxane based chemotherapy']","[""Association between ƒkill-path and ƒkill-rad as calculated with the investigator's mathematical model and response to neoadjuvant chemotherapy at the time of surgery"", 'Association between ƒkill-path and ƒkill-rad and biomarkers as calculated with a mathematical model']",,,,,1,United States,"University of New Mexico Comprehensive Cancer Center [Albuquerque, United States]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2018.0,7.0,0,NA/Other
NCT03985267,A New Mindfulness Intervention Called Mindfulness Based Swinging Technique (MBST) for Women With Breast Cancer,"Efficacy of Mindfulness Based Swinging Technique (MBST) for Improving Anxiety, Stress, Hopelessness and Self Efficacy Among Breast Cancer Patients in Treatment",COMPLETED,,University of Barcelona,2018-11-29,2021-08-01,2022-10-20,2019-06-13,2022-11-03,"['Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety', 'Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to increase self-efficacy', 'Evaluation of the immediate efficacy of the Mindfulness Based Swinging Technique (MBST) to increase hopefulness', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to increase self-efficacy', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to increase hopefulness', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using the State Trait Anxiety Inventory.', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using Emotion Thermometer.', 'Evaluation of the long lasting efficacy of the Mindfulness Based Swinging Technique (MBST) to reduce stress and anxiety using the Hospital Anxiety and Depression Scale.']","['Impact of education level on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of marital status on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of living arrangements on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of time for learning cancer diagnosis on efficacy of the Mindfulness Based Swinging Technique (MBST)', 'Impact of having any metastasis on efficacy of the Mindfulness Based Swinging Technique (MBST)']",,,,,2,Turkey (Türkiye),"Ozel Oz Psikoloji Aile Danisma Merkezi (Oz Psychology Family Counselling Centre) [Izmir, Turkey (Türkiye)] | EgeMed Hospital [Aydin, Turkey (Türkiye)]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The text describes a new intervention (Mindfulness Based Swinging Technique) specifically designed for women with breast cancer, indicating it is a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT03986268,Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy,The Effect of Vitamin D Replacement Therapy on Pathological Response in Breast Cancer Patients Treated With Neoadjuvant Therapy,COMPLETED,,"Florence Nightingale Hospital, Istanbul",2019-05-10,2020-12-10,2020-12-10,2019-06-14,2024-02-22,['pathological complete response (PCR)'],"['pathological complete response (PCR) relations with vitamin D levels', 'pathological complete response (PCR) ratio regarding molecular sub types']",,,,,1,Turkey (Türkiye),"İstanbul Florence Nightingale Hospital Breast Health Center [Istanbul, Turkey (Türkiye)]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT03988036,A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),"A Prospective, Multicenter, Open Label, Neoadjuvant Phase II Single Arm Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype",COMPLETED,PHASE2,West German Study Group,2020-08-18,2022-05-31,2022-05-31,2019-06-17,2023-05-15,['Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-HER2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with HER2-enriched early breast cancer assessed by PAM50 testing'],"['Number and percentage of fatal adverse events as assessed by CTCAE 5.0', 'Number and percentage of serious treatment-emergent adverse events as assessed by CTCAE 5.0', 'Number and percentage of treatment-related adverse events as assessed by CTCAE 5.0', 'Number and percentage of treatment-emergent adverse events of interest as assessed by CTCAE 5.0', 'Number and percentage of adverse events leading to investigational product discontinuation', 'Number and percentage of severity of adverse events as assessed by CTCAE 5.0', 'Number and percentage of causality of adverse events as assessed by investigator and sponsor', 'Number and percentage of outcome of adverse events as per investigator assessment', 'Number and percentage of seriousness of adverse events as assessed by CTCAE 5.0']",,,,,12,Germany,"Universitätsklinikum Tübingen Frauenklinik [Tübingen, Germany] | Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern [Munich, Germany] | Rotkreuzklinikum München GmbH Frauenklinik [Munich, Germany] | Niels-Stensen-Kliniken Franziskus-Hospital Harderberg Zentrum für Frauenheilkunde und Abteilung für Senologie [Georgsmarienhütte, Germany] | Diakoniekrankenhaus Henriettenstiftung GmbH [Hanover, Germany] | Onkologische Praxis [Bielefeld, Germany] | St. Elisabeth Krankenhaus GmbH Brustzentrum [Cologne, Germany] | Onkodok GmbH [Gütersloh, Germany] | Ev. Krankenhaus Bethesda Brustzentrum Niederrhein [Mönchengladbach, Germany] | Praxisnetzwerk [Troisdorf, Germany] | Charité Campus Mitte Klinik für Gynäkologie [Berlin, Germany] | Mammazentrum Hamburg [Hamburg, Germany]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study evaluates the combination of pembrolizumab with existing treatments (trastuzumab and pertuzumab) in a specific patient population, indicating an extension of indication for pembrolizumab rather than a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT03988556,Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis,Feasibility and Safety of CareMin650 in Cancer Patients at High Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis Due to the Administration of Radiotherapy: A Prospective Non-comparative Study,COMPLETED,,NeoMedLight,2019-07-04,2020-12-17,2020-12-17,2019-06-17,2021-04-30,"['Occurence of adverse events', 'Rate of discontinuation due to AEs']","['Skin lesions assessment - time of lesion occurrence', 'Skin lesions assessment - size of lesions', 'Skin lesions assessment - location', 'Skin lesions assessment - Grade', 'Skin lesions assessment - Time until resolution', 'Oral mucosa lesions assessment - time of lesion occurrence', 'Oral mucosa lesions assessment - size of lesions', 'Oral mucosa lesions assessment - location', 'Oral mucosa lesions assessment - Grade', 'Oral mucosa lesions assessment - Time until resolution']",,,,,5,France,"Institut de radiothérapie et radiochirurgie Hartmann [Levallois-Perret, France] | Centre Oscar Lambret [Lille, France] | Centre de Haute Energie [Nice, France] | Institut Curie [Paris, France] | Institut de Cancérologie Lucien Neuwirth [Saint-Priest-en-Jarez, France]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating the feasibility and safety of CareMin650, indicating it is a new medicine being tested for specific conditions (oral mucositis and radiation dermatitis) in cancer patients.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT03988777,Magnetic Seed Localisation for Nonpalpable Breast Lesions,Magnetic Seed Localisation for Nonpalpable Breast Lesions: a Combined Retrospective and Prospective Analysis,COMPLETED,,Universitaire Ziekenhuizen KU Leuven,2018-09-10,2019-03-29,2019-05-23,2019-06-17,2019-06-17,"['Number of participant with device-related adverse events', 'Total breast volume resected during breast conserving surgery', 'Number of participants with positive surgical margins as assessed by pathological examination of the specimen', 'Re-operation rate due to positive surgical margins', 'Surgeon satisfaction based on a questionnaire']",[],,,,,1,Belgium,"University Hospitals Leuven [Leuven, Belgium]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a procedure (Magnetic Seed Localisation) for breast lesions rather than a new medicine or an extension of indication for an existing medicine.,OTHER,False,2019.0,6.0,0,NA/Other
NCT03992859,Continuous Serrates Plane Block in Axillary Dissection,Continuous Serratus Plane Block Added to PECS II vs PECS II Alone for Post Operative Analgesia After Axillary Dissection in Breast Cancer Surgery,COMPLETED,,Azienda USL Reggio Emilia - IRCCS,2018-01-12,2019-11-13,2021-12-30,2019-06-20,2025-06-25,['Morphine consumption'],['persistent post-surgical pain: numerical rating scale'],,,,,1,Italy,"Ausl-Irccs Reggio Emilia [Reggio Emilia, Italy]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of a continuous serratus plane block in conjunction with an existing technique (PECS II) for postoperative analgesia, indicating an extension of indication for the existing method rather than testing a new medicine.",OTHER_GOV,False,2021.0,4.0,0,NA/Other
NCT03997188,Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy,Study for the Evaluation of the Impact of HEPILOR on the Possible Delay in the Development of Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy on the Breast/Thoracic Wall and Lymph Node Drainage.,COMPLETED,PHASE3,Cynthia Aristei,2015-12-21,2017-11-14,2017-12-20,2019-06-25,2019-06-25,"['Zinc-L-Carnosine prevents dysphagia in breast cancer patients undergoing adjuvant radiotherapy: clinical outcome assessed by Eating Assessment Tool (EAT-10) questionaire', 'Degree of dysphagia']",[],,,,,1,Italy,"University of Perugia [Perugia, Italy]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2017.0,8.0,0,Phase 3
NCT03999177,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises,COMPLETED,,NYU Langone Health,2019-06-01,2019-09-01,2019-09-01,2019-06-26,2020-07-10,"['The Perceived Ease of Use and Usefulness', 'The Post Study System Usability Questionnaire']",[],,,,,1,United States,"NYU Langone Health [New York, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot usability and feasibility study for a training system, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04001634,Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC,Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study,COMPLETED,,Fudan University,2015-01-01,2019-05-15,2020-08-15,2019-06-28,2024-02-26,"['PFS', 'OS', 'ORR']",['Treatment Pattern'],,,,,1,China,"Biyun Wang, MD [Shanghai, China]",2015.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text discusses the use of existing drugs (Lapatinib and Trastuzumab) in a specific patient population (HER2-positive metastatic breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04001751,Feasibility Study: Yoga Educational Project,"Feasibility Study of the ""SKYPE"" Educational Project in Patients With Breast Cancer Treated With Hormonotherapy",COMPLETED,,Institut du Cancer de Montpellier - Val d'Aurelle,2018-08-31,2019-07-30,2019-07-30,2019-06-28,2025-05-18,['proportion of patient compliance to the educational yoga program'],"[""the patients' satisfaction towards the program"", 'the induced self-competency feeling', 'To assess quality of life by Quality of Life Questionnaire', 'To assess quality of life by Quality of Life Questionnaire specify for Breast Cancer', 'To assess fatigue and stress', 'Anxiety and depression prevalence', 'Osteoarticular pain', 'Forward-flexion flexibility', 'Respiratory capacity', 'Compliance to hormonotherapy treatment', 'Patient enrolment rate', 'Reasons of non-participation to the study.']",,,,,1,France,"Institut du Cancer de Montpellier [Montpellier, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study for an educational yoga program for breast cancer patients undergoing hormonotherapy, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04002284,Anlotinib in Metastatic HER2 Negative Breast Cancer,"The Efficacy and Safety of Anlotinib in Metastatic HER2 Negative Breast Cancer, a Single Arm Phase II Clinical Trial",COMPLETED,PHASE2,Peng Yuan,2018-07-12,2020-01-10,2020-03-15,2019-06-28,2020-07-29,['objective response rate(ORR)'],"['disease control rate(DCR)', 'Progression free survival (PFS)', 'overall survival(OS)', 'Safety and Tolerability']",,,,,1,China,"National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College [Beijing, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating Anlotinib, which is being tested for a specific indication (metastatic HER2 negative breast cancer) and does not appear to be an existing treatment for this condition, indicating it is a new medicine.",UNKNOWN,False,2020.0,5.0,0,Phase 2
NCT04009278,Self-compression Mammography in Clinical Practice,Self-compression Mammography in Clinical Practice: A Randomized Clinical Trial Compared to Standard Compression Mammography,COMPLETED,,Azienda USL Reggio Emilia - IRCCS,2018-01-25,2019-07-31,2020-12-31,2019-07-05,2025-06-12,"['Average glandular dose administered (mSv)', ""Image quality: radiographers' scale."", ""Image quality: radiologists' scale.""]","['Breast thickness at the time of exposure (cm)', 'Maximum compression (daN)', 'Pain during compression', 'Memory of pain in previous mammography', 'Anxiety', 'Discomfort', 'Execution time of the exam:', 'Participation in follow up mammography']",,,,,1,Italy,"Laura Canovi [Reggio Emilia, Italy]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a clinical trial comparing self-compression mammography to standard compression mammography, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2020.0,5.0,0,NA/Other
NCT04009941,Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,Study on the Efficacy and Safety of 4.5mg Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer,COMPLETED,PHASE4,Peking University,2019-08-01,2020-01-18,2020-01-31,2019-07-08,2020-10-28,"['RDI for each EC chemotherapy', 'Chemotherapeutic dose adjustment due to neutropenia', 'overall completion rate of chemotherapy']","['Incidence of febrile neutropenia', 'Incidence of Grade 3/4 ACN reduction', 'Duration of Grade 3/4 ACN reduction']",,,,,1,China,"Beijing Cancer Hospital [Beijing, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study evaluates the efficacy and safety of a known drug (PEG-rhG-CSF) in a new context (preventing neutropenia after intensive chemotherapy for breast cancer), indicating an extension of its indication.",OTHER,False,2020.0,5.0,0,Other
NCT04012229,IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA),IMpact of BrcA Status on Survival in Adjuvant Breast Cancer (IMBASSA),COMPLETED,,Centre Hospitalier Universitaire de Besancon,2017-07-28,2018-06-21,2018-06-21,2019-07-09,2019-07-09,"['Age of diagnosis', 'Pathological tumor size', 'Pathological nodal involvement', 'Clinical tumor size', 'Clinical nodal involvement', 'Estrogen receptor expression status', 'Progesterone receptor expression status', 'HER2 status', 'Sexe', 'Scarff Bloom and Richardson grade (SBR)', 'In situ component', 'Pathological histotype', 'Metastatic sites (if available)', 'Medical treatment']","['Overall Survival', 'Invasive Disease Free Survival', 'Distant Disease Free Survival']",,,,,1,France,"University Hospital Jean Minjoz [Besançon, France]",2017.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2018.0,7.0,0,NA/Other
NCT04019834,Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy,Preoperative Regional Nerve Block to Decrease Acute and Chronic Post-Operative Pain and Narcotic Use Following Mastectomy,COMPLETED,EARLY_PHASE1,University of Alabama at Birmingham,2020-07-06,2021-11-25,2021-11-25,2019-07-15,2022-08-03,"['Postoperative Pain: Brief Pain Inventory- Short Form (BPI-SF)', 'Postoperative Pain', 'Postoperative Pain: Brief Pain Inventory- Short Form (BPI-SF)', 'Postoperative Pain: Brief Pain Inventory- Short Form (BPI-SF)', 'Postoperative Pain: Brief Pain Inventory- Short Form (BPI-SF)', 'Postoperative Pain: Brief Pain Inventory- Short Form (BPI-SF)']","['Postoperative narcotic consumption', 'Postoperative nausea', 'Postoperative length of stay']",,,,,1,United States,"University of Alabama at Birmingham Hospitals and Affiliated Clinics [Birmingham, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of a preoperative regional nerve block for managing postoperative pain, indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04025216,A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers,"A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma",TERMINATED,PHASE1,"Kite, A Gilead Company",2019-10-10,2022-12-02,2022-12-02,2019-07-18,2024-01-24,"['Dose Escalation: Dose Identification of CART-TnMUC1', 'Cohort Expansion: Objective Response in solid tumors']","['Safety of CART-TnMUC1 in solid tumors and multiple myeloma', 'Tolerability of CART-TnMUC1 in solid tumors and multiple myeloma', 'Feasibility of CART-TnMUC1 in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Overall Survival (OS) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Progression Free Survival (PFS) in solid tumors', 'Preliminary anti-tumor efficacy of CART as assessed by Objective Response Rate (ORR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Clinical Benefit Rate in solid tumors', 'Preliminary anti-tumor efficacy of CART as assessed by Duration of Response (DOR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Time to Response (TTR) in solid tumors and multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Time to Progression (TTP) in multiple myeloma', 'Preliminary anti-tumor efficacy of CART as assessed by Minimal Residual Disease (MRD) in multiple myeloma', 'Peripheral expansion and persistence of CART-TnMUC1 cells in solid tumors and multiple myeloma']",,,,,10,United States,"Mayo Clinic of Arizona [Phoenix, United States] | The Angeles Clinic and Research Institute [Los Angeles, United States] | Moffitt Cancer Center [Tampa, United States] | University of Chicago Medical Center [Chicago, United States] | Washington University School of Medicine [St Louis, United States] | Hospital of the University of Pennsylvania [Philadelphia, United States] | University of Pittsburgh Medical Center [Pittsburgh, United States] | Sarah Cannon Research Institute [Nashville, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | University of Washington Medical Center [Seattle, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves a first-in-human study of CART-TnMUC1, which indicates it is a new medicine being tested for advanced TnMUC1-positive solid tumors and multiple myeloma.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04036370,Continuous Pectoral Nerve Block in Breast Cancer Surgery,The Effect of Continuous Pectoral Nerve Block on Postoperative Analgesia Consumption in Breast Cancer Surgery,COMPLETED,,Antalya Training and Research Hospital,2019-07-30,2019-11-15,2019-11-15,2019-07-29,2019-11-18,['analgesia consumption'],"['analgesia consumption', 'postoperative Numeric Rating Scale (NRS) score']",,,,,1,Turkey (Türkiye),"Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation [Antalya, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of Continuous Pectoral Nerve Block in the context of breast cancer surgery, which suggests an extension of indication for an existing analgesic technique rather than the introduction of a new medicine.",OTHER_GOV,False,2019.0,6.0,0,NA/Other
NCT04041128,PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer,Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer,COMPLETED,EARLY_PHASE1,University of Texas Southwestern Medical Center,2019-07-23,2021-06-15,2021-06-15,2019-08-01,2023-03-20,"['Measure DNA damage response to PARP inhibition', 'Characterize changes in ADP ribosylation to PARP inhibition', 'Correlate DNA damage response to ADP ribosylated proteome']",[],,,,,1,United States,"University of Texas Southwestern Medical Center [Dallas, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the effects of PARP inhibition in the context of breast and ovarian cancer, suggesting an extension of indication for an existing treatment rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04042051,Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer,"Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer ""Panthera""",TERMINATED,PHASE1,Cancer Trials Ireland,2019-11-12,2020-11-02,2020-11-02,2019-08-01,2025-07-22,['To determine the incidence of dose limiting toxicity (DLT) of copanlisib in combination with trastuzumab emtansine within the 1st cycle at each dose level.'],"['Clinical Benefit Rate (CBR) is defined as complete response (CR) or partial response (PR) at any time-point on the study; or stable disease (SD) lasting at least 24 weeks based on radiological assessment.', 'Overall Survival (OS).', 'Progression-Free Survival (PFS) assessed according to RECIST criteria version 1.1.', 'Time to Treatment Failure (TTF) is defined as time from registration to discontinuation of therapy or add-on of new anti-cancer therapy for any reason (including death, progression and toxicity).', 'Confirmed tumour response rate as assessed by RECIST criteria version 1.1', 'Duration of response (DR) as assessed by standard RECIST criteria version 1.1.', 'To evaluate the safety and tolerability of this regimen as measured by incidence of adverse events reported and toxicity evaluation as per the NCI Common Terminology Criteria for Adverse Events (CTCAE version 5.0).', 'To assess the incidence of cardiotoxicity in patients treated with this regimen.']",,,,,3,Ireland; Spain,"Cancer Trials Ireland Investigative Site [Cork, Ireland] | Cancer Trials Ireland Investigative Site [Dublin, Ireland] | Cancer Trials Ireland Investigative Site [Seville, Spain]",2019.0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Best Overall Response""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial involves copanlisib in combination with T-DM1 for a specific patient population (HER2-positive breast cancer) that has already been treated, indicating an extension of indication for the existing drugs rather than testing a new medicine.",NETWORK,False,2020.0,5.0,1,Phase 1
NCT04042870,Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors,Effect of Sukshma Vyayama Joint Loosening Yoga on Aromatase Inhibitor-Induced Arthralgia in Post-Menopausal Breast Cancer Survivors: A Feasibility Study Conducted on Facebook,COMPLETED,,"AshtaYoga, LLC",2018-09-04,2018-09-28,2018-10-19,2019-08-02,2019-08-02,"['Change in Patient-Reported Arthralgia Inventory (PRAI) Measure for Joint Arthralgia', 'Change in Brief Pain Inventory Short Form (BPI SF) Measure for Body Pain', 'Change in Brief Pain Inventory Short Form (BPI SF) Measure for Quality of Life', 'Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measure for Pain, Stiffness, and Physical Function of Knee and Hip', 'Change in Disability of the Arm, Shoulder and Hand (DASH) Measure of Ability to Use Arm, Shoulder, and Hand']",['Effectiveness of Delivering Intervention on Facebook'],,,,,1,United States,"Columbia University Medical Center [New York, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a feasibility study on the effects of a yoga intervention for managing symptoms in breast cancer survivors, which does not indicate a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT04060342,GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma,"A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors",TERMINATED,PHASE1,"GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",2019-08-13,2022-04-11,2022-04-11,2019-08-19,2022-08-18,"['Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs)', 'Phase 1 Dose Escalation - Regimens A, B, and C and Phase 1 Expansion - Regimen B: Incidence of adverse events (AEs)', 'Phase 1 Dose Escalation - Regimens A and B: Cmax of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: Ctrough of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: Tmax of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: t1/2 of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: AUC of GB1275', 'Phase 1 Dose Escalation - Regimens A and B: CL/F of GB1275', 'Phase 2 - Basket Cohorts 1, 2 and 3: Objective Response Rate (ORR)']","['Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Cmax of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Ctrough of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: Tmax of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: t1/2 of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: AUC of GB1275', 'Phase 1 - Regimen C and Phase 1 Expansion - Regimen B: CL/F of GB1275', 'Phase 1 - Regimen C: Cmax of nab-paclitaxel and gemcitabine', 'Phase 1 - Regimen C: Tmax of nab-paclitaxel and gemcitabine)', 'Phase 1 - Regimen C: AUC of nab-paclitaxel and gemcitabine', 'Phase 2 - Basket Cohorts 1, 2, and 3: Duration of Response (DOR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Time to Response (TTR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Clinical Benefit Rate (CBR)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Progression Free Survival (PFS)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Time to Progression (TTP)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Overall Survival (OS)', 'Phase 2 - Basket Cohorts 1, 2, and 3: Incidence of AEs', 'Phase 2 - Basket Cohort 1, 2 and 3: PK profile of GB1275']",,,,,8,United Kingdom; United States,"UCSF Medical Center at Mission Bay [San Francisco, United States] | University of Colorado Hospital, Anschutz Cancer Pavilion (ACP) [Aurora, United States] | Washington University School of Medicine - Siteman Cancer Center [St Louis, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Duke University Medical Center [Durham, United States] | The Sarah Cannon Research Institute/Tennessee Oncology [Nashville, United States] | South Texas Accelerated Research Therapeutics, LLC [San Antonio, United States] | The Royals Marsden NHS Foundation Trust [Sutton, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is a Phase 1/2 study of GB1275, indicating it is a new medicine being tested for the first time in humans.",INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT04066361,OPTimizing Treatment Focused Genetic Testing IN Cancer,OPTimizing Treatment Focused Genetic Testing IN Cancer - OPT-IN,COMPLETED,,Dana-Farber Cancer Institute,2019-12-19,2022-11-30,2022-11-30,2019-08-26,2024-01-25,"['The measurement of genetic testing uptake', 'Meaningful cancer treatment changes', 'Satisfaction with pre-genetic test education']","['Communication of results with family members', 'Intent to disclose genetic test results', 'Cascade testing of family members', 'Decisional regret', 'Knowledge of multi-gene panel testing']",,,,,1,United States,"Dana Farber Cancer Institute [Boston, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses genetic testing in cancer treatment but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04072718,Simultaneous Integrated Boost With Volumetric Arc Radiotherapy in Patients With Breast Cancer,A Phase II Study of Simultaneous Integrated Boost With Volumetric Arc Radiotherapy After Breast Conservative Surgery in Patients With Breast Cancer,COMPLETED,PHASE2,"Post Graduate Institute of Medical Education and Research, Chandigarh",2017-08-10,2020-03-31,2020-03-31,2019-08-28,2020-07-14,['Acute radiation toxicities'],"['cosmetic score analysis', 'local control', 'Late toxicity']",,,,,1,India,"Dr Budhi Singh Yadav [Chandigarh, India]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on a radiotherapy technique for breast cancer, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,Phase 2
NCT04079556,Reducing Breast Cancer Risk in Korean American Women,Reducing Breast Cancer Risk in Korean American Women,COMPLETED,,"University of California, San Francisco",2019-03-16,2019-12-31,2019-12-31,2019-09-06,2020-03-26,['SHS exposure of non-smokers'],"[""Smoker's adoption of smoke-free rules"", ""Smoker's Utilization of smoking cessation resources"", 'Smoking Abstinence']",,,,,1,United States,"Korean Community Center of the East Bay [San Leandro, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses reducing breast cancer risk in a specific population and mentions smoking-related behaviors, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04088435,Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer,A Prospective Observational Trial of Xoft® Intraoperative Radiotherapy (IORT) as a Component of Breast Conserving Therapy (BCT) in Patients With Early-Stage Breast Cancer,TERMINATED,,University of Louisville,2019-09-10,2022-06-05,2022-06-05,2019-09-12,2023-05-12,['Percentage of patients with greater than or equal to grade 2 acute radiation toxicities'],"['Percentage of patients with greater than or equal to grade 2 late radiation toxicities', 'Percentage of patients with good or excellent cosmetic outcome as assessed by the Harvard cosmesis scale', 'Percentage of patients who are very satisfied or somewhat satisfied by their cosmetic outcome as determined by the Breast-Q patient satisfaction self assessment']",,,,,1,United States,"James Graham Brown Cancer Center at the University of Louisville [Louisville, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04091542,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment,Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment (HOBBIT): Development of Support Technique to Prolong Breath Hold Time During Radiotherapy,COMPLETED,,"University Hospital, Ghent",2019-03-15,2019-12-31,2021-02-22,2019-09-16,2023-01-04,['conditions for a technique for L-DIBHs of more than two minutes thirty seconds'],"['Oxygen saturation', 'heart rate', 'diastolic and systolic blood pressure', 'EtCO2', 'average L-DIBH time', 'average time needed for SpO2 to recover to normal', 'average total time needed to perform three L-DIBHs consequently', 'Measurement of linear anteroposterior displacement', 'dizziness', 'fear', 'headache', 'syncope', 'coughing', 'dyspnea', 'nausea', 'vomiting', 'itching', 'pain', 'palpitations', 'blurred vision', 'muscle cramps']",,,,,1,Belgium,"University Hospital - Radiotherapy Department [Ghent, Belgium]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a technique related to radiotherapy for breast cancer, focusing on breath hold time and associated measurements, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04094519,A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer,COMPLETED,PHASE1,"Astellas Pharma Global Development, Inc.",2020-01-27,2020-12-27,2020-12-27,2019-09-19,2024-11-20,"['Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: maximum concentration (Cmax)', 'Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)', 'Pharmacokinetics (PK) of Digoxin in combination with rosuvastatin in plasma: area under the concentration time curve from the time of dosing extrapolated to time infinity (AUCinf)']","['Number of participants with Adverse Events (AEs)', 'Number of participants with laboratory value abnormalities and/or adverse events (AEs)', 'Number of participants with vital sign abnormalities and /or adverse events (AEs)', 'Number of participants with routine 12-lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: maximum concentration (Cmax)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: area under the concentration-time curve during a dosing interval, where tau (τ) is the length of the dosing interval (AUCtau)', 'Pharmacokinetics (PK) of enzalutamide and its metabolite (N-desmethyl) in plasma: concentration immediately prior to dosing at multiple dosing (Ctrough)']",,,,,1,Moldova,"Site MD37301 [Chisinau, Moldova]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04096469,"Impact of Diet and Physical Activity Changes on Body Weight, Biomarkers and Quality of Life in Breast Cancer Survivors","Intervention Program to Promote Changes in Diet and Physical Activity and to Evaluate Its Impact on Body Weight, Biomarkers of Disease and Quality of Life in Breast Cancer Survivors",COMPLETED,,Centro de Investigación en Alimentación y Desarrollo A.C.,2016-05-01,2019-06-01,2019-09-01,2019-09-19,2019-10-29,"['Change in Body Weight', 'Change in Breast Density', 'Change in Quality life', 'Change in Sleep Quality', 'Change in telomere length', 'Change in Bone Mineral Density']","['Change in the activity of telomerase', 'Change in C-reactive protein levels', 'Change in interleukin 6 levels', 'Change in interleukin 8 levels', 'Change in levels of tumor necrosis factor alpha', 'Change in vascular endothelial growth factor levels', 'Change in leptin levels', 'Change in adiponectin levels', 'Change in the percentage of fat mass', 'Change in percentage of muscle mass', 'change in the optimism scale', 'change in the anxiety scale']",,,,,1,Mexico,"Centro de Investigación en Alimentación y Desarrollo [Hermosillo, Mexico]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an intervention program focused on diet and physical activity changes for breast cancer survivors, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04102618,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer,A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1),TERMINATED,EARLY_PHASE1,Oncolytics Biotech,2019-03-29,2022-04-20,2022-04-20,2019-09-25,2022-08-15,['To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.'],"['To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HR+/HER2-negative breast cancer.', 'To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with HER2-positive breast cancer.', 'To identify biological changes, as defined by gene expression between posttreatment and pretreatment samples following pelareorep in combination with different therapies.', 'To describe the safety profile of the combination therapies']",,,,,14,Spain,"ICO Badalona [Badalona, Spain] | Hospital Clínic de Barcelona [Barcelona, Spain] | Hospital Quirón Dexeus [Barcelona, Spain] | Hospital Moisés Broggi [Esplugues de Llobregat, Spain] | Hospital Fuenlabrada [Madrid, Spain] | Hospital La Paz [Madrid, Spain] | Hospital Puerta de Hierro de Majadahonda [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario Fundación Jiménez Díaz [Madrid, Spain] | Hospital Clínico Universitario Virgen Arrixaca [Murcia, Spain] | Hospital Universitario Virgen Macarena [Seville, Spain] | Hospital Clínico Universitario de Valencia [Valencia, Spain] | Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clínico Lozano Blesa [Zaragoza, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is evaluating pelareorep, which is a new treatment being tested in combination with other therapies for early breast cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04103853,"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer: an Open-label, Multi-center, Dose-escalating，Phase I/Ib Study.",COMPLETED,PHASE1,"Suzhou Kintor Pharmaceutical Inc,",2017-09-06,2019-05-22,2020-06-30,2019-09-26,2021-09-24,"['Dose-limiting Toxicity(DLT)', 'maximum tolerated dose (MTD)', 'Disease Control Rate(DCR)']","['maximum concentration (Cmax)', 'time that maximum concentration is observed (tmax)', 'area under the concentration time-curve from time zero to infinity (AUC0∞)', 'terminal elimination half life (t½)', 'drug clearance (CL)', 'apparent volume of distribution (Vd)', 'Number of participants with treatment-related adverse events as assessed by CTCAE V4.03']",,,,,7,China,"Beijing Cancer Hospital [Beijing, China] | Sun-Yat-sen University Cancer center [Guangzhou, China] | The Fourth Hospital of Hebei Medical University [Shijiazhuang, China] | Hunan Cancer Hospital [Changsha, China] | Jiangsu Province Hospital [Nanjing, China] | Ruijin Hospital, Shanghai Jiaotong University School of Medicine [Shanghai, China] | Tianjin Medical University Cancer Institute and Hospital [Tianjin, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04111848,Magnesium and Ketamine in Postoperative Analgesia,Evaluation of the Effect of Adding Magnesium Sulfate Infusion to Ketamine Infusion on Improvement of the Analgesic Efficacy in Cancer Breast Surgeries.,COMPLETED,PHASE4,"National Cancer Institute, Egypt",2019-11-01,2020-11-01,2020-12-01,2019-10-01,2021-03-02,['the total amount of morphine required during the first postoperative 24 hours'],"['the total amount of intraoperative fentanyl consumption', '(Visual Analogue scale) VAS scores', 'Douleur Neuropathique 4 (DN4']",,,,,1,Egypt,"National Cancer Institute [Cairo, Egypt]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effect of adding Magnesium Sulfate to an existing treatment (Ketamine) for postoperative analgesia, indicating an extension of indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,Other
NCT04119154,Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza),COMPLETED,,Harvard School of Public Health (HSPH),2019-08-01,2021-09-20,2021-09-20,2019-10-08,2022-05-02,"['Accuracy for diagnosis of non-Hodgkin lymphoma', 'Accuracy for diagnosis of invasive breast cancer', 'Time to diagnosis', 'Proficiency in testing using CEM platform']","['Accuracy for sub-type diagnosis (aggressive vs. indolent) of non-Hodgkin lymphoma', 'Accuracy for molecular subtype diagnosis of invasive breast cancer']",,,,,1,Botswana,"Botswana Harvard AIDS Institute [Gaborone, Botswana]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the accuracy of nanosensor-based cancer diagnosis for specific types of cancer, indicating an extension of indication for existing diagnostic methods rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04121286,A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China,"A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors",COMPLETED,PHASE1,"Allist Pharmaceuticals, Inc.",2020-07-14,2022-06-17,2022-06-17,2019-10-09,2025-05-20,"['Number of participants with dose limiting toxicities', 'Find Recommended Phase 2 Dose (RP2D) of JAB-3312']","['Number of participants with adverse events', 'Area under the curve', 'Cmax', 'Tmax', 'T1/2', 'Objective response rate ( ORR )', 'Duration of response ( DOR )']",,,,,5,China,"Cancer Hospital, Chinese Academy of Medical Sciences [Beijing, China] | Beijing Cancer Hospital [Beijing, China] | Peking Union Medical Collage Hospital [Beijing, China] | Peking University Third Hospital [Beijing, China] | Henan Provovential Cancer Hospital [Henan, China]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04125693,Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety,A Roll-over Study to Provide Continued Treatment With Rogaratinib in Participants Who Were Enrolled in Rogaratinib Studies,COMPLETED,PHASE2,Bayer,2019-10-30,2021-02-16,2021-02-16,2019-10-14,2022-04-01,"['Incidence of treatment-emergent adverse events (TEAEs)', 'Incidence of treatment-emergent serious adverse events (TESAEs)', 'Incidence of drug-related TEAEs', 'Incidence of drug-related TESAEs']",['Frequency of dose modifications'],,,,,1,Switzerland,"Kantonsspital St. Gallen [Sankt Gallen, Switzerland]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 2
NCT04130152,Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy,Palbociclib in Combination With Letrozole in Patients With Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Residual Disease After Standard Neoadjuvant Chemotherapy (PROMETEO II),COMPLETED,EARLY_PHASE1,SOLTI Breast Cancer Research Group,2019-11-21,2022-01-26,2022-02-24,2019-10-17,2022-10-25,['Complete Cell Cycle Arrest (CCCA)'],"['Residual Cancer Burden (RCB)', 'Residual Cancer Burden (RCB)', 'Pathological complete response (pCR)', 'Incidence, duration and severity of Adverse Events (AEs)']",,,,,8,Spain,"Hospital General de Catalunya [Barcelona, Spain] | ICO Hospitalet [Barcelona, Spain] | Hospital 12 de octubre [Madrid, Spain] | Hospital Universitario Infanta Sofía [Madrid, Spain] | Hospital Virgen de la Victoria [Málaga, Spain] | Hospital Son Espases [Palma de Mallorca, Spain] | Complejo Hospitalario Santiago de Compostela (CHUS) [Santiago de Compostela, Spain] | Hospital Virgen del Rocío [Seville, Spain]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 1
NCT04132817,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,"A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HER2 Negative Advanced Breast Cancer",COMPLETED,PHASE1,Bristol-Myers Squibb,2020-09-22,2022-08-15,2022-08-15,2019-10-21,2022-12-02,"['Incidence of Adverse Events (AEs)', 'Incidence of Serious Adverse Events (SAEs)', 'Incidence of AEs leading to dose and asset limiting toxicity (DALT)', 'Incidence of AEs leading to discontinuation', 'Incidence of laboratory abnormalities']","['Change from baseline in programmed cell death receptor-ligand 1 (PD-L1) by immunohistochemistry (IHC)', 'Objective Response Rate (ORR)', 'Median duration of response (mDOR)', 'Progression-free survival rate (PFSR)']",,,,,8,United States,"Local Institution [Los Angeles, United States] | Local Institution - 0003 [Sacramento, United States] | Local Institution - 0009 [Aurora, United States] | Local Institution - 0002 [St Louis, United States] | Local Institution - 0008 [New York, United States] | Local Institution [Pittsburgh, United States] | Local Institution [Dallas, United States] | South Texas Accelerated Research Therapeutics [San Antonio, United States]",2020.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04133207,Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy,Registry Study of Patients With Advanced Breast Cancer Treated With Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group,COMPLETED,,Hellenic Cooperative Oncology Group,2019-01-01,2019-08-01,2021-01-02,2019-10-21,2021-02-12,['Toxicity rates'],['Overall Survival'],,,,,1,Greece,"Hellenic Oncology Cooperative Group [Athens, Greece]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of CDK inhibitors combined with endocrine therapy in patients with advanced breast cancer, indicating an extension of indication for existing treatments rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04135157,Pectoral Nerve Block II and Erector Spine Plane Block in Breast Cancer Surgery,Research of the Effects of Pectoralis Nerve Block II and Erector Spina Plan Block in Breast Cancer Surgery,COMPLETED,,Ondokuz Mayıs University,2019-07-01,2020-09-01,2020-09-01,2019-10-22,2021-08-18,['Opioid consumption in the first 24 hours after surgery'],"['Post-operative acute pain', 'Remifentanil consumption during the surgery', 'The incidences of post-operative nausea and vomiting (PONV)', 'The number of patient required rescue analgesia', 'Post-operative chronic pain']",,,,,1,Turkey (Türkiye),"Ondokuz Mayıs University Faculty of Medicine [Samsun, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the effects of specific nerve blocks (Pectoral Nerve Block II and Erector Spine Plane Block) in the context of breast cancer surgery, indicating an extension of indication for these techniques in managing post-operative pain and related outcomes.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04142060,Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC,Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer,TERMINATED,PHASE2,SOLTI Breast Cancer Research Group,2020-06-01,2022-10-10,2022-10-10,2019-10-29,2022-10-28,['changes of the PAM50 11-gene proliferation signature'],"['Incidence, duration and severity of Adverse Events', 'Relative changes of 33 gene signatures', 'somatic mutations', 'AR expression by IHC', 'changes in percentage of cells expressing Ki67 by IHC', 'changes of It-TIL and Str-TIL', 'ctDNA levels', 'tumor ORR']",,,,,8,Spain,"ICO Badalona [Badalona, Spain] | Institut Català d'Oncologia Hospitalet [L'Hospitalet de Llobregat, Spain] | Hospital Clinic de Barcelona [Barcelona, Spain] | Hospital Universitari Vall d' Hebrón [Barcelona, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario Fundación de Alcorcón [Madrid, Spain] | Hospital Universitario Virgen del Rocio [Seville, Spain] | Fundación Instituto Valenciano de Oncología [Valencia, Spain]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text discusses the use of Enzalutamide, which is an existing medication, in a new context (targeting the PAM50 Her2-Enriched phenotype in a specific breast cancer subtype), indicating an extension of its indication.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04142892,Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer,A Window of Opportunity Trial of Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor-Positive and HER2-negative Breast Cancer,COMPLETED,EARLY_PHASE1,SOLTI Breast Cancer Research Group,2020-11-06,2021-04-30,2021-04-30,2019-10-29,2022-04-01,['Complete Cell Cycle Arrest (CCCA)'],"['IHC of tumor expression', 'PAM50 (Prediction Analysis of Microarray 50) subtype change', 'antiproliferative effect', 'proliferation score', 'gene expression changes', 'molecular markers in blood', 'identification putative prognostic and predictive biomarkers', 'Adverse Events (AEs)']",,,,,4,Spain,"Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Clínic de Barcelona [Barcelona, Spain] | Hospital Universitari Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital Universitario Sant Joan de Reus [Tarragona, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial is investigating Onapristone as a new treatment for a specific patient population (postmenopausal women with hormone receptor-positive and HER2-negative breast cancer), indicating it is a New Medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04143282,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment,COMPLETED,PHASE2,Hager salah el din,2019-10-20,2020-04-20,2020-06-30,2019-10-29,2021-12-07,"['The radiologic response rate', 'Overall survival (OS)', 'Progression-free survival']",['Insulin Growth like Factor -1 (IGF-1) at base line and after 3 cycle.'],,,,,1,Egypt,"Beni-Seuf University Hospital [Banī Suwayf, Egypt]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,Phase 2
NCT04144309,Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy,"The Effect of Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy: A Randomized, Sham-Controlled Trial",COMPLETED,,The University of Hong Kong,2019-11-18,2022-01-30,2022-07-30,2019-10-30,2024-05-17,['Insomnia Severity Index (ISI)'],"['Actiwatch', 'Sleep diary', 'Pittsburgh Sleep Quality Index (PSQI)', 'Hospital Anxiety and Depression Scale (HADS)', 'Brief Pain Inventory-Short Form (BPI-SF)', 'Brief Fatigue Inventory (BPI)', 'Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)']",,,,,2,Hong Kong,"Department of Clinical Oncology, Queen Mary Hospital [Hong Kong, Hong Kong] | Hong Kong Sanatorium & Hospital [Hong Kong, Hong Kong]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the use of acupuncture, which is an existing treatment, for a specific condition (insomnia) in a specific patient population (breast cancer patients undergoing chemotherapy), indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04145323,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients,COMPLETED,EARLY_PHASE1,"University of Wisconsin, Madison",2019-09-25,2019-12-19,2019-12-19,2019-10-30,2020-01-18,"['Comparison of Necrotic tissue area determined visually by the operating surgeon vs indocyanine Green (ICG) microangiography', 'Time to achieve the peak fluorescent signal from necrotic tissue using ICG', 'Percentage overlap of identified areas of necrosis determined by ICG and clinical standard of care']",[],,,,,1,United States,"University of Wisconsin [Madison, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2019.0,6.0,0,Phase 1
NCT04145817,Breast Cancer Risk After Diagnostic Gene Sequencing,"Clinical Application of the European Horizon 2020 Research Project ""BRIDGES"" - Study of the Psychological Impact of Breast Cancer Risk Communication in Cancer Genetics Based on the Personalized Estimation of the BOADICEA V5/PLUS Model",COMPLETED,,Institut Curie,2019-10-22,2021-08-27,2022-03-03,2019-10-31,2023-01-20,['Psychosocial Assessment in Hereditary Cancer questionnaire (PAHC).'],"['Difference on the PAHC score between counselees who receive a pathogenic variant indicating breast cancer versus (VS) who did not receive such result', 'Percentage of counselees intending to undertake risk reducing mastectomy (the one who received a pathogenic variant VS who did not receive such result)', 'Percentage of counselees who communicate their result to their sister(s) (the one who received a pathogenic variant VS who did not receive such result)']",,,,,2,France; Germany,"Institut Curie [Paris, France] | University Hospital of Cologne [Cologne, Germany]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study related to the psychological impact of breast cancer risk communication and does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,1,NA/Other
NCT04148586,Trial Comparing 3 Schedules of Hypofractionated Whole Breast Irradiation in Females With Early Stage Breast Cancer,Randomized Trial Comparing 3 Schedules of Hypofractionated Whole Breast Irradiation in Females With Early Stage Breast Cancer,COMPLETED,,"National Cancer Institute, Egypt",2017-11-01,2020-03-01,2020-03-01,2019-11-01,2020-09-16,"['Acute toxicity', 'Cosmetic outcome', 'Ibsilateral locoregional tumor control', 'patient-reported outcome measures (PROMs)']","['late toxicity', 'Distant disease-free survival', 'Overall survival']",,,,,1,Egypt,"NCI. Cairo University [Cairo, Egypt]",2017.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Disease-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is focused on comparing different schedules of an existing treatment (hypofractionated whole breast irradiation) for a specific patient population (females with early stage breast cancer), indicating an extension of indication rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04150484,"Influence of an Intervention on Diet, Physical Exercise and Mindfulness in the Quality of Life of Survivors With Breast Cancer","Influence of an Intervention on Diet, Physical Exercise and Mindfulness in the Quality of Life of Survivors With Breast Cancer",COMPLETED,,Universidad de Granada,2016-12-01,2017-12-23,2019-05-25,2019-11-04,2019-11-04,['Quality of life test (EORTC QOL-C30)'],"['Mediterranean diet adherence test', 'Levels of glucose', 'Levels of triglycerides', 'Levels of cholesterol', '24 hours recall']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses an intervention related to diet, exercise, and mindfulness for improving quality of life in breast cancer survivors, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04163692,Progressive Relaxation Training in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy,"Effects of Progressive Relaxation Training on Artralgia, Quality of Life and Emotional Status in Breast Cancer Patients Receiving Aromatatase Inhibitor Therapy",COMPLETED,,Hacettepe University,2019-10-25,2020-09-24,2020-09-24,2019-11-15,2021-04-01,['Brief pain inventory (BPI)'],"['Functional Assessment of Chronic Illness Therapy - Breast (FACT-B)', 'Hospital Anxiety and Depression scale (HAD)']",,,,,1,Turkey (Türkiye),"Florence Nightingale Hospital [Istanbul, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a training intervention (Progressive Relaxation Training) in breast cancer patients receiving a specific therapy (Aromatase Inhibitor Therapy), but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04170465,Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),Investigation of the Potential Beneficial Effect of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO),COMPLETED,PHASE2,Damanhour University,2019-10-29,2022-04-02,2022-06-28,2019-11-20,2022-09-10,"['Evaluation of the effect on tumor apoptosis', 'Chemotherapy toxicities']",['Pathologic complete response rate (pCR)'],,,,,1,Egypt,"Damanhour University [Beheira, Egypt]",2019.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Pathologic Complete Response""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,Phase 2
NCT04170920,Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs,Pilot Study of a Mobile Health Strategy to Improve Medication Adherence in Breast Cancer Survivors Receiving Aromatase Inhibitors,COMPLETED,,Indiana University,2020-02-17,2022-04-29,2022-08-09,2019-11-20,2022-09-14,['Participants who use the LifeExtend-AI application 5 or more days per week'],"['Mean medication adherence using the Brief Medication Questionnaire (BMQ)', 'Mean pain score of self -reported aromatase inhibitor arthralgia using the Basic Pain Inventory (BPI)', 'Mean quality of life score, measured by the Functional Assessment of Cancer Therapy- Endocrine symptoms (FACT-ES)', 'Mean satisfaction with healthcare team communication, measured by the FACIT- Treatment Satisfaction-Patient Satisfaction questionnaire (FACIT-TS-PS)', 'Mean quality of life, as measured by the Hospital Anxiety and Depression Scale (HADS)', 'Mean quality of life, as measured by the International Physical Activity Questionnaire (IPAQ)', 'Mean quality of life, as measured by the eHEALTH literacy scale (ehEALS)', 'Mean quality of life, as measured by the Patient Activation Measure (PAM)', 'Mean quality of life, as measured by the assessment of cancer worry in aromatase inhibitor users']",,,,,1,United States,"Indiana University Melvin & Bren Simon Cancer Center [Indianapolis, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on improving medication adherence for breast cancer survivors already receiving aromatase inhibitors, indicating an extension of indication for the existing treatment rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04172220,Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?,"Variation of the Neutrophil To Lymphocyte Ratio During Opioid-Free General Anesthesia Associated With Thoracic Wall Blocks Vs General Anesthesia, in Breast Cancer Quadrantectomy: a Randomized Controlled Trial",COMPLETED,,Centro di Riferimento Oncologico - Aviano,2019-10-31,2021-11-01,2022-11-01,2019-11-21,2024-10-16,['24h NLR variation'],"['1h NLR variation', 'Opioid consumption', 'Complication', 'Chronic pain', 'Change in the levels of circulating cytokines in the post-operative period (one hour and 24 hours after surgery), compared to the baseline pre-operative values, in the two arms']",,,,,1,Italy,"Centro di Riferimento Oncologico di Aviano (CRO), IRCCS [Aviano, Italy]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses the influence of anesthesia types on inflammation and various outcomes after breast surgery, but it does not introduce a new medicine or extend the indication of an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04176757,A Study of ZN-c5 in Participants With Breast Cancer,"A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer",COMPLETED,PHASE1,Zeno Alpha Inc.,2020-01-03,2021-04-27,2021-05-25,2019-11-25,2022-08-01,['Corroborate the single agent Recommended Phase 2 Dose'],"['Dose-biomarker relationship', 'Dose-biomarker relationship', 'Dose-biomarker relationship']",,,,,10,Australia; Bosnia and Herzegovina; United States,"Site 3 [Tucson, United States] | Site 2 [New York, United States] | Site 4 [Nashville, United States] | Site 1 [Houston, United States] | Site 5 [Seattle, United States] | Site 11 [Liverpool, Australia] | Site 9 [Sydney, Australia] | Site 10 [Cairns, Australia] | Site 8 [Richmond, Australia] | Site 7 [Banja Luka, Bosnia and Herzegovina]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,1,Phase 1
NCT04197206,Ultrasound Guided Costotransverse Block for Breast Cancer Surgery,Evaluation of Ultrasound Guided Costotransverse Block in Breast Canser Surgery Patients,COMPLETED,,Cigli Regional Training Hospital,2020-01-06,2020-04-29,2020-04-29,2019-12-13,2020-04-30,['24 hours morphine consumption'],['Numeric rating scale for postoperative pain intensity'],,,,,1,Turkey (Türkiye),"Cigli regional research hospital [Izmir, Turkey (Türkiye)]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the use of an existing technique (Ultrasound Guided Costotransverse Block) in a new patient population (Breast Cancer Surgery Patients), indicating an extension of indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04197999,A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer,"A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects",TERMINATED,PHASE1,GlycoMimetics Incorporated,2019-11-21,2021-08-25,2021-08-25,2019-12-13,2022-03-22,"['Occurrences of dose-limiting toxicities (DLT) including protocol-defined adverse events (AEs)/serious adverse events (SAEs), and/or laboratory abnormalities will be assessed in order to determine recommended phase II dose (Safety and Tolerability)']","['Area under the plasma concentration-time curve [AUC0-t and AUC0-∞] of GMI-1359', 'Maximum plasma concentration [Cmax] of GMI-1359', 'Time to reach maximum plasma concentration [tmax] of GMI-1359', 'Individual estimate of the terminal elimination rate constant [Λz] of GMI-1359', 'Half-life [t1/2] of GMI-1359', 'Total plasma clearance [CL] of GMI-1359', 'Apparent volume of distribution estimated at the terminal phase [Vz] of GMI-1359', 'Pre- and post-dose circulating tumor cells (CTC) enumeration to determine tumor cell mobilization [digital pathology assay]', 'Pre-and post-dose CD34+ cell quantification to determine mobilization into peripheral blood [standard flow cytometry]']",,,,,1,United States,"Duke University Medical Center [Durham, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is focused on GMI-1359, which is being evaluated for safety and tolerability in a specific patient population (HR+ metastatic breast cancer), indicating it is a new medicine.",INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT04200482,Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors,Testing a Scalable Nutrition and Physical Activity Program for Breast Cancer Survivors: A Dose-Finding Pilot Study,COMPLETED,PHASE2,Fred Hutchinson Cancer Center,2020-02-21,2021-08-24,2021-10-28,2019-12-16,2021-11-04,"['Accrual rate', 'Adherence: Session(s) Attendance', 'Adherence: Responsiveness to eHealth communication', 'Biospecimen collection rate', 'Retention', 'Acceptability: Questions during exit interview']","['Change in daily servings of fruits and vegetables per day', 'Change in minutes per week of moderate-to-vigorous physical activity', 'Change in systemic inflammation', 'Change in gut barrier permeability']",,,,,1,United States,"Fred Hutch/University of Washington Cancer Consortium [Seattle, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a lifestyle program aimed at improving nutrition and physical activity for breast cancer survivors, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT04208724,Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization,"Implementation Studio, an Innovative, Structured Approach to Facilitate Rural Community-Based Organizations' Adaptation and Implementation of Evidence-Based Interventions",COMPLETED,,Fred Hutchinson Cancer Center,2020-11-18,2022-06-30,2022-06-30,2019-12-23,2022-07-26,"['Develop the structural program', 'Implementation Monitoring', 'Intention to get screened for cancer (type of cancer will be determined by the community-based organization) pre- and post-intervention']",[],,,,,1,United States,"Fred Hutch/University of Washington Cancer Consortium [Seattle, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a support program for cancer screening interventions and does not mention any new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04209010,Immediate Breast Reconstruction With Acellular Dermal Matrix,Comparison of One-stage Direct-to-implant With Acellular Dermal Matrix and Two-stage Implant-based Breast Reconstruction: A Cohort Study,COMPLETED,,Aarhus University Hospital,2012-12-01,2016-03-17,2016-03-17,2019-12-23,2020-01-03,"['Postoperative complications', 'Postoperative complications']","['Patient assessed satisfaction with aesthetic result', 'Investigator assessed satisfaction with aesthetic result', 'Patient reported outcome measures', 'Cost']",,,,,0,,,2012.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares different methods of breast reconstruction using acellular dermal matrix, indicating an extension of indication for existing treatments rather than testing a new medicine.",OTHER,False,2016.0,9.0,0,NA/Other
NCT04218149,Serratus Plane Block vs Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,Comparison of the Effects of Serratus Plane Block and Erector Spinae Plane Block on Postoperative Analgesia in Patients Undergoing Unilateral Breast Surgery,COMPLETED,PHASE4,Sisli Hamidiye Etfal Training and Research Hospital,2019-05-01,2019-09-29,2019-10-01,2020-01-06,2020-01-31,"['Postoperative pain score', 'Postoperative tramadol consumption', 'Rescue analgesic']",['Analgesia time'],,,,,1,Turkey (Türkiye),"SBÜ Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi [Istanbul, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a comparison of two existing analgesic techniques (Serratus Plane Block and Erector Spinae Plane Block) for postoperative pain management, rather than introducing a new medicine or extending the indication of an existing one.",OTHER,False,2019.0,6.0,0,Other
NCT04219267,Effectiveness of Character Strengths-based Intervention Among Breast Cancer Patients,"Effectiveness of Character Strengths-based Intervention in Enhancing Self-esteem, Quality of Life and Alleviating Depression Among Breast Cancer Patients: A Randomized Controlled Study",COMPLETED,,Chinese University of Hong Kong,2020-05-04,2020-11-30,2020-12-20,2020-01-07,2021-01-27,"['Change from baseline self-esteem at 2 months,The Rosenberg Self-esteem Scale (RSES)']","['Change from baseline quality of life at 2 months, The Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B, version 4)', 'Change from baseline depression at 2 months, The Patient Health Questionnaire 9 (PHQ-9)', 'Change from baseline character strengths at 2 months, The Chinese Virtues Questionnaire (CVQ)']",,,,,2,China,"Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University) [Zhengzhou, China] | The Second Affiliated Hospital of Zhengzhou University [Zhengzhou, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on the effectiveness of a psychological intervention for breast cancer patients, focusing on self-esteem, quality of life, and depression. It does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04225741,Theory-based Training to Promote Breast Cancer Screening,Theory-based Training to Promote Breast Cancer Screening Among Women With Breast Cancer Worries: Randomized Controlled Trial,COMPLETED,,Inonu University,2015-01-22,2017-08-11,2017-08-30,2020-01-13,2020-01-14,['Breast Cancer Worry Scale'],[],,,,,0,,,2015.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a randomized controlled trial focused on promoting breast cancer screening through training, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT04227613,Aspects of Breast-conserving Surgery,Prospective Study of Cosmetic Outcome and Quality of Life for Women Undergoing Breast Cancer Surgery,COMPLETED,,Lund University,2019-01-01,2021-12-31,2022-06-30,2020-01-13,2022-11-21,"['Quality of life', 'Cosmetic outcome']",[],,,,,1,Sweden,"Central Hospital of Kristianstad [Kristianstad, Sweden]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on cosmetic outcomes and quality of life for women undergoing breast cancer surgery, but does not mention a new medicine or an extension of indication for an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04237090,Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,Feasibility of a Randomized Controlled Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel,COMPLETED,PHASE3,Ciusss de L'Est de l'Île de Montréal,2020-02-14,2020-08-28,2020-09-04,2020-01-22,2020-10-12,"['Change from baseline of drowsiness on Stanford Sleepiness Scale 1 hour after the administration of diphenhydramine', 'Change from baseline of drowsiness on Stanford Sleepiness Scale upon arrival at home', 'Change from baseline of drowsiness on Stanford Sleepiness Scale the morning after the administration of diphenhydramine', 'Recruitment rate accomplished to recruit 24 participants for which a first dose of paclitaxel was administered between February and September 2020.', 'Percentage of participants recruited, randomized and having received the first treatment of paclitaxel planned in the study between February and September 2020 following an assessment of their eligibility.']","['Proportion of participants per group who required stopping the infusion and/or using rescue medication.', 'Infusion-related reactions grade according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 classification']",,,,,1,Canada,"CIUSSS de l'Est-de-l'île-de-Montréal [Montreal, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares the use of Cetirizine to replace Diphenhydramine for a specific indication related to the prevention of reactions to Paclitaxel, indicating an extension of indication for Cetirizine.",OTHER,False,2020.0,5.0,0,Phase 3
NCT04247763,"Fast Food, Fatigue, and Inflammation","Fast Food, Fatigue, and Inflammation: The FOOD Study",COMPLETED,,Ohio State University Comprehensive Cancer Center,2010-12-13,2013-06-11,2013-06-11,2020-01-30,2023-09-06,"['Post-Meal Change in C-reactive Protein', 'Post-Meal Change in Serum Amyloid A', 'Change in Intercellular adhesion molecule-1', 'Change in Vascular cell adhesion molecule-1', 'Fatigue at Follow-Up Visits']",[],,,,,1,United States,"Ohio State University Comprehensive Cancer Center [Columbus, United States]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study related to the effects of fast food on inflammation and fatigue, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2013.0,12.0,0,NA/Other
NCT04248179,The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery.,"The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial.",COMPLETED,PHASE4,Zealand University Hospital,2019-11-29,2021-12-08,2021-12-08,2020-01-30,2023-02-09,['Morphine Consumption'],"['Pain intensity', 'Morphine consumption at 4, 8, 12, 16 and 20 postoperative hours.', 'Duration of block (time to first opioid).', 'Patient satisfaction with application of the block.', 'The degree of morphine-related side effects (PONV, itching, fatigue, etc.).', 'Time from operation (T0) to ambulation (bed to chair to walking)', 'Time to discharge (days).', 'Quality of recovery']",,,,,1,Denmark,"Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital, Roskilde [Roskilde, Denmark]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the effectiveness of an existing procedure (Ultrasound-guided Multiple-injection Costotransverse Block) in a new context (mastectomy and primary reconstructive surgery), indicating an extension of indication rather than a new medicine.",OTHER,False,2021.0,4.0,0,Other
NCT04249440,Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer,Preoperative Systemic Therapy Versus Upfront Surgery in HER2 Positive Early Breast Cancer: a Prospective Nested Case-control Study in Real World,COMPLETED,,Zhejiang Cancer Hospital,2012-01-01,2019-12-30,2020-03-30,2020-01-31,2020-09-28,['Disease free survival'],['Overall survival'],,,,,0,,,2012.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,"[""Disease-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial compares preoperative systemic therapy with upfront surgery in a specific patient population (HER2 positive early breast cancer), indicating an extension of indication for existing treatments rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04252300,"Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants","Open Label, Fixed Sequences, One-way Cross-over Study to Determine the Effects of Multiple Doses BAY1817080 (150 mg) on the Pharmacokinetics of a 5 mg Dose Rosuvastatin in Healthy Participants",COMPLETED,PHASE1,Bayer,2020-03-02,2020-08-29,2020-12-07,2020-02-05,2021-03-11,"['Maximum plasma concentration of rosuvastatin without concomitant administration of BAY1817080 (Cmax)', 'Maximum plasma concentration of rosuvastatin after concomitant administration of BAY1817080 (Cmax1)', 'Area under the concentration-time curve of rosuvastatin without concomitant administration of BAY1817080 (AUC)', 'Area under the concentration-time curve of rosuvastatin after concomitant administration of BAY1817080 (AUC1)']","['Number of participants with treatment-emergent adverse events (TEAEs)', 'Severity of treatment-emergent adverse events']",,,,,1,United States,"Covance Clinical Research Unit, Inc. [Daytona Beach, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The study involves a new drug (BAY1817080) and its effects on the pharmacokinetics of an existing drug (rosuvastatin), indicating it is a new medicine.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04253366,Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection,"A Multicentric, Single Arm, Prospective, Stratified Clinical Investigation to Evaluate the Ability of MammoWave in Breast Lesions Detection",COMPLETED,,Umbria Bioengineering Technologies,2020-09-16,2021-08-20,2021-08-20,2020-02-05,2021-08-24,"[""MammoWave sensitivity (number of 'true positive' results)""]","['MammoWave specificity and sensitivity (against Reference Standard)', 'Percentage of correct BL localization in terms of quadrant (against Reference Standard)', 'Absolute and rate agreement between different evaluator (i.e. local radiologist versus central)', 'Sensitivity for each breast density group', 'Sensitivity for patients which had recent mammography', 'Patient satisfaction questionnaire.']",,,,,3,Italy; Spain,"Istituto Clinico Humanitas [Rozzano, Italy] | Azienda Ospedaliera Universitaria S. Martino Di Genova [Genova, Italy] | Hospital Virgen de la Salud [Toledo, Spain]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a clinical investigation evaluating a device (MammoWave) for breast lesion detection, which does not indicate a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2021.0,4.0,1,NA/Other
NCT04257799,Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging,Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging,COMPLETED,,Dartmouth-Hitchcock Medical Center,2020-02-06,2022-03-16,2022-03-16,2020-02-06,2022-06-22,['Sensitivity and Specificity of 3D tomography-SLI as measured by concurrence with standard of care 2-D mammography'],"['Sensitivity and Specificity of 3D tomography alone in identifying true positive margins and true negative margins', 'Sensitivity and Specificity of SLI alone in identifying true positive margins and true negative margins', 'Sensitivity and Specificity of standard-of-care 2D specimen mammography', 'Determine the logistics of use of the imaging system, software interface and specimen holder.']",,,,,1,United States,"Dartmouth Hitchcock Medical Center [Lebanon, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on imaging techniques for evaluating lumpectomy specimens, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04258085,Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System,Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System,COMPLETED,,Brigham and Women's Hospital,2020-07-01,2021-12-31,2022-03-25,2020-02-06,2022-04-07,"['Cancer detection rate', 'Loss to follow-up', 'Patient volume and services received']","['Breast cancer stage', ""Patients' costs""]",,,,,1,Rwanda,"Rwanda Biomedical Centre [Kigali, Rwanda]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a program for early detection of breast cancer in Rwanda and does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04258163,Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy,Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy,COMPLETED,,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2019-01-01,2019-06-01,2019-07-01,2020-02-06,2020-02-10,['Overall Survival (OS)'],['Progression free survival (PFS)'],,,,,3,China,"First People's Hospital of Foshan [Foshan, China] | Sun Yat-sen Memorial Hospital,Sun Yat-sen University [Guangzhou, China] | Sun Yat-sen University Cancer Center [Guangzhou, China]",2019.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT04261218,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer","A Trial to Assess the Safety, Pharmacodynamic Effects, Pharmacokinetics and Efficacy of the MNK Inhibitor Tomivosertib (eFT508) in Combination With Paclitaxel, Following a Run-in Period of Tomivosertib Monotherapy, in Patients With Advanced Breast Cancer",COMPLETED,PHASE1,Translational Research in Oncology,2020-08-25,2022-07-04,2022-07-04,2020-02-07,2022-07-20,"['Number of Patients with Adverse Events (AEs)', 'Change from Baseline Pharmacodynamic Effects (PD) Following 14 Days of Tomivosertib Monotherapy']","['Overall Response Rate (ORR)', 'Clinical Benefit Rate (CBR)', 'Pharmacokinetic Effects (PK)']",,,,,3,Canada,"Cross Cancer Institute [Edmonton, Canada] | British Columbia Cancer Vancouver [Vancouver, Canada] | Jewish General Hospital [Montreal, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing the safety and efficacy of Tomivosertib, which is identified as a MNK inhibitor, indicating it is a new medicine being tested in combination with an existing treatment (Paclitaxel) for advanced breast cancer.",OTHER,False,2022.0,3.0,0,Phase 1
NCT04265547,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,Family-Based Intervention Study of the Effects of Environmental Exposures on Breast Tissue Composition,COMPLETED,,Columbia University,2020-01-25,2020-11-21,2020-11-21,2020-02-11,2025-09-23,"[""Feasibility of measuring pre/post-intervention change in participants' breast tissue concentration of lipid (mg/cm^3) measured using an Optical Spectroscopy machine."", ""Feasibility of measuring pre/post-intervention change in participants' breast tissue concentration of water (mg/cm^3) measured using an Optical Spectroscopy machine."", ""Feasibility of measuring pre/post-intervention change in participants' breast tissue concentration of collagen (mg/cm^3) measured using an Optical Spectroscopy machine."", ""Feasibility of measuring pre/post-intervention change in participants' breast tissue concentration of total hemoglobin (μM) measured using an Optical Spectroscopy machine."", ""Feasibility of measuring pre/post-intervention change in participants' breast tissue concentration of oxygenated hemoglobin (%) measured using an Optical Spectroscopy machine."", 'Feasibility of measuring pre/post-intervention change in urinary metabolites of endocrine disrupting chemicals, including polycyclic aromatic hydrocarbons (PAH), phthalates, and parabens (all measured in μg/L units) .']",[],,,,,1,United States,"Columbia University Mailman School of Public Health [New York, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study focused on environmental exposures and their effects on breast tissue composition, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04274933,"A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy","A Phase 1b Study of Venetoclax and Capecitabine In Subjects With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy",TERMINATED,PHASE1,AbbVie,2020-05-21,2020-10-08,2020-10-08,2020-02-18,2020-10-29,"['Number of participants with Dose Limiting Toxicities (DLTs)', 'Maximum observed plasma concentration (Cmax) of venetoclax', 'Maximum observed plasma concentration (Cmax) of capecitabine', 'Maximum observed plasma concentration (Cmax) of 5-fluorouracil', 'Time to Cmax (peak time, Tmax) of venetoclax', 'Time to Cmax (peak time, Tmax) of 5-fluorouracil', 'Time to Cmax (peak time, Tmax) of capecitabine', 'Area under the plasma concentration versus time curve (AUC) for venetoclax up to 24 hours post-dose (AUC0-24)', 'Area under the plasma concentration versus time curve (AUC) for capecitabine/5-fluorouracil up to 12 hours post-dose (AUC0-12)']",[],,,,,18,Germany; Japan; Puerto Rico; United States,"Joliet Oncology-Hematology Associates, LTD /ID# 215051 [Joliet, United States] | Massachusetts General Hospital /ID# 214833 [Boston, United States] | Dana-Farber Cancer Institute /ID# 214832 [Boston, United States] | Masonic Cancer Center /ID# 216101 [Minneapolis, United States] | Memorial Sloan Kettering Cancer Center /ID# 214886 [New York, United States] | University of Pennsylvania /ID# 216357 [Philadelphia, United States] | Greenville Health System Cance /ID# 216059 [Greenville, United States] | Vanderbilt University Med Ctr /ID# 213852 [Nashville, United States] | MD Anderson Cancer Center /ID# 214867 [Houston, United States] | Utah Cancer Specialists /ID# 215375 [Salt Lake City, United States] | Swedish Cancer Institute /ID# 216120 [Seattle, United States] | Universitaetsklinik Heidelberg /ID# 214679 [Heidelberg, Germany] | Universitaetsklinikum Ulm /ID# 214678 [Ulm, Germany] | Charite Universitaetsmedizin Berlin /ID# 215287 [Berlin, Germany] | Universitatsklinikum Tubingen /ID# 217021 [Tübingen, Germany] | Aichi Cancer Center Hospital /ID# 224527 [Nagoya, Japan] | Pan American Center for Oncology Trials, LLC /ID# 216862 [Rio Piedras, Puerto Rico] | GCM Medical Group PSC - Hato Rey /ID# 216904 [San Juan, Puerto Rico]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the combination of Venetoclax with Capecitabine in a specific patient population (hormone receptor-positive, HER2-negative breast cancer) who have progressed after prior therapy, indicating an extension of indication for Venetoclax.",INDUSTRY,False,2020.0,5.0,1,Phase 1
NCT04290585,Technology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography,Text for Health: Integrating Technology and Health Communication to Improve Health Outcomes (Part 2 of 2),COMPLETED,,Fox Chase Cancer Center,2014-03-05,2014-10-28,2017-10,2020-03-02,2020-03-02,['Change in no-show rate pre- and post-intervention'],['Acceptability of using text messaging as a reminder: survey'],,,,,1,United States,"Fox Chase Cancer Center [Philadelphia, United States]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the use of technology and health communication to improve health outcomes related to mammography, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2017.0,8.0,0,NA/Other
NCT04297384,Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,Breast Cancer Pathways Impact on Patient Shared Decision Making and Experience in Academic and Community Practice,COMPLETED,,Roswell Park Cancer Institute,2019-02-06,2022-08-30,2022-08-30,2020-03-05,2023-04-10,"['change in Patient quality of life', 'Change in Patient quality of decision', 'Number of physician visits and diagnostic tests']",[],,,,,1,United States,"Roswell Park Cancer Institute [Buffalo, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a program's impact on patient decision making and experience in breast cancer care, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04306003,ERAS in Autologous Breast Reconstruction: A Pilot RCT,Enhanced Recovery After Surgery in Autologous Breast Reconstruction: A Pilot Randomized Controlled Trial,COMPLETED,,Hamilton Health Sciences Corporation,2019-11-05,2020-06-30,2020-06-30,2020-03-12,2020-07-29,"['Feasibility (pertaining to patient eligibility)', 'Feasibility (pertaining to patient recruitment)', 'Feasibility (pertaining to adherence to follow-up assignment)', 'Feasibility (pertaining to adherence to ERAS protocol)']","['Hospital Length of Stay', 'In-hospital opioid consumption', 'BREAST-Q', 'EQ-5D-5L', '30-days adverse event (composite outcome)', '30-days additional resource utilization (composite outcome)']",,,,,2,Canada,"Juravinski Hospital [Hamilton, Canada] | St. Joseph's Healthcare [Hamilton, Canada]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot randomized controlled trial focused on the feasibility of Enhanced Recovery After Surgery (ERAS) in autologous breast reconstruction, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04309929,Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery,Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery,COMPLETED,,Careggi Hospital,2016-09-12,2018-07-31,2018-07-31,2020-03-17,2020-03-17,['Assessment of the change of level of anesthesia'],"['Describing the total amount of morphine used in the first 24 post-operative hours.', 'Describing the incidence of PONV (Postoperative Nausea and Vomiting).', 'Describing of change in severity of PONV (Postoperative Nausea and Vomiting).', 'Description of the change of the intensity of pain on daily activities reported by patients undergoing breast surgery.', 'Description of the change of the interference of pain on daily activities reported by patients undergoing breast surgery.', 'Description of the change of the incidence and impact on daily activities of the pain reported by patients undergoing breast surgery.']",,,,,1,Italy,"Azienda Ospedaliero Universitaria Careggi [Florence, Italy]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an assessment of analgesia protocols and their effects in breast surgery, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT04312347,Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels,Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis,COMPLETED,,Nalagenetics Pte Ltd,2019-09-06,2021-05-01,2021-06-30,2020-03-18,2021-08-05,"['Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites', 'Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levels', 'Frequencies of CYP2D6 alleles in female Indonesian population']",[],,,,,1,Indonesia,"MRCCC Siloam Hospital Semanggi [Jakarta, Indonesia]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on adjusting the dose of an existing medication (Tamoxifen) based on genetic factors and metabolite levels, which indicates an extension of its indication rather than testing a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT04320030,[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers,Pilot Feasibility Study: Inflammation and Presence of M2 Macrophages Explorations With[18F]-DPA-714 PET/CT in Triple Negative Breast Cancers,COMPLETED,PHASE2,Institut Cancerologie de l'Ouest,2020-06-11,2021-07-21,2021-07-21,2020-03-24,2023-02-21,['Correlation between M1/M2 macrophage polarization and [18F]DPA-714 PET/CT binding'],"['Correlation between TSPO genotyping (HAB = High Affinity Binder, MAB = Mixed Affinity Binder and LAB = Low Affinity Binder) and [18F]DPA-714 PET/CT binding', 'Assess the value of early and late [18F]-DPA-714 PET/CT acquisitions', 'Evaluate the performance of the three types of imaging used in this study: [18F]-DPA-714 PET/CT (early and late), 18FDG PET/CT and diffusion-weighted breast MRI in the characterization of triple negative breast cancer', 'Perform tumor molecular subtyping', '[18F]-DPA-714 toxicity']",,,,,3,France,"APHP - Hôpital Tenon [Paris, France] | Institut de cancerologie de l'Ouest [Saint-Herblain, France] | CHU Bretonneau [Tours, France]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves the use of [18F]-DPA-714 PET/CT, which suggests it is being evaluated as a new imaging agent in the context of triple negative breast cancer, indicating it is a new medicine.",OTHER,False,2021.0,4.0,0,Phase 2
NCT04321135,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,Avanzando Juntas: Adapting an Evidence Based Weight Loss Program for Hispanic Breast Cancer Survivors,COMPLETED,,Medical College of Wisconsin,2019-11-01,2022-07-30,2022-07-30,2020-03-25,2022-12-16,"['Change in body composition', 'Change in intake of fruits and vegetables', 'Change of intake of red meat/processed meat', 'Change in levels of physical activity- minutes per week', 'Change in levels of physical activity- #times per week', 'Change in resistance training- Handgrip strength', 'Change in resistance training- Strength and endurance', 'Change in Quality of Life- PROMIS (Patient Reported Outcomes Measurement Information System)', 'Changes in Systolic and Diastolic Blood Pressure', 'Change in Biomarkers- Lipids', 'Change in Biomarkers- Glycohem', 'Change in Biomarkers- Glucose', 'Change in Biomarkers- C-Peptide', 'Change in Biomarkers- Insulin', 'Change in Biomarkers- hs CRP', 'Change in Biomarkers-Adipokines- Adiponectin', 'Change in Biomarkers-Adipokines- Leptin', 'Change in waist circumference']",[],,,,,1,United States,"Medical College of Wisconsin [Milwaukee, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a weight loss program tailored for Hispanic breast cancer survivors, focusing on lifestyle changes and health outcomes rather than introducing a new medicine or extending the indication of an existing one.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04327063,MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer Surgery,A Double-blind Randomized Trial of Interpectoral Nerve Block (Pecs 1 and 2) With Ropivacaine Versus Placebo Before Breast Cancer Surgery: Effects on Acute Postoperative Pain. (MIRs 04),COMPLETED,PHASE3,Institut Curie,2020-08-04,2021-12-30,2022-01-28,2020-03-30,2025-09-19,['To compare the effect of ropivacaine versus placebo pectoral nerve block (Pecs 1 and 2) on acute pain after tumorectomy plus sentinel lymph node dissection on one day surgery'],"['Evaluation of acute pain at rest and after shoulder movement until 48 postoperative hours', 'Evaluation of acute pain until 48 postoperative hours', ""Evaluation of patient's satisfaction on pain management"", 'Evaluation of Remifentanil consumption during anesthesia', 'Evaluation of analgesic consumption during the first 48 postoperative hours', 'Evaluation of the incidence of nausea and vomiting during the first 48 postoperative hours', 'Evaluation of complications of Pecs during 48 postoperative hours', 'Evaluation of the incidence of serious adverse events during 30 days']",,,,,4,France,"Centre Jean Perrin [Clermont-Ferrand, France] | Institut Curie [Paris, France] | Hopital Tenon [Paris, France] | Institut de Cancérologie de Lorraine [Vandœuvre-lès-Nancy, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the use of ropivacaine, which is an existing medication, in a new application (pectoral nerve block) for managing acute postoperative pain in breast cancer surgery, indicating an extension of its indication.",OTHER,False,2022.0,3.0,0,Phase 3
NCT04330339,Prolonged Nightly Fasting in Breast Cancer Survivors,Pilot Study to Assess Prolonged Nightly Fasting in Breast Cancer Survivors,COMPLETED,,Massachusetts General Hospital,2020-07-24,2021-01-31,2022-07-05,2020-04-01,2022-07-21,['Percentage of Participants adhere to 13 hours of fasting'],"['Change in body mass index (BMI) (kg/m^2)', 'Quality of life (QOL) Change using the Functional Assessment of Cancer Therapy General Scale (FACT-G)', 'Change in Hospital Anxiety and Depression Scale (HADS) (min score: 0; max score: 21. A higher score indicates more anxiety and/or depression)', 'Change in fatigue as assessed by Functional Assessment of Chronic Illness Therapy - Fatigue', 'Change in physical activity using the Godin Leisure-Time Exercise Questionnaire', 'Change in lipid profile', 'Change in hemoglobin A1c (%)', 'Change in c-reactive protein (mg/L)', 'Change in interleukin-6 (pg/mL)', 'Change in tumor necrosis factor alpha (pg/mL)', 'Change in insulin (mcU/mL)', 'Change in leptin (ng/mL)', 'Change in adiponectin level (microgram/mL)', 'Change in insulin-like growth factor (ng/mL)', 'Change in homeostatic model assessment of insulin resistance (estimates beta cell function (%B) and insulin sensitivity (%S), as percentages of a normal reference population)']",,,,,1,United States,"Massachusetts General Hospital Cancer Center [Boston, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on assessing the effects of prolonged nightly fasting in breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine. It is more of a lifestyle intervention study.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04334239,Effectiveness of Care in Certified Cancer Centres in Germany,Wirksamkeit Der Versorgung in Onkologischen Zentren,COMPLETED,,Technische Universität Dresden,2017-05-01,2021-05-31,2021-08-31,2020-04-06,2022-08-23,"['Overall survival', '1- and 5-year survival', '30-day mortality']","['2-, 3-, 4-year survival', 'Recurrence-free survival', 'Cumulative recurrence rate', 'Complications due to surgery', 'Successive resection', 'Entity-specific outcomes defined by clinical experts', 'Fraction of patients', 'Regional differences', 'Differences in patient characteristics', 'Pathways of treatment', 'Severity Levels in insurance data']",,,,,1,Germany,"Technische Universität Dresden [Dresden, Germany]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effectiveness of care in certified cancer centers and various survival metrics, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04336917,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,Ultrasound Guided Rhomboid Intercostal and Subserratus Plane Block in Breast Cancer Surgeries,COMPLETED,PHASE4,Konya Meram State Hospital,2020-08-31,2021-02-05,2021-03-01,2020-04-07,2021-04-20,['Postoperative opiod consumption'],['Postoperative pain scores'],,,,,1,Turkey (Türkiye),"Konya Education and Training Hospital [Konya, Turkey (Türkiye)]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a procedural technique (ultrasound-guided block) used in breast cancer surgeries rather than introducing a new medicine or extending the indication of an existing medicine.,OTHER,False,2021.0,4.0,0,Other
NCT04343950,SMS Messaging as a Tool to Improve Cancer Screening Programs,Implementation of Text Messaging (SMS) as an Improvement Tool in Population-based Cancer Screening Programs,COMPLETED,,Institut Català d'Oncologia,2021-06-05,2022-10-31,2022-12-31,2020-04-14,2025-09-24,"['Intervention 1: Participation in colorectal cancer screening program', 'Intervention 2: Participation in colorectal cancer screening program among individuals who pick the test at the pharmacy', 'Intervention 3: Participation in breast cancer screening program']",['Incremental cost ratio'],,,,,1,Spain,"Institut Català d'Oncologia [L'Hospitalet de Llobregat, Spain]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the implementation of SMS messaging to improve cancer screening programs, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04348955,Interest of Touch-massage in Hospital Day Care,Interest of Touch-massage in Hospital Day Care,COMPLETED,,Institut Cancerologie de l'Ouest,2019-10-07,2020-05-12,2020-05-12,2020-04-16,2022-04-22,"['Evaluate the quality of life of patients with an adjuvant breast cancer treated at the ICO depending on the patient benefit or not from the TM during the chemotherapy in a hospital day care', 'Change from basline quality of life during breast cancer treatment']","['Estimate the prevalence of the patients interested by the TM as part of the adjuvant care of a breast cancer at the ICO site of Angers', 'Evaluate the benefits of the TM on the anxiety']",,,,,2,France,"Insitut de Cancérologie de l'Ouest [Angers, France] | Insitut de Cancérologie de l'Ouest [Angers, France]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT04350229,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,Endocrinological Changes Due to Pre-medications of Chemotherapy in Patients With Breast Cancer,COMPLETED,,Instituto do Cancer do Estado de São Paulo,2020-03-27,2022-06-20,2022-06-20,2020-04-16,2023-10-05,['The incidence and change of endocrine dysfunction.'],"['Inflammatory markers evaluation.', 'Evaluation of the correlation between inflammatory markers and corticosteroid dose.', 'Progression Free Survival.', 'Change of Quality of life.', 'Cost change.']",,,,,1,Brazil,"Vanessa Scontre [São Paulo, Brazil]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of pre-medications of chemotherapy on endocrine dysfunction in breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04350398,Rehabilitation Through Hippotherapy for the Management of Women After Primary Treatment of Breast Cancer,Effect of Multidisciplinary Management by Hippotherapy on the Quality of Life of Women With a Diagnosis of Breast Cancer: Randomized Controlled Clinical Trial on the Effectiveness of the Therapeutic Intervention,COMPLETED,,Alliance Equiphoria,2017-04-20,2022-08-30,2022-08-30,2020-04-17,2022-10-03,['Change in Quality of life through EORTC QLQ-C30'],"['Changes in Body image representation through Body Image Scale (BIS)', 'Changes in Fatigue sensation through Multidimensional Fatigue Inventory (MFI-20)', 'Changes in anxiety and depression through Hospital Anxiety and Depression Scale (HADS)', 'Changes in the Cognitive sphere assessment through Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)']",,,,,1,France,"Institut Equiphoria [La Canourgue, France]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on the effectiveness of hippotherapy as a therapeutic intervention for women after breast cancer treatment, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04359420,What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol,What Are the Benefits and Harms of Risk Stratified Screening as Part of the NHS Breast Screening Programme: Study Protocol for a Multi-site Non-randomised Comparison of BC-Predict Versus Usual Screening,COMPLETED,,University of Manchester,2019-08-01,2021-12-28,2022-06-30,2020-04-24,2023-01-10,['Prescription of chemoprevention.'],"['Screening attendance at first offered screening episode', 'Screening attendance within 180 days', 'number of recalls', 'Number of breast cancer diagnoses', 'Uptake of consultation at Family History, Risk and Prevention clinics', 'Enrolment for more frequent screening', 'State anxiety', 'Cancer worry', 'Informed choices to attend screening or not']",,,,,1,United Kingdom,"Manchester University NHS Foundation Trust [Manchester, United Kingdom]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study protocol for screening methods and does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04363892,Combined Optical and Infrared Imaging for Early Prediction of Erythema During Breast and Chestwall Radiotherapy,A Prospective Cohort Clinical Trial to Assess the Skin Imaging Spectral and Morphological Changes During Breast Adjuvant Radiotherapy as an Early Predictor of Acute Skin Toxicities,TERMINATED,,Nova Scotia Health Authority,2020-07-01,2021-06-14,2021-06-14,2020-04-27,2024-08-21,"['Establish the correlation between optical and IR skin imaging and skin toxicity', 'Establish the correlation between optical and IR skin imaging and skin toxicity', 'Establish the correlation between optical and IR skin imaging and skin toxicity', 'Establish the correlation between optical and IR skin imaging and skin toxicity', 'Establish the correlation between optical and IR skin imaging and skin toxicity']","['Establish the correlation between optical and IR skin imaging and skin itchiness and pain.', 'Establish the correlation between optical and IR skin imaging and skin itchiness and pain.', 'Establish the correlation between optical and IR skin imaging and skin itchiness and pain.', 'Establish the correlation between optical and IR skin imaging and skin itchiness and pain.', 'Establish the correlation between optical and IR skin imaging and skin itchiness and pain.', 'Establish the correlation between optical and IR skin and Quality Of Life (QOL).', 'Establish the correlation between optical and IR skin and Quality Of Life (QOL).', 'Establish the correlation between optical and IR skin and Quality Of Life (QOL).', 'Establish the correlation between optical and IR skin and Quality Of Life (QOL).', 'Establish the correlation between optical and IR skin and Quality Of Life (QOL).']",,,,,1,Canada,"Dalhousie University - Radiation Oncology Department [Halifax, Canada]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT04367467,Effect of PARP Inhibitors on Glomerular Filtration Rate,Effect of PARP Inhibitors on Glomerular Filtration Rate,TERMINATED,,University of Pennsylvania,2020-02-03,2021-07-01,2021-07-01,2020-04-29,2022-01-26,"['Change in eGFR from Baseline to On-Treatment, 3-9 weeks after PARPi Initiation (Time Point B)']","['Within 4 Weeks of Post-discontinuation of PARPi (Time Point C) for patients with clinically significant changes in eGFR based on serum creatinine, cystatin C, or 24 hour urinalysis at Timepoint B']",,,,,1,United States,"University of Pennsylvania [Philadelphia, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the effects of PARP inhibitors on glomerular filtration rate, indicating a study on the extension of their indication related to renal function.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04368468,Modifications of Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative BC,Study of the Modifications of the Immune Microenvironment Induced by Neoadjuvant Chemotherapy in Triple-negative Breast Cancers,COMPLETED,,Institut Claudius Regaud,2020-06-15,2020-12-15,2021-01-31,2020-04-29,2022-12-23,"['Identify Change of immune ME by TILS quantification of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients', 'Identify Change of immune ME by PDL1 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients', 'Identify Change of immune ME by TIM3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients', 'Identify Change of immune ME by LAG3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients']","['Compare change ofTILs quantification of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like', 'Compare change of PDL1 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like', 'Compare change of TIM3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like', 'Compare change of LAG3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for pCR patients and those not pCR and for subtype basal-like or not basal-like', 'determination of predictive factors of TILs quantification for response to neoadjuvant chemotherapy and disease free survival', 'determination of predictive factors of PDL1 expression for response to neoadjuvant chemotherapy and disease free survival', 'determination of predictive factors of TIM3 for response to neoadjuvant chemotherapy and disease free survival', 'determination of predictive factors of LAG3 for response to neoadjuvant chemotherapy and disease free survival']",,,,,1,France,"Institut claudius regaud [Toulouse, France]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT04374825,Optimizing Quality of Life in Women Living With Metastatic Breast Cancer,"Optimizing Quality of Life in Women Living With Metastatic Breast Cancer: Feasibility and Preliminary Efficacy of a Tailored, eHealth Supportive Oncology Intervention",COMPLETED,,Northwestern University,2019-04-24,2021-03-08,2021-03-08,2020-05-05,2021-09-02,"['Change in health-related quality of life (HRQoL)', 'Change in wellbeing and disease symptom bother']","['Change in meaning and purpose in life and positive affect', 'Change in social support']",,,,,1,United States,"Northwestern University Feinberg School of Medicine [Chicago, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a supportive oncology intervention aimed at improving quality of life for women with metastatic breast cancer, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04379908,Healthy Lifestyles and Quality of Life in Women With Breast Cancer,Healthy Lifestyles and Quality of Life in Women With Breast Cancer (Health-EpiGEICAM),COMPLETED,,Spanish Breast Cancer Research Group,2017-11-07,2019-04-04,2019-04-04,2020-05-08,2023-03-15,"['Degree of adherence of breast cancer survivors to international guidelines regarding modifiable lifestyles by questionnaires', 'Quantify changes in modifiable lifestyles by questionnaires', 'Differences in adherence to recommendations of survivors of breast cancer', 'Estimate the health-related quality of life (HRQL) of these patients in all its dimensions and compare it with that observed in the general population and with the self-reported by these women at the time of diagnosis', 'Adherence effect to the WCRF, AICR and CECC4 recommendations on the HRQL', 'Compliance effect to the WCRF, AICR and CECC4 recommendations on survival of these women.']",[],,,,,18,Spain,"Hospital Mutua de Terrassa [Terrassa, Spain] | Consorci Sanitari de Terrassa [Terrassa, Spain] | Complejo Hospitalario Universitario A Coruña (CHUAC) [A Coruña, Spain] | Hospital Universitario Fundación Alcorcón [Alcorcón, Spain] | Centro Oncológico de Galicia [A Coruña, Spain] | Hospital General Universitario de Alicante [Alicante, Spain] | Hospital Universitario Virgen de los Lirios [Alicante, Spain] | Hospital Clinic i Provincial [Barcelona, Spain] | Hospital Universitario de Burgos [Burgos, Spain] | Hospital Puerta del Mar [Cadiz, Spain] | ICO de Girona, Hospital Dr. Josep Trueta [Girona, Spain] | Complejo Hospitalario de Jaén [Jaén, Spain] | Hospital Clínico San Carlos [Madrid, Spain] | Hospital Universitario Virgen del Rocío [Seville, Spain] | Hospital Universitario Virgen de la Salud [Toledo, Spain] | Instituto Valenciano de Oncología [Valencia, Spain] | Hospital Clinico Universitario de Valencia [Valencia, Spain] | Hospital Universitario Miguel Servet [Zaragoza, Spain]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on healthy lifestyles and quality of life in breast cancer survivors, focusing on adherence to guidelines and health-related quality of life, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04382352,B002 in Patients With HER2-positive Breast Cancer,"Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.",COMPLETED,PHASE1,"Shanghai Pharmaceuticals Holding Co., Ltd",2019-05-28,2022-04-26,2022-04-26,2020-05-11,2023-03-24,"['Maximum Tolerated Dose (MTD)', 'Dose-Limiting Toxicity (DLT)']","['Tmax', 'Cmax', 'AUC', 'Anti-drug antibody (ADA)', 'Objective Remission Rate (ORR)']",,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The text describes an experimental study on a new treatment (B002) for HER2-positive breast cancer, indicating it is a new medicine being tested for this specific condition.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04386629,Health Economy Register,Evaluation of CANKADO in Breast Cancer Patients in Germany,COMPLETED,,Cankado GmbH,2019-07-05,2020-12-31,2020-12-31,2020-05-13,2021-02-08,"['Occasion of consultation', 'Frequency of consultation', 'Duration of consultation']","['Quality of life (QoL): Quality of Life Questionnaire (FACT-B)', 'Estimate usage satisfaction of healthcare professionals: minutes', 'Age', 'Gender', 'Grade of education', 'Number of inhabitants in hometown', 'German home state', 'Location of treatment', 'Year of primary brest cancer diagnosis', 'Radiotherapy treatment of patient', 'Oral cancer treatment of patient', 'Treatment of patient with osteopretectics', 'Treatment of patient against high blood pressure', 'Treatment of patient against diabetes', 'Treatment of patient against asthma', 'employment status of patient']",,,,,10,Germany,"Hämato-onkologischer Studienkreis am Klinikum Aschaffenburg [Aschaffenburg, Germany] | Kliniken der Stadt Köln - Krankenhaus Holweide, Brustzentrum [Cologne, Germany] | Kliniken Essen Mitte [Essen, Germany] | Onkology Bethanien Frankfurt [Frankfurt, Germany] | Mammazentrum Hamburg Am Krankenhaus Jerusalem [Hamburg, Germany] | University Hospital [Mainz, Germany] | University Hospital [Mannheim, Germany] | University Hospital [München, Germany] | Johanna Etienne Krankenhaus [Neuss, Germany] | Praxisnetzwerk Hämatologie/ intern. Onkologie [Troisdorf, Germany]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses an evaluation of a health economy register related to the use of CANKADO in breast cancer patients, but does not indicate a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT04390698,Opioid Free Anesthesia in Breast Cancer Surgery,Opioid Free Anesthesia in Breast Cancer Surgery: a Prospective Randomized Study,COMPLETED,,Peking University People's Hospital,2020-07-01,2021-03-15,2022-03-15,2020-05-15,2022-04-05,['quality of recovery'],"['health related quality of life', 'postoperative pain', 'cancer recurrence and metastasis']",,,,,1,China,"Peking University People's Hospital [Beijing, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04400552,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients,Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients- A Randomized Controlled Trial,COMPLETED,,"IMU University, Malaysia",2018-12-26,2021-06-30,2021-06-30,2020-05-22,2021-08-25,"['Change in body weight', 'Change in body mass index (BMI)', 'Change in serum albumin level', 'Change in serum pre-albumin level']","['Change in handgrip force', 'Change in muscle mass', 'Change in fat mass', 'Change in serum transferrin level', 'Change in hemoglobin level', 'Change in high sensitivity c-reactive protein (HsCRP) level', 'Change in Interleukin-6 (IL-6)', 'Change in salivary cortisol level', 'Change in energy intake', 'Change in protein intake', 'Change in Pittsburgh Sleep Quality Index (PSQI) scores', 'Presence of post-surgical complications', 'Length of hospital stay']",,,,,1,Malaysia,"International Medical University [Kuala Lumpur, Malaysia]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a randomized controlled trial on perioperative oral nutrition supplementation in malnourished surgical cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04408560,Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer,Evaluation of the Efficacy of a Homeopathic Protocol to Reduce the Onset or Aggravation of Joint Pain or Stiffness Following the Taking of Anti-aromatases (AI) in Patients With Non-metastatic Breast Cancer,COMPLETED,,Institut Jean-Godinot,2018-09-13,2021-08-27,2022-03-23,2020-05-29,2022-09-19,"['Evolution of the score of ""most intense pain"" during the first 3 months of treatment with AI']","['Evolution of joint pain', 'Rate of onset of joint pain and stiffness', 'Rate of onset of pain and joint stiffness', 'Time of onset or aggravation of pain']",,,,,1,France,"Philippe GUILBERT [Reims, France]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the efficacy of a homeopathic protocol in patients already receiving anti-aromatase treatment for non-metastatic breast cancer, indicating an extension of indication for the homeopathic protocol in this specific patient population.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04411966,Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer,Integrating 18F-FDG PET/CT With 18F-FLT PET/CT in Predicting Treatment Response and Prognosis of Metastatic/Recurrent Breast Cancer,COMPLETED,,Chang Gung Memorial Hospital,2014-01-01,2017-08-30,2019-05-30,2020-06-02,2020-06-02,['Change in 18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) maximal standardized uptake value (SUV) as response to therapy'],['Compare Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) and European Organization for Research and Treatment of Cancer (EORCT) response by 18F-FLT-PET and 18F-FDG-PET for the prediction of anatomic treatment response'],,,,,0,,,2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2019.0,6.0,0,NA/Other
NCT04430842,"Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S","A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma",COMPLETED,PHASE1,"Quadriga Biosciences, Inc.",2020-07-20,2022-09-21,2022-12-22,2020-06-12,2023-01-18,['Determination of maximum tolerated dose (MTD)'],"['Safety and tolerability assessed by adverse events and serious adverse events', 'Peak Plasma Concentration (Cmax)', 'Area under the plasma concentration versus time curve (AUC) of QBS10072S', 'Half-life of QBS10072S in plasma (t1/2)', 'Time to maximum concentration of QBS10072S in plasma (Tmax)']",,,,,2,Australia,"St George Private Hospital [Kogarah, Australia] | Sydney Southwest Private Hospital [Liverpool, Australia]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing a new drug (QBS10072S) in patients with specific types of cancer, indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04436393,Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer,Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer,COMPLETED,,"Guardant Health, Inc.",2020-07-02,2022-03-17,2022-03-17,2020-06-18,2022-06-22,"['Overall Survival', 'Progression Events', 'Subject Lost-to-Follow-Up']","['Rate of biomarker discovery', 'Time to Next Treatment', 'Real-world Time to Tumor Progression', 'Real-world Overall Survival', 'Demographics']",,,,,1,United States,"Guardant Health [Redwood City, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses clinical outcomes related to the use of Guardant360® in breast cancer patients but does not indicate a new medicine or an extension of indication for an existing medicine.,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT04440995,The Effects of Perioperative PECS Block During Robotic Breast Surgery and Breast Reconstruction,The Effects of Perioperative PECS Block on Postoperative Pain Control During Robotic Breast Surgery and Breast Reconstruction - Double Blind Randomized Controlled Trial -,COMPLETED,,Yonsei University,2020-07-08,2021-10-10,2021-10-10,2020-06-22,2021-11-17,['Total dose of fentanyl consumption during the postoperative 24h'],"['a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at rest', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement', 'a numeric rating score at movement']",,,,,1,South Korea,"Yonsei Severance Hospital [Seoul, South Korea]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial focuses on the effects of a specific anesthetic technique (PECS block) during surgery, rather than testing a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04444427,Evaluation of GLR2007 for Advanced Solid Tumors,"An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors",COMPLETED,PHASE1; PHASE2,"Gan and Lee Pharmaceuticals, USA",2020-07-15,2022-07-29,2022-07-29,2020-06-23,2022-12-23,"['Dose Escalation: Dose-limiting Toxicities', 'Dose Escalation: Incidence And Severity Of Adverse Events, Including The Incidence Of Dose-limiting Toxicities Within The First Cycle', 'Dose Expansion: Incidence And Severity Of Adverse Events']","['Dose Escalation: Objective Response Rate', 'Dose Expansion: Objective Response Rate', 'Dose Escalation And Expansion: Maximum Observed Plasma Concentration After Single And Multiple Oral Dose Administrations', 'Dose Escalation And Expansion: Time At Which Maximum Plasma Concentration Is Observed And Apparent Half-life After Single And Multiple Oral Dose Administrations', 'Dose Escalation And Expansion: Area Under The Plasma Concentration-time Curve From 0 To Last Measurable Concentration And From 0 To Infinity After Single And Multiple Oral Dose Administrations', 'Dose Escalation And Expansion: Accumulation Ratio After Single And Multiple Oral Dose Administrations', 'Dose Escalation And Expansion: Steady-state Volume Of Distribution After Single And Multiple Oral Dose Administrations', 'Dose Escalation And Expansion: Clearance After Single And Multiple Oral Dose Administrations']",,,,,4,United States,"USA002 [Lafayette, United States] | USA005 [Omaha, United States] | USA001 [Philadelphia, United States] | USA004 [Dallas, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT04444882,"Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care","Complications After Lumpectomy, Sentinel Node and Radiotherapy in Breast Cancer Patients and Physiotherapy Care",COMPLETED,,"University Hospital, Grenoble",2021-06-01,2022-01-28,2022-01-28,2020-06-24,2022-08-09,"['Inventory of the physiotherapeutic care of patients who have undergone lumpectomy, sentinel node and radiotherapy treatment']","['Description of the post-operative complications of patients who have undergone lumpectomy, sentinel node and radiotherapy treatment']",,,,,1,France,"Chu Grenoble Alpes [Grenoble, France]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses complications and physiotherapy care related to existing treatments for breast cancer, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04454086,Exercise and Diet Counseling Program in Improving Quality of Life in Stage I-III Breast Cancer Survivors,Healthy New Albany: Breast Cancer Project,COMPLETED,,Ohio State University Comprehensive Cancer Center,2019-03-06,2021-07-27,2021-07-27,2020-07-01,2024-04-02,['Mobility disability'],"['Self-reported physical function', 'Objective functional performance', 'Balance deficits assessment', 'Muscular strength assessement', 'Body composition', 'Body weight', 'Quality of life (QOL) surveys using the Rand Short Form Health Survey (SF-12)', 'Quality of life (QOL) survey using the Functional Assessment of Cancer Therapy- breast (FACT-B).', 'Brief Fatigue Inventory (BFI)', 'Adherence assessment', 'Feasibility measures']",,,,,1,United States,"Ohio State University Comprehensive Cancer Center [Columbus, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a counseling program focused on exercise and diet for breast cancer survivors, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04456140,"Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study",Inherit - A Trial of Pro-Active Genetic Testing in Cancer Patients at St. Vincent's Mayo Clinic Embedded Cancer Center,COMPLETED,PHASE1,Mayo Clinic,2020-06-29,2021-09-21,2021-09-21,2020-07-02,2023-07-24,"['Prevalence of pathogenic germline mutations', 'Difference between prevalence of positive pathogenic germline mutations', 'Rate of mutation detection', ""Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families"", ""Incidence rate of germline pathogenic genetic mutations in cancer patients seen at St Vincent's and uptake rate of cascade testing in families""]",['Differences in survey responses between patient groups'],,,,,2,United States,"Mayo Clinic in Arizona [Scottsdale, United States] | Mayo Clinic in Florida [Jacksonville, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial text focuses on genetic testing and the prevalence of mutations in cancer patients rather than testing a new medicine or extending the indication of an existing medicine.,OTHER,False,2021.0,4.0,0,Phase 1
NCT04460430,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer,TERMINATED,PHASE2,SOLTI Breast Cancer Research Group,2020-07-23,2021-11-29,2021-11-29,2020-07-07,2022-10-25,['Progression-Free survival PFS6 (Efficacy)'],"['Clinical Benefit Rate at 6 months (CBR6)', 'Overall Response rate (ORR)', 'Progression free survival (PFS)', 'Duration of response (DoR)', 'Time to response (TtR)', 'Incidence, duration and severity of Adverse Events (AEs)']",,,,,15,Portugal; Spain,"IPO Lisboa [Lisbon, Portugal] | Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE [Porto, Portugal] | H. Clínico San Cecilio de Granada [Granada, Spain] | ICO Badalona [Badalona, Spain] | Hospital Clínic de Barcelona [Barcelona, Spain] | Hospital General de Catalunya [Barcelona, Spain] | Hospital Universitari Vall d' Hebron [Barcelona, Spain] | Hospital Marina Salud de Denia [Denia, Spain] | Complejo Hospitalario de Jaén [Jaén, Spain] | Hospital Universitari Arnau de Vilanova de Lleida [Lleida, Spain] | Hospital Universitario 12 de octubre [Madrid, Spain] | Hospital Universitario Ramon y Cajal [Madrid, Spain] | Hospital Son Llatzer [Palma de Mallorca, Spain] | Hospital Universitario Virgen del Rocio [Seville, Spain] | Hospital Virgen de Macarena [Seville, Spain]",2020.0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text indicates the use of Neratinib in a specific patient population (HR-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer), suggesting it is an extension of indication for an existing drug rather than a new medicine.",OTHER,False,2021.0,4.0,1,Phase 2
NCT04473378,Glucose Monitoring During Chemotherapy,Pilot Study of Glucose Monitoring to Determine Rates of Hyperglycemia During Chemotherapy for Early Stage Breast Cancer,COMPLETED,,Columbia University,2019-10-31,2022-08-01,2022-08-17,2020-07-16,2025-01-10,['Prevalence of hyperglycemia'],"['Prevalence of impaired glucose tolerance at baseline in nondiabetic patients.', 'Patient-Reported Outcomes Measurement Information System (PROMIS)-29']",,,,,1,United States,"Herbert Irving Pavilion [New York, United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial text focuses on glucose monitoring during chemotherapy and does not indicate the testing of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04477616,Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy,Injection Regimen Trial of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in Preventing Bone Marrow Suppression and/or Febrile Neutropenia (FN) During Breast Cancer Chemotherapy,COMPLETED,PHASE2,The First Affiliated Hospital with Nanjing Medical University,2021-07-13,2022-10-06,2022-11-06,2020-07-20,2023-02-23,"['the rates of grade III/IV neutropenia during the first and second chemotherapy cycle', 'the rates of FN during the first and second chemotherapy cycle']","['Proportion of patients with down-regulated dosage of PEG-rhG-CSF from 6mg to 3mg', 'Adverse reactions after injection of PEG-rhG-CSF during first and second chemotherapy cycle']",,,,,1,China,"the First Affiliated Hospital of Nanjing Medical University [Nanjing, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is evaluating the use of PEG-rhG-CSF in a new context (breast cancer chemotherapy) to prevent bone marrow suppression and febrile neutropenia, indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04478669,Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer,Optimal Imaging Methods to Reduce Repeat Surgery in Invasive Breast Cancer,COMPLETED,,Aarhus University Hospital,2020-09-17,2022-02-15,2022-02-15,2020-07-21,2022-02-17,"['Positive resection margin(s) in the final histopathology', 'Re-excision-rate during primary breast conserving surgery', 'Rate of repeat surgery']","['Diagnostic performance of the tested method to predict correct resection margins status.', 'Weight of the re-excised breast tumor during initial breast conserving surgery', 'Type of repeat surgery (both secondary and if any tertiar surgery)']",,,,,1,Denmark,"Department og Plastic- and Breast Surgery [Aarhus, Denmark]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses imaging methods and assessment techniques for breast cancer surgery rather than introducing a new medicine or extending the indication of an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04481230,"Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer","Assessment of 99mTc-NTP 15-5 Uptake on Cartilage, a New Proteoglycan Tracer: Phase I Clinical Trial",COMPLETED,EARLY_PHASE1,Centre Jean Perrin,2020-11-12,2022-07-28,2022-09-19,2020-07-22,2024-10-01,"['determination of the recommended dose of 99mTc-NTP 15-5 to obtain the best tracer joints contrast on images without any toxicity', 'dose-limiting toxicity (DLT)']","['3D quantification analysis', 'Safety of 99mTc-NTP 15-5 (frequence of adverse events)', 'Biodistribution of 99mTc-NTP 15-5', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Area Under the Curve (AUC)', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of Maximum Concentration (Cmax)', 'Pharmacokinetics of 99mTc-NTP 15-5 by assessment of the time take to reach Cmax (Tmax)', 'Urinary elimination of 99mTc-NTP 15-5', 'Dosimetry']",,,,,2,France,"Centre Jean Perrin [Clermont-Ferrand, France] | CHU Clermont-Ferrand [Clermont-Ferrand, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,Phase 1
NCT04496492,Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.,Preoperative Use of Tocotrienol Associated With Personalized Nutritional and Psychoeducational Support in Women With Primary Breast Cancer.,COMPLETED,PHASE2,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",2016-02-09,2016-02-09,2017-07-06,2020-08-03,2020-08-03,"['Changes in blood oxidant capacity', 'Changes in blood antioxidant capacity', 'Absolute and relative changes in peripheral blood mononuclear cells obtained before and after four weeks of tocotrienol treatment, as detected by 13-colors citofluorimetry analysis', ""Changes of immune-related miRNA levels in patients' serum samples obtained before and after four weeks of tocotrienol treatment, as determined by quantitative real-time PCR analysis"", 'Changes in immune response associated gene levels in preoperative tissue tumor biopsies and in surgical specimens, obtained before and after four weeks of tocotrienol treatment, respectively, as determined by gene expression profiling analysis', 'Changes in serum inflammatory cytokines and growth factor']","['Treatment-induced changes in proliferation/apoptosis, anti-inflammatory and anti-oxidant activity of breast cancer cell lines', 'Changes in expression of tumor proliferation, hormone receptors and HER2']",,,,,1,Italy,"Fondazione IRCCS Istituto Nazionale Tumori [Milan, Italy]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial investigates the use of tocotrienol, a compound derived from annatto, in breast cancer patients, indicating it is a new medicine being tested for a specific condition.",OTHER,False,2017.0,8.0,0,Phase 2
NCT04498481,TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.,TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB PLUS AROMATASE INHIBITOR OR PALBOCICLIB PLUS FULVESTRANT AS TREATMENT OF HORMONE RECEPTOR POSITIVE (HR+)/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN A REAL WORLD COMMUNITY ONCOLOGY SETTING,COMPLETED,,Pfizer,2018-03-01,2018-07-01,2018-07-01,2020-08-04,2020-08-04,"['Proportion of patients receiving various cancer treatment regimens', 'Proportion of patients receiving each therapy sequence across lines', 'Treatment persistence', 'Progression Free Survival (PFS)', 'Overall Survival (OS)', 'Tumor response rate', 'Proportion of patients that experience dose adjustment', 'Proportion of patients who discontinue therapy']",[],,,,,1,United States,"Pfizer United States [New York, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The text discusses the use of Palbociclib in combination with other treatments for a specific type of breast cancer, indicating an extension of its indication to include new treatment combinations for HR+/HER2- advanced or metastatic breast cancer.",INDUSTRY,False,2018.0,7.0,0,NA/Other
NCT04498611,Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy,Prediction of Upgrade to Invasive Cancer in Patients Diagnosed With Ductal Carcinoma in Situ by Percutaneous Core Needle Biopsy: A Development and Validation Study,COMPLETED,,Seoul National University Hospital,2020-07-13,2021-04-30,2021-08-15,2020-08-04,2022-03-14,['Comparing of Preoperative MRI and Postoperative histopathologic results'],['Comparing the predicted upstaging rate through the MRI and histopathologic results'],,,,,1,South Korea,"Seoul National University Hospital [Seoul, South Korea]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study related to predicting cancer progression and does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT04509284,Analgesic Effect of Resistance Training for Breast Cancer Survivors,Effect of Resistance Training of Persistent Pain After Breast Cancer,COMPLETED,,Aalborg University,2020-08-10,2021-09-23,2021-09-23,2020-08-12,2022-01-12,"['Change in pain sensitivity, assessed through pressure pain thresholds.', 'Change in pain intensity, assessed through a 11 point numeric rating scale (0 = no pain, 10 = worst pain imaginable).']","['Muscular strength assesses through a 1 repetition maximum (1RM)', 'Active shoulder range of motion assessed with a universal goniometer.', 'Body composition assessed through bioelectrical impedance measurements.', 'Arm circumference measured bilaterally at a single point 30cm above the styloid process.', 'Physical activity level assessed through the international physical activity questionnaire (IPAQ).', 'Health related quality of life assessed through the European Organisation for Research and Treatment of Cancer (EORCT)-C30 quality of life questionaire', 'Quality of life assessed through the breast cancer specific European Organisation for Research and Treatment of Cancer (EORCT)-BR23 quality of life questionaire', 'Cancer fatigue assessed through the Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue scale.', 'Mental health assessed through the Major Depression Index (MDI)']",,,,,1,Denmark,"Department of Health Science and Technology, Aalborg University [Aalborg, Denmark]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of resistance training on pain and quality of life in breast cancer survivors, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04509596,"DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer","A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD1516 in Combination With Trastuzumab and Capecitabine, or DZD1516 in Combination With T-DM1, in Patients With Metastatic HER2 Positive (HER2+) Breast Cancer",COMPLETED,PHASE1,Dizal Pharmaceuticals,2020-09-21,2022-07-07,2022-07-07,2020-08-12,2025-04-01,"['Incidence of adverse events (AEs) and serious adverse events (SAEs)', 'Incidence of dose limiting toxicities (DLTs)', 'To define maximum tolerated dose (MTD) of DZD1516 if possible (Part A only)', 'To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with trastuzumab and capecitabine (Part B only)', 'To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with T-DM1 (Part C only)']","['Drug concentrations of DZD1516 and its metabolite DZ2678 in plasma, urine and CSF', 'Maximum plasma concentration (Cmax) of DZD1516 and its metabolite DZ2678', 'Area under the plasma concentration-time curve (AUC) of DZD1516 and its metabolite DZ2678', 'Plasma concentration of capecitabine and metabolites 5-FU (Part B only)', 'Plasma Cmax of capecitabine and 5-FU (Part B only)', 'Plasma AUC of capecitabine and 5-FU (Part B only)', 'Plasma concentration of DM1 (Part C only)', 'Objective Response Rate (ORR)', 'Disease Control Rate (DCR)', 'Duration of Response (DoR)', 'Progression free survival (PFS) (Part B and Part C on)', 'Overall survival (for patients with leptomeningeal metastasis in Part B and Part C only)']",,,,,3,China; United States,"UCLA Hematology/Oncology Parkside [Santa Monica, United States] | Zhejiang Cancer Hospital [Hangzhou, China] | Cancer Hospital, Fudan University [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 1
NCT04515888,Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer,Evaluation of the Prevalence of Pelvic Static Disorders in Women Treated for Localized Breast Cancer During Adjuvant Hormone Therapy.,COMPLETED,,Institut du Cancer de Montpellier - Val d'Aurelle,2020-09-18,2021-02-12,2021-07-06,2020-08-17,2021-11-04,['Evaluate the prevalence of pelvic static disorders in patients treated for localized breast cancer and undergoing adjuvant hormone therapy (Hormontherapy +).'],"['Evaluate the prevalence of pelvic static disorders in patients (hormonotherapy -)', 'Compare the prevalence of Pelvic static disorders between the 2 groups Hormonotherapy - /Hormonotherapy +', 'Evaluate the impact of pelvic static disorders on quality of life', 'Estimate pelvic symptoms in the hormone therapy (Hormonotherapy +) / Non hormone therapy (Hormonotherapy -) groups', 'Evaluate the correlation between hormone therapy and pelvic static disorders', 'Research the risk factors for pelvic static disorders']",,,,,1,France,"Icm Val D'Aurelle [Montpellier, France]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT04517305,Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients,Pyrotinib Plus Vinorelbine in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study,COMPLETED,,Fudan University,2018-05-15,2021-05-15,2021-05-15,2020-08-18,2021-06-18,"['PFS', 'Adverse events']",[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text indicates a study involving Pyrotinib, which is already an approved treatment, in combination with Vinorelbine for a specific patient population (HER2+ metastatic breast cancer), suggesting an extension of indication for the use of Pyrotinib.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04517318,Treatment After Palbociclib-containing Regimens,A Multi-center Study of the Treatment Patterns and Clinical Outcomes of Subsequent Therapies After Progression on Palbociclib in HR+/HER2- Metastatic Breast Cancer,COMPLETED,,Fudan University,2017-08-15,2021-04-15,2021-07-15,2020-08-18,2021-08-03,"['PFS', 'Adverse events']",[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial focuses on treatment patterns and outcomes after progression on a specific existing therapy (Palbociclib) in a defined patient population, indicating an extension of indication for subsequent therapies.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04522557,Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction,Type I Interferon Alfa-2a in Postmastectomy Breast Reconstruction,COMPLETED,PHASE1,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2020-08-06,2021-07-14,2021-07-14,2020-08-21,2022-02-09,"['Dose-limiting toxicity (DLT)', 'Maximal tolerable dose (MTD)']","['Adverse events (AE)', 'Server adverse events (SAE)']",,,,,1,China,"Shicheng Su [Guangzhou, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Type I Interferon Alfa-2a in a specific context (postmastectomy breast reconstruction), indicating an extension of its indication rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 1
NCT04541225,Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors,"Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",TERMINATED,PHASE1,Nuvation Bio Inc.,2020-12-08,2022-08-31,2022-08-31,2020-09-09,2023-07-14,['Phase 1 Dose Escalation: Safety and tolerability of NUV-422 to determine the recommended Phase 2 dose (RP2D)'],[],,,,,12,United States,"Arizona Oncology Associates [Tucson, United States] | Miami Cancer Institute [Miami, United States] | Dana-Farber Cancer Institute [Boston, United States] | Memorial Sloan Kettering Cancer Center [New York, United States] | Carolina BioOncology Institute [Huntersville, United States] | Prisma Health Cancer Institute [Greenville, United States] | Texas Oncology P.A. Austin [Austin, United States] | Texas Oncology-Baylor Charles A. Sammons Cancer Center [Dallas, United States] | The University of Texas MD Anderson Cancer Center [Houston, United States] | Texas Oncology [Tyler, United States] | University of Utah Huntsman Cancer Institute [Salt Lake City, United States] | Virginia Cancer Specialists [Fairfax, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04541420,Eribulin in mTNBC Patients,"An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer",COMPLETED,,Fudan University,2019-12-15,2020-12-15,2020-12-20,2020-09-09,2021-02-03,"['PFS', 'Adverse events']",[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2019.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of Eribulin in a specific patient population (mTNBC) for advanced breast cancer, indicating an extension of its indication rather than introducing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04541537,Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer. (KDOGCOV),Feasibility Study on the Possibility of Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer,COMPLETED,,Institut Curie,2021-01-25,2021-12-09,2021-12-20,2020-09-09,2025-09-22,['To ascertain the possibilities to isolate the breast cancer olfactive signature'],"['Ascertain breast cancer olfactive signature from the tumor (Isolation of volatile Organic Compounds to tumor breast samples by a sensitive technique with an odor-sensing polymer (Sorbstar®)', 'Ascertain breast cancer detection by the dogs of Curie Institut']",,,,,1,France,"Institut Curie [Paris, France]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a feasibility study on isolating volatile organic compounds related to breast cancer detection, but it does not indicate the development of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04543851,CARA Treatment Pilot Study for Breast Positioning,CARA Treatment Pilot Study for Breast Positioning,COMPLETED,,British Columbia Cancer Agency,2018-10-08,2019-11-04,2019-11-18,2020-09-10,2020-09-10,"['Number of participants for whom dose volume treatment planning constraints are not met using CARA support for breast setup', 'Number of participants having measured breast skin dose => 110% of the prescribed dose to an area of skin => 1 cm^2', 'Number of participants scoring =>6 on the CTCAE Version 4.0 skin assessment']","['Workflow measures', 'Setup reproducability', 'Doses to organs at risk comparison with standard of care', 'Skin assessment versus skin dose', 'Patient Reported outcome - skin reaction']",,,,,1,Canada,"BC Cancer [Vancouver, Canada]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the use of CARA support for breast positioning, which suggests an extension of indication for an existing treatment rather than the introduction of a new medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04549584,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer,Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer,TERMINATED,,Seoul National University Hospital,2020-10-01,2020-12-16,2020-12-16,2020-09-16,2020-12-17,['response rate of neoadjuvant chemotherapy'],[],,,,,1,South Korea,"Seoul National University Hospital [Seoul, South Korea]",2020.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT04554056,Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF,"A Phase II/III,Multi-Center,Randomized,Double-blind,Active-Controlled Trial to Compare the Efficacy , Safety and Immunogenicity of MW05 and PEG-rhG-CSF in Prophylactic Treatment for Chemotherapy-Induced Neutropenia",COMPLETED,PHASE2; PHASE3,"Mabwell (Shanghai) Bioscience Co., Ltd.",2020-09-21,2022-08-20,2022-11-05,2020-09-18,2022-12-02,['The primary objective of this study will be to evaluate the efficacy of MW05 pre-filled syringe as compared to PEG-rhG-CSF standard dosing (6 mg) in the first chemotherapy cycle.'],"['The duration of grade 4 neutropenia in cycle 2~4 assessed by ANC（ANC < 0.5 × 109/L）', 'The incidence of grade 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 0.5 × 109/L）', 'The incidence of grade 3 or 4 neutropenia in cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）', 'The duration of grade 3 or 4 neutropenia In cycle 1~4 assessed by ANC（ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively）', 'Incidence of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)', 'The proportion of subjects rescued by short-acting G-CSF in cycle 1~4.']",,,,,1,China,"Fudan University Affiliated Cancer Hospital [Shanghai, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is comparing a new treatment (MW05) against an existing standard (PEG-rhG-CSF) for a specific condition (chemotherapy-induced neutropenia), indicating that MW05 is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT04555902,Evaluation of Mailers Promoting Mammogram Screening,Evaluation of Postcard Mailers Enhanced With Behavioral Nudges to Promote Mammogram Screening,COMPLETED,,Geisinger Clinic,2020-10-02,2021-10-05,2021-10-05,2020-09-21,2021-11-15,['Mammogram Completion at 6 months (2020)'],"['Mammogram Completion at 12 months (2020)', 'Primary Care Provider Visits at 6 months (2020)', 'Primary Care Provider Visits at 12 months (2020)', 'Obstetrician-Gynecologist Visits at 6 months (2020)', 'Obstetrician-Gynecologist Visits at 12 months (2020)', 'Breast Cancer Diagnosis at 6 months (2020)', 'Breast Cancer Diagnosis at 12 months (2020)', 'Emergency Department Visits at 6 months (2020)', 'Emergency Department Visits at 12 months (2020)']",,,,,1,United States,"Geisinger [Danville, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses an evaluation of mailers promoting mammogram screening, which does not pertain to a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04565600,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib,Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib for Breast Cancer Patients: A Phase II Randomized Trial,COMPLETED,PHASE2,Guangdong Provincial People's Hospital,2020-03-01,2021-04-22,2021-06-28,2020-09-25,2022-02-14,['overall incidence of taxane-associated acute pain syndrome across all cycles of chemotherapy'],"['incidence of taxane-associated acute pain syndrome at each cycle', 'severity of taxane-associated acute pain syndrome at each cycle', 'duration of taxane-associated acute pain syndrome at each cycle', 'incidence of severe taxane-associated acute pain syndrome by cycle and across all cycles', 'Functional Assessment of Cancer Therapy-Breast (FACT-B) subscale at each cycle', 'incidence of peripheral neuropathy after all cycles of chemotherapy', 'adverse events']",,,,,1,China,"Guangdong General Hospital [Guangzhou, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial is investigating the use of Etoricoxib, which is an existing medication, for a new indication (prevention of taxane-associated acute pain syndrome in breast cancer patients).",OTHER,False,2021.0,4.0,0,Phase 2
NCT04566458,RWD Study in HER2+ mBC Patients in Third-Line Therapy,Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy,COMPLETED,,Exactis Innovation,2020-10-01,2021-05-30,2021-05-30,2020-09-28,2021-10-07,"['To describe treatment sequences of all lines of therapy received by HER2 + mBC patients in Canada', 'To describe the brain metastatic HER2+ mBC subpopulation during third line', 'To describe radiation therapies received for brain metastasis in HER2+ mBC during third line.', 'To calculate the median overall survival (OS) of HER2+ mBC patients who received third-line therapy in Canada.', 'To calculate the median PFS of HER2+ mBC patients receiving third-line therapy in Canada', 'To calculate the median time to next active anticancer treatment of HER2+ mBC patients receiving third-line therapy in Canada', 'To assess HRU for HER2+ mBC patients in Canada during third-line therapy.']",[],,,,,8,Canada,"Centre hospitalier universitaire Dr-Georges-L.-Dumont [Moncton, Canada] | The Moncton Hospital [Moncton, Canada] | The Ottawa Hospital [Ottawa, Canada] | Sunnybrook Health Center [Toronto, Canada] | CHUM- Centre hospitalier de l'universite de Montreal [Montreal, Canada] | Jewish General Hospital [Montreal, Canada] | CHUQ- Centre hospitalier universitaire de Québec [Québec, Canada] | CHUS-CIUSSS de l'Estrie - CHUS - Hôtel-Dieu and CHUS - Hôpital Fleurimont [Sherbrooke, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,"The text describes a real-world data study focusing on treatment sequences and outcomes for HER2+ metastatic breast cancer patients in third-line therapy, but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04574323,Effects of a Paleolithic Lifestyle Intervention in Breast Cancer Patients Undergoing Radiotherapy,Short-term Effects of a Paleolithic Lifestyle Intervention in Breast Cancer Patients Undergoing Radiotherapy: A Pilot and Feasibility Study,COMPLETED,,MVZ Leopoldina GmbH,2020-03-19,2020-06-13,2020-07-16,2020-10-05,2020-12-04,"['Dropout rate in the Paleolithic lifestyle intervention group', 'Longitudinal body composition changes', 'Change in vitamin D levels']",['Change in beta-hydroxybutyrate levels'],,,,,1,Germany,"Leopoldina Hospital Schweinfurt, Department of Radiotherapy and Radiation Oncology [Schweinfurt, Germany]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a lifestyle intervention (Paleolithic lifestyle) in breast cancer patients undergoing radiotherapy, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04586751,The Impact of Pecs Blocks on Postmastectomy Pain Syndrome,The Impact of Pecs Blocks on the Appearance of Post Mastectomy Chronic Pain Symptoms,COMPLETED,,Aretaieion University Hospital,2020-08-01,2022-03-31,2022-03-31,2020-10-14,2023-02-08,"['pain score 6 hours postoperatively', 'pain score 12 hours postoperatively', 'pain score 24 hours postoperatively']","['incidence of chronic pain', 'incidence of chronic pain', 'time of first request for analgesia', 'analgesic consumption in mg of morphine', 'satisfaction from postoperative analgesia', 'Pecs block related complications']",,,,,3,Cyprus; Greece,"General Hospital of Limassol [Limassol, Cyprus] | General Hospital of Nicosia [Nicosia, Cyprus] | Aretaieion University Hospital [Athens, Greece]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the impact of Pecs blocks on postmastectomy pain but does not introduce a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,1,NA/Other
NCT04592484,"A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors","A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma",COMPLETED,PHASE1; PHASE2,Codiak BioSciences,2020-09-15,2022-08-03,2022-12-23,2020-10-19,2023-02-08,['To determine the safety and tolerability of ascending doses of CDK-002'],[],,,,,8,United Kingdom; United States,"Honor Health [Scottsdale, United States] | Columbia University/CUMC [New York, United States] | University of Pennsylvania [Philadelphia, United States] | NEXT Oncology [San Antonio, United States] | The Beatson West of Scotland Cancer Centre/ Gartnavel General Hospital [Glasgow, United Kingdom] | Oxford University Hospitals NHS Trust [Headington, United Kingdom] | The Royal Marsden Hospital [London, United Kingdom] | The Christie NHS Foundation Trust [Manchester, United Kingdom]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,1,Phase 2
NCT04606147,Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy,"Comparison of Effectiveness of Ultrasound Guided Erector Spinae Plane Block With Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy, Randomized Single Blinded Comparative Study.",COMPLETED,,"National Cancer Institute, Egypt",2020-01-10,2020-05-20,2020-05-20,2020-10-28,2020-10-28,['Total amount of postoperative morphine consumption in 24 hours. (mg)'],"['Total amount of intraoperative fentanyl consumption (mcg)', 'Change in heart rate intraoperatively', 'The degree of postoperative sedation according to Ramsay scores.', 'Time to first rescue analgesia (hours)', 'Numeric Pain Rating Scale score, both at rest and during movement', 'Block related complications', 'Patient satisfaction', 'Change in mean arterial blood pressure intraoperatively']",,,,,1,Egypt,"National Cancer Institute - Cairo University [Cairo, Egypt]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses a comparison of two existing techniques (Erector Spinae Plane Block and Serratus Anterior Block) for pain management in a specific surgical procedure, rather than testing a new medicine or extending the indication of an existing one.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04618120,Virtual Reality-based Exercise Training in Radiotherapy Period After Breast Cancer Surgery,Comparison of Exercise Practices With Virtual Reality-based Exercise Training in Radiotherapy Period After Breast Cancer Surgery,COMPLETED,,Gazi University,2017-05-22,2019-01-02,2019-03-02,2020-11-05,2020-11-05,"['Change in the shoulder range of motion', 'Change in the grip strength assessed by hydraulic hand dynamometer', 'Change in the shoulder proprioception assessed by isokinetic dynamometer', 'Change in circumference of upper extremities', 'Change in the functionality of upper extremities assessed by the Disability of Arm, Shoulder and Hand Questionnaire', 'Change in kinesiophobia assessed by theTampa Kinesiophobia Scale', 'Change in anxiety and depression level assessed by the Hospital Anxiety and Depression Scale', 'Change in fatigue assessed by Piper Fatigue Scale', 'Change in quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)']",['Patient Satisfaction'],,,,,1,Turkey (Türkiye),"Gazi University Faculty of Health Sciences [Ankara, Turkey (Türkiye)]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on the effects of virtual reality-based exercise training in patients after breast cancer surgery, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT04626895,Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers,Measuring the Efficacy of Paxman Scalp Cooling to Prevent Chemotherapy Induced Alopecia (CIA) in Black Patients With Stage I-III Breast or Gynecological Cancers,COMPLETED,,Medstar Health Research Institute,2019-06-04,2020-08-31,2020-10-01,2020-11-13,2020-11-13,['Patient reported rate of alopecia rate of alopecia'],"['Psychosocial assessments of chemotherapy-induced alopecia', 'Quality of life assessments of chemotherapy-induced alopecia']",,,,,1,United States,"MedStar Washington Hospital Center [Washington D.C., United States]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2020.0,5.0,0,NA/Other
NCT04630327,Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory,Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory Among Female Cancer Patients,COMPLETED,,Kazakh Medical University of Continuing Education,2020-01-13,2022-04-28,2022-05-01,2020-11-16,2022-06-21,"['BDI-II Score at Baseline:', 'BDI-II Score on day 14', 'BAI Score at Baseline', 'BAI Score Day 14', 'ICD-10 diagnosis at baseline', 'ICD-10 diagnosis on Day 14', 'Internal consistency of the BAI', 'Internal consistency of the BDI-II', 'Test - retest reliability of the BDI-II questtionaire', 'Test - retest reliability of the BAI questtionaire', 'Sensitivity and Specificity of the BDI-II at baseline', 'Sensitivity and Specificity of the BAI at baseline']",[],,,,,2,Kazakhstan,"Kazakh Scientific Research Institute of Oncology and Radiology [Almaty, Kazakhstan] | Almaty Oncology Center [Almaty, Kazakhstan]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the validation of existing psychological assessment tools (Beck Depression Inventory and Beck Anxiety Inventory) rather than introducing a new medicine or extending the indication of an existing one.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04638712,Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,COMPLETED,,Institut de cancérologie Strasbourg Europe,2020-09-16,2021-05-20,2021-05-20,2020-11-20,2023-02-09,['Change in vastus lateralis cross-sectional area'],"['Alteration of patients body composition', 'Alteration of patients strength', 'Alteration of patients muscle architecture', 'Alteration of patients quality of life', 'Evaluation of patient cachexia']",,,,,1,France,"Institut de Cancerologie Strasbourg Europe [Strasbourg, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT04639609,Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy (PROTECT-04),Characterization of Neuromuscular Function and Fatigue After Breast Cancer Treated With Adjuvant Chemotherapy,COMPLETED,,Institut de cancérologie Strasbourg Europe,2020-09-29,2021-09-06,2021-09-06,2020-11-20,2021-09-28,['Maximal isometric muscle strength for knee extensors'],"['Number of Participants with neuromuscular fatigue', 'Number of Participants with neuromuscular fatigue', 'Number of Participants with neuromuscular fatigue', 'Number of Participants with subjective fatigue.', 'Number of Participants with muscle architecture.', 'Number of Participants with body composition.']",,,,,1,France,"Institut de Cancerologie Strasbourg Europe [Strasbourg, France]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,NA/Other
NCT04659551,Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients,Engaging the Immune System to Improve the Efficacy of Neoadjuvant Chemo-endocrine Therapy for Premenopausal Luminal B Breast Cancer Patients,COMPLETED,PHASE2,Istituto Oncologico Veneto IRCCS,2017-10-05,2020-05-25,2020-05-25,2020-12-09,2020-12-09,['pathological complete response (pCR)'],"['clinical objective response', 'molecular response', 'Breast conserving surgery', 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'Correlative biomarkers']",,,,,5,Italy,"Arcispedale S. Anna [Cona, Italy] | Centro di Riferimento Oncologico di Aviano (CRO) [Aviano, Italy] | Azienda Ospedaliera Universitaria di Parma [Parma, Italy] | Arcispedale S. Maria Nuova [Reggio Emilia, Italy] | Istituto Oncologico veneto IRCCS [Padua, Italy]",2017.0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,"[""Pathologic Complete Response (pCR)"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,Phase 2
NCT04660188,Impact of a Breast cAncer Survivorship Interprofessional Community Care Model,Impact of a Breast cAncer Survivorship Interprofessional Community Care Model (BASIC): A Randomized Controlled Trial,COMPLETED,,"National Cancer Centre, Singapore",2021-03-01,2022-07-20,2022-07-20,2020-12-09,2022-11-23,"[""Change in participants' health-related quality of life"", ""Change in participants' physical and psychological symptom distress levels""]","[""Participants' satisfaction with the shared-care model"", ""Change in participants' health utilities"", 'Change in healthcare cost and productivity', 'Rate of adherence to breast cancer survivorship care guidelines']",,,,,1,Singapore,"National Cancer Center Singapore [Singapore, Singapore]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial focused on a community care model for breast cancer survivorship, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04664972,Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC,"Comparing TP (Docetaxel + Cisplatin) and TAC (Docetaxel + Doxorubicin + Cyclophosphamide) in Neoadjuvant Therapy for Operable Triple Negative Breast Cancer, A Multicenter, Randomized, Phase II Clinical Trial",COMPLETED,PHASE2,Henan Cancer Hospital,2018-11-23,2022-11-26,2022-11-26,2020-12-11,2024-09-20,['The pathological complete remission rate (pCR rate)'],"['Event free survival rate (EFS)', 'Clinical response rate (CRR)', 'Breast -conserving rate', 'Number of adverse events and serious adverse events']",,,,,1,China,"Henan Cancer Hospital [Zhengzhou, China]",2018.0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)"",""Event-Free Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER_GOV,False,2022.0,3.0,0,Phase 2
NCT04676438,Persistant Post-mastectomy Pain in Breast Cancer : Incidence and Risk Factors,Incidence and Risk Factors of Chronic (Persistant) Post-surgical Pain in Oncological Breast Surgery : a Prospective Cohort Study in a National Institute of Oncology,COMPLETED,,Moroccan Society of Surgery,2018-12-10,2020-09-08,2021-03-07,2020-12-21,2021-07-20,['Post-mastectomy pain'],[],,,,,2,Morocco,"National Institute of Oncology of Rabat [Rabat, Morocco] | National Institut of Oncology, Surgical oncology department [Rabat, Morocco]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study on the incidence and risk factors of post-mastectomy pain but does not indicate the development of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT04689945,Metabolomic Profiling of Erector Spinae Plane Block* for Breast Cancer Surgery,Metabolomic Profiling of Erector Spinae Plane Block for Breast Cancer Surgery,COMPLETED,,Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,2021-02-01,2021-05-01,2021-10-01,2020-12-30,2023-01-19,['Metabolomic profiling of ESP block for breast cancer surgery'],"['Defining the change in preoperative (baseline), postoperative hour 24 Vascular Endothelial Growth Factor (VEGF) levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).', 'Defining the change in preoperative (baseline), postoperative hour 1, postoperative hour 24 cortisol levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).', 'Defining the change in preoperative (baseline), postoperative hour 1, postoperative hour 24 C-reactive Protein levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).', 'Defining analgesic effects between the morphine group (group M), the ESP block group (group E), and the control group (group c) on patients who had breast cancer surgery.', 'Tramadol consumption between the ESP block group and the control group']",,,,,1,Turkey (Türkiye),"Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital [Ankara, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of the Erector Spinae Plane Block (ESP block) in the context of breast cancer surgery, indicating an extension of indication for an existing analgesic technique rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04692168,Influence of Chemotherapy on Postural Control in Women With Cancer,Influence of Chemotherapy on Postural Control and Quality of Life in Women With Gynaecological Cancer: a Prospective Observational Study,COMPLETED,,Aline Reinmann,2020-10-07,2022-12-31,2022-12-31,2020-12-31,2023-05-06,['Change from baseline : postural control under various conditions.'],"['Change from baseline : modifications of postural control according to the conditions tested.', 'Change from baseline : standing dynamic stability.', 'Change from baseline : quality of life assessed by the questionnaire Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-NTX).', 'Change from baseline : investigate the association between the severity of CIPN (mild, moderate, severe) and the postural control, dynamic balance and QoL of individuals with gynaecological cancer.']",,,,,1,Switzerland,"Geneva University Hospitals [Geneva, Switzerland]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the influence of chemotherapy on postural control and quality of life in women with gynaecological cancer, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04701801,Correlation of Preoperative Anxiety With Early Postoperative Cognitive Dysfunction in Breast Cancer Patients,Correlation of Preoperative Anxiety With Early Postoperative Cognitive Dysfunction in Breast Cancer Patients,COMPLETED,,Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital,2020-10-21,2021-05-31,2021-07-13,2021-01-08,2022-11-02,['Determining the preoperative anxiety level and evaluating the difference between the preoperative moca test and the moca test performed on the postoperative 7th day (early period)'],[],,,,,1,Turkey (Türkiye),"Dr.Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital clinic of Anesthesiology and Reanimation [Ankara, Turkey (Türkiye)]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on preoperative anxiety and its correlation with cognitive dysfunction in breast cancer patients, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04702061,Comparison of Erector Spina Plane Block and Thoracic Epidural Block,Comparison of Erector Spina Plane Block and Thoracic Epidural Block in Breast Surgery,COMPLETED,,Inonu University,2021-01-11,2021-03-31,2021-03-31,2021-01-08,2021-04-20,"['Sympathetic block level evaluation with skin conductivity', 'Sympathetic block level evaluation with skin temperature', 'Sympathetic block level evaluation with hot cold test', 'Sympathetic block level evaluation by hemodynamic data', 'Sensorial block level evaluation']","['intraoperative hemodynamic data', 'Postoperative pain scores', 'Rescue analgesics consumption', 'Rescue analgesics consumption']",,,,,1,Turkey (Türkiye),"Eskisehir Osmangazi University [Eskişehir, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a comparison of two existing techniques (Erector Spina Plane Block and Thoracic Epidural Block) in a specific surgical context, rather than introducing a new medicine or extending the indication of an existing one.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04714619,CB-103 Plus NSAI In Luminal Advanced Breast Cancer,CB-103 Plus NSAI In Luminal Advanced Breast Cancer: CAILA Study,TERMINATED,PHASE2,MedSIR,2021-05-06,2021-09-02,2022-04-26,2021-01-19,2023-12-19,['Progression-free survival (PFS)'],"['Safety and tolerability of CB-103 in combination with NSAI (anastrozole or letrozole)', 'Efficacy in terms of PFS of CB-103 in combination with NSAI in all patients and in sub.groups', 'Overall response rate (ORR)', 'Clinical benefit rate (CBR)', 'Clinical benefit rate (CBR)', 'Time to tumor response (TTR)', 'Duration of response (DoR)', 'Overall survival (OS)', 'Maximum tumor shrinkage (MTS)', 'Pharmacokinetics (PK), in terms of Cmax', 'PK, in terms of AUC', 'PK in terms of Vd/F', 'PK in terms of CL/F', 'Pharmacokinetics (PK), in terms of Tmax']",,,,,2,Spain,"Complejo Hospitalario de Jaen [Jaén, Spain] | Hospital Sant Joan de Reus [Reus, Spain]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves CB-103, which is being tested in combination with NSAI for luminal advanced breast cancer, indicating it is a new medicine being evaluated for efficacy and safety.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04718324,PREMs on PROMs in Breast Disease (PREMs_PROMs),"Electronic Patient Reported Outcome Measures (ePROMs) in Patients With Breast Disease: An Open-label, Randomized Controlled Trial on Patient Reported Experience Measures (PREMs) and Effectivity (PREMs_PROMs)",COMPLETED,PHASE3,Uppsala University,2019-09-01,2021-03-30,2021-04-30,2021-01-22,2021-05-17,"['Response rate', 'Patient Reported Experience outcomes (PREMS)']","['Time of response', 'Procedure-related costs']",,,,,1,Sweden,"Uppsala University Hospital [Uppsala, Sweden]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial focused on patient-reported outcomes and experience measures in breast disease, but does not indicate the testing of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,Phase 3
NCT04756921,18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response,Pretreatment 18F-FDG Uptake Heterogeneity Predicts Response to Pyrotinib in Patients With Metastatic HER2-positive Breast Cancer,COMPLETED,,"Biyun Wang, MD",2018-09-01,2020-07-24,2020-07-24,2021-02-16,2021-02-16,['PFS'],[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial text indicates the use of Pyrotinib, which is an existing medication, in a specific patient population (metastatic HER2-positive breast cancer), suggesting an extension of its indication rather than a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT04770129,"Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey",Demographic Data and Outcomes Of Metastatic Breast Cancer Patients Treated Over The Last Decade At Tertiary Oncology Clinics In Highly Populated Cities In Turkey: A Turkish Oncology Collaborative Group Analysis,COMPLETED,,Turkish Oncology Group,2021-03-22,2022-06-02,2022-08-08,2021-02-25,2023-01-20,"['Treatment outcome data: Overall survival (OS)', 'Treatment outcome data: Progression-free survival (PFS)']","['Time to progression (TTP)', 'Demographic characteristics at baseline', 'Clinical and pathological characteristics: Diagnosis', 'Clinical and pathological characteristics: Clinical and/or pathological stage', 'Clinical and pathological characteristics: Lymph nodes', 'Clinical and pathological characteristics: Tumor size', 'Clinical and pathological characteristics: Pathological subtype', 'Clinical and pathological characteristics: Hormone-receptor expression', 'Clinical and pathological characteristics: Human Epidermal Growth Factor Receptor 2 (HER-2) expression', 'Clinical and pathological characteristics: Histological type', 'Clinical and pathological characteristics: Histological grade', 'Clinical and pathological characteristics: Nuclear grade', 'Anatomopathological characteristics of the tumor: Ki-67', 'Treatment data: type of chemotherapy', 'Treatment data: adjuvant hormonotherapy', 'Treatment data: radiotherapy', 'Treatment data: surgery', 'Treatment data: locally ablative treatment', 'Follow-up data: initial recurrence', 'Follow-up data: current condition', 'Follow-up data: date and cause of death']",,,,,6,Turkey (Türkiye),"Ege University Hospital [Izmir, Turkey (Türkiye)] | Istanbul University [Istanbul, Turkey (Türkiye)] | Acibadem Maslak Hospital [Istanbul, Turkey (Türkiye)] | Marmara University Pendik Training and Research Hospital [Istanbul, Turkey (Türkiye)] | Acibadem Altunizade Hospital, Istanbul [Istanbul, Turkey (Türkiye)] | American Hospital [Istanbul, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,NETWORK,False,2022.0,3.0,0,NA/Other
NCT04771975,Connecting Breast Cancer Survivors for Exercise,Connecting Breast Cancer Survivors for Exercise: A Randomized Controlled Trial Phase I and II,COMPLETED,,Jenna Smith,2021-05-10,2021-12-30,2022-01-30,2021-02-25,2023-08-21,"['Phase 1 and Phase 2: Change in exercise volume', 'Phase 1 and Phase 2: Change in exercise volume', 'Phase 1 and Phase 2: Change in exercise volume']","['Phase 1 and Phase 2: Change in exercise volume', 'Phase 1: Change in social support', 'Phase 1: Change in health-related quality of life assessed by the Short-Form-12', 'Phase 1: Change in quality of life assessed by the EuroQol-5 Dimension-3 level (EQ-5D-3L)', 'Phase 1 and Phase 2: Cost of intervention arms', 'Phase 1: Use of health care resources', 'Phase 1 and Phase 2: Intervention adherence', 'Phase 2: Resistance Exercise Self-Efficacy', 'Phase 2: Physical Self', 'Phase 2: Body Functionality appreciation']",,,,,1,Canada,"University of Toronto [Toronto, Canada]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04772118,Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.,Improving Cancer Outcomes Through Personalized Care Planning and Symptom Managment,COMPLETED,,"Carevive Systems, Inc.",2021-02-16,2021-10-07,2021-11-01,2021-02-26,2022-01-18,"['Outcomes for Primary Aim 1 - 50 intervention participants with a diagnosis for lung, breast or ovarian cancer measuring the prevalence and severity of 18 different symptoms reported from home over 3 months.']","['Outcomes for Secondary Aim 2 - 50 intervention patients will complete the Patient Satisfaction Survey at the 3month timepoint to measure satisfaction with treatment decision and care experience.', 'Outcomes for Secondary Aim 3 - Feasibility will be measured by completion of the patient questionnaires and patient symptom reports by the 50 intervention patients. Usability will be measured through provider feedback.']",,,,,1,United States,"Mitchell Cancer Institute [Mobile, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study focused on personalized care planning and symptom management for cancer patients, but it does not mention a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT04781712,Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer,Feasibility of a Modular mHealth for Tailored Rehabilitation During the Treatment of Breast Cancer,COMPLETED,,Samsung Medical Center,2019-04-22,2021-03-30,2021-03-30,2021-03-04,2022-10-26,"['satisfaction score in app contents', 'Needs score in app contents', 'DASH (Disabilities of Arm, Shoulder, Hands)']","['Physical measurement (handgrip strength)', 'Physical measurement (of body composition, BMI)', 'Physical measurement (of body composition, muscle mass)', 'Physical measurement (upper extremity volume)', 'Physical activity (IPAQ-SF Questionnaire)', 'PRO-CTCAE (patients reported outcomes)', 'Distress thermometer (distress level)', 'App use data (personal health record)_Exercise compliance rate', 'App use data (personal health record)_Physical activity change', 'App use data (personal health record)_interest of contents', 'App use data (personal health record)_sleep']",,,,,1,South Korea,"Samsung Medical Center [Seoul, South Korea]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a modular mHealth application for rehabilitation in breast cancer treatment, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04797728,"Elacestrant in Preoperative Setting, a Window of Opportunity Study","Elacestrant in Preoperative Setting, a Window of Opportunity Study",COMPLETED,EARLY_PHASE1,SOLTI Breast Cancer Research Group,2021-02-09,2022-02-08,2022-02-25,2021-03-15,2022-10-26,['Complete Cell Cycle Arrest'],"['PAM50 (Prediction Analysis of Microarray 50) subtype change', 'Gene expression change (post-treatment/pre-treatment)', 'Adverse Events', 'Global gene expression changes', 'Gene expression-based signature of response', 'Celularity/Tumor Infiltrating Lymphocytes (CelTIL) score', 'Mean change in Ki67', 'Changes in the distribution of somatic mutations', 'ctDNA (post-treatment/pre-treatment)']",,,,,4,Spain,"ICO Badalona [Badalona, Spain] | Hospital General de Catalunya [Sant Cugat del Vallès, Spain] | Hospital Universitari Vall d'Hebron [Barcelona, Spain] | Hospital Clinic Barcelona [Barcelona, Spain]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study focuses on the use of Elacestrant in a preoperative setting, suggesting an extension of its indication rather than introducing a new medicine.",OTHER,False,2022.0,3.0,0,Phase 1
NCT04807595,"Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status","A Multicenter Study to Estimate the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2-low Status - the RetroBC-HER2L Study",COMPLETED,,AstraZeneca,2021-05-28,2022-04-26,2022-04-26,2021-03-19,2023-03-06,"['Prevalence/Incidence of HER2 low among HER2-neg mBC patients, based on rescoring of historical HER2 fixed tissue IHC stained slides by Ventana 4B5 assay', 'Disease outcome: Time to first subsequent treatment (TFST)', 'Disease outcome: Time to treatment failure (TTF)', 'Disease outcome: Overall survival (OS)']","['Clinicopathological characteristics in patients with HER2 low BC', 'Concordance of HER2 rescore with historical HER2 score', 'Prevalence of HER2 low among unresectable and/or mBC patients identified as HER2-neg based on other IHC assays', 'Prevalence of HER2 low in HR-positive and HR-negative population']",,,,,13,Australia; Canada; France; Germany; Italy; Japan; Portugal; South Korea; United Kingdom; United States,"Research Site [Pittsburgh, United States] | Research Site [Melbourne, Australia] | Research Site [Montreal, Canada] | Research Site [Clermont-Ferrand, France] | Research Site [Erlangen, Germany] | Research Site [Milan, Italy] | Research Site [Chūōku, Japan] | Research Site [Fukuoka, Japan] | Research Site [Isehara, Japan] | Research Site [Lisbon, Portugal] | Research Site [Porto, Portugal] | Research Site [Seoul, South Korea] | Research Site [Manchester, United Kingdom]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study focuses on the prevalence and treatment patterns of HER2 low status in breast cancer patients, indicating an extension of indication for existing treatments to include patients with HER2 low status.",INDUSTRY,False,2022.0,3.0,1,NA/Other
NCT04811378,HaemoCerTM Application in Breast Cancer Surgery,Randomised Controlled Trial: HaemoCerTM Versus no HaemoCerTM in Breast Cancer Surgery to Reduce Postoperative Drainage Output,COMPLETED,,Medical University of Vienna,2017-10-05,2021-03-01,2021-03-01,2021-03-23,2021-09-13,"['Total volume of postoperative drained fluid (per breast)', 'Number of days until drain removal (n)']","['Total volume of postoperative drained fluid from the axillary fossa in case of axilla surgery (sentinel lymphonodectomy, axillary dissection)', 'Rate of immediate postoperative infection on the breast surgery site']",,,,,1,Austria,"Medical University of Vienna [Vienna, Austria]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the application of HaemoCerTM in a specific surgical context (breast cancer surgery), indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04818125,Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.,Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.,COMPLETED,,Institut Claudius Regaud,2021-03-31,2022-07-29,2022-07-29,2021-03-26,2022-09-28,['Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood defined as the ratio of the number of patients with hybrid cells to the total number of patients.'],"['Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.', 'Progression-free survival (PFS) defined as the time from the date of inclusion to the date of progression or death from any cause.']",,,,,1,France,"Institut Universitaire du Cancer de Toulouse - Oncopole [Toulouse, France]",2021.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the quantification of circulating cancer cells and hybrid cells in patients with breast cancer, but does not indicate the development of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04818996,Evaluation of the Effect of Mediterranean Diet on Breast Cancer Patients,"Evaluation of the Effect of Mediterranean Diet on Body Composition, Oxidant Stress and Proinflammatory Markers in Breast Cancer Patients",COMPLETED,,Aydin Adnan Menderes University,2019-10-22,2019-12-17,2021-01-20,2021-03-26,2021-03-26,"['Change in body weight', 'Change in body mass indexs', 'Change in fat mass measured by bioelectrical impedance analyzer', 'Change in fat-free mass measured by bioelectrical impedance analyzer', 'Change in resting metabolic rate (RMR) measured by bioelectrical impedance analyzer', 'Change in interleukin 6 (IL-6)', 'Change in tumor necrosis factor alpha (TNF-α)', 'Change in malondialdehyde (MDA)', 'Change in total antioxidant status (TAS)', 'Change in total oxidant status (TOS)']","['Change in waist circumference', 'Change in hip circumference', 'Change in dietary inflammatory index (DII)', 'Change in oxidative stress index (OSI)']",,,,,1,Turkey (Türkiye),"Aydın Adnan Menderes University, Faculty of Health Sciences, Department of Nutrition and Dietetics [Aydin, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the evaluation of the Mediterranean diet on breast cancer patients, focusing on various health metrics and markers, but does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04823871,Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing,Pilot Study of Early Detection of High Grade Ovarian Cancer Using Uterine Lavage and Duplex Sequencing,COMPLETED,,"Paul Speiser, Prof.MD,",2018-11-01,2022-06-30,2022-06-30,2021-04-01,2022-09-02,"['Variant allele frequencies (VAF) for variants identified in both unfiltered and filtrate uterine lavage from the same patient.', 'SNP allele fraction (AF) comparison at different dilutions: expected AF vs. observed AF, AF variation among replicates (UtLs).', 'Total mutation frequency (UtLs)', 'Mutant allele frequency (MAF) for all mutated positions, mutation spectrum (UtLs),', 'TP53 mutation frequencies in leukocytes', 'Variant allele frequencies (VAF) for variants identified in uterine lavage ans pap smear from the same patient.', 'dCT-PCR values from 96-plexed high-throughput MSREqPCR analysis']",[],,,,,9,Austria; Czechia; Germany; Ireland,"Medizinische Universität Graz [Graz, Austria] | Medical University Innsbruck [Innsbruck, Austria] | Kepler Universitätsklinikum Linz [Linz, Austria] | Medical University Vienna, Dptm. of Obstetrics & Gynaecology [Vienna, Austria] | Masaryk Memorial Cancer Institute Brno [Brno, Czechia] | Charles University Prag [Prague, Czechia] | University Hospital Bonn [Bonn, Germany] | Gynaecological Clinic TU of Munich [München, Germany] | St. James Hospital [Dublin, Ireland]",2018.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,1,NA/Other
NCT04824183,Music Intervention for Preoperative Anxiety and Acute Pain Among Mastectomy Patients,A Pilot Study on the Effect of Culturally-adapted Music Intervention on Preoperative Anxiety and Acute Postoperative Pain Among African Women Undergoing Mastectomy: A Randomised Controlled Trial,COMPLETED,,Chinese University of Hong Kong,2021-06-05,2022-03-22,2022-03-27,2021-04-01,2022-08-19,['Change in acute postoperative pain intensity'],"['Change in preoperative anxiety', 'Change in blood pressure', 'Analgesia consumption', 'Satisfaction with pain management', 'Change in heart rate', 'Change in respiratory rate']",,,,,3,Malawi; Nigeria,"Kamuzu Central Hospital [Lilongwe, Malawi] | Lagos State University Teaching Hospital [Ikeja, Nigeria] | Lagos University Teaching Hospital [Lagos, Nigeria]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses a music intervention for managing anxiety and pain in patients undergoing mastectomy, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,1,NA/Other
NCT04824599,Regional Anesthesia and Partial Mastectomy,Interpectoral and Pectoserratus Plane Block vs Local Anesthetic Infiltration for Partial Mastectomy - a Prospective Randomized Trial,COMPLETED,,Karlstad Central Hospital,2021-02-19,2022-05-01,2022-05-01,2021-04-01,2023-09-07,"['maximal pain in PACU measured with 11 point numerical rating scale (NRS)', 'Intraoperative fentanyl use']","['Postoperative analgesic use', 'Maximal postoperative nausea and vomiting(PONV) in PACU measured with 11 point numerical rating scale (NRS)', 'Length of stay in PACU', 'Maximal postoperative nausea and vomiting(PONV) after discharge from PACU measured with 11 point numerical rating scale (NRS)', 'Maximal pain after discharge from PACU measured with 11 point numerical rating scale (NRS)']",,,,,1,Sweden,"Central Hospital in Karlstad [Karlstad, Sweden]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The trial compares two existing methods of anesthesia (interpectoral and pectoserratus plane block vs local anesthetic infiltration) rather than testing a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04826367,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,Relaxation Training By Tele-Rehabilitation Program In Patients With Breast Cancer Receiving Chemotherapy During COVID-19.,COMPLETED,,Hacettepe University,2021-01-20,2022-11-01,2022-12-01,2021-04-01,2024-05-01,"['Brief Pain Inventory (BPI)', ""'Fatigue Impact Scale (FIS)"", 'Hospital Anxiety and Depression (HAD)"" scale', 'European Organization for Research and Treatment of Cancer- Quality of life (EORTC QLQ-C30) questionnaire', 'Functional Assessment of Chronic Illness Therapy-Cognitive Function (FACT-Cog)', 'Pittsburg Sleep Quality Index (PSQI)', 'Tampa Kinesophobia Scale (TKS)']",[],,,,,1,Turkey (Türkiye),"Florence Nightingale Hospital [Istanbul, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a relaxation training program for patients with breast cancer receiving chemotherapy, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04834154,Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients,Addressing Mental Health Disparities in Spanish Speaking Latina Breast Cancer Patients,COMPLETED,,Stanford University,2021-03-15,2022-06-16,2022-06-16,2021-04-08,2025-03-13,"['Acceptability change across session', 'Difference in Feasibility']","['Differences in Generalized Anxiety Disorder-7 (GAD7) between time points.', 'Differences in Center for Epidemiological Studies-Depression (CES-D) between time points.', 'Differences in PROMIS-SD between time points']",,,,,1,United States,"Stanford University [Palo Alto, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a study focused on mental health disparities in a specific patient population and does not indicate the development of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04841928,Optimizing Psychological Treatment for Pain After Breast Cancer: A Pilot Study,Optimization of Psychological Treatment for Pain After Breast Cancer Using the Multiphase Optimization Strategy (MOST): A Pilot Study,COMPLETED,,University of Aarhus,2021-03-01,2021-07-01,2021-08-01,2021-04-12,2021-09-30,"['Pain intensity (11-point Numeric Rating Scale, NRS)', 'Pain interference (the 7-item subscale of the Brief Pain Inventory, BPI)']","['Pain intensity (11-point Numeric Rating Scale, NRS)', '4. Pain interference (1 aggregated item assessing pain interference during the last 24 hours within the 7 domains measured with the Brief Pain Inventory, BPI, interference subscale)', 'Pain burden (11-point Numeric Rating Scale, NRS)', 'Pain quality (the 22-item pain descriptors from the McGill Pain Questionnaire, MPQ)', 'Pain catastrophizing (the 13-item Pain Catastrophizing Scale, PCS)', 'Psychological distress (the 14-item Hospital Anxiety and Depression Scale, HADS)', 'Fear of cancer recurrence (the 9-item Fear of Cancer Recurrence Inventory, FCRI)', 'Well-being (the 5-item WHO-5 Well-Being Index, WHO-5)']",,,,,1,Denmark,"Aarhus University [Aarhus, Denmark]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focused on optimizing psychological treatment for pain after breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04845256,Evaluation of SOMAVAC 100 Sustained Vacuum System,Evaluation of SOMAVAC 100 Sustained Vacuum System Versus Manual Suction Bulbs After Mastectomy With Immediate Breast Reconstruction,COMPLETED,,University of Tennessee,2021-05-01,2022-10-05,2022-10-30,2021-04-14,2023-02-13,"['Impact of the SOMAVAC continuous suction device on postoperative fluid drainage after mastectomy reconstruction', 'The SOMAVAC continuous suction device and seroma development on reconstructed mastectomy patients']",[],,,,,1,United States,"Plastic Surgery Group [Chattanooga, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the evaluation of the SOMAVAC 100 Sustained Vacuum System, which appears to be an existing device being tested for a new application (postoperative fluid drainage after mastectomy reconstruction), indicating an extension of its indication.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04850625,Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine,"Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study",COMPLETED,,Fudan University,2020-01-15,2021-06-15,2021-06-15,2021-04-20,2022-07-05,['PFS'],['Number of participants with treatment-related adverse events as assessed by CTCAE v4.0'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2020.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves Pyrotinib, which is a new medicine being tested in combination with Vinorelbine for a specific patient population (HER2-Positive Metastatic Breast Cancer).",OTHER,False,2021.0,4.0,0,NA/Other
NCT04852419,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,A PHASE 1B STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ZN-C5 IN CHINESE SUBJECTS WITH ADVANCED BREAST CANCER,COMPLETED,PHASE1,Zentera Therapeutics HK Limited,2021-05-31,2022-06-23,2022-06-23,2021-04-21,2022-08-11,"['Observed Dose Limited Toxicities (DLTs) in safety lead in phase', 'Incidence of treatment-emergent adverse events', 'Incidence of treatment-emergent adverse events']","['CBR (CR [+ PR] + SD ≥ 24 weeks).', 'bjective Response Rate (ORR)', 'Duration of Response (DOR)', 'Progression-Free Survival (PFS)']",,,,,1,China,"Fudan University Cancer Hospital [Shanghai, China]",2021.0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,"[""Overall Survival"",""Duration of Response""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing a new drug (ZN-C5) in a specific patient population (Chinese subjects with advanced breast cancer), indicating it is a New Medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT04857619,Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer,"A Multicountry, Multicentre, Non-interventional, Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer",COMPLETED,,AstraZeneca,2021-05-14,2022-10-31,2022-10-31,2021-04-23,2024-07-11,"['Percentage of patients receiving each treatment regimen with or without hormonal therapy in each LOT', 'Duration of therapy (DoT) for each regimen in each LOT', 'Percentage of patients receiving local and regional treatment for metastasis']","['Demographic and clinico-pathological characteristics of patients with HER2-positive unresectable or mBC', 'Real-world disease progression', 'Real-world progression free survival (rwPFS)', 'Overall survival', 'Real-world objective response rate', 'Real-world disease control rate', 'Percentage of Proportion of patients with AESIs that led to treatment discontinuations, hospitalisatons and deaths.']",,,,,44,Australia; Brazil; Hong Kong; Singapore; South Korea; Taiwan,"Research Site [Macquarie, Australia] | Research Site [Newcastle, Australia] | Research Site [Parramatta, Australia] | Research Site [St Leonards, Australia] | Research Site [Perth, Australia] | Research Site [Manaus, Brazil] | Research Site [Fortaleza, Brazil] | Research Site [Cachoeiro de Itapemirim, Brazil] | Research Site [Salvador, Brazil] | Research Site [Salvador, Brazil] | Research Site [Curitiba, Brazil] | Research Site [Caxias do Sul, Brazil] | Research Site [Porto Alegre, Brazil] | Research Site [Porto Alegre, Brazil] | Research Site [Itajaí, Brazil] | Research Site [Santo André, Brazil] | Research Site [Fortaleza, Brazil] | Research Site [Goiânia, Brazil] | Research Site [Rio de Janeiro, Brazil] | Research Site [São Paulo, Brazil] | Research Site [São Paulo, Brazil] | Research Site [Hong Kong, Hong Kong] | Research Site [Hong Kong, Hong Kong] | Research Site [Kowloon, Hong Kong] | Research Site [Singapore, Singapore] | Research Site [Singapore, Singapore] | Research Site [Singapore, Singapore] | Research Site [Singapore, Singapore] | Research Site [Incheon, South Korea] | Research Site [Seoul, South Korea] | Research Site [Seoul, South Korea] | Research Site [Seoul, South Korea] | Research Site [Seoul, South Korea] | Research Site [Seoul, South Korea] | Research Site [Goyang, South Korea] | Research Site [Seoul, South Korea] | Research Site [Tainan County, Taiwan] | Research Site [Kaohsiung City, Taiwan] | Research Site [Taichung, Taiwan] | Research Site [Taichung, Taiwan] | Research Site [Tainan City, Taiwan] | Research Site [Taipei, Taiwan] | Research Site [Taipei, Taiwan] | Research Site [Taipei, Taiwan]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,"The text describes a study focused on real-world treatment patterns and outcomes for patients with HER2-positive unresectable or metastatic breast cancer, but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",INDUSTRY,False,2022.0,3.0,1,NA/Other
NCT04866992,Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM),Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy,COMPLETED,,University of Texas Southwestern Medical Center,2020-02-01,2021-07-14,2021-09-24,2021-04-30,2022-01-21,"['Feasibility of completion of SPrNSM through axillary incision', 'Complication rate of patients requiring re-operation', 'Complication rate of patients with infection requiring explantation of tissue expander', 'Complication rate of patients with mastectomy flap necrosis', 'Operative surgery time trends with peri-operative outcomes']","['Patient reported outcomes', 'Patient reported outcomes']",,,,,1,United States,"UT Southwestern Medical Center [Dallas, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a trial focused on a surgical procedure (Single Port Robot-assisted Nipple Sparing Mastectomy) rather than a new medicine or an extension of indication for an existing medicine.,OTHER,False,2021.0,4.0,0,NA/Other
NCT04868812,Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment,Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated CO2 Laser,COMPLETED,,IRCCS San Raffaele,2019-12-03,2020-06-01,2021-12-01,2021-05-03,2022-09-13,"['Microscopic evaluation for vaginal epithelial thickness', 'Microscopic evaluation of number of papillae', 'Microscopic evaluation of glycogen amount', 'Microscopic evaluation of number and size of the vessels']","['Validated questionnaires VHI', 'Validated questionnaires FSFI', 'Validated questionnaires UDI-6', 'Validated questionnaires ICIQ-UI', 'Validated questionnaires LIKERT']",,,,,1,Italy,"IRCCS San Raffaele Hospital [Milan, Italy]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the effects of CO2 laser treatment on postmenopausal vaginal mucosa, indicating an extension of indication for an existing treatment rather than introducing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04871854,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Comparative Study Evaluating Clinical Outcomes for Patients Treated With Tocilizumab for Sever COVID-19 Infection in Breast Cancer Patients Versus Non Cancer Patients,COMPLETED,PHASE2,Beni-Suef University,2021-04-26,2022-07-26,2022-08-26,2021-05-04,2022-11-01,"['Overall survival (OS) after treatment of Tocilizumab', 'progression free survival (PFS)', 'time of improvement or worsening at least one point change in ordinal scale']","['measure percentage of patients need Mechanical Ventilation Required (Including CPAP) during Follow up period, Supplemental Oxygen required', 'Duration of mechanical ventilation', 'adverse effect', 'length of stay in Intensive care unit']",,,,,1,Egypt,"ALsafwa specialized hospital [Al Fayyum, Egypt]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the use of Tocilizumab, which is an existing medication, in a new patient population (breast cancer patients) for a specific indication (severe COVID-19 infection), indicating an extension of its indication.",OTHER,False,2022.0,3.0,0,Phase 2
NCT04874025,Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer,Observational Analysis of Treatment With Palbociclib in Patients With Locally Advanced and / or Metastatic RH + / HER 2- Breast Cancer in the First Line of Treatment Within Routine Clinical Practice.,COMPLETED,,"Hospital San Carlos, Madrid",2021-07-31,2022-06-08,2022-06-08,2021-05-05,2022-08-08,['Real-world progression free survival (rwPFS)'],"['Overall Survival', 'Real-world tumor response (rwTR)', 'Time to next line of therapy', 'Time to first use of chemotherapy']",,,,,36,Spain,"Hospital Universitario Reina Sofía [Córdoba, Spain] | Hospital Universitario Virgen de las Nieves [Granada, Spain] | Hospital Universitario Virgen Macarena [Seville, Spain] | Hospital Univesitario Virgen del Rocío [Seville, Spain] | Hospital Clínico Universitario Lozano Blesa [Zaragoza, Spain] | Hospital Universitario Miguel Servet [Zaragoza, Spain] | Hospital Son Espases [Palma de Mallorca, Spain] | Hospital Universitario de Basurto [Bilbao, Spain] | Hospital Universitario Donostia [Donostia / San Sebastian, Spain] | Hospital Universitario Marqués de Valdecilla [Santander, Spain] | Hospital Universitario de Guadalajara [Guadalajara, Spain] | Hospital Virgen de la Salud [Toledo, Spain] | Hospital Universitario de Burgos [Burgos, Spain] | Hospital Universitario de León [León, Spain] | Hospital del Mar [Barcelona, Spain] | Hospital Universitario Vall d´Hebrón [Barcelona, Spain] | Hospital de la Santa Creu i Sant Pau [Barcelona, Spain] | ICO Hospitalet [L'Hospitalet de Llobregat, Spain] | Arnau Vilanova Lleida [Lleida, Spain] | Hospital Universitario de Cáceres [Cáceres, Spain] | Hospital Universitario de La Coruña [A Coruña, Spain] | Hospital Universitario de Ferrol [Ferrol, Spain] | Hospital Cínico Universitario de Santiago de Compostela [Santiago de Compostela, Spain] | Clínica Universitaria de Navarra [Pamplona, Spain] | Complejo Hospitalario de Navarra [Pamplona, Spain] | Hospital Universitario de Cabueñes [Gijón, Spain] | Hospital Central de Asturias [Oviedo, Spain] | Hospital General Universitario de Elche [Elche, Spain] | Hospital Universitario de la Princesa [Madrid, Spain] | Hospital Universitario Gregorio Marañón [Madrid, Spain] | Hospital Universitario Ramón y Cajal [Madrid, Spain] | Hospital Clínico San Carlos [Madrid, Spain] | Hospital Universitario 12 de Octubre [Madrid, Spain] | Hospital Universitario La Paz [Madrid, Spain] | Hospital General Universitario Morales Meseguer [Murcia, Spain] | Arnau Vilanova Valencia [Valencia, Spain]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04875559,Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study,Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study,COMPLETED,,Zealand University Hospital,2021-04-19,2022-08-04,2022-08-18,2021-05-06,2023-07-14,['Postoperative pain'],"['Pain at the day-case post anaesthesia care unit (dcPACU)', 'Postanaesthesia recovery time', 'Postoperative nausea and vomiting', 'Daily use of analgesics', 'Location of pain', 'Quality of sleep', 'Well-being', 'Quality of recovery, QoR-15D']",,,,,1,Denmark,"Zealand University Hospital, Department of Anaesthesiology [Roskilde, Denmark]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on multimodal pain treatment for breast cancer surgery, which does not indicate a new medicine or an extension of indication for an existing medicine. It focuses on treatment methods and outcomes rather than a specific drug or indication.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04876378,"Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand","Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand",TERMINATED,,"University of California, San Francisco",2020-05-18,2022-05-24,2022-05-24,2021-05-06,2022-09-09,"['Mean differences in hyaline cartilage biochemical composition', 'Differences in morphological joint abnormalities']",[],,,,,1,United States,"University of California San Francisco [San Francisco, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the impact of breast cancer treatment on joint health and does not indicate the development of a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT04903652,Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer,A Prospective Phase Ⅱ Clinical Study of Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer That Has Failed Trastuzumab Therapy,COMPLETED,PHASE2,Tianjin Medical University Cancer Institute and Hospital,2021-01-01,2022-02-01,2022-02-06,2021-05-26,2022-04-07,['Progression-free survival (PFS)'],"['Objective response rate (ORR)', 'Disease Control Rate (DCR)', 'Overall survival (OS)', 'Security (CTCAE 5.0)']",,,,,1,China,"Tianjin Cancer Hospital [Tianjin, China]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2022.0,3.0,0,Phase 2
NCT04916509,Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region,"Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region Like Saudi Arabia, UAE and Other GCC Countries: A Retrospective Study (Treasure Study)",COMPLETED,,Pfizer,2021-09-13,2022-12-27,2022-12-27,2021-06-07,2023-06-06,"['Demographical Characteristics of Participants', 'Demographical Characteristics of Participants: Biomarker status', 'Clinical Characteristics of Participants: Description of diagnosis', 'Number of patients receiving adjuvant therapies', 'Number of participants receiving treatment for advanced/metastatic BC before and after palbociclib combination use', 'Number of participants with dose changes associated with palbociclib use', 'Number of participants to discontinue treatment associated with palbociclib use', 'Number of participant receiving supportive therapies while receiving palbociclib combination treatment', 'Proportion of patients who are progression free at multiple intervals', 'Objective response rate (ORR)', 'Proportion of patients alive 1 and 2 years post palbociclib combination initiation depending on availability of follow-up data (if available)']",[],,,,,7,Qatar; Saudi Arabia; United Arab Emirates,"Hamad Medical Corporation [Doha, Qatar] | King Abdulaziz Medical City National Guard Hospital [Jeddah, Saudi Arabia] | King Abdulaziz Medical City National Guard Hospital Riyahd [Riyadh, Saudi Arabia] | King Saud University Medical City Riyadh PO BOX 7805 [Riyadh, Saudi Arabia] | Tawam [Al Ain City, United Arab Emirates] | Dubai Hospital [Dubai, United Arab Emirates] | Mediclinic City Hospital [Dubai, United Arab Emirates]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,1,NA/Other
NCT04920669,Dexmedetomidine in Erector Spinae Block in Postoperative Analgesia,Can Dexmedetomidine Improve the Analgesic Duration and Efficacy of Erector Spinae Plane Block in Breast Cancer Surgeries?,COMPLETED,,Mohamed Elsayed Hassan,2021-07-01,2021-09-30,2021-09-30,2021-06-10,2022-04-06,['Time to first request of analgesia'],"['Total morphine consumption in first postoperative 24 hours', 'Intraoperative fentanyl requirement', 'Numerical rating scale']",,,,,1,Egypt,"National Cancer Institute [Cairo, Egypt]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the use of dexmedetomidine in a specific application (erector spinae block) for postoperative analgesia, indicating an extension of its indication rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04929964,COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer,COVID 19 Pandemic: Effect on Management of Patients With Breast Cancer; Single Center Study,COMPLETED,,"Mehwish Mooghal , MBBS",2020-01-01,2021-01-31,2021-01-31,2021-06-18,2021-08-11,"['Duration of delay in presentation to hospital', 'Duration of delay in definitive treatment', 'Cancer upstaging']",[],,,,,1,Pakistan,"Bahria University Medical and Dental College Karachi [Karachi, Pakistan]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the impact of the COVID-19 pandemic on the management of breast cancer patients, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT04936243,TIPOPS (Telemedicine vs In Person Oncology Patient Surveillance),A Randomized Control Trial of Telemedicine vs In Person Oncology Patient Surveillance,COMPLETED,,Dana-Farber Cancer Institute,2021-08-01,2022-11-01,2022-11-01,2021-06-23,2022-12-20,['Patient Experience Comparison'],"['Patient preference Comparison', 'Indirect Health Care Costs Comparison', 'Health system use Comparison', 'Clinician Experience Comparison', 'Clinician Preference', 'Symptom severity-prostate cancer patients Comparison']",,,,,2,United States,"Brigham and Women's Hospital [Boston, United States] | Dana Farber Cancer Institute [Boston, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text describes a comparison between telemedicine and in-person patient surveillance in oncology, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04940026,"Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women","A Phase 1, Open-label, Single Center, One Period, One Sequence Study to Determine Absorption, Metabolism, and Excretion of a Single Oral Dose of Radiolabeled [14C]- SAR439859 and an Assessment of the Absolute Oral Bioavailability Using the Microdosing Technique in Healthy Post-menopausal Women",COMPLETED,PHASE1,Sanofi,2021-06-15,2021-08-19,2021-08-19,2021-06-25,2025-09-24,"['Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administration', 'Percentage of radioactive dose excreted in urine and feces after oral administration', 'Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administration', 'Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administration', 'Assessment of PK parameter: CL for SAR439859 after IV administration', 'Assessment of PK parameter: AUC ratios after IV administration', 'Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administration', 'Assessment of PK parameter: AUC ratios after oral administration', 'Assessment of PK parameter: Cmax for M7 after IV and oral administration', 'Assessment of PK parameter: AUC for M7 after IV and oral administration', 'Assessment of PK parameter: t1/2z for M7 after IV and oral administration', 'Assessment of PK parameter: Rmet Cmax after IV and oral administration', 'Assessment of PK parameter: Rmet AUC after IV and oral administration', 'Absolute oral bioavailability of SAR439859', 'Relative bioavailability of SAR439859 after oral administration']",['Number of participants with adverse events'],,,,,1,United Kingdom,"Investigational Site Number 8260001 [Nottingham, United Kingdom]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2021.0,4.0,0,Phase 1
NCT04951245,Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy,"Ultrasound-assisted Carbon Nanoparticle Suspensions Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy in Patients With Early Breast Cancer (UltraCars): a Prospective, Randomized Controlled Phase 3 Trial",COMPLETED,PHASE3,Guangdong Provincial People's Hospital,2019-12-01,2021-04-30,2021-06-01,2021-07-06,2022-01-28,['The identification rate of SLNs'],"['The mean number of SLNs collected', 'Operative time', 'Intraoperative or postoperative complications']",,,,,1,China,"Guangdong General Hospital [Guangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial compares two existing methods (ultrasound-assisted mapping and dual-tracer-guided biopsy) in a specific patient population (early breast cancer), indicating an extension of indication rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,Phase 3
NCT04957186,Personalized Follow-up After Breast Cancer Surgery Via Electronic Patient Reported Outcomes,Development of a Multidisciplinary Care Pathway With Postoperative Follow-up Via Electronic Patient Reported Outcomes (ePRO) of Complications of Breast Cancer Surgery to Optimise Patients' Quality of Life.,COMPLETED,,Centre Hospitalier Universitaire de Nīmes,2021-04-01,2021-05-31,2022-06-30,2021-07-12,2022-09-28,"['Specific needs of patients who have undergone breast cancer surgery : ePRO results', 'Use of ePROs as a means of collecting post-surgical complications', 'Results of the interview with the nurse for collecting post-surgical complications', 'Actions desired in the event of an onset of complications in patients who have undergone breast cancer surgery.', 'Degree of anxiety/reassurance of patients who have undergone breast cancer surgery.', 'Expectations of patients who have undergone breast cancer surgery.']",[],,,,,1,France,"Nîmes University Hospital [Nîmes, France]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a follow-up care pathway and the use of electronic patient-reported outcomes (ePRO) for monitoring complications after breast cancer surgery, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04966923,Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53,Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53 (BREAST TP53),COMPLETED,,Instituto do Cancer do Estado de São Paulo,2018-12-02,2021-08-07,2022-02-22,2021-07-19,2022-08-09,['Progression free survival'],"['Overall Survival, causes of deaths, local breast cancer recurrence and contra-lateral breast cancer recurrence']",,,,,1,Brazil,"ICESP [São Paulo, Brazil]",2018.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the phenotype and prognosis of breast cancer patients with specific genetic variants, but does not indicate the introduction of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04976556,"Breast Cancer Detection in Breast Surgical Specimens With the Histolog Scanner, Slide-free Confocal Microscope","Breast Carcinoma Detection in Ex-vivo Fresh Breast Surgical Specimens Using the Histolog Scanner, Slide-free Confocal Microscopy Scanner",COMPLETED,,SamanTree Medical SA,2019-06-26,2021-01-15,2021-12-31,2021-07-26,2023-06-15,"['Accuracy, Sensitivity, Specificity, Positive predictive value, Negative predictive value for breast cancer detection']",['Accuracy for breast cancer diagnosis'],,,,,1,France,"Institut Gustave Roussy [Villejuif, France]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the use of a specific technology (Histolog Scanner) for detecting breast cancer in surgical specimens, which suggests an extension of indication for an existing diagnostic method rather than introducing a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT04979715,The Effect of Early Rehabilitation After Breast Cancer Surgery on Physical and Psychosocial Functions,The Effect of Early Rehabilitation After Breast Cancer Surgery on Physical and Psychosocial Functions,COMPLETED,,Pamukkale University,2020-07-01,2021-12-19,2022-01-19,2021-07-28,2023-06-12,"['determination of limb volume changes', 'determination of shoulder and upper extremity functions', 'muscle shortness test', 'Bioimpedance analysis for body composition determination; weight', 'Bioimpedance analysis for body composition determination;body mass index', 'Bioimpedance analysis for body composition determination; body fat and water percentage', 'Bioimpedance analysis for body composition determination; visceral fat level', 'Bioimpedance analysis for body composition determination; energy consumption', 'Bioimpedance analysis for body composition determination; metabolic age', 'determination of subdermal fluid ratio', 'assesment of fatigue', 'determination of cardiovascular endurance']","['determination of emotional status', 'Determination of quality of life']",,,,,1,Turkey (Türkiye),"Pamukkale University [Denizli, Turkey (Türkiye)]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effects of early rehabilitation after breast cancer surgery, focusing on physical and psychosocial functions, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04983342,Apollo Device for Metastatic Breast Cancer (MBC),Apollo Device for Fatigue in Metastatic Breast Cancer,COMPLETED,,Margaret Quinn Rosenzweig,2021-02-01,2022-08-09,2022-08-09,2021-07-30,2024-06-21,"['Change in Fatigue (PROMIS-Fatigue)', 'Change in Fatigue (FACT-F)']","['Degree of Pain', 'Use of pain medications', 'Health Related quality of life (HRQOL)', 'Promis Sleep Measurement', 'Hospital Anxiety and Depression Scale (HADS)']",,,,,1,United States,"Magee Womens Hospital [Pittsburgh, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text indicates the use of the Apollo Device for a new indication (fatigue) in patients with metastatic breast cancer, which suggests an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT04992156,Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET,A Retrospective Study of Prediction of 18F-FES-PET/CT Parameters on the Outcome of Palbociclib Combined With Endocrine Therapy in Patients With HR+ and HER2-metastatic Breast Cancer,COMPLETED,,Fudan University,2017-03-15,2022-03-15,2022-04-15,2021-08-05,2022-05-19,['PFS'],[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2017.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT04993040,A PK Study of Oraxol in Breast Cancer Patients,A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients,COMPLETED,PHASE1,"Athenex, Inc.",2019-04-22,2019-12-09,2020-12-09,2021-08-06,2021-08-06,"['Cmax', 'Cmin', 'Cavg', 'AUC0-t', 'AUC']","['Safety', 'Tumor response rate', 'Progression-free survival', 'Overall survival']",,,,,1,China,"Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University [Guangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study of Oraxol, which suggests it is a new medicine being evaluated for its pharmacokinetics in breast cancer patients.",INDUSTRY,False,2020.0,5.0,0,Phase 1
NCT04995328,Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel,"A Single Center, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® Gel",COMPLETED,,China Medical University Hospital,2021-08-03,2022-08-26,2022-10-07,2021-08-06,2023-09-06,['To observe the proportion of patients with grade 2 radiation dermatitis (according to CTCAE) at week 5.'],"['To evaluate radiation-irritated situation after 3 months of Radiation Care® gel application in breast cancer and head and neck cancer patients who completed the post-operative radiotherapy.', 'To compare the moisture percentage at the radiotherapy site from baseline to follow-up visit.', 'The score of quality of life with the Skindex-16 questionnaire performed every two weeks.']",,,,,1,Taiwan,"China Medical University Hospital [Taichung, Taiwan]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial investigates the use of an existing product (Radiation Care® Gel) for a new application (treatment of radiation-induced dermatitis), indicating an extension of indication.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05005650,Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy,Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy on Stage IVB Ovarian Cancer With Supradiaphragmatic Lymph Node Metastasis,COMPLETED,,Seoul National University Hospital,2021-06-01,2021-08-31,2021-12-31,2021-08-13,2023-06-26,['Progression-free survival'],['Overall survival'],,,,,1,South Korea,"Seoul National University Hospital [Seoul, South Korea]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text suggests an investigation into the survival impact of a surgical procedure (lymphadenectomy) in a specific patient population (Stage IVB ovarian cancer), indicating an extension of indication for an existing treatment rather than testing a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05021172,Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults,"Incorporating ePrognosis to Encourage ""Smarter Screening"" for Breast and Colorectal Cancer in Older Adults",COMPLETED,,"University of California, San Francisco",2021-08-24,2022-06-30,2022-06-30,2021-08-25,2022-07-11,"['Proportion of participants enrolled', 'Proportion of primary care physicians (PCPs) enrolled', 'Percentage of participants enrolled at 6 months', 'Proportion of participants who received an ePrognosis report', 'Proportion of physicians who utilized the ePrognosis clinician report', 'Responses to Qualitative Acceptability survey']",[],,,,,1,United States,"University of California San Francisco [San Francisco, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a screening approach using ePrognosis for breast and colorectal cancer in older adults, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05047575,Remote Electronic Assessment of Survivors With Feedback Communication and Directed Referrals,Pilot Study of a Follow-up Intervention to Improve the Quality of Care for Low-Risk Breast Cancer Survivors,COMPLETED,,"University of Wisconsin, Madison",2021-08-24,2022-07-28,2022-07-28,2021-09-17,2022-09-09,"['Feasibility: Number of Eligible Participants Enrolled', 'Number of survivorship symptoms/concerns that were addressed during the follow-up visit following clinician review of the REASSURE PRO assessment', 'Number of Participants who Replace or are Eligible to Replace a Medical Oncology Follow-Up visit with Feedback Communication', 'Number of PRO-generated Referral Recommendations that are Concordant with Medical Oncology Opinion']","['Percent of Survivors Who Would Recommend this Approach to other survivors', 'Number of Participants Whose Concerns Were Addressed During the Preceding Visit', 'Satisfaction with survivorship information measured with the Satisfaction with Information and Care Scale', 'Knowledge about survivorship issues measured with the Preparing for Life as a (New) Survivor (PLANS) Scale', 'Preparedness for survivorship issues measured with the Preparing for Life as a (New) Survivor (PLANS) Scale']",,,,,1,United States,"University of Wisconsin School of Medicine and Public Health [Madison, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a pilot study focused on a follow-up intervention for low-risk breast cancer survivors, assessing the feasibility and effectiveness of a communication approach rather than introducing a new medicine or extending the indication of an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05048095,Artificial Intelligence in Breast Cancer Screening in Region Östergötland Linkoping,The Use of AI as a Third Reader and During Consensus in a Double Reading Breast Cancer Screening Program in Sweden,COMPLETED,,"Ostergotland County Council, Sweden",2021-10-15,2022-02-15,2022-02-15,2021-09-17,2022-04-20,"['Cancer Detection rate', 'Recall or referral rate', 'Positive predictive value of referrals']",['Positive predictive value of Transpara® scores'],,,,,1,Sweden,"Region Östergötland [Linköping, Sweden]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the use of AI in breast cancer screening but does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT05054166,Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study,Efficacy of Everolimus-containing Chemotherapy in HER2 Negative Metastatic Breast Cancer Patients With PI3K/AKT/mTOR Mutations: A Retrospective Study,COMPLETED,,Zhejiang Cancer Hospital,2021-05-01,2021-08-01,2021-08-30,2021-09-23,2021-09-23,['PFS'],[],,,,,1,China,"Zhejiang Cancer Hospital [Hangzhou, China]",2021.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial evaluates the efficacy of an existing drug (Everolimus) in a specific patient population (HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations), indicating an extension of indication rather than a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05063604,Antidepressant Efficacy of Psychotherapy and Citalopram in Patients With Breast Cancer and Major Depression,"Randomized, Controlled, Open and Unicentric Phase II Clinical Trial, With Two Parallel Groups, to Evaluate the Antidepressant Efficacy of Psychotherapy and Citalopram in Women Diagnosed With Breast Cancer and Major Depression",TERMINATED,PHASE2,Hospital Universitari de Bellvitge,2022-05-10,2022-05-10,2022-06-29,2021-10-01,2022-07-05,['Change from Baseline in severity of depression on the Beck Depression Inventory (BDI) at week 12.'],"['Change from Baseline in quality of life on the European Quality of Life Scale Five Dimensions and Three Levels (EQ-5D-3L) at week 12.', 'Change from Baseline in social-labor adaptation measured by number of days off work at week 12.', 'Age of patients.', 'Marital status.', 'Cancer treatment received.', 'Breast cancer stage.', 'Basal whole-brain activity by performing a functional Magnetic Resonance Imaging (fMRI).', 'Change from baseline in emotional processing on the Dot-Probe Task (DPT).', 'Cost-effectiveness ratio differences between pharmacological treatment with citalopram and psychological treatment in patients in our environment with breast cancer (BC) and major depression (MD).', 'Number and severity of secondary side effects related to the consumption of pharmacological treatment with citalopram according to the side effects rating scale Udvalg für Kliniske Undersogelser (UKU).']",,,,,1,Spain,"Catalan Institute of Oncology [L'Hospitalet de Llobregat, Spain]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the efficacy of citalopram, which is an existing antidepressant, in a new patient population (women with breast cancer and major depression), indicating an extension of indication.",OTHER,False,2022.0,3.0,0,Phase 2
NCT05076773,"TPVB, PECSB, ESPB for Postmastectmy Pain","A Comparative Study Between Ultrasound-guided Thoracic Paravertebral Block, Pectoral Nerves Block, and Erector Spinae Block for Pain Management in Cancer Breast Surgeries. A Randomized Controlled Study",COMPLETED,,Menoufia University,2019-04-10,2021-08-10,2021-08-10,2021-10-13,2021-10-13,['The primary outcome of the study will be duration of analgesia (time to first rescue analgesia after administration of the block).'],"['Postoperative pain', 'Total morphine consumption', 'Postoperative nausea and vomiting (PONV)']",,,,,1,Egypt,"Faculty of Medicine Menofia University [Shibīn al Kawm, Egypt]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a comparative study of existing pain management techniques (TPVB, PECSB, ESPB) rather than introducing a new medicine or extending the indication of an existing one.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05090098,Breast Cancer and Kinesiophobia and Physical Activity,"Comparison of the Effects of Fear of Movement and Physical Activity Barriers on Physical Activity, Quality of Life and Psychological State of Women Who Have Had or Are Having Breast Cancer With Healthy People - Case Control Study",COMPLETED,,Acibadem University,2021-08-01,2021-11-15,2022-05-15,2021-10-22,2022-06-01,"['Tampa Kinesiophobia Scale', 'Questionnaire on exercise barriers', 'INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRES (IPAQ)']","['Fatigue Severity Scale', 'Hospital Anxiety and Depression Scale', 'Evaluation of Quality of Life: EORTC-Quality of Life -C 30']",,,,,1,Turkey (Türkiye),"Acıbadem University [Istanbul, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text describes a study comparing the effects of kinesiophobia and physical activity on women with breast cancer and does not mention a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT05100277,Impact of Oncotype DX® on Treatment Recommendation and Its Economic Evaluation Under the Brazilian Society Perspective,Impact of Oncotype DX® on Treatment Recommendation of for Early-stage Hormone Receptor-positive Breast Cancer and Its Economic Evaluation Under the Brazilian Society Perspective,COMPLETED,,Hospital Perola Byington,2018-08-08,2019-02-04,2019-02-04,2021-10-29,2022-01-06,"['The proportion of patients whose choice of treatment is changed as a result of Oncotype Test Low risk', 'Economic evaluation']",[],,,,,1,Brazil,"Andre Mattar [São Paulo, Brazil]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the impact of Oncotype DX® on treatment recommendations for a specific type of breast cancer, indicating an extension of indication for an existing test rather than introducing a new medicine.",OTHER_GOV,False,2019.0,6.0,0,NA/Other
NCT05110170,Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®,"A Multicenter, Randomized, Open-Label Phase Ⅲ Trial to Compare Efficacy and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® in Patients With Breast Cancer",COMPLETED,PHASE3,Luye Pharma Group Ltd.,2020-10-15,2022-04-05,2022-06-24,2021-11-05,2023-05-16,['Non-inferiority of LY01005 compared with ZOLADEX®: the percentage of subjects with serum E2 maintaining at postmenopausal level (≤30 pg/mL) from Week 4 to Week 12 after the first dose.'],"['Incidence of adverse events (AE).', 'Changes in serum E2 level after administration.', 'Changes in serum LH level after administration.', 'Changes in serum FSH level after administration.', 'PK subgroup: changes in serum E2 level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum LH level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum FSH level after administration to assess PD characteristic of LY01005.', 'PK subgroup: changes in serum goserelin level after administration to assess PK characteristic of LY01005.']",,,,,1,China,"Zhejiang Cancer Hospital [Hangzhou, China]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is evaluating LY01005, which is a new formulation of goserelin acetate, indicating it is a new medicine being tested for efficacy and safety in patients with breast cancer.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05114525,Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer,Analysis of Patient Understanding of Radiation Therapy Among Patients With Breast Cancer,COMPLETED,,Stanford University,2021-01-20,2021-10-12,2021-10-12,2021-11-10,2021-11-10,['post-consultation telephone questionnaire'],['correlations between patient survey score as a measure of patient understanding'],,,,,1,United States,"Stanford University [Palo Alto, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Overall Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on patient understanding of radiation therapy in breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05132101,Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea,Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a 1st Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea,COMPLETED,,Pfizer,2021-12-20,2022-03-14,2022-03-14,2021-11-24,2025-06-19,['Total treatment duration and cycle for Palbociclib'],['Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting.'],,,,,1,South Korea,"Pfizer Local Country Office [Seoul, South Korea]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT05134194,A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer,"A Muti-center, Open-label, Randomized, Phase III Study of Camrelizumab Plus Treatment of Physician Choice Versus Treatment of Physician Choice for Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Systemic Chemotherapy Regimens for Advanced/Metastatic Setting",TERMINATED,PHASE3,"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",2022-01-17,2022-01-17,2022-12-15,2021-11-24,2024-04-16,['Progression free survival (PFS)'],[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves Camrelizumab, which is being studied in combination with chemotherapy for a specific cancer type, indicating it is a new medicine being evaluated for a new use.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05141240,A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors,A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors,COMPLETED,,Novartis Pharmaceuticals,2020-04-15,2020-06-15,2020-06-15,2021-12-02,2021-12-16,"['Number of participants with a prescription fill of ribociclib, palbociclib, or abemaciclib', 'Number of participants who took concomitant medications in baseline period, by drug name', 'Number of participants who took concomitant medications in follow-up period, by drug name', 'Number of participants with no use of concomitant medications', 'Number of participants with proportion of days covered (PDC) >80%', 'Number of participants with proportion of days covered (PDC) ≤80%', 'Number of other breast cancer medications used']","['Mean starting dose for each CDK4/6', 'Number of participants who had any dose change (increase, decrease)', 'Number of participants who had a dose increase', 'Number of participants who had a dose decrease', 'Number of participants discontinuing each CDK4/6i (ribociclib, palbociclib, or abemaciclib)', 'Median duration of treatment (in months) by each CDK4/6i (ribociclib, palbociclib, or abemaciclib)']",,,,,1,United States,"Novartis Investigational site [East Hanover, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT05153135,Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors,Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors,COMPLETED,,Novartis Pharmaceuticals,2020-05-08,2020-07-31,2020-07-31,2021-12-10,2021-12-21,"['Number of inpatient (IP) admissions', 'Number of IP days', 'Number of days with durable medical equipment (DME) services', 'Number of days with emergency department (ED) visits', 'Number of days with outpatient (OP) services or visits', 'Other medical services', 'Total healthcare costs (medical service + pharmacy costs)']","['Treatment patterns', 'Monitoring']",,,,,1,United States,"Novartis Investigative Site [East Hanover, United States]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,"The text discusses treatment patterns and healthcare resource utilization for women with metastatic HR+/HER2- breast cancer treated with CDK4/6 inhibitors, indicating an extension of indication for an existing treatment rather than a new medicine.",INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT05153187,Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan,Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib (Ibrance(Registered)) Treatment in Japan by Using MDV Database,COMPLETED,,Pfizer,2019-08-31,2020-11-26,2020-11-26,2021-12-10,2024-11-13,"['Demographic and clinical characteristics of ABC patients at the initiation of treatment with palbociclib', 'Treatment patterns of palbociclib, including line of therapy and type of endocrine therapy combined with palbociclib, and initial dosage', 'Time to treatment failure (TTF) of palbociclib in combination with endocrine therapy by the line of therapy', 'Treatment patterns of subsequent therapy after end of palbociclib treatment, including line of therapy and type of treatment', 'TTF of subsequent therapy after end of palbociclib treatment', 'Changes in treatment pattern before and after the launch of palbociclib, the revision of clinical guideline in Japan', 'Use of antibiotics and/or granulocyte-colony stimulating factor (G-CSF) during treatment with palbociclib', 'Frequency of blood tests during treatment with palbociclib']","['Demographic and clinical characteristics of ABC patients at the initiation of treatment for ABC', 'Treatment patterns of each line of therapy for ABC patients', 'TTF of endocrine therapy for ABC patients', 'Treatment patterns of subsequent therapy after end of endocrine therapy for ABC patients, including line of therapy and type of treatment', 'TTF of subsequent therapy after end of endocrine therapy for ABC patients', 'Use of antibiotics and/or G-CSF during treatment with endocrine therapy for ABC']",,,,,1,Japan,"Pfizer Japan Inc. [Tokyo, Japan]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2020.0,5.0,0,NA/Other
NCT05161312,A Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients - a Randomised Clinical Trial,Oncovox - An Acceptance and Commitment Therapy Guided Online Intervention to Improve Quality of Life in Breast Cancer Patients: a Randomised Clinical Trial,COMPLETED,,Babes-Bolyai University,2021-11-15,2022-02-25,2022-05-25,2021-12-17,2024-02-28,"['Quality of life - Functional Assessment of Cancer Therapy - Breast (FACT-B)', 'Behavioral activation - Behavioral activation scale (BAS)', 'Symptom interference - MD Anderson Symptom Inventory (MDASI)', 'Reward observation - Environmental reward observation scale (EROS)']","['Distress - Distress Thermometer (DT)', 'Anxiety & depression - Hospital Anxiety and Depression Scale (HADS)', 'Psychological flexibility - Acceptance and Action Questionnaire for Cancer (AAQ-II-C)']",,,,,1,Romania,"Babes-Bolyai University [Cluj-Napoca, Romania]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT05176405,Entertainment Media to Deliver Educational Messages About Mammography in Saudi Arabia,Using Entertainment Media to Deliver Educational Messages About Mammography in Saudi Arabia,COMPLETED,,Virginia Commonwealth University,2022-02-10,2022-03-14,2022-03-14,2022-01-04,2022-09-02,['Measure the role of issue involvement in predicting intention to perform breast cancer early screening via mammogram among Saudi females after exposure to EE message.'],"[""Measure the Theory of Planned Behavior (TPB) construct attitude, to predict Saudi females' intention to perform breast cancer early screening via mammogram"", ""Measure the TPB construct, subject norm, to predict Saudi females' intention to perform breast cancer early screening via mammogram"", ""Measure the TPB construct perceived behavioral control, to predict Saudi females' intention to perform breast cancer early screening via mammogram"", 'Compare the differences between EE viewers and non EE viewers in terms of issue involvement', 'Compare the differences between EE viewers and none EE viewers in terms of attitude.', 'Compare the differences between EE viewers and none EE viewers in terms of perceived behavioral control.', 'Measure intention toward mammography']",,,,,1,United States,"Virginia Commonwealth University [Richmond, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses educational messages about mammography and does not indicate a new medicine or an extension of indication for an existing medicine.,OTHER,False,2022.0,3.0,0,NA/Other
NCT05179161,Validation of Prone Crawl Radiotherapy for Whole-breast Irradiation After Breast Conserving Surgery,Validation of Prone Crawl Radiotherapy for Whole-breast Irradiation After Breast Conserving Surgery,COMPLETED,,"University Hospital, Ghent",2016-05-31,2016-09-29,2017-03-29,2022-01-05,2022-01-05,['Setup error'],"['Patient comfort', 'Setup Time', 'Reproducibility of DIBH', 'Acute toxicity', 'Dose to target and dose to organs at risk']",,,,,0,,,2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a radiotherapy technique rather than a new medicine or an extension of indication for an existing medicine.,OTHER,False,2017.0,8.0,0,NA/Other
NCT05185752,Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery,Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery,COMPLETED,,University of Valencia,2018-06-01,2019-06-30,2020-06-30,2022-01-11,2022-01-11,"['Which technique presents less pain in visual analogue scale (VAS score) in the immediate postoperative', 'Which technique presents less pain in visual analogue scale (VAS score) 24 hours after surgery', 'Which technique presents less pain in visual analogue scale (VAS score) 3 months after surgery.', 'Which technique presents less pain in visual analogue scale (VAS score) 1 year after surgery.', 'Rate of participants that required opioid consumption.', 'Rate of participants that required consumption of analgesia 1 year after surgery.']","['Rate of participants that presented intraoperative hemodynamic alterations', 'The Length (number of hours) of Hospital Stay: comparison between the three study groups.', 'Assistance by Pain Unit: comparison between the three study groups.', 'Compare the incidence of location of chronic postoperative pain between the three study groups.']",,,,,1,Spain,"José De Andrés Ibáñez [Valencia, Spain]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a comparative analysis of anesthesia methods in surgery, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT05206656,Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer,"Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer Patients: An Open-Labeled, Single-center, Prospective Study",COMPLETED,PHASE2,Hunan Cancer Hospital,2020-10-09,2022-04-30,2022-07-20,2022-01-25,2022-11-23,['Progression-Free Survival'],"['Disease Control Rate (DCR)', 'Overall survival (OS)', 'Objective response rate (ORR)', 'Adverse Events', 'Patient Report Outcome (PRO)']",,,,,1,China,"Hunan Cancer Hospital [Changsha, China]",2020.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial evaluates the safety and efficacy of Eribulin, which is an existing medication, in combination with Anlotinib for a specific patient population (metastatic breast cancer), indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT05218876,Effects of Moderate and High-intensity Exercise During Chemotherapy on Muscle Cells in Women With Breast Cancer,Effects of Moderate and High-Intensity Exercise During (Neo-)Adjuvant Chemotherapy on Muscle Cellular Outcomes in Women With Breast Cancer: a Randomized Controlled Trial,COMPLETED,,Norwegian School of Sport Sciences,2016-12-08,2022-11-30,2022-11-30,2022-02-01,2023-11-28,['Muscle fiber cross-sectional area'],"['Muscle fiber cross-sectional area', 'Satellite cell content in muscle fiber cross-sections', 'Myonuclei content in muscle fiber cross-sections', 'Protein levels of regulators of muscle fiber size (proteins involved in muscle protein synthesis and protein degradation (e.i. mTOR, MuRF, S6K1, p70S6k)', 'Protein levels of regulators of muscle fiber cellular stress (Heat Shock proteins: Hsp 27, αB-crystalline, Hsp 60 and Hsp 70)', 'Protein levels of regulators of mitochondrial function (Citric syntase, Cox 4 and HADH)', 'Myokines with potential anti-tumor effects', 'Maximal muscle strength', 'Cardiorespiratory fitness', 'Muscular endurance', 'Fat free mass', 'Fat mass']",,,,,1,Norway,"Haukeland University Hospital [Bergen, Norway]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,NA/Other
NCT05219578,RTX-224 Monotherapy in Patients With Solid Tumors,A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors,TERMINATED,PHASE1; PHASE2,Rubius Therapeutics,2022-01-12,2022-11-30,2022-11-30,2022-02-02,2022-12-09,"['Safety Assessment by rate of Adverse Events (AEs)', 'Dose limiting toxicities (DLTs) of RTX-224']","['Pharmacodynamics (PD) of RTX-224', 'Pharmacokinetics (PK) of RTX-224', 'Pharmacokinetics (PK) of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224', 'Anti-tumor activity of RTX-224']",,,,,5,United States,"HonorHealth [Scottsdale, United States] | USC Norris Comprehensive Cancer Center [Los Angeles, United States] | University of California San Francisco Health [San Francisco, United States] | Sarah Cannon Research Institute [Nashville, United States] | Virginia Cancer Specialists [Fairfax, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 2
NCT05224310,Comparing the Quality of Analgesia With Pectoral Nerve Block and Serratus Plane Block in Modified Radical Mastectomy,Comparing the Quality of Analgesia With Ultrasound-guided Pectoral Nerve Block and Serratus Plane Block in Patients Undergoing Modified Radical Mastectomy,COMPLETED,,Suez Canal University,2022-04-01,2022-06-30,2022-07-30,2022-02-04,2022-08-05,['The first request for analgesia'],['Post-operative pain'],,,,,1,Egypt,"Suez Canal University [Ismailia, Egypt]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a comparison of analgesia techniques (pectoral nerve block and serratus plane block) in a specific surgical context, but does not introduce a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05266300,Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.,Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines,COMPLETED,,University of Southern Denmark,2020-09-01,2022-06-01,2022-10-01,2022-03-04,2022-11-01,['Adverse events'],"['5-FU or capecitabine or S1-related mortality, all patients', '5-FU or capecitabine or S1-related mortality, DPYD variant carriers', 'Overall mortality, all patients', 'Overall mortality, DPYD variant carriers', 'Length of hospital stay', 'Rate of discontinuation of fluoropyrimidines due to adverse events']",,,,,1,Denmark,"The Department of Oncology at University of southern denmark [Odense, Denmark]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses the implementation of DPYD-genotyping in patients treated with existing fluoropyrimidines, indicating an extension of indication for these treatments based on genetic testing.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05275361,Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women,Pilot Study Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women,COMPLETED,,Washington University School of Medicine,2022-03-18,2022-06-30,2022-06-30,2022-03-11,2022-07-07,"[""Feasibility of recruiting patients' social contacts to serve as healthcare facilitators as measured by number of participants enrolled to the study with a social contact that agrees to participate""]","['Describe demographic characteristics of the social contacts and any associations with patient appointment attendance', 'Rate of mammography attendance', 'Using a structured survey interview, determine the percentage of patients and their social contacts who respond positively (agree or strongly agree) that the intervention helped them keep their scheduled screening mammogram appointment']",,,,,1,United States,"Washington University School of Medicine [St Louis, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a pilot study focused on facilitating mammogram screening among African American women through social contacts, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05283616,Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer,A Randomized Controlled Study Comparing Different Doses of Pegfilgrastim as Support for Adjuvant Chemotherapy for Breast Cancer,COMPLETED,PHASE3,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",2017-05-15,2019-10-10,2021-10-15,2022-03-17,2024-03-19,['timely recovery of ANC'],"['febrile neutropenia in cycle1', 'grade 3/4 neutropenia in cycle 1', 'grade 4 neutropenia in cycle 1', 'hospitalization due to neutropenia']",,,,,1,China,"Department of Medical Oncology [Beijing, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,Phase 3
NCT05291494,A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients,A Study on the Effectiveness of WeChat-based Online Education to Reduce Perioperative Anxiety in Breast Cancer Patients: a Prospective Randomized Controlled Study,COMPLETED,,West China Hospital,2021-02-01,2022-03-31,2022-03-31,2022-03-22,2022-08-31,['the incidence of preoperative anxiety'],"['incidence of severe anxiety (S-AI > 44) on 1day before and at 72 hours after surgery', 'incidence of anxiety 72 hours after surgery', 'NRS scores for pain at rest and during movement', 'incidence of PONV within 24 hours after surgery', 'subjective sleep score (Sleep Quality Score (SQS))', 'quality of life QoR-15 scores at 1 and 3 months postoperatively']",,,,,1,China,"West China Hospital [Chengdu, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a study on the effectiveness of an educational intervention (WeChat-based online education) to reduce anxiety in breast cancer patients, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05301010,Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients,"Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2",COMPLETED,PHASE3,Nanogen Pharmaceutical Biotechnology Joint Stock Company,2018-02-02,2021-02-19,2021-02-19,2022-03-29,2023-02-27,"['Overall Response Rate (ORR) according to RECIST 1.1 after 6 cycles', 'Overall Response Rate (ORR) according to RECIST 1.1 at the end of study']","['Progressive Disease Rate (PDR) according to RECIST 1.1', 'Stable Disease Rate (SDR) according to RECIST 1.1', 'Progression-free survival (PFS) according to RECIST 1.1', ""Evaluate the patient's quality of life"", 'Anti-drug antibody evaluation', 'Rate of AE and SAE occurence']",,,,,2,Vietnam,"19-8 Hospital [Hanoi, Vietnam] | HCMC Oncology Hospital [Ho Chi Minh City, Vietnam]",2018.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Progression-Free Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The trial assesses the efficacy and safety of Trastuzumab, which is an existing medication, in a new patient population (recurrent or metastatic breast cancer patients with positive HER2), indicating an extension of indication.",INDUSTRY,False,2021.0,4.0,0,Phase 3
NCT05306002,Nutritional Intervention and DNA Damage of Patients With HBOC,Effects of a Nutritional Intervention in DNA Damage of Patients With Hereditary Breast and Ovarian Cancer Syndrome,COMPLETED,,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,2017-11-28,2020-03-22,2022-12-31,2022-03-31,2024-03-05,['DNA damage change'],"['Body composition change', 'Muscular strength change', 'Dietary change: Energy', 'Dietary change: Macronutrients', 'Dietary change: Micronutrients']",,,,,1,Mexico,"María Fernanda Díaz Yáñez [Mexico City, Mexico]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses a nutritional intervention for patients with hereditary breast and ovarian cancer syndrome, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER_GOV,False,2022.0,3.0,0,NA/Other
NCT05360407,The Effect of Mobile Application-based Information About Before and After Surgery,"The Effect of Mobile Application-based Information About Before and After Surgery on Anxiety, Distress and Quality of Life of Women With Breast Cancer",COMPLETED,,Suleyman Demirel University,2021-04-01,2021-08-30,2021-08-30,2022-05-04,2022-05-04,['Change of NCCN Distress Thermometer score at baseline and one month later'],"['Change of Hospital Anxiety and Depression Scale score at baseline and one month later', 'Change of FACT-G Quality of Life Scale score at baseline and one month later']",,,,,1,Turkey (Türkiye),"Suleyman Demirel University [Isparta, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of a mobile application on anxiety, distress, and quality of life in women with breast cancer, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05364255,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833","A Phase I, Open-Label, Single-Dose, Single-Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 After Oral Administration in Healthy Post-Menopausal Female Subjects",COMPLETED,PHASE1,AstraZeneca,2022-05-10,2022-06-20,2022-06-20,2022-05-06,2024-06-21,"['The cumulative amount of AZD9833 excreted (CumAe)', 'The cumulative amount of AZD9833 excreted, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry', 'Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry', 'Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry']","['The amount of total radioactivity eliminated in urine (Ae)', 'The amount of total radioactivity eliminated in urine expressed as a percentage of the radioactive dose administered (%Ae)', 'The cumulative amount of AZD9833 excreted in urine (CumAe)', 'The cumulative amount of AZD9833 excreted in urine, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'The amount of total radioactivity eliminated in faeces (Ae)', 'The amount of total radioactivity eliminated in faeces expressed as a percentage of the radioactive dose administered (%Ae)', 'The cumulative amount of AZD9833 excreted in faeces (CumAe)', 'The cumulative amount of AZD9833 excreted in faeces, expressed as a percentage of the radioactive dose administered (Cum%Ae)', 'Time to maximum concentration (tmax) for AZD9833 and total radioactivity', 'Maximum observed concentration (cmax) for AZD9833 and total radioactivity', 'Area under the curve from time 0 to the time of last measurable concentration for AZD9833 and total radioactivity (AUC0-t)', 'Area under the curve from time 0 extrapolated to infinity for AZD9833 and total radioactivity (AUC0-inf)', 'Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC%extr) and total radioactivity', 'Terminal elimination half-life for AZD9833 (t1/2) and total radioactivity', 'First order rate constant associated with the terminal (log-linear) portion of the curve for AZD9833 (λz) and total radioactivity', 'Total body clearance calculated after a single extravascular administration for AZD9833 (CL/F) and total radioactivity', 'Apparent volume of distribution based on the terminal phase for AZD9833 (Vz/F) and total radioactivity', 'Renal clearance for AZD9833 (CLr) and total radioactivity', 'Evaluation of whole blood:plasma concentration ratios for total radioactivity', ""Number of AE's experienced by subjects""]",,,,,1,United Kingdom,"Research Site [Ruddington, United Kingdom]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05389605,Outcomes of Local Perforator Flaps in Oncoplastic Surgery,A Single Centre Experience of Local Perforator Flaps in Oncoplastic Breast Surgery; a Cross-sectional Study,COMPLETED,,Aga Khan University,2020-04-18,2021-06-29,2021-06-30,2022-05-25,2022-05-27,"['Surgical techniques of pedicled local fasciocutaneous perforator flaps in partial breast reconstruction in terms of flap anatomy', 'Surgical techniques of pedicled local fasciocutaneous perforator flaps in partial breast reconstruction in terms of location of perforators', 'Surgical techniques of pedicled local fasciocutaneous perforator flaps in partial breast reconstruction in terms of operative time', 'Surgical techniques of pedicled local fasciocutaneous perforator flaps in partial breast reconstruction in terms of post-operative morbidities']","['Cosmetic outcomes of patients following local perforator flaps in oncoplastic breast conserving surgery', 'Patient satisfaction following local perforator flaps in oncoplastic breast conserving surgery']",,,,,1,Pakistan,"The Aga Khan University [Karachi, Pakistan]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses surgical techniques and outcomes related to local perforator flaps in oncoplastic breast surgery, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05392985,Detection and Analysis of MBC With Heterogeneous ER Expression,Chemotherapy Versus Endocrine Therapy in Metastatic Breast Cancer Patients With Heterogeneous Estrogen Receptor Expression,COMPLETED,,Fudan University,2022-01-15,2022-12-15,2022-12-15,2022-05-26,2024-02-26,['PFS'],['Adverse events'],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses treatment options (chemotherapy vs endocrine therapy) for a specific patient population (metastatic breast cancer patients with heterogeneous estrogen receptor expression), indicating an extension of indication for existing therapies rather than testing a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05395117,"A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin","A Fixed Sequence, Open-label Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Probe), Rosuvastatin (OATP1B1/3, BCRP Probe), and Digoxin (P-gp Probe) in Healthy Participants",COMPLETED,PHASE1,AstraZeneca,2022-06-30,2022-09-12,2022-09-12,2022-05-27,2023-12-13,"['Area under the concentration-versus-time curve from pre-dose (time 0) extrapolated to infinite time (AUCinf)', 'Area under the concentration-versus-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (AUClast)', 'Maximum observed serum (peak) drug concentration [Cmax]']","['Time to reach peak or maximum observed concentration or response following drug administration (tmax)', 'Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t1/2λz)', 'Partial area under the serum concentration time curve from time 0 to time 12 (AUC0-12h)', 'Maximum observed serum (peak) drug concentration [Cmax]', 'Time to reach peak or maximum observed concentration or response following drug administration (tmax)', 'Trough plasma exposure of AZD5462 (Ctrough)', 'Incidence of Adverse Events (AEs)']",,,,,1,United States,"Research Site [Brooklyn, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial text indicates a study involving AZD5462, which suggests it is a new medicine being assessed for its pharmacokinetic interactions with other drugs.",INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05427617,Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer,Clinical Application of Circulating Tumor DNA (ctDNA) to Guided the Late-Line Treatment for Patients With Late-Stage Breast Cancer,COMPLETED,,Hunan Cancer Hospital,2016-12-01,2019-06-30,2021-06-30,2022-06-22,2022-06-22,"['Disease Control Rate (DCR)', 'Progression-Free Survival']",[],,,,,0,,,2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the application of ctDNA in guiding treatment for late-stage breast cancer, which suggests an extension of indication for existing treatments rather than the introduction of a new medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05435911,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil vs. Propofol,Comparison of Recovery From General Anesthesia in Remimazolam With Flumazenil Compared to Propofol-based Total Intravenous Anesthesia in Patients Undergoing Breast Cancer Surgery: a Randomized Controlled Trial,COMPLETED,,Seoul National University Hospital,2022-08-02,2022-12-21,2022-12-21,2022-06-28,2023-01-13,['Time to eye opening (minute)'],"['Time to emergence (minutes)', 'Bispectral index score (Score)', 'Incidence of emergence agitation at operating room (n(%))', 'The modified Aldrete score (Score)', 'The modified Observers Assessment of Alertness/Sedation Scale (Score)', 'Postoperative Pain (score)', 'Postoperative opioid consumption (The number of analgesic use)', 'Postoperative nausea and vomiting (The incidence of PONV, n(%))', 'Postoperative quality of recovery (score)', 'Postoperative opioid consumption (The number of analgesic use)', 'Postoperative Pain (score)']",,,,,1,South Korea,"Department of Anesthesiology and Pain Medicine, Seoul National University Hospital [Seoul, South Korea]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial compares the effects of Remimazolam, which is a new medicine, against Flumazenil and Propofol in a specific surgical context.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05438303,"Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers","A Phase 1, Multi-center, Open-label, 3-arm, Fixed Sequence Study to Assess the Effect of Co-administration of AZD9833 on the Pharmacokinetics of Midazolam (CYP3A4/5 Substrate), of Omeprazole (CYP2C19 Substrate), of Celecoxib (CYP2C9 Substrate) and of Dabigatran Etexilate (P-gp Transporter Substrate) in Healthy Postmenopausal Female Volunteers",COMPLETED,PHASE1,AstraZeneca,2022-06-13,2022-12-13,2022-12-13,2022-06-29,2023-01-12,"['Area under plasma concentration time curve from zero to infinity (AUCinf) of midazolam, omeprazole, total dabigatran, and celecoxib', 'Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of midazolam, omeprazole, total dabigatran, and celecoxib', 'Maximum observed plasma concentration (Cmax) of midazolam, omeprazole, dabigatran etexilate and celecoxib']","['Number of participants with Adverse Events (AEs)', 'AUCinf for AZD9833 and free dabigatran', 'AUClast for AZD9833 and free dabigatran', 'Area under plasma concentration-time curve in the dose interval (AUCt) for AZD9833 and free dabigatran', 'Cmax for AZD9833 and free dabigatran', 'Time to reach maximum observed concentration (tmax) for AZD9833 and free dabigatran', 'Half-life associated with terminal slope of a semi-logarithmic concentration-time curve (t½λz) for AZD9833 and free dabigatran', 'Apparent total body clearance from plasma after extravascular administration (CL/F) for AZD9833 and free dabigatran', 'Apparent volume of distribution based on terminal phase (Vz/F) for AZD9833 and free dabigatran', 'tmax for midazolam, omeprazole, total dabigatran, and celecoxib', 't½λz for midazolam, omeprazole, total dabigatran, and celecoxib', 'CL/F for midazolam, omeprazole, total dabigatran, and celecoxib', 'Vz/F for midazolam, omeprazole, total dabigatran, and celecoxib', 'Area under the plasma concentration-curve from zero to 24 hours post dose (AUC0-24) for celecoxib']",,,,,2,United States,"Research Site [Long Beach, United States] | Research Site [Berlin, United States]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,,INDUSTRY,False,2022.0,3.0,0,Phase 1
NCT05447949,Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy,"Comparison of Dexmedetomidine Versus Dexamethasone as Adjuncts to Levobupivacaine in Ultrasound Guided Erector Spinae Plane Block for Patients Undergoing Modified Radical Mastectomy, Randomized Double-Blinded Comparative Study.",COMPLETED,,"National Cancer Institute, Egypt",2020-12-15,2022-03-15,2022-03-15,2022-07-07,2022-07-07,['Total amount of morphine consumed postoperatively for 24 hours.'],"['Total amount of fentanyl consumed intraoperatively.', 'Change in heart rate intraoperatively', 'Change in mean arterial blood pressure intraoperatively', 'Postoperative sedation according to Ramsay scores.', 'Time to first rescue analgesia.', 'Numeric Pain Rating Scale score, both at rest and during movement', 'Block related complications', ""Patient's satisfaction"", 'Incidence of Postoperative nausea and vomiting (PONV).']",,,,,1,Egypt,"National Cancer Institute - Cairo University [Cairo, Egypt]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT05448586,Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit?,Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? Retrospective Observational Study,COMPLETED,,Instituto de Investigación Hospital Universitario La Paz,2019-02-02,2021-01-30,2021-01-30,2022-07-07,2022-07-07,"['Postoperative Systemic Inflammatory Response (C-Reactive Protein)', 'Postoperative Systemic Inflammatory Response (Leucocytes Ratio)', 'Postoperative Systemic Inflammatory Response (Platelet Level)']","['Time spent in the Post-Anesthesia Care Unit (PACU)', 'Hospital stay', 'Rate of later postoperative complications', 'Number of Participants with Cancer recurrence after surgery', 'Number of patients who Survive 12 months after surgery']",,,,,1,Spain,"Julia Albano Polo [Madrid, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2021.0,4.0,0,NA/Other
NCT05455385,The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study,The Added Value of a Third Supervised Training Session (Ground Exercises or Hydrotherapy) to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study,COMPLETED,,Universitaire Ziekenhuizen KU Leuven,2021-06-05,2022-01-31,2022-01-31,2022-07-13,2022-07-14,"['Shoulder mobility', 'Arm volume', 'Force based on handgrip strength', 'Flexibility by means of the sit-and-reach test', 'Exercise capacity based on 6-minute walk test', 'Body image using the Body Image Scale', 'self-reported pain using the Brief Pain Inventory', 'Fatigue using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale', 'Anxiety and depression using the Hospital Anxiety and Depression Scale', 'Quality of life using the McGill Quality Of Life questionnaire', 'Physical functioning using the Patient-Reported Outcomes Measurement Information System', 'Patient Specific Complaints', 'Global Perceived Effect', 'Attendance: number of times the participant was present']",[],,,,,1,Belgium,"University Hospital Leuven [Leuven, Belgium]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a pilot study on the effectiveness of an additional supervised training session in a rehabilitation program for breast cancer patients, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05478590,A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting,"HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY",COMPLETED,,Pfizer,2021-11-22,2022-09-30,2022-09-30,2022-07-28,2023-12-18,['Number of Participants With HR+ HER2- Advanced Breast Cancer (ABC) Treatment Patterns'],"['Number of Changes in Clinical Practice During One Year Observational Period in Relation to the Local Breast Cancer (BC) Treatment Guidelines', 'Correlation of Treatment Patterns With the Reference of the si.+-te Defined by Number of Enrolled Patients', 'Demographical Characteristics of Participants', 'Correlation of Treatment Type to Demographical Characteristics of Participants', 'Disease Characteristics of Treated BC Participants', 'Clinical Characteristics of Treated BC Participants', 'Treatment Modalities of Neoadjuvant Therapies Early BC', 'Treatment Modalities of Adjuvant Therapies Early BC', 'Time to Disease Free Interval', 'Number of Participants With Association Between Disease Characteristic and ABC Treatment Patterns', 'Number of Participants With Association Between Clinical Characteristic and ABC Treatment Patterns', 'Number of Participants With Association Between Neoadjuvant Therapy and ABC Treatment Patterns', 'Number of Participants With Association Between Adjuvant Therapy and ABC Treatment Patterns', 'Number of Participants With Association Between Time to Relapse in early BC Treatment and ABC Treatment Patterns', 'Number of Participants With Association Between Concomitant Therapy and ABC Treatment Patterns', 'Proportion of Participants With Diagnosed Visceral Crisis', 'Number of Visceral Crisis Diagnosis in Compliance With ABC5 Guidelines']",,,,,19,Poland,"Ambulatorium Chemioterapii Centrum Onkologii [Bydgoszcz, Poland] | Wojewodzki Szpital Zespolony w Elblągu - oddzial onkologii [Elblag, Poland] | Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii [Gdansk, Poland] | Oddział onkologii Szpital Specjalistyczny im. H. Klimontowicza [Gorlice, Poland] | Oddział Onkologii Klinicznej [Kalisz, Poland] | Narodowy Instytut Onkologii [Krakow, Poland] | Oddział Onkologii Klinicznej z Pododdziałem Dziennym [Krakow, Poland] | Klinika Onkologii, Instytut Centrum Zdrowia Matki Polki [Lodz, Poland] | Opolskie Centrum Onkologii [Opole, Poland] | Oddział/Poradnia Onkologiczna Wojewodzki Szpital w Przemyślu [Przemyśl, Poland] | Podkarpackie Centrum Onkologii [Rzeszów, Poland] | SPZOZ Oddział onkologii klinicznej [Swidnica, Poland] | Zachodniopomorskie Centrum Onkologii [Szczecin, Poland] | Izerskie Centrum Pulmonologii i Chemioterapii ""Izer-Med"" Sp. z o.o [Szklarska Poręba, Poland] | Specjalistyczny Szpital Onkologiczny NU-MED [Tomaszów Mazowiecki, Poland] | Centralny Szpital Kliniczny MSWiA w Warszawie [Warsaw, Poland] | Pfizer Polska [Warsaw, Poland] | Wojewodzki Szpital Specjalistyczny we Wroclawiu [Wroclaw, Poland] | Dolnośląskie Centrum Onkologii [Wroclaw, Poland]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT05510037,Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions,Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions,COMPLETED,,Fudan University,2021-01-01,2022-06-01,2022-06-01,2022-08-22,2022-08-22,['overall survival'],[],,,,,1,China,"Fudan University Shanghai Cancer Center [Shanghai, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses the incidence and prognostic significance of HER-2 status discordance in breast cancer but does not indicate the introduction of a new medicine or an extension of indication for an existing treatment.,OTHER,False,2022.0,3.0,0,NA/Other
NCT05569187,Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer,"An Observational, Retrospective, Multicenter, National Study of the Effectiveness of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in First-line Treatment of Brazilian Patients With HR+/HER2- Advanced Breast Cancer",COMPLETED,,Novartis Pharmaceuticals,2021-03-23,2021-10-29,2021-10-29,2022-10-06,2022-11-08,['Proportion of patients alive and progression-free from disease at 1 year'],"['Proportion of patients alive and progression-free from disease at 6 months', 'Proportion of patients who had disease progression at 6 months', 'Proportion of patients who had disease progression at 1 year', 'Proportion of patients who died at 6 months', 'Proportion of patients who died at 1 year', 'Proportion and cause of patients who reduced a treatment dose at 6 months', 'Proportion and cause of patients who reduced a treatment dose at 1 year', 'Frequency of dose interruption and cause, per patient, at 1 year', 'Adverse Event frequency and classification of the severity degree', 'Pattern of the treatment of AE of interest at 6 months', 'Pattern of the treatment of AE of interest at 12 months']",,,,,1,Brazil,"Novartis Investigative Site [São Paulo, Brazil]",2021.0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,0,1,"The study evaluates the effectiveness of Ribociclib in combination with non-steroidal aromatase inhibitors for a specific patient population (HR+/HER2- advanced breast cancer), indicating an extension of indication rather than a new medicine.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT05600257,The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study,The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study,COMPLETED,,Kaohsiung Veterans General Hospital.,2011-09-01,2021-08-31,2021-08-31,2022-10-31,2022-11-04,['Overall survival rate'],[],,,,,1,Taiwan,"Kaohsiung Veterans General Hospital [Kaohsiung City, Taiwan]",2011.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the effect of a diagnostic imaging technique (Digital Breast Tomosynthesis) on long-term survival in breast cancer patients, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05609903,Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer,Atezolizumab in Combination With Nab-paclitaxel for Patients With Previously Untreated Metastatic Triple-negative Breast Cancer in a Real World Experience,COMPLETED,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,2019-11-01,2020-08-01,2022-05-31,2022-11-08,2022-11-08,"['Objective responce rate', 'Time-to-treatment discontinuation']",[],,,,,1,Italy,"Policlinico A. Gemelli - IRCCS [Roma, Italy]",2019.0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text discusses the use of Atezolizumab in combination with Nab-paclitaxel for a specific patient population (triple-negative stage IV breast cancer), indicating an extension of indication for an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05614518,Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT,"A Randomized, Open-Label, Crossover, Controlled, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases of Malignant Tumors Compared With 99mTc⁃MDP-BS±SPECT",COMPLETED,PHASE3,"HTA Co., Ltd.",2021-03-29,2022-06-02,2022-06-02,2022-11-14,2022-11-14,['Assess the sensitivity and specificity of 18F-NaF-PET/CT compared with 99mTc-MDP-BS±SPECT based on subjects.'],"['Number of participants with adverse events as assessed by CTCAE v5.0.', 'Assess the positive and negative predictive value of 18F-NaF-PET/CT compared with 99mTc-MDP-BS±SPECT based on subjects.', 'Assess the sensitivity, specificity, positive and negative predictive value of 18F-NaF-PET/CT compared with 99mTc⁃MDP-BS±SPECT based on lesions.']",,,,,1,China,"Chinese Academy of Medical Sciences Peking Union Medical College Hospital [Beijing, China]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial is assessing the diagnostic performance and safety of 18F-NaF-PET/CT, which indicates it is a new medicine being evaluated for its effectiveness in a specific application (bone metastases).",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT05639829,Time-restricted Eating in Survivors Trial,Time-restricted Eating in Survivors Trial,COMPLETED,,University of Alberta,2020-08-05,2021-07-28,2021-07-28,2022-12-06,2023-04-12,['Framingham 10-year cardiovascular risk score (%)'],"['Visceral adipose tissue', 'Thigh adipose tissue fraction', 'Liver adipose tissue fraction', 'Cardiorespiratory fitness', 'Resting energy expenditure', 'Respiratory quotient', 'Lipid profile', 'Hemoglobin A1c', 'Waist circumference', 'Fasting glucose', 'Fasting insulin', 'Resting systolic and diastolic blood pressure', 'Body mass', 'Whole-body fat mass', 'Whole-body fat-free mass']",,,,,1,Canada,"Edmonton Clinic Health Academy [Edmonton, Canada]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a trial focused on time-restricted eating in survivors, which does not indicate a new medicine or an extension of indication for an existing medicine. It appears to be a study on dietary intervention rather than a pharmaceutical trial.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05663021,Feasibility in Identification of Breast Cancer Candidates for Elimination of Axillary Surgery,Feasibility in Identification of Suitable Candidates for Elimination of Axillary Surgery in Breast Cancer Patients With Initial Biopsy-confirmed Nodal Metastases,COMPLETED,,Fudan University,2017-07-01,2021-06-26,2022-02-28,2022-12-23,2022-12-23,['Diagnostic Accuracy of Ultrasound-Guided Core Biopsy of Initial Breast Cancer Region Compared to Axillary Surgery with Pathologic Evaluation Cancer Region Compared to Standard Surgery with Pathologic Evaluation'],[],,,,,1,China,"Zhi-Min Shao [Shanghai, China]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a feasibility study related to surgical procedures in breast cancer patients, but does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05764577,DIEP Flap Surgery and Intraabdominal Pressure,Intraabdominal Pressure Increases Peri-operatively in Patients Undergoing DIEP Flap Reconstruction: A Prospective Study Linking High IAP to Non-fatal Lung Embolism in One Patient,COMPLETED,,Aalborg University Hospital,2021-04-19,2021-11-29,2022-01-25,2023-03-10,2023-03-10,['Changes from Baseline in intraabdominal pressure at timepoint immediate after- and 24 hours after abdominal skin closure.'],[],,,,,1,Denmark,"University hospital Aalborg [Aalborg, Denmark]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a surgical procedure and its effects on intraabdominal pressure, but it does not introduce a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05776433,"The Effects of Upper Extremity Lymphedema on Posture, Upper Extremity Functions, and Quality of Life","The Effects of Extremity With Lymphedema on Posture, Upper Extremity Functions, and Quality of Life in Patients With Lymphedema After Unilateral Breast Cancer",COMPLETED,,Yeditepe University,2022-05-02,2022-05-02,2022-10-31,2023-03-20,2023-03-20,"['Disabilities of the Arm, Shoulder, and Hand (DASH)', 'Lymphedema Functionality, Disability, and Health Questionnaire (Lymph-ICF)', 'Upper Extremity Lymphedema-27 (ULL-27)', 'Quality of Life Measure for Limb Lymphedema-Arm (LYMQOL-Arm)', 'The New York Posture Analysis (NYPA)']",[],,,,,1,Turkey (Türkiye),"Dr. Nazif Bağrıaçık Kadıköy Hospital [Kadıköy, Turkey (Türkiye)]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses the effects of lymphedema on various aspects of health and quality of life, but does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05789771,Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.,"Abemaciclib Combined With Endocrine Therapy or as a Single Agent for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia. Prospective, Multicentre, Non-interventional, Observational Study.",COMPLETED,,Blokhin's Russian Cancer Research Center,2022-04-01,2022-12-01,2022-12-01,2023-03-29,2023-03-31,['Progression-free Survival (PFS) of patients receiving abemaciclib'],"['Overall Response Rate (ORR)', 'Time To Chemotherapy (TTC)', 'Time To New Treatment Options (TTN)', 'Frequency of AE/SAE']",,,,,1,Russia,"Russian Society of Clinical Oncology [Moscow, Russia]",2022.0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,"[""Progression-Free Survival"",""Objective Response Rate""]",2,1,0,1,0,0,0,0,0,1,0,0,0,0,,OTHER,False,2022.0,3.0,0,NA/Other
NCT05793710,Effects o Laughing Qigong Program on Psychological Outcomes and the Physiological Immunological Responses,Effects of a 12-week Laughing Qigong Program on Psychological Outcomes and the Physiological Immunological Responses Among Female Breast Cancer Survivors: A Quasi-experimental Nonequivalent Control Group,COMPLETED,,National Taipei University of Nursing and Health Sciences,2013-12-30,2014-12-29,2014-12-29,2023-03-31,2023-03-31,"['Resilience scale', 'Pre-intervention(T0)]', 'Resilience Scale', 'Resilience Scale', 'Thai Mental Health Indicator (TMHI)', 'Thai Mental Health Indicator (TMHI)']","['Ｍucosal immunity (secretory(s)-IgA) immunoglobulin A', 'Ｍucosal immunity (secretory(s)-IgA) immunoglobulin A', 'Ｍucosal immunity (secretory(s)-IgA) immunoglobulin A', 'Saliva Interleukin-6 (IL-6', 'Saliva Interleukin-6 (IL-6', 'Saliva Interleukin-6 (IL-6']",,,,,1,Taiwan,"National Taipei University of Nursing and Health Sciences [Taipei, Taiwan]",2013.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a program (Laughing Qigong) and its effects on psychological and physiological outcomes in breast cancer survivors, but it does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2014.0,11.0,0,NA/Other
NCT05797129,CEDM as a Screening Tool for Breast Cancer in Higher-risk Women: A Prospective Study,CEDM as a Screening Tool for Breast Cancer in Higher-risk Women: A Prospective Study,COMPLETED,,Kaohsiung Veterans General Hospital.,2019-01-01,2021-12-31,2021-12-31,2023-04-04,2023-04-04,['Total number of cases received and diagnosed with breast cancer (Number)'],"['Total number of cases received and diagnosed as positive requiring a biopsy and MRI (Number)', 'True positive results obtained by the diagnostic method (Number)', 'True negative results obtained by the diagnostic method (Number)']",,,,,1,Taiwan,"Kaohsiung Veterans General Hospital [Kaohsiung City, Taiwan]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on the use of CEDM as a screening tool for breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05808569,Evaluating Breast Cancer Patients Modesty During Radiotherapy. A Multicentric Study,Evaluating Breast Cancer Patients Modesty During Radiotherapy. A Multicentric Study,COMPLETED,,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,2020-06-03,2022-09-28,2022-09-28,2023-04-11,2023-04-11,['Primary aim of this study is to identify patients perception of modesty during RT for breast cancer through the use of a dedicated 16 items questionnaire validated in a Delphi consensus for the purposes of this study'],[],,,,,1,Italy,"Fondazione Policlinico Universitario ""A.Gemelli"" IRCCS [Rome, Italy]",2020.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study focused on patient perception and modesty during radiotherapy for breast cancer, which does not involve the introduction of a new medicine or an extension of indication for an existing treatment.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05812326,PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer,Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer,COMPLETED,PHASE1; PHASE2,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,2019-05-17,2022-11-16,2022-11-16,2023-04-13,2023-04-13,"['Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v5.0', 'Incidence of treatment-emergent adverse events [safety and tolerability] of dose of PD-1 Knockout CAR-T cells will be assessed using CTCAE v5.0', 'Monitoring the numbers of circulating AJMUC1 after infusion will be evaluated.']","['Response rate will be assessed according to the revised RECIST guideline iRECIST', 'Overall Survival - OS (Measure the time from enrollment to death)', 'Progression free survival - PFS (Time from enrollment to date of first documented progression or date of death)', 'Median CAR-T cell persistence--Will be measured by quantitative RT-PCR']",,,,,1,China,"Sun Yat-sen Memorial Hospital of Sun Yat-sen University [Guangzhou, China]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,"[""Overall Survival"",""Pathologic Complete Response (pCR)""]",2,1,0,1,0,0,0,0,0,1,0,0,1,0,"The trial involves PD-1 Knockout Anti-MUC1 CAR-T Cells, which indicates a new therapeutic approach for treating advanced breast cancer, suggesting it is a new medicine.",OTHER,False,2022.0,3.0,0,Phase 2
NCT05834933,Nigerian Breast Cancer Risk-Reduction Study,Effects of Risk Assessment and Counselling on Adherence to Risk Reduction Recommendations Among Female Relatives of Breast Cancer Patients in Southwestern Nigeria,COMPLETED,,University of Ibadan,2017-02-13,2021-10-29,2021-10-29,2023-04-28,2023-08-03,"['Effects of BC risk assessment and counselling on adherence to breast screening recommendations among first-degree female relatives of BC patients in South-West Nigeria', 'Effects of BC risk assessment and counselling on adherence to lifestyle risk reduction recommendations among first-degree female relatives of BC patients in South-West, Nigeria', 'Predictors of BSE among first-degree female relatives of BC patients in South-West Nigeria', 'Predictors of time to first BC screening post-intervention among first-degree female relatives of BC patients in South-West Nigeria']","['Determine the perception of familial BC risk among first-degree female relatives of BC patients in South-West Nigeria.', 'Determine the knowledge of familiar BC risk among first-degree female relatives of BC patients in South-West Nigeria.', 'Determine the knowledge, attitude, and perception towards genetic testing and BC aetiology among first-degree female relatives of BC patients in South-West Nigeria']",,,,,4,Nigeria,"Obafemi Awolowo University Teaching Hospital Complex (OAUTHC) [Ile-Ife, Nigeria] | University College Hospital (UCH) [Ibadan, Nigeria] | Lagos State University Teaching Hospital (LASUTH) [Lagos, Nigeria] | Lagos University Teaching Hospital (LUTH) [Lagos, Nigeria]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study focused on risk assessment and counseling related to breast cancer, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2021.0,4.0,0,NA/Other
NCT05836337,Clinical Trial Evaluating the Effectiveness of a Tattoo Compared to a Clip Applied to Axillary Lymph Nodes in Breast Cancer Patients Who Undergo SLNBx,A Tattoo or a Clip? A Single-center Prospective Quasi Double-blind Randomized Parallel Two-arm Clinical Trial Evaluating the Effectiveness of a Tattoo Compared to a Clip Applied to Axillary Lymph Nodes in Breast Cancer Patients Who Undergo Sentinel Lymph Node Biopsy- SLNBx,COMPLETED,,King Hussein Cancer Center,2017-02-01,2019-11-20,2020-08-20,2023-05-01,2023-05-01,"['comparing effectiveness of tattooing versus clipping in SLNBx identification in breast cancer patients in upfront surgery setting, by comparing no. of identified positive or negative intraoperative SLN that were marked with tattooing versus clipping']","['convenience for radiologist to apply clip or tattoo from time and technical perspectives by comparing time spent in applying clip or tattoo and convenience of the application using a questionnaire completed by radiologists after each application', 'convenience for surgeon to perform SLNBx after lymph node marking from time & technical perspectives by comparing time and ease to identify the marked lymph nodes during surgery using a questionnaire completed by surgeons after each surgery', 'The convenience for the surgeon to confirm clip or tattoo presence during the SLNBx from time and technical perspectives using a questionnaire completed by surgeons after each surgery']",,,,,1,Jordan,"King Hussein Cancer Center [Amman, Jordan]",2017.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial is comparing two existing methods (tattooing vs clipping) for marking lymph nodes in breast cancer surgery, rather than testing a new medicine or extending the indication of an existing treatment.",OTHER,False,2020.0,5.0,0,NA/Other
NCT05840068,IGF Level in Breast Cancer Patients Treated With Metformin,Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients,COMPLETED,PHASE4,Beni-Suef University,2020-06-01,2021-07-31,2021-07-31,2023-05-03,2023-05-03,['IGF-1 levels'],['Progression-free survival (PFS)'],,,,,1,Egypt,"Marian S. Boshra [Banī Suwayf, Egypt]",2020.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2021.0,4.0,0,Other
NCT05853432,"A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy","A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy",COMPLETED,,Novartis Pharmaceuticals,2022-03-16,2022-05-02,2022-05-02,2023-05-10,2023-05-10,"['Overall survival (OS)', 'Real-world progression-free survival (rwPFS)', 'Line of treatment of ALP+FUL received', 'Line of treatment number of index regimens stratified by index year', 'Starting dose of alpelisib', 'Number of prior regimens', 'Prior fulvestrant treatment category', 'Prior regimens of patients who received alpelisib plus fulvestrant as first-line treatment', 'Number of prior fulvestrant regimens prior to alpelisib plus fulvestrant', 'Percentage of patients with prior exposure to CDK4/6i in the adjuvant setting', 'Percentage of patients with prior exposure to chemotherapy in the metastatic setting', 'Time to treatment discontinuation', 'First antineoplastic regimen received after discontinuation of the alpelisib plus fulvestrant regimen']","['Overall survival (OS) in subgroups of patients according to the prior lines of treatment', 'Real-world progression-free survival (rwPFS) in subgroups of patients according to the prior lines of treatment', 'Line of treatment of ALP+FUL received in subgroups of patients according to the prior lines of treatment', 'Line of treatment number of index regimens stratified by index year in subgroups of patients according to the prior lines of treatment', 'Starting dose of alpelisib in subgroups of patients according to the prior lines of treatment', 'Number of prior regimens in subgroups of patients according to the prior lines of treatment', 'Prior fulvestrant treatment category in subgroups of patients according to the prior lines of treatment', 'Prior regimens of patients who received alpelisib plus fulvestrant as first-line treatment in subgroups of patients according to the prior lines of treatment', 'Number of prior fulvestrant regimens prior to alpelisib plus fulvestrant in subgroups of patients according to the prior lines of treatment', 'Percentage of patients with prior exposure to CDK4/6i in the adjuvant setting in subgroups of patients according to the prior lines of treatment', 'Percentage of patients with prior exposure to chemotherapy in the metastatic setting in subgroups of patients according to the prior lines of treatment', 'Time to treatment discontinuation in subgroups of patients according to the prior lines of treatment', 'First antineoplastic regimen received after discontinuation of the alpelisib plus fulvestrant regimen in subgroups of patients according to the prior lines of treatment']",,,,,1,Ireland,"Novartis Pharmaceuticals [Dublin, Ireland]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,INDUSTRY,False,2022.0,3.0,0,NA/Other
NCT05909813,Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.,A Feasibility Study on Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.,COMPLETED,,University of Miami,2018-01-08,2018-04-04,2018-06-29,2023-06-18,2024-05-16,"['Post-Individualized Piano Instruction Feasibility Questionnaire', 'Change in Cognition Scores: NIH Toolbox Cognition Battery', 'Change in Quality of Life (QOL) Scores: Generalized Anxiety Disorder Assessment (GAD-7)', 'Change in Quality of Life (QOL) Scores: Patient Health Questionnaire (PHQ-9)', 'Change in Cognition Scores: FACT-Cog', 'Change in Quality of Life (QOL) Scores: FACT-B']",[],,,,,1,United States,"University of Miami [Miami, United States]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes a feasibility study on a non-pharmaceutical intervention (Individualized Piano Instruction) aimed at improving cognition in breast cancer survivors, which does not qualify as a new medicine or an extension of indication for an existing medicine.",OTHER,False,2018.0,7.0,0,NA/Other
NCT05917834,Comparison of Nipple-areolar Complex Sensation According to Incision Types in Nipple-sparing Mastectomy,Comparison of Nipple-areolar Complex Sensation According to Incision Types in Nipple-sparing Mastectomy,COMPLETED,,Gangnam Severance Hospital,2019-10-21,2021-11-29,2021-11-29,2023-06-26,2023-06-26,['Loss of NAC sensory by pinprick test'],[],,,,,1,South Korea,"GangnamSeverance Hospital [Seoul, South Korea]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,The text discusses a comparison of sensory outcomes related to surgical techniques rather than introducing a new medicine or extending the indication of an existing treatment.,OTHER,False,2021.0,4.0,0,NA/Other
NCT05963412,Online Individual Intervention Program to Make Sense of People's Experiences After a Breast Cancer Diagnosis,Developing an Online Individual Intervention Program to Make Sense of People's Experiences After a Breast Cancer Diagnosis and Examining Its Effectiveness,COMPLETED,,Dokuz Eylul University,2021-10-30,2022-10-30,2022-12-30,2023-07-27,2024-09-23,"['Socio-demographic and Disease-Related Information Form', 'Change in the Meaning in Life Questionnaire', 'Change in Post-traumatic Growth Inventory-X']","['Change in The Stress Appraisal Measure', 'Change in Global Meaning Violation Scale', 'Change in The Impact of Event Scale-Revised', 'Change in Acceptance and Action Questionnaire-II', 'Change in The Hospital Anxiety and Depression Scale']",,,,,1,Turkey (Türkiye),"Dokuz Eylul University, Faculty of Letters [Izmir, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text describes an online intervention program aimed at addressing experiences after a breast cancer diagnosis, which does not involve a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT05982886,Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer,Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer,COMPLETED,,Novartis Pharmaceuticals,2021-01-15,2021-04-01,2021-04-01,2023-08-09,2023-08-09,"['Number of patients with PIK3CA mutations', 'Time from first BC diagnosis to first PIK3CA evaluation', 'Time from advanced BC diagnosis to first PIK3CA evaluation', 'Time from initiation of first-line treatment for advanced BC diagnosis to first PIK3CA evaluation', 'Number of tests for patients with CDK4/6 inhibitor treatment', 'Time from progression on CDK4/6 inhibitor to first PIK3CA evaluation', 'Year of (first, where applicable) PIK3CA evaluation', 'Result of PIK3CA evaluation (negative, positive, unknown)', 'Type of biopsy', 'Type of tissue sample, for patients who had tissue biopsy', 'Source of tissue sample, for patients who had tissue biopsy', 'Analytical method used for PIK3CA evaluation']","['Age at advanced breast cancer diagnosis', 'Stage when patients were diagnosed with BC', 'Number of patients with known metastatic sites', 'Performance as assessed by Karnofsky Performace Scale', 'Performance as assessed by the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale', 'Height', 'Weight', 'Body mass index (BMI)', 'Number of patients per stage of cancer', 'Number of patients per line of treatment', 'Time from advanced diagnosis to initiation of lines of treatment', 'Number of patients per systemic therapy', 'Number of patients per treatment sequence', 'Number of patients per supportive treatment']",,,,,1,United States,"Novartis [East Hanover, United States]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The text discusses biomarker testing and treatment patterns specifically related to PIK3CA mutations in advanced breast cancer, indicating an extension of indication for existing treatments based on biomarker status.",INDUSTRY,False,2021.0,4.0,0,NA/Other
NCT06082505,Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 1,A Community Based Program to Increase Breast and Cervical Cancer Screening and HPV Vaccination to Reduce the Impact of Breast and Cervical Cancer Among Latinas.,COMPLETED,,"The University of Texas Health Science Center, Houston",2016-11-01,2019-05-29,2019-05-29,2023-10-13,2023-12-01,"['Number of women 40 years and older who complete mammogram screening', 'Number of women 21-65 years old who complete Pap test screening', 'Number of women 21-26 years old who initiate their HPV vaccination series.']","['Number of participants who received the second dose of HPV vaccine', 'Number of participants who received the third dose of HPV vaccine', 'Number of participants who received a clinical breast exam']",,,,,1,United States,"The University of Texas Health Science Center at Houston [Houston, United States]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2019.0,6.0,0,NA/Other
NCT06107790,"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer","Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer",COMPLETED,PHASE3,Zhejiang Hisun Pharmaceutical Co. Ltd.,2018-05-16,2022-01-28,2022-01-28,2023-10-30,2023-10-30,['ORR'],"['DCR', 'PFS', 'OS', 'Vital signs', 'Vital signs', 'Vital signs', 'Vital signs', 'physical examination,', 'ADAs', 'Ctrough', 'ECOG physical condition', 'left ventricular ejection fraction (LVEF),', 'adverse events (AE)']",,,,,1,China,"Jiangsu Province People's Hospital (First Affiliated Hospital of Nanjing Medical University) [Nanjing, China]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves HS022, which appears to be a new treatment being compared to an existing drug (Trastuzumab) in a specific patient population (HER2-positive breast cancer), indicating it is a new medicine.",INDUSTRY,False,2022.0,3.0,0,Phase 3
NCT06354478,IV Dexmedetomidine vs Oral Gabapentin and Their Combination for Postoperative Analgesia in Cancer Patients Undergoing Modified Radical Mastectomy,"A Randomized, Double-blind Study to Compare the Efficacy of Intravenous Dexmedetomidine Infusion, Oral Gabapentin and Their Combination on Postoperative Analgesia in Cancer Patients Undergoing Modified Radical Mastectomy",COMPLETED,,"National Cancer Institute, Egypt",2021-01-01,2022-02-01,2022-07-01,2024-04-09,2024-04-09,['The time to first rescue analgesia during the first 24 hour Postoperatively.'],"['Total postoperative morphine consumption till the first 24 hours', 'The degree of postoperative sedation according to Ramsay scores', 'VAS scores both at rest and during shoulder movement', 'Postoperative nausea and vomiting (PONV) as side effects of morphine.']",,,,,1,Egypt,"National Cancer Institute [Cairo, Egypt]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The study compares the efficacy of existing medications (Dexmedetomidine and Gabapentin) for a specific new application (postoperative analgesia in cancer patients), indicating an extension of indication rather than a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT06370234,The Prediction Model of NAC Response for Breast Cancer Based on The Parametric Dynamics Features.,The Prediction Model of Neoadjuvant Chemotherapy Response for Breast Cancer Based on The Parametric Dynamics Features of The Pretreatment and Early-Treatment MR-PET and QDS-IR Images.,COMPLETED,,National Taiwan University Hospital,2015-04-21,2019-06-30,2020-03-03,2024-04-17,2024-04-17,"['Model Prediction power of pathological complete response(pCR)', 'Comparison of models in prediction of pathological complete response(pCR)']",[],,,,,0,,,2015.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,"[""Pathologic Complete Response (pCR)""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2020.0,5.0,0,NA/Other
NCT06371989,Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL,Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL,COMPLETED,,Hospital Universitario 12 de Octubre,2019-03-11,2021-03-20,2022-12-20,2024-04-17,2024-04-17,"['The negative Predictive Value (NPV), Positive predictive value, specificity and sensibility of the VAB compared to Standard Surgery with Pathologic Evaluation']",[],,,,,1,Spain,"Sara Jimenez Arranz [Madrid, Spain]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,1,0,0,1,,OTHER,False,2022.0,3.0,0,NA/Other
NCT06376578,Exercise Interventions for Improving Health in Breast Cancer Survivors,"Comparing a Technology-enabled, Remotely Delivered Exercise Intervention to Partly-supervised Structured Exercise in Breast Cancer Survivors: a Randomised and Controlled Non- Inferiority Trial",COMPLETED,,University of Bath,2018-09-05,2020-01-30,2020-01-30,2024-04-19,2024-04-19,['Change in VO2max (maximum oxygen uptake)'],['Change in Body composition'],,,,,1,United Kingdom,"University of Bath [Bath, United Kingdom]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial focuses on exercise interventions for breast cancer survivors, which suggests an extension of indication for existing treatments or interventions rather than testing a new medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT06541769,CIPN-prevention Trial Evaluating the Efficacy of Hand-cooling and Hand-compression,CIPN-prevention Trial Evaluating the Efficacy of Hand-cooling and Hand-compression in Patients Undergoing (Neo-) Adjuvant Chemotherapy for Primary Breast Cancer,COMPLETED,,University Hospital Heidelberg,2019-10-15,2022-07-15,2022-07-15,2024-08-07,2024-08-07,['Incidence of CIPN grade >1 on the interventional hand compared to the non-interventional hand'],"['Incidence of onycholysis/onychodystrophy grade >1 on the interventional hand compared to the non-interventional hand', 'Magnetic resonance neurography (MRI) as a possible marker of CIPN', 'Influence of CIPN on the quality of life']",,,,,1,Germany,"National Center for Tumor diseases (NCT) [Heidelberg, Germany]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,,OTHER,False,2022.0,3.0,0,NA/Other
NCT06555354,MicroRNAs and Prognosis in Breast Cancer,MicroRNAs Methylation and Expression Profiling for Identification of Breast Cancer Patients at High Risk to Develop Distant Metastases,COMPLETED,,Casa Sollievo della Sofferenza IRCCS,2014-10-28,2018-10-28,2019-11-28,2024-08-15,2024-08-15,['Risk of metastases development'],['Overall Survival'],,,,,1,Italy,"Casa sollievo della Sofferenza IRCCS [San Giovanni Rotondo, Italy]",2014.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses microRNAs in the context of prognosis and risk assessment in breast cancer, but does not indicate a new medicine or an extension of indication for an existing treatment.",OTHER,False,2019.0,6.0,0,NA/Other
NCT06683404,GISEL:Registry of Breast Cancer Patients Treated With ECT,GISEL (Italian Senologic Group for Electrochemotherapy): Prospective Multicenter Registry of Breast Cancer Patients With Skin Metastases Treated by Electrochemotherapy,COMPLETED,,Istituto Oncologico Veneto IRCCS,2016-04-22,2021-10-21,2022-12-10,2024-11-12,2024-11-12,"['Local response', 'Treatment toxicity']","['Local progression-free survival (LPFS)', 'Quality of life and pain relief', 'Quality of life and pain relief']",,,,,1,Italy,"Veneto Institute of Oncology IRCCS [Padua, Italy]",2016.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[""Progression-Free Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,1,"The trial text indicates a study on the use of electrochemotherapy for breast cancer patients, which suggests an extension of indication for an existing treatment rather than the introduction of a new medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT06706141,The Effect of Breast Cancer and Breast Self-Examination,"The Effect of Breast Cancer and Breast Self-Examination Health Education on Awareness, Beliefs and Practices Given to Female Students At the Faculty of Health Sciences of a University in Mogadishu, Somalia",COMPLETED,,Saglik Bilimleri Universitesi,2021-10-01,2022-10-01,2022-10-01,2024-11-26,2024-12-10,['post intervention'],[],,,,,1,Turkey (Türkiye),"University of Health Sciences [Ankara, Turkey (Türkiye)]",2021.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a health education intervention related to breast cancer awareness and self-examination, but it does not mention a new medicine or an extension of indication for an existing medicine.",OTHER,False,2022.0,3.0,0,NA/Other
NCT06758765,Erector Spinae Plane Block vs. PECS I-II Blocks After Breast-conserving Surgery,Comparison of the Effects of the Erector Spinae Plane Block and PECS I-II Blocks on Postoperative Opioid Consumption and Pain Scores of Patients After Breast-conserving Surgery: A Prospective Randomized Controlled Trial,COMPLETED,,Istanbul Saglik Bilimleri University,2022-03-01,2022-08-31,2022-11-30,2025-01-06,2025-01-06,['Early postoperative Visual Analog Scale (VAS) scores'],"['Additional opioid analgesic requirement in the postanesthesia care unit', 'Total opioid consumption after discharging from postanesthesia care unit', 'Visual Analog Scale (VAS) during 24 hours follow-up after surgery']",,,,,1,Turkey (Türkiye),"Basaksehir Cam ve Sakura City Hospital [Istanbul, Turkey (Türkiye)]",2022.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial compares two existing techniques (Erector Spinae Plane Block and PECS I-II Blocks) for pain management after surgery, rather than testing a new medicine or extending the indication of an existing one.",OTHER,False,2022.0,3.0,0,NA/Other
NCT06766708,"The Effect of a Self-Management Lymphedema Education Program on Lymphedema, Symptoms, Compliance, Daily Living Activities, and Patient Activation in Breast Cancer-Related Lymphedema: A Quasi-Experimental Study","The Effect of a Self-Management Lymphedema Education Program on Lymphedema, Lymphedema-Related Symptoms, Patient Compliance, Daily Living Activities and Patient Activation in Patients With Breast Cancer-Related Lymphedema: A Quasi-Experimental Study",COMPLETED,,Gizem Cansiz Ucar,2019-12-01,2020-12-15,2020-12-15,2025-01-09,2025-01-09,"['The Impact of a Lymphedema Management Education Program on Symptoms in Breast Cancer-Related Lymphedema Patients Using Circumferential Measurements and Bioimpedance Spectroscopy (BIS)', 'The Impact of a Lymphedema Management Education Program on Patient Compliance Using the Patient Activation Measure (PAM)', 'The Impact of a Lymphedema Management Education Program on Activity Levels Using the Patient Activation Measure (PAM)', 'The Impact of a Lymphedema Management Education Program on Activity Levels Using the Daily Living (Katz ADL) Index', 'The Impact of a Lymphedema Management Education Program on Independence in Daily Living Activities Using the Katz Activities of Daily Living (Katz ADL) Index']",[],,,,,1,Turkey (Türkiye),"Hacettepe University [Ankara, Turkey (Türkiye)]",2019.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a self-management education program for lymphedema related to breast cancer, which does not indicate a new medicine or an extension of indication for an existing medicine.",OTHER,False,2020.0,5.0,0,NA/Other
NCT07064317,Catheter Tip Position and Contrast Distribution Following Paravertebral Catheter Insertion: a CT Study,Catheter Tip Position and Contrast Distribution Following Paravertebral Catheter Insertion: a CT Study,COMPLETED,,Ziekenhuis Oost-Limburg,2010-01-27,2012-01-25,2012-01-25,2025-07-14,2025-07-14,['Paravertebral catheter tip position'],['Paravertebral contrast distribution'],,,,,1,Belgium,"Clinique Sainte-Anne Saint Rémi [Brussels, Belgium]",2010.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The text discusses a study on catheter tip position and contrast distribution, which does not indicate the introduction of a new medicine or an extension of indication for an existing medicine.",OTHER,False,2012.0,13.0,0,NA/Other
NCT07134933,The Effects of Erector Spinae Plane Block on Pain Scores in Unilateral Breast Cancer Surgery,"The Effects of Erector Spinae Plane Block on Pain Scores and Patient Experience in Unilateral Breast Cancer Surgery: A Prospective, Randomized Clinical Trial",COMPLETED,,Inonu University,2018-12-25,2019-03-01,2019-04-20,2025-08-21,2025-08-21,['Remifentanil Consumption'],"['postoperative morphine consumption', 'The VAS scores', 'patient satisfaction']",,,,,1,Turkey (Türkiye),"İnonu University Medicine Faculty Turgut ozal Medical Center [Malatya, Turkey (Türkiye)]",2018.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,"[""Overall Survival""]",1,1,0,1,0,0,0,0,0,1,0,0,0,0,"The trial text discusses the effects of a specific anesthetic technique (Erector Spinae Plane Block) on pain management in a surgical context, rather than introducing a new medicine or extending the indication of an existing medicine.",OTHER,False,2019.0,6.0,0,NA/Other
NCT07166367,Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer,"A Phase II Single Arm Trial to Assess the Efficacy of ASLAN001 Plus Capecitabine in Previously Irradiated, Progressing Central Nervous System (CNS) Metastases for HER2 Positive Breast Cancer Patients",TERMINATED,PHASE2,"National Cancer Centre, Singapore",2016-08-11,2020-01-14,2020-01-14,2025-09-10,2025-09-10,['CNS objective response rate (ORR) based on RANO-BM criteria'],"['Safety/toxicity', 'Clinical benefit rate', 'Progression free survival', 'Overall survival']",,,,,1,Singapore,"National Cancer Centre Singapore [Singapore, Singapore]",2016.0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,"[""Objective Response Rate"",""Overall Survival""]",2,1,0,1,0,0,0,0,0,1,1,0,1,0,"The trial involves ASLAN001, which is being assessed for a specific indication (CNS metastases in HER2+ breast cancer), indicating it is a new medicine being tested for a new application.",OTHER,False,2020.0,5.0,0,Phase 2
